

Drug Recognition Expert Course (DRE) 7-Day School

R5/13 Edition

Instructor Guide



DRE 7-Day School Instructor Guide – Table of Contents

R5/13 Curriculum

Acknowledgements

Preface Page

Administrators Guide

Session 1: Introduction and Overview

- Glossary of Terms

Session 2: Drugs in Society and in Vehicle Operation

Session 3: Development and Effectiveness of the DEC Program

- Frye Decisions Regarding Admissibility of DRE Testimony
- American Prosecutors Research Institute – HGN Case Law Summary
- Scientific Publications and Research Reports Addressing Nystagmus

Session 4: Overview of the Drug Recognition Expert Procedures

- Blank DRE Face Sheet

Session 5: Eye Examinations

- Pupil Size Chart
- SFST Proficiency Examination Form

Session 6: Physiology and Drugs: An Overview

- Physiological Pursuit Questions

Session 7: Examinations of Vital Signs

Session 8: Demonstrations of the Evaluation Sequence

Session 9: Central Nervous System Depressants

- Drug Exemplar Report – Cramer
- Drug Exemplar Report – Henry

Session 10: Central Nervous System Stimulants

- Drug Exemplar Report – Hedlund
- Drug Exemplar Report – Kohlhepp

Session 11: Practice Eye Examinations

Session 12: Alcohol Workshop

Session 13: Physician's Desk Reference and Other Reference Resources

Session 14: Hallucinogens

- Drug Exemplar Report – Hoeckle
- Drug Exemplar Report – Warburton
- Drug Exemplar Report – Buchanan

Session 15: Practice: Test Administration

- Drug Exemplar Report – Adams (I)
- Drug Exemplar Report – Baker (I)
- Drug Exemplar Report – Charles (I)
- Drug Exemplar Report – Dodge (I)
- Drug Exemplar Report – Edwards (I)

Session 16: Dissociative Anesthetics

- Drug Exemplar Report – Albright
- Drug Exemplar Report – George
- Drug Exemplar Report – Ross

Session 17: Narcotic Analgesics

- Drug Exemplar Report – Vaughn
- Drug Exemplar Report – Bursten
- Drug Exemplar Report – Sheehan

Session 18: Practice: Test Administration

- Drug Exemplar Report – Martinez (I)
- Drug Exemplar Report – Groves (I)
- Drug Exemplar Report – Hatos (I)
- Drug Exemplar Report – Jackson (I)
- Drug Exemplar Report – Stevens (I)
- Drug Exemplar Report – Sholly (I)

Mid-Course Review

Session 19: Inhalants

- Drug Exemplar Report – Graves
- Drug Exemplar Report – Mashburn

Session 20: Practice: Vital Signs Examinations

- Vital Signs Examination Sheet

Session 21: Cannabis

- Drug Exemplar Report – Clark
- Drug Exemplar Report – Peltier
- Drug Exemplar Report – Wright

Session 22: Overview of Signs and Symptoms

- Comparison of DRE Symptomatology Sources

Session 23: Curriculum Vitae Preparation and Maintenance

- Two sample CV's

Session 24: Drug Combinations

- Indicators Consistent With Drug Categories Chart
- Drug Combination Charts (5 total)

Session 25: Practice: Test Interpretation

- Drug Categories for Interpretation Practice
- Drug Exemplar Report – Allen (I)
- Drug Exemplar Report – Brown (I)
- Drug Exemplar Report – Cole (I)
- Drug Exemplar Report – Davis (I)
- Drug Exemplar Report – Elliott (I)

Session 26: Preparing the Narrative Report

- Drug Exemplar Report – Richardson

Session 27: Practice: Test Administration

Session 28: Case Preparation and Testimony

- DRE Defense Cross Examination Questions

Review of the DRE School

- Self Quiz
- Answer Key to Self Quiz

Session 29: Classifying a Suspect (Role Play)

- Drug Exemplar Report – Alpha

- Drug Exemplar Report – Bravo
- Drug Exemplar Report – Charlie
- Drug Exemplar Report - Delta
- Drug Exemplar Report – Echo
- Drug Exemplar Report – Foxtrot
- Drug Exemplar Report – Golf
- Drug Exemplar Report – Hotel
- Drug Exemplar Report – India
- Drug Exemplar Report – Juliet
- Drug Exemplar Report – Kilo
- Drug Exemplar Report – Lima

Session 30: Transition to Certification Phase of Training

- Instructor Guidelines for the Final Examination
- DRE Log of Drug Influence Evaluations (Rolling Log)
- Proficiency Examination Checklist

Acknowledgements

The International Association of Chiefs of Police (IACP) and the National Highway Traffic Safety Administration (NHTSA) would like to thank the following individuals for their contributions in updating and revising the 2013 DRE curricula.

Jonlee Anderle, Laramie, WY Police Department

Kyle Clark, Institute of Police Technology and Management

Don Decker, Nahant, MA Police Department

Ernie Floegel, International Association of Chiefs of Police

Chuck Hayes, International Association of Chiefs of Police

Mike Iwai, Oregon State Police

Jim Maisano, Norman, OK Police Department

Evan Graham, Royal Canadian Mounted Police

Bill O'Leary, National Highway Traffic Safety Administration

Doug Paquette, New York State Police

Preface

The Drug Recognition Expert course is a series of three training phases that, collectively, prepare police officers and other qualified persons to serve as drug recognition experts (DRE). Throughout this manual, the terms “drug recognition expert” and “DRE” are used to designate an individual who is specially trained and has continued training to conduct examinations of drug-impaired drivers. This training, developed as part of the Drug Evaluation and Classification Program (DECP) under the auspices and direction of the International Association of Chiefs of Police (IACP) and the National Highway Traffic Safety Administration (NHTSA) has experienced remarkable success since its inception in the 1980s.

As in any educational training program, an instruction manual is considered a “living document” that is subject to updates and changes based on advances in technology and science. A thorough review is made of information by the DECP Technical Advisory Panel (TAP) of the Highway Safety Committee of the IACP with contributions from many sources in health care science, toxicology, jurisprudence, and law enforcement. Based on this information, any appropriate revisions and modifications in background theory, facts, examination and decision making methods are made to improve the quality of the instruction as well as the standardization of guidelines for the implementation of the Drug Recognition Expert Training Curriculum. The reorganized manuals are then prepared and disseminated, both domestically and internationally, to the DECP state coordinators.

Changes will take effect 90 days after approval by the TAP, unless otherwise specified or when so designated by a state coordinator.

**DRUG EVALUATION AND CLASSIFICATION TRAINING
"THE DRUG RECOGNITION EXPERT SCHOOL"**

ADMINISTRATOR'S GUIDE

R5/13 EDITION

TABLE OF CONTENTS

A.	<u>Purpose of this Document</u>	3
B.	Overview of the Course	5
	. For whom is the training intended?	5
	. What are the purposes of the course?	8
	. What will the students get out of this course?	8
	. What subject matter does the course cover?	9
	. What activities take place during the training?	10
	. How long does the training take?	10
	THE DRE SCHOOL - SCHEDULE	14
	ALTERNATE SCHEDULE #1	16
	ALTERNATE SCHEDULE #2	20
	ALTERNATE SCHEDULE #3	24
C.	Overview of the Curriculum Package	29
	. Instructor's Lesson Plans Manual	29
	. Audio-Visual Aids	30
	. Student's Manual	31
	. Set of Drug Evaluation Exemplars	32
D.	<u>General Administrative Requirements</u>	32
	. Facility Requirements	32
	. Instructor Qualifications.	34
	. Class Size Considerations.	35
E.	<u>Course Planning and Preparation Requirements</u>	35
F.	<u>Examinations of Students' Knowledge and Proficiency</u>	36
G.	<u>Follow-Up Requirements</u>	36
H.	<u>Guidelines for Preparing Post-Course Evaluation</u>	37
I.	<u>Requests for Information, Assistance or Materials</u>	39

A. Purpose of this Document

This Administrator's Guide provides an introduction to and an overview of the seven-day classroom training course on drug evaluation and classification. This course is perhaps better known as **The DRE School**. It is the second in a series of three stages of training that, collectively, prepare persons to serve as Drug Recognition Experts (DREs).

Throughout this manual, the term "DRE" is used to designate an individual who is specially-trained to conduct examinations of drug-impaired drivers. In some participating agencies, the term stands for "Drug Recognition Expert"; in others, it means "drug recognition evaluator", and in others, "drug recognition examiner". In addition, some agencies use the term "DRT" -- Drug Recognition Technician -- and others prefer "DRS" -- Drug Recognition Specialist. All of these and similar terms are acceptable and considered synonymous. But for this training program, the standard term is DRE.

It is worth repeating that this seven-day DRE School is neither the beginning nor the end of an officer's preparation to serve as a DRE. No one can be admitted to this course unless he or she has successfully completed the two-day program titled "Preliminary Training for Drug Evaluation and Classification" (the "PRE-School"), or demonstrates that he or she has mastered the subject-matter of that PRE-School via previous training and experience. And, the fact that an officer successfully completes this seven-day program does not qualify him or her to serve as a DRE. He or she still must complete the Certification Phase of training, a supervised on-the-job phase in which the trainee conducts examinations of persons suspected of drug impairment.

This seven-day course, then, is only the middle phase of DRE training. But it is a very important phase. It is during this phase that the student will learn to conduct systematic and standardized examinations of persons suspected of drug impairment to determine:

- (1) Whether the subject actually is impaired; and if so,
- (2) Whether the impairment is drug- or medically-related; and if drugs,
- (3) The broad category or combination of categories of drugs that is the likely cause of the observed impairment.

This Administrator's Guide is concerned only with the second phase of training. During this phase, the student becomes familiar with the various types of drugs that people use and -- too often -- abuse. The student learns how the different drugs affect people, and especially how they affect a person's ability to operate a vehicle. The student learns how the different drugs manifest their presence in an individual.

In particular, the student learns how to examine a subject's eyes and vital signs to detect evidence of various kinds of drugs. By the time the student successfully completes the training, he or she is able to conduct a complete drug influence examination, and is able to describe the evidence that the examination will disclose to help determine if the subject suffers a medical condition or if a subject is under the influence of a particular category or combination of categories of drugs.

This Administrator's Guide is intended to facilitate planning and implementation of the Drug Evaluation and Classification Classroom Training Program. The Guide overviews the 7-day course of instruction, and the documents and other materials that make up the curriculum package for the course. It describes course administrative requirements and offers guidelines for discharging those requirements satisfactorily. It outlines the preparatory work that must be accomplished by a law enforcement agency before the course can be offered to that agency's personnel. And, it outlines the follow-up work that should be undertaken to ensure that the highest possible quality of instruction continues to be delivered, during all phases of a DRE's training.

Before addressing the details of this classroom training in Drug Evaluation and Classification Program procedures, a few words are appropriate concerning the procedures themselves. **In particular, it is important to make clear what the Drug Evaluation and Classification Program procedures are not:**

- o These procedures are not a field test, or a pre-arrest investigative tool. It is highly unlikely that they could be conducted with adequate care in an outdoors, scene-of-investigation setting. In any event, they are not designed to provide probable cause for a subject's arrest. Rather, they are a post-arrest investigative tool, intended for application to arrestees for whom there is at least some articulable suspicion of drug use or drug impairment.
- o These procedures do not, generally speaking, disclose what specific drug or drugs the subject has used. That may seem to be a startling, and upsetting statement. Nevertheless, it is true. What the procedures will do, however, is to disclose (with reasonable accuracy) the broad category or combination of categories that produce distinguishable "signatures" visible to a qualified DRE. Some of the categories include relatively few individual drugs. Others include many drugs. The DRE can tell, usually, if a particular category is present. But except in special circumstances, he or she cannot tell which individual member of that category is the drug in question. Thus for example, a DRE usually will not be able to distinguish a person impaired by Diazepam from a person impaired by Secobarbital. Will not be able to tell the difference between a codeine-impaired subject and someone under the influence of Demerol. Won't see a difference between someone under the influence of peyote and someone under the influence of psilocybin.

- o The procedures are not a substitute for chemical testing. Laboratory analysis of blood samples by qualified personnel remains an important step in the acquisition of evidence in drug-related cases. The drug evaluation and classification procedures provide articulable bases for requesting a subject to supply the urine or blood sample; guide the laboratory technicians toward the general categories of drugs they can expect to find in the sample; and, disclose important evidence to supplement the laboratory analysis. But the drug recognition expert does not eliminate the need for the laboratory technician.

None of the foregoing remarks is intended to lessen the importance of the drug evaluation and classification procedures. A cadre of skilled DREs definitely will enhance a department's ability to recognize and convict persons under the influence of drugs. The DRE is a very important "weapon" in law enforcement's anti-drug arsenal. But the DRE is not the entire arsenal.

One final word of introduction: the primary orientation of this course is toward traffic law enforcement. Without doubt, persons under the influence of drugs endanger society in many ways. But it is the danger they cause as drivers of motor vehicles that is of principal interest here. This course assumes that the DRE will devote his or her skills in large part to conducting examinations of suspected impaired drivers. This is not to say that the skills that this training seeks to develop do not have many non-traffic applications. Nevertheless, it is the traffic applications that will receive most of the student's attention.

B. Overview of the Course

1. For whom is the training intended?

This training definitely is not intended for just anyone. The candidate DRE isn't just any police officer, but an officer who already has some very special knowledge and skills, and a very definite commitment to DWI and drug enforcement. And, that officer isn't employed by just any department. Instead, he or she works for a department that has taken pains to provide the command and logistics support needed to allow the DRE to function at maximum effectiveness. And the department has concrete proof of its commitment to deterring impaired driving. Finally, that department doesn't serve just any community or state. Instead, it operates in a jurisdiction that has a legal and political framework that is consistent with effective enforcement of drug-impaired driving violations.

The following lists the prerequisites and desirable characteristics of the students for whom this training is intended; of the departments that employ those students; and, of the communities served by those departments.

a. Student Prerequisites

To be considered a qualified candidate for this training, the proposed student must be a law enforcement officer or an employee of a public criminal justice agency or an institution providing law enforcement training, and must:

- o have achieved the learning objectives of the two-day PRE-School;
- o have demonstrated proficiency in the use of the Standardized Field Sobriety Tests (i.e., Horizontal Gaze Nystagmus, walk and turn and one leg stand);
- o have good communications skills, and a demonstrated ability to testify in court;
- o be willing to continue to serve as a DRE for at least two years following completion of the training.

Of course, it is highly desirable, although not essential, that the proposed student have prior knowledge of drug symptomatology and experience in drug enforcement.

b. Departmental Prerequisites

To be considered qualified to submit students for this training, the interested law enforcement agency must:

- o have active drug enforcement and DWI enforcement programs;
- o be pro-active in training officers in Standardized Field Sobriety Testing; also, the training must be consistent with IACP/NHTSA guidelines, and the agency must maintain records of officers' Standardized Field Sobriety Testing enforcement activities;
- o have access to adequate chemical testing resources to support the Drug Evaluation and Classification Program, and ensure effective prosecution of drug-impaired subjects;
- o have adequate facilities and equipment to support the Drug Evaluation and Classification Examinations;
- o demonstrate the firm support and commitment of the chief law enforcement officer and other appropriate officials for the drug evaluation and classification program. Evidence of this support

includes but is not limited to:

- Willingness to conduct DRE training in a manner that complies fully with IACP/NHTSA curricula and guidelines.
- Willingness to adopt IACP/NHTSA-approved DRE evaluation forms.
- Willingness to authorize DREs and DRE candidates to devote sufficient time to the DRE function to develop and maintain proficiency.
- Willingness to provide the services of qualified DRE instructors to assist IACP/NHTSA in training candidate DREs from other agencies.

c. Legal and Political Prerequisites

To be considered qualified to recommend a law enforcement agency for this training, a state or community must have laws or court-established precedents that:

- o specifically allow for the analysis of chemical samples obtained from persons suspected of impaired driving, to determine the presence and/or concentration of drugs other than alcohol;
- o allow the arresting officer or law enforcement agency to specify the chemical test or tests (e.g., blood, breath or urine) to be given to suspected impaired drivers;
- o specifically facilitate testing for drugs other than alcohol.

In addition, it is desirable that the state or community have laws that:

- o make the fact of the driver's refusal to submit to the test or tests admissible in court;
- o make it an offense to be under the influence of alcohol and/or illicit drugs, whether or not the person is operating a vehicle.

Furthermore, the state's or community's prosecutors must:

- o demonstrate a willingness to introduce Standardized Field Sobriety Test evidence in alcohol/drug cases;

- o express a willingness to participate in this training to become familiar with Drug Evaluation and Classification procedures and related information.

The state's or community's judges must:

- o demonstrate a willingness to accept and consider Standardized Field Sobriety Test evidence in alcohol/drug cases;
- o express a willingness to consider Drug Evaluation and Classification evidence in alcohol/drug cases.

Finally, it is desirable that the jurisdiction's political and community leaders express support for the Drug Evaluation and Classification Program.

2. What are the purposes of the course?

The ultimate goal of this course is to help prevent crashes, deaths and injuries by improving enforcement of drug-impaired driving violations. It is not exactly clear how many drug-impaired drivers are on our nation's roads, or how many crashes they cause. But even the most conservative estimates indicate that these drivers kill thousands of Americans, and injure at least tens of thousands of others each year.

3. What will the students get out of this course?

The classroom training course is designed to help the students achieve three broad goals, and eight specific learning objectives.

Goals: The student who successfully completes this phase of DRE training will be able to...

- ... distinguish if an individual is under the influence of a drug or drugs other than alcohol, or under the combined influence of alcohol and other drugs, or suffering from some injury or illness that produces signs similar to alcohol/drug impairment;
- ... identify the broad category or categories of drugs inducing the observable signs of impairment; and,
- ... progress to the Certification Phase of the training.

Objectives: In order to pass this course, the student must be able to...

- ... describe the involvement of drugs in impaired driving incidents;

- ... name the seven categories of drugs and recognize their effects;
- ... describe and properly administer the psychophysical and physiologic evaluations used in the drug evaluation and classification procedures;
- ... document the results of the drug evaluation and classification examination;
- ... properly interpret the results of the examination;
- ... prepare a narrative drug influence report;
- ... discuss appropriate procedures for testifying in typical Drug Evaluation and Classification cases; and,
- ... maintain an up-to-date relevant Curriculum Vitae (CV).

4. What subject matter does the course cover?

The course focuses primarily on two broad topics:

- (1) The examinations, observations, measurements, etc. that constitute the Drug Evaluation and Classification procedures.
- (2) The nature, effects, signs and symptoms of each of the seven categories of drugs, and of the combination of categories.

More specifically, the course provides formal presentations on:

- o Drugs in Society and in Motor Vehicle Operation.
- o Development and Effectiveness of the Drug Evaluation and Classification Program Procedures.
- o An Overview of Physiology and Drugs.
- o An Overview of the DEC Program Procedures.
- o Eye Examinations
(Horizontal Gaze Nystagmus; Vertical Gaze Nystagmus; Lack of Convergence; Estimation of Pupil Size; Pupil Reaction to Light).
- o Vital Signs Examinations
(Pulse Rate; Blood Pressure; Temperature)

- o The Physician's Desk Reference, and other reference materials.
 - o The Seven Categories of Drugs
(Central Nervous System Depressants; Central Nervous System Stimulants; Hallucinogens; Dissociative Anesthetics; Narcotic Analgesics; Inhalants; Cannabis).
 - o Drug Combinations.
 - o Narrative Arrest Report in Drug Evaluation Cases.
 - o Case Preparation and Testimony.
 - o Curriculum Vitae (C.V.) Preparation and Maintenance.
5. What activities take place during the training?

Formal presentations, or lectures, occupy approximately one-half of the course. These presentations cover the content topics outlined earlier. The presentations are supplemented by DVD segments, and by reading material contained in the Student's Manual.

Most of the remainder of the course is devoted to demonstrations and hands-on practice of the Drug Evaluation and Classification procedures. Students repeatedly practice in teams, developing and sharpening their skills in administering eye examinations, vital signs examinations, and other components of the drug recognition expert's job. Students also participate in several test interpretation practice sessions, in which they review sample drug evaluation and classification reports and identify the category or categories of drugs responsible for the "evidence" described in the reports.

The remaining major activity is testing of the students' knowledge and proficiency. A written knowledge examination is administered, at the end of the course. A formal assessment of each student's skill in administering the Drug Evaluation and Classification procedures is conducted during the next-to-last session.

6. How long does the training take?

This classroom training course occupies 7 training days. A typical schedule calls for each day to begin at 8 am and conclude at 5 pm. A 1-hour lunch period and hourly breaks of 10 minutes are accommodated in that schedule.

The course is divided into thirty-two (32) sessions. Of those, two are review

sessions, conducted after normal class hours on the fourth and sixth days of the School. No student can progress to the Certification Phase of training until he or she has attended all mandatory sessions. In the event that some emergency causes a student to miss all or a portion of a session, after-hours tutoring must be conducted for that student prior to his or her enrollment in Certification training.

The titles, durations and sequence of the sessions are given below.

Session I Introduction and Overview	(1 hour, 50 minutes)
Session II Drugs in Society and in Motor Vehicle Operation	(50 minutes)
Session III Development and Effectiveness of the DEC Program	(50 minutes)
Session IV Overview of Drug Recognition Expert Procedures	(2 hours, 30 minutes)
Session V Eye Examinations	(1 hour, 45 minutes)
Session VI Physiology & Drugs: An Overview	(2 hours)
Session VII Examination of Vital Signs	(2 hours)
Session VIII Demonstration of the Evaluation Sequence	(1 hour, 20 minutes)
Session IX Central Nervous System Depressants	(1 hour, 45 minutes)
Session X Central Nervous System Stimulants	(1 hour, 45 minutes)
Session XI Practice: Eye Examinations	(1 hour)
Session XII	

Alcohol Workshop	(1 hour, 45 minutes)
Session XIII Physician's Desk Reference and Other Reference Sources	(30 minutes)
Session XIV Hallucinogens	(1 hour, 45 minutes)
Session XV Practice: Test Interpretation	(45 minutes)
Session XVI Dissociative Anesthetics	(1 hour, 40 minutes)
Session XVII Narcotic Analgesics	(3 hours)
REVIEW SESSION (Mid-Course Review)	(2 hours, 30 minutes)
Session XVIII Practice: Test Interpretation	(45 minutes)
Session XIX Inhalants	(1 hour, 35 minutes)
Session XX Practice: Vital Signs Examinations	(50 minutes)
Session XXI Cannabis	(1 hour, 35 minutes)
Session XXII Overview of Signs and Symptoms	(1 hour)
Session XXIII C.V. Preparation and Maintenance	(50 minutes)
Session XXIV Drug Combinations	(1 hour, 50 minutes)
Session XXV Practice: Test Interpretation	(45 minutes)
Session XXVI	

Preparing the Narrative Report	(50 minutes)
Session XXVII Practice: Test Administration	(1 hour, 45 minutes)
Session XXVIII Case Preparation and Testimony	(1 hour 30 minutes)
REVIEW SESSION Review of the DRE School	(2 hours, 30 minutes)
Session XXIX Classifying a Suspect (Role Play)	(4 hours)
Session XXX Transition to the Certification Phase of Training	(2 hours, 30 minutes)

NOTE: All sessions of this course are absolutely essential. No short-cuts are permissible.

A model schedule for the seven-day course is given on the next page.

Alternate Schedule #1 combines the Pre-School and Seven-Day School.

Alternate Schedule #2 combines the DWI Detection and Standardized Field Sobriety Testing, Pre-School, and Seven-Day School.

If you use Alternate Schedule #1 or #2, you will need to make copies of those schedules for the students.

THE DRE SCHOOL - SCHEDULE (page 1)

WEDNESDAY	THURSDAY	FRIDAY
0800-0850 SESSION I: Intro & Overview	0800-0850 SESSION V: (cont)	0800-0850 SESSION IX: CNS Depressants
0850-0900 BREAK	0850-0900 BREAK	0850-0900 BREAK
0900-1000 SESSION I: (cont)	0900-1005 SESSION VI: Physiology & Drugs	0900-1000 SESSION IX: (cont)
1000-1010 BREAK	1005-1015 BREAK	1000-1010 BREAK
1010-1030 Pre-Test	1015-1110 SESSION VI: (cont)	1010-1100 SESSION X: CNS Stim.
1030-1120 SESSION II: Drugs In Soc.	1110-1120 BREAK	1100-1110 BREAK
1120-1130 BREAK	1120-1200 SESSION VII: Vital Signs	1110-1200 SESSION X: (cont)
1130-1230 SESSION III: Devel, of DEC Program	1200-1300 LUNCH	1200-1300 LUNCH
1230-1330 LUNCH	1300-140 SESSION VII: (cont)	1300-1400 SESSION XI: Eye Examinations
1330-1440 SESSION IV: Overview of DEC Proc.	1400-1410 BREAK	1400-1415 BREAK
1440-1450 BREAK	1410-1430 SESSION VII: (cont)	1415-1700 SESSION XII: Alcohol Workshop
1450-1550 SESSION IV: (cont)	1430-1515 SESSION VIII: Demo's of the Eval.Seq.	
1550-1600 BREAK	1515-1530 BREAK	
1600-1630 SESSION IV: (cont)	1530-1605 SESSION VIII: (cont)	
1630-1730 SESSION V: Eye Examinations	1605-1635 QUIZ NUMBER ONE	

THE DRE SCHOOL - SCHEDULE (page 2)

MONDAY	TUESDAY	WEDNESDAY	THURSDAY
0800-0830 SESSION XIII: PDR & Other References	0800-0820 QUIZ NUMBER TWO	0800-0930 SESSION XXIV: Drug Combinations	0800-1000 FINAL EXAM
0830-0915 SESSION XIV: Hallucinogens	0820-0850 SESSION XVII: (cont.)	1005-1050 SESSION XXV: Practice Test Interp.	1000-1015 BREAK
0915-0930 BREAK	0850-0900 BREAK	1050-1100 BREAK	1015-1200 SESSION XXIX: Classifying a Suspect-Role Play
0930-1030 SESSION XIV: (cont.)	0900-0945 SESSION XVIII: Practice Test Interp.	1100-1150 SESSION XXVI: Narrative Report	1200-1300 LUNCH
1030-1045 BREAK	0945-1020 SESSION XIX: Inhalants	1150-1210 QUIZ NUMBER FOUR	1300-1600 ADMINISTRATION OF THE TEST VALIDATION
1045-1130 SESSION XV: Test Interpretation	1020-1030 BREAK	1210-1310 LUNCH	1600-1630 SESSION XXX: Transition to Certification Training
1130-1200 SESSION XVI: Dissociative Anesthetics	1030-1130 SESSION XIX: (cont.)	1310-1440 SESSION XXVII: Practice Test Administration	1630-1700 Course Critique; Closing Remarks and Certificates
1200-1300 LUNCH	1130-1145 BREAK	1440-1450 BREAK	
1300-1410 SESSION XVI: (cont.)	1145-1300 SESSION XX: Vital Signs & Exams	1450-1535 SESSION XXVIII: Case Preparation and Testimony	
1410-1420 BREAK	1300-1400 LUNCH	1535-1545 BREAK	
1420-1515 SESSION XVII: Narcotics	1400-1530 SESSION XXI: Cannabis	1545-1630 SESSION XXVIII: (cont.)	
1515-1530 BREAK	1530-1540 BREAK	1630-1700 QUIZ NUMBER FIVE	
1530-1630 SESSION XVII: (cont.)	1540-1640 SESSION XXII: Overview of Signs & Symptoms	1700-1800 BREAK	
1630-1730 SESSION XVII: (cont.)	1640-1650 BREAK	1800-2000 OPTIONAL REVIEW - SESSION #2	
1730-1800 BREAK	1650-1730 SESSION XXIII: C.V. Preparation & Maintenance		
1800-2030 OPTIONAL REVIEW - SESSION #1	1730-1800 QUIZ NUMBER THREE		

ALTERNATE SCHEDULE #1: COMBINED PRE-SCHOOL AND 7-DAY SCHOOL

Time	Session Title	D - 7-day DRE School P - Pre-School	Duration
8:00A - 10:00A	Introduction and Overview	D	2hrs
10:00A - 11:00A	Drugs and Society	D	1hr
11:00A - 12:00P	Development and Effectiveness	D	1hr
12:00P - 1:00P	Lunch		1hr
1:00P - 3:30P	Overview of DRE Classification Procedures	D	2.5hrs
3:30P - 5:00P	Psychophysical Tests	P	1.5hrs
END OF DAY			
8:00A - 11:00A	Eye Examinations	D	3hrs
11:00A - 12:00P	Vital Signs	D	1hr
12:00P - 1:00P	Lunch		1hr
1:00P - 2:30P	Vital Signs (cont.)	D	1.5hrs
2:30P - 4:00P	Overview of Signs and Symptoms	P	1.5hrs
4:00P - 5:00P	Alcohol as a Drug	P	1hr
END OF DAY			
8:00A - 9:30A	Demonstration of the Evaluation Sequence	D	1.5hrs
9:30A - 12:00P	Physiology of Drugs	D	2.5hrs
12:00P - 1:00P	Lunch		1hr
1:00P - 2:30P	Central Nervous System Depressants	D	1.5hrs
2:30P - 5:00P	Alcohol Workshop All Instructors	P	2.5hrs
END OF DAY			

Time	Session Title	D - 7-day DRE School P - Pre-School	Duration
8:00A - 9:00A	Central Nervous System Depressants (cont.)	D	1hr
9:00A - 11:30A	Central Nervous System Stimulants	D	2.5hrs
11:30A - 12:00P	Quiz Number One	D	.5hr
12:00P - 1:00P	Lunch		1hr
1:00P - 2:00P	Eye Examinations	D	1hr
2:00P - 2:30P	PDR and Other Drug References	D	.5hr
2:30P - 5:00P	Review and Pre-School Final Examination	P	2.5hrs
END OF DAY			
8:00A - 10:00A	Hallucinogens	D	2hrs
10:00A - 11:00A	Practice Test Interpretation	D	1hr
11:00A - 12:00P	Dissociative Anesthetics	D	1hr
12:00P - 1:00P	Lunch		1hr
1:00P - 2:00P	Dissociative Anesthetics (cont.)	D	1hr
2:00P - 4:00P	Mid-Course ReviewAll Instructors	D	2hrs
END OF DAY			
8:00A - 11:00A	Narcotic Analgesics	D	3hrs
11:00A - 12:00P	Practice Test Interpretation	D	1hr
12:00P - 1:00P	Lunch		1hr

1:00P - 2:00P	Inhalants	D	1hr
2:00P - 3:00P	Practice Vital Signs All Instructors	D	1hr
3:00P - 4:00P	Quiz Number Two	D	.5hr
END OF DAY			
Time	Session Title	D - 7-day DRE School P - Pre-School	Duration
8:00A - 11:00A	Cannabis	D	3hrs
11:00A - 12:00P	Overview of Signs and Symptoms	D	1hr
12:00P - 1:00P	Lunch		1hr
1:00P - 2:00P	Curriculum Vitae		1hr
2:00P - 3:00P	Drug Combinations	D	1hr
3:00P - 3:30P	Quiz Number Three	D	.5hr
3:30P - 5:00P	Alcohol Workshop All Instructors	D	2.5hrs
END OF DAY			
8:00A - 9:00A	Drug Combinations	D	1hr
9:00A - 10:00A	Practice Test Interpretation	D	1hr
10:00A - 11:00A	Preparing the Narrative Report	D	1hr
11:00A - 12:00P	Practice Test Administration All Instructors	D	1hr
12:00P - 1:00P	Lunch		1hr

1:00P - 2:30P	Case Preparation and Testimony	D	1.5hrs
2:30P - 3:00P	Quiz Number Four	D	.5hr
3:00P - 5:00P	Final Course Review All Instructors	D	2hrs
END OF DAY			
8:00A - 11:00A	Final Examination All Instructors	D	3hrs
11:00A - 12:00P	Transition to Certification Training	D	1hr
12:00P - 1:00P	Lunch		1hr
1:00P - 3:00P	Classifying a Suspect (Role Play) All Instructors	D	2hrs
3:00P - 4:00P	Graduation		2hrs

**ALTERNATE SCHEDULE #2
COMBINED DWI DETECTION AND STANDARDIZED FIELD SOBRIETY, PRE-
SCHOOL AND 7-DAY SCHOOL**

WEEK ONE Day One	DURATION
Block 1 - <i>Introduction and Overview</i> (merger of DWI Detection and SFST manual session I and the DRE manual session I) <i>SFST and DRE School Pre-tests</i>	2hrs
Block 2 - <i>Definition of drug and overview of the drug categories</i> (modified Pre-School session I, Introduction and Overview)	1hr
Block 3 - <i>Detection and Deterrence</i> (SFST manual session II)	1hr
Block 4 - <i>The Legal Environment</i> (SFST manual session III)	45min
Block 5 - <i>Overview of Detection, Note-taking and Testimony</i> (SFST manual session IV)	45min
Block 6 - <i>Phase One: Vehicle in Motion</i> (SFST manual session V)	1hr
Block 7 - <i>Phase Two: Personal Contact</i> (SFST manual session VI)	1hr
Block 8 - Phase Three: Pre-Arrest Screening (SFST manual session VII)	30min
DAY TWO	DURATION
Block 9 - <i>Concepts and Principles of the SFST</i> (SFST manual session VIII, segments A (development and validity) and B (types of nystagmus))	1hr
Block 10 - <i>Eye examinations</i> (Pre-School manual session IV, segments A (purposes of the eye examinations) and B 1, 2 and 3 (procedures and clues for HGN, VGN, and Lack of Convergence))	1hr
Block 11 - <i>Psychophysical Tests</i> (Pre-School manual session III, segments A and B, Modified Romberg and Walk and Turn)	1hr
Block 12 - <i>Psychophysical Tests</i> (Pre-School manual session III, segments C and D, One Leg Stand and Finger to Nose)	1hr
Block 13 - <i>SFST Battery Demonstrations</i> (SFST manual session IX, plus Modified Romberg and Finger to Nose, utilizing the DRE order)	1hr
Block 14 - <i>SFST Dry Run Practice</i> (SFST manual session X, plus	1hr

Modified Romberg and Finger to Nose, in the DRE order)	
Block 15 - <i>Alcohol Correlation Study #1</i> (merger of SFST manual session XI and Pre-School manual session V)	2hrs
DAY THREE	DURATION
Block 16 - <i>Alcohol as a Drug</i> (Pre-School manual session VIII)	2hrs
Block 17 - <i>Overview of Signs and Symptoms</i> (Pre-School manual session VII)	1hr
Block 18 - <i>Eye Examinations</i> (Pre-School manual session IV, beginning with B4 (estimation of pupil size) through 5 (reaction to light)).	1hr
Block 19 - <i>Drugs in Society and in Motor Vehicle Operation</i> (DRE manual session II)	1hr
Block 20 - <i>Development and Effectiveness</i> (DRE manual session III)	2hrs
Block 21 - <i>Review Session - SFST curriculum</i>	1hr
DAY FOUR	DURATION
Block 22 - <i>SFST Course Final Examination</i> (SFST manual session X)	30min
Block 23 - <i>Eye Examinations - Practice Session</i> (merger of the practice sessions in DRE manual session XI and Pre-School manual session IV)	30min
Block 24 - <i>Examination of Vital Signs</i> (merger of Pre-School manual session VI and DRE manual session VII)	3hrs
Block 25 - <i>Overview of Drug Evaluation and Classification Procedures</i> (merger of Pre-School manual session II and DRE manual session IV)	1hr
Block 26 - <i>Demonstrations of the Evaluation Sequence</i> (DRE manual session VIII)	2hrs
Block 27 - <i>Review Session - Pre-School Curriculum</i>	1hr
DAY FIVE	DURATION
Block 28 - <i>Pre-School Final Examination</i> (Pre-School manual session X)	30min
Block 29 - <i>Physiology and Drugs: An Overview</i>	4hrs
Block 30 - <i>SFST Report Writing</i> (SFST manual session XIII and SFST practice session)	1hr, 30min

Block 31 - <i>Alcohol Correlation Study #2</i> (merger of Pre-School manual session V and SFST manual session XIV; includes SFST Proficiency Test)	2hrs
WEEK TWO DAY SIX	DURATION
<i>Quiz #1</i>	30min
Block 32 - <i>Physician's Desk Reference, CPS and Additional Resources</i> (DRE manual session XIII)	2hrs
Block 33 - <i>Methods of Administration and Elimination</i> (Note: This is not a current standard manual session, but is an LAPD curriculum addition)	30min
Block 34 - <i>Central Nervous System Depressants</i> (DRE manual session IX)	2hrs
Block 35 - <i>Central Nervous System Stimulants</i> (DRE manual session X)	3hrs
DAY SEVEN	DURATION
<i>Quiz #2</i>	30min
Block 36 - <i>Hallucinogens</i> (DRE manual session XIV)	2hrs
Block 37 - <i>Practice: Test Interpretation</i> (DRE manual session XV)	1hr
Block 38 - <i>Dissociative Anesthetics</i> - (DRE manual session XVI)	2hrs
Block 39 - <i>Narcotic Analgesics</i> (DRE manual session XVII, including examination of injection marks)	2hrs, 30min
DAY EIGHT	DURATION
<i>Quiz #3</i>	30min
Block 40 - <i>Inhalants</i> (DRE manual session XIX)	1hr, 30min
Block 41 - <i>Practice: Test Interpretation</i> (DRE manual session XVIII)	1hr
Block 42 - <i>Cannabis</i> (DRE manual session XXI)	2hrs
Block 43 - <i>C.V. Preparation and Maintenance</i> (DRE manual session XXIII)	1hr
Block 44 - <i>Practice: Vital Signs</i> (DRE session XX)	30min
Block 45 - <i>Alcohol Correlation Study #3</i> (DRE manual session XII)	1hr, 30min

DAY NINE	DURATION
Quiz #4	30min
Block 46 - Overview of Signs and Symptoms (DRE manual session XXII)	1hr
Block 47 - Drug Combinations (DRE manual session XXIV)	2hrs
Block 48 - Practice Session: Eye Examinations (Note: Students practice the pupil size examinations in this segment. There is no standard lesson plan for this segment.)	1hr
DAY NINE (cont.)	DURATION
Block 49 - <i>Practice: Test Interpretation</i> (DRE manual session XXV)	1hr
Block 50 - <i>Practice: Test Administration</i> (DRE manual session XXVII)	30min
Block 51 - <i>Review of the DRE School</i> <i>Quiz #5 is also incorporated into this session.</i>	2hrs
DAY TEN	DURATION
Block 52 - <i>DRE School Final Examination</i> (DRE manual session XXX)	1hr
Block 53 - <i>Preparing the Narrative Report</i> (DRE manual session XXVI)	1hr
Block 54 - <i>Case Preparation and Testimony</i> (DRE manual session XXVIII)	1hr
Block 55 - <i>Classifying a Suspect (Role Plays)</i> (DRE manual session XXIX)	3hrs
Block 56 - <i>Transition to Certification Phase of Training</i> (DRE manual session XXX)	1hr
Block 57 - <i>Graduation - Presentation of Certificates and Achievement Awards</i> (Note: Course critiques are finished during this segment.)	1hr

**ALTERNATE SCHEDULE #3
ACCELERATED DRE SCHOOL**

Week One					
<u>Day</u>	<u>Time</u>	<u>Manual</u>	<u>Session/Segment</u>	<u>Title</u>	
Monday	(1) 1000 to 1200	SFST DRE	Session I Session I	<i>Introduction & Overview (SFST Script and Matrix Handouts); student/instructor introductions</i>	
	1200 to 1300			<i>SFST & DRE Pre-tests</i>	
	(2) 1300 to 1400	Pre-School	Session I	<i>Introduction</i>	
	1400 to 1500			Lunch Break	
	(3) 1500 to 1545	SFST	Session II	<i>Detection and Deterrence</i>	
	(4) 1545 to 1630	SFST	Session III	<i>The Legal Environment</i>	
	(5) 1630 to 1730	SFST	Session IV	<i>Overview of Detection, Note-taking & Testimony</i>	
	(6) 1730 to 1815	SFST	Session V	<i>Phase One: Vehicle in Motion & Explanation of Divided Attention Impairment</i>	
	(7) 1815 to 1900	SFST	Session VI	<i>Phase Two: Personal Contact</i>	
	Tuesday	(8) 1200 to 1230	SFST	Session VII	<i>Phase Three: Pre-Arrest Screening (modified PBT Session)</i>
		(9) 1230 to 1330	SFST	Session VIII/A, B	<i>Concepts and Principles of the SFST (development and types of nystagmus)</i>
(10) 1330 to 1400		Pre-School	Session IV/A & B, 1, 2, & 3	<i>Eye Exams (Purpose of Eye examinations, procedures and clues for HGN, VGN and LOC)</i>	
(11) 1400 to 1500		Pre-School	Session III/A & B	<i>Modified Romberg & Walk and Turn</i>	

	(12) 1500 to 1600	Pre-School	Session III/C&D	<i>One Leg Stand & Finger to Nose</i>
	1600 to 1700			Lunch Break
	(13) 1700 to 1800	SFST	Session IX	<i>SFST Test Battery Demonstrations</i> (includes Modified Romberg, Finger to Nose in DRE order)
	(14) 1800 to 1900	SFST	Session X	<i>SFST "Dry Run" Practice</i> (includes Modified Romberg, Finger to Nose, in DRE order)
	(15) 1900 to 2100	SFST Pre-School	Session IX Session V	<i>Alcohol Correlation Study #1</i> - coordinator; wrap-up; bartender; log; vitals
Wednesday	(16) 1000 to 1200	Pre-School	Session VIII	<i>Alcohol as a Drug</i> (Magic Mountain DVD alcohol driving study)
	(17) 1200 to 1300	Pre-School	Session VII	<i>Overview of Signs and Symptoms</i> (distribution of blank drug matrix)
	(18) 1300 to 1400	Pre-School	Session IV/B4, 5	<i>Eye Exams</i> (pupil size & reaction to light)
	1400 to 1500			Lunch Break
	(19) 1500 to 1600	DRE	Session II	<i>Drugs in Society and Motor Vehicle Operation</i>
	(20) 1600 to 1800	DRE	Session III	<i>Development and Effectiveness</i>
	(21) 1800 to 1900			<i>SFST Review Session</i>
Thursday	(22) 1000 to 1030	SFST	Session X	<i>Final Examination</i>
	(23) 1030 to 1100	DRE Pre-School	Session XI Session IV	<i>Eye Exams: Practice Session</i>
	(24) 1100 to 1300	Pre-School DRE	Session VI Session VII	<i>Examination of Vital Signs</i>
	1300 to 1400			<i>Vital Signs: Practice</i>
	1400 to 1500			Lunch Break

	(25) 1500 to 1600	Pre-School DRE	Session II Session IV	<i>Overview: Drug Evaluation and Classification Process (LETN & Chevron)</i>
	(26) 1600 to 1800	DRE	Session VIII	<i>Demonstrations of the Evaluation Sequence</i>
	(27) 1800 to 1900			<i>Pre-School Review Session</i>
Friday	(28) 1200 to 1230	Pre-School	Session X	<i>Final Examination</i>
	(29) 1230 to 1530	DRE	Session VI	<i>Physiology and Drugs: An Overview</i>
	1530 to 1630			Lunch Break
	1630 to 1730			<i>Physiology and Drugs: Physiological Pursuit</i>
	(30) 1730 to 1800	SFST	Session XIII	<i>Report Writing</i>
	1800 to 1900			<i>SFST Practice</i>
	(31) 1900 to 2100	Pre-School SFST	Session V Session XIV	<i>Alcohol Correlation Study #2 & SFST Proficiency Test - coordinator; wrap-up; log; vitals; bartender</i>
Week Two				
<u>Day</u>	<u>Time</u>	<u>Manual</u>	<u>Session/Segment</u>	<u>Title</u>
Monday	1000 to 1030			<i>DRE Quiz #1</i>
	(32) 1030 to 1230	DRE	Session XIII	<i>Physician's Desk Reference & Additional Resources</i>
	(33) 1230 to 1330	non-manual session		<i>Methods of Administration & Elimination</i>
	(34) 1330 to 1400	DRE	Session IX	<i>CNS Depressants</i>
	1400 to 1500			Lunch Break
	1500 to 1630	DRE	Session IX	<i>continued</i>
	(35) 1630 to 1900	DRE	Session X	<i>CNS Stimulants</i>

Tuesday	1000 to 1030			<i>DRE Quiz #2</i>
	1030 to 1130	DRE	Session X/E	<i>continued</i>
	(36) 1130 to 1230	DRE	Session XIV	<i>Hallucinogens</i>
	1230 to 1300	DRE	Session XIV	<i>continued</i>
	(37) 1300 to 1400	DRE	Session XV	<i>Practice: Test Interpretation (includes Clinton Williams evaluation)</i>
	1400 to 1500			Lunch Break
	(38) 1500 to 1600	DRE	Session XVI	<i>Dissociative Anesthetics</i>
	1600 to 1700	DRE	Session XVI/E	<i>continued</i>
	(39) 1700 to 1900	DRE	Session XVII/ includes E	<i>Narcotic Analgesics</i>
Wednesday	1200 to 1230			<i>DRE Quiz #3</i>
	1230 to 1330	DRE	Session XVII	<i>Injection Marks Examination</i>
	(40) 1330 to 1430	DRE	Session XIX	<i>Inhalants</i>
	(41) 1430 to 1530	DRE	Session XVIII	<i>Practice: Test Interpretation</i>
	(42) 1530 to 1700	DRE	Session XXII	<i>Cannabis</i>
	1700 to 1800			Lunch Break
	(43) 1800 to 1900	DRE	Session XXIII	<i>C.V. Preparation & Maintenance</i>
	(44) 1900 to 1930	DRE	Session XX	<i>Practice: Vital Signs</i>
	(45) 1930 to 2100	DRE	Session XII	<i>Alcohol Correlation Study #3 - coordinator; wrap-up; vitals; bartender; log</i>
Thursday	1000 to 1030			<i>DRE Quiz #4</i>
	(46) 1030 to 1130	DRE	Session XXII	<i>Overview of Signs & Symptoms</i>
	(47) 1130 to 1330	DRE	Session XXIV	<i>Drug Combinations</i>
		non-		<i>Practice: Eye</i>

	(48) 1330 to 1430	manual session			E x a m s
	1430 to 1530				Lunch Break
	(49) 1530 to 1630	DRE	Session XXV		<i>Practice: Test Interpretation</i>
	(50) 1630 to 1700	DRE	Session XXVII		<i>Practice: Test Administration</i>
	(51) 1700 to 1900				<i>DRE Full Course Review "Your Brain on DRE" DRE Quiz #5</i>
Friday	(52) 1000 to 1100				<i>Final Examination: DRE School</i>
	(53) 1100 to 1200	DRE	Session XXVI		<i>Preparing the Narrative Report</i>
	(54) 1200 to 1300	DRE	Session XXVIII		<i>Case Preparation & Testimony</i>
	1300 to 1400				Lunch Break
	(55) 1400 to 1700	DRE	Session XXIX		<i>Classifying a Suspect: Role Plays - coordinator</i>
	(56) 1700 to 1800	DRE	Session XXX		<i>Transition to the Certification Phase of Training</i>
	(57) 1800 to 1900				<i>Graduation: Presentation of Certificates and Achievement Awards</i>

C. Overview of the Curriculum Package

In addition to this Administrator's Guide, the curriculum package for the classroom training program in DEC Program training consists of the following documents and materials:

- o Instructor's Guide
- o Audio-Visual Aids
- o Participant's Manual
- o Set of Drug Evaluation Exemplars

1. Instructor's Guide

The Instructor's Guide is a complete and detailed blueprint of what the course covers and of how it is to be taught. It is organized into thirty-two modules, with each module corresponding to one of the training sessions.

Each module consists of a cover page, an outline page and the lesson plans themselves.

The cover page presents the module's (or session's) title and the estimated instructional time required to complete the module.

The outline page lists the specific performance objectives of the module, i.e., the capabilities that the participants will achieve once they have successfully completed the module. The outline page also lists the module's major content segments and the major types of learning activities that are employed during the module.

The lesson plans themselves are arranged in a standard, content/instructional notes format. The "content" of each page outlines what is to be taught. This content includes:

- o facts
- o concepts
- o procedural steps
- o rules and regulations
- o etc.

The "Instructional Notes" on each page are listed in bold italicized print and serve as reminders of important information the instructor should elicit during the training and relate to the students. These notes define how the instructor is to present the material and involve the students in the presentation and ensure that they understand and assimilate the material.

Typical "Instructional Notes" include:

- o the approximate amount of time to be devoted to each major content segment
- o indications of what visual aids are to be used and when they are to be used
- o questions to be posed to students to involve them actively in the presentation
- o indications of points requiring special emphasis
- o guidelines for conducting particular demonstrations to clarify how drug examinations are to be performed
- o specifications of group exercises and other methods of involving students more actively in the lesson

The Instructor's Guide serves, first, as a means of preparing the instructor to teach the course. He or she should review the entire guide become familiar with the content and develop a clear understanding of how the course "fits together". He or she is also expected to become thoroughly familiar with each Session that he or she is assigned to teach, to prepare the visual aids, to assemble all "props" and other instructional equipment referenced in the lesson plans, and to augment the "instructional notes" as necessary to ensure that his or her own teaching style is applied to the content.

Subsequently, the Instructor's Guide serves as an in-class reference document for the instructor, to help him or her maintain the sequence and pace of presentations and other learning activities.

It is worth emphasizing that the Instructor's Guide does not contain the text of a speech. Although its content information is fairly well detailed and comprehensive, it is not to be read verbatim to the participants. This training program is intended to be a dynamic, highly interactive learning experience in which the students are active participants. It should not be permitted to degenerate into a series of mere lectures.

2. Audio-Visual Aids

Four types of audio-visuals are used in this course:

- o wall charts
- o dry-erase board/flip-chart presentations

- o "visuals" (PowerPoint)
- o DVDs

The wall charts are permanently-displayed items or information, intended to depict major themes and segments of the training. The wall charts should be handmade, using colored marker pens, on flip chart sheets. The text must be large enough so that they may be viewed from any seat in the classroom.

Wall charts should be placed high on the far left and right sides of the classroom's front wall, or on the side walls, where they will be visible without distracting from the screen or dry-erase board. The dry-erase board/flip chart presentations, as recommended in the lesson plans, are self-explanatory.

The "visuals" (PowerPoint slides) are simple displays of graphic and/or narrative material that emphasize key points and support the instructor's presentation. Each "visual" is numbered to indicate the session to which it belongs and its sequence within that session. For example, Visual VII-3 would be the third slide used in Session VII.

The DVDs consist of a number of segments that demonstrate the Drug Evaluation and Classification procedures, and that exhibit the kinds of evidence associated with various categories of drugs. These segments feature persons who are actually under the influence of various drugs.

3. Participant's Manual

The Participant's Manual is the basic textbook and study source for the course. It provides a session-by-session summary of the subject matter, and a list of study topics to help the students assimilate the material.

During the course, the Participant's Manual will be primarily useful for previewing the sessions, and for studying the subject matter in preparation for the final knowledge and proficiency examinations. After the classroom training is completed, the student will find that the manual is a useful reference document, especially during the Certification Phase of training.

Students are expected to be familiar with all of the contents of their Student Manual. Instructors must encourage the students to study the manual carefully as they progress through the school. Note: Students are expected to be able to answer the "topics for study" review questions that appear at the end of various sections of their Student Manual.

4. Set of Drug Evaluation Exemplars

The exemplars are the documented results of simulated drug evaluation and classification examinations. A standardized reporting form is used for the exemplars. This is the same form that the students use as a test recording instrument when they practice administering and documenting the drug evaluation and classification examination.

The exemplars support learning activities that take place during eleven sessions:

- o Sessions IX, X, XIV, XVI, XVII, XIX, and XXI cover the seven individual drug categories. Several exemplars have been prepared for each session, to illustrate the kinds of clues that can be expected when the examination is conducted for a person under the influence of that category. For example, the exemplars designed for Session IX illustrate the results of typical examinations of persons under the influence of CNS depressants. These exemplars will be found in the Instructor's Guide and the Participant's Manual.
- o Session XV, XVIII and XXV are "Test Interpretation Practice" sessions. Students work in small groups, reviewing exemplars and determining, from the documented "evidence" they contain, what category or categories of drugs are present in each case. These exemplars also will be found in the Participant's Manual.
- o Session XXIX is the "role play" practice session. Instructors serve as "test subjects". Students work in small groups, administering the entire drug influence evaluation to each instructor. Each instructor uses an exemplar to inform the students as to what data they should record at each stage of the evaluation. For example, as part of the evaluation, the students will actually measure blood pressure. The instructor will observe the students' technique and offer constructive criticism. The instructor will inquire as to the pressure readings that the students obtain. But, the instructor will tell the students to record the blood pressure readings documented on his or her assigned exemplar. Subsequently, the students must review their completed exemplars and determine what category or categories of drugs the instructor was "simulating". These exemplars are found at the end of the lesson plans for Session XXIX.

D. General Administrative Requirements

1. Facility Requirements

Several types of facilities are needed to support this training. First, a standard classroom is required. This should provide comfortable seating and adequate desk/table space for each student, and should be equipped with a large screen, projectors, dry-erase boards and/or flip-charts and DVD players and monitors. All visuals should be readily and fully visible from all seating locations. The classroom should also provide adequate unobstructed space to allow the instructors to demonstrate examination procedures. A "U"-shaped seating arrangement is preferable for the classroom.

A large, open area also is needed to support the hands-on practice sessions. A gymnasium or similar facility will serve this need very well. Ideally, it should be possible to control the lighting in this practice facility to the point of total darkness, to demonstrate and practice key elements of the drug evaluation and classification procedures that take place in a darkroom.

A separate room must be available, ideally adjacent to the gymnasium or practice facility. This room will serve as the "staging area" for the volunteer drinkers who will participate in the alcohol workshop (Session XII).

Another separate room is recommended to serve as the instructors' "office", i.e., the place where they can prepare for their teaching assignments, store materials, etc.

2. Special Instructional Equipment and Personnel

For the alcohol workshop, volunteer drinkers must be available. The volunteer drinkers cannot be members of the class. There should be one volunteer for every three or four students. For example, if there are 25 students in the class, there should be 7-9 volunteer drinkers. Sufficient alcohol, mixers, cups, napkins, ice, etc. must be provided. Adequate breath testing devices must be available to provide for monitoring volunteers' blood alcohol concentrations. At least three people must be assigned to monitor and escort the volunteers; ideally, each volunteer should have his or her own monitor.

Note: Every volunteer must read and sign the "Statement of Informed Consent" prior to receiving any alcohol. Any person who refuses to sign the Statement cannot serve as a volunteer drinker.

For the hands-on practice sessions involving eye examinations, at least one pupillometer and one onset angle template should be provided for every two students. Ideally, each student should have his or her own pupillometer and template. The pupillometer should be capable of measuring pupil diameters across the range from 1.0 mm to 9.5 mm, in one-half millimeter increments. The template should display angles between 30 and 50 degrees, in 5 degree increments.

For the hands-on practice sessions involving vital signs examinations, a sphygmomanometer and stethoscope must be provided for every three students. Ideally, each student should have his or her own. Also, it is desirable that several training stethoscopes be available. These are stethoscopes that have two sets of earpieces, and allow an instructor to monitor exactly what the student is hearing.

Each student should be provided with a penlight suitable for conducting the various eye examinations.

At the beginning of DRE training, it is essential that every student have his or her own full complement of DRE equipment. In addition, every student must have access to a PDR, and ideally should own a PDR.

3. Instructor Qualifications

The principal instructors for this course must be IACP-credentialed Drug Recognition Expert Instructors. That means that they (1) hold currently-valid certificates as DREs; (2) have completed the IACP/NHTSA DRE Instructor Training Course; and, (3) have completed the required delivery of both classroom and certification training, under the supervision of teacher-trainers. Only a certified DRE instructor can credibly teach:

- o Session IV (Overview of Drug Evaluation and Classification Procedures)
- o Session V (Eye Examinations)
- o Session VIII (Demonstrations of the Evaluation Sequence)
- o The segment entitled "Expected Results of the Evaluation" in Sessions IX, X, XIV, XVI, XVII, XIX XXI and XXIV (The sessions covering individual drug categories and combinations of categories)
- o The hands-on practice sessions (Sessions XI, XX, XVIII and XXIX)
- o The Test Interpretation Practice Sessions (Sessions XV, XVII and XXV)
- o Session XXVI (Narrative Drug Report)
- o Session XXIII (C.V. Preparation and Maintenance)

The above-listed sessions and segments constitute approximately 75% of the course.

A qualified DRE could instruct the remaining 25% of the course, as well. However, some agencies may wish to enlist instructors with special credentials for certain blocks of instruction. For example, a physician would be well qualified to teach Session VII (Examination of Vital Signs), and a prosecutor might be a good choice as the instructor for Session XXVIII (Case Preparation and Testimony), and for Session XXVI (Preparing the Narrative Report).

In addition to their occupational competencies, all instructors must be qualified teachers. They need to understand, and be able to apply, fundamental principles of instruction. Perhaps most importantly, they need to be competent coaches. Much of this classroom training is devoted to hands-on practice. The quality of coaching will have a major impact on the success of those practice sessions. It is highly recommended that every instructor be a graduate of the IACP/NHTSA DRE Instructor Training School.

For the hands-on practice sessions, there should be at least one instructor for every three students, to permit adequate monitoring and coaching.

4. Class Size Considerations

The recommended maximum class size for this course is 25 students. Larger classes make it difficult to devote sufficient attention to each student to ensure that he or she develops examination skills to a level sufficient to progress to the Certification Phase. The preferred class size is 15-20 students.

E. Course Planning and Preparation Requirements

The fundamental preparatory step for any law enforcement agency desiring this training is to ensure that the agency and its community or state satisfy the prerequisites outlined in Section B, part 1 of this Administrator's Guide.

The next step is to select a cadre of appropriate candidate DREs. Make sure that each candidate satisfies the student prerequisites outlined in Section B.

The third step is to provide preliminary training to the candidate DREs. The IACP/NHTSA has developed a curriculum to support preliminary training for potential DREs. This training enables the candidates to become familiar with, and to start to develop skills in, the vital signs examinations and other elements of the drug evaluation and classification procedures.

The next step will be to schedule the class. States with well-established DEC Programs, including a cadre of experienced DRE instructors, are expected to plan and manage their own DRE Schools. However, they may be able to receive the services of additional (in-State and out-of-State) instructors, at IACP/NHTSA's

expense. The IACP supplies manuals on-line for copying and other standard instructional materials at no charge. For States whose DEC Programs are new or developing, IACP/NHTSA assists with the planning and management of the Schools, and supplies most or all instructors.

In general, this classroom training course is conducted at facilities operated by the delivery agency or at other suitable locations. Departments are responsible for all costs associated with transporting their personnel to and from the training site, and for their lodging and subsistence during the training.

F. Examinations of Students' Knowledge and Proficiency

It is very important to test the students' knowledge and skill development. Testing in this course is conducted for two principle reasons: (1) to assess students' progress, and identify deficiencies that need correction; and, (2) as a learning activity for the students. Knowledge testing starts in the very first session of the course, when a PRE-Test is given. After the students have finished the PRE-Test, they can use it as a study guide throughout the course. Five formal quizzes also will be given. The first of these is given at the start of the third day of the school. The second quiz is given at the start of the fifth day, and the third quiz at the start of the sixth day. The fourth quiz is given at the end of the sixth day. The fifth quiz is given during the Optional Review Session that occurs during the evening of the sixth day. In addition, a self-study quiz is provided in the Participant's Manual.

The most important knowledge test, of course, is the Final Examination. It is given on the final day of the School. The student must achieve a grade of at least 80% in order to progress to certification training. If a student fails the examination, the IACP International Standards permit one additional attempt. The additional attempt must be based on an examination approved for that purpose by the IACP, and cannot occur earlier than two weeks, nor later than four weeks, following completion of the DRE School.

A skill examination also occurs during the next-to-last session of the DRE School. That is the session in which the students will examine instructors who are "playing the roles" of drug-impaired person. A Proficiency Examination Checklist (found in Session XXX of this Manual) is used to evaluate the students' performance.

G. Follow-Up Requirements

Upon completion of the classroom training, students will commence the Certification Phase, i.e., the application of drug evaluation and classification procedures in an actual enforcement context. During certification training, the students are supervised by certified DRE instructors. Under the IACP International Standards for certification, each student must participate in conducting at least 12 drug evaluations, at least six of which he or she must personally administer.

The student must also identify at least three of the seven drug categories in his or her evaluations. And, toxicologic specimens must be submitted from at least nine of the examined subjects, and analysis of those specimens must corroborate the student's opinion for at least 75% of the specimens submitted. Most importantly, the numbers and percentages cited here are minimum requirements: no student can be certified as a DRE until two instructors attest that he or she qualifies for certification.

The training delivery agency will compile the information needed to support an assessment of the classroom training each time it is conducted. This assessment will be based primarily on the (anonymous) Student's Critique Form, which appears in Session XXX of the Instructor's Lesson Plans Manual. Guidelines for preparing a post-course evaluation report based on the Student's Critique Form are covered in Section H.

H. Guidelines for Preparing Post-Course Evaluation

A standard IACP/NHTSA participant's critique form is provided to document participant's initial ratings of course content and activities. The form is divided into eight parts:

- A. Workshop/Seminar Objectives
- B. Course Activities
- C. Course Design
- D. Topic Deletions
- E. Topic Additions
- F. Ability to Identify Drug Categories
- G. Overall Quality of the Course
- H. Quality of Instruction
- I. Final Comments or Suggestions

The following instructions are provided to guide review, analysis and interpretation of participant's comments:

Section A - Workshop/Seminar Objectives

Determine raw tabulation and percentages for each objective:

- o If the "no"/"not sure" responses total 20% or more, some explanation should be provided. Assess the problem and explain or recommend changes as appropriate.

Section B - Course Activities

The rating choices are as follows:

1. Very Important
2. Somewhat Important
3. Un-Important
4. Not Sure

Analysis Procedures

Step 1: Tabulate total number of responses in each category for each activity.

Step 2: The following values should be applied:

- o +2 for each "very important"
- o 0 for each "somewhat important"
- o -2 for each "un-important"
- o -1 for each "not sure"

Step 3: Determine total number of points for each activity.

Step 4: Divide the totals by twice the number of votes (N).

Step 5: The result is the final rating.

Any rating of +.5 or higher indicated the participant's consensus was that the activity (segment) was "very important".

If the rating is below +.2, some explanation should be provided...assess the reason(s) and explain or recommend changes as appropriate.

If the rating is below 0 there is a serious problem...assess the problem(s) and explain or recommend changes as appropriate.

Section C - Course Design

Determine raw tabulation and percentage for each statement.

Some comment or explanation should be provided if the inappropriate ("agree"/"disagree") or "not sure" responses exceed 20%.

Section D & E - Topic Deletion/Additions

Prepare a summary of responses for each section. Comment as appropriate.

Section F - Ability to Identify Drug Categories

Total the numerical ratings, and divide by the number of responding participants. That gives the average rating for the section, on the scale from 1 ("very confident") to 3 ("not confident"). Comment as appropriate.

Section G - Overall Quality of the Seminar

Total the numerical ratings, and divide by the number of responding participants. That gives the average rating for the seminar, on the scale from 1 ("poor") to 5 ("excellent"). Comment as appropriate.

Section H - Quality of Instruction

For each instructor, tabulate his or her numerical ratings, and divide by the number of responding participants. Comment as appropriate.

Section I - Final Comments

Prepare a summary of responses for each section. Comment as appropriate.

NOTE: A copy of the completed post course evaluation report should be collected by the DEC Program State Coordinator or his/her designee. These reports will be used to assist in determining what revisions are needed to the course curriculum in the future when periodic course reviews are conducted by the IACP/NHTSA.

I. Requests for Information, Assistance or Materials

Departments interested in this program should contact their state's Office of Highway Safety or the individual State DEC Program Coordinator. Formal requests for this training should come from the State Highway Safety Office, and should be directed to the cognizant NHTSA Regional Office and the IACP.

Session 1 - Introduction

Drug Recognition Expert



7-Day School



Drug Recognition Expert Course

Materials needed for this session:

- ***Course Pre-tests***
- ***Participant Manuals with current course schedule***

Session 1 - Introduction

110 Minutes

Session 1

Introduction and Overview





Drug Recognition Expert Course

1-2

A. Welcoming Remarks and Goals

Welcoming Remarks

Welcome to the second phase of DRE training. The DRE training focuses on a set of examination procedures, or steps that make up the drug influence evaluation. The DRE School provides detailed explanations of the evaluation procedures; careful demonstrations of these procedures, both "live" and via video; and ample opportunities for the participants to practice administering the evaluations.

Introductions - Representatives of Host Agencies and Other Dignitaries

Dignitary introductions and their welcoming remarks must be kept brief; no more than 10 minutes can be devoted to this.

Faculty Introductions

Lead off instructors introduce the instructor faculty. State names, agency affiliations, and experience. Ask each instructor to stand as they are introduced.

Session 1 - Introduction

Housekeeping

- Paperwork
- Mandatory attendance
- Breaks
- Facility
- Interruptions
 - All electronic devices off





Drug Recognition Expert Course

1-3

B. Housekeeping

Paperwork

- ***Completion of registration forms, travel vouchers, etc.***

Attendance

Attendance is mandatory at all sessions of this school.

- ***If a Participant misses any portion of this school, he or she must make up the deficiency via after hours tutoring before beginning certification training.***

Breaks

- ***Time is allotted for breaks and reconvening.***

Facility

- ***Locations of restrooms, lunchrooms, etc.***

Interruptions

- ***No texting or email monitoring. Turn off all electronic devices.***



The term "DRE" is used to designate an individual who is specially trained to conduct evaluations of suspected drug-impaired subjects. In some agencies, the term stands for "drug recognition expert"; in others, it means "drug recognition examiners"; and in others "drug recognition evaluator".

In addition, some agencies use the terms "DRT" (for drug recognition technician) or "DRS" (drug recognition specialists). All of these are acceptable and synonymous. But for this training program, the standard term is DRE.

DRE Certification Phases

You have all completed the DRE Pre-School and we look forward to working with you to successfully complete phase two of the certification process. Upon completion of this course, you will be fully proficient in checking vital signs, conducting careful examinations of the eyes, administering divided attention tests and, in general, carrying out the procedural steps of the DRE's job.



There is one essential learning experience that this classroom training cannot provide – the opportunity to practice examining subjects who are under the influence of drugs other than alcohol. For this reason, this classroom training only constitutes Phase II in the process of developing DRE skills. Phase III of the training (which commences upon the successful completion of this course) involves hands-on practice in an actual enforcement context, i.e. examining persons who are under the influence of drugs.

Although this DRE School will not conclude with the participant's immediate certification as a DRE, successful completion of this classroom training is highly important. No one can advance to Certification Training until they demonstrate a mastery of basic knowledge of drug categories and their effects on the human mind and body, and of the basic skills in administering and interpreting the examinations in the Drug Evaluation and Classification process.

Session 1 - Introduction

Course Goal

Prevent crashes, deaths and injuries caused by drug-impaired drivers



Drug Recognition Expert Course

1-6

The ultimate goal of the Drug Evaluation and Classification (DEC) program, and of this course of instruction, is to "help you prevent crashes, deaths and injuries caused by drug-impaired drivers".

No one knows precisely how many people operate motor vehicles while under the influence of drugs, or how many crashes, deaths and injuries these people cause. But even the most conservative estimates suggest that America's drug-impaired drivers kill thousands of people each year, and seriously injure tens of thousands of others. There are numerous studies that illustrate these facts.

Session 1 - Introduction

Learning Objectives

- **State the objectives and goals of the course**
- **Outline the major course content**
- **Outline the schedule of major course activities**
- **Outline the Participant Manual content and organization**
- **Recognize course administrative matters**




Drug Recognition Expert Course 1-7

Upon successfully completing this session participants will be able to:

- State the objectives and goals of the course.
- Outline the major course content.
- Outline the schedule of major course activities.
- Outline the Participant Manual content and organization.
- Recognize course administrative matters.

During this session, participants will demonstrate current knowledge of basic concepts and terminology relevant to the Drug Evaluation and Classification Process.

CONTENT SEGMENTS

- A. Welcoming Remarks and Goals
- B. Housekeeping
- C. Participant Introductions
- D. Training Goals
- E. Training Objectives
- F. Overview of Content and Schedule
- G. Course Activities
- H. Overview of Participant Manual
- I. Glossary of Terms
- J. Course Pre-Test Administration

LEARNING ACTIVITIES

- Instructor Led Presentations
- Participant Led Presentations
- Knowledge Examination
- Reading Assignments

Session 1 - Introduction

Drugged Driving Incidence

Maryland Shock Trauma Center Study (1985-1986)

**32% of drivers treated at the Shock
Trauma Center had used marijuana
prior to their crashes**



Drug Recognition Expert Course 1-8

Maryland Shock Trauma Center study (1985 – 1986)

- 32% of drivers treated at the Shock Trauma Center had used marijuana prior to their crashes.

Session 1 - Introduction

University of Tennessee Study (1988)

40% of drivers receiving emergency treatment had used drugs prior to the crash



Drug Recognition Expert Course

1-9

University of Tennessee study (1988)

- 40% of drivers treated at Trauma Center for crash injuries had drugs other than alcohol in them.

Session 1 - Introduction

National Highway Traffic Safety Administration (NHTSA)

1992 study revealed 17.8% of 1,882 drivers involved in fatal crashes tested positive for drugs other than alcohol



Drug Recognition Expert Course

1-10

NHTSA (Terhune, Ippolito, Hendricks et al., 1992)

- 1,882 operators involved in fatal crashes from 13 locations from eight states were tested for alcohol and 43 other drugs.
- Alcohol was the most prevalent drug detected in 51.5 % of the crashes, while other drugs were involved in 17.8 % of the crashes.

Session 1 - Introduction

Washington State (2006)

Results of blood and/or urine tests from 370 fatally injured drivers revealed the following drugs:

- **Marijuana (12%)**
- **Benzodiazepines (5%)**
- **Cocaine (4.8%)**
- **Amphetamines (4.8%)**



Drug Recognition Expert Course 1-11

Washington State (Schwilke, et al., 2006)

The results of tests of blood and/or urine from 370 fatally injured drivers revealed that:

- Marijuana was the most encountered drug (12 %), followed by:
- Benzodiazepines (5 %)
- Cocaine (4.8 %)
- Amphetamines (4.8 %)

Session 1 - Introduction

Drugged Driving Incidence

- **2010: More than 19% of high school seniors admitted driving under the influence of marijuana. (SADD)**
- **2010: 10.6 million people reported driving under the influence of an illicit drug during the past year. (NSDUH)**



Drug Recognition Expert Course 1-12

Drugged Driving Incidence

- In 2010, more than 19 % of high school seniors admitted driving under the influence of marijuana.

Source: Liberty Mutual Insurance and Students Against Destructive Decisions (Liberty Mutual Insurance and SADD) Study, 2012.

- In 2010, 10.6 million people reported driving under the influence of an illicit drug during the past year.

We can do something to remove drugged drivers from our roads.

Session 1 - Introduction

DEC Program

- **Based on solid medical and scientific facts**
- **Laboratory and field research**
- **Elite international program**
- **DREs share and maintain quality**



Drug Recognition Expert Course 1-13

The Drug Evaluation and Classification Program (DECP) is based on solid medical and scientific facts.

The validity of the DECP has been tested in carefully controlled research in both the laboratory and the field.

By enrolling in Drug Recognition Expert (DRE) training, you have become part of an elite international program. DREs form one of the tightest knit fraternities in law enforcement.

DREs from many agencies and from many parts of the country work closely together to share information and other resources, and to maintain the highest standards of quality.

Each of you has been selected to receive this training because you were recognized by your department as a skilled and dedicated law enforcement professional.

Your instructors welcome you to this school and are proud to have you here, and we're sure that you are proud to be here.

Session 1 - Introduction

Participant Introductions

- Name
- Agency
- Affiliation
- Experience



Drug Recognition Expert Course

1-14

C. Participant Introductions

Whenever possible, the instructor should consider using creative and innovative icebreaking techniques.

At a minimum, instruct each participant to stand and give their name, agency affiliation and experience.

Session 1 - Introduction

Classroom Training Goals Three Fold

1. Distinguish individuals under influence of:

- **Alcohol**
- **Other drugs**
- **Combinations of alcohol and other drugs**

-or-

- **Injury and illness**



Drug Recognition Expert Course 1-15

D. Training Goals

The goals of the classroom training, from the viewpoint of the law enforcement agencies participating in it, are three fold:

1. To help police officers acquire the knowledge and skills needed to distinguish individuals under the influence of:
 - Alcohol
 - Other drugs
 - Combinations of alcohol and other drugs

-or-

 - Who are suffering from an injury or illness

Session 1 - Introduction

Classroom Training Goals (Cont.)

2. Identify broad categories of drugs inducing the observable signs of impairment manifested by an individual
3. Qualify police officers to progress to Certification Training



Drug Recognition Expert Course

1-16

2. To enable police officers to identify the broad category or categories of drugs inducing the observable signs of impairment manifested by an individual.
3. To qualify police officers to progress to Certification Training.

Session 1 - Introduction

Classroom Training Objectives

- Describe the involvement of drugs in impaired driving incidents
- Name the seven drug categories and recognize their effects
- Describe and properly conduct the drug influence evaluation



Drug Recognition Expert Course 1-17

E. Training Objectives

Refer to wall charts when previewing the content topics. Give a brief overview of the contents covered under each major topic.

When you successfully complete this school, you will be able to:

- Describe the involvement of drugs in impaired driving incidents
- Name the seven categories of drugs and recognize their effects
- Describe and properly conduct the drug influence evaluation

Session 1 - Introduction

Classroom Training Objectives (Cont.)

- **Document the results of the drug influence evaluation**
- **Properly interpret the results of the evaluation**
- **Prepare a narrative for the Drug Influence Report**



Drug Recognition Expert Course

1-18

- Document the results of the drug influence evaluation
- Properly interpret the results of the evaluation
- Prepare a narrative for the Drug Influence Report

Session 1 - Introduction

Classroom Training Objectives (Cont.)

- **Discuss appropriate procedures for testifying in typical drug evaluation and classification cases**
- **Prepare and maintain a relevant and up-to-date Curriculum Vitae (C.V.)**



Drug Recognition Expert Course 1-19

- Discuss appropriate procedures for testifying in typical drug evaluation and classification cases
- Prepare and maintain a relevant and up-to-date Curriculum Vitae (C.V.)

Before you can be certified as a DRE, you will have to demonstrate that you can do each of these things.

Session 1 - Introduction

Course Content

- **Drugs in society and vehicle operation**
- **Development and effectiveness of the Drug Evaluation and Classification Program (DECP)**
- **Overview of the DEC procedures**
- **Eye examinations**
- **Physiology and drugs**
- **Vital signs examinations**
- **The seven categories of drugs**



Drug Recognition Expert Course

1-20

F. Overview of Course Content and Schedule

The course will cover the following topics:

- Drugs in society and in vehicle operation
- Development and effectiveness of the Drug Evaluation and Classification Program (DECP)
- Overview of the DEC Procedures
- Eye Examinations (a major component of the DEC procedures)
- Physiology and Drugs
- Vital signs examinations (a major component of the DEC procedures)
- The seven categories of drugs

Session 1 - Introduction

Course Content (Cont.)

- **Physician's Desk Reference (PDR) and other reference sources**
- **Interviewing suspects**
- **Curriculum Vitae (C.V.)**
 - Preparation
 - Maintenance
- **Case preparation and testimony**
- **Classifying a suspect**
 - Interpreting and documenting examination results



Drug Recognition Expert Course

1-21

- The Physician's Desk Reference (PDR) and other reference sources
- Interviewing suspects (a major component of the DEC procedures)
- Curriculum Vitae (C.V.) preparation and maintenance
- Case preparation and testimony
- Classifying a suspect (interpreting and documenting the results of an examination)

Solicit questions concerning the course content major topics.

Session 1 - Introduction

Course Activities

- Eye examinations
- Alcohol workshop
- Interpretation of examination results
- Vital signs examinations



Drug Recognition Expert Course

1-22

G. Course Activities

Refer to the wall chart outlining practice sessions.

Hands-on practice is the principal learning activity of the course.

Eye Examinations Practice:

- Nystagmus, Lack of Convergence, Pupil Size, and Reaction to Light

Alcohol Workshop:

- Psychophysical testing practice
- Volunteer drinkers from outside the class will be recruited for this session.

Practicing interpretation of the examination results:

- Several sessions will be devoted to this allowing the participants to review drug evaluation reports and identify the probable drug category or combinations of categories.

Vital signs examinations:

- Pulse, Blood Pressure, Body Temperature

Session 1 - Introduction

Course Activities (Cont.)

- **Administration of drug influence evaluation**
- **Simulated drug impaired subject examinations**



Drug Recognition Expert Course 1-23

Practicing administration of the drug influence evaluation:

- Several sessions will be devoted to this. In each, participants will practice administering the drug influence examinations to each other. No hands-on practice with actual drugged subjects is included in the classroom portion of DRE training.

Simulated drug impaired subject examinations:

- Participants will work in teams to conduct and document examinations of instructors who will be simulating the indicators of drug-impaired subjects.

Solicit questions concerning the hands-on practice sessions.

Session 1 - Introduction

Course Schedule

Reference Your
Participant Manual



Drug Recognition Expert Course

1-24

Schedule

Refer to the wall chart outlining practice sessions.

- ***Course schedule is located in the Participant Manual.***
- ***Give a brief overview of the schedule of sessions.***

Solicit questions concerning the schedule.

Session 1 - Introduction

Participant Manual

- **Basic course reference**
- **Class notes for every session**
- **Manual organization**
- **Preview sessions in advance**
- **Review prior to exam**



Drug Recognition Expert Course

1-25

H. Overview of Participant Manual

- The Participant manual is the basic reference document for this course.
- The manual contains thumbnails of each instructor presentation per session that includes key messages for each frame.

Open the manual to Session I, and briefly review the content which illustrates how the document is organized.

- Read each session prior to each day's classes.
- Use the manual to review the material prior to taking the final exam.

Session 1 - Introduction

Criteria for Passing

- Numerous quizzes
- **Written test: Score 80% or better to progress to certification phase**

80%



Drug Recognition Expert Course

1-26

By taking good notes, and by studying the manual carefully, participants should have no trouble in passing the course.

- There will be numerous quizzes during the class.

At the conclusion of the classroom training, the Participant must pass the written test with a score of 80% or better in order to progress to the certification phase.

Session 1 - Introduction

Glossary of Terms



DRUG EVALUATION AND CLASSIFICATION PROGRAM

GLOSSARY OF TERMS

ACCOMMODATION REFLEX
The adjustment of the eyes at various distances. Meaning the pupils will automatically constrict as objects move closer.

ADDICTION
Habitual, psychological, and physiological dependence on a substance beyond one's voluntary control.

ADDITIVE EFFECT
One mechanism of polydrug interaction. For a particular indicator of impairment, two drugs produce an additive effect if they both affect the indicator in the same way. For example, cocaine elevates pulse rate and PCP also elevates pulse rate. The combination of cocaine and PCP produces an additive effect on pulse rate.

AFFERENT NERVES
See "Sensory Nerves."

ALKALOID
A chemical that is found in, and can be physically extracted from, some substance. For example, morphine is a natural alkaloid of opium. It does not require a chemical reaction to produce morphine from opium.

ANALGESIC
A drug that relieves or allays pain.




Drug Recognition Expert Course 1-27

I. Glossary of Terms

The Glossary of Terms used in the course is located in the Participant Manual.

Session 1 - Introduction

Course Pre-Test Administration

- 10 minutes
- Some questions have more than one correct answer
- Scores not entered in permanent record



Drug Recognition Expert Course

1-28

J. Course Pre-Test Administration

Instructor: Hand out pre-tests.

- ***The pre-test scores do not affect passage of this course, nor will the pre-test be a part of the participants' permanent record. Allow 10 minutes for the participants to complete, then collect the pre-tests.***
- ***A "clean" copy of the pre-test is located at the end of Session I in the Participant Manual. Use the pre-test as a study guide while progressing through the course.***

Session 1 - Introduction

QUESTIONS?



Drug Recognition Expert Course

1-29

Solicit participants' comments or questions concerning the Introduction and Overview.

DRUG EVALUATION AND CLASSIFICATION PROGRAM

GLOSSARY OF TERMS

ACCOMMODATION REFLEX

The adjustment of the eyes for viewing at various distances. Meaning the pupils will automatically constrict as objects move closer and dilate as objects move further away.

ADDICTION

Habitual, psychological, and physiological dependence on a substance beyond one's voluntary control.

ADDITIVE EFFECT

One mechanism of polydrug interaction. For a particular indicator of impairment, two drugs produce an additive effect if they both affect the indicator in the same way. For example, cocaine elevates pulse rate and PCP also elevates pulse rate. The combination of cocaine and PCP produces an additive effect on pulse rate.

AFFERENT NERVES

See: "Sensory Nerves."

ALKALOID

A chemical that is found in, and can be physically extracted from, some substance. For example, morphine is a natural alkaloid of opium. It does not require a chemical reaction to produce morphine from opium.

ANALGESIC

A drug that relieves or allays pain.

ANALOG (of a drug)

An analog of a drug is a chemical that is very similar to the drug, both in terms of molecular structure and in terms of psychoactive effects. For example, the drug Ketamine is an analog of PCP.

ANESTHETIC

A drug that produces a general or local insensibility to pain and other sensation.

ANTAGONISTIC EFFECT

One mechanism of polydrug interaction. For a particular indicator of impairment, two drugs produce an antagonistic effect if they affect the indicator in opposite ways. For example, heroin constricts pupils while cocaine dilates pupils. The combination of heroin and cocaine produces an antagonistic effect on pupil size. Depending on how much of each drug was taken, and on when they were taken, the suspect's pupils could be constricted, or dilated, or within the DRE Average range of pupil size.

ARRHYTHMIA

An abnormal heart rhythm.

DRUG EVALUATION AND CLASSIFICATION PROGRAM

ARTERY

The strong, elastic blood vessels that carry blood away the heart.

ATAXIA

A blocked ability to coordinate movements. A staggering walk and poor balance may be caused by damage to the brain or spinal cord. This can be the result of trauma, birth defect, infection, tumor, or drug use.

AUTONOMIC NERVE

A motor nerve that carries messages to the muscles and organs that we do not consciously control. There are two kinds of autonomic nerves, the sympathetic nerves and parasympathetic nerves.

AXON

The part of a neuron (nerve cell) that sends out a neurotransmitter.

BAC

(Blood Alcohol Concentration) - The percentage of alcohol in a person's blood.

BrAC

(Breath Alcohol Concentration) - The percentage of alcohol in a person's blood as measured by a breath testing device.

BLOOD PRESSURE

The force exerted by blood on the walls of the arteries. Blood pressure changes continuously, as the heart cycles between contraction and expansion.

BRADYCARDIA

Abnormally slow heart rate.

BRADYPNEA

Abnormally slow rate of breathing.

BRUXISM

Grinding the teeth. This behavior is often seen in person who are under the influence of cocaine or other CNS Stimulants.

CANNABIS

This is the drug category that includes marijuana. Marijuana comes primarily from the leaves of certain species of Cannabis plants that grow readily all over the temperate zones of the earth. Hashish is another drug in this category, and consists of the compressed leaves from female Cannabis plants. The active ingredient in both Marijuana and Hashish is a chemical called delta-9 tetrahydrocannabinol, usually abbreviated THC.

CARBOXY THC

A metabolite of THC (tetrahydrocannabinol).

CHEYNE- STOKES RESPIRATION

Abnormal pattern of breathing. Marked by breathlessness and deep, fast breathing.

DRUG EVALUATION AND CLASSIFICATION PROGRAM

CNS (Central Nervous System)

A system within the body consisting of the brain, the brain stem, and the spinal cord.

CNS DEPRESSANTS

One of the seven drug categories. CNS Depressants include alcohol, barbiturates, anti-anxiety tranquilizers, and numerous other drugs.

CNS STIMULANTS

One of the seven drug categories. CNS Stimulants include Cocaine, the Amphetamines, Ritalin, Desoxyn, and numerous other drugs.

CONJUNCTIVITIS

An inflammation of the mucous membrane that lines the inner surface of the eyelids caused by infection, allergy, or outside factors. May be bacterial or viral. Persons suffering from conjunctivitis may show symptoms in one eye only. This condition is commonly referred to as "pink eye", a condition that could be mistaken for the bloodshot eyes produced by alcohol or Cannabis.

CONVERGENCE

The "crossing" of the eyes that occurs when a person is able to focus on a stimulus as it is pushed slowly toward the bridge of their nose. (See, also, "Lack of Convergence".)

CRACK/ROCK

Cocaine base, appears as a hard chunk form resembling pebbles or small rocks. It produces a very intense, but relatively short duration "high".

CURRICULUM VITAE

A written summary of a person's education, training, experience, noteworthy achievements and other relevant information about a particular topic.

CYCLIC BEHAVIOR

A manifestation of impairment due to certain drugs, in which the suspect alternates between periods (or cycles) of intense agitation and relative calm. Cyclic behavior, for example, sometimes will be observed in persons under the influence of PCP.

DELIRIUM

A brief state characterized by incoherent excitement, confused speech, restlessness, and possible hallucinations.

DENDRITE

The part of a neuron (nerve cell) that receives a neurotransmitter.

DIACETYL MORPHINE

The chemical name for Heroin.

DIASTOLIC

The lowest value of blood pressure. The blood pressure reaches its diastolic value when the heart is fully expanded, or relaxed (Diastole).

DIPLOPIA

Double vision.

DRUG EVALUATION AND CLASSIFICATION PROGRAM

DISSOCIATIVE ANESTHETICS

One of the seven drug categories. Includes drugs that inhibits pain by cutting off or disassociating the brain's perception of pain. PCP and its analogs are considered Dissociative Anesthetics.

DIVIDED ATTENTION

Concentrating on more than one thing at a time. The four psychophysical tests used by DREs require the suspect to divide attention.

DOWNSIDE EFFECT

An effect that may occur when the body reacts to the presence of a drug by producing hormones or neurotransmitters to counteract the effects of the drug consumed.

DRUG

Any substance that, when taken into the human body, can impair the ability of the person to operate a vehicle safely.

DYSARTHIA

Slurred speech. Difficult, poorly articulated speech.

DYSPNEA

Shortness of breath.

DYSMETRIA

An abnormal condition that prevents the affected person from properly estimating distances linked to muscular movements.

DYSPHORIA

A disorder of mood. Feelings of depression and anguish.

EFFERENT NERVES

See: "Motor Nerves".

ENDOCRINE SYSTEM

The network of glands that do not have ducts and other structures. They secrete hormones into the blood stream to affect a number of functions in the body.

EXPERT WITNESS

A person skilled in some art, trade, science or profession, having knowledge of matters not within knowledge of persons of average education, learning and experience, may assist a jury in arriving at a verdict by expressing an opinion on a state of facts shown by the evidence and based upon his or her special knowledge. (NOTE: Only the court can determine whether a witness is qualified to testify as an expert.)

FLASHBACK

A vivid recollection of a portion of an hallucinogenic experience. Essentially, it is a very intense daydream. There are three types: (1) emotional -- feelings of panic, fear, etc.; (2) somatic -- altered body sensations, tremors, dizziness, etc.; and (3) perceptual -- distortions of vision, hearing, smell, etc.

DRUG EVALUATION AND CLASSIFICATION PROGRAM

GARRULITY

Chatter, rambling or pointless speech. Talkative.

GENERAL INDICATOR

Behavior or observations of the subject that are observed and not specifically tested for. (Observational and Behavioral Indicators)

HALLUCINATION

A sensory experience of something that does not exist outside the mind, e.g., seeing, hearing, smelling, or feeling something that isn't really there. Also, having a distorted sensory perception, so that things appear differently than they are.

HALLUCINOGENS

One of the seven drug categories. Hallucinogens include LSD, MDMA, Peyote, Psilocybin, and numerous other drugs.

HASHISH

A form of cannabis made from the dried and pressed resin of a marijuana plant.

HASH OIL

Sometimes referred to as "marijuana oil" it is a highly concentrated syrup-like oil extracted from marijuana. It is normally produced by soaking marijuana in a container of solvent, such as acetone or alcohol for several hours and after the solvent has evaporated, a thick syrup-like oil is produced with a high THC content.

HEROIN

A powerful and widely-abused narcotic analgesic that is chemically derived from morphine. The chemical, or generic name of heroin is "diacetyl morphine".

HIPPUS

A rhythmic change in the pupil size of the eyes, as they dilate and constrict when observed in darkness independent of changes in light intensity, accommodation (focusing), or other forms of sensory stimulation. Normally only observed with specialized equipment.

HOMEOSTASIS

The dynamic balance, or steady state, involving levels of salts, water, sugars, and other materials in the body's fluids.

HORIZONTAL GAZE NYSTAGMUS (HGN)

Involuntary jerking of the eyes occurring as the eyes gaze to the side.

HORMONES

Chemicals produced by the body's endocrine system that are carried through the blood stream to the target organ. They exert great influence on the growth and development of the individual, and that aid in the regulation of numerous body processes.

HYDROXY THC

A metabolite of THC (tetrahydrocannabinol).

DRUG EVALUATION AND CLASSIFICATION PROGRAM

HYPERFLEXIA

Exaggerated or over extended motions.

HYPERGLYCEMIA

Excess sugar in the blood.

HYPERPNEA

A deep, rapid or labored breathing.

HYPERPYREXIA

Extremely high body temperature.

HYPERREFLEXIA

A neurological condition marked by increased reflex reactions.

HYPERTENSION

Abnormally high blood pressure. Do not confuse this with hypotension.

HYPOGLYCEMIA

An abnormal decrease of blood sugar levels.

HYPOPNEA

Shallow or slow breathing.

HYPOTENSION

Abnormally low blood pressure. Do not confuse this with hypertension.

HYPOTHERMIA

Decreased body temperature.

ICE

A crystalline form of methamphetamine that produces a very intense and fairly long-lasting "high".

INHALANTS

One of the seven drug categories. The inhalants include volatile solvents (such as glue and gasoline), aerosols (such as hair spray and insecticides) and anesthetic gases (such as nitrous oxide).

INSUFFLATION

See "snorting".

INTEGUMENTARY SYSTEM

The skin and accessory structures, hair and nails. Functions include protection, maintenance of body temperature, excretion of waste, and sensory perceptions.

INTRAOCULAR

"Within the eyeball".

DRUG EVALUATION AND CLASSIFICATION PROGRAM

KOROTKOFF SOUNDS

A series of distinct sounds produced by blood passing through an artery, as the external pressure on the artery drops from the systolic value to the diastolic value.

LACK OF CONVERGENCE

The inability of a person's eyes to converge, or "cross" as the person attempts to focus on a stimulus as it is pushed slowly toward the bridge of his or her nose.

MAJOR INDICATORS

Physiological signs that are specifically assessed and are, for the most part, involuntary reflecting the status of the central nervous system (CNS) homeostasis (Physiological Indicators)

MARIJUANA

Common term for the Cannabis Sativa plant. Usually refers to the dried leaves of the plant. This is the most common form of the cannabis category.

MARINOL

A drug containing a synthetic form of THC (tetrahydrocannabinol). Marinol belongs to the cannabis category of drugs, but marinol is not produced from any species of cannabis plant.

MEDICAL RULEOUT

A determination made by a DRE that the condition of a suspected impaired driver is more likely related to a medical issue that effected the person's ability to operate a vehicle safely.

METABOLISM

The sum of all chemical processes that take place in the body as they relate to the movements of nutrients in the blood after digestion, resulting in growth, energy, release of wastes, and other body functions. The process by which the body, using oxygen, enzymes and other internal chemicals, breaks down ingested substances such as food and drugs so they may be consumed and eliminated. Metabolism takes place in two phases. The first step is the constructive phase (anabolism) where smaller molecules are converted to larger molecules. The second steps is the destructive phase (catabolism) where large molecules are broken down into smaller molecules.

METABOLITE

A chemical product, formed by the reaction of a drug with oxygen and/or other substances in the body.

MIOSIS

Abnormally small (constricted) pupils.

MOTOR NERVES

Nerves that carry messages away from the brain, to be body's muscles, tissues, and organs. Motor nerves are also known as efferent nerves.

MUSCULAR HYPERTONICITY

Rigid muscle tone.

DRUG EVALUATION AND CLASSIFICATION PROGRAM

MYDRIASIS

Abnormally large (dilated) pupils.

NARCOTIC ANALGESICS

One of the seven drug categories. Narcotic analgesics include opium, the natural alkaloids of opium (such as morphine, codeine and thebaine), the derivatives of opium (such as heroin, dilaudid, oxycodone and percodan), and the synthetic narcotics.

NERVE

A cord-like fiber that carries messages either to or from the brain. For drug evaluation and classification purposes, a nerve can be pictured as a series of "wire-like" segments, with small spaces or gaps between the segments.

NEURON

A nerve cell. The basic functional unit of a nerve. It contains a nucleus within a cell body with one or more axons and dendrites.

NEUROTRANSMITTER

Chemicals that pass from the axon of one nerve cell to the dendrite of the next cell, and that carry messages across the gap between the two nerve cells.

NULL EFFECT

One mechanism of polydrug interaction. For a particular indicator of impairment, two drugs produce a null effect if neither of them affects that indicator. For example, PCP does not affect pupil size, and alcohol does not affect pupil size. The combination of PCP and alcohol produces a null effect on pupil size.

NYSTAGMUS

An involuntary jerking of the eyes.

"ON THE NOD"

A semi-conscious state of deep relaxation. Typically induced by impairment due to Heroin or other narcotic analgesics. The suspect's eyelids droop, and chin rests on the chest. Suspect may appear to be asleep, but can be easily aroused and will respond to questions.

OVERLAPPING EFFECT

One mechanism of polydrug interaction. For a particular indicator of impairment, two drugs produce an overlapping effect if one of them affects the indicator but the other doesn't. For example, cocaine dilates pupils while alcohol doesn't affect pupil size. The combination of cocaine and alcohol produces an overlapping effect on pupil size: the combination will cause the pupils to dilate.

PALLOR

An abnormal paleness or lack of color in the skin.

PARANOIA

Mental disorder characterized delusions and the projection of personal conflicts, that are ascribed to the supposed hostility of others.

DRUG EVALUATION AND CLASSIFICATION PROGRAM

PARAPHERNALIA

Drug paraphernalia are the various kinds of tools and other equipment used to store, transport or ingest a drug. Hypodermic needles, small pipes, bent spoons, etc., are examples of drug paraphernalia. The singular form of the word is "paraphernalium". For example, one hypodermic needle would be called a "drug paraphernalium".

PARASYMPATHETIC NERVE

An autonomic nerve that commands the body to relax and to carry out tranquil activities. The brain uses parasympathetic nerves to send "at ease" commands to the muscles, tissues, and organs.

PARASYMPATHOMIMETIC DRUGS

Drugs that mimic neurotransmitter associated with the parasympathetic nerves. These drugs artificially cause the transmission of messages that produce lower blood pressure, drowsiness, etc.

PDR (Physician's Desk Reference)

A basic reference source for drug recognition experts. The PDR provides detailed information on the physical appearance and psychoactive effects of licitly-manufactured drugs.

PHENCYCLIDINE

A contraction of PHENYL CYCLOHEXYL PIPERIDINE, or PCP. Formerly used as a surgical anesthetic, however, it has no current legitimate medical use in humans.

PHENYL CYCLOHEXYL PIPERIDINE (PCP)

Often called "phencyclidine" or "PCP", it is a specific drug belonging to the Dissociative Anesthetics category.

PHYSIOLOGY

Physiology is the branch of biology dealing with the functions and activities of life or living matter and the physical and chemical phenomena involved.

PILOERECTION

Literally, "hair standing up", or goose bumps. This condition of the skin is often observed in persons who are under the influence of LSD.

POLYDRUG USE

Ingesting drugs from two or more drug categories.

PSYCHEDELIC

A mental state characterized by a profound sense of intensified or altered sensory perception sometimes accompanied by hallucinations.

PSYCHOPHYSICAL TESTS

Methods of investigating the mental (psycho-) and physical characteristics of a person suspected of alcohol or drug impairment. Most psychophysical tests employ the concept of divided attention to assess a suspect's impairment.

DRUG EVALUATION AND CLASSIFICATION PROGRAM

PSYCHOTOGENIC

Literally, "creating psychosis" or "giving birth to insanity". A drug is considered to be psychotogenic if persons who are under the influence of the drug become insane, and remain so after the drug wears off.

PSYCHOTOMIMETIC

Literally, "mimicking psychosis" or "impersonating insanity". A drug is considered to be psychotomimetic if persons who are under the influence of the drug look and act insane while they are under the influence.

PTOSIS

Droopy eyelids.

PULSE

The expansion and contraction of the walls of an artery, generated by the pumping action of blood.

PULSE RATE

The number of expansions of an artery per minute.

PUPILLARY LIGHT REFLEX

The pupils of the eyes will constrict and dilate depending on changes in lighting.

PUPILLARY UNREST

The continuous, irregular change in the size of the pupils that may be observed under room or steady light conditions.

REBOUND DILATION

A period of pupillary constriction followed by a period of pupillary dilation where the pupil steadily increases in size and does not return to its original constricted size.

RESTING NYSTAGMUS

Jerking of the eyes as they look straight ahead.

SCLERA

A dense white fibrous membrane that, with the cornea, forms the external covering of the eyeball (i.e., the white part of the eye).

SENSORY NERVES

Nerves that carry messages to the brain, from the various parts of the body, including notably the sense organs(eyes, ears, etc.). Sensory nerves are also known as afferent nerves.

SINSEMILLA

The unpollinated female cannabis plant, having a relatively high concentration of THC.

DRUG EVALUATION AND CLASSIFICATION PROGRAM

SFST

Standardized Field Sobriety Testing. There are three SFSTs, namely Horizontal Gaze Nystagmus (HGN), Walk and Turn, and One Leg Stand. Based on a series of controlled laboratory studies, scientifically validated clues of alcohol impairment have been identified for each of these three tests. They are the only Standardized Field Sobriety Tests for which validated clues have been identified.

SNORTING

One method of ingesting certain drugs. Snorting requires that the drug be in powdered form. The user rapidly draws the drug up into the nostril, usually via a paper or glass tube. Snorting is also known as insufflation.

SPHYGMOMANOMETER

A medical device used to measure blood pressure. It consists of an arm or leg cuff with an air bag attached to a tube and a bulb for pumping air into the bag, and a gauge for showing the amount of air pressure being pressed against the artery.

STETHOSCOPE

A medical instrument used, for drug evaluation and classification purposes, to listen to the sounds produced by blood passing through an artery.

SYMPATHETIC NERVE

An autonomic nerve that commands the body to react in response to excitement, stress, fear, etc. The brain uses sympathetic nerves to send "wake up calls" and "fire alarms" to the muscles, tissues and organs.

SYMPATHOMIMETIC DRUGS

Drugs that mimic the neurotransmitter associated with the sympathetic nerves. These drugs artificially cause the transmission of messages that produce elevated blood pressure, dilated pupils, etc.

SYNAPSE (or Synaptic Gap)

The gap or space between two neurons (nerve cells).

SYNESTHESIA

A sensory perception disorder, in which an input via one sense is perceived by the brain as an input via another sense. An example of this would be a person "hearing" a phone ring and "seeing" the sound as a flash of light. Synesthesia sometimes occurs with persons under the influence of hallucinogens.

SYSTOLIC

The highest value of blood pressure. The blood pressure reaches its systolic value when the heart is fully contracted (systole), and blood is sent surging into the arteries.

TACHYCARDIA

Abnormally rapid heart rate.

TACHYPNEA

Abnormally rapid rate of breathing.

DRUG EVALUATION AND CLASSIFICATION PROGRAM

THC (Tetrahydrocannabinol)

The principal psychoactive ingredient in drugs belonging to the cannabis category.

TOLERANCE

An adjustment of the drug user's body and brain to the repeated presence of the drug. As tolerance develops, the user will experience diminishing psychoactive effects from the same dose of the drug. As a result, the user typically will steadily increase the dose he or she takes, in an effort to achieve the same psychoactive effect.

TRACKS

Scar tissue usually produced by repeated injection of drugs, via hypodermic needle, along a segment of a vein.

VERTICAL GAZE NYSTAGMUS

An involuntary jerking of the eyes (up-and-down) which occurs as the eyes are held at maximum elevation. The jerking should be distinct and sustained.

VOIR DIRE

A French expression literally meaning "to see, to say." Loosely, this would be rendered in English as "To seek the truth," or "to call it as you see it." In a law or court context, one application of voir dire is to question a witness to assess his or her qualifications to be considered an expert in some matter pending before the court.

VOLUNTARY NERVE

A motor nerve that carries messages to a muscle that we consciously control.

WITHDRAWAL

This occurs in someone who is physically addicted to a drug when he or she is deprived of the drug. If the craving is sufficiently intense, the person may become extremely agitated, and even physically ill.

Session 2

Drugs in Society and in Vehicle Operation



Session 2 - Drugs in Society and in Vehicle Operation

Learning Objectives

- **Define the term “drug” in the context of this course**
- **Name the seven drug categories relevant to the DEC program**
- **State in approximate, quantitative terms the incidence of drug use among various segments of the American public**




Drug Recognition Expert Course 2-2

Briefly review the objectives, content and activities of this session.

Upon completion of this session, participants will be able to:

- Define the term “drug” in the context of this course.
- Name the seven drug categories relevant to the Drug Evaluation and Classification program.
- State in approximate, quantitative terms the incidence of drug use among various segments of the American public.

CONTENT SEGMENTS

- A. Definition and Categories of Drugs
- B. Incidence and Characteristics of Drug Use in America
- C. Incidence of Drug Impaired Driving

LEARNING ACTIVITIES

- Instructor Led Presentations
Reading Assignments

Session 2 - Drugs in Society and in Vehicle Operation

Learning Objectives (Cont.)

- **State in approximate, quantitative terms the incidence of drug involvement in motor vehicle crashes and other driving incidents**
- **Correctly answer the “topics for study” questions at the end of this session**



Drug Recognition Expert Course 2-3

- State in approximate, quantitative terms the incidence of drug involvement in motor vehicle crashes and other driving incidents.
- Correctly answer the “topics for study” questions at the end of this session.

Session 2 - Drugs in Society and in Vehicle Operation

Working Definition of “Drug”

Any substance that, when taken into the human body, can impair the ability of the person to operate a vehicle safely




Drug Recognition Expert Course 2-4

A. Definition and Categories of Drugs

Instructor, if this has been covered in the Pre-School, pose this question - “What is our working definition of the word “drug”; and proceed to number 2-5.

Pose this question to the participants.

Solicit several responses.

What do we mean by the word “drug”?

- *Medicines? Are all drugs medicines? Are all medicines drugs?*
- *Narcotics? Are all drugs Narcotics?*
- *Habit forming substances? Are all drugs habit forming? Are all habit forming substances drugs.*
- *A simple, law enforcement oriented definition.*
- *This definition is derived from the California Vehicle Code.*

“Any substance that, when taken into the human body, can impair the ability of the person to operate a vehicle safely.”

Session 2 - Drugs in Society and in Vehicle Operation

Working Definition of “Drug” (Cont.)

Any substance that, when taken into the human body, can impair the ability of the person to operate a vehicle safely



Drug Recognition Expert Course 2-5

Point out that this definition excludes many substances that physicians, chemists, etc. might consider to be “drugs,” e.g., antibiotics, Novocain, vitamins, etc. It also includes some substances that aren’t normally thought of as “drugs,” such as model airplane glue, insecticides, etc.

- Within this simple, law enforcement oriented definition, there are seven categories of drugs.
- Each category consists of substances that impair a person’s ability to drive.
- The categories differ from one another in terms of how they impair driving ability and in terms of the kinds of impairment they cause.
- Because the categories produce different types of impairment, they generate different signs and symptoms.
- With training and practice, you will be able to recognize the different signs of drug influence and determine which category is causing the impairment you observe in a subject.

Session 2 - Drugs in Society and in Vehicle Operation

Central Nervous System Depressants

Examples:

- Alcohol
- Barbiturates
- Anti-Depressants
- Anti-Anxiety
Tranquilizers





Drug Recognition Expert Course 2-6

Ask participants: “What are the seven categories of drugs?”

Write the names of the categories on the dry erase board or flip-chart as they are mentioned by the participants.

Central Nervous System Depressants

The category of CNS Depressants includes some of the most commonly abused drugs.

Point out that tens of millions of prescriptions for such drugs are written in this country each year.

Alcohol remains the most familiar drug. In 2011, 51.8 % of the population aged 12 and older were current drinkers of alcohol.

Source: National Survey on Drug Use and Health (NSDUH) 2011.

CNS Depressants:

- Slow down the operation of the Central Nervous System (i.e., the brain, brain stem and spinal cord).
- Cause the user to react more slowly.
- Cause the user to process information more slowly.
- Relieve anxiety and tension.
- Induce sedation, drowsiness and sleep.
- In high doses, CNS Depressants will produce general anesthesia. i.e., depress the brain’s ability to sense pain.
- In very high doses, induce coma and death.

Session 2 - Drugs in Society and in Vehicle Operation

Central Nervous System Stimulants

Examples:

- **Amphetamine**
- **Cocaine**
- **Methamphetamine**
- **Ritalin**







Drug Recognition Expert Course 2-7

Central Nervous System Stimulants

CNS Stimulants constitute another widely abused category of drugs.

There appears to be approximately 1.4 million Cocaine users in the U.S.

Source: NSDUH Survey, 2011.

Cocaine is one of the most frequently reported drugs in overdose cases treated at hospital emergency rooms.

Estimates of drug use vary widely, especially for illicit drugs such as Cocaine, Methamphetamines, etc.

- In 2011, 6.1 million Americans aged 12 or older admitted using psychotherapeutic drugs non-medically at least once in their lifetime.

Source: NSDUH Survey, 2011.

- In 2010, 1.1 million persons aged 12 or older reported they had used methamphetamines at least once in their lifetime.

Source: 2010 National Survey on Drug Use and Health.

Session 2 - Drugs in Society and in Vehicle Operation

Central Nervous System Stimulants (Cont.)

Examples:

- **Amphetamine**
- **Cocaine**
- **Methamphetamine**
- **Ritalin**







Drug Recognition Expert Course 2-8

CNS Stimulants:

- Speed up the operation of the Central Nervous System, and of the various bodily functions controlled by the Central Nervous System
- Cause the user to become hyperactive, extremely talkative
- Speech may become rapid and repetitive
- Heart rate increases
- Blood pressure increases
- Body temperature rises, user may become excessively sweaty
- Induce emotional excitement, restlessness, irritability
- Can induce cardiac arrhythmia (abnormal beating of the heart), cardiac seizures and death

Session 2 - Drugs in Society and in Vehicle Operation

Hallucinogens

Examples:

- LSD
- MDMA (Ecstasy)
- Peyote
- Psilocybin



The images show: 1) LSD blotter papers with various patterns and colors. 2) MDMA (Ecstasy) pills in various colors and shapes, some with markings like '888'. 3) Peyote cactus, a small, spiny cactus. 4) Psilocybin mushrooms, also known as magic mushrooms, with their characteristic gills and stems.




Drug Recognition Expert Course

2-9

Hallucinogens

Hallucinogens are also widely abused.

LSD and Peyote are only two examples of Hallucinogens. There are many other Hallucinogens.

In recent years, significant increases in the abuse of both LSD and “Ecstasy” (MDMA) have been reported.

Hallucinogens :

- Create perceptions that differ from reality. These perceptions are often very distorted, so that the user sees, hears, and smells things in a way quite different from how they really look, sound, and smell.
- Hallucinogens cause the nervous system to send strange or false signals to the brain.
- Clarification: Hallucinogens confuse the Central Nervous System (as well as speeding it up, like CNS Stimulants).
- Produce sights, sounds, odors, feelings and tastes that aren’t real.
- Induce a temporary condition very much like psychosis or insanity.
- Can create a “mixing” of sensory modalities, so that the user “hears colors,” “sees music.”

This mixing of the senses is called Synesthesia. With all of these false, and distorted perceptions, a person under the influence of hallucinogens would be a very unsafe driver.

Session 2 - Drugs in Society and in Vehicle Operation

Dissociative Anesthetics

Examples:

- **Dextromethorphan**
- **Ketamine**
- **PCP (Phenyl Cyclohexyl Piperidine)**







Drug Recognition Expert Course 2-10

Dissociative Anesthetics

This category was changed from PCP to Dissociative Anesthetics in 2005.

PCP, its analogs and Dextromethorphan are examples of Dissociative Anesthetics. PCP is considered by the medical community to be a Hallucinogen. However, because of the symptomatology it presents, it is in a separate category.

People under the influence of Dissociative Anesthetics may exhibit a combination of the signs associated with CNS Depressants, CNS Stimulants, and Hallucinogens.

- Phencyclidine is a short form of the chemical name Phenyl Cyclohexyl Piperdine, from which we get the abbreviation “PCP.”

PCP is a synthetic drug, i.e., it does not occur naturally but must be produced in a laboratory-like setting.

PCP has many analogs, or “chemical cousins” that are very similar to PCP in chemical structure, and that produce essentially the same effects.

- Analogs of PCP include Ketamine, Ketalar and Ketajet.
- PCP is also a very powerful pain killer, or anesthetic.

Session 2 - Drugs in Society and in Vehicle Operation

Dissociative Anesthetics (Cont.)

Examples:

- **Dextromethorphan**
- **Ketamine**
- **PCP (Phenyl Cyclohexyl Piperidine)**



Drug Recognition Expert Course 2-11

Point out that the reason PCP is a Dissociative Anesthetic is because it “separates” the user from any sensation of pain without making him or her unconscious.

Dextromethorphan (DXM) is found in many over-the-counter anti-tussive cold medications such as Robitussin, Coricidin Cough and Cold, and Dimetapp. DXM is typically abused by school age children, teenagers or young adults to achieve impairment.

- DXM is normally used in liquid or pill form.
- In high doses, DXM impairment is similar to the effects of PCP or Hallucinogens.

Session 2 - Drugs in Society and in Vehicle Operation

Narcotic Analgesics

Examples:

- Codeine
- Demerol
- Heroin
- Methadone
- Morphine
- OxyContin®





Drug Recognition Expert Course 2-12

Narcotic Analgesics

There are two subcategories of Narcotic Analgesics:

1. Natural Opiates: are derivatives of Opium.

Point out that Morphine and Codeine are examples of Opiates.

2. Synthetics: are produced chemically in the laboratory. The synthetics are not derived in any way from Opium, but produce similar effects.

Point out that Methadone is an example of a Synthetic Narcotic.

The word “Analgesic” means pain reliever. All of the drugs in this category reduce the person’s reaction to pain.

- Heroin is one of the most commonly abused of the Narcotic Analgesics.
- Heroin is highly addictive.

Many addicts support their habit by stealing property and converting it to cash.

In addition to reducing pain, Narcotic Analgesics produce euphoria, drowsiness, apathy, lessened physical activity and sometimes impaired vision.

Persons under the influence of Narcotic Analgesics often pass into a semi-conscious type of sleep or near-sleep. This condition is often called being “on the nod”. They often are sufficiently alert to respond to questions effectively. Higher doses of Narcotic Analgesics can induce coma, respiratory failure and death.

Session 2 - Drugs in Society and in Vehicle Operation

Inhalants

Examples:

- **Volatile Solvents**
 - (Glue, Gasoline, Paint, etc.)
- **Aerosols**
 - (Hairspray, Insecticides, etc.)
- **Anesthetic Gases**
 - (Nitrous Oxide, Amyl Nitrite, etc.)






Drug Recognition Expert Course 2-13

Inhalants

Inhalants are the fumes of certain substances. Inhalant abuse is on the rise. These substances are found in many common products:

- Gasoline
- Oil-based paints
- Glue
- Aerosol cans
- Varnish remover
- Cleaning fluids
- Etc.

Examples:

- Volatile Solvents (Glue, Gasoline, Paint, etc.)
- Aerosols (Hairspray, Insecticides, etc.)
- Anesthetic Gases (Nitrous Oxide, Amyl Nitrite, etc.)

Different Inhalants produce different effects.

- Many produce effects similar to those of CNS Depressants.
- A few produce stimulant-like effects.
- Some produce hallucinogenic effects.

The Inhalant abuser's attitude and demeanor can vary from inattentive, stuporous and passive to irritable, violent and dangerous. The abuser's speech will often be slow, thick and slurred.

Session 2 - Drugs in Society and in Vehicle Operation

Cannabis

Active ingredient:

- **Tetrahydrocannabinol (THC)**

Examples:

- **Marijuana**
- **Hashish**
- **Marinol**






Drug Recognition Expert Course 2-14

Cannabis

The category “Cannabis” includes the various forms and products of the Cannabis Sativa plant and other species of Cannabis plants.

Write “Cannabis Sativa” on the dry erase board or flip-chart.

The primary active ingredient in Cannabis products is the substance known as “Delta-9 Tetrahydrocannabinol,” or “THC.”

Write “Δ-9 THC” on the dry erase board or flip-chart.

Apart from alcohol, marijuana is the most commonly abused drug in this country.

In a household survey from 2011, marijuana was listed as the most common illicit drug used in the U.S. There were 18.1 million Americans over the age of 12 reporting use in the past month.

Source: National Household Drug Use and Health Survey, 2011.

Cannabis appears to interfere with the attention process. Drivers under the influence of Marijuana often do not pay attention to their driving.

Divided attention Standardized Field Sobriety Tests usually disclose some of the best evidence of Cannabis impairment.

Cannabis also produces a distortion of the user’s perception of time, an increased heart rate (often over 100 beats per minute) and reddening of the eyes.

Session 2 - Drugs in Society and in Vehicle Operation

Drug Combinations


+





Drug Recognition Expert Course 2-15

Drug Combinations

Many drug users appear to be “chemical gluttons.” They often ingest drugs from two or more drug categories.

The term for this is “polydrug use.”


Write “polydrug use” on the dry erase board or flip-chart. “Poly” is the Greek prefix for “many.”

Some very common examples of polydrug use include:

- Alcohol with virtually any other drug
- Marijuana and PCP - A common way to ingest PCP is to sprinkle it on a Marijuana “joint” and smoke it.
- Cocaine and Heroin, sometimes called a “speedball.”
- Heroin and Amphetamine, sometimes called a “poor man’s speedball.”
- Heroin and PCP, sometimes called a “fireball.”
- “Crack” Cocaine and PCP, sometimes called a “space base.”
- “Crack” Cocaine and Marijuana, sometimes called a “primo.”
- “Crack” and Methamphetamine, sometimes called “croak.”

Session 2 - Drugs in Society and in Vehicle Operation

Drug Combinations (Cont.)



The slide features a central graphic with a plus sign between a bottle of heroin and a cannabis leaf. The bottle is dark with a white label and a cork stopper. The leaf is green with serrated edges. The slide is framed by a blue header and footer. The header contains the text 'Session 2 - Drugs in Society and in Vehicle Operation'. The footer contains the text 'Drug Recognition Expert Course' on the left and '2-16' on the right. There are also logos for the International Association of Chiefs of Police (IACP) and NHTSA.

Sometimes, people take two different drugs (such as Heroin and Cocaine) that produce some opposite effects.

Example: Heroin tends to lower blood pressure. Cocaine tends to elevate blood pressure.

Different drug combinations may produce unique, interactive effects.

When a person has ingested multiple drugs, that person will experience multiple drug effects.

Under proper medical supervision, specific drugs often are used to reverse overdose conditions. However, it is important to bear in mind that, in a polydrug situation, some of the signs of a particular drug may not be evident even though the person is under the influence of that drug.

Session 2 - Drugs in Society and in Vehicle Operation

Incidence and Characteristics of Drug Use in America

- **22.5 million Americans 12 or older are current illicit drug users (2011)**
- **Marijuana most commonly used – 18.1 million users (2011)**
- **6.1 million users of non-medical psychotherapeutic drugs (2011)**

Source: National Survey on Drug Use and Health (NSDUH)




Drug Recognition Expert Course 2-17

B. Incidence and Characteristics of Drug Use in America

- In 2011, 22.5 million Americans (8.0 % of the population) aged 12 years or older were current illicit drug users.
Source: 2011 National Survey on Drug Use and Health.
- Marijuana was the most commonly used illicit drug in 2011, with 18.1 million users reporting use.
Source: 2011 National Survey on Drug Use and Health.
- In 2011, 6.1 million people were users of prescription type psychotherapeutic drugs taken non-medically.
Source: 2011 National Survey on Drug Use and Health.
- In 2011, there were an estimated 1.4 million Cocaine users in the U.S.
Source: 2011 National Survey on Drug Use and Health.
- In 2008, there were an estimated 1.5 million users of Heroin.
Source: 2008 National Survey on Drug Use and Health.
- Data from the 2008 NSDUH report shows that there were 2.2. million new users of pain relievers in 2008, with an average age of first use of 21.2 years.
Source: NSDUH, 2008.

Session 2 - Drugs in Society and in Vehicle Operation

Drug Impaired Driving Facts

Fact: About 9.4 million people aged 12 years and older admitted driving under the influence of illicit drugs in the past year (2011)

Source: National Survey on Drug Use and Health (NSDUH) 2011




Drug Recognition Expert Course 2-18

C. Incidence of Drug Impaired Driving

Accurate data on the frequency with which people drive while under the influence of drugs is somewhat limited.

This is due to the various reasons that include:

- Many impaired drivers are never detected.
- Many drug users also consume alcohol, when they are stopped for impaired driving they may be arrested (and tabulated in statistics) as alcohol impaired drivers only.

Fact: About 9.4 million people aged 12 years and older admitted driving under the influence of illicit drugs in the past year (2011).

Source: SAMHSA, Results from the 2011 National Survey on Drug Use and Health.

When they are involved in crashes, they may not be tested for drugs.

Session 2 - Drugs in Society and in Vehicle Operation

Incidence of Drug Impaired Driving

Fact: California - A study of young male drivers fatally injured in crashes found that 51% had used drugs other than alcohol



 *Source: Compton, NHTSA 1985* 

Drug Recognition Expert Course 2-19

Fact: A study in California of young male (15-34 years old) drivers killed in crashes in the early 1980's revealed that more than half (51%) tested positive for drugs other than alcohol. The most prevalent drug (other than alcohol) was Cannabis at 37%. 30% of all cases had both alcohol and Cannabis.

Source: Compton, R. and Anderson, T., The Incidence of Driving Under the Influence of Drugs: 1985. National Highway Traffic Safety Administration, 1985.

Session 2 - Drugs in Society and in Vehicle Operation

University of Tennessee Study

Fact: In 1988, 40% of crash injured drivers had drugs other than alcohol in their system



Drug Recognition Expert Course 2-20

Fact: University of Tennessee (1988) found 40 % of crash injured drivers had drugs other than alcohol in them.

Fact: A NHTSA study of various locations in seven states revealed that alcohol was present in more than 50% of the drivers. Drugs other than alcohol were present in 18 % of the drivers.

Source: NHTSA: 1993 Traffic Tech.

Session 2 - Drugs in Society and in Vehicle Operation

2007 National Roadside Survey of Alcohol and Drug Use by Drivers

11,000 drivers tested - 60 locations

- **Daytime drug-positive: 11.0%**
- **Nighttime drug-positive: 14.4%**
 - **Nighttime blood tests indicated 13.8% of the drivers were drug-positive**
 - **Using combined results of oral fluid and blood tests, 16.3% of the nighttime drivers were drug-positive**




Drug Recognition Expert Course 2-21

NHTSA undertook a comprehensive study of the prevalence of potentially-impairing drug use by drivers in 2007.

Report: The 2007 National Roadside Survey of Alcohol and Drug Use by Drivers.

Approximately 11,000 drivers were asked to provide an oral fluid and blood sample. Samples were tested for legal prescription, illegal and OTC products.

Fact: Based on the oral fluid results, more nighttime drivers (14.4%) were drug positive than daytime drivers (11.0%).

Fact: Based on the blood test results administered only at nighttime, 13.8% of the drivers were drug-positive.

Fact: Using the combined results, 16.3% of the nighttime drivers were drug-positive.

Source: *NHTSA Traffic Safety Facts, DOT HS 811 175, July 2009.*

The facts are unmistakable: Drug use is common among many Americans. So is drug impaired driving.

Consult national and local resources for updated data on drugs and driving.

Session 2 - Drugs in Society and in Vehicle Operation

QUESTIONS?



Drug Recognition Expert Course

2-22

Solicit participants' comments and questions about drugs in society and in vehicle operation.

Session 2 - Drugs in Society and in Vehicle Operation

Topics for Study




Drug Recognition Expert Course 2-23

Topics for Study Questions / Answers:

1. What does the term “drug” mean, as it is used in this course?

ANSWER: A drug is any substance that, when taken into the human body, can impair the ability of the person to operate a vehicle safely.

2. What are the seven categories of drugs? To which category does alcohol belong? To which category does Cocaine belong?

ANSWER: CNS Depressants, CNS Stimulants, Hallucinogens, Dissociative Anesthetics, Narcotic Analgesics, Inhalants and Cannabis; CNS Depressants; CNS Stimulants

3. What does “polydrug use” mean?

ANSWER: Ingesting drugs from two or more drug categories.

4. What is a “Speedball”? What is a “Space Base”?

ANSWER: Cocaine and Heroin; Crack and PCP

5. In the 2007 National Roadside Survey of Alcohol and Drug Use by Drivers, what percentage of nighttime drivers, using both blood tests and oral fluids, tested positive for drugs?

ANSWER: 16.3%

Session 3

Development and Effectiveness of the Drug Evaluation and Classification Program



Session 3 - Development and Effectiveness of the Drug Evaluation and Classification Program

Learning Objectives

- **State the origin and evolution of the Drug Evaluation and Classification program**
- **Describe research and demonstration project results that validate the effectiveness of the program**
- **State the impact of legal precedents established by case law**
- **Correctly answer the "topics for study" questions at the end of this session**




Drug Recognition Expert Course 3-2

Upon successfully completing this session the participant will be able to:

- State the origin and evolution of the Drug Evaluation and Classification Program.
- Describe research and demonstration project results that validate the effectiveness of the program.
- State the impact of legal precedents established by case law.
- Correctly answer the “topics for study” questions at the end of this session.

CONTENT SEGMENTS

- A. Origin and Evolution of Drug Evaluation & Classification Program
- B. Evidence of Program Effectiveness
- C. Case Law Review

LEARNING ACTIVITIES

- Instructor Led Presentations
- Reading Assignments

Briefly review the objectives, content and activities of this session.



A. Origin and Evolution of the Drug Evaluation and Classification (DEC) Program

Write: “LAPD” on dry erase board or flip-chart.

The DEC program was developed by personnel of the Los Angeles Police Department.

Development of the DEC program began in the early 1970’s, in response to a growing awareness that many people apprehended for impaired driving were under the influence of drugs rather than alcohol.

Dick Studdard (Traffic Officer):

- Sergeant Studdard retired from the LAPD in June, 1990.
- Sgt. Studdard and his fellow officers often encountered many impaired drivers whose BACs were zero or very low.

They occasionally succeeded in having physicians examine some of these low BAC subjects, resulting in diagnosis of drug influence.

- Note: examining physicians subsequently would be subpoenaed to testify in contested cases.
- For various reasons, physicians were often reluctant or unwilling to conduct these examinations and offer opinions.

Session 3 - Development and Effectiveness of the Drug Evaluation and Classification Program

LAPD Developed DRE (Cont.)





Drug Recognition Expert Course 3-4

Some reasons why doctors may be reluctant:

- They typically receive little training in the recognition of specific signs of drug impairment, particularly at street level doses.
- They may not see the subject until hours after the drugs were used, by which time the signs and symptoms often have changed.

As a result, some drivers whom Studdard and other officers were certain were impaired were not prosecuted or convicted for DWI.

Studdard concluded that it was essential to develop appropriate procedures that officers could use when confronted with persons suspected of drugs.

Len Leeds (Narcotics Officer) and deceased in 1995:

- Was approached by Studdard and asked to collaborate in the development of a program to help identify drug-impaired subjects.
- Initiated some independent research by consulting with physicians, enrolling in relevant classes, studying text books, technical articles, etc.
- Secured management level support within the department to continue research and program development.

As time went on, many other key persons both within and outside LAPD contributed to the development and refinement of the program.

Session 3 - Development and Effectiveness of the Drug Evaluation and Classification Program

LAPD Developed DRE (Cont.)



Drug Recognition Expert Course

3-5

In 1979, the program was officially recognized by LAPD.

Note: The LAPD program was referred to as the Drug Recognition Expert (DRE) program.

Session 3 - Development and Effectiveness of the Drug Evaluation and Classification Program

LAPD and NHTSA

- Developed and validated a battery of Standardized Field Sobriety Tests for alcohol impaired driving
- By the early 1980's NHTSA began to assist LAPD in validating the DRE program



Drug Recognition Expert Course 3-6

B. Evidence of Program Effectiveness

LAPD began to work with the National Highway Traffic Safety Administration (NHTSA) on issues relating to this program in the early 1970's.

The first step was to develop and validate a battery of standardized field sobriety tests for investigating alcohol impaired driving.

LAPD personnel played a major role in the research that led to the wide spread use of Horizontal Gaze Nystagmus, the Walk and Turn test, and the One Leg Stand test.

By the early 1980's, NHTSA completed its validation of the standardized tests for DWI enforcement.

At this time, NHTSA began to assist LAPD in validating the Drug Recognition Expert program.

Session 3 - Development and Effectiveness of the Drug Evaluation and Classification Program

Three-Step Drug Evaluation Process

1. Establish that the subject is impaired
2. Rule out medical impairment
3. Determine the category of drugs involved




Drug Recognition Expert Course 3-7

The DEC program evolved into what is essentially a three-step process.

- First, establish that the subject is impaired and verify that his or her alcohol level is not consistent with the degree of impairment that is evident.

Clarification: the first portion of the drug influence evaluation is devoted principally to Standardized Field Sobriety Testing of the subject, and to the administration of a breath test.

Inconsistency between the observed impairment and the BAC suggests the presence of some other drug(s), or some other complicating factor such as an illness or injury.

- Second, use some simple evaluation procedures to determine whether the impairment may stem from illness or injury, requiring medical attention.
- Third, use evaluation procedures to determine what category (or categories) of drugs are the likely cause of the impairment.

Key Point

The entire evaluation process is standardized.

- Administered the same way to all subjects.
- Administered the same way by all officers.

Session 3 - Development and Effectiveness of the Drug Evaluation and Classification Program

Three-Step Drug Evaluation Process (Cont.)

1. Establish that the subject is impaired
2. Rule out medical impairment
3. Determine the category of drugs involved




Drug Recognition Expert Course 3-8

The Need for Reliable Standardized Assessment Procedure

Pose this question: “Why is it necessary for an officer to use reliable standardized assessment procedures to determine the category of drugs causing the impairment?”

Follow-up question: “If we see that a subject is impaired, and the BAC is too low to account for that impairment, why don’t we simply obtain a blood sample and ask the laboratory to analyze the sample for all drugs?”

Solicit responses from participants.

- One reason for needing a reliable standardized assessment procedure is that we may be called upon to submit evidence of an articulable suspicion of drug influence to support our request for a chemical test of the subject.
- Some courts or motor vehicle hearings officers may find that a low BAC result, by itself, does not provide adequate basis for requesting the subject to submit to a 2nd chemical test.
- Another reason is that the subject may refuse to submit to the chemical test, denying us of scientific evidence of drug influence. In that case, conviction or acquittal may hinge on the officer’s observations and expertise as a DRE.
- A third reason is that chemical tests usually disclose only that the subject has used a particular drug recently. The chemical test usually does not indicate whether the drug is psychoactive at the present time.
- Thus, the DRE procedures are needed to establish that the subject not only has used the drug, but also that he or she is under the influence.

Session 3 - Development and Effectiveness of the Drug Evaluation and Classification Program

Three-Step Drug Evaluation Process (Cont.)

1. Establish that the subject is impaired
2. Rule out medical impairment
3. Determine the category of drugs involved




Drug Recognition Expert Course 3-9

- A fourth reason is that it can be expensive and require a large sample of blood or urine to perform a broad analysis for any or all drugs. Practical constraints require that we be able to point the laboratory technician toward those types of drugs most likely to be found in the sample.

Pose this question: “Are there other toxicological samples that can be obtained for drug analysis by the lab?”

Solicit responses on hair and saliva sampling.

It is always possible that a person suspected of drug impairment is actually suffering from some medical problem. If a sample is collected, and the subject is not examined by someone who is qualified, evidence of medical problems may not come to light until it is too late.

Solicit participants’ questions and comments concerning the origin, evolution and need for the Drug Evaluation and Classification program.

Session 3 - Development and Effectiveness of the Drug Evaluation and Classification Program

Two Stages of Validation

Laboratory Validation Study

- Johns Hopkins University



Field Validation Study

- Los Angeles





Drug Recognition Expert Course 3-10

Two Stages of Validation

NHTSA assisted LAPD in a two-phase validation study.

- Laboratory validation, using volunteers who ingested selected drugs. The Johns Hopkins validation was conducted in 1984.
- Field validation, using persons actually arrested in Los Angeles on suspicion of drug influence. The LAPD Field Validation Study was conducted in 1985.

Session 3 - Development and Effectiveness of the Drug Evaluation and Classification Program

Laboratory Validation Study

Laboratory Validation Study

Johns Hopkins University



Drug Recognition Expert Course 3-11

1. Laboratory Validation Study

The Laboratory Validation took place at Johns Hopkins University in Maryland. The drug examiners were senior DREs from LAPD. The LAPD participants: Dick Studdard; Jerry Powell; Pat Russell; and Doug Laird.

The laboratory experiments were planned and conducted by researchers from Johns Hopkins.

Volunteers each took a “pill” and smoked a “cigarette.”

The “pill” contained either no drug (placebo) or one of the following drugs:

- Secobarbital (CNS Depressant)
- Valium (i.e., Diazepam – CNS Depressant)
- d-amphetamine (CNS Stimulant).

Session 3 - Development and Effectiveness of the Drug Evaluation and Classification Program

Laboratory Validation Study (Cont.)

Laboratory Validation Study

Johns Hopkins University





Drug Recognition Expert Course 3-12

Note: Secobarbital, diazepam and d-amphetamine were the pharmaceuticals used in the study. All were administered in identical gelatin capsules and were not brand name drugs.

A common brand name for secobarbital is Seconal; a common brand name for diazepam is Valium and a common brand name for d-amphetamine is Dexedrine.

The “cigarette” contained either THC or no drug (placebo). Neither the volunteers nor the LAPD officers knew what the volunteers had taken.

Note: this condition is known as a “double blind” experiment. The people being tested and the people doing the testing are kept uninformed of the test condition.

Two different dose levels of Marijuana, Diazepam and d-amphetamine were used.

Clarification: some of the Diazepam and d-amphetamine pills were “weak,” some were “strong.” Similarly, some of the Marijuana cigarettes were “weak,” some “strong.” All of the Secobarbital pills were “strong.”

Session 3 - Development and Effectiveness of the Drug Evaluation and Classification Program

Laboratory Validation Study (Cont.)

Laboratory Validation Study

Johns Hopkins University



Drug Recognition Expert Course 3-13

Normal daily dose for therapeutic purposes:

- Secobarbital: approx. 100 mg.
- Diazepam: 4-40 mg.
- d-amphetamine: 15 mg.

Doses administered for this study:

- Secobarbital: 300 mg.
- Diazepam: weak – 15mg, strong – 30mg.
- d-amphetamine: weak – 15 mg, strong – 30 mg.
- Marijuana: weak – 12 puffs or 1.3% THC cigarettes, strong – 12 puffs of 2.8% THC cigarettes.

Session 3 - Development and Effectiveness of the Drug Evaluation and Classification Program

Laboratory Study Results

- **DRE officers correctly identified 95% of drug-free subjects as "unimpaired"**
- **DRE officers classified 98.7% of high-dose subjects as "impaired"**



Drug Recognition Expert Course 3-14

Results

- The DREs were excellent in identifying subjects who received only placebo doses: they classified 95% of the drug free subjects as “not impaired.
- Similarly, they were excellent in identifying the high dose subjects.
- They classified as “impaired” 98.7% of the subjects who received Secobarbital or strong doses of Marijuana, Diazepam or d-amphetamine.

Session 3 - Development and Effectiveness of the Drug Evaluation and Classification Program

Laboratory Study Results (Cont.)

- **Correctly identified the category of drugs for 91.7% of high-dose subjects**
- **DRE officers were less successful in classifying low-dose subjects**
 - **17.5% of d-amphetamine impaired**
 - **32.5% of weak marijuana impaired**




Drug Recognition Expert Course 3-15

- They correctly identified the category of drug for 91.7% of those strong dose subjects.
- The DREs were less successful in identifying the weak dose subjects.
- Only 17.5% of the subjects who received the weak dose of d-amphetamine were classified as “impaired.”
- Only 32.5% of the subjects who smoked the “weak” Marijuana cigarettes were classified as “impaired.”

Emphasize that these low dose subjects probably would never have been stopped and arrested by police officers, if they had been driving.

- The results of the laboratory validation study were considered to be extremely positive.
- The DRE procedures correctly identified the category of drugs in more than 90% of the subjects who were impaired.
- The procedures only rarely indicated that unimpaired subjects were under the influence of drugs.
- Laboratory studies can only allow certain dose levels of drugs, which are much lower than those seen at street levels. Therefore, participants in laboratory studies may not show many of the signs of impairment that are seen with subjects ingesting street level doses of drugs.

Session 3 - Development and Effectiveness of the Drug Evaluation and Classification Program

Field Validation Study Los Angeles

173 drivers arrested for DUI-Drugs

- **None involved in crashes**
- **28 DREs participated**
- **Excluded all cases where no blood sample obtained**



Drug Recognition Expert Course 3-16

2. Field Validation Study

The field validation study was based on one hundred seventy-three people actually arrested on suspicion of driving under the influence of drugs.

Point out that during the study period, many other drugged driving arrests were made by LAPD officers.

None of the 173 cases involved a crash. In all of the cases, the arrested subjects agreed to submit to a blood test.

Twenty-eight different DREs from LAPD and the L.A. area participated in the examinations of these one hundred seventy-three subjects.

The researchers excluded all cases where the subjects refused to give blood, since it would have been impossible to check the DREs accuracy in those cases. Similarly, they excluded all cases that involved crashes, since the subjects' injuries could have confounded the drug examination. Also excluded were subjects who were found in possession of drugs or had any charges other than the drugged driving charge.

Session 3 - Development and Effectiveness of the Drug Evaluation and Classification Program

Field Validation Study (Cont.) Los Angeles

Blood tests confirmed:

- One suspect had no drugs or alcohol
- 10 had alcohol only
- 37 (21%) had one drug
- 82 (47%) had two drugs
- 43 (25%) had three or more drugs




Drug Recognition Expert Course 3-17

Results of the Field Study

Based on the independent blood tests, only one of the one hundred seventy-three subjects was found to have no alcohol or other drugs. Another ten subjects were found to have only alcohol in them.

Point out that it is possible that these eleven so-called “drug free” subjects may have used drugs that the independent laboratory could not identify, for various reasons. Even if we assume that these eleven people really had not used any drug other than alcohol, eleven out of one hundred seventy-three is a very small “false positive” rate.

Thirty-seven (21%) of the subjects were found to have only one drug other than alcohol. Eighty-two had two drugs other than alcohol (47%) and forty-three (25%) had three or more drugs other than alcohol.

Write on dry erase board “72% - two or more drugs other than alcohol.”

This means that one hundred twenty-five of the one hundred seventy-three subjects had ingested two or more drugs other than alcohol: that is more than 72% of the subjects.

Emphasize: Polydrug use is very common.

PCP was the drug most often found among these one hundred seventy-three subjects: more than half of them (56%) had used PCP.

Session 3 - Development and Effectiveness of the Drug Evaluation and Classification Program

Field Validation Study (Cont.) Los Angeles

Blood tests confirmed the presence of at least one “predicted” category of drugs for more than 90% of the suspects



Drug Recognition Expert Course 3-18

The key finding of this study was the following:

- For more than nine out of ten of the subjects (92.5%), the blood test confirmed the presence of at least one drug category “predicted” by the DREs.

Session 3 - Development and Effectiveness of the Drug Evaluation and Classification Program

Confirmation Rates for Specific Categories

- 92%: Phencyclidine (PCP)**
- 85%: Narcotic Analgesics**
- 78%: Cannabis**
- 50%: CNS Depressants**









Drug Recognition Expert Course 3-19

The confirmation rates for specific categories:

PCP: blood tests confirmed DREs' predictions in 92% of the cases.

Point out: Study data for PCP was collected when PCP was considered a DRE drug category. In the other 8% it is possible that a PCP analog might have been used.

Narcotic Analgesics: blood tests confirmed 85% of the DREs' predictions.

Cannabis: blood tests confirmed 78% of DREs' predictions.

CNS Depressants: blood tests confirmed 50% of DREs' predictions.

Point out that there are literally hundreds of different CNS Depressants, many of which may not have been identifiable by the independent laboratory.

Session 3 - Development and Effectiveness of the Drug Evaluation and Classification Program

Confirmation Rates for Specific Categories (Cont.)

33%: CNS Stimulants





Drug Recognition Expert Course 3-20

CNS Stimulants: blood tests confirmed 33% of DREs' predictions.

Emphasize that, in this study, the blood samples were not frozen after collection. Unfortunately, cocaine continues to degenerate in a blood sample if the sample isn't frozen. It is quite possible that the cocaine had metabolized from some samples before the lab analyzed them.

Numerous states have conducted comparisons of laboratory analysis and DRE opinions. The correlation rates exceeded 80% in those studies.

Emphasize: Simply because a lab cannot find "drugs" in a sample does not guarantee that no drug is present. All labs have some blind spots.

A Study conducted in 1990 by the Arizona Department of Public Safety Central Regional Crime Laboratory compiled records of the toxicological analysis corresponding to Arizona DREs were analyzed showing that a laboratory confirmation rate of 86.5% had been achieved.

The overall conclusion of the laboratory and field studies is that the DEC Program is an effective tool for law enforcement.

Solicit participants' questions about the laboratory and field studies.

Session 3 - Development and Effectiveness of the Drug Evaluation and Classification Program

Case Law Review

“Frye” Standard

“Is the procedure or principle espoused, accepted by the relevant scientific community?”






Drug Recognition Expert Course 3-21

C. Case Law Review

Court Rulings

Favorable Court Rulings on DEC Procedures.

Courts in various states have ruled favorably on the DEC Program. American courts employ either the Frye or Daubert Standard for determining the admissibility of scientific evidence.

The Frye standard is the traditional test for admissibility of “new” scientific evidence.

Print “Frye Standard” on the dry erase board or flip-chart

The Frye standard: “Is the procedure or principle espoused, accepted by the relevant scientific community?”

Frye standard was set by the US Supreme Court in 1923.

Session 3 - Development and Effectiveness of the Drug Evaluation and Classification Program

Case Law Review (Cont.)

“Daubert” Standard

- Shows reliability before scientific evidence can be admitted



Drug Recognition Expert Course 3-22

In Daubert, courts serve as a gatekeeper for all scientific evidence.

Print “Daubert” on the dry erase board or flip-chart.

Daubert standard requires a showing of reliability before scientific evidence can be admitted.

Courts assess evidence by considering four factors:

- Opinions are testable.
- Methods/principles have been subject to peer review.
- Known error rate can be identified.
- Opinions rest on methodology that is generally accepted within the relevant scientific/technical community.

Session 3 - Development and Effectiveness of the Drug Evaluation and Classification Program

Case Law Review (Cont.)

“Frye” Standard

- **Arizona v Johnson**
- **Washington v Baity**
- **Minnesota v Klawitter**
- **Colorado v Hernandez**





Drug Recognition Expert Course 3-23

- *State of Arizona v. Dayton Johnson and Samuel Rodriguez, et al, NOS 90056865 and 90035883, (1990)*. An Arizona court (Tucson Municipal Court) ruled that the Frye Standard was met. However, upon appeal, the Arizona State Supreme Court ruled that the Frye Standard did not apply to the DEC Program.
- *Washington v. Baity, 991P.2d, 1151, 140 Wn. 2d 1 (2000)*. A Washington Supreme Court ruled that the DRE protocols are the application of traditional techniques.
- *State of Minnesota, City of Minneapolis v. Larry Michael Klawitter, 518 N.W.2d 577, (1993)*. A Minnesota Court (City of Minneapolis) ruled that outside of nystagmus, the DEC Program is not subject to the Frye Standard.
- *State of Colorado v. Daniel Hernandez, 92M 181, (1992)*. The Colorado Supreme Court determined that the Frye Standard applies to the protocol because the process has “scientific elements.” A Colorado Court (Boulder County Court) ruled that the procedures used by DREs are not new or novel and the Frye Standard did not apply.

Session 3 - Development and Effectiveness of the Drug Evaluation and Classification Program

Case Law Review (Cont.)

“Daubert” Standard

- **New Mexico v Aleman**
- **Nebraska v Cubrich**





Drug Recognition Expert Course 3-24

- *New Mexico v. Mariam Aleman, Dona Ana County, 3rd District (2003)*. A New Mexico Court ruled the DRE’s opinion was correct and that the DRE protocol is admissible.
- *Nebraska v. Cubrich, Case No. CR03-8203 Sarpy County Court (2004)*. In this case, the court used the Daubert Standard. In many jurisdictions, it will not be necessary to have expert scientific testimony to secure admissibility of a DRE’s examination of a subject.

The DEC Program is gaining acceptance in many courts.

In fact, testimony based on DRE investigation have been accepted by courts for years.

Expert testimony regarding drug influence has long been accepted by numerous courts. The components of DRE evaluation are generally accepted in the scientific community.

The DEC Program simply combined those components into a systematic and standardized procedure. Thus, many prosecutors believe that FRYE standards do not apply to DRE evaluations and testimony.

Session 3 - Development and Effectiveness of the Drug Evaluation and Classification Program

HGN Case Law

Arizona v Blake





Drug Recognition Expert Course 3-25

HGN Case Law

One key element of DEC – namely, Horizontal Gaze Nystagmus – has been recognized as meeting the Frye standard by several State Supreme Courts. First to do so was Arizona, in the case known as State vs. Blake.

Print “Arizona vs. Blake” on the dry erase board or flip-chart.

Point out that additional court rulings on HGN are summarized in the participant’s Manual.

Emphasize that participants should familiarize themselves with the case law on HGN to ensure they avoid the errors that kept that evidence from being admitted in the past.

If there are significant cases concerning DEC or HGN from the participants’ State, review them at this time.

Solicit participants’ questions and comments about case law.

Session 3 - Development and Effectiveness of the Drug Evaluation and Classification Program

HGN Case Law (Cont.)

Arizona v Blake





Drug Recognition Expert Course 3-26

Summary of HGN Case Law

The prevailing trend is for courts to admit HGN as evidence of impairment, with the proper scientific foundation.

But courts consistently reject all attempts to introduce HGN as evidence of a quantitative BAC.

Write on dry erase board or flip-chart – “Cannot be used as evidence of specific BAC level.”

The court ruled that in cases where there is no chemical test to determine a BAC level, HGN test results can be admitted the same as of Standardized Field Sobriety Tests to show a “neurological dysfunction,” one cause of which could be the ingestion of alcohol.

Write “No Chemical Test – HGN Admissible.”

Session 3 - Development and Effectiveness of the Drug Evaluation and Classification Program

QUESTIONS?



Drug Recognition Expert Course 3-27

Solicit participants' questions and comments about development and effectiveness of the drug evaluation and classification process.

Session 3 - Development and Effectiveness of the Drug Evaluation and Classification Program

Topics for Study




Drug Recognition Expert Course 3-28

Topics for Study Questions /Answers:

1. State four reasons why it is important not to rely simply on a chemical test to establish a subject's drug impairment.

Answer: Develop articulable evidence of drug impairment; Suspect may refuse chemical test; Chemical tests do not indicate recency of use; Suspect may be suffering from injury or illness.

2. What categories of drugs were included in the Johns Hopkins Laboratory Study?

Answer: CNS Depressants, CNS Stimulants and Cannabis

3. In what percentage of cases in the Los Angeles Field Validation Study did blood tests confirm the DREs' opinion that PCP was present?

Answer: 92%

4. What percentage of subjects were found to be polydrug users in the LAPD Field Validation Study?

Answer: 72%

5. What was the landmark State Supreme Court case that upheld the use of HGN as evidence of impairment?

Answer: State (AZ) vs. Blake

6. What do we call the standards for admissibility of scientific evidence, set by the U.S. Supreme Court?

Answer: Frye Standard

7. Which State first found the Drug Evaluation and Classification procedures met the standards of scientific evidence?

Answer: Arizona

“Frye” Decisions Regarding Admissibility of Drug Recognition Expert Testimony

“Frye” refers to a United States Federal Court opinion dealing with the admissibility of scientific evidence. The court established that new or novel scientific evidence, or the novel application of scientific principles, must be shown to have met with general acceptance in the relevant scientific community before it can be admitted.

1990

**State of Arizona v. Dayton Johnson and Samuel Rodriguez, et al. Defendants
Nos 90056865 & 90035883 (Unpublished Opinion).
The Municipal Court of the City of Tucson, County of Pima, State of Arizona**

“Virtually all the witnesses agreed that the scientific procedures utilized by trained drug recognition experts are reliable and are generally accepted in the scientific community. The methodology in place, used by trained law enforcement personnel in the field, has been shown to produce reasonably reliable and uniform results that will contribute materially to the ascertainment of the truth.”

On May 7, 1992, the Arizona Supreme Court heard oral arguments in a special proceeding regarding this case. The Justices uniformly rejected the application of “Frye” to the DRE procedures. The Chief Justice observed that the component examination procedures had been established for fifty years.

The prosecutors in this case were Tom Rankin (Tucson) and Cliff Vanell (Phoenix). Expert witnesses for the prosecution included: Sgt. Richard Studdard, LAPD, Marcelline Burns, Ph.D., Sgt. Thomas Page, LAPD, Zenon Zuk, M.D., and Eugene Adler, toxicologist.

1992

**County Court, Boulder, Colorado
Case No. 92M181 (Unpublished Opinion)
People of the State of Colorado v. Daniel Hernandez**

“The DRE methods are accepted within the scientific community because they have found to be reliable.”

“The Court finds that the expert does have sufficient specialized knowledge to assist the jurors in better deciding whether the defendant drove his car when under the influence of a specific drug. The DRE testimony can be used at trial provided a sufficient foundation is laid.” Overall, this court ruled that the procedures used by DRE’s are not new or novel scientific techniques that must meet the “Frye” standard.

The prosecutor in this case was David Archeluta (Boulder County). Expert witnesses for the prosecution include: Sergeant Thomas Page, LAPD, Zenon Zuk, M.D., Marcelline Burns, Ph.D., Rick Abbott, M.D., and Laurel Farrell (chemist).

1993

State of Minnesota in Supreme Court, C6-93-2092, filed June 30, 1994.

(Unpublished Opinion)

State of Minnesota, City of Minneapolis vs. Larry Michael Klawitter, 518 N.W.2d 577 (1994)

“Given proper foundation and subject to other qualifications, opinion testimony by experienced police officers trained in use of so-called drug recognition protocol is generally admissible in evidence in a trial of a defendant for driving while under the influence of a controlled substance.”

The Court determined that the gaze nystagmus test satisfies the requirements of “Frye”.

“We agree with the trial court that the officer should be allowed to give an opinion based on the officer’s training and experience and his or her observations following the 12-step drug recognition protocol, as long as (a) there is sufficient foundation for the specific opinion expressed, (b) the state does not attempt to exaggerate the officer’s credentials by referring to the officer as a “Drug Recognition Expert” or to unfairly suggest that the officer’s opinion is entitled to greater weight than it deserves, and...” “We add only that it should be obvious that the mere fact that such opinion testimony by itself will be sufficient to support a guilty verdict.”

The court also determined that, outside of nystagmus, the components of a DRE examination are not scientifically new and are not subject to the “Frye” test.

The trial court stated, “...there is nothing scientifically new, novel, or controversial about any component of the DRE protocol itself. The symptomatology matrix used by DRE’s to reach their conclusions is not new and is generally accepted in the medical community as an accurate compilation of signs and symptoms or impairment by the various drug categories.”

The prosecutor in this case was Karen Herland (City of Minneapolis). Expert witnesses for the prosecution included: Sergeant Thomas Page, LAPD, Dr. Marcelline Burns (psychologist), Dr. David Peed (optometrist), Dr. Zenon Zuk (medical doctor), Eugene Adler (criminalist), Dr. S.J. Jejurikar (Minnesota Bureau of Criminal Apprehension), and Robert Meyer (toxicologist).

1994

11th Judicial Circuit in and for Dade County, Florida

Case No. 256998,9-I (Unpublished Opinion)

State of Florida v. Frederick Williams

Judge Maxine Cohen Lando

Original filed January 19, 1995

“Given proper foundation and subject to other qualifications, opinion testimony by an experienced police officer trained in the use of the drug recognition protocol is generally admissible in evidence in a trial of a defendant charged with driving under the influence of a controlled or chemical substance. Furthermore, Horizontal Gaze Nystagmus (HGN) test results are generally admissible to establish (1) that the defendant was impaired; and/or (2) that the defendant was over the legal limit; and/or (3) the defendant’s specific breath or blood alcohol level at the time he performed the test.”

This court found that the “Frye” standard is inapplicable to the DRE Protocol because neither the protocol nor any of its subsets (including HGN, VGN, and Lack of Convergence) are “scientific”.

Further, these tests are neither new nor novel. The Court also state that “Frye” is inapplicable to HGN, VGN, and LOC because none of them are new or novel. “None of these tests or the theories and procedures they encompass, are new, novel, or emerging scientific techniques. The medical and psychological professions have acknowledged the tests’ underlying theories and procedures for decades.”

The Court concluded:

“Drug recognition training is not designed to qualify police officers as scientists, but to train them as observers. The training is intended to refine and enhance the skill of acute observation...and to focus that power...in a particular situation.”

This court followed the Klawitter (Minnesota) decision, that it requires the state to “lay a proper predicate before referring to a DRE as anything other than a DRE or Drug Recognition Evaluator or Examiner.”

“The real issue is not the admissibility of the evidence, but the weight it should receive. That is a matter for the jury to decide.”

The prosecutor in this case was Steve Talpins (Dade County). Expert witnesses for the prosecution in this case included: Marcelline Burns, Ph.D., Zenon Zuk, M.D., Robert Dobie, M.D., Sergeant Thomas Page, LAPD, and others.

2000

Case No. 66876-1

State of Washington vs. Michael Baity

Judge J. Talmadge, WA Supreme Court

Original filed 2000

In this case, the court was asked to determine if a drug recognition protocol, used by trained drug recognition officers to determine if a suspect's driving is impaired by a drug other than alcohol, meets the requirements of *Frye v. United States*, 293 F. 1013,34 A.L.R. 145 (1923), for novel scientific evidence.

The issue brought before the court was; Is a drug recognition program novel scientific evidence generally accepted in the scientific community, thus satisfying the Frye test for admissibility?

The facts in this case were:

The state charged Baity with one count of DUI, in violation of RCW 46.61.502 (l) (b) (c), and one count of driving while license suspended in the third degree, in violation of RCW 46.20.342(l)(c), after he failed roadside SFST's and showed signs of drug impairments.

In a pretrial motion in Baity's case, the State sought to qualify the DREs as experts and to obtain a ruling on the admissibility of DRE evidence with respect to the defendant's drug impairment and the evaluation process used to determine that impairment.

Specifically, the State sought to admit testimony that Baity's impairment was consistent with the symptoms associated with one of seven categories of drugs. Additionally, the state moved to admit testimony regarding the use of the horizontal gaze nystagmus (HGN) test, both for the detection of alcohol and for the detection of drugs. Baity moved to suppress all DRE evidence, including the HGN test, on the basis that the DRE program and protocol constitute novel scientific evidence subject to the Frye test for admissibility.

On May 19, 1998, the Pierce County District Court judges issued their opinion titled, "Opinion Regarding Admissibility of HGN and DRE." In that opinion, they denied the defendants' motions to suppress the field sobriety tests (SFSTs) as to their alcohol impairment, holding those tests are "reasonably understandable to the ordinary person" and therefore not subject to Frye. Clerk's Papers at 56. The court also noted some features of the DRE protocol were either not of a scientific nature or were scientific, but not novel.

The court ruled that after analyzing the DRE protocol and the approach of other courts to its admissibility, that the DRE protocol and the chart used to classify the behavioral patterns associated with seven categories of drugs have scientific elements meriting evaluation under Frye. They also found that the protocol to be accepted in the relevant scientific communities. However, the court ruled that there is confined situations where

all 12-steps of the protocol have been undertaken. Moreover, an officer may not testify in a fashion that casts an aura of scientific certainty to the testimony. The officer also may not predict the specific level of drugs present in a suspect. The DRE officer, properly qualified, may express an opinion that a suspect's behavior and physical attributes are or are not consistent with the behavioral and physical signs associated with certain categories of drugs.

The court also held that the protocol meets the mandate of Frye. An officer may testify concerning such drug impairment, subject to the limitations set forth in this opinion, upon meeting the requirements of ER 702 and 703 for the admission of expert opinion testimony. The court reversed the suppression orders of the Pierce County District Court and remanded the cases for further proceedings consistent with this opinion.

2003

Case No. CR-2003-00025

State of New Mexico vs. Miriam Aleman

State of New Mexico, County of Dona Ana

Third Judicial District

Judge Silvia E. Cano-Garica

Defendant made a motion In Limine to exclude the testimony of the DRE officer. They heard the testimony of various witnesses and reviewed the State's Brief in support of the DRE testing. Testimony and other applicable documents found that:

The DRE officer was recognized as an expert of DRE testing based upon his specialized knowledge and experience, the DRE evaluation method is generally accepted in the particular scientific field of forensic toxicology, the DRE evaluation provides critical information which assists the toxicologist in forming an opinion as to whether the driver was impaired by the use of drugs at or near the time the driver was driving the motor vehicle.

The DRE protocols are the application or incorporation of traditional techniques in the biology, physiology, anatomy, chemistry, pharmacology and toxicology fields, and the ultimate decision as to the driver's alleged impairment, based on all of the testimony received, rests with the jury.

2004

Case No. CR 03-8203

State of Nebraska vs. Timothy J. Cubrich

Judge Todd J. Hutton, Sarpy Co. Court

The court was asked to determine the admissibility of the law enforcement officer's opinion that the defendant was under the influence of a drug, other than alcohol, to the extent that his abilities to safely operate the vehicle were appreciably impaired.

To this end the court applied the standards set forth in *Schafersman v. Agland Coop*, 262 Neb. 215, 631 N.W. 2d 862 (2001), having adopted *Daubert v. Merrel Dow Pharmaceuticals, Inc.*, 509 U.S.579 (1993), as the controlling authority in determining the admissibility of expert opinion testimony.

The court concluded: Since *Daubert*, the court now serves in the “gatekeeping” role in which it is called upon to determine the reliability and relevance of expert testimony. There is no Case Law in Nebraska which has specifically addressed the issue of expert testimony relating to impaired drivers suspected of using drugs. Nor is there a statutory procedure by which Drug Recognition Examinations or the opinions derived there from have been codified.

Application of the *Daubert* standard provided a number of considerations the court used in determining the admissibility of evidence through the testimony of an expert, which included:

The 12-step protocol which relies on determining if a person is drug impaired has been recognized in the scientific community, including physicians, ophthalmologists, and forensic toxicologists, as a dependable methodology by which an officer, properly trained, can identify impairment and the category of drug(s) which are impairing the suspect’s cognitive and physical capabilities.

The methodology is reliable because it is dependent on a fixed set of assessments which are verified by a toxicology test. The evaluation process includes HGN testing which has been found to meet the *Frye* standard of admissibility. Additionally, the HGN and VGN tests have been subject to peer review and publication. The remaining tests serve to screen the suspect’s mental and physical condition documenting clues explaining why the person may or may not be impaired and if so the source(s) involved.

The drug recognition assessment is a tool by which a specially trained officer can conclude “based on the totality of results” whether or not a person is impaired by a drug other than alcohol.

The court found that the DREs opinion was correct in that the Defendant showed signs of impairment from a drug, other than alcohol, which caused him to seek a toxicological examination. The category of drug is admissible for the limited purpose of establishing foundation for drug screen conducted by the toxicologists.

**American Prosecutors Research Institute
National Traffic Law Center**

**HORIZONTAL GAZE NYSTAGMUS
STATE CASE LAW SUMMARY**

INTRODUCTION

The following state case law summary contains the seminal cases for each state, the District of Columbia and the Federal courts on the admissibility of HGN. Three main issues regarding the admissibility of the HGN test are set out under each state: evidentiary admissibility, police officer testimony, and purpose and limits of the HGN test results. The case or cases that address each issue are then briefly summarized and cited.

Alabama

I. Evidentiary Admissibility

HGN is a scientific test that must satisfy the Frye standard of admissibility. The Supreme Court of Alabama found that the State had not presented “sufficient evidence regarding the HGN test’s reliability or its acceptance by the scientific community to determine if the Court of Criminal Appeals correctly determined that the test meets the Frye standards.”

Malone v. City of Silverhill, 575 So.2d 106 (Ala. 1990).

II. Police Officer Testimony Needed to Admit HGN Test Result

The Court did not address this issue.

III. Purpose and Limits of HGN

The Court did not address this issue.

Alaska

I. Evidentiary Admissibility

HGN is a scientific test. It is generally accepted within the relevant scientific community. Ballard v. Alaska, 955 P.2d 931, 939 (Alaska Ct. App. 1998).

II. Police Officer Testimony Needed to Admit HGN Test Result

A police officer may testify to the results of HGN testing as long as the government establishes a foundation that the officer has been adequately trained in the test. Ballard, 955 P.2d at 941.

III. Purpose and Limits of HGN

HGN testing is “a reliable indicator of a person’s alcohol consumption and, to that extent, HGN results are relevant.” The court cautioned that the HGN test could not be used to correlate the results with any particular blood-alcohol level, range of blood-alcohol levels, or level of impairment. Ballard, 955 P.2d at 940.

Arizona

I. Evidentiary Admissibility

HGN is a scientific test that needs to satisfy the Frye standard of admissibility. State has shown that HGN satisfies the Frye standard. State v. Superior Court (Blake), 718 P.2d 171, 181 (Ariz. 1986) (seminal case on the admissibility of HGN).

II. Police Officer Testimony Needed to Admit HGN Test Result

“The proper foundation for [admitting HGN test results] . . . includes a description of the officer's training, education, and experience in administering the test and showing that proper procedures were followed.”

Arizona ex. rel. Hamilton v. City Court of Mesa, 799 P.2d 855, 860 (Ariz. 1990).

See also Arizona ex. Rel. McDougall v. Ricke, 778 P.2d 1358, 1361 (Ariz. Ct. App. 1989).

III. Purpose and Limits of HGN

HGN test results are admissible to establish probable cause to arrest in a criminal hearing.

State v. Superior Court (Blake), 718 P.2d at 182.

“Where a chemical analysis has been conducted, the parties may introduce HGN test results in the form of estimates of BAC over .10% to challenge or corroborate that chemical analysis.” Ricke, 778 P.2d at 1361.

When no chemical analysis is conducted, the use of HGN test results “is to be limited to showing a symptom or clue of impairment.” Hamilton, 799 P.2d at 858.

Arkansas

I. Evidentiary Admissibility

Novel scientific evidence must meet the Prater (relevancy) standard for admissibility. Because law enforcement has used HGN for over thirty-five years, a Prater inquiry is not necessary as the test is not “novel” scientific evidence. Whitson v. Arkansas, 863 S.W.2d 794, 798 (Ark. 1993).

II. Police Officer Testimony Needed to Admit HGN Test Result

The Court did not address this issue.

III. Purpose and Limits of HGN

HGN may be admitted as evidence of impairment, but is not admissible to prove a specific BAC. Whitson, 863 S.W.2d at 798.

California

I. Evidentiary Admissibility

HGN is a scientific test and the Kelly/Frye “general acceptance” standard must be applied.

California v. Leahy, 882 P.2d 321 (Cal. 1994). California v. Joehnk, 35 Cal. App. 4th 1488, 1493, 42 Cal. Rptr. 2d 6, 8 (Cal. Ct. App. 1995).

“□A consensus drawn from a typical cross-section of the relevant, qualified scientific community accepts the HGN testing procedures□.”

Joehnk, 35 Cal. App. 4th at 1507, 42 Cal. Rptr. 2d at 17.

II. Police Officer Testimony Needed to Admit HGN Test Result

Police officer testimony is insufficient to establish “general acceptance in the relevant scientific community.” Leahy, 882 P2d. at 609. Also see People v. Williams, 3 Cal. App. 4th 1326 (Cal. Ct. App. 1992).

Police officer can give opinion, based on HGN and other test results, that defendant was intoxicated. Furthermore, police officer must testify as to the administration and result of the test. Joehnk, 35 Cal. App. 4th at 1508, 42 Cal. Rptr. 2d at 18.

III. Purpose and Limits of HGN

HGN may be used, along with other scientific tests, as some evidence that defendant was impaired. Joehnk, 35 Cal. App. 4th at 1508, 42 Cal. Rptr. 2d at 17.

HGN test results may not be used to quantify the BAC level of the defendant. California v. Loomis, 156 Cal. App. 3d Supp. 1, 5-6, 203 Cal. Rptr. 767, 769-70 (1984).

Connecticut

I. Evidentiary Admissibility

Proper foundation must be established in accordance with Daubert prior to the introduction of HGN test results. *State v. Russo*, 773 A. 2d 965 (Conn. App. Ct. 2001).

Also see, *Connecticut v. Merritt*, 647 A.2d 1021, 1028 (Conn. App. Ct. 1994). HGN must meet the Frye test of admissibility. In this case, the state presented no evidence to meet its burden under the Frye test.

HGN satisfies the Porter standards and is admissible. (In *State v. Porter*, 698 A.2d 739 (1997), the Connecticut Supreme Court held the Daubert approach should govern the admissibility of scientific evidence and expressed factors to be considered in assessing evidence.) *Connecticut v. Carlson*, 720 A.2d 886 (Conn. Super. Ct. 1998).

II. Police Officer Testimony Needed to Admit HGN Test Result

Must lay a proper foundation with a showing that the officer administering the test had the necessary qualifications and followed proper procedures. *Connecticut v. Merritt*, 647 A.2d 1021, 1028 (Conn. App. Ct. 1994).

III. Purpose and Limits of HGN

HGN test results can be used to establish probable cause to arrest in a criminal hearing. *Connecticut v. Royce*, 616 A.2d 284, 287 (Conn. App. Ct. 1992).

Delaware

I. Evidentiary Admissibility

HGN evidence is scientific and must satisfy the Delaware Rules of Evidence standard. *Delaware v. Ruthardt*, 680 A.2d 349, 356 (Del. Super. Ct. 1996).

HGN evidence is acceptable scientific testimony under the Delaware Rules of Evidence. *Ruthardt*, 680 A.2d at 362.

II. Police Officer Testimony Needed to Admit HGN Test Result

Police officer may be qualified as an expert to testify about the underlying scientific principles that correlate HGN and alcohol. Delaware police receiving three-day (twenty-four hour) instruction on HGN test administration are not qualified to do this. *Ruthardt*, 680 A.2d at 361-62.

Police officer testimony about training and experience alone, without expert testimony, is not enough foundation to admit HGN test results. *Zimmerman v. Delaware*, 693 A.2d 311, 314 (Del. 1997).

III. Purpose and Limits of HGN

HGN test results admissible to show probable cause in a criminal hearing.
Ruthardt, 680 A.2d at 355.

HGN test results admissible to show probable cause in a civil hearing.
Cantrell v. Division of Motor Vehicles, 1996 Del. Super. LEXIS 265 (Del. Super. Ct. Apr. 9, 1996).

HGN test results cannot be used to quantify the defendant's BAC. However, they can be used as substantive evidence that the defendant was "under the influence of intoxicating liquor." Ruthardt, 680 A.2d at 361-62.

District of Columbia

I. Evidentiary Admissibility

The Court does not address this issue.

II. Police Officer Testimony Needed to Admit HGN Test Result

The Court used the case law of other jurisdictions to come to the conclusion that the Officer in the case could testify as an expert on the administration and the results of the HGN test. Therefore, in this case, the evidence was properly admitted using the Officer as the expert. See Karamychev v. District of Columbia, 772 A. 2d 806 (D.C. App. 2001).

III. Purpose and Limits of HGN

The Court has not yet addressed this issue.

Florida

I. Evidentiary Admissibility

The 3rd District Court found HGN to be a "quasi-scientific" test. Its application is dependent on a scientific proposition and requires a particular expertise outside the realm of common knowledge of the average person. It does not have to meet the Frye standard because HGN has been established and generally accepted in the relevant scientific community, and has been Frye tested in the legal community. The court took judicial notice that HGN is reliable based on supportive case law from other jurisdictions, numerous testifying witnesses and studies submitted. It is "no longer 'new or novel' and there is simply no need to reapply a Frye analysis." Williams v. Florida, 710 So. 2d 24 (Fla. Dist. Ct. App. 1998).

The 4th District Court found HGN to be a scientific test. However, because it is not novel, the Frye standard is not applicable. However, “[e]ven if not involving a new scientific technique, evidence of scientific tests is admissible only after demonstration of the traditional predicates for scientific evidence including the test's general reliability, the qualifications of test administrators and technicians, and the meaning of the results.” Without this predicate, “the danger of unfair prejudice, confusion of issues or misleading the jury from admitting HGN test results outweighs any probative value.” The state did not establish the appropriate foundation for the admissibility of HGN test results. *Florida v. Meador*, 674 So. 2d 826, 835 (Fla. Dist. Ct. App. 1996), review denied, 686 So. 2d 580 (Fla. 1996).

II. Police Officer Testimony Needed to Admit HGN Test Result

“We take judicial notice that HGN test results are generally accepted as reliable and thus are admissible into evidence once a proper foundation has been laid that the test was correctly administered by a qualified DRE [Drug Recognition Expert].” *Williams*, 710 So. 2d at 32.

Also see *Bown v. Florida*, 745 So. 2d 1108 (Fl. Dist. Ct. App. 1999) which expands *Williams*. Allows trooper to explain HGN, but district requires confirmatory blood, breath or urine test before admitting HGN into evidence.

No evidence presented as to the police officer’s qualifications nor administration of the HGN test in this case. *Meador*, 674 So. 2d at 835.

III. Purpose and Limits of HGN

The HGN test results alone, in the absence of a chemical analysis of blood, breath, or urine, are inadmissible to trigger the presumption provided by the DUI statute, and may not be used to establish a BAC of .08 percent or more. *Williams*, 710 So. 2d at 36.

Georgia

I. Evidentiary Admissibility

The HGN test is admissible as a “scientifically reliable field sobriety evaluation” under the Harper “verifiable certainty” standard. *Manley v. Georgia*, 424 S.E.2d 818, 819-20 (Ga. Ct. App. 1992).

HGN testing is judicially noticed as a scientifically reliable test and therefore expert testimony is no longer required before the test results can be admitted. *Hawkins v. Georgia*, 476 S.E.2d 803, 808-09 (Ga. Ct. App. 1996).

II. Police Officer Testimony Needed to Admit HGN Test Result

Police officer, who received specialized training in DUI detection and worked with a DUI task force for two years, was permitted to testify that, in his opinion, defendant was under the influence. *Sieveking v. Georgia*, 469 S.E.2d 235, 219-20 (Ga. Ct. App. 1996).

A police officer who testifies to the results, administration, and procedure of HGN may be cross-examined about those areas even if the state only offers him as a POST-certified officer. This is because the analysis and expertise needed for HGN go far beyond those needed by a lay person who observes the walk and turn or one leg stance tests. *James v. State*, 2003 WL 1540235 (Ga. App.).

III. Purpose and Limits of HGN

HGN test can be admitted to show that the defendant “was under the influence of alcohol to the extent that it was less safe for him to drive.” *Sieveking*, 469 S.E.2d at 219.

Hawaii

I. Evidentiary Admissibility

HGN is a scientific test. The HGN test is reliable under the Hawaii Rules of Evidence and admissible as “evidence that police had probable cause to believe that a defendant was DUI.” Judicial notice of the “validity of the principles underlying HGN testing and the reliability of HGN test results” is appropriate. HGN test results can be admitted into evidence if the officer administering the test was duly qualified to conduct the test and the test was performed properly. *Hawaii v. Ito*, 978 P.2d 191 (Haw. Ct. App. 1999).

II. Police Officer Testimony Needed to Admit HGN Test Result

Before HGN test results can be admitted into evidence in a particular case, however, it must be shown that (1) the officer administering the test was duly qualified to conduct and grade the test; and (2) the test was performed properly in the instant case. *Hawaii v. Ito*, 978 P.2d 191 (Haw. Ct. App. 1999), See also *Hawaii v. Toyomura*, 904 P.2d 893, 911 (Haw. 1992) and *Hawaii v. Montalbo*, 828 P.2d. 1274, 1281 (Haw. 1992).

III. Purpose and Limits of HGN

HGN test can be admitted as “evidence that police had probable cause to believe that a defendant was DUI.” *Hawaii v. Ito*, 978 P.2d 191 (Haw. Ct. App. 1999).

*Idaho***I. Evidentiary Admissibility**

HGN test results admitted under the Idaho Rules of Evidence. Rule 702 is the correct test in determining the admissibility of HGN. *State v. Gleason*, 844 P.2d 691, 694 (Idaho 1992).

II. Police Officer Testimony Needed to Admit HGN Test Result

Officer may testify as to administration of HGN test, but not correlation of HGN and BAC.

State v. Garrett, 811 P.2d 488, 493 (Idaho 1991).

III. Purpose and Limits of HGN

“HGN test results may not be used at trial to establish the defendant's blood alcohol level. Although we note that in conjunction with other field sobriety tests, a positive HGN test result does supply probable cause for arrest, standing alone that result does not provide proof positive of DUI□.” *Garrett*, 811 P.2d at 493.

HGN may be “admitted for the same purpose as other field sobriety test evidence -- a physical act on the part of [defendant] observed by the officer contributing to the cumulative portrait of [defendant] intimating intoxication in the officer's opinion.” *Gleason*, 844 P.2d at 695.

*Illinois***I. Evidentiary Admissibility**

HGN meets Frye standard of admissibility.

People v. Buening, 592 N.E.2d 1222, 1227 (Ill. App. Ct. 1992).

Despite the ruling of the Buening appellate court, the Fourth District Court of Appeals declined to recognize HGN's general acceptance without a Frye hearing. The court criticized the Buening court for taking judicial notice of HGN's reliability based on the decisions of other jurisdictions. *People v. Kirk*, 681 N.E.2d 1073, 1077 (Ill. App. Ct. 1997).

The state supreme court held that the state was no longer required to show that an HGN test satisfied the Frye standard before introducing the results of the test into evidence. Absent proof by the defense that the HGN test was unsound, the State only had to show that the officer who gave the test was trained in the procedure and that the test was properly administered. *The People of the State of Illinois v. Linda Basler*, 740 N.E.2d 1 (Ill. 2000), 2000 Ill. LEXIS 1698 (Ill. 2000). (Plurality Opinion) According to Fourth Circuit, a Frye hearing must be held for HGN to be admitted. *People v. Herring*, 762 N.E.2d 1186.

II. Police Officer Testimony Needed to Admit HGN Test Result

“A proper foundation should consist of describing the officer's education and experience in administering the test and showing that the procedure was properly administered.”
Buening, 592 N.E.2d at 1227.

III. Purpose and Limits of HGN

HGN test results may be used to establish probable cause in a criminal hearing.
People v. Furness, 526 N.E.2d 947, 949 (Ill. App. Ct. 1988).

HGN test results admissible to show probable cause in a civil hearing.
People v. Hood, 638 N.E.2d 264, 274 (Ill. App. Ct. 1994).

HGN test results may be used “to prove that the defendant is under the influence of alcohol.” Buening, 592 N.E.2d at 1228.

Indiana

I. Evidentiary Admissibility

Results of properly administered HGN test are admissible to show impairment which may be caused by alcohol and, when accompanied by other evidence, will be sufficient to establish probable cause to believe a person may be intoxicated. Cooper v. Indiana, 751 N.E.2d 900, 903 (Ind. Ct. App. Feb. 2002)

II. Police Officer Testimony Needed to Admit HGN Test Result

The proper foundation for admitting HGN evidence should consist of describing the officer's education and experience in administering the test and showing that the procedure was properly administered. Cooper, 751 N.E.2d at 903.

The question of whether a trained officer might express an opinion that defendant was intoxicated based upon the results of field sobriety tests was not before the court, and thus, the court expressed no opinion concerning the admissibility of such testimony. Cooper, 751 N.E. 2d at 902, n. 1.

III. Purpose and Limits of HGN

HGN test results, when accompanied by other evidence, will be sufficient to establish probable cause that the person may be intoxicated. Cooper, 751 N.E.2d at 903.

Iowa

I. Evidentiary Admissibility

HGN admissible as a field test under the Iowa Rules of Evidence. “[T]estimony by a properly trained police officer with respect to the administration and results of the horizontal gaze nystagmus test are admissible without need for further scientific evidence.”

State v. Murphy, 451 N.W.2d 154, 158 (Iowa 1990).

II. Police Officer Testimony Needed to Admit HGN Test Result

Police officer may testify about HGN test results under Rule 702 if the officer is properly trained to administer the test and objectively records the results.

Murphy, 451 N.W.2d at 158.

III. Purpose and Limits of HGN

HGN test results may be used as an indicator of intoxication. Murphy, 451 N.W.2d at 158.

Kansas

I. Evidentiary Admissibility

HGN must meet Frye standard of admissibility and a Frye hearing is required at the trial level. There was no Frye hearing conducted and the appellate court refused to make a determination based on the record it had. State v. Witte, 836 P.2d 1110, 1121 (Kan. 1992).

HGN test has not achieved general acceptance within the relevant scientific community and its exclusion was appropriate. State v. Chastain, 960 P.2d 756 (Kan. 1998).

II. Police Officer Testimony Needed to Admit HGN Test Result

The Court did not address this issue.

III. Purpose and Limits of HGN

The Court did not address this issue.

Kentucky

I. Evidentiary Admissibility

HGN test results admitted due to defendant's failure to object.
Commonwealth v. Rhodes, 949 S.W.2d 621, 623 (Ky. Ct. App. 1996).

II. Police Officer Testimony Needed to Admit HGN Test Result

The Court did not address this issue.

III. Purpose and Limits of HGN

The Court did not address this issue.

Louisiana

I. Evidentiary Admissibility

HGN meets Frye standard of admissibility and with proper foundation may be admitted as evidence of intoxication.

State v. Breitung, 623 So. 2d 23, 25-6 (La. Ct. App. 1993).
State v. Regan, 601 So. 2d 5, 8 (La. Ct. App. 1992).
State v. Armstrong, 561 So. 2d 883, 887 (La. Ct. App. 1990).

The standard of admissibility for scientific evidence is currently the Louisiana Rules of Evidence. State v. Foret, 628 So. 2d 1116 (La. 1993).

II. Police Officer Testimony Needed to Admit HGN Test Result

Police officer may testify as to training in HGN procedure, certification in the administration of HGN test and that the HGN test was properly administered. Armstrong, 561 So. 2d at 887.

III. Purpose and Limits of HGN

The HGN test may be used by the officer "to determine whether or not he [needs] to 'go any further' and proceed with other field tests." Breitung, 623 So. 2d at 25.
HGN test results may be admitted as evidence of intoxication.
Armstrong, 561 So. 2d at 887.

Maine

I. Evidentiary Admissibility

Because the HGN test relies on greater scientific principles than other field sobriety tests, the reliability of the test must first be established. Either Daubert or Frye standard must be met. *State v. Taylor*, 694 A.2d 907, 912 (Me. 1997).

The Maine Supreme Court took judicial notice of the reliability of the HGN test to detect impaired drivers. *Taylor*, 694 A.2d at 910.

II. Police Officer Testimony Needed to Admit HGN Test Result

“A proper foundation shall consist of evidence that the officer or administrator of the HGN test is trained in the procedure and the [HGN] test was properly administered.” *Taylor*, 694 A.2d at 912.

III. Purpose and Limits of HGN

HGN test results may only be used as “evidence of probable cause to arrest without a warrant or as circumstantial evidence of intoxication. The HGN test may not be used by an officer to quantify a particular blood alcohol level in an individual case.” *Taylor*, 694 A.2d at 912.

Maryland

I. Evidentiary Admissibility

HGN is scientific and must satisfy the Frye/Reed standard of admissibility. The Court of Appeals took judicial notice of HGN's reliability and its acceptance in the relevant scientific communities. *Schultz v. State*, 664 A.2d 60, 74 (Md. Ct. Spec. App. 1995).

II. Police Officer Testimony Needed to Admit HGN Test Result

Police officer must be properly trained or certified to administer the HGN test. [NOTE: In *Schultz*, the police officer failed to articulate the training he received in HGN testing and the evidence was excluded.] *Schultz*, 664 A.2d at 77.

III. Purpose and Limits of HGN

HGN testing may not be used to establish a specific blood alcohol level. *Wilson v. State*, 723 A.2d 494 (Md. Ct. Spec. App. 1999).

Massachusetts

I. Evidentiary Admissibility

HGN is scientific and is admissible on a showing of either general acceptance in the scientific community or reliability of the scientific theory. See *Commonwealth v. Lanigan*, 641 N.E.2d 1342 (Mass. 1994). HGN test results are inadmissible until the Commonwealth introduces expert testimony to establish that the HGN test satisfies one of these two standards. *Commonwealth v. Sands*, 675 N.E.2d 370, 373 (Mass. 1997).

II. Police Officer Testimony Needed to Admit HGN Test Result

“There must be a determination as to the qualification of the individual administering the HGN test and the appropriate procedure to be followed.” In this case there was no testimony as to these facts, thus denying the defendant the opportunity to challenge the officer’s qualifications and administration of the test. *Sands*, 675 N.E.2d at 373.

III. Purpose and Limits of HGN

The Court did not address this issue.

Michigan

I. Evidentiary Admissibility

Court found that HGN test is scientific evidence and is admissible under the Frye standard of admissibility. *State v. Berger*, 551 N.W.2d 421, 424 (Mich. Ct. App. 1996).

II. Police Officer Testimony Needed to Admit HGN Test Result

Only foundation necessary for the introduction of HGN test results is evidence that the police officer properly performed the test and that the officer administering the test was qualified to perform it. *Berger*, 551 N.W.2d at 424.

III. Purpose and Limits of HGN

HGN test results are admissible to indicate the presence of alcohol. *Berger*, 551 N.W.2d at 424 n.1.

Minnesota

I. Evidentiary Admissibility

Court found that HGN meets the Frye standard of admissibility. *State v. Klawitter*, 518 N.W.2d 577, 585 (Minn. 1994).

II. Police Officer Testimony Needed to Admit HGN Test Result

Police officers must testify about their training in and experience with the HGN test. See generally *Klawitter*, 518 N.W.2d at 585-86.

III. Purpose and Limits of HGN

HGN admissible as evidence of impairment as part of a Drug Evaluation Examination in the prosecution of a person charged with driving while under the influence of drugs. See generally *Klawitter*, 518 N.W.2d at 585.

Mississippi

I. Evidentiary Admissibility

HGN is a scientific test. However, it is not generally accepted within the relevant scientific community and is inadmissible at trial in the State of Mississippi. *Young v. City of Brookhaven*, 693 So.2d 1355, 1360-61 (Miss. 1997).

II. Police Officer Testimony Needed to Admit HGN Test Result

Police officers cannot testify about the correlation between the HGN test and precise blood alcohol content. *Young*, 693 So.2d at 1361.

III. Purpose and Limits of HGN

HGN test results are admissible only to prove probable cause to arrest. *Young*, 693 So.2d at 1361.

HGN test results cannot be used as scientific evidence to prove intoxication or as a mere showing of impairment. *Young*, 693 So.2d at 1361.

Missouri

I. Evidentiary Admissibility

Court found that HGN test meets the Frye standard of admissibility. *State v. Hill*, 865 S.W.2d 702, 704 (Mo. Ct. App. 1993), rev'd on other grounds, *State v. Carson*, 941 S.W.2d 518, 520 (Mo. 1997).

II. Police Officer Testimony Needed to Admit HGN Test Result

Police officer must be adequately trained and able to properly administer the test. *Hill*, 865 S.W.2d at 704.

See also, *Duffy v. Director of Revenue*, 966 S.W. 2d 372 (Mo. Ct. App. 1998). HGN not admitted at trial because the administering officer was not aware of how to properly score the test and interpret its results.

III. Purpose and Limits of HGN

HGN can be admitted as evidence of intoxication. *Hill*, 865 S.W.2d at 704.

Montana

I. Evidentiary Admissibility

Court found that HGN is neither new nor novel; thus, *Daubert* does not apply. Court still finds that HGN must meet the state's rules of evidence that are identical to the Federal Rules of Evidence. *Hulse v. DOJ, Motor Vehicle Div.*, 961 P.2d 75, 88 (Mont. 1998).

II. Police Officer Testimony Needed to Admit HGN Test Result

The court held that before an arresting officer may testify as to HGN results, a proper foundation must show that the officer was properly trained to administer the HGN test and that he administered the test in accordance with this training. Before the officer can testify as to the correlation between alcohol and nystagmus, a foundation must be established that the officer has special training in the underlying scientific basis of the HGN test.

Hulse, 961 P.2d 75 (Mont. 1998).

See Also, *State v. Crawford*, 315 Mont. 480, 68 P.3d 848 (2003), in which the court ruled that the officer's credentials were sufficient to establish his expertise, along with evidence that he was previously qualified as an expert. They relied on *Russette* (2002 MT 200), stating that to establish an expert's qualifications, the proponent of the testimony must show that the expert has special training or education and adequate knowledge on which to base an opinion.

III. Purpose and Limits of HGN

HGN test results admissible as evidence of impairment.

State v. Clark, 762 P.2d 853, 856 (Mont. 1988).

Nebraska

I. Evidentiary Admissibility

HGN meets the *Frye* standard for acceptance in the relevant scientific communities, and when the test is given in conjunction with other field sobriety tests, the results are admissible for the limited purpose of establishing impairment that may be caused by alcohol. *State v. Baue*, 607 N.W.2d 191 (Neb. 2000)

II. Police Officer Testimony Needed to Admit HGN Test Result

A police officer may testify to the results of HGN testing if it is shown that the officer has been adequately trained in the administration and assessment of the HGN test and has conducted the testing and assessment in accordance with that training.
State v. Baue, 607 N.W.2d 191 (Neb. 2000)

III. Purpose and Limits of HGN

“Testimony concerning HGN is admissible on the issue of impairment, provided that the prosecution claims no greater reliability or weight for the HGN evidence than it does for evidence of the defendant's performance on any of the other standard field sobriety tests, and provided further that the prosecution makes no attempt to correlate the HGN test result with any particular blood-alcohol level, range of blood-alcohol levels, or level of impairment.” State v. Baue, 607 N.W.2d 191 (Neb. 2000) (quoting Ballard v. State, 955 P.2d 931, 940 (Alaska App. 1998))

New Hampshire

I. Evidentiary Admissibility

In State v. Dahoo (Dec. 20, 2002), the N.H. Supreme Court ruled that the HGN test is admissible under N.H. Rule of Evidence 702 and Daubert for the limited purpose of providing circumstantial evidence of intoxication. HGN test is a scientifically reliable and valid test.

N.H. Supreme Court ruled their findings binding in Dahoo and that courts “will not be required to establish the scientific reliability of the HGN.”

II. Police Officer Testimony Needed to Admit HGN Test Result

“Since we have already determined that the scientific principles underlying the HGN test are reliable, a properly trained and qualified police officer may introduce the HGN test results at trial.” State v. Dahoo, 2002 N.H. LEXIS 179.

III. Purpose and Limits of HGN

“HGN results cannot be introduced at trial for the purpose of establishing a defendant's BAC level. [T]he results are not sufficient alone to establish intoxication.”
State v. Dahoo, Id.

New Jersey

I. Evidentiary Admissibility

In New Jersey, the party offering the results of a scientific procedure into evidence must comply with Frye and show that the procedure is generally accepted in the relevant scientific communities. A party may prove this general acceptance via “(1) testimony of knowledgeable experts[,] (2) authoritative scientific literature[, or] (3) [p]ersuasive judicial decision.” Based on the testimony of Dr. Marcelline Burns and Dr. Jack Richman, the Court found the HGN test to be generally accepted and the results thus admissible. The Court also noted the “significant number” of jurisdictions that have accepted the HGN test as admissible scientific evidence. *State v. Maida*, 2000 N.J. Super. LEXIS 276 (N.J. Super. Ct. Law Div. 2000).

*But See, *State v. Doriguzzi*, 760 A.2d 336 (N.J. Super. 2000), which held that HGN is scientific evidence that must meet Frye Standard. However, in each trial, sufficient foundation evidence must be laid by expert testimony to assure defendants that a conviction for DUI, when based in part on HGN testing, is grounded in reliable scientific data. In this case, the appellate court reversed defendant’s conviction because at trial no such foundation was presented. The court found that because HGN testing has not achieved general acceptance in the community, it is not a matter of which a court can take judicial notice.

II. Police Officer Testimony Needed to Admit HGN Test Result

The Court did not address this issue.

III. Purpose and Limits of HGN

The Court found the HGN test admissible “as a reliable scientific indicator of likely intoxication.”

New Mexico

I. Evidentiary Admissibility

HGN is a scientific test. New Mexico follows the Daubert standard, which requires a showing of reliability before scientific evidence can be admitted. The court held that a scientific expert must testify to the underlying scientific reliability of HGN and that a police officer cannot qualify as a scientific expert. Because the State failed to present sufficient evidence regarding the HGN test’s reliability, the court remanded the case stating it would be appropriate for the trial court, on remand, to make the initial determination of whether HGN testing satisfies Daubert. In addition, the court found HGN to be “beyond common and general knowledge” and declined to take judicial notice of HGN reliability.

State v. Torres, 976 P.2d 20 (N.M. 1999).

State v. Lasworth, 42 P.3d 844 (Ct. App. N.M. 2001), cert. denied (2002). Results of HGN test were inadmissible at trial (State v. Torres, 976 P.2d 20 (N.M. 1999). The State needed to prove that HGN was both valid and reliable.

State called Dr. Marceline Burns as a witness (reliability) but did not call an expert in a discipline such as biology or medicine to explain how the amount of alcohol a person consumes correlates with HGN (validity).

II. Police Officer Testimony Needed to Admit HGN Test Result

Police officers can qualify as non-scientific experts based on their training and experience. Non-scientific experts may testify about the administration of the test and specific results of the test provided another scientific expert first establishes the reliability of the scientific principles underlying the test. In order to establish the “technical or specialized knowledge” required to qualify as an expert in the administration of the HGN test, “there must be a showing: (1) that the expert has the ability and training to administer the HGN test properly, and (2) that the expert did, in fact, administer the HGN test properly at the time and upon the person in question.” State v. Torres, 976 P.2d 20 (N.M. 1999).

State v. Lasworth, 42 P.3d 844 (Ct. App. N.M. 2001), cert. denied (2002). Court believed that state had to show that presence of HGN (BAC above .08) correlates with diminishment of driver’s mental or physical driving skills (which it failed to do) & a correlation between presence of HGN and BAC above or below .08 (which it did through testimony of Dr. Burns). Court did not preclude use of results of HGN to establish probable cause for arrest or to establish grounds for administering a chemical BAC test.

III. Purpose and Limits of HGN

The Court did not address this issue.

New York

I. Evidentiary Admissibility

Prue holds that HGN test results are admissible under Frye standard of “general acceptance.” People v. Prue, Indictment No. I-5-2001, Franklin County Court (November 2001).

In Gallup, the court said that it was only necessary to conduct a foundational inquiry into the techniques and the tester’s qualifications for admissibility.

People v. Gallup, Memorandum and order #13094, 302 A.D.2d 681 (3rd Dept)(2003).

The Court allowed the introduction of HGN and the results because it was properly administered and the burden of establishing that HGN is a reliable indicator of intoxication is generally accepted in the relevant scientific community was satisfied. *People v. William Miley*, NYLJ 12/6/02 p.30 col. 6 (Nassau Co. Ct 2002).

II. Police Officer Testimony Needed to Admit HGN Test Result

The People must lay a proper evidentiary foundation in order for HGN results to be admissible at trial.

III. Purpose and Limits of HGN

The Court held that HGN is generally accepted in the relevant scientific community as a reliable indicator of intoxication.

North Carolina

I. Evidentiary Admissibility

HGN is a scientific test. It “does not measure behavior a lay person would commonly associate with intoxication but rather represents specialized knowledge that must be presented to the jury by a qualified expert.” As a result, “until there is sufficient scientifically reliable evidence as to the correlation between intoxication and nystagmus, it is improper to permit a lay person to testify as to the meaning of HGN test results.” *State v. Helms*, 504 S.E.2d 293 (N.C. 1998).

II. Police Officer Testimony Needed to Admit HGN Test Result

Testimony of one police officer, whose training consisted of a “forty hour training class dealing with the HGN test”, was inadequate foundation for admission of HGN test results.

Helms, 504 S.E.2d 293 (N.C. 1998).

III. Purpose and Limits of HGN

HGN test results are evidence of impairment. *Helms*, 504 S.E.2d 293 (N.C. 1998).

North Dakota

I. Evidentiary Admissibility

Court found that HGN test is admissible as a standard field sobriety test. *City of Fargo v. McLaughin*, 512 N.W.2d 700, 706 (N.D. 1994).

II. Police Officer Testimony Needed to Admit HGN Test Result

Police officer must testify as to training and experience and that the test was properly administered. City of Fargo, 512 N.W.2d at 708.

III. Purpose and Limits of HGN

“ . . . HGN test results admissible only as circumstantial evidence of intoxication, and the officer may not attempt to quantify a specific BAC based upon the HGN test.”
City of Fargo, 512 N.W.2d at 708.

Ohio

I. Evidentiary Admissibility

HGN test is objective in nature and does not require an expert interpretation.
State v. Nagel, 506 N.E.2d 285, 286 (Ohio Ct. App. 1986).

Court determined that HGN was a reliable indicator of intoxication without specifically ruling on whether HGN meets Frye or some other standard of admissibility.
State v. Bresson, 554 N.E.2d 1330, 1334 (Ohio 1990).

Court held that SFSTs, including HGN, must be administered in strict compliance with NHTSA's directives in order for the test results to be admissible.
State v. Homan, 732 N.E.2d 952 (Ohio 2000).

II. Police Officer Testimony Needed to Admit HGN Test Result

Police officer need only testify to training in HGN procedure, knowledge of the test and ability to interpret results. Bresson, 554 N.E.2d at 1336.

III. Purpose and Limits of HGN

HGN can be used to establish probable cause to arrest and as substantive evidence of a defendant's guilt or innocence in a trial for DUI, but not to determine defendant's BAC.
Bresson, 554 N.E.2d at 1336.

Oklahoma

I. Evidentiary Admissibility

HGN test results excluded because state failed to lay adequate foundation regarding HGN's scientific admissibility under the Frye standard of admissibility. Police officer's testimony alone was insufficient. Yell v. State, 856 P.2d 996, 996-97 (Okla. Crim. App. 1993).

The Daubert rationale replaces the Frye standard as the admissibility standard for scientific evidence. Taylor v. State, 889 P.2d 319, 328-29 (Okla. Crim. App. 1995).

II. Police Officer Testimony Needed to Admit HGN Test Result

Police officer testified to training on how to administer HGN test and how the test was administered in this case. Officer also testified as to his training in analyzing HGN test results. Yell, 856 P.2d at 997.

III. Purpose and Limits of HGN

If HGN testing was found to satisfy the Frye standard of admissibility, HGN test results would be considered in the same manner as other field sobriety test results. HGN test results are inadmissible as scientific evidence creating a presumption of intoxication. Yell, 856 P.2d at 997.

Oregon

I. Evidentiary Admissibility

HGN test results are admissible under the Oregon Rules of Evidence. HGN test results are scientific in nature, are relevant in a DUI trial, and are not unfairly prejudicial to the defendant. State v. O'Key, 899 P.2d 663, 687 (Or. 1995).

II. Police Officer Testimony Needed to Admit HGN Test Result

“Admissibility is subject to a foundational showing that the officer who administered the test was properly qualified, that the test was administered properly, and that the test results were recorded accurately.” O'Key, 899 P.2d at 670.

III. Purpose and Limits of HGN

“□ HGN test results are admissible to establish that a person was under the influence of intoxicating liquor, but is not admissible □ to establish a person's BAC □.” O'Key, 899 P.2d at 689-90.

Officer may not testify that, based on HGN test results, the defendant's BAC was over .10. State v. Fiskens, 909 P.2d 206, 207 (Or. Ct. App. 1996).

Pennsylvania

I. Evidentiary Admissibility

The state laid an inadequate foundation for the admissibility of HGN under the Frye/Topa standard.

Commonwealth v. Moore, 635 A.2d 625, 629 (Pa. Super. Ct. 1993).

Commonwealth v. Apollo, 603 A.2d 1023, 1028 (Pa. Super. Ct. 1992).

Commonwealth v. Miller, 532 A.2d 1186, 1189-90 (Pa. Super. Ct. 1987).

Testimony of police officer is insufficient to establish scientific reliability of HGN test.
Moore, 635 A.2d at 692.
Miller, 532 A.2d at 1189-90.

Testimony of behavioral optometrist did not establish general acceptance of HGN test.
Apollo, 603 A.2d at 1027-28.

II. Police Officer Testimony Needed to Admit HGN Test Result

County detective certified as HGN instructor. Court did not comment on whether this would be enough foundation to allow the detective to testify about HGN test results.
Moore, 635 A.2d 629.

Police officer had one-day course on HGN. Court did not comment on whether this would be enough foundation to allow the officer to testify about HGN test results.
Miller, 603 A.2d at 1189.

III. Purpose and Limits of HGN

Not addressed by court.

South Carolina

I. Evidentiary Admissibility

HGN admissible in conjunction with other field sobriety tests. By implication, HGN is not regarded as a scientific test. State v. Sullivan, 426 S.E.2d 766, 769 (S.C. 1993).

II. Police Officer Testimony Needed to Admit HGN Test Result

Police officer given twenty hours of HGN training. Sullivan, 426 S.E.2d at 769.

III. Purpose and Limits of HGN

HGN test results admissible “to elicit objective manifestations of soberness or insobriety . . . Evidence from HGN tests is not conclusive proof of DUI. A positive HGN test result is to be regarded as merely circumstantial evidence of DUI. Furthermore, HGN test shall not constitute evidence to establish a specific degree of blood alcohol content.”
Sullivan, 426 S.E.2d at 769.

South Dakota

I. Evidentiary Admissibility

If it can be shown that a horizontal gaze nystagmus test was properly administered by a trained officer, such evidence should be admitted for a jury to consider at trial along with evidence of the other accepted field sobriety tests administered in South Dakota. STATE v. HULLINGER, 2002 SD 83; 649 N.W.2d 253 (S.D.S.Ct. 2002); 2002 S.D. LEXIS 99

II. Police Officer Testimony Needed to Admit HGN Test Result

Officer may testify if properly trained and test properly administered. At the pretrial hearing, the State presented three witnesses: 1) Monte Farnsworth, training director for the Office of Highway Safety at the Division of Criminal Investigation Law Enforcement Training Academy; 2) Deputy Ludwig; and 3) Dr. Larry Menning, optometrist and expert witness. South Dakota follows a Daubert standard in use of expert witnesses.

III. Purpose and Limits of HGN

The Court did not address this issue.

Tennessee

I. Evidentiary Admissibility

HGN is a scientific test. To be admissible at trial, such evidence must satisfy the requirements of Tenn. Rules of Evidence 702 and 703. State provided an inadequate amount of evidence to allow the court to conclude that HGN evidence meets this standard.

State v. Murphy, 953 S.W.2d 200 (Tenn. 1997).

II. Police Officer Testimony Needed to Admit HGN Test Result

HGN must be offered through an expert witness. To qualify as an expert, a police officer must establish that he is qualified by his “knowledge, skill, experience, training or education” to provide expert testimony to “substantially assist the trier of fact to understand the evidence or determine a fact in issue.” Although the court did not rule out the possibility that the officer can be considered an expert, the court set a high level of proof. In this case, the court felt that although the officer had attended law enforcement training in DUI offender apprehension and the HGN test, this training was not enough to establish him as an expert. State v. Grindstaff, 1998 Tenn. Crim. App. Lexis 339 (March 23, 1998).

III. Purpose and Limits of HGN

The Court did not address this issue.

Texas

I. Evidentiary Admissibility

HGN admissible under the Texas Rules of Evidence.
Emerson v. State, 880 S.W.2d 759, 769 (Tex. Crim. App. 1994).

II. Police Officer Testimony Needed to Admit HGN Test Result

A police officer must qualify as an expert on the HGN test, specifically concerning its administration and technique, before testifying about a defendant's performance on the test. Proof that the police officer is certified in the administration of the HGN test by the Texas Commission on Law Enforcement Officer Standards and Education satisfies this requirement. Emerson, 880 S.W.2d at 769.

III. Purpose and Limits of HGN

HGN admissible to prove intoxication, but not accurate enough to prove precise BAC.
Emerson, 880 S.W.2d at 769.

Utah

I. Evidentiary Admissibility

HGN test admissible as other field sobriety test. Court reserved judgment as to the scientific reliability of HGN. Salt Lake City v. Garcia, 912 P.2d 997, 1001 (Utah Ct. App. 1996).

II. Police Officer Testimony Needed to Admit HGN Test Result

Police officer need only testify as to training, experience and observations when HGN admitted as a field test. Garcia, 912 P.2d at 1001.

III. Purpose and Limits of HGN

Admissible as any other field sobriety test. Garcia, 912 P.2d at 1000-01.

Washington

I. Evidentiary Admissibility

It is "undisputed" in the relevant scientific communities that "an intoxicated person will exhibit nystagmus". HGN testing is not novel and has been used as a field sobriety test for "decades" and is administered the same whether investigating alcohol impairment or

drug impairment. Thus, the use of HGN in drug and alcohol impaired driving cases is acceptable.

State v. Baity, 140 Wn.2d 1, 991 P.2d 1151 (Wash. 2000).

“[T]he Frye standard applies to the admission of evidence based on HGN testing, unless . . . the State is able to prove that it rests on scientific principles and uses techniques which are not ‘novel’ and are readily understandable by ordinary persons.” The state failed to present any evidence to this fact and the court declined to take judicial notice of HGN.

State v. Cissne, 865 P.2d 564, 569 (Wash. Ct. App. 1994).

II. Police Officer Testimony Needed to Admit HGN Test Result

The Court did not address this issue.

III. Purpose and Limits of HGN

The Court did not address this issue.

West Virginia

I. Evidentiary Admissibility

The state did not present evidence for the court to reach “the question of whether the HGN test is sufficiently reliable to be admissible.” However, the court did conclude “that even if the reliability of the HGN test is demonstrated, an expert’s testimony as to a driver’s performance on the test is admissible only as evidence that the driver was under the influence. Estimates of blood alcohol content based on the HGN test are inadmissible.” State v. Barker, 366 S.E.2d 642, 646 (W. Va. 1988).

The West Virginia Supreme Court modified State v. Barker to the extent that the Daubert analysis of FRE 702 is applicable to the question of admissibility of expert testimony under the West Virginia Rules of Evidence Rule 702.

Wilt v. Buracker, 443 S.E. 2d 196 (W.Va. 1993).

II. Police Officer Testimony Needed to Admit HGN Test Result

Police officer's training consisted of a one-day, eight-hour training session conducted by the state police. Officer testified to giving the HGN test about 100 times. Court did not reach question of whether this would be enough to allow the officer to testify about the HGN test results. Barker, 366 S.E.2d at 644.

III. Purpose and Limits of HGN

HGN test results admissible to show probable cause in a civil hearing.

Muscattell v. Cline, 474 S.E.2d 518, 525 (W. Va. 1996).

Boley v. Cline, 456 S.E.2d 38, 41 (W. Va. 1995).

“If the reliability of the HGN test is demonstrated, an expert's testimony as to a driver's performance on the test is admissible only as evidence that the driver was under the influence,” the same as other field sobriety tests. Barker, 366 S.E.2d at 646.

Wisconsin

I. Evidentiary Admissibility

The court held that the HGN test results are admissible in this case because the test results were not the only evidence. The results were accompanied by the expert testimony of the officer. State v. Zivcic, 598 N.W.2d 565 (Wisc. Ct. App. 1999). See also, State v. Maxon, 633 N.W. 2d 278 (Wisc. Ct. App. 2001)

II. Police Officer Testimony Needed to Admit HGN Test Result

A police officer who is properly trained to administer and evaluate the HGN test can testify to the test results. A second expert witness is not needed. State v. Zivcic, 598 N.W.2d 565 (Wisc. Ct. App. 1999).

III. Purpose and Limits of HGN

The Court did not address this issue.

Wyoming

I. Evidentiary Admissibility

SFSTs, including HGN, are admissible to establish probable cause when administered in substantial compliance with NHTSA guidelines. Strict compliance is not necessary. The court took judicial notice of the number of states that allow HGN evidence on the basis of the “officer’s training, experience and ability to administer the test”. Smith v. Wyoming, 2000 Wyo. LEXIS 202 (Wyo. October 4, 2000).

II. Police Officer Testimony Needed to Admit HGN Test Result

A police officer that is properly trained to administer and evaluate the HGN test can testify to HGN results. Smith v. Wyoming, 2000 Wyo. LEXIS 202 (Wyo. October 4, 2000).

III. Purpose and Limits of HGN

HGN test results are admissible to show probable cause. Smith v. Wyoming, 2000 Wyo. LEXIS 202 (Wyo. October 4, 2000).

United States

I. Evidentiary Admissibility

U.S. V. Eric D. Horn, 185 F. Supp. 2d 530 (D. Maryland 2002) In this case, U.S. District Court in Maryland made the first application of the newly revised FRE 702 to the HGN and other SFSTs.

Results of properly administered WAT, OLS and HGN, SFSTs may be admitted into evidence in a DWI/DUI case only as circumstantial evidence of intoxication or impairment but not as direct evidence of specific BAC.

Officer must first establish his qualifications to administer the test - training and experience, not opinion about accuracy rate of test or causal connection between alcohol consumption and exaggerated HGN.

Government may prove causal connection by: judicial notice, expert testimony, or learned treatise. Horn may prove other causes by: judicial notice, cross-examination of state's expert, defense expert, or learned treatise.

U.S. V. Daras, 1998 WL 726748 (4th Cir. 1998)(Unpublished opinion). WAT and OLS were not scientific so no expert needed. Court would have applied Daubert to HGN test, but there was no need to because breathalyzer, WAT and OLS were sufficient.

HGN test was admitted as part of series of field tests. Its admission was not challenged on appeal. U.S. v. Van Griffin, 874 F.2d 634 (9th Cir. 1989).

II. Police Officer Testimony Needed to Admit HGN Test Result

Foundation for HGN must address validity & reliability under FRE 702. In Horn, prosecution had a medical doctor and a police officer, but defense used behavioral psychologist to attack HGN literature of Dr. Marceline Burns and others.

III. Purpose and Limits of HGN

SFSTs may be admitted into evidence in a DWI/DUI case only as circumstantial evidence of intoxication or impairment but not as direct evidence of specific BAC. Horn.

Properly qualified, Officer may give opinion of intoxication or impairment by alcohol. Horn.

Note: The following states were not listed above due to a lack of case law discussion on HGN:

Colorado
Nevada
Rhode Island

Vermont(HGN was mentioned in the context of a refusal being admissible as evidence of probative guilt. State v. Blouin, 168 Vt. 119 (Vt. 1998)
Virginia

Last Update: Jan. 2004

For future updates, please contact:

National Traffic Law Center, 99 Canal Center Plaza, Suite 510, Alexandria, Virginia, 22314

Phone:(703) 549-4253, Fax: 703-836-3195, email: trafficlaw@ndaa-apri.org

Or

Visit their website www.ndaa-apri.org

SCIENTIFIC PUBLICATIONS AND RESEARCH REPORTS ADDRESSING NYSTAGMUS

1. Anderson, Schweitz & Snyder, Field Evaluation of Behavioral Test Battery for DWI, U.S. Dept. of Transportation Rep. No. DOT HS 806 475 (1983) (field evaluation of the Standardized Field Sobriety Test battery (HGN, one leg stand, and walk and turn) conducted by police officers from four jurisdictions indicated that the battery was approximately 80% effective in determining BAC above and below .10 percent).
2. Aschan, Different Types of Alcohol Nystagmus, 140 ACTA OTOLARYNGOL SUPP. 69 (Sweden 1958) ("From a medico legal viewpoint, simultaneous recording of AGN (Alcohol Gaze Nystagmus) and PAN (positional alcoholic nystagmus) should be of value, since it will show in which phase the patient's blood alcohol curve is...").
3. Aschan & Bergstedt, Positional Alcoholic Nystagmus in Man Following Repeated Alcohol Doses, 80 ACTA OTOLARYNGOL SUPP. 330 (Sweden 1975) (abstract available on DIALOG, file 173: Embase 1975 79) (degree of intoxication influences both PAN I and PAN II).
4. Aschan, Bergstedt, Goldberg & Laurell, Positional Nystagmus in Man During and After Alcohol Intoxication, 17 Q.J. OF STUD. ON ALCOHOL, Sept. 1956, at 381. Study distinguishing two types of alcohol induced nystagmus, PAN (positional alcoholic nystagmus) I and PAN II, found intensity of PAN I, with onset about one half hour after alcohol ingestion, was proportional to amount of alcohol taken.
5. Baloh, Sharma, Moskowitz & Griffith, Effect of Alcohol and Marijuana on Eye Movements, 50 AVIAT. SPACE ENVIRON. MED., Jan 1979, at 18 (abstract available on DIALOG, file 153: Medline 1979 79) (smooth pursuit eye movement effects of alcohol overshadowed those of marijuana).
6. Barnes, The Effects of Ethyl Alcohol on Visual Pursuit and Suppression of the Vestibulo Ocular Reflex, 406 ACTA OTOLARYNGOL SUPP. 161 (Sweden 1984) (ethyl alcohol disrupted visual pursuit eye movement by increasing number of nystagmic "catch up saccades").
7. Burns & Moskowitz, Psychophysical Tests for DWI Arrest, U.S. Dept. of Transportation Rep. No. DOT HS 802 424 (1977) (recommended the three test battery developed by SCRI (one leg stand, walk and turn, and HGN) to aid officers in discriminating BAC level).
8. Burns, The Robustness of the Horizontal Gaze Nystagmus (HGN) Test, U.S. Dept. of Transportation 2004. Concludes that HGN as used by law enforcement is a robust procedure and the data obtained in this report does not support changes or revisions to the current testing or procedure

9. Church & Williams, Dose and Time Dependent Effects of Ethanol, 54 ELECTROENCEPHALOGRAPHY & CLIN. NEUROPHYSIOL., Aug. 1982, at 161 (abstract available on DIALOG, file 11: Psychinfo 1967 85 or file 72: Embase 1982 85) (positional alcohol nystagmus increased with dose levels of ethanol).
10. Citek, Ball and Rutledge, Nystagmus Testing in Intoxicated Individuals, Vol. 74, No. 11, Nov. 2003, Optometry, established that the HGN test administered in the standing, seated, and supine postures is able to discriminate impairment at criterion BAC's of 0.08% and 0.10%.
11. Compton, Use of the Gaze Nystagmus Test to Screen Drivers at DWI Sobriety Checkpoints, U.S. Dept. of Transportation (1984) (field evaluation of HGN test administered to drivers through car window in approximately 40 seconds: "the nystagmus test scored identified 95% of the impaired drivers" at 2; 15% false positive for sober drivers, id.).
12. Fregly, Bergstedt & Graybiel, Relationships Between Blood Alcohol, Positional Alcohol Nystagmus and Postural Equilibrium, 28 Q.J. OF STUD. ON ALCOHOL, March 1967, at 11, 17 (declines from baseline performance levels correlated with peak PAN I responses and peak blood alcohol levels).
13. Goldberg, Effects and After Effects of Alcohol, Tranquilizers and Fatigue on Ocular Phenomena, ALCOHOL AND ROAD TRAFFIC 123 (1963) (of different types of nystagmus, alcohol gaze nystagmus is the most easily observed).
14. Helzer, Detection DUIs Through the Use of Nystagmus, LAW AND ORDER, Oct. 1984, at 93 (nystagmus is "a powerful tool for officers to use at roadside to determine BAC of stopped drivers...(O)fficers can learn to estimate BACs to within an average of 0.02 percent of chemical test readings." Id. at 94).
15. L.R. Erwin, DEFENSE OF DRUNK DRIVING CASES (3d ed. 1985) ("A strong correlation exists between the BAC and the angle of onset of (gaze) nystagmus." Id. at 8.15A(3).
16. Lehti, The Effect of Blood Alcohol Concentration on the Onset of Gaze Nystagmus, 136 BLUTALKOHOL 414 (West Germany 1976) (abstract available on DIALOG, file 173: Embase 1975 79) (noted a statistically highly significant correlation between BAC and the angle of onset of nystagmus with respect to the midpoint of the field of vision).
17. Misoi, Hishida & Maeba, Diagnosis of Alcohol Intoxication by the Optokinetic Test, 30 Q.J. OF STUD. ON ALCOHOL 1 (March June 1969) (optokinetic nystagmus, ocular adaptation to movement of object before eyes, can also be used to detect central nervous system impairment caused by alcohol. Optokinetic nystagmus is

inhibited at BAC of only .051 percent and can be detected by optokinetic nystagmus test. Before dosage subjects could follow a speed of 90 degrees per second; after, less than 70 degrees per second).

18. Murphree, Price & Greenberg, Effect of Congeners in Alcohol Beverages on the Incidence of Nystagmus, 27 Q.J. OF STUD. ON ALCOHOL, June 1966, at 201 (positional nystagmus is a consistent, sensitive indicator of alcohol intoxication).
19. Nathan, Zare, Ferneau & Lowenstein, Effects of Congener Differences in Alcohol Beverages on the Behavior of Alcoholics, 5 Q.J. OF STUD. ON ALCOHOL SUPP., may 1970, at 87 (abstract available on DIALOG, file 11: Psychinfo 1967 85) (incidence of nystagmus and other nystagmoid movements increased with duration of drinking).
20. Norris, The Correlation of Angle of Onset of Nystagmus With Blood Alcohol Level: Report of a Field Trial, CALIF. ASS'N CRIMINALISTICS NEWSLETTER, June 1985, at 21 (The relationship between the ingestion of alcohol and the onset of various kinds of nystagmus "appears to be well documented." Id. "While nystagmus appears to be useful as a roadside sobriety test, at this time, its use to predict a person's blood alcohol level does not appear to be warranted." Id. at 22).
21. Nuotto, Palva & Seppala, Naloxone Ethanol Interaction in Experimental and Clinical Situations, 54 ACTA PHARMACOL. TOXICOL. 278 (1984) (abstract available on DIALOG, file 5: Biosis Previews 1981 86) (ethanol alone dose dependently induced nystagmus).
22. Oosterveld, Meineri & Paolucci, Quantitative Effect of Linear Acceleration on Positional Alcohol Nystagmus, 45 AEROSPACE MEDICINE, July 1974, at 695 (G-loading brings about PAN even when subject has not ingested alcohol; however when subjects ingested alcohol, no PAN was found when subjects were in supine position, even with G force at 3).
23. Penttila, Lehti & Lonnqvist, Nystagmus and Disturbances in Psychomotor Functions Induced by Psychotropic Drug Therapy, 1974 PSYCHIAT. FENN. 315 (abstract available on DIALOG, file 173: Embase 1975 79) (psychotropic drugs induce nystagmus).
24. Rashbass, The Relationship Between Saccadic and Smooth Tracking Eye Movements, 159 J. PHYSIOL. 326 (1961) (barbiturate drugs interfere with smooth tracking eye movement).
25. Richman, McAndrew, Decker and Mullaney, An Evaluation of Pupil Size Standards Used By Police Officers for Detecting Drug Impairment, Vol. 75, No. 3, March 2004, Opportunity, determined normative values and potential ranges for pupillary

responses using the specific DEC program protocols for pupil testing in non-impaired persons.

26. Savolainen, Riihimaki, Vaheri & Linnoila, Effects of Xylene and Alcohol on Vestibular and Visual Functions in Man, SCAND. J. WORK ENVIRON. HEALTH 94 (Sweden 1980) (abstract available on DIALOG, file 172: Embase 1980 81 on file 5: Biosis Previews 1981 86) (the effects of alcohol on vestibular functions (e.g., positional nystagmus) were dose dependent).
27. Seelmeyer, Nystagmus, A Valid DUI Test, LAW AND ORDER, July 1985, at 29 (Horizontal Gaze Nystagmus test is used in "at least one law enforcement agency in each of the 50 states" and is "a legitimate method of establishing probable cause." Id.).
28. Smith, Hayes, Yolton, Rutledge and Citek, Drug Recognition Expert Evaluations Made Using Limited Data, Forensic Science International 130 (2002), p. 167-173, demonstrated that DRE officers can make a correct positive identification of drug intoxication with limited information.
29. Tharp, Burns & Moskowitz, Circadian Effects on Alcohol Gaze Nystagmus (paper presented at 20th annual meeting of Society for Psychophysiological Research), abstract in 18 PSYCHOPHYSIOLOGY, March 1981 (highly significant correlation between angle of onset of AGN and BAC).
30. Tharp, Burns & Moskowitz, Development and Field Test of Psychophysical Tests for DWI Arrests, U.S. Dept. of Transportation Rep. No. DOT HS 805 864 (1981) (standardized procedures for administering and scoring the SCRI three test battery; participating officers able to classify 81% of volunteers above or below .10).
31. Umeda & Sakata, Alcohol and the Oculomotor System, 87 ANNALS OF OTOTOLOGY, RHINOLOGY & LARYNGOLOGY, May June 1978, at 392 (in volunteers whose "caloric eye tracking pattern" (CETP) was normal before alcohol intake, influence of alcohol on oculomotor system appeared consistently in the following order: (1) abnormality of CETP, (2) positional alcohol nystagmus, (3) abnormality of eye tracking pattern, (4) alcohol gaze nystagmus).
32. Wilkinson, Kime & Purnell, Alcohol and Human Eye Movement, 97 BRAIN 785 (1974) (oral dose of ethyl alcohol impaired smooth pursuit eye movement of all human subjects).
33. Zyo, Medico legal and Psychiatric Studies on the Alcohol Intoxicated Offender, 30 JAPANESE J. OF LEGAL MED., No. 3, 1976, at 169 (abstract available on DIALOG, file 21: National Criminal Justice Reference Service 1972 85) (recommends use of nystagmus test to determine somatic and mental symptoms of alcohol intoxication as well as BAC).

Session 4

Overview of Drug Recognition Expert Procedures



Session 4 - Overview of Drug Recognition Expert Procedures

Learning Objectives

- **Name the components of the Drug Evaluation and Classification program drug influence evaluation**
- **State the purpose of each component**
- **Describe the activities performed during each component**
- **Correctly answer the “topics for study” questions at the end of this session**




Drug Recognition Expert Course 4-2

Briefly describe the objectives for this session.

Upon successfully completing this session the participant will be able to:

- Name the components of the Drug Evaluation and Classification program drug influence evaluation.
- State the purpose of each component.
- Describe the activities performed during each component.
- Correctly answer the “topics for study” questions at the end of this session.

CONTENT SEGMENTS

- A. Components of the Drug Evaluation and Classification Procedure
- B. Interview of the Arresting Officer
- C. The Preliminary Examination
- D. Examinations of the Eyes
- E. Divided Attention Psychological Tests
- F. Examinations of Vital Signs
- G. Dark Room Checks of Pupil Size
- H. Examination of Muscle Tone
- I. Examination for Injection Sites
- J. Toxicological Examination
- K. Video Demonstration

LEARNING ACTIVITIES

- Instructor Led Presentations
- Instructor Led Demonstrations
- Video Presentations
- Reading Assignments

Session 4 - Overview of Drug Recognition Expert Procedures

The Drug Influence Evaluation

Systematic and Standardized Process

The DEC procedure is a systematic and standardized method of examining a subject to determine:

- Whether the subject is impaired, and if so
- Whether the impairment is caused by drugs or a medical condition
- And if drugs, the category (or categories) of drugs that is/are the likely cause of the subject's impairment




Drug Recognition Expert Course 4-3

A. Components of the Drug Evaluation and Classification Procedure

The Drug Influence Evaluation

The DEC procedure is a systematic and standardized method of examining a subject to determine:

- Whether the subject is impaired, and if so,
- Whether the impairment is caused by drugs or a medical condition.
- And if drugs, the category (or categories) of drugs that is/are the likely cause of the subject's impairment.

The process is systematic in that it is based on a careful assessment of a variety of observable signs and symptoms that are known to be reliable indicators of drug impairment.

Write on the dry erase board or flip-chart: "A SYSTEMATIC PROCESS."

- Some of these observable signs and symptoms relate to the subject's appearance.

Write "appearance" on the dry erase board or flip-chart.

- Some of these observable signs and symptoms relate to the subject's behavior.

Write "behavior" on the dry erase board or flip-chart.

- Some relate to the subject's performance of carefully administered psychophysical tests.

Ask participants: "What does 'psychophysical' mean?"

Point out that "psychophysical" relates to the subject's mind (psyche) and body (physique).

Write "psychophysical testing" on the dry erase board or flip-chart.

Session 4 - Overview of Drug Recognition Expert Procedures

The Drug Influence Evaluation (Cont.)

Systematic and Standardized Process

Why is it so important to perform the drug influence evaluation in exactly the same way, every time?




Drug Recognition Expert Course 4-4

Drugs impair the subject's ability to control his or her mind and body.

- Psychophysical tests can disclose that the subject's ability to control mind and body is impaired.
- The specific manner in which the subject performs the psychophysical tests may help indicate the category or categories of drugs causing the impairment.
- Some of the observable signs and symptoms relate to the subject's automatic responses to the specific drugs that are present.
- All of these reliable indicators are examined and carefully considered before a judgment is made concerning what categories of drugs are affecting the subject.

The evaluation is standardized in that it is administered the same way, every time.

Emphasize that DREs should always try to conduct the 12-step process in the same manner each time. However, there may be times when that is not possible, i.e., uncooperative subject, equipment failure, or refusals.

Explain that if they are unable to complete all the steps of the evaluation, that they must explain the reasons for this in their narrative report and if they are still able to form an opinion, what evidence and observations support their opinion.

Ask participants: "Why is it so important to perform the drug influence evaluation in exactly the same way, every time?"

Session 4 - Overview of Drug Recognition Expert Procedures

The Drug Influence Evaluation (Cont.)

Systematic and Standardized Process

There may be times when the DRE may be unable to complete each step of the evaluation, i.e., injuries, uncooperative subject, equipment failure, etc.




Drug Recognition Expert Course 4-5

Probe to draw out all major reasons for standardization.

- Standardization helps to ensure that no mistakes are made.
- No examinations are left out.
- No extraneous or unreliable “indicators” are included.
- Standardization helps to promote professionalism among drug recognition experts.

Discuss examples of reasons when the DRE may be unable to complete each step of the evaluation, i.e., injuries, uncooperative subject, equipment failure.

- Standardization helps to secure acceptance in court.

In such cases, the DRE may still be able to form an opinion based upon the evidence obtained. State v. Cammack, 1997 WL 104913 (Minnesota Ct. Appeals, 1997) ruled that a DRE need not complete the entire 12-step evaluation for an opinion to be admissible so long as there is sufficient admissible evidence.

Session 4 - Overview of Drug Recognition Expert Procedures

Drug Influence Evaluation Steps

1. Breath alcohol test
2. The interview of the arresting officer
3. Preliminary examination
4. Examinations of the eyes
5. Divided attention tests
6. Examination of vital signs



Drug Recognition Expert Course 4-6

Drug Influence Evaluation Steps

The Drug Evaluation and Classification drug influence evaluation has twelve components or steps.

Refer participants to the 12-step evaluation checklist of their participant manual.

Drug Influence Evaluation Steps (Cont.)

- 7. Dark room examinations**
- 8. Examination of muscle tone**
- 9. Examination for injection sites**
- 10. Subject's statements and other observations**
- 11. Opinion of Evaluator**
- 12. Toxicological examination**



Session 4 - Overview of Drug Recognition Expert Procedures

1. Breath Alcohol Test



Drug Recognition Expert Course 4-8

Breath Alcohol Test

The Breath Alcohol Test is needed to determine Blood Alcohol Concentration (BAC).

The purpose of the breath test is to determine whether the specific drug, alcohol, may be contributing to the impairment observed in the subject.

Obtaining an accurate measurement of BAC enables the DRE to assess whether alcohol may be the sole cause of the observable impairment, or whether it is likely that some other drug or drugs, or other complicating factors are contributing to the impairment.

Remind participants that many subjects who are under the influence of drugs other than alcohol also have alcohol in their system.

Session 4 - Overview of Drug Recognition Expert Procedures

2. Interview of the Arresting Officer



The image shows two police officers in dark uniforms standing in a room, looking at a document held by one of the officers. They appear to be in a professional setting, possibly a courtroom or a police station, with a table and chairs visible in the background.



Drug Recognition Expert Course

4-9

The Interview of the Arresting Officer

In most cases, the subjects you will examine will not be people that you arrested.

The arresting officer may have seen or heard things that would be valuable indicators of the kinds of drugs the subject has ingested.

The arresting officer, in searching the subject, may have uncovered drug related paraphernalia, or even drugs themselves.

The arresting officer also may be able to alert you to important information about the subject's behavior that could be very valuable for your own safety.

Session 4 - Overview of Drug Recognition Expert Procedures

3. Preliminary Examination





Drug Recognition Expert Course 4-10

The Preliminary Examination

Remind participants that protective gloves must be worn from this portion of the evaluation on.

- The preliminary examination is your first opportunity to observe the subject closely and directly.
- A major purpose of the preliminary examination is to determine if the subject may be suffering from an injury or some other medical condition not necessarily related to drugs.
- **Analogy: The preliminary examination is a “fork in the road.” It can help you decide whether to continue with the drug influence evaluation, to pursue a possible medical complication, or to proceed with a DWI (alcohol) case.**
- Another major purpose of the preliminary examination is to begin systematically assessing the subject’s appearance, behavior and automatic bodily responses for signs of drug induced impairment.

Emphasize that the term “preliminary” does not imply “unimportant.” Very valuable evidence often comes to light during the preliminary examination.

Session 4 - Overview of Drug Recognition Expert Procedures

3. Preliminary Examination (Cont.)

Drug Influence Evaluation

Evaluator		DRE No.		Rolling Log No.			
Recorder/Witness		Crash: <input type="checkbox"/> Fatal <input type="checkbox"/> Injury		<input type="checkbox"/> None <input type="checkbox"/> Property			
Arrestee's Name (Last, First, MI)		DOB	Sex	Race	Arresting Officer (Name, ID No.)		
Date Examined/Time/Location		Breath Results: Instrument #		Chemical Test <input type="checkbox"/> Urine <input type="checkbox"/> Blood <input type="checkbox"/> Refused			
Miranda Warning Given: <input type="checkbox"/> Yes <input type="checkbox"/> No		What have you eaten today? When?		Have you been drinking? How much?		Time of last drink?	
Time now?	When did you last sleep? How long?	Are you sick or injured? <input type="checkbox"/> Yes <input type="checkbox"/> No		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input type="checkbox"/> No			
Do you take insulin? <input type="checkbox"/> Yes <input type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input type="checkbox"/> No			
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input type="checkbox"/> No		Attitude		Coordination			
		Breath		Face			
Speech		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input type="checkbox"/> Watery		Blindness: <input type="checkbox"/> None <input type="checkbox"/> L Eye <input type="checkbox"/> R Eye		Tracking: <input type="checkbox"/> Equal <input type="checkbox"/> Unequal	
Corrective Lens: <input type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Pupil Size: <input type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Able to follow stimulus: <input type="checkbox"/> Yes <input type="checkbox"/> No		Eyelids: <input type="checkbox"/> Normal <input type="checkbox"/> Droopy	




Drug Recognition Expert Course 4-11

The preliminary examination consists of a series of questions dealing with possible injuries or medical problems; observations of the subject's face, speech and breath; pupil size and tracking ability; initial checks of the subject's eyes; and, an initial examination of the subject's pulse.

While you are assessing the subject's tracking ability, you can also perform a preliminary assessment of whether Horizontal Gaze Nystagmus is present in the subject's eyes. In particular, if the Nystagmus or "jerking" is observed, an initial estimation of the angle of onset can be made. The approximate angle of onset may help to determine whether the subject has consumed some drug other than alcohol.

Emphasize that courts generally accept these questions as not being in conflict with the subject's Constitutional rights. However, the participants must comply with their own department's policies as to whether they should advise the subjects of their Constitutional rights before asking these questions.

Session 4 - Overview of Drug Recognition Expert Procedures

4. Examinations of the Eyes



Drug Recognition Expert Course

4-12

Examinations of the Eyes

Certain drugs produce very easily observable effects on the eyes.

Ask participants: “What do we look for, in a subject’s eyes, to determine if he or she may be under the influence of alcohol?” Probe, as necessary, to draw out the response “Nystagmus.”

Session 4 - Overview of Drug Recognition Expert Procedures

4. Examinations of the Eyes (Cont.)

HGN	LEFT	RIGHT	Vertical Gaze Nystagmus? <input type="checkbox"/> Yes <input type="checkbox"/> No
Lack of Smooth Pursuit			Convergence <div style="display: flex; justify-content: space-around;"> <div style="text-align: center;">Right Eye </div> <div style="text-align: center;">Left Eye </div> </div>
Max. Deviation			
Angle of Onset			




Drug Recognition Expert Course
4-13

One of the most dramatic of these effects is Nystagmus, which means an involuntary jerking of the eyes.

Persons under the influence of alcohol usually will exhibit Horizontal Gaze Nystagmus, which is an involuntary jerking of the eyes occurring as the eyes gaze to the side.

Alcohol is not the only drug that causes Nystagmus.

Horizontal Gaze Nystagmus is not the only observable effect on the eyes that will be caused by various drugs.

Point out that the examinations of the eyes will be covered in much greater depth later in this training.

Session 4 - Overview of Drug Recognition Expert Procedures

5. Divided Attention Tests



Drug Recognition Expert Course 4-14

Divided Attention Psychophysical Tests

Ask participants: “What does ‘divided attention’ mean?” Probe, as necessary, to draw out responses indicating the concept of “concentrating on more than one thing at a time.”

All drugs that impair driving ability will also impair the subject’s ability to perform certain carefully designed divided attention tests.

These tests are familiar to you in the context of examining alcohol impaired subjects.

Session 4 - Overview of Drug Recognition Expert Procedures

5. Divided Attention Tests (Cont.)

Balance Eyes Closed

Internal Clock:
Estimated as 30 sec.

Walk And Turn Test

Describe Turn

Cannot keep balance _____
Starts too soon _____

	1st Nine	2nd Nine
Stops Walking		
Misses Heel-Toe		
Steps Off Line		
Raises Arms		
Actual Steps Taken		

Cannot Do Test (explain)

One Leg Stand:

Sways while balancing.
Uses arms to balance.
Hopping.
Puts foot down.

Type of Footwear

● Right ▲ Left
Draw lines to spots touched

Drug Recognition Expert Course 4-15

The same tests are very valuable for disclosing evidence of impairment due to drugs other than alcohol.

Point out that participants' will have opportunities to practice administering these tests subsequently in the course.

The divided attention tests used in the DRE examination include:

- The Modified Romberg Balance,
- The Walk and Turn,
- One Leg Stand,
- And, the Finger to Nose.

Session 4 - Overview of Drug Recognition Expert Procedures

6. Examination of Vital Signs



Drug Recognition Expert Course 4-16

Examination of Vital Signs

Many categories of drugs affect the operation of the heart, lungs and other major organs of the body.

Session 4 - Overview of Drug Recognition Expert Procedures

6. Examination of Vital Signs (Cont.)

Pulse & Time

1. _____ bpm / _____

2. _____ bpm / _____

3. _____ bpm / _____

Blood Pressure Body Temp

_____ / _____ mmHg _____ °



Drug Recognition Expert Course 4-17


These effects show up during examination of the subject's vital signs.

Point out that the examinations of vital signs will be covered in depth later, and that participants will have ample opportunity to practice measuring vital signs.

The vital signs that are reliable indicators of drug influence include blood pressure, pulse, and temperature.

Session 4 - Overview of Drug Recognition Expert Procedures

7. Dark Room Examinations



OCT 28 2005



Drug Recognition Expert Course

4-18

Dark Room Examinations

Many categories of drugs affect how the pupils will appear, and how they respond to light.

Session 4 - Overview of Drug Recognition Expert Procedures

7. Dark Room Examinations (Cont.)

Pupil Size	Room Light	Darkness	Direct	Nasal Area
Left Eye				Oral Cavity
Right Eye				
Rebound Dilation: <input type="checkbox"/> Yes <input type="checkbox"/> No			Reaction to Light	




Drug Recognition Expert Course 4-19

Certain kinds of drugs will cause the pupils to widen dramatically, or dilate. Some other drugs cause the pupils to narrow, or constrict.

By systematically changing the amount of light entering the subject's eyes, we can observe the pupils' appearance and reaction under controlled conditions.

We carry out these examinations in a dark room, using a penlight to control the amount of illumination entering the subject's eyes.

Exhibit a penlight.

We use a device called a pupillometer to estimate the size of the subject's pupils.

Exhibit a pupillometer.

Point out that the pupillometer has a series of circles or semi-circles of various sizes.

By lining the circles up along side the subject's pupil, the pupil's size can be determined.

Point out that participants will have several opportunities to practice conducting dark room examinations later in the course.

Other examinations are also conducted in the darkroom, using the penlight: i.e., examination of the nasal area and mouth for signs of drug use and for concealed contraband.

Session 4 - Overview of Drug Recognition Expert Procedures

8. Muscle Tone Examination

MUSCLE TONE: <input type="checkbox"/> Near Normal <input type="checkbox"/> Flaccid <input type="checkbox"/> Rigid
Comments:



Drug Recognition Expert Course 4-20

Certain categories of drugs can cause the user's muscles to become markedly tense, and rigid. Others may cause flaccidity, or "rubbery-like" muscle tone.

Evidence of this muscle tone may come to light when the subject attempts to perform the divided attention tests.

Point out that examination for muscle tone will be covered in greater depth subsequently in the course.

Session 4 - Overview of Drug Recognition Expert Procedures

8. Examination of Muscle Tone (Cont.)



Drug Recognition Expert Course 4-21

Examination of Muscle Tone

Evidence of muscle tone can also be observed when taking the subject's pulse, blood pressure or while examining for injection sites.

Session 4 - Overview of Drug Recognition Expert Procedures

9. Examination for Injection Sites



Drug Recognition Expert Course

4-22


Examination for Injection Sites

Certain drugs are commonly injected by their users, via hypodermic needles.

Ask participants: “What drug is most often associated with injection via hypodermic needle?”

Session 4 - Overview of Drug Recognition Expert Procedures

9. Examination for Injection Sites (Cont.)



RIGHT ARM

LEFT ARM

ATTACH PHOTOS OF FRESH PUNCTURE MARKS



Drug Recognition Expert Course

4-23

Heroin is probably most commonly associated with injection, but several other types of drugs also are injected by many users.

Uncovering injection sites on a subject provides evidence of possible drug use.

Session 4 - Overview of Drug Recognition Expert Procedures

10. Subject's Statements and Other Observations



Drug Recognition Expert Course 4-24

Subject's Statements and Other Observations

At this point in the examination, the trained DRE should have reasonable grounds to believe that the subject is under the influence of a drug or drugs.

The DRE should also have at least an articulable suspicion as to the category or categories of drugs causing the impairment.

The DRE should proceed to interview the subject to confirm their opinion concerning the drug category or categories involved.

Emphasize that any such interview can proceed only in conformance with formal admonition and strict observance of the subject's Miranda rights.

Session 4 - Overview of Drug Recognition Expert Procedures

10. Subject's Statements and Other Observations (Cont.)

What medicine or drug have you been using?	How much?	Time of use?	Where were the drugs used? (Location)
Date/Time of Arrest	Time DRE Notified	Eval. Start Time	Time Completed
Member Signature (Include Rank)	ID No.	Reviewed By	
Opinion of Evaluator:			
<input type="checkbox"/> Rule Out <input type="checkbox"/> Alcohol <input type="checkbox"/> Medical			
<input type="checkbox"/> CNS Stimulant <input type="checkbox"/> CNS Depressant <input type="checkbox"/> Hallucinogen <input type="checkbox"/> Dissociative Anesthetic			
<input type="checkbox"/> Narcotic Analgesic <input type="checkbox"/> Inhalant <input type="checkbox"/> Cannabis <input type="checkbox"/> Narcotic Analgesic			




Drug Recognition Expert Course 4-25

The DRE must carefully record the subject's statements, and any other observations that may constitute relevant evidence of drug induced impairment.

Point out that the appropriate procedures for interviewing subjects vary with the probable category or categories of drugs involved.

Session 4 - Overview of Drug Recognition Expert Procedures

11. Opinion of Evaluator



Drug Recognition Expert Course 4-26

Opinion of Evaluator

Based on all of the evidence and observations gleaned from the preceding ten steps, the DRE should be able to reach an informed conclusion as to:

- Whether the subject is under the influence of a drug or drugs, and if so,
- The probable category or categories of drugs causing impairment.

The DRE must record a narrative summary of the facts forming the basis for their conclusion.

Session 4 - Overview of Drug Recognition Expert Procedures

12. Toxicological Examination



The image shows a male scientist with glasses and a white lab coat working in a laboratory. He is using a pipette to transfer liquid into small vials arranged on a tray. The lab bench is equipped with various glassware, a blue machine, and other laboratory equipment. The background is a clean, professional laboratory setting.

Drug Recognition Expert Course 4-27

Toxicological Examination

The toxicological examination is a chemical test or tests designed to obtain scientific, admissible evidence to substantiate the DRE's opinion.

Departmental policy and procedures must be followed in requesting, obtaining and handling the toxicological sample.

Solicit participants' comments and questions concerning this preview of the Drug Evaluation and Classification procedures.

Session 4 - Overview of Drug Recognition Expert Procedures

Arresting Officer Interview

Issues concerning subject's behavior:

- **Was the subject operating a vehicle?**
- **What actions, maneuvers, etc. were observed?**
- **Was there a crash?**
- **Was the subject observed smoking, drinking or eating?**




Drug Recognition Expert Course 4-28

B. Interview of the Arresting Officer

The purpose of the interview of the arresting officer is to obtain a summary of the subject's actions, behaviors, etc. that led to the arrest and the suspicion that drugs other than alcohol may be involved.

Emphasize that DREs should form the habit of posing explicit questions to arresting officers using a systematic process. A cursory or open ended interview (e.g., "What do we have here?") may fail to elicit some relevant information, because arresting officers won't always know what is relevant to a drug evaluation.

Interview Behavior

Issues concerning the subject's behavior:

- Was the subject operating a vehicle?
- What actions, maneuvers, etc. were observed?
- Was there a crash? If yes, was the subject injured?
- Was the subject observed smoking, drinking or eating?

Session 4 - Overview of Drug Recognition Expert Procedures

Arresting Officer Interview (Cont.)

Issues concerning subject's behavior:

- Was the subject inhaling any substance?
- How did subject respond to the stop?
- Did subject try to conceal or throw away any items?
- What has been subject's attitude and demeanor? Has it changed?



Drug Recognition Expert Course 4-29

- Was the subject apparently inhaling any substance?
- How did the subject respond to the arresting officer's stop?
- Did the subject attempt to conceal or throw away any items or materials?
- What has been the subject's attitude and demeanor during contact with the arresting officer and have there been any changes?

Ask participants to suggest any other questions that might be relevant concerning the arresting officer's observations of the subject's behavior.

Remind the participants that they are acting as investigators and advisors to the arresting officers.

Session 4 - Overview of Drug Recognition Expert Procedures

Arresting Officer Interview (Cont.)

Interview Concerning Subject's Statements

- Has subject complained of illness/injury?
- Has subject used drug-related "street terms" or slang?
- How has subject responded to questions?
- Is subject's speech slurred, slow, thick, rapid, mumbled, etc.?
- What, specifically, has the subject said?




Drug Recognition Expert Course 4-30

Interview Concerning Subject's Statements

- Has the subject complained of an illness or injury?
- Has the subject used any "street terms" or slang associated with drugs or drug paraphernalia?
- How has the subject responded to the arresting officer's questions?
- Was the subject's speech slurred, slow, rapid, thick, mumbled, etc.?
- What, specifically, has the subject said to the arresting officer?

Ask participants to suggest any other questions that might be relevant concerning statements the subject made in the arresting officer's presence.

Session 4 - Overview of Drug Recognition Expert Procedures

Arresting Officer Interview (Cont.)

Issues concerning physical evidence:

- What items or materials were uncovered during search of subject and vehicle?
- Was any smoking paraphernalia uncovered?
- Were there any injection materials?
- Were there any balloons, plastic bags, small metal foil wrappings, etc.?
- What was the subject's BAC?




Drug Recognition Expert Course 4-31

Interview: Physical Evidence

Issues concerning physical evidence:

- What items or materials were uncovered during the search of the subject or vehicle?
- Were any smoking paraphernalia uncovered?
- Were any injection materials, i.e., needles, syringes, leather straps, rubber tubes, spoons, bottle caps, etc. found?
- Were there any balloons, plastic bags, small metal foil wrappings, etc. found?
- What was the subject's blood alcohol concentration?

Emphasize that the subject should be requested to submit to a breath test, if that has not already been done.

Ask participants to suggest any other relevant questions concerning physical evidence.

Solicit participants' comments and questions concerning the interview of the arresting officer.

Session 4 - Overview of Drug Recognition Expert Procedures

Overview of the Preliminary Examination

- Questions
- Observations of face, breath and speech
- Initial checks of the eyes
- First check of the pulse





Drug Recognition Expert Course 4-32

C. The Preliminary Examination Overview

The preliminary examination consists of:

- Questions.
- Observations of face, breath, and speech.
- Initial checks of the eyes.
- The initial check of the subject's pulse.

Point out that the pulse check actually is part of the examination of the subject's vital signs. Pulse is checked three times during the drug influence evaluation to rule out nervousness as a factor of elevated pulse. This gives a more accurate and reliable pulse.

Session 4 - Overview of Drug Recognition Expert Procedures

Preliminary Examination Questions

- Are you sick or injured?
- Do you have any physical defects?
- Are you diabetic or epileptic?
- Do you take insulin?
- Are you under a doctor's or dentist's care?
- Are you taking any medications or drugs?




Drug Recognition Expert Course 4-33

Preliminary Examination Questions

The questions deal with injuries or medical problems the subject may have. They include:

Point out that these questions are incorporated into the Drug Influence Evaluation Form, which the participants will use during all of their practice sessions.

Briefly discuss the relevance of each question.

- Are you sick or injured?
- Do you have any physical defects?
- Are you diabetic or epileptic?
- Do you take insulin?
- Are you under a doctor or dentist's care?
- Are you taking any medications or drugs?

Session 4 - Overview of Drug Recognition Expert Procedures

Initial Checks of the Eyes

- Check pupil size
- Assessment of tracking ability
- Initial estimate of Nystagmus angle of onset



Drug Recognition Expert Course

NHTSA
www.dhhs.gov

4-34

Initial Checks of the Eyes

The initial checks of the subject's eyes include several particularly important items.

Check of the size of each pupil.

Point out that, if the two pupils are of unequal size, this may indicate that the subject is suffering from a head injury, brain tumor, or other condition that may require prompt medical attention.

Also point out that the influence of certain categories of drugs may be indicated if the pupils are dilated or constricted.

Assessment of the ability of the eyes to track a moving object.

Demonstrate how to use a stimulus to assess the ability of eyes to track a moving object.

The presence of Nystagmus indicates the possible presence of certain categories of drugs.

Point out that, if the two eyes do not exhibit the same tracking ability, this too may indicate a head injury or other medical problem.

Initial estimation of the angle of onset of Horizontal Gaze Nystagmus.

The approximate angle of onset may indicate the presence of some drug other than alcohol.

Point out that certain categories of drugs cause Horizontal Gaze Nystagmus. For example, this will be true of CNS Depressants, Inhalants and Dissociative Anesthetics.

Session 4 - Overview of Drug Recognition Expert Procedures

Initial Checks of the Eyes (Cont.)

- Check pupil size
- Assessment of tracking ability
- Initial estimate of Nystagmus angle of onset



Drug Recognition Expert Course

NHTSA
www.nhtsa.gov

4-35

Remind participants that there is a general correspondence, or correlation, between blood alcohol concentration and the angle of onset of Nystagmus. Generally speaking, the higher the BAC, the earlier the angle of onset.

If the subject has also ingested some other drug that also causes Nystagmus, the angle of onset may occur even earlier than the Blood Alcohol Concentration would indicate.

Example: Suppose you are examining a subject who has an angle of onset at 45 degrees.

Based on that alone, you would expect the person's BAC to be in the .05 - .08 percent range. But if that subject has also ingested a Dissociative Anesthetic, the onset could occur much earlier, perhaps as soon as the eyes start to move to the side.

Emphasize if the angle of onset does not match the BAC level the DRE should be alert to the possible presence of some drug other than alcohol.

But also emphasize the Nystagmus onset angle could correspond very closely to what would be expected from the alcohol level alone even though the subject has ingested large quantities of other drugs.

For example: Cannabis, Narcotic Analgesics, CNS Stimulants and Hallucinogens do not cause Nystagmus, and will not affect the angle of onset.

Session 4 - Overview of Drug Recognition Expert Procedures

Eye Examinations



**Horizontal
Gaze
Nystagmus**





**Vertical
Gaze
Nystagmus**



Drug Recognition Expert Course 4-36

D. Examinations of the Eyes

Eye Examinations

Selectively reveal the items on the slide.

Emphasize that this is a full scale, formal and precise examination, unlike the initial estimation of angle of onset conducted during the preliminary examination.

The Examinations of the Eyes consist of three tests:

Horizontal Gaze Nystagmus (HGN)

Clue #1 – Lack of smooth pursuit.

Clue #2 – Distinct and sustained Nystagmus at maximum deviation.

Clue #3 – Angle of Onset

Point out if the subject's eyes begin to jerk before they have moved to the 30 degree angle, the DRE will not attempt to estimate the angle precisely, but will simply record that the subject exhibits "immediate onset."

Point out the importance of checking for each of these clues in every examination of the eyes.

Session 4 - Overview of Drug Recognition Expert Procedures

Eye Examinations (Cont.)



**Horizontal
Gaze
Nystagmus**





**Vertical
Gaze
Nystagmus**



Drug Recognition Expert Course 4-37

Vertical Gaze Nystagmus

Point out that Vertical Gaze Nystagmus is an involuntary jerking of the eyes (up-and-down) which occurs when the eyes gaze upward at maximum elevation.

Select a participant, and demonstrate how to perform a test of Vertical Gaze Nystagmus on that participant.

The instructor should hold the stimulus horizontally in front of the subject's face and about 12-15 inches in front of their face.

Instruct the person to focus on the center of the stimulus, and to keep the head steady. Raise the stimulus until the subject's eyes are elevated as far as possible. Hold the eyes at that position for a minimum four seconds.

If the eyes are observed to jerk noticeably, Vertical Gaze Nystagmus is present.

Point out that certain types of drugs tend to cause Vertical Gaze Nystagmus, while others do not.

Also point out that Vertical Gaze Nystagmus tends to develop with relatively high doses of certain drugs for that individual.

Session 4 - Overview of Drug Recognition Expert Procedures

Eye Examinations (Cont.)



Lack of Convergence




Drug Recognition Expert Course 4-38

Illustrate on the dry erase board or flip-chart different examples of Lack of Convergence.

Lack of Convergence

Point out that Lack of Convergence is the inability of the eyes to draw in toward the center (cross) while fixating on a stimulus being moved in toward the bridge of the nose.

Lack of Convergence is checked by first getting the subject to focus on and track the stimulus as it slowly moves in a circle in front of the subject's face.

Point out that the circular motion (either left or right) serves to demonstrate that the subject is tracking the stimulus.

Demonstrate this circular motion, using the participant volunteer.

Then, the stimulus is slowly pushed in toward the bridge of the subject's nose and held for approximately one (1) second.

Demonstrate, using the participant volunteer.

Point out that the stimulus does not actually touch the subjects nose, stopping approximately 2 inches from the nose.

Under the influence of certain types of drugs, the eyes may not be able to converge.

Point out that many people may not be able to converge their eyes.

Excuse the participant volunteer and thank him or her for participating.

Solicit participants' comments and questions concerning the Examinations of the Eyes.

Session 4 - Overview of Drug Recognition Expert Procedures

Divided Attention Tests

- **Modified Romberg Balance**
- **Walk and Turn**
- **One Leg Stand**
- **Finger to Nose**






Drug Recognition Expert Course 4-39

E. Divided Attention Psychophysical Tests

Several Divided Attention tests used for drug examinations are the same familiar tests used for examining alcohol impaired subjects.

- Modified Romberg Balance

Point out the Modified Romberg Balance test used by DREs is a modified version of the original test developed in the 19th Century.

Point out that the Modified Romberg test is administered by asking the subject to tilt their head back slightly and close the eyes, and estimate 30 seconds, when they believe 30 seconds have passed, they are to tilt their head forward, open their eyes and say "Stop."

- Walk and Turn

- One Leg Stand

Point out that the One Leg Stand is administered twice during the DEC drug influence evaluation (one on each leg).

- Finger to Nose

Point out that all of these tests were covered in their entirety in Session III of the Pre-School

Note: Instructors may need to review the tests. If so, the tests are detailed in the participant manual for this session.

Session 4 - Overview of Drug Recognition Expert Procedures

Divided Attention Tests (Cont.)

- Modified Romberg Balance
- Walk and Turn
- One Leg Stand
- Finger to Nose



INTERNATIONAL ASSOCIATION OF CHIEFS OF POLICE

NHTSA
www.nhtsa.gov

Drug Recognition Expert Course 4-40

Walk and Turn Demonstration

Instructions stage:

Select a participant known to be proficient in administering the Walk and Turn test.

Select another participant to serve as the test subject.

Instruct the participant administrator to administer the Walk and Turn test to the participant subject.

Point out that officer safety is of major importance during this test.

Ask the class if anything was missed or done incorrectly.

Excuse the participants, following the demonstration, and thank them for participating.

Point out that participants' will have numerous opportunities to observe and practice the divided attention tests during the remainder of the course.

One-Leg Stand Test Demonstration

Instructions stage:

Select a participant known to be proficient in administering the One-Leg Stand test.

Select another participant to serve as the test subject.

Instruct the participant administrator to administer the One-Leg Stand test to the participant subject.

Point out that officer safety is of major importance during this test.

Ask the class if anything was missed or done incorrectly.

Excuse the participants, following the demonstration, and thank them for participating.

Point out that participants' will have numerous opportunities to observe and practice the divided attention tests during the remainder of the course.

Session 4 - Overview of Drug Recognition Expert Procedures

Divided Attention Tests (Cont.)

- **Modified Romberg Balance**
- **Walk and Turn**
- **One Leg Stand**
- **Finger to Nose**





Drug Recognition Expert Course 4-41

Finger to Nose Demonstration

Instructions stage:

Select a participant known to be proficient in administering the Finger to Nose test to administer the test.

Select another participant to serve as the test subject.

Instruct the participant administrator to administer the test to the participant subject. Ask the class if anything was missed or done incorrectly.

Excuse the participants, following the demonstration, and thank them for participating.

Point out that participants' will have numerous opportunities to observe and practice the divided attention tests during the remainder of the course.

Session 4 - Overview of Drug Recognition Expert Procedures

Vital Signs Measurements

- Pulse
- Blood pressure
- Temperature






Drug Recognition Expert Course 4-42

F. Examinations of Vital Signs

Point out that these examinations will be covered in detail in Session VII.

The Vital Signs consist of three things routinely measured in basic physical examinations.

- Pulse
- Blood Pressure
- Temperature

These measurements require some familiar instruments.

Display these items.

- ***Stethoscope***
- ***Blood pressure cuff and gauge (sphygmomanometer)***
- ***Thermometer***

NOTE: An oral thermometer with disposable mouthpieces is recommended.

A time piece capable of measuring in seconds is also required.


Point out that procedures for measuring blood pressure, pulse and temperature will be explained and practiced later in this course.

Solicit participants' comments and questions concerning examinations of vital signs.

Session 4 - Overview of Drug Recognition Expert Procedures

Dark Room Checks of Pupil Size

- Room light
- Near-total darkness
- Direct light



INTERNATIONAL ASSOCIATION OF CHIEFS OF POLICE

NHTSA
www.nhtsa.gov

Drug Recognition Expert Course 4-43

G. Dark Room Checks of Pupil Size

Dark Room Checks for Pupil Size

The principal activity that takes place during the dark room examinations is the estimation of pupil size under three lighting conditions.

- Room light.
- Near total darkness.
- Direct light.

Point out that the Room Light measurement is conducted prior to darkening the room lights. Whenever possible, the room light estimation should be conducted in the same room where the other pupil estimations are conducted.

Another officer should always accompany you and the subject into the dark room. Point out that this is essential for officer safety. Remind participants that no one should normally be carrying a firearm when in the presence of a subject during the dark room examination.

Room Light

Before turning off the lights, you will estimate the size of the subject's pupils under room light.

Point out that some departments require that the subject be handcuffed before going into the darkroom.

You must always first estimate the left pupil, then the right.

Session 4 - Overview of Drug Recognition Expert Procedures

Dark Room Checks of Pupil Size (Cont.)

- Room light
- Near-total darkness
- Direct light



Drug Recognition Expert Course

NHTSA

4-44

Point out that the subject should be instructed not to try to focus on you or on the penlight, but to look “slightly up and at a specific focal point” (straight ahead and several feet away) during the estimation of pupil size.

You must position the pupillometer alongside the eye to ensure an accurate estimation.

After you have completed the room light estimations, turn off the lights and wait approximately 90 seconds to allow your eyes and the subject’s eyes to adapt to the darkness.

Near Total Darkness

The next check will be of pupil size under near total darkness.

You will need the bare minimum amount of light necessary to see the subject’s pupils and the pupillometer.

You can create the necessary light by covering the tip of the penlight with your finger or thumb.

Demonstrate this. Point out the reddish glow that emanates. If possible, darken the room and exhibit the reddish glow.

The light is then moved near the subjects left eye just until it is possible to distinguish the colored portion of the eye (Iris).


Hold the pupillometer alongside the eye and locate the circle or semi-circle closest in size to the pupil.

Repeat the procedure for the right eye.

Session 4 - Overview of Drug Recognition Expert Procedures

Dark Room Checks of Pupil Size (Cont.)

- Room light
- Near-total darkness
- Direct light



INTERNATIONAL ASSOCIATION OF CHIEFS OF POLICE

NHTSA
www.nhtsa.gov

Drug Recognition Expert Course 4-45

Direct Light

The third and final check will be of the pupil size under direct light.

You will shine the full strength of the penlight directly into the subject's eye for 15 seconds.

Point out that it is necessary to maintain reasonably fresh batteries in the penlight.

Do this by bringing the light in from the side of the subject's face.

Demonstrate this, using a participant volunteer.

The penlight should be held close enough to the subject's eye so that its beam fills the eye socket.

Demonstrate this. Point out that this will illuminate the area that usually would be discolored if the subject had a "black eye."

When the light is initially shown into the eye, you will check for the pupil's reaction to light.

Then immediately estimate the pupil size under direct light.

If possible, darken the room and exhibit the illumination using a participant volunteer.

Emphasize that it is very important not to position the penlight too closely or too far away, since this will affect the constriction or dilation of the pupil.

Excuse the participant and thank him or her for participating.

Other Activities

Two other activities are conducted while in the darkroom.

- Examination of the nasal area.
- Examination of the oral cavity.

Solicit participants' comments and questions concerning these checks of pupil size.

Session 4 - Overview of Drug Recognition Expert Procedures

Examination of Muscle Tone

- Flaccid
- Normal
- Rigid



Drug Recognition Expert Course 4-46

H. Examination of Muscle Tone

Muscle Tone

Starting with the subject's left arm, examine the arm muscles. Firmly grasp the upper arm and slowly move down to determine muscle tone. The muscles should appear flaccid, normal or rigid to the touch.

Demonstrate.

Examine the right arm in the same fashion.

Session 4 - Overview of Drug Recognition Expert Procedures

Examination For Injection Sites



INTERNATIONAL ASSOCIATION OF CHIEFS OF POLICE

NHTSA
www.nhtsa.gov

Drug Recognition Expert Course 4-47

I. Examination for Injection Sites

Some injection sites may be relatively easy to notice.

Persons who frequently inject certain drugs develop lengthy scars, commonly referred to as “tracks,” from repeated injections in the same veins.

Injection of certain drugs may result in severe caustic action against the skin and flesh, producing easily observable sores.


Often, a fresh injection site may not be readily observable.

Point out that injection sites can be observed with some drug categories. Injection sites will be covered in detail in Session XVII.

Frequently, a DRE will locate the injection site initially by touch, running the fingers along such commonly used locations as the neck, forearms, wrists, back of hand, etc.

Emphasize that gloves should be worn when touching the subject.

Select a participant and demonstrate a tactile search for injection sites.



When the DRE locates a possible injection site, a light magnifying lens, commonly known as a “ski light” is used to provide a magnified visual examination.

“Ski” – short for schematic

Display this instrument. Demonstrate its use.

Solicit participants’ comments and questions concerning examination for injection sites.

Point out that hypodermic needles are sized according to gauge. The gauge of a needle is a measurement of the inside diameter.

Point out that the gauge number represents how many needles of that size would be needed to equal one inch. The higher the gauge, the smaller the diameter of the needle, i.e., a 16 gauge needle is 1/16th of an inch.

During this step, the third pulse is taken.

Session 4 - Overview of Drug Recognition Expert Procedures

Subject Statements

- Document statements
- Ask additional probing questions if appropriate
- Miranda Rights



Drug Recognition Expert Course 4-49

J. Subject Statements

All spontaneous statements and subject's response to questions should be documented. Ask additional probing questions as appropriate.

Remind participants to make sure the subject has been advised of their constitutional rights.

Give specific examples of probing questions, admissions and denials.

Ask participants for additional examples and list all on dry erase board or flip-chart.

Session 4 - Overview of Drug Recognition Expert Procedures

Drug Influence Form Questions

What medication or drug have you been using? How much?	Time of use?	Where were the drugs used? (location)	
Date/Time of Arrest	Time DRE Notified	Evaluation Start Time	Time Completed
DRE signature (Include rank)	ID #	Reviewed by:	




Drug Recognition Expert Course 4-50

Drug Influence Form Questions:

- What medication or drug have you been using? How much?
- Time of use?
- Where were the drugs used? (location)

Be Sure to Record:

- Date/Time of Arrest
- Time DRE Notified
- Evaluation Start Time
- Time Completed
- DRE signature (Include rank)
- ID #
- Reviewed by:

Session 4 - Overview of Drug Recognition Expert Procedures

Opinion of Evaluator

Based on the totality of the evaluation



The image shows a police officer in a blue uniform sitting at a desk, writing on a document. The officer is looking down at the papers on the desk. The desk is wooden and has several papers on it. The officer is wearing a watch on his left wrist. The background is a plain wall.



Drug Recognition Expert Course

4-51

K. Opinion of Evaluator

By this point in the evaluation, the DRE should have formed an opinion of the category or categories of drugs responsible for any observed impairment.

This opinion is based on the totality of the evaluation.

Session 4 - Overview of Drug Recognition Expert Procedures

Toxicological Examination

- **Follow State implied consent laws**
- **Follow department or agency evidence policies**
- **Chain of custody**





Drug Recognition Expert Course 4-52

L. Toxicological Examination

Toxicology Samples

Your State's implied consent statutes will dictate the type of sample you can obtain; urine, blood, breath, or saliva.

Review the participants' department's policy and procedures for requesting, obtaining and handling toxicological samples.

Ask the participants to relate the law of their state. The implied consent laws may vary significantly from state to state.

Have the participants discuss their individual laws and possibly write their requirements on the flip-chart for comparison.

Specimen Containers

The type of container for collecting the sample will be dictated by the type of sample taken and the laboratory requirements where it will be tested.

Containers should be sterile and have a lid that will seal tightly. Make sure the seal is tight to prevent leaks.

Session 4 - Overview of Drug Recognition Expert Procedures

Toxicological Examination (Cont.)

- Follow State implied consent laws
- Follow department or agency evidence policies
- Chain of custody





Drug Recognition Expert Course 4-53

Obtaining a Sample

- Urine – normally the officer must witness the collection of the sample.
- Blood – should be drawn by a qualified technician and witnessed by the officer.
- The sample must include a preservative. This is often pre-packaged in the container intended for this use.

Samples should be refrigerated or frozen as soon as possible to minimize degeneration during storage.

Chain of Custody

Establish a policy dictating the chain of custody, if one does not already exist.

Establish a policy for your Department on:

- The sealing of evidence to include officer identification markings; (i.e., initials, labels, tags and packaging).
- Paperwork for the chain of custody and laboratory analysis of your sample.
- Transportation of the sample to the laboratory.
- Return reporting of the laboratory analysis.

NOTE: These are issues that must be addressed with the individual agencies to insure proper and standardized procedures. Participants should follow-up with the appropriate representatives from their agencies to coordinate this activity.

Solicit participants' comments and questions concerning toxicological examinations.

Session 4 - Overview of Drug Recognition Expert Procedures

Video Demonstrations



Drug Recognition Expert Course 4-54

M. Video Demonstrations (Optional)

Instruct participants to refer to their drug influence evaluation checklist and the drug evaluation form as they watch the video.

***Show the video, “Overview of DRE Procedures.” (This is the same video that is shown during Session II of the Pre-School and subsequently in Session VIII of this school).
Questions?***

Session 4 - Overview of Drug Recognition Expert Procedures

QUESTIONS?



Drug Recognition Expert Course 4-55

Solicit participants' comments and questions regarding Overview of DRE Procedures.

Session 4 - Overview of Drug Recognition Expert Procedures

Topics for Study




Drug Recognition Expert Course 4-56

Topics for Study Questions /Answers:

1. Give three important reasons for conducting drug evaluation and classification evaluations in a standardized fashion.

ANSWER: Help avoid mistakes, help promote and maintain professionalism and consistency among DREs, and help secure the court's acceptance of your testimony.

2. What are the twelve components of the drug evaluation process?

ANSWER: 1. Breath Test 2. Interview with Arresting Officer 3. Preliminary Exam 4. Eye Exam 5. Divided Attention Test 6. Vital Signs Exam 7. Dark Room Exam 8. Muscle Tone Exam 9. Injection Site Exam 10. Subject Interview 11. Opinion of the Evaluator 12. Toxicology

3. How many times is pulse rate measured during the drug influence evaluation ?

ANSWER: Three

Session 4 - Overview of Drug Recognition Expert Procedures

Topics for Study (Cont.)




Drug Recognition Expert Course 4-57

4. Are the diameters of a pupillometer's circles/semi-circles indicated in centimeters, millimeters or micrometers?

ANSWER: Millimeters

5. What formula expresses the approximate statistical relationship between blood alcohol concentration and nystagmus onset angle?

ANSWER: $BAC = 50 - \text{Angle of Onset}$

6. Which of the seven categories of drugs ordinarily do not cause nystagmus?

ANSWER: CNS Stimulants, Hallucinogens, Narcotic Analgesics, Cannabis

7. How many heel-to-toe steps is the subject instructed to take, in each direction, on the Walk and Turn test?

ANSWER: Nine

8. What period of time is the subject required to estimate during the Modified Romberg Balance test?

ANSWER: 30 seconds

Session 4 - Overview of Drug Recognition Expert Procedures

Topics for Study (Cont.)



Drug Recognition Expert Course 4-58

9. What is systolic pressure?

ANSWER: The force exerted on the arteries when the heart contracts.

10. What is the name of the instrument used to measure blood pressure?

ANSWER: Sphygmomanometer

11. Name the four validated clues of the One Leg Stand test.

ANSWER: Sways while balancing, Puts foot down, Hops, Uses arms for balance







12. Name the eight validated clues of the Walk and Turn test.

ANSWER: Loses balance during instructions, Starts too soon, Steps off line, Wrong number of steps, Does not touch heel-to-toe, Raises arms for balance, Improper turn.

13. Suppose you have two hypodermic needles, one is 14 gauge, the other is 20 gauge. Which needle has the smaller inside diameter?

ANSWER: 20 gauge

DRUG INFLUENCE EVALUATION

Evaluator 000235		DRE #	Rolling Log #	
Recorder/Witness		Crash: <input type="checkbox"/> None <input type="checkbox"/> Fatal <input type="checkbox"/> Injury <input type="checkbox"/> Property		Case #
Arrestee's Name (Last, First, Middle)		Date of Birth	Sex	Race
Arresting Officer (Name, ID#)				
Date Examined / Time /Location		Breath Results: Results:	Test Refused <input type="checkbox"/> Instrument #:	Chemical Test: Urine <input type="checkbox"/> Blood <input type="checkbox"/> Test or tests refused <input type="checkbox"/>
Miranda Warning Given Given By:	<input type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When?	What have you been drinking? How much?	Time of last drink?
Time now/ Actual	When did you last sleep? How long	Are you sick or injured? <input type="checkbox"/> Yes <input type="checkbox"/> No	Are you diabetic or epileptic? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Do you take insulin? <input type="checkbox"/> Yes <input type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input type="checkbox"/> No
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input type="checkbox"/> No		Attitude:		Coordination:
Speech:		Breath Odor:		Face:
Corrective Lenses: <input type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input type="checkbox"/> Watery		Blindness: <input type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right
Pupil Size: <input type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input type="checkbox"/> Yes <input type="checkbox"/> No		Tracking: <input type="checkbox"/> Equal <input type="checkbox"/> Unequal Able to follow stimulus <input type="checkbox"/> Yes <input type="checkbox"/> No
Pulse and time 1. _____ / _____ 2. _____ / _____ 3. _____ / _____		HGN	Left Eye	Right Eye
		Lack of Smooth Pursuit	Convergence 	
		Maximum Deviation	Right Eye	Left Eye
		Angle of Onset		
Modified Romberg Balance 		Walk and Turn Test 		ONE LEG STAND 
		Cannot keep balance _____		L R <input type="checkbox"/> <input type="checkbox"/> Sways while balancing <input type="checkbox"/> <input type="checkbox"/> Uses arms to balance <input type="checkbox"/> <input type="checkbox"/> Hopping <input type="checkbox"/> <input type="checkbox"/> Puts foot down
		Starts too soon _____		
		Stops walking _____		
		Misses heel-toe _____		
		Steps off line _____		
		Raises arms _____		
		Actual steps taken _____		
Internal clock estimated as 30 seconds		Describe turn		Cannot do test (explain)
Type of footwear:				
Draw lines to spots touched 		PUPIL SIZE	Room Light (2.5 - 5.0)	Darkness (5.0 - 8.5)
		Left Eye		
		Right Eye		
		Rebound Dilatation: <input type="checkbox"/> Yes <input type="checkbox"/> No		Reaction to Light:
		RIGHT ARM 		LEFT ARM 
Blood pressure	Temperature			
Muscle tone: <input type="checkbox"/> Normal <input type="checkbox"/> Flaccid <input type="checkbox"/> Rigid				
Comments:				
What drugs or medications have you been using?		How much?	Time of use?	Where were the drugs used? (Location)
Date / Time of arrest:	Time DRE was notified:	Evaluation start time:	Evaluation completion time:	Precinct/Station:
Officer's Signature:		DRE #	Reviewed/approved by / date:	
Opinion of Evaluator:		<input type="checkbox"/> Rule Out <input type="checkbox"/> Medical	<input type="checkbox"/> Alcohol <input type="checkbox"/> CNS Depressant	<input type="checkbox"/> CNS Stimulant <input type="checkbox"/> Hallucinogen
		<input type="checkbox"/> Dissociative Anesthetic <input type="checkbox"/> Narcotic Analgesic	<input type="checkbox"/> Inhalant <input type="checkbox"/> Cannabin	

Drug Influence Evaluation Checklist

- _____ 1. Breath Alcohol Test
- _____ 2. Interview of Arresting Officer
(NOTE: *Gloves must be worn from this point on*)
- _____ 3. Preliminary Examination
-first pulse, initial estimation of angle of onset, and initial estimation of pupil size
- _____ 4. Eye Examination
- _____ 5. Divided Attention Tests:
 - _____ *Romberg Balance*
 - _____ *Walk and Turn*
 - _____ *One Leg Stand*
 - _____ *Finger to Nose*
- _____ 6. Vital signs and Second Pulse
- _____ 7. Dark Room Check of Pupil Size and Ingestion Exam
- _____ 8. Check of Muscle Tone
- _____ 9. Check for Injection Sites and Third Pulse
- _____ 10. Interrogation, Statements, and Other Observations
- _____ 11. Opinion of Evaluator
- _____ 12. Toxicological Examination

Session 5

Eye Examinations



Session 5 - Eye Examinations

Learning Objectives

- **State the purpose of various eye examinations in the DEC Program drug influence evaluation procedure**
- **Describe the administrative procedures for the eye examinations**
- **Describe the clues for each eye examination**
- **Conduct the eye examinations and note the clues observed**
- **Prepare complete, clear and accurate records of the eye examinations**




Drug Recognition Expert Course 5-2

Briefly describe the objectives for this session.

Upon successfully completing this session the student will be able to:

- State the purpose of various eye examinations in the DEC Program drug influence evaluation procedure.
- Describe the administrative procedures for the eye examinations.
- Describe the clues for each eye examination.
- Conduct the eye examinations and note the clues observed.
- Prepare complete, clear and accurate records of the eye examinations.

CONTENT SEGMENTS

- A. Purpose of the Examinations
- B. Procedures and Clues
- C. Demonstrations
- D. Document Procedures
- E. Practice

LEARNING ACTIVITIES

- Instructor Led Presentations
- Instructor Led Demonstrations
- Student Led Demonstrations
- Students' Hands On Practice
- Reading Assignments

Session 5 - Eye Examinations

Purpose of the Eye Examinations

- The principle purpose of all of the eye examinations is to obtain articulable facts indicating the presence or absence of specific categories of drugs
- The tests of Horizontal and Vertical Gaze Nystagmus provide important indicators of the drug categories that may or may not be present




Drug Recognition Expert Course 5-3

A. Purposes of the Eye Examinations

- The principle purpose of all of the eye examinations is to obtain articulable facts indicating the presence or absence of specific categories of drugs.
- Certain drug categories usually cause the eyes to react in specific ways. Other drug categories usually do not cause those reactions.
- The tests of Horizontal and Vertical Gaze Nystagmus provide important indicators of the drug categories that may or may not be present.

Ask participants: “What causes Horizontal Gaze Nystagmus?” Alcohol and certain other drugs will cause Horizontal Gaze Nystagmus.

- If HGN is observed, it is likely that the subject may have ingested alcohol or another CNS Depressant, an Inhalant, a Dissociative Anesthetic, or a combination of those.
- If Vertical Gaze Nystagmus is observed, the implication may be that the subject ingested a large dose of alcohol for that individual, a Dissociative Anesthetic, such as PCP, or high doses of other Depressants or Inhalants.

Point out that it is very unlikely that a subject would exhibit Vertical Gaze Nystagmus without also exhibiting HGN.

Session 5 - Eye Examinations

Angle of Onset of Nystagmus

- By comparing the subject's BAC with the angle of onset of HGN, it may be possible to determine that alcohol is or is not the sole cause of the observed Nystagmus
- The consistency of the angle of onset and BAC can be compared using the following formula:

$$BAC = 50 - \text{Angle of Onset}$$



Drug Recognition Expert Course 5-4

By comparing the subject's blood alcohol concentration with the angle of onset of Horizontal Gaze Nystagmus, it may be possible to determine that alcohol is or is not the sole cause of the observed Nystagmus.

Clarification: If the angle of onset is significantly inconsistent with the BAC, the implication may be that the subject has also taken a Dissociative Anesthetic, such as PCP, an inhalant, or some CNS Depressant other than alcohol.

The consistency of the angle of onset and BAC can be compared using the following formula:

Write the formula on the dry erase board or flip-chart:

$BAC = 50 - \text{Angle of Onset}$

Note: Emphasize that this is not an absolute mathematical formula.

Explanation: $BAC = 100 \times \text{blood alcohol (i.e., if blood alcohol is 0.10, BAC = 10)}$

Example: If onset angle is 35 degrees, then: $BAC = 50 - 35 = 15$

The corresponding blood alcohol concentration would be approximately 0.15.

Keep in mind that this formula is only a statistical approximation. It is not an exact relationship for all subjects at all times.

Emphasize this point: The formula can easily be "off" by 0.05 or more, even though the subject has consumed no drug other than alcohol.

The purpose of comparing BAC and angle of onset is to obtain a gross indication of the possible presence of another CNS Depressant, a Dissociative Anesthetic, or an Inhalant.

Session 5 - Eye Examinations

Eye Examinations

- The purpose of comparing BAC and angle of onset is to obtain a gross indication of the possible presence of another “DID drug”
- Lack of Convergence can also provide another clue as to possible presence of “DIDC drugs”




Drug Recognition Expert Course 5-5

Emphasize that many other facts will also be considered that will help to determine whether Dissociative Anesthetics may be present.

The check for Lack of Convergence can provide another clue as to the possible presence of Depressants, Dissociative Anesthetics, or Inhalants.

Lack of Convergence is also an indicator of the possible presence of Cannabis.

Point out that a DRE might begin to suspect the presence of Cannabis if Lack of Convergence was observed but no nystagmus was observed.

- The checks of pupil size and reaction to light provide useful indicators of the possible presence of many drug categories.
- CNS Depressants, CNS Stimulants, and Inhalants will normally cause the pupils to react slowly. There will generally be little movement with Narcotic Analgesics.
- CNS Stimulants and Hallucinogens normally will cause the pupils to dilate.
- Cannabis normally causes dilation of the pupils, although this isn't always observed.

Point out: pupil dilation due to Cannabis isn't always observed in laboratory studies, but may be due to that lab dose levels are less than “street” doses.

Some specific Inhalants may cause pupil dilation.

Narcotic Analgesics will normally cause observable constriction of the pupils.

During the eye examinations you will also check for rebound dilation.

Note: A revision that removed the check for Hippus was approved by the IACP Technical Advisory Panel (TAP), November 2008.

Session 5 - Eye Examinations

Eye Examinations (Cont.)





Drug Recognition Expert Course

5-6

Point out: pupil dilation due to Cannabis isn't always observed in laboratory studies, but may be due to that lab dose levels are less than "street" doses.

Some specific Inhalants may cause pupil dilation.

Narcotic Analgesics will normally cause observable constriction of the pupils.

During the eye examinations you will also check for rebound dilation.

Note: A revision that removed the check for Hippus was approved by the IACP Technical Advisory Panel (TAP), November 2008.

Session 5 - Eye Examinations

Three Clues of Horizontal Gaze Nystagmus

1. Lack of Smooth Pursuit
2. Distinct and Sustained Nystagmus at Maximum Deviation
3. Angle of Onset of Nystagmus



Drug Recognition Expert Course 5-7

B. Procedures and Clues

Three Clues of Horizontal Gaze Nystagmus

- Lack of smooth pursuit
- Distinct and sustained nystagmus at maximum deviation
- Angle of onset of nystagmus

Remind participants that prior to checking for the three clues of nystagmus, they need to check for equal pupil size, equal tracking and resting nystagmus.

Horizontal Gaze Nystagmus test consists of three separate checks, administered independently to each eye.

Session 5 - Eye Examinations

First Clue: Lack of Smooth Pursuit






Drug Recognition Expert Course 5-8

First Clue: Lack of Smooth Pursuit

Select a participant, and demonstrate the first check of HGN on that participant.

If the subject is wearing contact lenses, note that fact on the report, but don't have the subject remove them.

Note: Research and testing has proven that contacts will not interfere with the HGN test or cause nystagmus.

If the subject is wearing eyeglasses, have him or her remove them.

- Position the stimulus approximately 12 – 15 inches in front of the subject's nose.
- Hold the tip of the stimulus slightly above the level of the subject's eye. Point out that this procedure ensures that the subject's eyes will be wide open and easy to observe.
- Instruct the subject to hold the head still and follow the stimulus with their eyes.

The first check is for "lack of smooth pursuit."

- Move the stimulus smoothly, all the way to the subject's left side and back all the way to the right side.

Point out that the stimulus should be moved at a speed that requires approximately 2 seconds to bring it from the center out all the way to the side. It should then be moved from side to side at the same speed. This means it should take approximately 4 seconds to move from the extreme left to the extreme right.

- Make at least two complete passes of the stimulus: to the left side, to the right side, back to the left side, and finally back to the right side.

Session 5 - Eye Examinations

First Clue: Lack of Smooth Pursuit (Cont.)






Drug Recognition Expert Course 5-9

- When doing this, don't pause at the center of the subject's face; move all the way to the left, then all the way to the right, then again all the way to the left and back all the way to the right, in a smooth, continuous motion.
- While the eye is moving, examine it for evidence of a lack of smooth pursuit.
- Use the following analogy:
 - A smoothly pursuing eye will move without friction, much the way that a windshield wiper glides across the windshield when it is raining steadily. An eye showing lack of smooth pursuit will move in a fashion similar to a wiper across a dry windshield.
- Also, check to be sure that both eyes are tracking in the same way: if one eye is moving smoothly but the other moves hesitantly or not at all, an illness or injury may be present.

Instruct participants to work in pairs, taking turns checking each other's eyes for lack of smooth pursuit.

Excuse the participant volunteer and thank him or her for participating.

Monitor, coach and critique the participants' practice.

Allow this practice to continue for only about 2 minutes.

Session 5 - Eye Examinations

Second Clue: Distinct and Sustained Nystagmus at Maximum Deviation






Drug Recognition Expert Course 5-10

Second Clue: Distinct and Sustained Nystagmus

The second check is for “distinct and sustained nystagmus at maximum deviation.”

Select a participant and demonstrate the second check of HGN on that participant.

- Again position the stimulus as before.
- Move the stimulus all the way to the subject’s left side and hold it there so that the subject’s eye is turned as far to the side as possible.
- Hold the eye at that position for a minimum of 4 seconds, to check carefully for jerking that may be present, and that is distinct.

Point out that for this to be a clue, the nystagmus (jerking) must be distinct and sustained.

When you have completed this check for the left eye, repeat the process for the right eye. Then, do it once again for the left eye, and again for the right, to verify that distinct and sustained nystagmus is or is not present.

With this cue, the examiner looks for a very distinct, unmistakable jerking.

Session 5 - Eye Examinations

Second Clue: Distinct and Sustained Nystagmus at Maximum Deviation (Cont.)






Drug Recognition Expert Course 5-11

Point out that some people exhibit slight jerking of the eye at maximum deviation, even when unimpaired, but this will not be evident or sustained for more than a few seconds. When impaired by alcohol and CNS Depressants, Inhalants or Dissociative Anesthetics (“D.I.D.” drugs), the jerking will be larger, more pronounced, sustained for more than 4 seconds, and easily observable.

A slight or barely visible tremor is not sufficient to consider this clue present.

A definite, sustained jerking must be seen.

Excuse the participant volunteer and thank him or her for participating.

Instruct participants to work in pairs, taking turns checking each other’s eyes for distinct and sustained nystagmus at maximum deviation.

Monitor, coach and critique the participants’ practice.

Allow this practice to continue for only about 2 minutes.

Session 5 - Eye Examinations

Third Clue: Angle of Onset of Nystagmus






Drug Recognition Expert Course 5-12

Third Clue: Angle of Onset

The final check is for the “angle of onset.”

Select a participant and demonstrate the third check of HGN on that participant.

- Position the stimulus as before.
- Slowly move the stimulus to the subject’s left side, carefully watching the eye for the first sign of jerking.

Note: Stimulus should be moved at a speed that requires approximately four seconds to travel from center to approximately 45 degrees.

- When you think that you see the eye jerk, stop moving the stimulus and hold it still.
- Verify that the eye is, in fact, jerking.

Point out that, if the eye is not jerking, it will be necessary to resume moving the stimulus slowly to the side, again observing for the first sign of jerking.

- Once you have established that you have located the point of onset, estimate the angle.

Point out that angle estimation simply requires practice.

- Then, repeat the process for the right eye.
- Then, again check onset for the left eye, and again for the right.

**Excuse the participant volunteer and thank him/her for participating.
Exhibit a template (if available).**

Point out that the template (if available) will be used during practice only.

Emphasize that if the clues of Horizontal Gaze Nystagmus are markedly different for the two eyes, a neurological or other medical problem (such as head injury) may be present.

Session 5 - Eye Examinations

Third Clue: Angle of Onset of Nystagmus (Cont.)



Drug Recognition Expert Course 5-13

Participants' Initial Practice of Angle Estimation

Instruct participants to work in pairs, taking turns estimating angles of each other's eyes.

Instruct participants that they are to try to draw their partner's eyes to three different angles:

- 30 degrees
- 35 degrees
- 40 degrees

Participants will check their accuracy using a template (if available).

Monitor, coach and critique the participants' practice.

Allow this practice to continue for only about 3 minutes.

Session 5 - Eye Examinations

Vertical Gaze Nystagmus






Drug Recognition Expert Course 5-14

Vertical Gaze Nystagmus

The Vertical Gaze Nystagmus test is very simple check of the eyes.

Select a participant and demonstrate the Vertical Gaze Nystagmus test on the participant.

- Position the stimulus horizontally, approximately 12 – 15 inches in front of the subject's nose.
- Instruct the subject to hold the head still and follow the stimulus with the eyes only.
- Raise the stimulus until the subject's eyes are elevated as far as possible.
- Watch closely for evidence of jerking.

Point out that the examiner should keep the subject's eyes elevated for approximately four (4) seconds to verify that the jerking really is present.

Point out that it is permissible to repeat the VGN check to verify if the jerking was or was not observed.

Excuse the participant volunteer and thank them for participating.

Participants' Initial Practice of the Vertical Gaze Nystagmus Test

Instruct participants to work in pairs, taking turns administering the Vertical Gaze Nystagmus test to each other.

Monitor, coach and critique the participants' practice.

Allow this practice to continue for only about 2 minutes.

Session 5 - Eye Examinations

Lack of Convergence



INTERNATIONAL ASSOCIATION OF CHIEFS OF POLICE

NHTSA
www.nhtsa.gov

Drug Recognition Expert Course 5-15

Lack of Convergence

The test for Lack of Convergence (LOC) is also very simple. But it should be noted that this test is the least reliable of any of the eye tests due to the fact that a significant portion of the population may have an inability to cross their eyes.


Select a participant and demonstrate the check for Lack of Convergence on that participant.

- Lack of Convergence means an inability to cross the eyes.
- Prior to conducting the check for Lack of Convergence the DRE should determine if the subject to be tested routinely wears eyeglasses during reading and near visual tasks and if so, are they readily available for the test.
- If the subject wears glasses during reading and near visual tasks and they are readily available, ensure that the eyeglasses are worn for the check for Lack of Convergence.

Note: In testing for Lack of Convergence (LOC), the role of clear vision and focusing can have significant effect on the convergence of the eyes. In the clinical setting, the LOC check is routinely conducted with the eyeglasses on if normally worn by the subject during reading and near visual tasks. If the subject's eyeglasses are not readily available, the DRE should still conduct the test.

Session 5 - Eye Examinations

Lack of Convergence (Cont.)



INTERNATIONAL ASSOCIATION OF POLICE OFFICERS

NHTSA
www.nhtsa.gov

Drug Recognition Expert Course 5-16

Note: This revision to the LOC exam was approved by the IACP Technical Advisory Panel (TAP), November 2008.

Note: Citations for clinical use of testing with subject wearing eyeglasses for LOC:

“Clinical Procedures for Ocular Examination”: Kurtz and Carlson; McGraw-Hill Medical, 3rd edition, Sept. 26, 2003.

“A Recognized Clinical Trial of Treatments for Convergence Insufficiency in Children”: Scheiman, Cotter, Cooper, etc.; Arch Ophthalmol, Jan 2005.

- Position the stimulus approximately 12-15 inches in front of the subject’s face.
- Instruct the person to hold their head still and follow the stimulus with the eyes only.
- Keep the object 12-15 inches away from the person’s nose, and start to move the stimulus slowly in a circle, approximately the same size as the subject’s face.

Point out that this initial circular motion helps to verify that the subject has focused on the stimulus and is able to track it. Emphasize that it doesn’t matter whether the circular motion is clockwise or counter-clockwise.

- Once you have verified that the subject is tracking the stimulus, move it slowly and steadily toward the bridge of the nose.
- Hold the stimulus near the bridge of the nose for approximately one (1) second. The stimulus should not come any closer than approximately two (2) inches from the bridge of the nose.
- Carefully observe the subject’s eyes to determine whether both eyes converge.

Session 5 - Eye Examinations

Lack of Convergence (Cont.)



Drug Recognition Expert Course

5-17

Point out that if the subject being tested is wearing contact lenses, make note of the fact and conduct the check for LOC as normal.

Excuse the participant volunteer and thank him/her for participating.

Participants' Initial Practice of the Check for the Lack of Convergence



Instruct participants to work in pairs, taking turns testing each other's eyes for Lack of Convergence.

Monitor, coach and critique the participants' practice.

Allow this practice to continue for only about 2 minutes.

Session 5 - Eye Examinations

Estimation of Pupil Size



Drug Recognition Expert Course

5-18

Estimating Pupil Size

The pupils of our eyes continually adjust in size to accommodate different lighting conditions.

Exhibit a pupillometer.

The pupillometer is held alongside the subject's eye, moved up and down until the circle or semi-circle closest in size to the pupil is located.

We use a device called a pupillometer to estimate the size of the subject's pupils.

Demonstrate the positioning of the pupillometer.

Pupil size estimations are recorded as the numeric value that corresponds to the diameter of the circle or semi-circle that is closest in size to the subject's pupil in each lighting condition.

Select a participant and demonstrate pupil size estimation using the participant.

Session 5 - Eye Examinations

Accommodation Reflex





Drug Recognition Expert Course

5-19

Explain to the participants that “Accommodation Reflex” is an adjustment of the eyes for viewing at various distances. Meaning the pupils will automatically constrict as objects move closer and dilate as objects move further away.

Note: Refer participants to the glossary of terms in their manual for the definition of Accommodation Reflex.

This should not be confused with pupillary unrest, the continuous, irregular change in the size of the pupils that may be observed under room or steady light conditions or with pupillary light reflex which is the pupil's normal reaction to the changes in light.


Point out the importance of keeping the stimulus steady and having the subject maintain his/her focus on the stimulus.

Demonstrate the Accommodation Reflex by having the participants focus on an object very close and one at a distance.

Note: Accommodation Reflex was approved for addition into this session by the IACP Technical Advisory Panel (TAP), November 2008.

Session 5 - Eye Examinations

Three Lighting Conditions



Drug Recognition Expert Course

5-20

Write on the dry erase board or flip-chart “The Three Lighting Conditions.”

The Three Lighting Conditions


Pupil sizes are estimated under three different lighting conditions:

- Room Light
- Near Total Darkness
- Direct Light

Session 5 - Eye Examinations

Estimation of Pupil Size – Room Light

The pupils are examined in room light prior to darkening the room.



Drug Recognition Expert Course 5-21

Estimation of Pupil Size under Room Light

- The pupils are examined in room light prior to darkening the room.

Point out that since room lighting conditions can vary considerably and often cannot be controlled, the range of pupil sizes may be broad.

Participant's Initial Practice of Pupil Size Estimation—Room Light

Instruct participants to work in pairs, taking turns checking each other's pupils.

Monitor, coach and critique the participants' practice.

Allow this practice to continue for only about 2 minutes.

Session 5 - Eye Examinations

Estimation of Pupil Size in the Dark Room

- **After you have completed the pupil size estimations in room light, you must darken the room, wait 90 seconds, and then proceed with the dark room exam**




Drug Recognition Expert Course 5-22

Participant's Initial Practice of Pupil Size Estimation—Dark Room

- After you have completed the pupil size estimations in room light, you must darken the room, wait approximately 90 seconds (for the officers eyes to adjust to the light), and then proceed with the dark room exam.

Session 5 - Eye Examinations

Estimation of Pupil Size – Near Total Darkness






Drug Recognition Expert Course 5-23

Estimation of Pupil Size under Near Total Darkness

- For the check under near total darkness completely cover the tip of the penlight with your finger or thumb, so that only a reddish glow and no white light emerges.

Demonstrate this.

Select a participant to participate in demonstrations of dark room pupil estimations.

- Bring the glowing tip up toward the subject's left eye until you can just distinguish the pupil from the colored portion of the eye (iris).

Demonstrate this.

- Continue to hold the glowing red tip in that position and bring the pupillometer up alongside the subject's left eye and locate the circle or semi-circle that is closest in size to the pupil.
- Repeat this procedure for the subject's right eye.


Demonstrate this.

Monitor, coach and critique the participants' practice.

Allow this practice to continue for only about 2 minutes.

Session 5 - Eye Examinations

Estimation of Pupil Size – Direct Light






Drug Recognition Expert Course 5-24

Estimation of Pupil Size under Direct Light

- Bring the penlight from the side of the subject's face and shine it directly into their left eye.

Demonstrate this.

- Position the penlight so that it illuminates and approximately fills the subject's eye socket.

Demonstrate this.

Emphasize that the penlight should be positioned so that the beam just "fits" the eye socket.

- Hold the penlight in that position for 15 seconds, and bring the pupillometer up alongside the left eye.
- Find the circle or semi-circle that is closest in size to the pupil.

Remind participants to position the penlight so that the beam exactly "fits" the eye socket when the beam is brought directly into the eye.

- Repeat this procedure for the subject's right eye.

Monitor, coach and critique the participants' practice.

Allow the practice to continue for only about 2 minutes.

Solicit participants' comments and questions concerning the eye examinations.

Session 5 - Eye Examinations

Pupillary Unrest

Double Click Picture to Play



Pupillary Unrest is the continuous, irregular change in the size of the pupils that may be observed under room or steady light conditions




Drug Recognition Expert Course 5-25

Point out that this term is defined in the glossary at the front of the participant's Manual.

Pupillary Unrest

Another eye sign that may be observed by the DRE is Pupillary Unrest.

Pupillary Unrest is defined as the continuous, irregular change in the size of the pupils that may be observed under room or steady light conditions.

The unique indicators of Pupillary Unrest are the unevenness and fluctuations in the rate and size of the pupils under lighted conditions and its disappearance in darkness.

Pupillary Unrest may be similar to "Hippus" which is defined as a rhythmic change in the pupil size of the eyes, as they dilate and constrict when observed in darkness independent of changes in light intensity, accommodation (focusing), or other forms of sensory stimulation.

Note: This new definition was approved by the IACP Technical Advisory Panel (TAP), November 2008.


Note: Research has shown that Hippus is primarily observed in total darkness conditions and is therefore difficult to detect under the current DRE protocol.

Session 5 - Eye Examinations

Rebound Dilation

A period of pupillary constriction followed by a period of pupillary dilation where the pupil steadily increases in size and does not return to its original constricted size

Double Click Picture to Play



INTERNATIONAL ASSOCIATION OF POLICE OFFICERS

NHTSA
www.nhtsa.gov

Drug Recognition Expert Course 5-26

Rebound Dilation

Print on dry erase board or flip-chart: "REBOUND DILATION."

Rebound dilation is defined as a period of pupillary constriction followed by a period of pupillary dilation where the pupil steadily increases in size and does not return to its original constricted size.

Note: This revision was approved by the IACP Technical Advisory Panel (TAP), November 2008.

Point out: The DRE will record rebound dilation if observed by recording the constricted or the smallest size and the largest or dilated size, i.e., 3.0 - 4.5 mm.

Example: The pupil is estimated at 8.5mm in near total darkness. Once the penlight is shined into the pupil it constricts to 4.0 mm then steadily dilates to 6.0 mm and remains that diameter while the direct light is shined into the eye.

Rebound dilation has been reported with persons impaired by drugs that cause pupillary dilation. Cannabis is most common.

Session 5 - Eye Examinations

Pupil Ranges

For most people, even under very bright light the pupils will not constrict much below a diameter of 2.0 millimeters (mm) or dilate to a diameter of not more than 8.5 mm in near total dark conditions



Drug Recognition Expert Course 5-27

Pupil Ranges

For most people, even under very bright light the pupils will not constrict much below a diameter of 2.0 millimeters (mm) or dilate to a diameter of not more than 8.5 mm in near total dark conditions.

Point out that results of studies indicated there are significant differences between the average pupil size ranges in the three test conditions. (Source: "An Evaluation of Pupil Size Standards Used By Police Officers for Detecting Drug Impairment" JAOA, March 2004, Richman, McAndrew, Decker & Mullaney.)

Consequently, the use of three distinct pupil size ranges for each of the different testing conditions may be considered more useful in the evaluation to determine impairment vs. non-impairment.

Session 5 - Eye Examinations

Pupil Size Technical Terms

- **Miosis** – abnormally constricted pupil (small)
- **Mydriasis** – abnormally dilated pupil (large)



Drug Recognition Expert Course

5-28

Pupil Size Technical Terms

Two key technical terms regarding pupil sizes are: Miosis – abnormally small pupil, i.e., constricted, and Mydriasis – an abnormally large pupil, i.e., dilated.

Session 5 - Eye Examinations

Non-Impaired Pupil Sizes

With pupil size and range:

Room light

- Approximately 4.0 mm
with pupil sizes ranging from 2.5 to 5.0 mm

Near total darkness

- Approximately 6.5 mm
with pupil sizes ranging from 5.0 to 8.5 mm

Direct light

- Approximately 3.0 mm
with pupil sizes ranging from 2.0 to 4.5 mm




Drug Recognition Expert Course 5-29

Non-Impaired Pupil Sizes

Room Light

- For a non-impaired person, the average pupil size and range for room light is approximately 4.0 mm, with pupil sizes ranging from 2.5 to 5.0 mm.

Near Total Darkness

- For a non-impaired person, the average pupil size and range for near total darkness is approximately 6.5 mm with pupil sizes ranging from 5.0 to 8.5 mm.

Direct Light

- For a non-impaired person, the average pupil size and range for direct light is approximately 3.0 mm with pupil sizes ranging from 2.0 to 4.5 mm.

Session 5 - Eye Examinations

Reaction to Light

Assessment of the pupil's reaction to light takes place during the check of pupil size under direct light




Drug Recognition Expert Course 5-30

Reaction to Light

Assessment of the pupil's reaction to light takes place during the check of pupil size under direct light when the uncovered light is brought from the side of the subject's face and the light beam is moved directly into his or her left eye.

Demonstrate this.

- As you bring the beam of light directly into the subject's eye, note how the pupil reacts.

Demonstrate this.

- Under ordinary conditions, the pupil should react very quickly, and constrict noticeably when the light beam strikes the eye.
- Under the influence of certain categories of drugs, the pupil's reaction may be slow, or there may be no visible reaction at all.

Emphasize: We consider the pupil's reaction to be slow if it takes more than one second to reach full constriction.

- Hold the direct light on the subject's eye for 15 seconds to assess pupil reaction.
- Also check for Rebound Dilation during this 15 second period.
- Caution should be used by the officer so as not to move the light beam or allow the bulb to change in light intensity.
- When you have completed this process for the left eye, repeat it for the right eye.

Participants' initial practice in assessing the pupil's reaction to light.

Have participants work in pairs, checking each others pupil reaction.

Monitor, coach and critique the participants' practice.

Allow the practice to continue for only about 2 minutes.

Session 5 - Eye Examinations

Demonstrations







Drug Recognition Expert Course 5-31

C. Demonstrations

Select two participants to come before the class.

Instruct one participant to demonstrate the administration of Horizontal Gaze Nystagmus (HGN) to the other participant.

- Check for Lack of Smooth Pursuit
- Check for Distinct and Sustained Nystagmus at Maximum Deviation
- Check for an Onset of Nystagmus prior to 45 degrees

Coach and critique the participant administrator's performance. Make sure that the participant administrator checks both eyes.

Estimation of Angle of Onset

When the participant administrator has completed the HGN test, instruct the participant administrator to draw the participant subject's eye to an angle of 35 degrees. Check the accuracy of this estimate, using the template.

Excuse the two participants and thank them for participating.

Demonstration of Vertical Gaze Nystagmus and Lack of Convergence

Select two other participants to come before the class.

Instruct one participant to check the other for Vertical Gaze Nystagmus.

Coach and critique the participant administrator's performance.

Instruct the second participant to check the eyes of the first participant for Lack of Convergence.

Coach and critique the participant administrator's performance.

Excuse the two participants and thank them for participating.

Session 5 - Eye Examinations

Demonstration of Pupil Size and Reaction to Light Checks

- Room Light

Dark Room Checks of Pupil Size

- Near Total Darkness
- Direct Light
- Reaction to Light




Drug Recognition Expert Course 5-32

Demonstration of Pupil Size and Reaction to Light Checks

- Room Light

***Select two other participants to come before the class.
Instruct one participant to check the other's pupils under room light.***

Coach and critique the participant administrator's performance.

- Dark room checks of pupil size
- Near total darkness
- Direct light
- Reaction to light

Instruct the second participant to demonstrate how to perform the dark room checks of pupil size.

Coach and critique the participant administrator's performance.

Point out that assessment of the pupil's reaction to light takes place in conjunction with the direct light check.

Excuse the two participants and thank them for participating.

Solicit participants' comments and questions concerning these demonstrations of the eye examinations.

Session 5 - Eye Examinations

Documentation Procedures

- Check for equal pupil size
- Check for resting nystagmus
- Assessment of tracking ability
- Initial assessment of Nystagmus angle of onset



Drug Recognition Expert Course 5-33

D. Documentation Procedures

Instruct participants to turn to the Standardized Drug Influence Evaluation Form in their manuals, or handout forms to the participants.

A brief examination of the eyes is made during the Preliminary Examination.

- Check for equal pupil size.
- Check for resting nystagmus.
- Assessment of tracking ability.
- Initial assessment of Nystagmus angle of onset.

Session 5 - Eye Examinations

Documentation Procedures (Cont.)

- Horizontal Gaze Nystagmus
- Vertical Gaze Nystagmus
- Lack of Convergence




Drug Recognition Expert Course 5-34

Horizontal Gaze Nystagmus

Emphasize that all three checks of the HGN test must be documented for each eye.

Remind participants that they must indicate the numerical number of the angle of onset and not just check-mark the box.

Vertical Gaze Nystagmus

Point out that “yes” implies that Vertical Gaze Nystagmus was present, “No” implies that it was not present.

Lack of Convergence

Point out that it will be necessary to diagram the movement of the eyes.

The dark room eye examinations are documented in a subsequent section of the form.

Point out the location of that section.

Emphasize that all dark room checks of the eyes must be performed and documented independently for each eye.

Solicit participants’ comments and questions concerning procedures for documenting the eye examinations.

Session 5 - Eye Examinations

Sample Eye Examination

Corrective Lens: <input type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Pupil Size: <input type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input type="checkbox"/> Watery	Blindness: <input type="checkbox"/> None <input type="checkbox"/> L. Eye <input type="checkbox"/> R. Eye	Tracking: <input type="checkbox"/> Equal <input type="checkbox"/> Unequal
Able to follow stimulus: <input type="checkbox"/> Yes <input type="checkbox"/> No				Eyelids: <input type="checkbox"/> Normal <input type="checkbox"/> Droopy		

HGN	Left Eye	Right Eye	Vertical Nystagmus? <input type="checkbox"/> Yes <input type="checkbox"/> No
Lack of Smooth Pursuit			Convergence Right Eye Left Eye
Max. Deviation			
Angle of Onset			

PUPIL SIZE	ROOM LIGHT (2.5-5.0)	DARKNESS (5.0-8.5)	DIRECT LIGHT (2.0-4.5)
Left Eye			
Right Eye			

Rebound Dilation: <input type="checkbox"/> Yes <input type="checkbox"/> No	Reaction to Light:
--	--------------------




Drug Recognition Expert Course 5-35

Sample Eye Examination

Instruct participants to turn to the Standardized Drug Influence Evaluation Form in their manuals, or handout forms to the participants.

A brief examination of the eyes is made during the Preliminary Examination.

- Check for equal pupil size.
- Check for resting nystagmus.
- Assessment of tracking ability.
- Initial assessment of Nystagmus angle of onset.

Horizontal Gaze Nystagmus

Emphasize that all three checks of the HGN test must be documented for each eye.

Remind participants that they must indicate the numerical number of the angle of onset and not just check-mark the box.

Session 5 - Eye Examinations

Sample Eye Examination (Cont.)

Corrective Lens: <input type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Pupil Size: <input type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input type="checkbox"/> Watery	Blindness: <input type="checkbox"/> None <input type="checkbox"/> L. Eye <input type="checkbox"/> R. Eye	Tracking: <input type="checkbox"/> Equal <input type="checkbox"/> Unequal
Able to follow stimulus: <input type="checkbox"/> Yes <input type="checkbox"/> No				Eyelids: <input type="checkbox"/> Normal <input type="checkbox"/> Droopy		

HGN	Left Eye	Right Eye	Vertical Nystagmus? <input type="checkbox"/> Yes <input type="checkbox"/> No
Lack of Smooth Pursuit			Convergence Right Eye Left Eye 
Max. Deviation			
Angle of Onset			

PUPIL SIZE	ROOM LIGHT (2.5-5.0)	DARKNESS (5.0-8.5)	DIRECT LIGHT (2.0-4.5)
Left Eye			
Right Eye			

Rebound Dilation: <input type="checkbox"/> Yes <input type="checkbox"/> No	Reaction to Light:
--	--------------------




Drug Recognition Expert Course 5-36

Solicit participants' comments and questions concerning procedures for documenting the eye examinations

Vertical Gaze Nystagmus

Remind students that "Yes" implies that Vertical Gaze Nystagmus was present, "No" implies that it was not present.

Lack of Convergence

Point out that it will be necessary to diagram the movement of the eyes.

The dark room eye examinations are documented in a subsequent section of the form.

Point out the location of that section.

Emphasize that all dark room checks of the eyes must be performed and documented independently for each eye.

Session 5 - Eye Examinations

Sample Eye Examination (Cont.)

Corrective Lens: <input type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Pupil Size: <input type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input type="checkbox"/> Watery	Blindness: <input type="checkbox"/> None <input type="checkbox"/> L. Eye <input type="checkbox"/> R. Eye	Tracking: <input type="checkbox"/> Equal <input type="checkbox"/> Unequal
HGN				Vertical Nystagmus? <input type="checkbox"/> Yes <input type="checkbox"/> No		
Lack of Smooth Pursuit		Left Eye	Right Eye	Convergence Right Eye Left Eye		
Max. Deviation						
Angle of Onset						

PUPIL SIZE	ROOM LIGHT (2.5-5.0)	DARKNESS (5.0-8.5)	DIRECT LIGHT (2.0-4.5)
Left Eye			
Right Eye			

Rebound Dilation: <input type="checkbox"/> Yes <input type="checkbox"/> No	Reaction to Light:
--	--------------------




Drug Recognition Expert Course 5-37

***Instruct participants to practice in pairs.
Each participant will conduct a complete set of eye examinations on his or her partner.***

Participants then will “reverse roles.”

Preliminary Eye Exams

Tell the participants to record their estimations of their partner’s pupil sizes on the Drug Influence Evaluation Form.

Monitor, coach and critique participants’ practice.

- Check for equal pupil size.
- Check for resting nystagmus.
- Assessment of tracking ability.
- Initial estimation of nystagmus angle of onset.

Eye Exams

Make sure each participant administers a complete series of eye examinations at least once.

Session 5 - Eye Examinations

Pupil Size Estimations

- Room Light
- Near Total Darkness
- Direct Light



Drug Recognition Expert Course 5-38

Pupil Size Estimations

- Room Light
- Near Total Darkness
- Direct Light

If possible, the training room should be at least somewhat darkened for this final stage of practice.

Reporting out of Pupil Size Estimations

Instructor: While the participants practice is still going on, print the matrix at the end of this session on the dry erase board or flip-chart.

Tell the participants that we will tabulate the pupil sizes of everyone in the class, for each of the three lighting conditions. For simplicity, tell the participants that we will tabulate the left eye pupil sizes only.

Session 5 - Eye Examinations

Tabulations

- Room Light
- Near Total Darkness
- Direct Light




Drug Recognition Expert Course 5-39

Tabulations:

Room Light

Direct the participants' attention to the first column of the matrix.

Say: "Let's concentrate now only on the room light estimations."

Ask: "How many of you found that your partners had pupils of 2.0 mm or less in room light?" (Get a show of hands; count them; print the number in the first box of the first column).

Then ask: "How many had partners with a 2.5 mm pupil in room light?" (Count the hands and print the number in the 2nd box).

Continue this until you get to the last box in the 1st column: "How many had partners with pupils of 8.0 mm or larger?" (Count the hands; print the number).

Repeat this process for each of the other two lighting conditions.

Near Total Darkness Tabulation:

Use same process as above.

Direct Light Tabulation:

Make appropriate comments about the number of participants whose pupils are outside the normal range of size under the various lighting levels.

Session 5 - Eye Examinations

Eye Exams Practice

- Check for equal pupil size
- Check for resting nystagmus
- Assessment of tracking ability
- Initial estimation of nystagmus angle of onset
- Horizontal Gaze Nystagmus
- Vertical Gaze Nystagmus
- Lack of Convergence




Drug Recognition Expert Course 5-40

E. Practice

Instruct participants to practice in pairs.

Each participant will conduct a complete set of eye examinations on his or her partner. Participants then will “reverse roles.”

Preliminary Eye Exams

Tell the participants to record their estimations of their partner’s pupil sizes on the Drug Influence Evaluation Form.

Monitor, coach and critique participants’ practice.

- Check for equal pupil size.
- Check for resting nystagmus.
- Assessment of tracking ability.
- Initial estimation of nystagmus angle of onset.

Eye Exams

Make sure each participant administers a complete series of eye examinations at least once.

- Horizontal Gaze Nystagmus.
- Vertical Gaze Nystagmus.
- Lack of Convergence.

Session 5 - Eye Examinations

QUESTIONS?



Drug Recognition Expert Course

5-41

Solicit participants' comments and questions concerning Eye Examinations.

Pupil Size Chart

Pupil Size	Room Light	Near Total Darkness	Direct Light
2.0 mm			
2.5 mm			
3.0 mm			
3.5 mm			
4.0 mm			
4.5 mm			
5.0 mm			
5.5 mm			
6.0 mm			
6.5 mm			
7.0 mm			
7.5 mm			
8.0 mm and above			

Session 6

Physiology and Drugs: An Overview



Session 6 - Physiology and Drugs: An Overview

Learning Objectives

- Explain in layman's terms the general concept of human physiology
- Explain in layman's terms the purpose and functions of major systems in the body (nervous system, circulatory system, respiratory system, etc.)




Drug Recognition Expert Course 6-2

A. Physiology and Drugs: An Overview

Briefly review the content, objectives and activities of this session.

Upon successfully completing this session the participant will be able to:

- Explain in layman's terms the general concept of human physiology.
- Explain in layman's terms the purpose and functions of major systems in the body (nervous system, circulatory system, respiratory system, etc.)

CONTENT SEGMENTS

- A. Physiology and Drugs: An Overview
- B. Body Systems
- C. The Concept of Homeostasis
- D. A Simple View of the Heart and Circulatory System
- E. A Simplified Concept of the Nervous System
- F. How Drugs Work
- G. Medical Conditions Which Sometimes Mimic Drug Impairment

LEARNING ACTIVITIES

- Instructor-Led Presentations
- Reading Assignments

Session 6 - Physiology and Drugs: An Overview

Learning Objectives (Cont.)

- Explain in layman's terms how drugs work in the body
- Explain in general terms how the drug evaluation is used to detect signs or symptoms indicative of drug impairment
- Correctly answer the "topics for study" questions at the end of this session



Drug Recognition Expert Course 6-3

- Explain in layman's terms how drugs work in the body.
- Explain in general terms how the drug evaluation is used to detect signs or symptoms indicative of drug impairment.
- Correctly answer the "topics for study" questions at the end of this session.

Session 6 - Physiology and Drugs: An Overview

How Does the Body Work?



The image shows a full-body anatomical illustration of a human figure, viewed from the front. The skin is removed, revealing the underlying muscles in shades of red and pink, and internal organs in various colors like yellow, green, and blue. The figure has its arms slightly out to the sides and legs straight. The illustration is centered on a white background within a blue-bordered frame.

INTERNATIONAL ASSOCIATION OF CHIEFS OF POLICE

NHTSA
www.nhtsa.gov

Drug Recognition Expert Course 6-4

Before we can understand how drugs work, we must have a basic understanding of how the body works.

Point out that it is not necessary to have detailed knowledge of specific functions or medical terminology. Participants will not become medical specialists as a result of this limited overview, however, they should be encouraged to learn as much as possible about human physiology through additional instruction and independent reading.

We will review general concepts of how the body functions in a “normal” or “standard” human.

Point out that all human beings are different and a “normal” or “standard” human does not exist. However, experience and scientific studies have produced an average range of values that can be used for comparison purposes.

We will briefly review the primary functions of the body systems.

Session 6 - Physiology and Drugs: An Overview

“Average” or “Normal” Within the DEC Program

- “Average” is a quantity that represents the “middle” or “typical” value that the majority of healthy, non-impaired people would exhibit or have in a specific test that is measured numerically
- “Normal” describes both a range of values or results that are “close to” average, but can be above or below the “average” value for the majority of healthy non-impaired people as well as to describe unremarkable muscle tone, etc.




Drug Recognition Expert Course 6-5

“Normal” or DRE Averages

In the DEC Program we use the terms “Normal”, “Average”, “Average Ranges” or “DRE Average Range”.

- **“Average”** is a quantity that represents the “middle” or “typical” value that the majority of healthy, non-impaired people would exhibit or have in a specific test that is measured numerically.
- **“Normal”** describes both a range of values or results that are “close to” average, but can be above or below the “average” value for the majority of healthy non-impaired people. “Normal” can also be used to describe unremarkable conditions on tests that are not measured numerically such as muscle tone, etc.

Within the DEC Program, “normal” means the same thing as “healthy” or “non-impaired” or within the “DRE average ranges.”

For example, the “Average”, or typical value, for pupil size in near total darkness is 6.5 mm. This means that when **ALL** the sizes were measured **using the DRE test protocol**, in a large number of pupils in healthy, non-impaired adults, the average pupil size for those was approximately 6.5 mm while the average range, or for normal pupil size was 5.0-8.5 mm.

Point out that in the DEC Program “normal” or “normals” is commonly used to refer to a result within the DRE average ranges, such as pupil sizes, pulse rate, blood pressure, etc.

Point out that when using the term “normal” or “normals” the DRE should understand what these terms refer to. Although the term “normal range” has been historically used in the DEC Program, we now use the term “average range” to provide a better description of what we observe.

Session 6 - Physiology and Drugs: An Overview

Bodily Functions Examined During Drug Influence Evaluation

- **Central Nervous System**
- **Eyes**
- **Blood Pressure and Pulse**
- **Balance and Coordination**
- **Body Temperature**



Drug Recognition Expert Course 6-6


Primary focus will be on the systems or component parts of those systems that are examined during the drug influence evaluation.

- Central Nervous System
- Eyes
- Blood Pressure and Pulse
- Balance and Coordination
- Body Temperature

Session 6 - Physiology and Drugs: An Overview

Physiology:

The study of the functions of living organisms and their parts



Drug Recognition Expert Course 6-7

B. Body Systems

Physiology is the branch of biology that deals with the functions and activities of life or living matter and the physical and chemical phenomena involved.

For the purposes of this course, physiology is the study of the functions of living organisms and their parts.

Source: Merriam-Webster's Medical Dictionary (2008).

Point out: For the purposes of this course, physiology is the study of the functions of living organisms and their parts.

Session 6 - Physiology and Drugs: An Overview

MURDERS, INC.



Drug Recognition Expert Course 6-8

A convenient way of discussing human physiology is to list the ten major systems of the body.

The phrase “MURDERS INC” helps us remember the names of the ten systems.

Each letter stands for the name of one system.

Session 6 - Physiology and Drugs: An Overview

The Ten Systems of Human Physiology: *MURDERS, INC.*

M is for Muscular System
U is for Urinary System
R is for Respiratory System
D is for Digestive System
E is for Endocrine System
R is for Reproductive System
S is for Skeletal System




Drug Recognition Expert Course 6-9

Muscular System

M stands for the MUSCULAR SYSTEM

Point out that we assess the muscular system in the drug influence evaluation when we test coordination and balance by administering divided attention tests, and when we check for muscle rigidity.

The body has three different kinds of muscles.

- The heart or cardiac muscle.
- Smooth muscles, which control the body's involuntary operations.
- Striated muscles, which carry out our voluntary movements.

Examples: Smooth muscles control breathing, the operation of the pyloric valve (a muscle located at the base of the stomach), dilation and constriction of pupils, and all other things that we do not consciously control.

All three types of muscles are examined at various stages of the drug influence evaluation.

Urinary System

U is for the URINARY SYSTEM.

Point out that drugs can usually be detected in the urine, and that collection of a urine specimen or other suitable bodily substance is an important part of the drug influence evaluation.

The system consists of two kidneys, the bladder, ureters connecting the kidneys to the bladder, and the urethra, which transports the urine out of the body.

Kidneys filter waste or harmful products, such as drugs and their metabolites, from the blood, and dump these waste products into the bladder.

Session 6 - Physiology and Drugs: An Overview

The Ten Systems of Human Physiology: *MURDERS, INC.* (Cont.)

M is for Muscular System
U is for Urinary System
R is for Respiratory System
D is for Digestive System
E is for Endocrine System
R is for Reproductive System
S is for Skeletal System




Drug Recognition Expert Course 6-10

Respiratory System

The first R in “MURDERS INC” stands for the RESPIRATORY SYSTEM.

Point out that some drugs cause the user to breath slowly and shallowly, while others cause rapid breathing.

The major parts of the Respiratory System are the lungs and the diaphragm.

The diaphragm is a smooth muscle that draws the air into the lungs and forces it out.

Lungs take in oxygen and transfer it to the blood, and remove carbon dioxide and some other waste products from the blood, and expel them into the outside air.

Point out that important clues of drug use, i.e., odors of alcoholic beverages, marijuana, chemicals, etc. may be present on a suspect’s breath.

Digestive System

D stands for the DIGESTIVE SYSTEM.

Major components of this system are the tongue, teeth, esophagus, stomach, intestines, liver, and pancreas.

The Digestive System breaks down large particles of food, until they are of a size and chemical composition that can be absorbed in the blood.

Remind participants that, when drugs are taken orally, they might be retained in the stomach for a while, until any food that is there has been broken down sufficiently to allow passage into the small intestine.

Endocrine System

E is for the ENDOCRINE SYSTEM.

The Endocrine System is made up of a number of different glands that secrete hormones.

INSTRUCTOR, FOR YOUR INFORMATION: the glands that make up the Endocrine System include the Thyroid, Parathyroid, Pituitary and Adrenal glands, as well as portions of the pancreas, testes and ovaries.

Session 6 - Physiology and Drugs: An Overview

The Ten Systems of Human Physiology: *MURDERS, INC.* (Cont.)

M is for Muscular System
U is for Urinary System
R is for Respiratory System
D is for Digestive System
E is for Endocrine System
R is for Reproductive System
S is for Skeletal System




Drug Recognition Expert Course 6-11

Print HORMONES on the dry erase board or flip-chart.

Hormones are complex chemicals that travel through the blood stream and that control or regulate certain body processes.

Some drugs can mimic the effects of certain hormones, or can react with the hormones in ways that alter the hormones' effects.

Reproductive System

The second R in "MURDERS INC" stands for the REPRODUCTIVE SYSTEM.

The functions of the reproductive system fall into two categories:

- self-producing (cytogenic), and
- hormone producing (endocrinic).

We are primarily concerned with hormone production since the hormones produced by the reproductive system aid the nervous system in its regulatory role.

Point out that the Reproductive and Skeletal Systems are the only major components of physiology and that are not directly involved in the drug influence evaluation.

Skeletal System

S is for the SKELETAL SYSTEM.

Consists of bones, cartilage and ligaments.

The Skeletal System provides support to the body, permits movement, and forms blood cells.

Session 6 - Physiology and Drugs: An Overview

The Ten Systems of Human Physiology: *MURDERS, INC.* (Cont.)

I is for Integumentary System
 N is for Nervous System*
 C is for Circulatory System*

* For DRE officers, these are key systems




Drug Recognition Expert Course 6-12

Integumentary System

The I in “INC” stands for the INTEGUMENTARY SYSTEM.

Consists of the skin, hair, fingernails and toe nails, and accessory structures.

Point out that DREs examine the skin for hypodermic injection sites, and for sweating, clamminess, and temperature.

The chief functions of the Integumentary System include protection of the body, control of the body temperature, excretion of wastes (i.e. through sweat) and sensory perception.

Nervous System

N is for the NERVOUS SYSTEM.

EMPHASIZE that the Nervous System is one of the most important components of physiology, as far as the drug influence evaluation is concerned.

This system consists of the brain, the brain stem, the spinal cord and the nerves.


Nerves keep the brain informed of changes in the body’s external and internal environments.

CLARIFICATION: Nerves carry messages to the brain from the sense organs (eyes, ears, nose, etc, and also from pain sensors).

Nerves also carry messages from the brain to the body’s muscles, tissues and organs.

CLARIFICATION: The brain uses nerves to send messages commanding the heart to beat, the fingers to move, the pupils to dilate, etc.

The nervous system controls, coordinates and integrates all physiological processes, so that normal body functions can be maintained.



Circulatory System

C is for the CIRCULATORY SYSTEM.

Point out that this is another very important component of physiology, as far as the drug influence evaluation is concerned.

For our purposes, the most important parts of the Circulatory System are the heart, the blood vessels (e.g., arteries, veins, capillaries, etc.) and the blood.

Blood is the body's primary transport mechanism: it carries food, water, oxygen, hormones, antibodies, etc. to the body's tissues and organs.

Blood is also primarily responsible for carrying heat throughout the body.

Blood is the main transport mechanism for bringing drugs to the brain.

The heart, of course, pumps the blood and causes it to circulate throughout the body.

Solicit participants' comments and questions about "MURDERS INC," the ten major systems of human physiology. Point out that much more will be covered about the last two systems (Nervous and Circulatory) later in this session.

Session 6 - Physiology and Drugs: An Overview

Homeostasis

Dynamic balance, or steady state, involving levels of salts, water, sugars and other material in the body's fluids




Drug Recognition Expert Course 6-14

C. The Concept of Homeostasis

Homeostasis is the dynamic balance, or steady state, involving levels of salts, water, sugars and other materials in the body's fluids.

Human body is exposed to a constantly changing external environment.

Changes are neutralized by the internal environment – the blood.

Oxygen, foods, water and other substances are constantly leaving bodily fluids to enter cells, while carbon dioxide and other wastes are leaving the cells to enter these fluids.


Yet, the chemical composition of these fluids remains within very narrow limits.

This phenomenon is called homeostasis.

Point out that “homeo” means similar or the same elements and “stasis” means balance.

Point out that the rhythm of the heart, breathing, constancy of body temperature, and the steady level of blood pressure under specific circumstances or conditions are all manifestations of homeostatic mechanisms at work within the body.

Drugs interfere with the homeostatic mechanisms and produce signs and symptoms that can be recognized by a trained DRE.



D. A Simple View of the Heart and Circulatory System

Heart and Circulatory System


Circulation is a closed system, where blood is propelled by contractions of the heart.

Blood is driven into arteries, arteries divide into smaller and smaller branches and finally into meshwork of fine capillaries which pervade body tissues.

Point out that arteries constrict to aid distribution of blood.

Meshwork joins up again to form small veins which become larger trunks as they travel centrally towards the heart.


Point out that blood does not come into direct contact with the cells, but rather stays in the blood vessels.



There are two separate circulation systems:

Systemic system involves the whole body and is driven by the left side of the heart.

Pulmonary system deals with the passage of blood through the lungs and is driven by the right side of the heart.



The heart is the pump and has two sides:

Consists of the left atrium and ventricle. The upper chamber (atrium) receives blood from the great veins, the lower chamber discharges blood into the great arteries.

Left side pumps blood through the aorta and the arteries to the tissues.

Blood, after passing through the tissues, returns via the veins to the right side.

Right side pumps blood through the pulmonary artery to the lungs and returns it to the left side of the heart again via the four pulmonary veins.

Consists of the right atrium and ventricle.

NOTE: The pulmonary artery is the only artery that carries de-oxygenated blood; all other arteries carry blood that has received fresh oxygen from the lungs. Likewise, the pulmonary vein is the only vein that carries blood rich in oxygen; all other veins carry blood depleted of oxygen back to the heart.

The normal heart continues to beat regularly and continuously, with a rest interval never longer than a fraction of a second.

Heart rate is the number of beats per minute.


Point out that heart rate is regulated by the autonomic nervous system: sympathetic nerve fibers insure that the heart beats fast enough to maintain circulation during any activity. Parasympathetic nerve fibers tend to slow the heart. This coordinated nerve supply assures that the heart does not beat too fast or too slowly.

Pulse rate is the number of pulsations per minute.

For DRE purposes, the average range for the pulse rate is 60-90 pulsation beats per minute.

Session 6 - Physiology and Drugs: An Overview

Blood Pressure



- Blood pressure (BP) is the force of the blood circulating in the arteries
- BP is categorized as systolic or diastolic BP
- Systolic pressure is the maximum force that occurs during contraction
- Diastolic pressure represents the minimum force that occurs when the heart relaxes




Drug Recognition Expert Course 6-18

Blood pressure (BP) is the force of the blood circulating in the arteries.

Point out that some people may exhibit irregular (or arrhythmic) heart beats, i.e. where the interval between pulses varies.

BP is categorized as systolic or diastolic BP.

Ask participants to define “systolic” and “diastolic.”

Systolic pressure is the maximum force that occurs during contraction.

Diastolic pressure represents the minimum force that occurs when the heart relaxes.

Point out that physical conditioning can also affect blood pressure and pulse rate.

Both systolic and diastolic pressures are measured and recorded as follows:

- 120 systolic
- 80 diastolic

Demonstrate proper method of recording on flip-chart or dry erase board.

Point out that the ranges of BP varies widely based on a number of factors, including age.

The DRE average range for systolic blood pressure is 120 to 140. The DRE average range for diastolic blood pressure is 70 to 90.

Control Systems


The functions of the organs of the body are controlled in two ways:

This is a function of the endocrine system.

Remind participants that the hormones modify the activity of specific organs.

One, by sending “chemical messengers” known as hormones via the blood stream from an endocrine gland where they are produced.

Second, system of control is by means of the nervous system.



E. The Nervous System

Clarification: Nerves are often pictured as telephone or telegraph wires.

The nerves that carry messages to and from the brain often are pictured as “wires” that carry electrical signals.

A more accurate, but still simplified concept would envision a nerve as a series of broken wire segments, with the segments separated by short spaces, or gaps.

Point to the close up of the gap.

We can imagine messages running along the “wire segments” in much the same manner that electrical impulses run along telephone wires.

When the message reaches the end of the “wire segment,” it triggers the release of chemicals that flow across the gap, and contact the next “wire segment.”

When the chemical contacts the next wire segment, it generates an electrical impulse which runs along the wire until it reaches the next gap.

At that gap, the message again triggers the release of chemicals that flow across to the next “wire segment,” and the process continues.

Point out that this concept of a nerve as a series of separated “wire segments” is not a true physical model. But it does accurately convey the basic idea of message transmission along nerves.

Solicit participants’ questions about this concept.

Session 6 - Physiology and Drugs: An Overview

How a Neurotransmitter Works

Steps are numbered sequentially:

1. Neuron makes a neurotransmitter
2. Synaptic vesicles are small membrane bound structures in the axon terminals of nerve cells that contain neurotransmitters. The vesicles release neurotransmitters into the synaptic gap
3. Neurotransmitter enters gap to transmit electrical impulse to receptor site
4. Receptor performs a function



Drug Recognition Expert Course 6-20

In our simple model of nerves, each “wire segment” corresponds to a nerve cell, called a neuron.


The chemical that flows across the gaps separating neurons is called a neurotransmitter.

Clarification: neurotransmitters are the body’s chemical messengers.

The body has a number of different neurotransmitters; each carries a different chemical message.

The sequence of how a neurotransmitter works:

1. The neuron makes a neurotransmitter.
2. Synaptic vesicles are small membrane bound structures in the axon terminals of nerve cells that contain neurotransmitters. These vesicles release neurotransmitters into the synaptic gap.
3. The neurotransmitter enters the synaptic gap to transmit electrical impulse to the receptor site.
4. The receptor performs a function



Each neuron, or “wire segment” has three main parts:

- the cell body
- the axon
- the dendrite


The axon is the part of the neuron that sends out the neurotransmitter, or chemical messenger.

Point out that by using a baseball analogy, the Axon would be the “pitcher” of the neurotransmitter and the dendrite is the “catcher” of the neurotransmitter.

The dendrite is the part that receives the neurotransmitter.

The gap between two neurons is called a synapse, or synaptic gap.

Solicit participants’ questions about nerve cells (neurons).



Classification of Nerves

Some nerves carry messages away from the brain, to the body's muscles and organs.

These are called motor, or efferent nerves.

The brain uses motor nerves to send commands to the heart to beat, the lungs to breathe, the muscles to contract or expand, and so forth.

Other nerves carry messages to the brain, i.e. from the eyes, ears and other senses, from the muscles, etc.

These are called Sensory, or Afferent nerves.

The brain decodes the messages that come along the sensory nerves to monitor the condition of the body and of the outside world.

A fundamental notion: if something interferes with the messages the brain sends along the motor nerves, the brain's control over the heart, the lungs, the muscles and other organs will be distorted.

Another fundamental notion: if something interferes with the messages the brain receives from the sensory nerves, the brain's perception of the outside world and of the body's status will be distorted.

Point out that, basically, this is how drugs work: they interfere with transmission or reception of the messages that travel along nerves.

Session 6 - Physiology and Drugs: An Overview

Sub-Systems of Motor Nerves

- Voluntary
- Autonomic





Drug Recognition Expert Course 6-23

There are two sub-systems of motor nerves:

- The voluntary nerves send messages to the striated muscles that we consciously control.
- The autonomic nerves send messages to the muscles and organs that we do not consciously control, i.e. smooth muscle and cardiac muscle.

On the dry erase board or flip-chart print the word “autonomic,” and then draw two lines from the word “autonomic”, one line angling down toward the left, the other angling down toward the right.



- The Autonomic sub-system is divided into two groups.
- The Sympathetic nerves command the body to react in response to fear, stress, excitement, etc.

CLARIFICATION: Sympathetic nerves control the body’s “fight or flight” responses.

EXAMPLES: Sympathetic nerves carry the messages that cause: blood pressure to elevate, pupils to dilate, sweat glands to activate, hair to stand on end, heartbeat to increase and strengthen, blood vessels of the skin to constrict, the walls of the hollow viscera to relax (inhibiting digestion).

- Parasympathetic nerves carry messages that produce relaxed and tranquil activities.

Session 6 - Physiology and Drugs: An Overview

Autonomic Sub-Systems

- Sympathetic nerves
- Parasympathetic nerves




Drug Recognition Expert Course 6-24

EXAMPLES: Parasympathetic nerves carry messages that cause: pupils to constrict, heartbeat to slow, peripheral blood vessels to dilate, blood pressure to decrease.

Write “Sympathomimetic” on the dry erase board or flip-chart.

Certain neurotransmitters (i.e. chemical messengers) aid in the transmission of messages along sympathetic and parasympathetic nerves.

Some drugs mimic the action of these neurotransmitters: when taken into the body, these drugs artificially cause the transmission of messages along sympathetic or parasympathetic nerves.

Drugs that mimic the neurotransmitter associated with sympathetic nerves are called sympathomimetic drugs.

Sympathomimetic drugs artificially cause the transmission of messages that produce elevated blood pressure, dilated pupils, etc.

Ask participants to name a category of drugs that would be considered sympathomimetic.

Examples: CNS Stimulants, Hallucinogens, and to some extent Dissociative Anesthetics and Cannabis.

Drugs that mimic neurotransmitters associated with parasympathetic nerves are called parasympathomimetic drugs.

Session 6 - Physiology and Drugs: An Overview

Autonomic Sub-Systems

- Sympathetic nerves – control body’s “fight or flight” responses
- Parasympathetic nerves – produce relaxed and tranquil activities






Drug Recognition Expert Course 6-25

Write “Parasympathomimetic” on the dry erase board or flip-chart.

Parasympathomimetic drugs artificially cause the transmission of messages that produce lowered blood pressure, drowsiness, etc.

Ask participants to name a drug category that would be considered parasympathomimetic.

Examples: Narcotic Analgesics and CNS Depressants.

Session 6 - Physiology and Drugs: An Overview

Neurotransmitters ("Chemical Messengers")

- Norepinephrine (Noradrenaline)
- Acetylcholine
- Dopamine
- Serotonin
- Gamma Amino Butyric Acid (GABA)




Drug Recognition Expert Course 6-26

Neurotransmitters

Although there are more than 100 chemicals in the brain, only about two dozen probably are true neurotransmitters.

Among the primary neurotransmitters that have been identified are:

Write these neurotransmitters on the dry erase board or flip-chart

- Norepinephrine (also called Noradrenaline)

Point out that Norepinephrine is a neurotransmitter that produces effects on the body that are similar to the effects produced by Adrenaline (a hormone). Many neurotransmitters correspond to hormones that produce similar effects.

- Acetylcholine
Acetylcholine plays a role in muscle control, and affects neuromuscular or myoneural junctions.
- Dopamine
Dopamine plays a role in mood control and is used in treating Parkinson's Disease.
- Serotonin
Serotonin is a vasoconstrictor, thought to be involved in sleep, wakefulness, and sensory perception. Tryptophan is a precursor to serotonin, and has been used to treat insomnia.
- Gamma Amino Butyric Acid (Abbreviated GABA)
GABA inhibits various neurotransmitters and also causes a release of growth hormones.

Session 6 - Physiology and Drugs: An Overview

Endorphins and Enkephalins

- The body's natural pain relievers
- Many drugs artificially induce the effects of neurotransmitters and hormones



Drug Recognition Expert Course 6-27

Endorphins and Enkephalins

These are the body's natural pain relievers.

There are many drugs that artificially induce the effects of neurotransmitters and hormones.

Solicit participants' questions and comments about nerves and neurotransmitter.

Session 6 - Physiology and Drugs: An Overview

How Drugs Work

By artificially creating natural body reactions generally associated with the work of neurotransmitters and hormones




Drug Recognition Expert Course 6-28

F. How Drugs Work

In very simple terms, drugs work by artificially creating natural body reactions generally associated with the work of neurotransmitters and hormones.

Therapeutic doses of legitimate prescription and over the counter drugs are designed to produce mild and carefully controlled simulations of the natural action of neurotransmitters and hormones.

Ask participants: What drug do many people take to overcome artificially the drowsiness they feel in the morning?

Large, abusive doses of drugs may produce greatly exaggerated simulations of the natural action of hormones and neurotransmitters, sometimes with disastrous results.

Example: Cocaine (a sympathomimetic drug) may artificially create a message commanding the heart to beat so rapidly that cardiac arrest results.

When a person ingests a drug and artificially simulates the natural action of hormones and neurotransmitters, the body's dynamic balance is disrupted.

Remind participants that the body struggles to maintain homeostasis, the dynamic balance of salts, sugars, and other substances.

The body automatically responds to the presence of the drug by producing other hormones and chemicals that can oppose the drug's effects, and bring the body back into balance.

Example Number One

If a person ingests a stimulant drug that mimics neurotransmitters associated with the sympathetic nerves, the body may react by excreting hormones that depress the bodily functions that the drug is exciting.

Session 6 - Physiology and Drugs: An Overview

How Drugs Work (Cont.)

By artificially creating natural body reactions generally associated with the work of neurotransmitters and hormones



Drug Recognition Expert Course 6-29

If a person ingested Cocaine, for example, the Cocaine would artificially stimulate the body functions. The body would then produce hormones and neurotransmitters to slow down the body functions to try to maintain homeostasis.

Example Number Two

If a person ingests a drug that depresses some bodily function, the body may pour out one of its natural chemicals that stimulate that same function.

An interesting situation can occur when the drug is no longer psychoactive.

The chemicals produced by the body in an effort to counteract the drug may still be active.

These natural chemicals have exactly the opposite effect on the body that the drug had: after all, that is precisely why the body produced those chemicals.

As a result, the person may feel, appear and act in a manner exactly opposite to the way he or she would feel, appear and act when under the influence of the drug.

Session 6 - Physiology and Drugs: An Overview

“Downside Effect”

When the body reacts to the presence of a drug by releasing hormones or neurotransmitters to counteract the effects of the drug consumed




Drug Recognition Expert Course 6-30

Downside

It is not uncommon for a DRE to encounter someone on the “downside.”

Example: Ask participants if they have ever experienced this situation...After drinking several drinks, they become drowsy, go to bed and fall asleep quickly. But, after a few hours, when it is still the middle of the night, they suddenly awaken and are wide awake, unable to fall asleep again. What has happened is that the alcohol has worn off, but the natural CNS Stimulants the body produced to counteract the alcohol are still around.

Write “Downside” on the dry erase board or flip-chart.

We call this situation being on the “downside” of the drug.

Example: with cocaine (a drug that is metabolized, or broken down by the body fairly quickly) the user may be exhibiting drowsiness and general depression by the time the DRE is called to the scene.

The concept of “downside” will be especially important to us when we discuss the effects of CNS Stimulants and drug combinations.

Point out that persons on the “downside” can be dangerous when trying to operate a motor vehicle.

Point out that two common examples of “downside” occur with Cocaine and Methamphetamine. Both drugs stimulate the body.

Then the body attempts to “counteract” the stimulant effects. When the effects of the drug diminish, the results may mimic a CNS Depressant or a Narcotic Analgesic.

Solicit participants’ questions about Downside.

Session 6 - Physiology and Drugs: An Overview

“Negative Feedback”

When the brain accommodates the routine presence of a drug by turning off the supply of natural chemicals that correspond to the drug




Drug Recognition Expert Course 6-31

Negative Feedback

Write “Negative Feedback” on the dry erase board or flip-chart.

Another interesting effect that drugs can produce is called Negative Feedback.

Write “The Body Quits Producing the Natural Chemicals” on the dry erase board or flip-chart.

By taking the drug, the person artificially simulates the action of certain hormones and / or neurotransmitters.

If the person continues to take the drug, the body may simply cease producing the natural chemicals that the drug simulates.

In effect, the body comes to rely on the drug to supply itself with those chemicals.

Example of Negative Feedback: when people regularly use heroin, cocaine, or marijuana, their bodies may cease producing the neurotransmitters and hormones known to be crucial for proper pain relief, stress reduction, mental stability and motivation.

Point out that because of this Negative Feedback, the user becomes dependent on the drug to cope with the stresses and strains of daily life.

One result of this may be increased tolerance to the drug: since the body isn’t producing its own natural chemicals, it can more easily stand the drug.

Session 6 - Physiology and Drugs: An Overview

Tolerance

- **May exhibit relatively little evidence of impairment on the psychophysical tests**
- **Even tolerant drug users, when impaired, usually exhibit clinical evidence (i.e. vital signs, eye signs, etc.)**




Drug Recognition Expert Course 6-32

Write “Increased Tolerance” on the dry erase board or flip-chart.

Emphasize: Habitual users of drugs may develop tolerance to the drug. As a result, they may exhibit relatively little evidence of impairment on the psychophysical tests.

Even tolerant drug users, when impaired, usually exhibit clinical evidence (i.e., in the vital signs and eye signs – such as HGN).

Physical Dependence

Write “Physical Dependence” on the dry erase board or flip-chart.

Another result may be physical dependence, or addiction.

Pose this question to the class: Why do people take drugs? Solicit responses.

In simplest terms, people take drugs because they like the feelings the drugs produce.

The artificial simulation of the natural action of hormones and neurotransmitters appears to permit the user to create any feeling or mood he or she desires.

As time goes on, and negative feedback develops, the user finds that he or she can only achieve those feelings and moods if the drug is taken.

Session 6 - Physiology and Drugs: An Overview

Metabolite

A chemical product formed by the reaction of a drug with oxygen and/or other substances in the body




Drug Recognition Expert Course 6-33

Metabolite

One final concept is important for an understanding of how drugs work.

A Metabolite is a product of metabolism which is the chemical changes that take place when the drug reacts with enzymes and other substances in the body.

Write “Metabolite” on the dry erase board or flip-chart.

Instructor information: Metabolism is defined as the combined chemical and physical processes that take place in the body involving the distribution of nutrients and resulting in growth, energy production, the elimination of wastes, and other body functions. There are two basic phases of metabolism: anabolism, the constructive phase during which molecules resulting from the digestive process are built up into complex compounds that form the tissues and organs of the body; and catabolism, the destructive phase during which larger molecules are broken down into simpler substances with the release of energy.

The body uses chemical reactions to break down the drug, and ultimately to eliminate it.

Example: when we drink alcohol, we initiate a series of chemical reactions that ultimately transform the alcohol into harmless carbon dioxide and water.

Sometimes, metabolites of the original drug are themselves drugs, and cause impairment.

For example, the body quickly metabolizes heroin into morphine, and it is the morphine that actually produces the effects the heroin user experiences.

Solicit participants’ questions and comments about how drugs work.

Session 6 - Physiology and Drugs: An Overview

Medical Conditions

- **Bipolar Disorder**
- **Conjunctivitis**
- **Diabetes**
- **Head Trauma**




Drug Recognition Expert Course 6-34

G. Medical Conditions Which Sometimes Mimic Drug Impairment

Certain medical conditions or injuries may cause signs and symptoms similar to those of drug impairment.

Refer participants to the list contained in their manuals.

Point out that many of the conditions listed are serious enough to prevent driving:

- Bipolar Disorder (Manic Depression) – a condition characterized by the alteration of manic and depressive states.
- Conjunctivitis – inflammation of the conjunctiva.
Conjunctivitis is a condition caused by infection, allergy, or irritation of the mucous membrane lining of the eyes, resulting in a “pink eye” appearance. A casual observer might mistake this for the bloodshot conditions associated with Cannabis or alcohol.
- Diabetes – a condition that can result in insulin shock (taking too much insulin) which may produce tremors, increased blood pressure, rapid respiration, lack of coordination, headache, confusion, and seizures.
The most common problem with diabetics arises when they take too much insulin, so that their blood sugar levels become extremely low. They may be very confused, sweat profusely, and exhibit increased pulse rate and increased blood pressure.
- Head Trauma – normally due to a severe blow or bump to the head.
Head trauma may injure the brain and create disorientation, confusion, lack of coordination, slowed responses and speech impairment.

Point out that head trauma may produce disorientation, confusion, unequal pupil size, unequal tracking ability of the eyes, or the drooping of one eyelid while the other remains normal.

Session 6 - Physiology and Drugs: An Overview

Other Medical Conditions

- **Multiple Sclerosis and similar conditions**
- **Shock**
- **Stroke**




Drug Recognition Expert Course 6-35

- Multiple Sclerosis (MS) – a degenerative muscular disorder.
MS is a progressive disease in which the nerve fibers of the brain and spinal cord lose their myelin cover. Some signs and symptoms are abnormal sensations in the face or extremities, weakness, double vision, etc.
- Shock – a sudden or violent disturbance in the mental or emotional faculties.
A shock victim may be dazed, uncoordinated, non-responsive.
Other indicators include: extremely low blood pressure, fast but weak pulse, dizziness, moist clammy skin, profuse sweating, rapid shallow breathing, blue lips and fingernails.
- Stroke – a medical condition caused by a rupture or obstruction (as if by clot) of an artery of the brain.

Point out that stroke may produce many of the same indicators as will head trauma. In addition, stroke victims may have pupils that are markedly different in size, and one pupil may exhibit no visible reaction to light while the other reacts normally.

Point out that there will be noticeably a difference in their physical appearance and actions such as drooling and slurred speech.

Others – Carbon Monoxide poisoning, Seizures, Endocrine disorders, Neurological conditions, Psychiatric conditions and infections.

Review physiologic changes that may be mistaken for drug induced symptoms. For example, strenuous exercise increases heart rate and rate of respiration; surprise, fear and pain dilate the pupils markedly.

Normal conditions can affect vital signs: Exercise, Excitement, Fear, Anxiety, Depression, Other

Session 6 - Physiology and Drugs: An Overview

Medical Rule Out

- **For purposes of DRE and the DEC Program, a medical rule out is defined as:**

“A determination made by a DRE that the condition of a suspected impaired driver is more likely related to a medical issue that has affected the subject’s ability to operate a vehicle safely”




Drug Recognition Expert Course 6-36

DRE Medical Rule Out Definition

There are times when a DRE may encounter situations where a subject arrested for drugged driving may be suffering from a medical condition that has affected the subject’s ability to operate a vehicle safely. Once the DRE makes this determination the evaluation is considered a “medical rule out.” In other words, the DRE through his or her evaluation has ruled out impairing substances and while doing so, identified signs and symptoms that are consistent with a medical issue. Once the DRE makes the determination, the DRE should consider taking appropriate steps to ensure the subject is referred to the proper medical personnel.

In such cases, the DRE should prepare the DRE drug evaluation report documenting his or her findings that support an opinion of a DRE medical rule out.

For purposes of DRE and the DEC Program, a medical rule out is defined as, **“A determination made by a DRE that the condition of a suspected impaired driver is more likely related to a medical issue that has affected the subject’s ability to operate a vehicle safely.”**

The suggested way to document this type of opinion in Step 11 of the DRE report would be: “It is my opinion that (Subject’s name) is a medical rule out and is unable to operate a vehicle safely.”

Session 6 - Physiology and Drugs: An Overview

Summary

- **Research in drug intoxication and the interaction with neurotransmitters is in its infancy**
- **The best response to questions regarding bodily functions and or specific drug interactions may be “I don’t know...”**




Drug Recognition Expert Course 6-37

H. Summary

Briefly review main points of the lesson.

Basic understanding of how the body works is necessary to:

Understand why the drug evaluation is conducted in a systematic manner.

Understand why the results, when viewed in their totality, provide reliable indicators of impairment within broad categories of drugs.

Emphasize that research in drug intoxication and the interaction with neurotransmitters is in its infancy.

This limited overview will not qualify participants as medical specialists.

The knowledge gained during this session must be supplemented by additional reading and/or instruction.

The body of knowledge in this area is being constantly expanded.

Point out that the best response to questions regarding bodily functions and or specific drug interactions may be “I don’t know. I conducted a series of evaluations and documented my observations. Based on my training and experience the results of my observations are consistent with those produced by persons impaired by _____.”

The body maintains homeostasis (equilibrium) by constantly adjusting to changes in the external and internal environment:

Point out that the body functions as a total unit in an integrated and coordinated manner.

When drugs are introduced into the body this process comes into play.

When drugs interact in the body they tend to:

speed things up, or slow things down, or confuse signals, or block signals, or some combination of the above.

Session 6 - Physiology and Drugs: An Overview

Summary (Cont.)

- **The body functions as a total unit in an integrated and coordinated manner**
- **This is a very simplistic overview of how drugs work**



Drug Recognition Expert Course 6-38

Point out that this is a very simplistic overview of how drugs work.

The effects of drugs can be detected and / or observed in the drug evaluation.

Drug Evaluations

Detailed instructions on procedures and expected results will be covered in following sessions.

Solicit and answer participants' questions.

Session 6 - Physiology and Drugs: An Overview

Physiological Pursuit



Drug Recognition Expert Course 6-39

Physiological Pursuit

For review of the Physiology and Drugs session, questions can be asked of the participants as if it were a game of Trivial Pursuit. See attachment.

Session 6 - Physiology and Drugs: An Overview

QUESTIONS?



Drug Recognition Expert Course 6-40

Solicit participants' comments and questions concerning Physiology and drugs : an overview.

Session 6 - Physiology and Drugs: An Overview

Topics for Study




Drug Recognition Expert Course 6-41

TOPICS FOR STUDY

1. What is a neurotransmitter? What is a hormone?

ANSWER: A neurotransmitter is a chemical that passes from the axon of one nerve cell to the dendrite of the next cell, and that carry messages across the gap between the two nerve cells.

Hormones are chemicals produced by the body's endocrine system that are carried through the blood stream to the target organ. They exert great influence on the growth and development of the individual, and they aid in the regulation of numerous body processes.

2. What is a dendrite? What is an axon? What is a synapse?

ANSWER: The dendrite is the part of a neuron (nerve cell) that receives a neurotransmitter.

The axon is the part of a neuron (nerve cell) that sends out a neurotransmitter.

The synapse is the gap or space between two neurons (nerve cell).

3. Do arteries carry blood toward the heart or away from the heart?

ANSWER: Arteries carry blood away from the heart.

4. What is unique about the Pulmonary Artery?

ANSWER: The pulmonary artery is the only artery that carries blood depleted of oxygen.

Session 6 - Physiology and Drugs: An Overview

Topics for Study (Cont.)




Drug Recognition Expert Course 6-42

5. What are the two types of nerves that make up the Autonomic Nervous Sub-System?

ANSWER: Sympathetic Nerves and Parasympathetic Nerves

6. Is Cocaine sympathomimetic or parasympathomimetic? What about Heroin?

ANSWER: Cocaine is a sympathomimetic drug. Heroin is a parasympathomimetic drug.

7. Explain the concept of the “downside effect.” Explain the concept of “Negative Feedback.”

ANSWER: Downside effect occurs when the body reacts to the presence of a drug by producing hormones or neurotransmitters to counteract the effects of the drug consumed.

Negative Feedback occurs when the brain becomes accustomed to the presence of drugs and stops producing the natural chemicals that correspond to the drug.

8. What do we call the nerves that carry messages away from the brain? What do we call the nerves that carry messages toward the brain?

ANSWER: The nerves that carry messages away from the brain are called the Motor Nerves, or the Efferent Nerves.

The nerves that carry messages toward the brain are called the Sensory Nerves, or the Afferent Nerves.

QUESTIONS FOR PHYSIOLOGICAL PURSUIT

1. Name the major body systems.
Muscular, Urinary, Respiratory, Digestive, Endocrine, Reproductive, Skeletal, Integumentary, Nervous, and Circulatory.
2. What vein carries oxygenated blood?
Pulmonary vein. The pulmonary vein returns oxygenated blood from the lungs to the left side of the heart. The left side of the heart then pumps the oxygenated blood via arteries throughout the body. The pulmonary artery carries de-oxygenated blood from the right side of the heart to the lungs.
3. What is the function of the endocrine system?
The endocrine system is composed of ductless glands that release chemical messengers, called hormones, into the bloodstream. The function is the regulation of various bodily processes by the production and release of hormones.
4. Explain the “downside” effect of a drug.

The “downside” effect of a drug refers to the post euphoric stage of a drug’s effects. As the effects of a drug wear off, the individual may display effects that are essentially the opposite of the “high” state that was brought about by the drug. This effect is in part due to the body’s attempt to counteract the effects of a drug.
5. Define homeostasis.
Homeostasis is basically a physiological equilibrium or dynamic balance. Homeostasis refers to the body’s mechanisms that keep the levels of fluids, salts, chemicals and other internal substances in a safe balance. The regulation of temperature is an example of homeostasis at work.
6. Hair and nails are part of what system?
The Integumentary system. This system also includes the skin.
7. Name the two circulatory systems.
The systemic circulatory system, which is driven by the left side of the heart, and pulmonary circulatory system, driven by the heart’s right side.
8. The functions of the organs of the body are controlled by what two systems?
The endocrine and nervous system.
9. Define synapse, axon, and dendrite.
These structures are all part of the nerve cell, or neuron. The axon is the part of the neuron that releases neurotransmitter from a terminal into the synapse. An electrical impulse causes the axon to release the neurotransmitter. The synapse is the gap between nerve cells and is also called the synaptic gap. The dendrite refers to a structure that receives the chemical message from the neurotransmitter. There are often many dendrites on each neuron. The neurotransmitter fits into receptor sites on the dendrite and causes an electrical message to be sent to the neuron’s body.

10. Define neurotransmitter and hormone.

Both are chemical messengers. Neurotransmitters are chemicals that send messages within the nervous system. Hormones are released by glands in the endocrine system into the bloodstream.

11. _____ nerves carry messages AWAY from the brain to the body's muscles and organs.

Efferent, or Motor nerves. These nerves cause a motor response. Afferent nerves send sensory messages to the brain. The central nervous system interprets these messages and if appropriate, calls for a response through the efferent nerves.

12. The _____ nervous system commands the body to react to stress, fear, and excitement.

The Sympathetic nervous system, a division of the Autonomic Nervous System, produces the body's "fight or flight" response to real or perceived danger. Drugs that mimic the activation of the sympathetic nervous system are "sympathomimetics". CNS Stimulants have effects closest to the effects of sympathetic nervous system activation.

13. Explain "negative feedback."

Refers to the body's response to taking a drug that has effects similar to natural internal chemicals. After repeated exposure to the drug, the body responds by slowing, or even stopping the production of the internal chemical. In time, the body begins to rely on the drug. An example of negative feedback involving legitimate substances is insulin dependant diabetics. Once an individual begins to take insulin, the person's body will eventually stop making its own insulin. The person must obtain insulin by administering it.

14. What two types of nerves make up the autonomic nervous subsystem?

The Sympathetic and Parasympathetic nerves. The sympathetic nervous system initiates the body's "fight or flight" response to real or perceived danger. The parasympathetic nervous system parallels or balances the sympathetic nervous system. This system initiates calming and digestive processes.

15. Define metabolite.

A metabolite is the by-product of the body's chemical breakdown of various substances for elimination. Metabolites may or may not be psychoactive by themselves. Often times a toxicological analysis will disclose various metabolites of a drug, rather than the parent drug.

Session 7 - Examination of Vital Signs

120 Minutes

Session 7

Examination of Vital Signs



Drug Recognition Expert Course

Session 7 - Examination of Vital Signs

Learning Objectives

- Explain the purposes of various vital signs examinations in the drug influence evaluation procedure
- Explain administrative procedures for these examinations
- Explain clues obtained from these examinations
- Document examinations of vital signs accurately and completely
- Correctly answer the “topics for study”




Drug Recognition Expert Course 7-2

Briefly review the content, objectives and activities of this session.

Upon successfully completing this session the participant will be able to:

- Explain the purposes of the various vital signs examinations in the drug influence evaluation procedure.
- Explain the administrative procedures for these examinations.
- Explain the clues obtained from these examinations.
- Document the examinations of vital signs accurately and completely.
- Correctly answer the “topics for study” at the end of this session.

CONTENT SEGMENTS

- A. Purpose of the Examinations
- B. Procedures and Clues
- C. Demonstrations
- D. Documentation Procedures
- E. Practice

LEARNING ACTIVITIES

Instructor-Led Presentations
 Instructor-Led Demonstrations
 Audio Tape Presentation
 Participant-Led Demonstrations
 Participants’ Hands On Practice
 Reading Assignments

Session 7 - Examination of Vital Signs

Drug Influence Evaluation Vital Signs

- **Pulse Rate**
- **Blood Pressure**
- **Temperature**




Drug Recognition Expert Course 7-3

A. Purposes of the Examinations

The vital signs that are relevant to the drug influence evaluation include:

Point out these vital signs on the wall chart.

- Pulse Rate
- Blood Pressure
- Temperature

Different types of drugs affect these vital signs in different ways. Certain drugs tend to “speed up” the body and elevate these vital signs.

Clarification:

- Pulse may quicken
- Blood pressure may rise
- Temperature may rise

Other drugs tend to “slow down” the body and lower these vital signs.

Clarification:

- Pulse may slow
- Blood pressure may drop

Systematic examination of the vital signs gives us much useful information concerning the possible presence or absence of various categories of drugs.

Session 7 - Examination of Vital Signs

Definitions Concerning “Pulse”

- **Pulse**
The expansion and contraction of an artery generated by the pumping action of the heart
- **Pulse Rate**
The number of pulsations in an artery per minute
- **Artery**
A strong, elastic blood vessel that carries blood from the heart to the body tissues
- **Vein**
A blood vessel that carries blood back to the heart from the body tissues




Drug Recognition Expert Course 7-4

B. Procedures and Clues

Measurement of Pulse Rate

Pulse is the expansion and contraction of an artery generated by the pumping action of the heart. Pulse Rate is the number of pulsations in an artery per minute.

Point out that pulse rate is equal to the number of contractions of the heart per minute. Instructor, for your information: technically speaking, pulse rate is not quite the same thing as heart beat rate. There are rare and very serious conditions that could cause the heart to beat so weakly that it is unable to force blood through some or all arteries. In that case, there might be no discernable pulse even though the heart is beating. But with a normal, healthy heart, pulse rate will equal heart beat rate.

- An artery is a strong, elastic blood vessel that carries blood from the heart to the body tissues.
- A vein is a blood vessel that carries blood back to the heart from the body tissues.
- When the heart contracts, it squeezes blood out of its chambers into the arteries.
- The surging blood causes the arteries to expand.
- By placing your fingers on the skin next to an artery and pressing down, you can feel the artery expand as the blood surges through.

Emphasize: the “surge” can be felt as the blood is squeezed from the heart through an artery. The pulse cannot be felt in a vein.

By keeping your fingers on the artery and counting the number of pulses that occur in one minute, you will measure the pulse rate.

Demonstrate this, by holding your fingers on your own radial artery.

Pulse is easy to measure, once you locate an artery close to the surface of the skin.

Session 7 - Examination of Vital Signs

Radial Artery Pulse Point



INTERNATIONAL ASSOCIATION OF CHIEFS OF POLICE

NHTSA
www.nhtsa.gov

Drug Recognition Expert Course 7-5

Radial Artery Pulse Point

One convenient pulse point involves the radial artery.

The radial artery can be located in or near the natural crease of the wrist, on the side of the wrist next to the thumb.

Point to the radial artery pulse point on your own wrist.

Hold your left hand out, with the palm up.

Demonstrate this.

Place the tips of your right hand's index finger and middle finger into the crease of your wrist, and exert a slight pressure.

Demonstrate this.

You should be able to feel the pulse in your radial artery.

Ask participants whether they can feel their pulses. Coach any participants who have difficulty in locating the pulse.

Session 7 - Examination of Vital Signs

Brachial Artery Pulse Point



INTERNATIONAL ASSOCIATION OF CHIEFS OF POLICE

NHTSA
www.nhtsa.gov

Drug Recognition Expert Course 7-6

Brachial Artery Pulse Point

Another pulse point involves the brachial artery.

The brachial artery can be located in the crook of the arm, halfway between the center of the arm and the side of the arm closest to the body.

Point to the brachial artery pulse point in your own arm.

Instruct participants to roll up their sleeves, if necessary, to expose their brachial artery pulse points.

Hold your left hand out, with the palm up.


Demonstrate this.

Place the tips of your right hand's index and middle fingers into the crook of your left arm, close to the body, and exert a slight pressure.

Demonstrate this.

You should be able to feel the pulse in your brachial artery.

Ask participants whether they can feel their pulses. Coach any participants who have difficulty locating the pulse.



Carotid Artery Pulse Point

Another pulse point involves the carotid artery.

The carotid artery can be located in the neck, on either side of the Adam's apple.

Point out the carotid artery pulse point on your own neck.

- Place the tips of your right hand's index and middle fingers alongside the right side of your Adam's apple.

Demonstrate this.

- You should be able to feel the pulse in your carotid artery.

Ask participants whether they can feel their pulses. Coach any participants who have difficulty locating the pulse.

Session 7 - Examination of Vital Signs

Basic Do's and Don'ts of Measuring Pulse

- **Don't use your thumb to apply pressure while measuring a subject's pulse**
- **When measuring the pulse rate, use time intervals of 30 seconds**



Drug Recognition Expert Course 7-8

Basic Do's and Don'ts of Measuring Pulse

- Don't use your thumb to apply pressure while measuring a subject's pulse
- Point out that there is an artery located in the thumb close to the surface of the skin. If you apply pressure with the thumb, you may wind up measuring your own pulse when you think you are measuring the subject's.
- If you use the carotid artery pulse point, don't apply pressure to both sides of the Adam's apple: this can cut off the supply of blood to the brain
- When measuring the pulse rate, use time intervals of 30 seconds

Session 7 - Examination of Vital Signs

Technical Terms Associated With Pulse Rate

- **Tachycardia:**
Abnormally rapid heart rate
- **Bradycardia:**
Unusually slow heart rate
- **Arrhythmia:**
Abnormal heart rate rhythm




Drug Recognition Expert Course 7-9

Some Technical Terms Associated with Pulse Rate

- Tachycardia: abnormally rapid heart rate
- Bradycardia: unusually slow heart rate
- Arrhythmia: abnormal heart rhythm

Participants' Initial Practice at Measuring Pulse Rate

Instruct participants to work in pairs, taking turns measuring each other's pulse.

Tell participants to record on paper their partner's pulse rate.

Monitor, coach and critique the participants' practice.

Allow the practice to continue for only about 5 minutes.

PRINT the following lists on the dry erase board or flip-chart.

50 or less _____	76 – 78 _____
52 – 54 _____	80 – 82 _____
56 – 58 _____	84 – 86 _____
60 – 62 _____	88 – 90 _____
64 – 66 _____	92 – 94 _____
68 – 70 _____	96 – 98 _____
72 – 74 _____	100 or more _____

TABULATE the numbers of participants whose pulse rates were in each of the listed intervals.

Point out that there is a wide variation in human pulse rates.

Point out that the DRE range for an average pulse rate is 60-90 beats per minute.

Session 7 - Examination of Vital Signs

Blood Pressure

Millimeters of Mercury = mmHg



Drug Recognition Expert Course 7-10

Example: a blood pressure of 120 means that the blood is pressing on the walls of the artery with enough force to push liquid mercury 120 millimeters up a glass tube. Point out that 120 millimeters is approximately four and three-quarter inches.

We commonly abbreviate “millimeters of mercury” as mmHg.

Print “mmHg” on the dry erase board or flip-chart.

Instructor, for your information: “Hg” is the chemical symbol for the element mercury. It comes from Hydrargyrum, the Latin word for mercury.

Session 7 - Examination of Vital Signs

Definitions Concerning Blood Pressure

- **Blood Pressure**
The force that the circulating blood exerts on the walls of the arteries
- **Systolic Pressure**
The maximum blood pressure, reached as the heart contracts
- **Diastolic Pressure**
The minimum pressure, reached when the heart is fully expanded




Drug Recognition Expert Course 7-11

Measurement of Blood Pressure

- Blood Pressure is the force that the circulating blood exerts on the walls of the arteries.
- Blood pressure is measured in millimeters of mercury.
- Blood Pressure changes constantly as the heart contracts and relaxes.
- Blood Pressure reaches its maximum as the heart contracts and sends the blood surging through the arteries. This is called the systolic pressure.
- Blood Pressure reaches its minimum when the heart is fully expanded. This is called the diastolic pressure.
- It is always necessary to measure and record both the systolic and diastolic blood pressure.

Memory aid:

- **Systolic: “S” for “Superior”**
- **Diastolic: “D” for “Down”**

Remind participants that “systolic” is the higher number, “diastolic” the lower number.

Session 7 - Examination of Vital Signs

Sphygmomanometer





Drug Recognition Expert Course

7-12

Sphygmomanometer

The device used for measuring blood pressure is called a sphygmomanometer. The sphygmomanometer has a special cuff that can be wrapped around the subject's arm and inflated with air pressure.

Exhibit a sphygmomanometer.

Select a participant to come before the class. Have the participant sit in a chair facing the class, and roll up a sleeve (if necessary) to expose a bicep.

Advise participants to check for birth control implants in the upper left arm. If the subject has an implant or has a Dialysis Fistula (enlarged vein procedure), blood pressure should be taken on the right arm and documented.

As the pressure in the cuff increases, the cuff squeezes tightly on the arm. Wrap the cuff around the participant volunteer's arm and inflate it. When the pressure gets high enough, it will squeeze the artery completely shut.

Ask the participant volunteer whether they can feel the pressure of the cuff.

Blood will cease flowing through the brachial artery. And, since the brachial artery "feeds" the radial artery, blood will also cease flowing through the radial artery.

Session 7 - Examination of Vital Signs

Sphygmomanometer (Cont.)





Drug Recognition Expert Course 7-13

Ask participants: “What artery is located in the crease of the elbow?” (Point to that location on the participant volunteer’s arm).

If we slowly release the air in the cuff, the pressure on the arm and on the artery will start to drop.

Release the pressure in the cuff on the participant volunteer’s arm.

Eventually, the pressure will drop enough so that blood will once again start to flow through the artery.

Ask participants: “How far must the pressure in the cuff drop before the blood can start to squeeze through the artery?”

Blood will start flowing in the artery once the pressure inside the artery equals the pressure outside the artery.

The two pressures will become equal when the air pressure in the cuff drops down to the systolic pressure.

When that happens, blood will spurt through the artery each time the heart contracts.

Session 7 - Examination of Vital Signs

Sphygmomanometer (Cont.)



Drug Recognition Expert Course

7-14

Ask participants: “What would happen if we allowed the pressure in the cuff to drop down to the systolic level, and held the air pressure at that level?”

Point out that the blood would spurt through the artery each time the heart contracted, but would cease flowing when the heart expanded.

Ask participants: “How far down must the air pressure in the cuff drop before the blood will flow through the artery continuously?”

Once the air pressure in the cuff drops down to the diastolic level, the blood will flow continuously through the artery.

Session 7 - Examination of Vital Signs

The Basics of Blood Pressure Measurement

- Apply enough air pressure to cut off the flow of blood through the artery
- Slowly release the air, 2 mmHg per second, until the blood just begins to spurt through the artery: that will be the systolic pressure
- Continue to release the air until the blood flows continuously: that will be the diastolic pressure




Drug Recognition Expert Course 7-15

Overview of Procedures for Measuring Blood Pressure

Apply enough air pressure to the cuff to cut off the flow of blood through the artery.

Demonstrate, using the participant volunteer (apply pressure to the cuff).

Slowly release the air pressure until the blood just begins to spurt through the artery: that level will be the systolic pressure.

Slowly release the pressure in the cuff.

Continue to release the air pressure until the blood flows continuously through the artery: that level will be the diastolic pressure.

Ask participants:

“How can we tell when the blood starts to spurt through the artery?”

“How can we tell when the blood is flowing continuously through the artery?”

We can listen to the spurting blood, using a stethoscope.

Exhibit a stethoscope

Apply the stethoscope to the skin directly above the artery.

Demonstrate, using the participant volunteer.

Apply pressure to the cuff, enough to cut off the flow of blood.

When no blood is flowing through the artery, we hear nothing through the stethoscope.

Inflate the cuff on the participant volunteer's arm.

Slowly release the air from the cuff, letting the pressure start to drop.

Release the air in the cuff.

When we drop to the systolic pressure, we start to hear a spurting sound.

Note: this begins as a clear, tapping sound.

Session 7 - Examination of Vital Signs

The Basics of Blood Pressure Measurement (Cont.)

- Apply enough air pressure to cut off the flow of blood through the artery
- Slowly release the air, 2 mmHg per second, until the blood just begins to spurt through the artery: that will be the systolic pressure
- Continue to release the air until the blood flows continuously: that will be the diastolic pressure




Drug Recognition Expert Course 7-16

As we continue to allow the air pressure to drop, the surges of blood become steadily longer.

Note: the sounds take on a swishing quality, and become fainter.

When we drop to the diastolic pressure, the blood flows steadily and all sounds cease.

Excuse the participant volunteer and thank them for participating.



Korotkoff Sounds

The sounds that we listen to are called Korotkoff Sounds. They are divided into 5 phases:

Note: Slide 7-18 contains a sound clip of the Korotkoff sounds.

- Phase 1 – the first appearance of clear, tapping sounds that gradually increase in intensity.

Point out that the beginning of Phase 1 corresponds to the systolic pressure.

- Phase 2 – the sounds change to a murmur and take on a swishing quality.
- Phase 3 – the sounds develop a loud, knocking quality (not quite as clear as the Phase 1 sounds).
- Phase 4 – the sounds become muffled and again have a faint swishing quality.
- Phase 5 – the sounds cease.

Point out that the beginning of Phase 5 corresponds to the diastolic pressure.

Session 7 - Examination of Vital Signs

Korotkoff Sounds




Double Click Icon to Play



Drug Recognition Expert Course

7-18



Familiarization with the Sphygmomanometer

Hand out stethoscopes and sphygmomanometers (one per each participant is desirable. At minimum, there should be one for every four participants).

The compression cuff contains an inflatable rubber bladder.

Point out the components of the sphygmomanometer on the visual.

Point out that blood pressure cuffs come in three sizes: child, adult, and extra large, depending on the size of the bladder.

A tube connects the bladder to the manometer, or pressure gauge.

Clarification: the manometer displays the air pressure inside the bladder. In the DEC program, we use an aneroid (without fluid) pressure gauge.

Another tube connects the bladder to the pressure bulb, which can be squeezed to inflate the bladder.

The pressure control valve permits inflation of the bladder and regulates the rate at which the bladder is deflated.

To inflate the bladder, the pressure control valve must be twisted all the way to the right.

Demonstrate this.

When the valve is twisted all the way to the right, air can be pumped into the bladder, but no air can escape from the bladder.

To deflate the bladder, twist the valve to the left.

The more the valve is twisted to the left, the faster the bladder will deflate.

Session 7 - Examination of Vital Signs

Details of Blood Pressure Measurement

- Position cuff on bicep so that tubes extend down middle of arm
- Wrap cuff snugly around bicep
- Clip manometer to subject's sleeve
- Twist pressure control valve all the way to the right
- Put stethoscope earpieces in your ears





Drug Recognition Expert Course 7-20

Details of Blood Pressure Measurement

Select a participant to serve as a blood pressure subject. Demonstrate the procedures using the participant.

If it proves difficult to hear the Korotkoff sounds, simply have the subject elevate the arm and squeeze the fist several times, to drain the arm: the Korotkoff sounds louder.

The manometer (pressure gauge) may be clipped on the subject's sleeve, so that it is readily viewable.

Twist the pressure control valve all the way to the right.

Session 7 - Examination of Vital Signs

Details of Blood Pressure Measurement (Cont.)

- Place stethoscope over brachial artery
- Rapidly inflate bladder to 180 mmHg
- Twist the valve slightly to the left
- Keep your eyes on the gauge and listen for the Korotkoff sounds





Drug Recognition Expert Course 7-21

Put the stethoscope earpieces in your ears.

Make sure the earpieces are turned forward, i.e. toward the nose.

Place the diaphragm or bell of the stethoscope over the brachial artery.

Rapidly inflate the bladder to a pressure of at least 180.

Point out that, if the subject's blood pressure is very elevated, it may be necessary to inflate the bladder to a higher pressure.

Twist the pressure control valve slightly to the left to release the pressure slowly.

Emphasize the need to release the pressure slowly. If the pressure drops too fast, the needle will sweep down the gauge too quickly to be read accurately.

The pressure should be released at a speed that takes one full second for the needle to move a single gradation (i.e. 2 millimeters of mercury) on the gauge.

Keep your eyes on the gauge and listen for the Korotkoff sounds.

Point out that the needle on the pressure gauge generally will "bounce" slightly when blood starts to spurt through the artery.

Excuse the participant and thank him or her for participating. Solicit participants' questions concerning these procedures.

Remind the students that for DRE purposes, the average ranges of blood pressure are:

Systolic: 120 – 140

Diastolic: 70 – 90

Note, however, that people can have significantly different blood pressures: there is wide variation in human blood pressure.

Session 7 - Examination of Vital Signs

Do's and Don'ts of Blood Pressure Measurement

- Do wait 3 minutes to repeat the measurement, if needed
- Don't re-inflate cuff once you start releasing the pressure



INTERNATIONAL ASSOCIATION OF CHIEFS OF POLICE

NHTSA
www.nhtsa.gov

Drug Recognition Expert Course 7-22

Do's and Don'ts of Blood Pressure Measurement

If you inflate the bladder and then need to repeat the measurement, wait at least three minutes to allow the subject's artery's to return to normal.

- Do wait 3 minutes to repeat the measurement if a second measurement is needed.
- Don't re-inflate cuff once you start releasing the pressure.

Point out that DRE's primarily use manual sphygmomanometers that have only even numbered markings on the manometer (gauge) so we document even numbers that best represent the Systolic and Diastolic readings. Odd numbered readings would indicate that an electronic digital monitor was used which is not the current recommended blood pressure measuring device for DRE purposes.

Session 7 - Examination of Vital Signs

Technical Terms Associated With Blood Pressure

- **Hypertension:**
Abnormally high blood pressure
- **Hypotension:**
Abnormally low blood pressure



Drug Recognition Expert Course 7-23

Some Technical Terms Associated with Blood Pressure

- Hypertension: abnormally high blood pressure.
- Hypotension: abnormally low blood pressure.

Participants Initial Practice at Measuring Blood Pressure

If at least one sphygmomanometer and stethoscope are available for every two participants, instruct participants to practice in pairs. Otherwise, assign participants to practice in teams of 3 or 4 members. Monitor, coach and critique the participants' practice.

Allow this practice to continue for only about 10 minutes. If a dual hearing training stethoscope is available, this would be a good opportunity for instructors to check on how the students do in detecting the blood pressure measurements.

Remind participants that when they measure and record blood pressure it is not necessary to use the symbols "mmHg." Simply record the numbers.

Session 7 - Examination of Vital Signs

Measurement of Temperature



Drug Recognition Expert Course 7-24

Measurement of Temperature

Body temperature is measured using a oral digital thermometer.

Exhibit this.

Note: a digital thermometer with plastic sleeves is recommended.

Point out that when measuring temperature to ensure that the thermometer remains under the subject's tongue. DRE's should also try to refrain from letting the subject's drink hot or cold fluids immediately prior to measuring temperature.

Make sure that a fresh disposable mouthpiece is used each time.

Solicit participants' comments and questions concerning this overview of procedures and cues.

Session 7 - Examination of Vital Signs

Demonstrations

- **Pulse Rate**
- **Blood Pressure**
- **Review Standardized Form used to Record Vital Sign Measurements**




Drug Recognition Expert Course 7-25

C. Demonstrations

Pulse Rate Measurement

Select two participants to come before the class.

- Radial artery pulse point:

Instruct the first participant to measure the second participant's pulse using the radial artery pulse point. (Simultaneously, the instructor should measure the subject's pulse using a carotid artery pulse point).

- Carotid artery pulse point:

Instruct the second participant to measure the first participant's pulse using the carotid artery pulse point. (Simultaneously, the instructor should measure the subject's pulse using a radial artery pulse point).

Excuse the two participants and thank them for participating.

Blood Pressure Measurement

Select two other participants to come before the class.

Instruct the first participant to measure the second participant's blood pressure.

Have the participants reverse roles.

Excuse the two participants and thank them for participating.

D. Documentation Procedures

Review the sections of the Standardized Form used to record vital signs measurements.

Session 7 - Examination of Vital Signs

Practice

In teams of 2 – 4 members, take turns measuring each other's vital signs.



Drug Recognition Expert Course 7-26

E. Practice

Instruct participants to practice in teams of 2 – 4 members, taking in turns measuring each other's vital signs.

Monitor, coach and critique the participants' practice.

Session 7 - Examination of Vital Signs

QUESTIONS?



Drug Recognition Expert Course

7-27

Solicit participants' questions and comments about the Examination of Vital Signs.

Session 7 - Examination of Vital Signs

Topics for Study




Drug Recognition Expert Course 7-28

TOPICS FOR STUDY / ANSWERS

1. Where is the Radial Artery pulse point?

ANSWER: Crease of the wrist

2. Why should you never attempt to feel a subject's pulse with your thumb?

ANSWER: You can mistakenly measure your own pulse

3. Does an artery carry blood to the heart or from the heart?

ANSWER: Away from the heart

4. What does the symbol "Hg" represent?

ANSWER: Mercury (Hydrargyrum)

5. What is Diastolic pressure?

ANSWER: The pressure when the heart relaxes

6. When do the Korotkoff Sounds begin?

ANSWER: At the systolic level when the blood begins to spurt through the brachial artery.

7. Name and describe the major components of a Sphygmomanometer.

ANSWER: Compression cuff, Pressure bulb, Manometer, Pressure control valve, Tubes

8. Which of the seven categories of drugs generally will cause blood pressure to be elevated?

ANSWER: CNS Stimulants, Hallucinogens, Dissociative Anesthetics, Inhalants, Cannabis

Session 8

Demonstrations of the Evaluation Sequence



Session 8 - Demonstrations of the Evaluation Sequence

Learning Objective

- **Describe the sequence in which examinations and other activities are performed during the drug influence evaluation procedure**




Drug Recognition Expert Course 8-2

Briefly review the objectives, content and activities of this session.

Upon successfully completing this session the student will be able to:

- Describe the sequence in which examinations and other activities are performed during the drug influence evaluation procedure.

CONTENT SEGMENTS

- A. Live Demonstrations
- B. Video Demonstrations

LEARNING ACTIVITIES

- Instructor Led Presentations
- Instructor Led Demonstrations
- Video Presentations
- Reading Assignments

Live Demonstrations



A. Live Demonstrations

For these live demonstrations, participants must be grouped into teams of not more than 12 members. Each team must be taken to a separate classroom. At least two instructors must work with each team. This is to ensure that all participants have the opportunity for a close and detailed observation of the demonstrations.

Instructors should conduct at least two complete demonstrations of the evaluation sequence, articulating each step in the process.

Instruct participants to follow along with copies of the drug influence evaluation form. Hand-out a 12-Step checklist to the participants if needed.

Preliminary Examinations

Select a participant or one of the volunteer drinkers for Session 12 (prior to drinking) to serve as the “subject” for the preliminary examination.

Preliminary eye checks:

- equal tracking
- equal pupil size
- resting nystagmus
- blindness
- eyelids

Ask each question, exactly as it should be asked during an actual preliminary examination.

Explain the kinds of clues and evidence that may be gleaned during the preliminary examination.

Session 8 - Demonstrations of the Evaluation Sequence

Live Demonstrations (Cont.)



INTERNATIONAL ASSOCIATION OF POLICE OFFICERS

NHTSA
www.nhtsa.gov

Drug Recognition Expert Course 8-4

Ensure that the participant examiner checks:

The participant subject's eyes for tracking, equal pupil size, resting nystagmus, and eyelid condition.

The participant subject's pulse.

Solicit participants' comments or questions about the preliminary examination.

Excuse the participant subject and thank him/her for participating in the demonstration.

Eye Examinations.

Select another participant or a volunteer drinker to serve as the "subject" for the eye examinations, which will include:

- **Horizontal Gaze Nystagmus**
- **Vertical Gaze Nystagmus**
- **Lack of Convergence**

Session 8 - Demonstrations of the Evaluation Sequence

Live Demonstrations (Cont.)





Drug Recognition Expert Course 8-5

Conduct a complete demonstration of an eye examination.

Explain the kinds of clues and other evidence that may be seen during the eye examinations.

Solicit participants' comments or questions about the eye examinations.

Excuse the participant and thank him or her for participating in the demonstration.

Psychophysical Tests.

Select another participant or a volunteer drinker to serve as the "subject" for the psychophysical tests, which include:

- ***Modified Romberg Balance***
- ***Walk and Turn***
- ***One Leg Stand***
- ***Finger to Nose***

Session 8 - Demonstrations of the Evaluation Sequence

Live Demonstrations (Cont.)





Drug Recognition Expert Course 8-6

Conduct a complete set of psychophysical tests on the participant subject.

Explain the kinds of clues and other evidence that may be gleaned during the psychophysical tests.

Solicit participants' comments or questions about the psychophysical tests.

Excuse the participant subject and thank them for participating in the demonstration.

Vital Signs Examinations

Select another participant to serve as the "subject" for the vital signs examinations, which include:

- Blood Pressure
- Temperature
- Second Check of Pulse

Conduct a complete set of vital signs examinations on the participant subject.

Explain the kinds of clues and other evidence that may be gleaned during the vital signs examinations.

Solicit participants' comments or questions about the vital signs examinations.

Excuse the participant subject, and thank them for participating in the demonstration.

Session 8 - Demonstrations of the Evaluation Sequence

Live Demonstrations (Cont.)

- **Pupil Size Estimations**
 - **Room Light**
 - **Near Total Darkness**
 - **Direct Light**



Drug Recognition Expert Course 8-7

Dark Room Examinations

Select another participant to serve as the “subject” for the dark room examination.

Pupil Size Estimations:

- Room light
- Near Total Darkness
- Direct light

Session 8 - Demonstrations of the Evaluation Sequence

Live Demonstrations (Cont.)





Drug Recognition Expert Course 8-8

Point out that this portion of the drug influence evaluation procedure is to be carried out in a darkened room. However, this demonstration will be conducted in normal room light, so that all participants can observe the proper procedures for using the penlight.

Conduct a complete set of “dark room” examinations on the participant subject.

Explain the kinds of clues and other evidence that may be gleaned during the dark room examinations.

Reaction to Light

Point out that the checks of the oral and nasal cavities actually are part of the examination for signs of ingestion.

Check of Nasal Area
Check of Oral Cavity

Solicit participants’ comments or questions about the dark room examinations. Excuse the participant subject and thank them for participating in the demonstration.

Session 8 - Demonstrations of the Evaluation Sequence

Live Demonstrations (Cont.)





Drug Recognition Expert Course 8-9

Examination for Muscle Tone and Injection Sites and Third Check for Pulse.

Select another participant to serve as the “subject” for this portion of the examination.

Point out that Heroin is not the only drug that abusers inject: “puncture marks” in the skin may also be found on the arms (and elsewhere) of abusers of several other drugs.

Explain how to check for injection sites and muscle rigidity on the participant subject.

Solicit participants’ comments or questions about this portion of the examination.

Excuse the participant subject, and thank them for participating in the demonstration.

Session 8 - Demonstrations of the Evaluation Sequence

Live Demonstrations (Cont.)





Drug Recognition Expert Course 8-10

Final Interview

Explain the kinds of clues and other evidence that may be gleaned during the final interview.

Statements made by subject
Behavior during entire evaluation

Give examples of typical statements or behaviors of drug impaired subjects.

Solicit participants' comments or questions about the final interview.

Opinion of the Evaluator

Point out that participants subsequently will learn the clues and indicators of the various categories of drugs.

Session 8 - Demonstrations of the Evaluation Sequence

QUESTIONS?



Drug Recognition Expert Course 8-11

Solicit participants' comments and questions concerning the entire drug influence evaluation procedure.

Be sure to conduct at least two complete, live demonstrations of the drug influence evaluation procedure.

Review of the 12-Step Process

Show the video on the 12-Step Process as a review if time permits.

Session 9

Central Nervous System Depressants



Session 9 - Central Nervous System Depressants

Learning Objectives

- Explain a brief history of the CNS Depressant category of drugs
- Identify common drug names and terms associated with this category
- Identify common methods of administration for this category
- Describe the symptoms, observable signs and other effects associated with this category




Drug Recognition Expert Course 9-2

Briefly review the objectives, content and activities of this session.

Upon successfully completing this session the participant will be able to:

- Explain a brief history of the CNS Depressant category of drugs.
- Identify common drug names and terms associated with this category.
- Identify common methods of administration for this category.
- Describe the symptoms, observable signs and other effects associated with this category.

CONTENT SEGMENTS

- A. Overview of the Category
- B. Possible Effects
- C. Onset and Duration of Effects
- D. Overdose Signs and Symptoms
- E. Expected Results of the Evaluation
- F. Classification Exemplar

LEARNING ACTIVITIES

- Instructor-Led Presentations
- Instructor Led Demonstrations
- Reading Assignments
- Video Presentations
- Slide Presentations

Session 9 - Central Nervous System Depressants

Learning Objectives (Cont.)

- **Explain the typical time parameters, i.e. on-set and duration of effects associated with this category**
- **List the clues that are likely to emerge when the drug influence evaluation is conducted for a person under the influence of this category of drugs**
- **Correctly answer the “topics for study” questions at the end of this session**



Drug Recognition Expert Course 9-3

- Explain the typical time parameters, i.e. onset and duration of effects, associated with this category.
- List the clues that are likely to emerge when the drug influence evaluation is conducted for a person under the influence of this category of drugs.
- Correctly answer the “topics for study” questions at the end of this session.

Session 9 - Central Nervous System Depressants

Alcohol - The Most Familiar CNS Depressant






Drug Recognition Expert Course 9-4

A. Overview of the Category

CNS Depressants

Central Nervous System Depressants slow down the operations of the brain.

Point out that other common names for CNS Depressants are “downers” and “sedative-hypnotics.”

- Depressants first affect those areas of the brain that control a person’s conscious, voluntary actions.
- Judgment, inhibitions and reaction time are some of the things that CNS Depressants affect first.
- As the dose is increased, depressants begin to affect the parts of the brain that control the body’s automatic processes, heartbeat, respiration, etc.

The CNS Depressant category includes the single most commonly abused drug in America.

Ask this question: “What is the single most commonly abused drug?”

- Alcohol has been used and abused since prehistoric times.
- Alcohol and its effects are familiar to most people.
- Alcohol is a model for the CNS Depressant category: with some exceptions, all depressants produce effects that are quite similar to the effects of alcohol.

Point out that the remainder of the session will focus on the non-alcohol CNS depressants.

Session 9 - Central Nervous System Depressants

Chloral Hydrate ("Mickey Finn")

The first non-alcohol CNS depressant



The image shows a brown glass bottle of Chloral Hydrate Oral Solution, USP, with a white cap. The label on the bottle reads "NDC 5000-1000-00 CHLORAL HYDRATE ORAL SOLUTION, USP" and "Qualitest". To the right of the bottle is a red circular object, possibly a tablet or a cap.



Drug Recognition Expert Course 9-5

Chloral Hydrate

Non-alcohol CNS Depressants have been around for more than 150 years.

The first non-alcohol CNS Depressant was Chloral Hydrate.

It was developed in 1832 and utilized clinically in 1869.

Chloral Hydrate was derived from alcohol.

It is commonly referred to as "Mickey Finn" or "Knockout drops" because of its fast acting effects.

Chloral Hydrate is still produced and prescribed today. It is a sedative used in the short term treatment of insomnia and to relieve anxiety and induce sleep before surgery.

"Noctec" is a registered brand name of Chloral Hydrate.

Session 9 - Central Nervous System Depressants

Major Types of Sub Categories of CNS Depressants

- **Barbiturates**
- **Non-Barbiturates**
- **Anti-Anxiety Tranquilizers**




Drug Recognition Expert Course 9-6

Sub Categories of CNS Depressants

There are six major subcategories of CNS Depressants other than alcohol.

Barbiturates

More than 250 different barbiturates have been produced; of these, about 50 have been accepted for medical use.

- Derivatives of Barbituric Acid
- First produced in 1864
- Very common in use and abuse today

Non-Barbiturates

Note: Chloral Hydrate belongs to the non-barbiturate subcategory.

- Synthetic compounds with a variety of chemical structures
- Prescribed to help with some of the unintended side effects of barbiturates including sleepiness or drowsiness
- Still produce physical and psychological dependence

Anti-Anxiety Tranquilizers

The Anti-Anxiety Tranquilizers are also known as the “minor tranquilizers.” They include the group of drugs known as the “Benzodiazepines” examples of which are Valium, Xanax, and Librium.

- First produced in 1950
- In very wide spread use
- Frequently abused

Session 9 - Central Nervous System Depressants

Major Types of Sub Categories of CNS Depressants

- **Anti-Depressants**
- **Anti-Psychotic Tranquilizers**



Drug Recognition Expert Course 9-7

Anti-Depressants

Point out that it is not a contradiction to call one subcategory of CNS Depressants the Anti-Depressants. It is psychological depression that they are “anti.”

Sometimes called the “mood elevators.”

Point out that some Anti-Depressants can produce effects which may mimic many of the signs associated with CNS Stimulants.

Anti-Psychotic Tranquilizers

Point out that the Anti-Psychotic Tranquilizers are generally more powerful than the Anti-Anxiety Tranquilizers.

Sometimes called the “major tranquilizers.”

Anti-psychotic tranquilizers were first introduced in the early 1950's. They provide a way to manage schizophrenia and other mental disorders, and allow psychiatric patients to be released from hospitals and to lead fairly normal lives.

The most familiar Anti-Psychotic Tranquilizer is “Thorazine.”

Session 9 - Central Nervous System Depressants

Major Types of Sub Categories of CNS Depressants

- **Combinations**



Drug Recognition Expert Course 9-8

Combinations

This subcategory includes a small class of depressants involving various combinations of the other five subcategories.

Note: Briefly review these examples.

Emphasize that participants are not expected to memorize the names of these various CNS Depressants. But, if they see the names, they should be able to recognize them as depressants.

Session 9 - Central Nervous System Depressants

Specific Barbiturates Examples

Drug	Brand Name	Street Names
Amobarbital	Amytal	Blues, Blue Heavens
Amosecobarbital	Tuinal	Rainbows, Christmas Trees
Pentobarbital	Nembutal	Yellows, Yellow Jackets
Phenobarbital	Luminal	Pink Ladies
Secobarbital	Seconal	Reds, Red Devils, RDs, Fender Benders, F-40's



Drug Recognition Expert Course 9-9

The Barbiturates

- Amobarbital (Trade name "Amytal") Street names "blues"; "blue heavens"
Point out this is a barbiturate derivative of intermediate duration of action first prepared in 1924. Used as a sedative or hypnotic.
- Amosecobarbital (Trade name "Tuinal") Street names "rainbows"; "Christmas Trees"
Point out this is a combination containing amobarbital sodium and secobarbital sodium, Used for short term treatment of insomnia and to relieve anxiety, including anxiety before surgery.

NOTE: This is a combination of Amobarbital and Secobarbital.

- Pentobarbital (Trade name "Nembutal") Street names "yellows"; "yellow jackets"
Point out this is a short acting barbiturate used clinically as a sedative-hypnotic agent. According to the "Physician's Guide to Psychoactive Drugs." 1 ounce of 80 proof alcohol is equivalent to about 15 milligrams of Phenobarbital.
- Phenobarbital (Includes Luminal and other trade names) Street name "pink ladies"
A barbiturate derivative that has been used as a daytime sedative and anticonvulsant since 1912. Often times found in combination with bronchodilators, vascodilators, analgesics and anticholinergic agents.
- Secobarbital (Trade name "Seconal") Street names "reds"; "red devils"; "RDs"; "fender benders"; "F-40s"

Point out that it is a barbiturate derivative of short duration used as either a sedative or hypnotic.

Session 9 - Central Nervous System Depressants

Specific Non-Barbiturates Examples

Drug	Brand Name	Street Names
Carisoprodol	Soma	
Chloral hydrate	Felsule, Noctec	Knock Out Drops, Mickey Finn
Diphenhydramine Hydrochloride	Benadryl, Sominex	
Diphenylhydantoin Sodium	Dilantin	
Eszopiclone	Lunesta	




Drug Recognition Expert Course 9-10

If available, display slides of these various drugs.

The Non-Barbiturates

Point out that one of the primary medical uses for the Non-Barbiturate is the treatment of insomnia.

Note: The absence of street names implies only that illicitly manufactured versions of these drugs are not common. The legally manufactured versions are abused, however.

- Carisoprodol (Trade name “Soma”)

Point out that this is a carbamate derivative first synthesized in 1959. Used clinically as a muscle relaxant and sedative.

- Chloral Hydrate (Trade names “Noctec”, “Somnos”) (Street names “Knockout drops”; “Mickey Finn”)

Point out that this first appeared in 1932 and utilized clinically in 1869. Once a very popular hypnotic agent, it is now used relatively infrequently.

- Diphenhydramine Hydrochloride (Trade names “Benadryl”; “Sominex”; “Dramamine” and “Nytol”)

Point out that this is one of the first effective antihistamine agents discovered. Also used for its sedative and antiemetic effects.

- Diphenylhydantoin Sodium (Trade name “Dilantin”)

Point out that this is used primarily for most forms of epilepsy

- Eszopiclone (Trade names “eszopiclone”, “Estorra” and “Lunesta”)

Point out that this is used clinically since 2001 as a sedative-hypnotic drug.

Session 9 - Central Nervous System Depressants

Specific Non-Barbiturates Examples (Cont.)

Drug	Brand Name	Street Names
Ethchlorvynol	Placidyl	
Gamma Hydroxybutyrate		GHB, Liquid X
Methyprylon	Noludar	
Methaqualone	Parest, Quaalude, Sopor, Optimil, Mandrax	Ludes
Paraldehyde	Paral	
Zolpidem	Ambien	




Drug Recognition Expert Course 9-11

- Ethchlorvynol (Trade name "Placidyl")

Point out that this is an acetylenic alcohol first used as a sedative and hypnotic in 1955

- Gamma Hydroxybutyrate (Street name "GHB"; "GBL"; "Liquid X"; "1,4-butanediol")

Point out that this is was originally used as an anesthetic and hypnotic agent. No longer legally produced in the U.S.

- Methaqualone (Trade names "Parest"; "Quaalude"; "Sopor"; "Optimil"; "Mandrax") (Street name "ludes")

Point out that this is a quinazoline derivative synthesized in 1951 and found clinically effective as a sedative and hypnotic. Removed from the U.S. market in 1984.

Note: Methaqualone continues to be pharmaceutically manufactured in Mexico, trade name "Mandrax."

- Paraldehyde (Trade name "Paral")

Point out that this is was first used therapeutically in 1882 as a sedative or hypnotic when administered in low doses.

- Zolpidem (Trade names "Ambien", "Edluar" and "Stilncot")

Point out that this is an imidazopyridine derivative used since 1986 in European countries and since 1993 in the U.S. as a hypnotic agent. Available in normal-release or extended-release tablets. Intended for once-nightly consumption at a dose of 5-12.5 mg for short term treatment of insomnia.

Session 9 - Central Nervous System Depressants

Specific Anti-Anxiety Tranquilizers Examples

Drug	Brand Name	Street Names
Alprazolam	Xanax	Bars, Zanny Bars
Chlordiazepoxide	Librium	
Clonazepam	Klonopin	
Diazepam	Valium	
Estazolam	ProSom	



Drug Recognition Expert Course 9-12

If available, display slides of these various drugs.

The Anti-Anxiety Tranquilizers

- Alprazolam (Trade names “Xanax”, “Niravam”) (Street name “Bars”; “Zannys”; “Blues”)

Point out that this has been used clinically since 1976 as a short-acting antidepressant and anxiolytic agent.

- Chlordiazepoxide (Trade name “Librium”)

Point out that this is considered the prototype of the benzodiazepine class of sedative-hypnotic drugs. Used as an anti-anxiety agent or hypnotic since 1960.

- Clonazepam (Trade name “Klonopin”)

Point out that this was approved as an anticonvulsant in 1975 and considered a potent sedative.

- Diazepam (Trade name “Valium”)

Point out that this was the second benzodiazepine derivative approved in U.S. for human use in 1963. Frequently employed as an anti-anxiety agent, muscle relaxant or anticonvulsant.

- Estazolam (Trade name “ProSom”)

Point out that this is similar to alprazolam and triazolam. Classified as an intermediate-acting benzodiazepine hypnotic.

Session 9 - Central Nervous System Depressants

Specific Anti-Anxiety Tranquilizers Examples (Cont.)

Drug	Brand Name	Street Names
Flunitrazepam	Rohypnol	
Flurazepam	Dalmadorm, Dalmane	
Lorazepam	Ativan, Temesta	
Meprobamate	Equanil, Miltown	
Oxazepam	Serax	
Temazepam	Restoril	
Triazolam	Halcion	




Drug Recognition Expert Course 9-13

- Flunitrazepam (Trade name “Rohypnol”) (Street name “Roofies”; “Roches”) ***Point out that this is available in numerous European countries since 1965 for use as a hypnotic and anesthetic agent.***
- Flurazepam (Trade names Dalmadorm”, “Dalmane”) ***Point out that this was first introduced in 1970 s a benzodiazepine derivative with hypnotic efficacy.***
- Lorazepam (Trade names “Ativan” and “Temesta”) ***Point out that this is structurally related to oxazepam and temazepam. Used clinically since 1971 as an anti-anxiety agent.***
- Meprobamate (Trade names “Equanil”, “Miltown”) ***Point out that this was introduced in 1955 for clinical use. Frequently employed as a sedative, anti-anxiety agent and muscle relaxant.***
- Oxazepam (Trade name “Serax”) ***Point out that this a benzodiazepine derivative that has been used clinically as an anti-anxiety agent since 1965. It is a metabolite of diazepam, nordiazepam, prazepam and temazepam.***
- Temazepam (Trade name “Restoril”) ***Point out that this has been clinically used as a hypnotic drug since 1979.***
- Triazolam (Trade name “Halcion”) ***Point out that this a hypnotic agent structurally related to valprazolam and estazolam used for short-term management of insomnia since 1978.***

Session 9 - Central Nervous System Depressants

Specific Anti-Depressants

Drug	Brand Name	Street Names
Amitriptyline Hydrochloride	Elavil, Endep	
Bupropion	Wellbutrin, Zyban	
Citalopram	Celexa	
Desipramine Hydrochloride	Norpramin, Pertofrane	
Doxepin Hydrochloride	Adapin, Sinequan	
Duloxetine	Cymbalta	




Drug Recognition Expert Course 9-14

The Anti-Depressants

- Amitriptyline Hydrochloride (Trade names “Elavil”; “Endep”)
Point out that this a tricyclic antidepressant that affects chemicals in the brain that may become unbalanced and used to treat symptoms of depression
- Bupropion (Trade name “Wellbutrin”)
Point out that this an antidepressant that works in the brain to treat depression and used to treat major depressive disorder and seasonal affective disorder. Zyban is used to help people stop smoking by reducing cravings.
- Citalopram (Trade name “Celexa”)
Point out that this a selective serotonin reuptake inhibitor (SSRI) used to treat depression.
- Desipramine Hydrochloride (Trade names “Norpramin”; “Pertofrane”)
Point out that this a tricyclic antidepressant used to treat symptoms of depression.
- Doxepin Hydrochloride (Trade names “Adapin”; “Sinequan”)
Point out that this is used to treat symptoms of depression and/or anxiety associated with alcoholism, psychiatric conditions, or manic-depressive conditions.
- Duloxetine (Trade name “Cymbalta”)
Point out that this a selective serotonin and norepinephrine reuptake inhibitor antidepressant (SSNRI) used to treat major depressive disorder and general anxiety disorder.

Session 9 - Central Nervous System Depressants

Specific Anti-Depressants (Cont.)

Drug	Brand Name	Street Names
Escitalopram	Lexapro	
Fluoxetine	Prozac, Sarafem	
Fluvoxamine	Luvox	
Imipramine	Tofranil	
Paroxetine	Paxil	




Drug Recognition Expert Course 9-15

- Escitalopram (Trade name “Lexapro”)
Point out that this is a selective serotonin reuptake inhibitor (SSRI) used to treat anxiety in adults and major depressive disorder in adults.
- Fluoxetine (Trade names “Prozac”; “Sarafem”)
Point out that this is a selective serotonin reuptake inhibitors (SSRI) antidepressant used to treat panic, anxiety, or obsessive-compulsive symptoms.
- Fluvoxamine (Trade name “Luvox”)
Point out that this is a selective serotonin reuptake inhibitors (SSRI) used to treat social anxiety disorder (social phobia), or obsessive-compulsive disorders.
- Imipramine (Trade name “Tofranil”)
Point out that this is a tricyclic antidepressant used to treat symptoms of depression.
- Paroxetine (Trade name “Paxil”)
Point out that this is a selective serotonin reuptake inhibitor (SSRI) used to treat depression, obsessive-compulsive disorder, anxiety disorders, post-traumatic stress disorder (PTSD).

Session 9 - Central Nervous System Depressants

Specific Anti-Depressants (Cont.)

Drug	Brand Name	Street Names
Phenelzine Sulfate	Nardil	
Sertraline	Zoloft	
Trazodone	Desyrel	
Venlafaxine	Effexor	




Drug Recognition Expert Course 9-16

- Phenelzine Sulfate (Trade name “Nardil”)
Point out that this is a monoamine oxidase inhibitor (MAOI) used to treat symptoms of depression that may include feelings of sadness, fear, anxiety, or worry about physical health (hypochondria).
- Sertraline (Trade name “Zoloft”)
Point out that this is a selective serotonin reuptake inhibitors (SSRI) used to treat the causes of depression, panic, anxiety, or obsessive-compulsive symptoms.
- Trazodone (Trade name “Desyrel”)
Point out that this increases the activity of Serotonin in the brain and is used to treat depression. It may also be used for relief of certain anxiety disorders.
- Venlafaxine (Trade name “Effexor”)
Point out that this is a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) used to treat major depressive disorder, anxiety, and panic attack.

Anti-Depressants Exceptions

Note: Remind participants that some anti-depressants may cause an elevated pulse rate and pupil dilation.

Anti-Depressants may cause dry mouth, sore throat, blurred vision, urinary retention, muscle twitching, restlessness, and increased anxiety.

Session 9 - Central Nervous System Depressants

Specific Anti-Psychotic Tranquilizers Examples

Drug	Brand Name
Chlorpromazine	Thorazine
Droperidol	Inapsine, Innovar
Haloperidol	Haldol
Lithium Carbonate	Lithane




Drug Recognition Expert Course 9-17

The Anti-Psychotic Tranquilizers

- Chlorpromazine (Trade name “Thorazine”)
Point out that this is used clinically as an antipsychotic agent since 1952.
- Droperidol (Trade name “Inapsine”)
Point out that this is structurally related to haloperidol and used clinically as a neurlaptic.
- Haloperidol (Trade name “Haldol”)
Point out that this is first marketed in the U.S. in 1967 as an antipsychotic agent.
- Lithium Carbonate (Trade name “Lithane”)
Point out that this is used since 1949 as an effective treatment for certain forms of mania and endogenous depression.

Session 9 - Central Nervous System Depressants

Some Combinations of Depressants

- **Chlordiazepoxide in combination with Amitriptyline**
Trade name: “Limbitrol”
- **Chlordiazepoxide Hydrochloride in combination with Clidinium Bromide**
Trade name: “Librax”
- **Perphenazine in combination with Amitriptyline Hydrochloride**
Trade name: “Triavil” and “Etrafon”





Drug Recognition Expert Course 9-18

The Combinations

- Chlordiazepoxide in combination with Amitriptyline (trade name “Limbitrol”)
Point out that “Limbitrol” is a combination of an anti-anxiety tranquilizer and an anti-depressant.
- Chlordiazepoxide Hydrochloride in combination with Clidinium Bromide (Trade name “Librax”)
Point out that “Librax” is a combination of a benzodiazepine and an anti spasmodic, used to relax the muscles in the stomach walls.
- Perphenazine in combination with Amitriptyline Hydrochloride (Trade name “Triavil” and “Etrafon”)
Point out that “Triavil” is a combination of an anti-psychotic tranquilizer and an anti-depressant.

Session 9 - Central Nervous System Depressants

Methods of Ingestion CNS Depressants



Orally



Injection




Drug Recognition Expert Course 9-19

Methods of ingestion of CNS Depressants

- Most common and easiest method is orally
- Some abusers prefer to use intravenous injection for Barbiturates
- Some abusers experience a “flash” or “rush” from intravenous injection of Barbiturates, that they do not experience from oral ingestion

The injection paraphernalia used for Barbiturates are very similar to those used for Heroin. Examples:

- Spoon, for heating and dissolving the barbiturate
- Cotton, for filtering the solution when drawing it into the needle
- Hypodermic syringe
- Tourniquet


However, the Barbiturate abuser will use a larger hypodermic needle because the barbiturate solution is thicker than the heroin solution.

Note: The “gauge” of a hypodermic needle indicates the width of the needle’s inside diameter. The smaller the number, the larger the needle. For example, a 16 gauge needle is larger in diameter than a 20 gauge needle.

The injection sites on the skin of a Barbiturate abuser appear quite different from those of a Heroin addict.

Session 9 - Central Nervous System Depressants

Methods of Ingestion CNS Depressants (Cont.)



Orally



Injection

Drug Recognition Expert Course

NHTSA

9-20

A large swelling, about the size of a quarter or fifty cent piece frequently will appear at the Barbiturate injection site.

Point out that these effects result from the skin's reaction to the high alkaline content of the barbiturate solution.

Necrosis may occur: i.e. a decaying of the body's tissue at the injection site.

If available, display a slide showing ulcerated injection sites.

The dead tissue may begin to separate from the living tissue, producing ulcerations.

Point out that these ulcerations resemble burns placed on the skin by the tip of a cigarette.

The Barbiturate user who injects the drug usually will not display the same type of track marks as the heroin addict who uses repeated injections along the same vein.

Barbiturate abusers often will inject in parts of the body other than the forearm, and will commonly exhibit the characteristic swellings at random locations on the extremities.

Solicit participants' questions and comments about the overview of CNS Depressants.

Session 9 - Central Nervous System Depressants

Possible Effects of CNS Depressants

- Reduced inhibitions
- Divided attention impairment
- Slowed reflexes
- Impaired judgment and concentration
- Impaired vision
- Lack of coordination
- Slurred, mumbled or incoherent speech
- Emotional instability




Drug Recognition Expert Course 9-21

B. Possible Effects

CNS Depressants produce impairments of the human mind and body that essentially mirror alcohol impairment.

Point out that these effects will not necessarily appear in a predictable sequence as dose increases.

- Reduced social inhibitions
- Divided attention impairment
 - Clarification: impede the person's ability to concentrate on more than one thing at a time.
- Slowed reflexes
- Impaired judgment and concentration
- Impaired vision
 - Elaboration: ability to focus eyes may be impaired; "double vision" may develop.
- Lack of coordination
- Slurred, mumbled, or incoherent speech
- Produce a variety of emotional effects, such as euphoria, depression, suicidal tendencies, laughing or crying without provocation, etc.

Session 9 - Central Nervous System Depressants

Possible Effects of CNS Depressants (Cont.)

- Reduced inhibitions
- Divided attention impairment
- Slowed reflexes
- Impaired judgment and concentration
- Impaired vision
- Lack of coordination
- Slurred, mumbled or incoherent speech
- Emotional instability



Drug Recognition Expert Course

9-22

Emphasize: the extent to which a CNS Depressant user will exhibit these effects will depend, in part, on the user's tolerance to these drugs. Person's habituated to a drug often won't exhibit its effects as clearly as will a novice user.

Generally speaking, a person under the influence of CNS Depressants will look and act drunk.

Solicit participants' questions and comments concerning possible effects of CNS Depressants.

Session 9 - Central Nervous System Depressants

Onset and Duration Classes

- **Ultrashort**
Very fast acting, very brief effects
- **Short**
Fairly fast acting, effects last several hours
- **Intermediate**
Relatively slow acting but prolonged effects
- **Long**
Delayed but long-lasting effects




Drug Recognition Expert Course 9-23

Selectively reveal.

C. Onset and Duration Effects

Depressant drugs can be grouped loosely into four classes based on how quickly they take effect and how long their effects last.

Ask participants: “Why is there little or no street abuse of the ultrashort CNS Depressants?”

Solicit responses.

Guide respondents to bring out the point that abusers seek drugs that will produce reasonable long lasting effects. Effects that last for only a few minutes aren’t attractive or satisfying to most drug abusers.

Ultrashort:

- Very fast acting, very brief effects
- Take effect in a matter of seconds
- Effects last only a few minutes
- Very rarely are the “drugs of choice” for drug abusers

Ultrashort depressants are sometimes used at the beginning of a surgical operation, in conjunction with an inhaled anesthetic.

Session 9 - Central Nervous System Depressants

Onset and Duration Classes (Cont.)

- **Ultrashort**
Very fast acting, very brief effects
- **Short**
Fairly fast acting, effects last several hours
- **Intermediate**
Relatively slow acting but prolonged effects
- **Long**
Delayed but long-lasting effects



Drug Recognition Expert Course 9-24

Clarification: to provide a momentary sedation to ease the patient's anxiety and allow for the proper administration of the anesthetic.

Psychiatrists sometimes use ultrashort depressants at the beginning of a session, to reduce the client's inhibitions and foster a free and open communication.

An example of an ultra short depressant is Brevital Sodium which is a rapid, injectable barbiturate anesthetic mainly used in hospital settings.

Session 9 - Central Nervous System Depressants

Short Acting CNS Depressants

- They produce effects reasonably quickly
- Effects last long enough to “enjoy” the effects
- Most commonly abused class of CNS Depressants



Drug Recognition Expert Course 9-25

Short Acting

Short: fairly fast acting, effects last for approximately 4-5 hours.

Point out that short acting depressants are attractive to many drug abusers because:

- They produce effects reasonably quickly
- The effects last long enough to “enjoy” the effects
- The effects can take up to 40 minutes to be activated
- Effects last for approximately 5 hours
- This is the most commonly abused class of CNS Depressants

Short Acting Depressants frequently are prescribed as a treatment for insomnia. They also may be used as a pre-anesthetic medication to calm a patient prior to surgery.

A common example of a short acting Depressant, Secobarbital, Brand name “Seconal”

Session 9 - Central Nervous System Depressants

Intermediate Acting CNS Depressants

- **Relatively slow acting, but prolonged effects**
- **Generally take effect in about 30 minutes**
- **Effects typically last about 6-8 hours**




Drug Recognition Expert Course 9-26

Intermediate Acting

Intermediate: relatively slow acting, but prolonged effects.

“Point out that Tuinal is a combination of a fast acting drug (10-20 minutes onset, due to the Seconal) with prolonged effects (up to 8 hours, due to the Amytal).”

- Generally take effect in about 30 minutes
- Effects typically last about 6 – 8 hours
- Fairly often abused, especially by users who desire a longer lasting state of intoxication. Medical use of this class of drugs is similar to that of short acting Depressants (i.e. treat insomnia, etc.) Common example of an intermediate Depressant: Amobarbital, brand name “Amytal”.

Session 9 - Central Nervous System Depressants

Long Acting CNS Depressants

- Generally take effect about one hour after ingestion
- Effects typically last 8-14 hours
- Phenobarbital (Luminal), Diazepam (Valium), and Flurazepam (Dalmane) are examples



Drug Recognition Expert Course 9-27

Long Acting: delayed but long lasting effects.

Ask participants: “*Why don’t drug abusers usually prefer the long acting depressants?*”

- Generally take effect about one hour after ingestion
- Effects typically last 8 – 14 hours.
- Generally not the “drugs of choice” for abusers, however, some people will abuse the long acting Depressants if the more popular short and intermediate types are not readily available.

Long acting Depressants are used medically in the control of epilepsy and of other conditions that can cause convulsions.

They can also be used to provide continuing sedation to patients suffering from extreme anxiety.

A common example of a long acting depressant is Phenobarbital (Luminal) used primarily as a daytime sedative and anticonvulsant.

Other long acting depressants include:

- Diazepam (Valium) and
- Flurazepam (Dalmane).

Session 9 - Central Nervous System Depressants

How would you classify Alcohol in terms of the onset and duration of its effects?




Drug Recognition Expert Course 9-28

Alcohol as a Specific Example

Ask participants: “How would you classify Alcohol in terms of the onset and duration of its effects?”

Probe question: Suppose an average person drank two shots of whiskey. How long would it be before he or she started to feel the effects? (Solicit Responses).

Probe question: How long would the average person continue to feel the effects of those two shots?

(Solicit Responses)

Guide participants toward the conclusion that alcohol would be classified as a short or short to intermediate depressant.

Point out that these are frequently abused CNS Depressants, but they are not the only depressants that are abused.

Session 9 - Central Nervous System Depressants

Examples of Short-to-Intermediate CNS Depressants

Non-barbiturates

- Noctec or Felsule (“Mickey Finn”)
- Methaqualone (Quaalude)
- Placidyl
- Equanil or Miltown
- Soma
- Gamma Hydroxybutyrate (GHB)
- Zolpidem (Ambien)



Drug Recognition Expert Course 9-29

Non-Barbiturates

- Noctec or Felsule (“Mickey Finn”)
- Methaqualone (Quaalude) (“Ludes”) – removed from U.S. market in 1984. Mainly produced illicitly.
- Ethchlorvynol (Placidyl)
- Meprobamate (Equanil or Miltown)
- Carisoprodol (Soma)
- Gamma Hydroxybutyrate (GHB)
- Zolpidem (Ambien)

Session 9 - Central Nervous System Depressants

Examples of Short-to-Intermediate CNS Depressants (Cont.)

Anti-anxiety tranquilizers

- Valium
- Librium
- Xanax
- Serax
- Klonopin
- Ativan
- Rohypnol



Drug Recognition Expert Course 9-30

Anti-Anxiety Tranquilizers

- Diazepam (Valium)
- Chlordiazepoxide (Librium)
- Alprazolam (Xanax)
- Oxazepam (Serax)
- Clonazepam (Klonopin)
- Lorazepam (Ativan)
- Flunitrazepam (Rohypnol)

Point out that Rohypnol is currently not legally manufactured in the United States and is illegal to possess. However, it is legally manufactured and prescribed in other countries along with GHB, it is known as one of the “date rape” drugs.

Solicit participants’ questions and comments about the onset and duration of effects of CNS Depressants.

Session 9 - Central Nervous System Depressants

Overdose Signs and Symptoms

- **Subject will become extremely drowsy and may pass out**
- **The heartbeat (pulse) will be rapid and weak**
- **Respiration will become shallow**
- **Skin may feel cold and clammy**



Drug Recognition Expert Course 9-31

D. Overdose Signs and Symptoms

Overdoses of the Central Nervous System Depressants produce symptoms essentially identical to those of alcohol overdoses.

- Subject will become extremely drowsy and may pass out
- The heartbeat (pulse) will be rapid and weak
- Respiration will become shallow
- Skin may feel cold and clammy
- One major danger with CNS Depressant overdoses is death from respiratory failure
- A sufficiently high dose of CNS Depressant will suppress the portions of the brain that control respiration

This situation only rarely occurs from alcohol intoxication: usually, a drinker will pass out before he or she consumes enough alcohol to suppress respiration completely. With other depressants, it is relatively easy to take a fatal overdose.

Session 9 - Central Nervous System Depressants

Danger

- **CNS Depressants combined with Alcohol**
- **More than an additive effect**





Drug Recognition Expert Course 9-32

Point out that CNS Depressants are often used as a means of suicide.

Another major danger with CNS Depressants occurs when they are combined with alcohol.

Clarification: the combination of alcohol and certain other CNS Depressants may produce an effect greater than the sum of the effects of the two drugs independently. There is at least an additive effect when alcohol and another depressant are taken together.

With many CNS Depressants, there may be more than an additive effect. Coroners have reported a number of cases in which neither the alcohol level nor the depressant level independently would have been close to a fatal dose.

It is not possible to predict how great an effect will occur when alcohol is mixed with another depressant.

However, it is clear that the combination is always risky.

Solicit participants' questions and comments concerning overdose signs and symptoms of CNS Depressants.

Session 9 - Central Nervous System Depressants

Evaluation of Subjects Under the Influence of CNS Depressants

- HGN - Present
- VGN - may be Present
(with high doses for that individual)
- Lack of Convergence - Present
- Impaired performance will be evident on Modified Romberg, Walk and Turn, One Leg Stand and Finger to Nose




Drug Recognition Expert Course 9-33

E. Expected Results of the Evaluation

Observable Evidence of Impairment

Point out that, if a person is under the influence of a combination of alcohol and some other CNS Depressant, the onset angle of HGN will not be consistent with the person's BAC; in other words, the eyes will start to jerk earlier than would be expected due to the alcohol alone.

Horizontal Gaze Nystagmus will be present with subjects under the influence of CNS Depressants.

Vertical Gaze Nystagmus may be present, with high doses, of depressants for that individual.

Performance on Modified Romberg Balance, Walk and Turn, One Leg Stand, and Finger to Nose tests will be similar to that of subjects impaired by alcohol.

Point out that subject's perception of time (on Modified Romberg) may be slowed, i.e. may estimate "30 seconds" after more than 30 seconds has elapsed.

Session 9 - Central Nervous System Depressants

Evaluation of Subjects Under the Influence of CNS Depressants (Cont.)

Vital Signs

- Blood pressure - Down
- Pulse - Down ⁽²⁾
- Body temperature - Normal

⁽²⁾ Quaaludes, ETOH and some anti-depressants may elevate

Muscle Tone - Flaccid




Drug Recognition Expert Course 9-34

Vital Signs

- Blood pressure will be Down.
- Pulse will be Down ⁽²⁾

Ask the students if the Pulse will be down with all CNS Depressants. Solicit their responses and then point out the Footnote (2) to the students.

- ⁽²⁾ Quaaludes, ETOH and possibly some anti-depressants may elevate.
- Body temperature generally will be in the Normal Range (98.6 plus or minus one degree)

Point out that “normal” refers to body temperature generally being in the DRE average ranges.

Muscle Tone

- Muscle tone will be Flaccid

Session 9 - Central Nervous System Depressants

Evaluation of Subjects Under the Influence of CNS Depressants (Cont.)

Dark Room Examinations

- Pupil size - Normal ⁽¹⁾
- Pupillary reaction to light - Slow

⁽¹⁾ Soma, Quaaludes and some anti-depressants usually dilate pupils



Drug Recognition Expert Course 9-35

Dark Room Examinations

- Pupil sizes will generally be Normal

Point out that “normal” refers to pupil size generally being in the DRE average ranges.

Ask the students if the pupil size will be normal with all CNS Depressants. Solicit their responses and then point out the foot note (1) to the students.

- ⁽¹⁾ Soma, Quaaludes and possibly some anti-depressants usually dilate pupils.
- Pupillary reaction to light will be Slowed.

Session 9 - Central Nervous System Depressants

Evaluation of Subjects Under the Influence of CNS Depressants (Cont.)

General Indicators:

- **Disoriented**
- **Droopy eyelids (Ptosis)**
- **Drowsiness**
- **Drunk-like behavior**
- **Flaccid muscle tone**
- **Gait Ataxia**
- **Slow, sluggish reactions**
- **Thick, slurred speech**
- **Uncoordinated**



Drug Recognition Expert Course 9-36

General Indicators

- Disoriented
- Droopy eyes (ptosis)
- Drowsiness
- Drunk-like behavior
- Flaccid muscle tone
- Gait ataxia
- Slow, sluggish reactions
- Thick, slurred speech
- Uncoordinated

NOTE:

- With Methaqualone, pulse will be elevated and body tremors will be evident.
- Alcohol, Quaaludes and possibly some anti-depressants elevate the pulse
- Soma, Quaaludes and possibly some anti-depressants usually dilate pupils

Note: speech may also be incoherent.

Analogy: drunken behavior without the odor of alcoholic beverages.

But remind participants: subjects may have consumed alcohol and some other CNS Depressant. Hence, odor of alcoholic beverage may also be present.

Anti-Depressant Exceptions:

- As a reminder, some Anti-Depressants may cause elevated pulse rate and pupil dilation.
- Anti-Depressants may cause dry, sore throat, dry mouth, blurred vision, urinary retention, muscle twitching, restlessness, and increased anxiety.

Session 9 - Central Nervous System Depressants

CNS Depressant Symptomatology Chart

HGN	Present
VGN	Present (High dose for that individual)
Lack of Convergence	Present
Pupil Size	Normal ⁽¹⁾
Reaction to Light	Slow
Pulse Rate	Down ⁽²⁾
Blood Pressure	Down
Temperature	Normal
Muscle Tone	Flaccid



(1) Soma, Quaaludes and some anti-depressants usually dilate pupils
 (2) Quaaludes, ETOH and some anti-depressants may elevate




Drug Recognition Expert Course 9-37

Point out that “Normal” references refer to the DRE and DEC program averages for those specific examinations, such as pupil size, pulse rate, temperature , reaction to light, etc.

Session 9 - Central Nervous System Depressants

CNS Depressants




Drug Recognition Expert Course

9-38

VIDEO DEMONSTRATION

***Show video example of subject under the influence of a CNS Depressant.
(Approximately 20 minutes).***



F. Classification Exemplar

Refer students to the exemplars found at the end of Session 9 of their participant manuals.

Point out that the one-page narrative in the example exemplars are not to be construed as the recommended or approved narrative report. The actual narrative report submitted by DREs will be more detailed.

Relate the items on the exemplars to the CNS Depressant Symptomatology Chart.

VIDEO DEMONSTRATION

Show video example of subject under the influence of a CNS Depressant. (Approximately 20 minutes).

Relate behavior and observations to the CNS Depressant Symptomatology Chart.

Solicit students' questions or suggestions concerning Expected Results of the Evaluation of subjects under the influence of Depressants.

Session 9 - Central Nervous System Depressants

QUESTIONS?



Drug Recognition Expert Course 9-40

Solicit participants' comments and questions concerning Central Nervous System Depressants.

Session 9 - Central Nervous System Depressants

Topics for Study



Drug Recognition Expert Course 9-41

TOPICS FOR STUDY / ANSWERS

1. Name the six major subcategories of CNS Depressants.

ANSWER: Barbiturates, Non-barbiturates, Anti-Anxiety Tranquilizers, Anti-Depressants, Anti-Psychotic Tranquilizers, Combinations

2. Name the four groups of Depressants based on onset and duration time factors.

ANSWER: Ultra short, Short, Intermediate, Long

3. To which subcategory of Depressants does Thorazine belong? To which subcategory does Chloral Hydrate belong? To which subcategory does Xanax belong?

ANSWER: Anti-Psychotic Tranquilizers, Non-barbiturates, Anti-Anxiety Tranquilizers

4. Name a CNS Depressant that usually causes the pupils to dilate.

ANSWER: Soma, Methaqualone

5. What is the generic name for the drug that has the trade name "Prozac"?

ANSWER: Fluoxetine

6. What is a trade name for the generic drug "Alprazolam"?

ANSWER: Xanax

7. What is the name of the subcategory of CNS Depressants that is also known as the "Minor Tranquilizers"?

ANSWER: Anti-Anxiety Tranquilizers

DRUG INFLUENCE EVALUATION

Evaluator Leo Hegarty, PA State Police		DRE # 11947	Rolling Log # 12-08-155	Session IX #1	
Recorder/Witness George Geisler, Old Lycoming PD		Crash: <input checked="" type="checkbox"/> None <input type="checkbox"/> Fatal <input type="checkbox"/> Injury <input type="checkbox"/> Property		Case # 12-445788	
Arrestee's Name (Last, First, Middle) Cramer, Carolyn L.		Date of Birth 4/21/64	Sex F	Race W	Arresting Officer (Name, ID#) Trooper Frank Cichra, PA SP #13886
Date Examined / Time / Location 08-06-12, 0145, Harrisburg SP Barracks		Breath Results: Results: 0.00	Test Refused <input type="checkbox"/> Instrument #: 100324	Chemical Test: Urine <input checked="" type="checkbox"/> Blood <input type="checkbox"/> Test or tests refused <input type="checkbox"/>	
Miranda Warning Given Given By: Tpr. Cichra	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? Chicken Soup 8 pm	What have you been drinking? Nothing	How much? N/A	Time of last drink? N/A
Time now/ Actual "Midnight" / 0145	When did you last sleep? How long Last night/ 6 hours	Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input type="checkbox"/> No "None of your business"		Attitude: Sullen, With-drawn, non-responsive at times		Coordination: Poor, Stumbling, Staggering	
Speech: Slurred at times		Breath Odor: Normal		Face: Normal	
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input checked="" type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right	
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	
Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal		Eyelids: <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Droopy			
Pulse and time		HGN	Left Eye	Right Eye	Convergence
1. <u>60</u> / <u>0222</u>		Lack of Smooth Pursuit	Yes	Yes	
2. <u>58</u> / <u>0230</u>		Maximum Deviation	Yes	Yes	
3. <u>58</u> / <u>0244</u>		Angle of Onset	35	35	
Modified Romberg Balance		Walk and Turn test		ONE LEG STAND	
		Cannot keep balance <input checked="" type="checkbox"/> Starts too soon <input checked="" type="checkbox"/> Stops walking <input type="checkbox"/> Misses heel-toe <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Steps off line <input checked="" type="checkbox"/> Raises arms <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Actual steps taken: 9 / 11		26 28 L R <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Sways while balancing <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Uses arms to balance <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Hopping <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Puts foot down	
Internal clock 46 estimated as 30 seconds	Describe Turn Lost balance	Cannot do test (explain) N/A		Type of footwear: Loafers	
Draw lines to spots touched 		PUPIL SIZE	Room light 2.5 - 5.0	Darkness 5.0 - 8.5	Direct 2.0 - 4.5
		Left Eye	4.0	6.0	3.5
		Right Eye	4.0	6.0	3.5
		REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		REACTION TO LIGHT: Slow	
		RIGHT ARM		LEFT ARM	
		Nothing observed			
Blood pressure 110/70	Temperature 98.2	Muscle tone: <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Flaccid <input type="checkbox"/> Rigid			
Comments: What drugs or medications have you been using? "I told you, it's none of your business"		How much? No response	Time of use? No response	Where were the drugs used? (Location) No response	
Date / Time of arrest: 08/06/12 0115	Time DRE was notified: 0130	Evaluation start time: 0145	Evaluation completion time: 0300	Precinct/Station: Harrisburg	
Officer's Signature:		DRE # 13886	Reviewed/approved by / date:		
Opinion of Evaluator:		<input type="checkbox"/> Rule Out	<input type="checkbox"/> Alcohol	<input type="checkbox"/> CNS Stimulant	<input type="checkbox"/> Dissociative Anesthetic
		<input type="checkbox"/> Medical	<input checked="" type="checkbox"/> CNS Depressant	<input type="checkbox"/> Hallucinogen	<input type="checkbox"/> Narcotic Analgesic
				<input type="checkbox"/> Inhalant	<input type="checkbox"/> Cannabis

DRUG INFLUENCE EVALUATION NARRATIVE








Suspect: Cramer, Carolyn

1. **LOCATION:** The evaluation was conducted at Harrisburg State Police Barracks.
2. **WITNESSES:** George Geisler of the Old Lycoming PD recorded the evaluation.
3. **BREATH ALCOHOL TEST:** Cramer's breath test was 0.00%
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** I was notified that Trooper Cichra had arrested a subject for DUI and was requesting a drug evaluation. Writer contacted Trooper Cichra at the Harrisburg SP Barracks where it was determined that the suspect had been observed driving at 30 MPH on I-283. When contacted, the suspect appeared dazed and disoriented. She was unable to perform the roadside SFST's as directed and was arrested for DUI.
5. **INITIAL OBSERVATION OF SUSPECT:** Writer first observed the suspect in the Interview Room. She was quiet, withdrawn and slow to respond to questions. When she would try to walk, she would stumble and several times nearly fell.
6. **MEDICAL PROBLEMS AND TREATMENT:** None observed or stated.
7. **PSYCHOPHYSICAL TESTS:** Modified Romberg Balance: The suspect exhibited a 2" front to back and side to side sway. She estimated 30 seconds in 46 seconds. Walk and Turn: The suspect lost her balance during the instructions, started too soon, stepped off the line twice, missed heel to toe, raised her arms for balance, staggered to the right while turning and took two extra steps returning back down the line. One Leg Stand: The suspect swayed, raised her arms for balance, hopped and put her foot down. Finger to Nose: Suspect missed the tip of her nose on five of the six attempts.
8. **CLINICAL INDICATORS:** The suspect exhibited six clues of HGN and a Lack of Convergence. Two of her pulse rates were below the DRE average range and her Systolic blood pressure was also below the DRE average range.
9. **SIGNS OF INGESTION:** None were evident.
10. **SUSPECT'S STATEMENTS:** The suspect admitted taking "some medicine" her brother gave her. She also stated she did not know what the medicine was.
11. **DRE'S OPINION:** In my opinion Cramer is under the influence of a CNS **Depressant** and unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** The suspect provided a urine sample for analysis.
13. **MISCELLANEOUS:**

R5/13

DRUG INFLUENCE EVALUATION

Session IX #2

Evaluator Sgt. Helena Williams, California H.P.		DRE # 5249	Rolling Log # 12-09-32		Case # 12-889775		
Recorder/Witness Officer Travis Herbert, CHP		Crash: <input checked="" type="checkbox"/> None <input type="checkbox"/> Fatal <input type="checkbox"/> Injury <input type="checkbox"/> Property					
Arrestee's Name (Last, First, Middle) Henry, Michael James		Date of Birth 3/11/70	Sex M	Race W	Arresting Officer (Name, ID#) Officer Cindy Morgan, CHP #5881		
Date Examined / Time / Location 09-06-12, 2110 W. Sacramento		Breath Results: Results: 0.00		Test Refused <input type="checkbox"/> Instrument #: 200548	Chemical Test: Urine <input checked="" type="checkbox"/> Blood <input type="checkbox"/> Test or tests refused <input type="checkbox"/>		
Miranda Warning Given Given By: Ofc. Morgan	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? Cheeseburger 10		What have you been drinking? Nothing	How much? N/A	Time of last drink? N/A	
Time now/ Actual 10 pm / 2115	When did you last sleep? How long Last night / 8 hours	Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No Doctor for Stress			
Are you taking any medication or drugs? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No "Just Xanax"		Attitude: Withdrawn, Cooperative		Coordination: Poor, Slow, Sluggish			
Speech: Slurred, thick at times		Breath Odor: Normal		Face: Normal			
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right		Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal	
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		Eyelids <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Droopy	
Pulse and time 1. <u>62</u> / <u>2130</u> 2. <u>62</u> / <u>2142</u> 3. <u>58</u> / <u>2200</u>		HGN Lack of Smooth Pursuit Maximum Deviation Angle of Onset	Left Eye Yes Yes 40	Right Eye Yes Yes 40	Convergence  Right eye Left eye		
Modified Romberg Balance 		Walk and turn test 		Cannot keep balance <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Starts too soon _____ Stops walking _____ Misses heel-toe <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Steps off line <input checked="" type="checkbox"/> Raises arms <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Actual steps taken 9 9		29 ONE LEG STAND 27  L R <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Sways while balancing <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Uses arms to balance <input type="checkbox"/> <input type="checkbox"/> Hopping <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Puts foot down	
Internal clock 50 estimated as 30 seconds		Describe Turn Lost balance		Cannot do test (explain) N/A		Type of footwear: Lace up boots	
Draw lines to spots touched 		PUPIL SIZE	Room light 2.5-5.0	Darkness 5.0-8.5	Direct 2.0-4.5		
		Left Eye	4.5	6.5	3.5		
		Right Eye	4.5	6.5	3.5		
		REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			REACTION TO LIGHT: Slow		
		RIGHT ARM 		LEFT ARM 			
Blood pressure 106/66		Temperature 98.6		Nothing observed			
Muscle tone: <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Flaccid <input type="checkbox"/> Rigid		Comments:					
What drugs or medications have you been using? Xanax		How much? A couple		Time of use? 6 pm	Where were the drugs used? (Location) McDonald's		
Date / Time of arrest: 09/06/12 2015		Time DRE was notified: 2040		Evaluation start time: 2110	Evaluation completion time: 2220		
Officer's Signature:		DRE # 5249	Reviewed/approved by / date:				
Opinion of Evaluator:		<input type="checkbox"/> Rule Out	<input type="checkbox"/> Alcohol	<input type="checkbox"/> CNS Stimulant	<input type="checkbox"/> Dissociative Anesthetic	<input type="checkbox"/> Inhalant	
		<input type="checkbox"/> Medical	<input checked="" type="checkbox"/> CNS Depressant	<input type="checkbox"/> Hallucinogen	<input type="checkbox"/> Narcotic Analgesic	<input type="checkbox"/> Cannabis	

DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: Henry, Michael J.

- 1. LOCATION:** The evaluation took place at the West Sacramento CHP office.
- 2. WITNESSES:** Officer Travis Herbert of the CHP recorded the evaluation.
- 3. BREATH ALCOHOL TEST:** Henry's breath test was a 0.00%
- 4. NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** I was requested to conduct a drug evaluation for Officer Morgan at the West Sacramento CHP office. Officer Morgan advised that she had located the suspect slumped over in the driver's seat of a vehicle stopped in the S/B traffic lane of S.R. 49. Officer Morgan further advised that the suspect appeared to be impaired and performed poorly on the SFST's.
- 5. INITIAL OBSERVATION OF SUSPECT:** I first observed the suspect in a slumped position in a chair next to the interview room desk. The suspect was mumbling, had thick, slurred speech and was slow to respond to questions.
- 6. MEDICAL PROBLEMS AND TREATMENT:** The suspect stated he was under the care of a doctor for stress and was not in need of any medical assistance.
- 7. PSYCHOPHYSICAL TESTS:** Modified Romberg Balance: The suspect swayed approximately 3" front to back and estimated 30 seconds in 50 seconds. Walk and Turn: The suspect lost his balance twice during the instructions, stepped off the line, missed heel to toe three times, raised his arms for balance and lost his balance while turning. One Leg Stand: Suspect swayed, raised his arms for balance and put his foot down once while standing on the left foot and twice while standing on the right foot. Finger to Nose: The suspect missed the tip of his nose on each of the six attempts.
- 8. CLINICAL INDICATORS:** Henry exhibited six clues of HGN and a Lack of Convergence. One of his pulse rates was below the DRE average range and his blood pressure was also below the DRE average ranges.
- 9. SIGNS OF INGESTION:** None observed.
- 10. SUSPECT'S STATEMENTS:** The suspect admitted taking Xanax. He stated he normally takes the Xanax three times a day for stress and may have taken more today.
- 11. DRE'S OPINION:** In my opinion Henry is under the influence of a **CNS Depressant** and was unable to operate a vehicle safely.
- 12. TOXICOLOGICAL SAMPLE:** The suspect provided a urine sample.
- 13. MISCELLANEOUS:** The suspect voluntarily produced a pill bottle containing Xanax pills. A prescription for 30 pills had been filled two days earlier and there were 12 pills in the bottle.

R5/13

Session 10

Central Nervous System Stimulants



Session 10 - Central Nervous System Stimulants

Learning Objectives

- Explain a brief history of the CNS Stimulant category of drugs
- Identify common drug names and terms associated with this category
- Identify common methods of administration for this category
- Describe the symptoms, observable signs and other effects associated with this category



Drug Recognition Expert Course

10-2

Briefly review the objectives, content and activities of this session.

Upon successfully completing this session the participant will be able to:

- Explain a brief history of the CNS Stimulant category of drugs.
- Identify common drug names and terms associated with this category.
- Identify common methods of administration for this category.
- Describe the symptoms, observable signs and other effects associated with this category.

Session 10 - Central Nervous System Stimulants

Learning Objectives (Cont.)

- Describe the typical time parameters, i.e. onset and duration of effects associated with this category
- List the clues that are likely to emerge when the drug influence evaluation is conducted for a person under the influence of this category of drugs
- Correctly answer the “topics for study” questions at the end of this session




Drug Recognition Expert Course 10-3

- Describe typical time parameters, i.e. onset and duration of effects, associated with this category.
- List the clues that are likely to emerge when the drug influence evaluation is conducted for a person under the influence of this category of drugs.
- Correctly answer the “topics for study” questions at the end of this session.

CONTENT SEGMENTS

- Overview of the Category
- Possible Effects
- Onset and Duration Effects
- Overdose Signs and Symptoms
- Expected Results of the Evaluation
- Classification Exemplar

LEARNING ACTIVITIES

- Instructor Led Presentations
- Review of the Drug Evaluation and Classification Exemplars
- Reading Assignments
- Video Presentations
- Slide Presentations

Session 10 - Central Nervous System Stimulants

CNS Stimulant Overview

CNS Stimulants:

- **Speed up the operation of the Central Nervous System**
- **Increase heartbeat, pulse, respiration, blood pressure, and temperature**
- **Produce nervousness, irritability and an inability to concentrate or think clearly**
- **Lead to unpredictable and bizarre behavior**




Drug Recognition Expert Course 10-4

A. Overview of the Category

CNS Stimulants speed up the operation of the Central Nervous System.

- “Speed Up” does not mean “improve.”
- Emphasize that abuse of CNS Stimulants does not make the brain work “better” or “smarter.” Rather, they induce the brain to cause many of the body’s organs to work harder, but not better.
- The “speeding up” results in increased heartbeat, pulse, respiration, blood pressure, and temperature.

All of these effects can lead to physical harm to the stimulant user.

- However, Robert Louis Stevenson wrote “The Strange Case of Dr. Jekyll and Mr. Hyde” while under the influence of Cocaine. He wrote sixty thousand words in six days.

The “speeding up” also produces nervousness, irritability and an inability to concentrate or think clearly.

These psychological effects can lead to unpredictable and bizarre behavior by the stimulant user.

Session 10 - Central Nervous System Stimulants

Subcategories of CNS Stimulants Cocaine



The collage consists of five images: top-left shows a clear plastic bag containing a white, powdery substance; top-right shows a hand holding a large, white, rock-like chunk of cocaine; middle-left shows a white, diamond-shaped paper with a small amount of white powder on it; middle is a glass vial with a red label that reads 'POISON A 2225 COCAINE HYDROCHLORIDE MERCK 50443 U. S. P.—LARGE CRYSTALS WARNING—May be habit forming. (100)—Subject to the Federal Narcotic Law. MERCK & CO., INC. RAHWAY, N.J.'; bottom-right shows a pile of small, white, crystalline pieces of cocaine on a dark surface, with a paperclip placed next to them for scale.

Drug Recognition Expert Course 10-5

Subcategories of CNS Stimulants

There are three major subcategories of Central Nervous System Stimulants.

Cocaine

Session 10 - Central Nervous System Stimulants

Subcategories of CNS Stimulants (Cont.)

Amphetamines

- Methamphetamine
- Amphetamine Sulfate
- Desoxyn






NDC 0555-0767-02
Adderall®
 (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets) (Mixed Salts of a Single Entity Amphetamine Product)
20 mg
 PHARMACIST: Dispense the accompanying Medication Guide to each patient.
 Rx only
100 TABLETS
TEVA




Drug Recognition Expert Course 10-6

The Amphetamines

Amphetamines include a large number of individual drugs.

Examples:

- Methamphetamine
- Amphetamine Sulfate
- Desoxyn
 - Also includes (d-methamphetamine) (d-desoxyephedrine) and Methedrine.
 - Desoxyn was first developed in 1919 and has been used clinically since 1930. Mainly used for the treatment of obesity, narcolepsy and attention disorder.

Session 10 - Central Nervous System Stimulants

Sub Categories of CNS Stimulants (Cont.)

Others

- Ritalin
- Ephedrine
- Caffeine



Drug Recognition Expert Course

NHTSA

10-7

Others

There are many “other” CNS Stimulants (i.e., non-Cocaine and non-Amphetamines); the ones listed on the visual are only a few of those.

- Ritalin (methylphenidate hydrochloride)
 - Also brand names of Concerta, Daytrana. Used in the treatment of depression, narcolepsy and ADD (Attention Deficit Disorder)
- Ephedrine –(Primatene, Quadrinal)
 - Can be found in some naturally-occurring plants such as the Chinese herb ma huang. Used as a nasal decongestant and bronchodilator. Contained in numerous OTC supplements and energy products
- Caffeine
 - Contained in coffee and numerous energy drinks. Some “Monster drinks” contain as much as 240 milligrams of caffeine. Can be fatal at about 10 grams.

We will focus on Cocaine and the Amphetamines, because they are the most widely abused CNS Stimulants. But, the participants should be aware that there are many other stimulant drugs.

Session 10 - Central Nervous System Stimulants

Coca Plant

“Erythroxylon Coca”



The slide features three photographs. The top-left photo shows a large white sack filled with fresh, green coca leaves. The top-right photo shows a coca plantation with rows of plants on a hillside. The bottom-center photo shows several green packets of 'Harina de Hoja de Coca' (coca leaf powder) and a clear plastic container filled with the powder. In the bottom-left corner of the slide is the logo of the National Highway Traffic Safety Administration (NHTSA), and in the bottom-right corner is the NHTSA logo with the text '10-8'.

Drug Recognition Expert Course 10-8

Cocaine

Coca plant: Scientific name “Erythroxylon Coca.”

Cocaine derives from the coca plant.

- The plant is native to South America.
- Cocaine is made from the leaves of the coca plant.

Note: the coca plant should not be confused with the cocoa plant, from which chocolate is made.

- Archaeological evidence indicates that natives of Peru chewed coca leaves 5,000 years ago.
- Sigmund Freud personally experimented with Cocaine for approximately 3 years.
- Small quantities of Cocaine originally were included in the formula of Coca Cola.
- Use of Cocaine in products as Coca Cola was outlawed by the Pure Food and Drug Law of 1906.

Session 10 - Central Nervous System Stimulants

Amphetamines

- Initial medical application – cold treatment
- Cause the nasal membranes to shrink.
- No longer prescribed as cold remedies







Drug Recognition Expert Course 10-9

Amphetamines

Amphetamines were first synthesized near the end of the 19th Century.

The first use of Amphetamines for medical purposes began in the 1920's.

Initial medical application was to treat colds.

- Amphetamines cause the nasal membranes to shrink.
- This gives temporary relief from stuffy nasal passages.

Much more effective drugs have been developed to treat cold symptoms.

Amphetamines were prescribed for the treatment of narcolepsy and ADHD (attention deficit hyperactivity disorder).

Amphetamine use grew rapidly when amphetamines were distributed to soldiers during World War II.

Amphetamines are no longer prescribed as cold remedies. In 1971, amphetamines were scheduled in the United States and prescriptions became required for possession.

Session 10 - Central Nervous System Stimulants

Medical Uses of Amphetamines

- **Control appetite**
- **Control symptoms of narcolepsy**
- **Control hyperactivity in children**
- **Relieve or prevent fatigue**
- **Treat mild depression**



Drug Recognition Expert Course 10-10

Present day medical purposes for amphetamines include:

- Control appetite. Many over the counter appetite control products contain CNS Stimulants as their active ingredient.
- Control symptoms of narcolepsy. Narcolepsy is an extremely rare disorder that causes the individual to fall asleep compulsively, often several hundred times per day.
- Control certain hyperactive behavioral disorders. Example: Ritalin is commonly prescribed for children diagnosed with ADD or similar disorders.
- Relieve or prevent fatigue to allow persons to perform essential tasks of long duration. The U.S. Air Force previously gave pilots amphetamines to keep them alert on long flights. Amphetamines have also had other short term military applications.
- Treat mild depression.

Session 10 - Central Nervous System Stimulants

Other Medical Uses of Amphetamines

- Antagonize effects of depressants
- Prevent and treat surgical shock
- Maintain blood pressure during surgery
- Treat Parkinson's disease
- Enhance the action of analgesic drugs




Drug Recognition Expert Course 10-11

- Antagonize the effects of depressant drugs.

Remind participants that two drugs are antagonistic when the signs and symptoms of one are opposite to the signs and symptoms of the other.

- Prevent and treat surgical shock.
- Maintain blood pressure during surgery.
- Treat Parkinson's Disease.

Parkinson's Disease: a form of paralysis characterized by muscular rigidity, tremor and weakness.

- Enhance the action of certain analgesic (pain killer) drugs.

Numerous pharmaceutical companies manufacture Amphetamines for these purposes.

Session 10 - Central Nervous System Stimulants

Commonly Prescribed Pharmaceutical Amphetamines

- **Dexedrine**
Dextroamphetamine Sulfate
- **Adderall**
Dextroamphetamine and Amphetamine
- **Benzedrine**
Amphetamine Sulfate
- **Desoxyn**
Methamphetamine Hydrochloride




Drug Recognition Expert Course 10-12

Examples of common pharmaceutical Amphetamines:

- Dexedrine (dextroamphetamine sulfate) used to treat narcolepsy and hyperkinetic behavior, and for weight control. (Street names “Dexies”; “Hearts”)

Note: Dexedrine probably is the most commonly prescribed Amphetamine.

- Adderall (Combination of Dextroamphetamine and Amphetamine Sulfate) It is used for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy.
- Benzedrine (Amphetamine Sulfate) used to treat narcolepsy, hyperkinetic behavior and weight problems. (Street names “Bennies”; “Whites”; “Cartwheels”)
- Desoxyn (Methamphetamine Hydrochloride, also known as Desoxyephedrine) used in weight reduction.

Session 10 - Central Nervous System Stimulants

Commonly Abused Illicit Amphetamines

Methamphetamine





Drug Recognition Expert Course 10-13

Large quantities of Amphetamines are also illegally manufactured in this country.

If available, display slides of illicitly manufactured methamphetamine.

The most commonly abused illicit Amphetamine is Methamphetamine. Methamphetamine Hydrochloride is a white to light brown crystalline powder, or clear chunky crystals resembling ice. Methamphetamine base is a liquid.

The majority of street Methamphetamine is produced in Clandestine laboratories.

Note: Clandestine production normally involves the reduction of l-ephedrine or d-pseudoephedrine over red phosphorus with hydroiodic acid, or reduction with sodium or lithium in condensed liquid ammonia.

Medicinally, forms of Methamphetamine can be used in the treatment of:

- Narcolepsy
- Attention Deficit Disorder (ADD)
- Attention Deficit Hyperactivity Disorder (ADHD)

Methamphetamine is also known as Methedrine or Methamphetamine Hydrochloride
Its' more common street names are "speed"; "crank"; "ice"; "crystal"; "meth"; and "water."

Session 10 - Central Nervous System Stimulants

Other CNS Stimulants (Besides Cocaine or Amphetamines)

- **Ritalin**
Methylphenidate Hydrochloride
- **Ephedrine**
- **Cathine and Cathinone**
- **Methcathinone**






Drug Recognition Expert Course

10-14

Other CNS Stimulants

There are some other CNS Stimulants, apart from Cocaine or the Amphetamines.

Ritalin

If available, display slides of Ritalin.

Ritalin is a manufactured, non-Amphetamine CNS Stimulant:

Ask participants if they know of any children for whom Ritalin has been prescribed.

- Generic name Methylphenidate Hydrochloride
- Used to treat mild depression, hyperkinetic behavior, narcolepsy and drug induced lethargy produced by CNS Depressants.
- Has many of the basic clinical effects of Amphetamine.

Remind the participants that we will focus on Cocaine and the Amphetamines for our discussion of CNS Stimulants and their effects.

Ephedrine is a licitly manufactured stimulant used in diet aides and body building supplements. It can also be found in herbal preparations and numerous over-the-counter (OTC) substances.

Cathine and Cathinone are the two psychoactive chemicals derived from the Khat plant. It originates from the sub-Sahara regions of Africa. Also known as "cat."


Methcathinone is illicitly manufactured from common household chemicals. Effects are very similar to Methamphetamine.

Session 10 - Central Nervous System Stimulants

Methods of Ingesting Stimulants

Cocaine

- Injection
- Orally
- Snorting
- Smoking



Drug Recognition Expert Course

NHTSA

10-15

Methods of Ingestion of CNS Stimulants

There are a variety of ways in which the different CNS Stimulants may be ingested.

Cocaine is commonly insufflated (snorted), smoked, injected and taken orally.

In order to be smoked, a pure form of Cocaine is required.

- Much of the Cocaine sold in this country is mixed with other materials, or chemically bonded to other elements.
- Various chemical processes can be used to “free” the Cocaine from other elements and impurities.
- One such process produces pure Cocaine in the form of small chunks.
- These chunks are known as “Crack” or “Rock Cocaine.”

Note: the term “Crack” derives from the cracking sound produced when the chunks are burned for smoking.

- Licitly manufactured Amphetamines are taken orally, in the form of tablets, capsules and liquid elixirs.

Session 10 - Central Nervous System Stimulants

Methods of Ingesting Stimulants (Cont.)

- **Methamphetamine**
 - Injection
 - Orally
 - Snorting
 - Smoking
- **Other Amphetamines**
 - Orally
(tablets, capsules, etc.)






Drug Recognition Expert Course

10-16

- Illicitly manufactured Methamphetamine most commonly is injected or smoked but sometimes may be snorted or taken orally.

Bruising is often seen around a Methamphetamine injection site.

- The smokable forms of Methamphetamine are known as “Crystal Meth” or “Ice.” They contain the same active chemical compound as powdered Methamphetamine, but undergo a re-crystallization process in which some impurities are removed.

“Ice” is a clear crystal similar in appearance to rock candy, crushed ice, or broken glass. “Crystal Meth” is less pure and has a cloudy appearance or maybe yellowish, tan, or even brown in color.

- Amphetamine Sulfate usually is produced in tablet form (called “mini bennies”) and is taken orally.

Solicit participant questions and comments about the overview of CNS Stimulants.

Session 10 - Central Nervous System Stimulants

Possible Effects of CNS Stimulants

- Euphoria
- Hyperactivity
- Release of inhibitions
- Misperception of time and distance
- Inability to concentrate
- Bruxism (Grinding of the teeth)





Drug Recognition Expert Course 10-17

B. Possible Effects

Cocaine, Amphetamines and most stimulants produce euphoria, a feeling that there are no problems.

- A feeling of super strength and absolute self-confidence may also be present.
- With Cocaine, but not with Amphetamines, there is an anesthetic effect, and the dulling of pain may contribute to the euphoria.

CNS Stimulant users tend to become hyperactive, indicated by nervousness, extreme talkativeness, an inability to sit still, and users may grind their teeth (which is called Bruxism).

CNS Stimulants tend to release inhibitions, allowing users to commit acts that they normally would avoid.

CNS Stimulant users misperceive time and distance.

Example: to the subject, time seems to be speeded up, so that 2 hours may seem like two minutes.

Persons under the influence of CNS Stimulants become easily confused, and lose the ability to concentrate or to think clearly for any length of time.

This lack of concentration makes it very difficult for the user to perform divided attention tests successfully.

Solicit participants' questions and comments concerning possible effects of CNS Stimulants.

Session 10 - Central Nervous System Stimulants

Cocaine Time Factors

<ul style="list-style-type: none"> • Smoked (freebase) • Virtually immediate effects • Very intense “rush” • Effects last 5-10 minutes 	<ul style="list-style-type: none"> • Injected • Effects are felt within seconds • Very intense “rush” • Effects generally last 5-15 minutes
---	--







Drug Recognition Expert Course 10-18

C. Onset and Duration of Effects

The onset and duration of effects are quite different for Cocaine as compared to Amphetamines.

- Generally speaking, Cocaine's effects are much briefer than are Amphetamine's.
- The time parameters of Cocaine vary with the method of ingestion.

Note: Subjects that have ingested both Cocaine and Alcohol will produce a metabolite known as “Cocaethylene”; which has a half-life of four hours possibly extending the effects of Cocaine longer than the normal.

Cocaine: Smoked

When Cocaine is smoked, or “freebased,” the drug goes immediately to the lungs, and is absorbed into the blood stream very rapidly.

- The smoker begins to feel the effects of the Cocaine virtually immediately.
- Note: Injection sites will be discussed in Session 17 (Narcotic Analgesics).
- The “rush” or euphoria is reported to be very intense.
- However, the euphoric effect only last 5 – 10 minutes after the Cocaine is smoked.

Cocaine: Injected

When Cocaine is injected, the drug is passed directly to the blood stream, where it is carried swiftly to the brain.

- The effects are felt within seconds.
- The onset of effects is very intense.
- Note: Injection sites will be discussed in Narcotic Analgesics
- The effects generally last 5 - 15 minutes.

Source: “Disposition of Toxic Drugs and Chemicals in Man”, 9th Edition, R. Baselt

Session 10 - Central Nervous System Stimulants

Cocaine Time Factors (Cont.)

- **Snorted (insufflated)**
 - Effects are felt within 30 seconds
 - Intense “rush”
 - Effects last 30-90 minutes



Drug Recognition Expert Course

10-19

Cocaine: Snorted

When Cocaine is snorted (insufflated), the onset of effects is not quite as rapid as with smoking or injecting.

Snorting remains a very popular method of ingesting Cocaine.

- The user typically feels the onset of effects within 30 seconds after snorting the drug.
- Although the “rush” occurs, it is not quite as intense as it is when the Cocaine is smoked or injected.
- The effects from snorting usually last from 30 – 90 minutes.

Session 10 - Central Nervous System Stimulants

Cocaine Time Factors (Cont.)

- **Oral Ingestion**
 - **Effects last 45-120 minutes**
 - **Effects begin within 3-5 minutes**
 - **Effects are less intense**



Drug Recognition Expert Course 10-20

Cocaine: Oral Ingestion

- Oral ingestion of Cocaine usually is the least preferred method.
- The effects of Cocaine taken orally may last from 45 – 120 minutes.
- The user generally does not begin to feel the effects for 3 – 5 minutes.
- The effects are not as intense as they are with other methods of ingestion.
- However, the effects may last 15 – 30 minutes longer than with other methods.

With all methods of ingestion, the duration of Cocaine's effects tend to be briefer than the effects of most other drugs.

It is very possible that a Cocaine user may not be examined by a DRE until at least 30 minutes following the use of the drug. Often, much more time will have elapsed. For this reason, Cocaine use may be difficult to ascertain from the drug evaluation.

- As the effects wear off, it becomes very difficult to observe evidence of impairment.
- If the subject is not evaluated by a DRE fairly soon after the subject has been apprehended, the DRE may not uncover evidence of the CNS Stimulant.

Session 10 - Central Nervous System Stimulants

Methamphetamine Time Factors

- Effects are felt within seconds
- “Rush” is very intense for 5-30 seconds
- Effects can last up to 12 hours




Drug Recognition Expert Course 10-21

Methamphetamine: Injected

When Methamphetamine is injected, the initial effects are very similar to the injection of Cocaine.

- The user begins to feel the effects within a few seconds.
- The “rush” is very intense, and lasts at a high level of intensity for 5 – 30 seconds.
- Unlike Cocaine, Methamphetamine’s effects are longer and may last up to 12 hours after injection.

Methamphetamine: Smoked

When Methamphetamine is smoked, the rush is very intense, and the effects are long lasting.

The user stays “high” for 4 – 8 hours with residual effects lasting up to 12 hours.

Source: *Drugs and Human Performance Fact Sheets, NHTSA (2004).*

Methamphetamine: Snorted

When Methamphetamine is snorted or taken orally, the onset takes longer, the rush is much less intense, and the effects are much briefer.

Methamphetamine: Orally

When taken orally the onset of effects is delayed, the rush is much less intense and the effects last longer.

Solicit participants’ comments and questions concerning time parameters of Cocaine and Methamphetamine.

Session 10 - Central Nervous System Stimulants

Overdose Signs and Symptoms

Cocaine Psychosis or Cocaine Delirium:

- Convulsions, faint, or pass into a coma
- Heartbeat (pulse) increases
- Hallucinations may occur




Drug Recognition Expert Course 10-22

D. Overdose Signs and Symptoms

Overdose of Cocaine or Amphetamines can cause the pleasurable effects to turn into panic and often violent behavior. If the overdose is caused by Cocaine, it is commonly referred to as Cocaine Psychosis or Cocaine Delirium.

Write on dry erase board or flip-chart “Cocaine Psychosis or Cocaine Delirium.”

- Subject may suffer convulsions and faint or pass into a coma.
- Heartbeat (pulse) will increase, possibly dramatically.
- Hallucinations may occur.
Example: The feeling that bugs are crawling under the skin is also known as “Coke Bugs.” The medical term for this condition is formication.

Session 10 - Central Nervous System Stimulants

Death from Sudden Respiratory Failure

- Death can occur from sudden respiratory failure, or from heart arrhythmia, leading to cardiac arrest



Drug Recognition Expert Course 10-23

- Death can occur from sudden respiratory failure, or from heart arrhythmia, leading to cardiac arrest.
- Another danger is that subjects may attempt to treat CNS Stimulant overdoses with Barbiturates, possibly leading to overdose of CNS Depressants.

Note: It is important that officers are aware of this to avoid custody deaths.

Solicit participants' comments and questions concerning overdoses of CNS Stimulants.

Session 10 - Central Nervous System Stimulants

Evaluation of Subjects Under the Influence of CNS Stimulants

- HGN or VGN - None
- Lack of Convergence - None
- Impaired performance should be evident on Modified Romberg Balance, Walk and Turn, One Leg Stand and Finger to Nose




Drug Recognition Expert Course

10-24

E. Expected Results of the Evaluation

Observable Evidence of Impairment

- Horizontal Gaze Nystagmus will not be present with subjects under the influence of CNS Stimulants.
- Vertical Gaze Nystagmus will not be present.
- Lack of Convergence will not be evident.
- Performance on Modified Romberg Balance should be impaired.

CNS Stimulants impair the user's perception of time, so that the subject's estimate of 30 seconds, on the Modified Romberg Balance test, may be sped up.

- Performance on Walk and Turn may be impaired due to the subject's hyperactivity and inability to concentrate. Example: subject may start too soon on the Walk and Turn, and may tend to walk fast, thus losing balance or missing heel-to-toe.
- Performance on the One Leg Stand may be impaired due to the subject's hyperactivity. Example: subject may also count very rapidly on the One Leg Stand test.
- Performance on the Finger to Nose test should be impaired. His or her finger movements may be abrupt, jerky and inaccurate.

Session 10 - Central Nervous System Stimulants

Evaluation of Subjects Under the Influence of CNS Stimulants (Cont.)

Vital Signs:

- Blood pressure - Up
- Pulse - Up
- Body temperature - Up

Muscle Tone - Rigid



Drug Recognition Expert Course 10-25

Vital Signs

- Blood pressure will generally be elevated.
- Pulse generally will be increased.
- Body temperature generally will be elevated.

Muscle Tone

- Muscle tone will be Rigid.

Session 10 - Central Nervous System Stimulants

Evaluation of Subjects Under the Influence of CNS Stimulants (Cont.)

Dark Room Examinations:

- Pupils - Dilated (Mydriasis)
- Pupillary reaction to light - Slow



Drug Recognition Expert Course 10-26

Dark Room Examinations

- Pupils generally will be dilated.
- The technical term for “dilated pupils” is Mydriasis.
- Pupil reaction to light generally will be slow.

Session 10 - Central Nervous System Stimulants

Evaluation of Subjects Under the Influence of CNS Stimulants (Cont.)

General Indicators:

- Anxiety
- Body tremors
- Bruxism
- Dry mouth
- Euphoria
- Excited
- Exaggerated reflexes
- Eyelid and leg tremors
- Increased alertness
- Insomnia
- Irritability
- Restlessness
- Ridged muscle tone
- Talkative
- Redness to nasal area
- Runny nose




Drug Recognition Expert Course 10-27

General Indicators

- Anxiety
- Body tremors
- Bruxism (grinding teeth)
- Dry mouth
- Euphoria
- Excited
- Exaggerated reflexes
- Eyelid and leg tremors
- Increased alertness
- Insomnia
- Irritability
- Restlessness
- Rigid muscle tone
- Talkative
- Redness to nasal area
- Runny nose

Note: Indicators associated with the nasal area may be evident if the subject is in the habit of snorting Cocaine.

Session 10 - Central Nervous System Stimulants

CNS Stimulant Symptomatology Chart


HGN	None
VGN	None
Lack of Convergence	None
Pupil Size	Dilated
Reaction to Light	Slow
Pulse Rate	Up
Blood Pressure	Up
Temperature	Up
Muscle Tone	Normal



Drug Recognition Expert Course 10-28

Session 10 - Central Nervous System Stimulants

CNS Stimulants



Drug Recognition Expert Course

1-29

Click video to start movie.

VIDEO DEMONSTRATION

***Show video example of subject under the influence of a CNS Stimulants.
(Approximately 15 minutes).***

Session 10 - Central Nervous System Stimulants

Drug Evaluation and Classification

Exemplar Demonstrations




Drug Recognition Expert Course 10-30

F. Drug Evaluation and Classification Exemplar Demonstrations

Refer students to the exemplars found at the end of Session 10 of their participant manuals.

Point out that the one-page narrative in the example exemplars are not to be construed as the recommended or approved narrative report. The actual narrative report submitted by DREs will be more detailed.

Relate the items on the exemplars to the CNS Stimulants Symptomatology Chart.

Relate behavior and observations to the CNS Stimulant Symptomatology Chart.

Solicit students' questions or suggestions concerning Expected Results of the Evaluation of subjects under the influence of Stimulants.

Session 10 - Central Nervous System Stimulants

QUESTIONS?



Drug Recognition Expert Course 10-31

Solicit participants' questions or comments concerning expected results of the evaluation of subjects under the influence of CNS Stimulants.

Session 10 - Central Nervous System Stimulants

Topics for Study




Drug Recognition Expert Course 10-32

TOPICS FOR STUDY / ANSWERS

1. Why is it sometimes difficult for a DRE to obtain evidence of CNS Stimulant influence when examining a cocaine user?

ANSWER: Cocaine, in general, is a fairly fast-acting, but short duration drug. When smoked, the user feels a “rush,” or very intense euphoria, but the effects only continue for 5 – 10 minutes. When injected, the effects begin quickly but generally only last 5 – 15 minutes.

2. What kinds of illicitly manufactured Amphetamines are most commonly abused?

ANSWER: The two most commonly illicitly abused amphetamines are Methamphetamine and Amphetamine Sulfate.

3. Name two CNS Stimulants other than Cocaine or the Amphetamine compounds.

ANSWER: Ritalin and Ephedrine, Methcathinone or Cathinone

4. How do CNS Stimulants usually affect the blood pressure and pulse rate?

ANSWER: CNS Stimulants usually elevate both blood pressure and pulse rate.

5. True or False: A person under the influence of a CNS Stimulant alone usually will not exhibit Horizontal Gaze Nystagmus?








ANSWER: True

6. What is “bruxism”?

ANSWER: Grinding the teeth. This behavior is often seen in persons who are under the influence of Cocaine or other CNS Stimulants.

DRUG INFLUENCE EVALUATION

Session X - #1

Evaluator Sgt. Ross Batson, Arkansas H.P.		DRE # 2189	Rolling Log # 12-02-009	Session X - #1	
Recorder/Witness Pam Mays, Arkansas CJJ		Crash: <input checked="" type="checkbox"/> None <input type="checkbox"/> Fatal <input type="checkbox"/> Injury <input type="checkbox"/> Property		Case # 12-0077890	
Arrestee's Name (Last, First, Middle) Hedlund, James R.		Date of Birth 7/10/63	Sex M	Race W	Arresting Officer (Name, ID#) TFC Jeff Hust, Arkansas S.P. #9896
Date Examined / Time / Location 02-08-12, 2230 Pulaski Co. Jail		Breath Results: Results: 0.00		Test Refused <input type="checkbox"/> Instrument #: 600458	Chemical Test: Urine <input checked="" type="checkbox"/> Blood <input type="checkbox"/> Test or tests refused <input type="checkbox"/>
Miranda Warning Given Given By: TFC Hust	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? Candy bar About 6 pm	What have you been drinking? Nothing	How much?	Time of last drink? N/A
Time now/ Actual 8 pm/10:45 pm	When did you last sleep? How long Last night / 2 - 3 hours	Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Attitude: Talkative, Cooperative		Coordination: Poor, Quick, Unsteady	
Speech: Quick, Slurred at times		Breath Odor: Normal		Face: Normal	
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right	Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Eyelids <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Droopy
Pulse and time 1. <u>102</u> / <u>2240</u> 2. <u>100</u> / <u>2253</u> 3. <u>100</u> / <u>2315</u>	HGN Lack of Smooth Pursuit Maximum Deviation Angle of Onset	Left Eye No	Right Eye No	Convergence 	24 ONE LEG STAND 22 
Modified Romberg Balance 	Walk and Turn test 	Cannot keep balance <input checked="" type="checkbox"/> Starts too soon <input checked="" type="checkbox"/> Stops walking Misses heel-toe Steps off line Raises arms Actual steps taken		1st Nine 2nd Nine <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> 9 9	L R <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Sways while balancing <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Uses arms to balance <input checked="" type="checkbox"/> <input type="checkbox"/> Hopping <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Puts foot down Counted quickly
Internal clock 22 estimated as 30 seconds	Describe Turn Quick, spun around	Cannot do test (explain) N/A		Type of footwear: Boots	
Draw lines to spots touched 		PUPIL SIZE	Room light 2.5 - 5.0	Darkness 5.0 - 8.5	Direct 2.0 - 4.5
Quick movements		Left Eye	6.0	9.0	5.5
		Right Eye	6.0	9.0	5.5
		REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		REACTION TO LIGHT: Slow	
		RIGHT ARM 		LEFT ARM 	
		Nothing observed			
Blood pressure 142/96	Temperature 99.8	Muscle tone: <input type="checkbox"/> Normal <input type="checkbox"/> Flaccid <input checked="" type="checkbox"/> Rigid		Comments:	
What drugs or medications have you been using? "Nothing"		How much? N/A	Time of use? N/A	Where were the drugs used? (Location) N/A	
Date / Time of arrest: 02-08-12	Time DRE was notified: 2205	Evaluation start time: 2230	Evaluation completion time: 2335	Precinct/Station: North Precinct	
Officer's Signature:		DRE # 2189	Reviewed/approved by / date:		
Opinion of Evaluator:		<input type="checkbox"/> Rule Out	<input type="checkbox"/> Alcohol	<input checked="" type="checkbox"/> CNS Stimulant	<input type="checkbox"/> Dissociative Anesthetic
		<input type="checkbox"/> Medical	<input type="checkbox"/> CNS Depressant	<input type="checkbox"/> Hallucinogen	<input type="checkbox"/> Narcotic Analgesic
				<input type="checkbox"/> Inhalant	<input type="checkbox"/> Cannabis

DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: Hedlund, James R.

1. **LOCATION:** The evaluation of James Hedlund was conducted at the Pulaski County Jail.
2. **WITNESSES:** Arresting Officer, TPC Jeff Hust, Arkansas State Police and Pam Mays of the Arkansas Criminal Justice Institute.
3. **BREATH ALCOHOL TEST:** Hedlund's breath test was a 0.00%.
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** I was contacted by Trooper Hust requesting a drug evaluation. Writer contacted Trooper Hust at the County Jail where it was determined that he had stopped the suspect for driving 100 mph and for driving without headlights on I-30 East. The suspect was excited, talkative and very restless. He performed poorly on the roadside SFST's and was arrested for DUI.
5. **INITIAL OBSERVATION OF SUSPECT:** I first observed the suspect in the interview room with Trooper Hust. The suspect was rocking back in forth in his chair and could not remain still. His speech was fast and his reflexes were quick and exaggerated.
6. **MEDICAL PROBLEMS AND TREATMENT:** None observed and none stated.
7. **PSYCHOPHYSICAL TESTS:** Modified Romberg Balance: Suspect swayed approximately 3" front to back and estimated 30 seconds in 22 seconds. Walk and Turn: Suspect started too soon, lost his balance twice during the instructions, raised his arms for balance, made an abrupt quick turn, and missed heel to toe twice on the second nine steps. One Leg Stand: Suspect swayed, raised his arms, hopped and put his foot down once standing on the left foot and once while standing on the right foot. Finger to Nose: Suspect missed the tip of his nose on four of the six attempts.
8. **CLINICAL INDICATORS:** The suspect's pulse, blood pressure and temperature were elevated and above the DRE average ranges. His pupils were dilated in all three lighting levels and they reacted slowly to light.
9. **SIGNS OF INGESTION:** White powder residue was located in the suspect's left nostril.
10. **SUSPECT'S STATEMENTS:** The suspect denied using any drugs.
11. **DRE'S OPINION:** In my opinion Hedlund is under the influence of a **CNS Stimulant** and unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** The suspect provided a urine sample.
13. **MISCELLANEOUS:**

DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: Kohlhepp, Kim J.

1. **LOCATION:** The evaluation was conducted at the Oklahoma County Jail.
2. **WITNESSES:** The evaluation was witnessed by the arresting officer; Officer Kirk Dowell of the OKC PD and by DRE instructor Officer Lance Arnold of the Norman P.D.
3. **BREATH ALCOHOL TEST:** Kohlhepp's breath test was 0.00%.
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** The writer was contacted by Officer Dowell requesting a drug evaluation. After arriving at the County Jail, Officer Dowell reported that he had stopped the suspect for driving 65 mph in a 30 mph zone and for failing to stop at a traffic signal. The suspect was very talkative and restless. She was unable to perform the SFST's as directed and was arrested for DUI.
5. **INITIAL OBSERVATION OF SUSPECT:** Writer first observed the suspect in the interview room standing next to Officer Dowell. She was very fidgety and could not stand still. When told to sit down she would sit for a few seconds and then quickly get back up.
6. **MEDICAL PROBLEMS AND TREATMENT:** None observed and none stated.
7. **PSYCHOPHYSICAL TESTS:** Modified Romberg Balance: Suspect swayed approximately 2" side to side and estimated 30 seconds in 20 seconds. Walk & Turn: Suspect stepped off the line twice, raised her arms for balance and turned using an abrupt swivel-like movement. One Leg Stand: Suspect swayed, raised her arms, hopped once when standing on the left foot, and put her foot down one time while standing on each foot. Finger to Nose: Suspect missed the tip of her nose on each attempt and had eyelid tremors.
8. **CLINICAL INDICATORS:** The suspect's pulse, blood pressure and temperature were above the DRE average ranges. Her pupils were dilated in all three lighting conditions.
9. **SIGNS OF INGESTION:** The suspect's nostrils were red and ulcerated.
10. **SUSPECT'S STATEMENTS:** She denied using drugs, stating "I don't use anymore."
11. **DRE'S OPINION:** In my opinion Kohlhepp is under the influence of a **CNS Stimulant** and unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** The suspect provided a blood sample.
13. **MISCELLANEOUS:** There was an outstanding warrant for the suspect for failure to appear on a charge of possession of methamphetamine.

Session 11

Practice: Eye Examinations



Session 11 - Practice: Eye Examinations

Learning Objectives

- **Conduct examinations of pupil size and reaction to light, under both lighted and darkened room conditions**
- **Describe the eye examination procedures**
- **Document the results of the eye examinations**




Drug Recognition Expert Course
11-2

Briefly review the objectives, content and activities of this session.

Upon successfully completing this session the participant will be able to:

- Conduct examinations of pupil size and reaction to light under both lighted and darkened room conditions.
- Describe the eye examination procedures.
- Document the results of the eye examinations.

CONTENT SEGMENTS

- A. Procedures for this Session
- B. Room Light Examinations
- C. Dark Room Examinations
- D. Session Wrap-Up

LEARNING ACTIVITIES

- Instructor Led Presentations
- Participants' Hands-On Practice
- Instructor Led Coaching
- Participant Led Coaching

Session 11 - Practice: Eye Examinations

Procedures

- **Team Assignments**
- **Member(s) will help coach and critique the participant who is conducting the examinations**



Drug Recognition Expert Course 11-3

A. Procedures for this Session

Team Assignments

- Participants will work in three or four member teams.
- Make team assignments.
- At any given time, one member of the team will be engaged in conducting and recording eye examinations of another member.
- The remaining member(s) will help coach and critique the participant who is conducting the examinations.

Emphasize that participants can help each other learn by pointing out errors of omission or commission.

Session 11 - Practice: Eye Examinations

Team Practice

- Take turns serving as test administrator, test subject and coach
- Practice under lighted room conditions
- Practice under darkened room conditions
- Record estimations using Eye Examinations Data Sheet




Drug Recognition Expert Course
11-4

Team Practice

Participants will take turns serving as test administrator, test subject and coach.

Teams initially will practice under lighted room conditions.

- Check pupil size under normal room light.
- Check reaction to light and pupil size using a penlight in a lighted room.

Clarification: participants will shine a penlight directly into the subject's eye. Demonstrate this, using a participant subject.

Teams subsequently will practice under darkened room conditions.

- Check pupil size in near total darkness.
- Check reaction to light and pupil size under direct light.
- Participants will record their estimations using Eye Examinations Data Sheet. There are copies of the Eye Examination Data Sheet in the Participant's Manual.

Solicit participants' questions concerning procedures for this practice session.

Session 11 - Practice: Eye Examinations

Room Light Examinations

- Pupil size estimation, under room light
- Pupil reaction and size estimation, under direct light




Drug Recognition Expert Course 11-5

B. Room Light Examinations

Pupil Size Estimation

- Pupil size estimation, under room light.
- Pupil reaction and size estimation, under direct light.

Monitor teams and coach participants as necessary and appropriate.

When the first participant completes the two estimations, have the team members exchange roles. Continue this process.

Sequence of roles should be as follows:

- Test Administrator
- Test Subject
- Coach
- Test Administrator (continue cycle)

Terminate this segment after 20 minutes, or after each participant has twice served as a test administrator (whichever comes first).

Offer appropriate comments and observations about the participant's performance.

Session 11 - Practice: Eye Examinations

Dark Room Examinations

- Pupil size estimation, under near total darkness
- Pupil reaction and size estimation, under direct light
- Allow participants approximately 90 seconds for the eyes to adapt to the darkened conditions




Drug Recognition Expert Course 11-6

C. Dark Room Examinations

Pupil Size Estimation

- Pupil size estimation, under near total darkness.
- Pupil reaction and size estimation, under direct light.

Allow participants approximately 90 seconds for the eyes to adapt to the darkened conditions.

Monitor teams and coach participants as necessary and appropriate. When the first participant completes the two checks, have the team members exchange roles. Continue this process.

Sequence of roles should be as follows:

- Test Administrator
- Test Subject
- Coach
- Test Administrator (continue cycle)

Terminate this segment after 25 minutes, or after each participant has twice served as a test administrator (whichever comes first).

Offer appropriate comments and observations about the participants' performance.

Session 11 - Practice: Eye Examinations

QUESTIONS?



Drug Recognition Expert Course 11-7

D. Session Wrap-Up

Solicit participants' comments concerning the practice session.

Session 12

Alcohol Workshop



Session 12 - Alcohol Workshop

Learning Objectives

- **Correctly administer the preliminary examinations and psychophysical tests used in the drug influence evaluation procedure**
- **Observe and record the subject's performance on the preliminary examinations and psychophysical tests**
- **Determine the level of impairment based on the results of the subject's preliminary examinations and psychophysical tests**




Drug Recognition Expert Course
12-2

Briefly review the objectives, content and activities of this session.

Upon successfully completing this session the participant will be able to:

- Correctly administer the preliminary examinations and psychophysical tests used in the drug influence evaluation procedure.
- Observe and record the subject's performance on the preliminary examinations and psychophysical tests.
- Determine the level of impairment based on the results of the subject's preliminary examinations and psychophysical tests.

CONTENT SEGMENTS

- A. Procedures
- B. Hands-On Practice
- C. Session Wrap-Up

LEARNING ACTIVITIES

- Instructor Led Presentations
- Participant Led Practice
- Instructor Discussion

Session 12 - Alcohol Workshop

Examinations and Tests Conducted

- Pupil Size (Room Light)
- Horizontal Gaze Nystagmus
- Vertical Gaze Nystagmus
- Lack of Convergence
- Modified Romberg Balance
- Walk and Turn
- One Leg Stand (Both Legs)
- Finger to Nose
- Pulse Rate




Drug Recognition Expert Course 12-3

A. Procedures

Participants will work in three or four member teams during this session.

Make team assignments.

Each team will administer a battery of tests to each volunteer.

The preliminary examinations and psychophysical tests include:

- Pupil Size Estimation (Room Light)
- Horizontal Gaze Nystagmus
- Vertical Gaze Nystagmus
- Lack of Convergence
- Modified Romberg Balance
- Walk and Turn
- One Leg Stand (both legs)
- Finger to Nose
- Pulse Rate

Session 12 - Alcohol Workshop

Examinations and Tests Conducted (Cont.)

- Pupil Size (Room Light)
- Horizontal Gaze Nystagmus
- Vertical Gaze Nystagmus
- Lack of Convergence
- Modified Romberg Balance
- Walk and Turn
- One Leg Stand (Both Legs)
- Finger to Nose
- Pulse Rate



Drug Recognition Expert Course 12-4

Point out that for the drug influence evaluation, it is helpful to estimate angle of onset for HGN, and to relate it to BAC.

Results/observations of all tests will be recorded on the Drug Evaluation Report form.

Point out that copies of the report form are in the Participant's Manual.

Each team will need one report form for each volunteer.

Session 12 - Alcohol Workshop

Team Member Duties

- One team member will administer the tests to the volunteer
- One team member will record the results on the report form
- The other team member(s) will assist the test administrator in observing the volunteer's performance on the tests




Drug Recognition Expert Course
12-5

For each volunteer, team members should perform the following duties:

- ***One team member will administer the tests to the volunteer.***
- ***One team member will record the results on the report form.***
- ***The other team member(s) will assist the test administrator in observing the volunteer's performance on the tests.***

Emphasize that team members will take turns performing the various duties, as they deal with the different volunteers.

Some volunteers will have BACs above 0.10, others will have lower BACs.

The following safety precautions will be strictly enforced:

- No weapons will be present.
- Volunteers will not be left unattended at any time.

Solicit participant's questions concerning the procedures for the Alcohol Workshop.

Session 12 - Alcohol Workshop

Hands-On Practice

Drug Recognition Expert Course

12-6

B. Hands-On Practice

Test Administration

Test recording:

- ***Monitor teams as they test the volunteers.***
- ***Make sure that each participant takes at least one turn as a test administrator.***
- ***Coach participants, as necessary, to improve their performance as test administrators.***
- ***Terminate the hands on practice after 75 minutes, or after each team has tested 5 volunteers (whichever occurs first).***

Session 12 - Alcohol Workshop

Wrap-Up

- **Team Assessments**
- **Feedback**
- **Discussion**




Drug Recognition Expert Course 12-7

C. Session Wrap-Up

Record teams' assessments of each volunteer's probable BAC status on the dry erase board or flip-chart (see next page for a sample dry erase board array).

Feedback of teams' assessments:

Ask each team briefly to describe the evidence that led the members to their conclusions about a particular volunteer's BAC.

Record each volunteer's actual BAC on the dry erase board array.

Feedback of volunteer's BACs:

Make appropriate comments concerning teams' assessment of the volunteers' BACs. These comments should take into account such factors as absorption and elimination rates, differences in tolerance to alcohol, volunteers' medical conditions, etc.

Discussion

Session 12 - Alcohol Workshop

Sample Dry Erase Board Array

TEAMS' ESTIMATES OF BAC (TABLE ENTRIES REPRESENT TEAMS' "VOTES")

Volunteer	.05 or less	.06 - .07	.08 - .09	.10 - .11	.12 - .13	.14 - .15	.16 or more	Actual BAC



Drug Recognition Expert Course

12-8

Session 12 - Alcohol Workshop

QUESTIONS?





Drug Recognition Expert Course

12-9

Solicit participants' comments or questions concerning the alcohol workshop.

Session 13

Physician's Desk Reference (PDR) and Other Reference Sources



Session 13- Physician's Desk Reference (PDR) and Other Reference Sources

Learning Objectives

- Explain how the various sections of the PDR can provide information that will:
 - a) aid in the drug influence evaluation
 - b) aid in courtroom testimony
- Use the PDR in a practical exercise
- Learn about other resources available to assist DREs




Drug Recognition Expert Course 13-2

Briefly review the objectives, content and activities of this session.

Upon successfully completing the session, the participant will be able to:

- Explain how the various sections of the PDR can provide information that will:
 - a) aid in the drug influence evaluation
 - b) aid in courtroom testimony.
- Use the PDR in a practical exercise.
- Learn about other resources available to assist DREs.

CONTENT SEGMENTS

- A. Procedures
- B. Practical Exercises
- C. Other Resources Available

LEARNING ACTIVITIES

Instructor-led Presentation


Point out that the PDR has been admitted as a “learned treatise” (a book or treatise (a formal book) regarded as authoritative, generally of long-accepted value within a profession or field of study) in court in previous court cases. (Source: Federal Rule of Evidence 803(18) “Statements in Learned Treatises, Periodicals or Pamphlets”)

Point out that we will use the PDR for prescription drugs.

Session 13- Physician's Desk Reference (PDR) and Other Reference Sources

Physician's Desk Reference (PDR)

- **Published annually**
- **Versions:**
 - **Prescription**
 - **Non-prescription**
 - **Ophthalmology**






Drug Recognition Expert Course 13-3

A. Procedures

Due to the unique nature of this session, instructors teaching this session should strive to develop innovative and interactive creative learning activities.

PDR: Physician's Desk Reference

PDR is published annually.

Many versions are published:

- PDR for prescription drugs
- PDR for non-prescription drugs
- PDR for ophthalmology
- PDR Consumer Guide to Prescription Drug
- PDR for Herbal Medicines
- PDR for Nutritional Supplement
- PDR Nurse's Drug Handbook

Exhibit copy of a PDR.

PDR supplements are published periodically as new products are introduced during the year.

Function of the publisher is compilation, organization and distribution of information.

Product descriptions are prepared by the manufacturer, and edited and approved by their respective medical directors.

Additional information on the various drugs can be obtained from the manufacturer.

Session 13- Physician's Desk Reference (PDR) and Other Reference Sources

Sections of a Physician's Desk Reference

Section 1:

- **Manufacturers' index**

Section 2:

- **Product name index and discontinued products**

Section 3:

- **Product category index**




Drug Recognition Expert Course 13-4

Sections of a PDR

Point out that the sections are color coded for easy use.

- Section 1
 - Manufacturers Index
List of manufacturers (with phone numbers) who have provided prescribing information.
- Section 2
 - Product Name Index and Discontinued Products
Alphabetical listing of products available and a listing of discontinued products. Newer editions of the PDR will have a merging of Sections 2 and 4.
- Section 3
 - Product Category Index
Products listed according to appropriate category.

Session 13- Physician's Desk Reference (PDR) and Other Reference Sources

Sections of a Physician's Desk Reference (Cont.)

Section 4:

- **Generic and chemical name index**

Section 5:

- **Product identification section**

Section 6:

- **Product information section**




Drug Recognition Expert Course 13-5

- Section 4
 - Generic and Chemical Name Index
Products listed under generic and chemical name headings according to the principal ingredient(s).
- Section 5
 - Product Identification Section

Point out that this section contains actual size, full color reproductions.

- Section 6
 - Product Information Section

Point out that this section describes composition, action, uses, administration, dosage, contraindications, precautions, side effects, the form in which supplied and other information concerning use.

It also includes common names, generic compositions, or chemical names.

Session 13- Physician's Desk Reference (PDR) and Other Reference Sources

Sections of a Physician's Desk Reference (Cont.)

- Section 7:**
 - **Diagnostic product information**
- Section 8:**
 - **Poison control centers**
- Section 9:**
 - **Guide to management of drug overdose**




Drug Recognition Expert Course 13-6

- Section 7
 - Diagnostic Product Information
Diagnostic product descriptions.
- Section 8
 - Poison Control Centers
List of centers and emergency telephone numbers.
- Section 9
 - Guide to Management of Drug Overdose
Information concerning drug over dosage.

Use of the PDR in DEC Program

To identify prescription drugs.

This information is contained in the product identification section.

To identify the effects of prescription drugs for comparison with observed effects.

This information is contained in the product information section.

How to use the PDR

Identification of an unknown product.

Demonstrate how to identify a tablet, capsule, etc. using the product identification section.

Identification of drug pharmacology.

Demonstrate how to use the product identification section.

Session 13- Physician's Desk Reference (PDR) and Other Reference Sources

Product Information Section Example

MS Contin tablets (Morphine Sulfate)

- Description
- Clinical pharmacology
- Indications and usage
- Warnings
- Precautions
- Dosage and administration
- Drug abuse and dependence
- How supplied




Drug Recognition Expert Course 13-7

Example: MS Contin tablets (Morphine Sulfate).

Location and acquisition of agency's PDR(s)

Point out that PDRs can be obtained from physicians, hospitals, etc. It is not essential to have the current version for typical enforcement.

Solicit participants' questions and comments concerning procedures for using a PDR.

B. Practical Exercise

Assign students to small groups and provide photographs or examples of typical prescription drugs encountered during enforcement contacts. Have the group identify the drugs and describe typical "actions" or symptoms that can be observed and documented during a drug influence evaluation.

Small group exercise.

Each group must have a PDR.

Group reports.

Session 13- Physician's Desk Reference (PDR) and Other Reference Sources

Suggested Criteria for Identifying a Non-PDR Source

- **Be less than five years old** (by copyright date)
- **Be readily available in print or online**
- **Be periodically updated**
- **Be utilized by practitioners in the scientific and healthcare fields**
- **At a minimum, contain information on a particular drug's: name, forms, actions and side effects**




Drug Recognition Expert Course 13-8

C. Other Resources

Suggested criteria to identify a non-PDR drug reference

When selecting an acceptable drug reference DRE's should consult references that meet the below criteria:

- Be less than five years old (by copyright date).
- Be readily available in print or online.
- Be periodically updated.
- Be utilized by practitioners in the scientific and healthcare fields.
- At a minimum, contain information on a particular drug's:
 - Trade (brand), generic, and alternate common names.
 - Available forms (liquid, pill, injectable, etc.).
 - Pharmacologic / therapeutic actions (as used clinically, both "on" and "off" label).
 - Adverse reactions and side effects.

The reason for this is to keep from consulting references that have become outdated and inaccurate.

Session 13- Physician's Desk Reference (PDR) and Other Reference Sources

Other Written Sources

Acceptable written examples include:

- **The Complete Guide to Prescription and Non-prescription Drugs 2012**
- **The Pill Book (currently the 15th Edition)**
- **Nursing 2013 Drug Handbook**
- **Nurse Pocket Drug Guide 2012**
- **Drug Identification Bible**



Drug Recognition Expert Course 13-9

Acceptable resources may be in-print, electronic, or a combination. Non-representative, non-ranked.

Acceptable written examples include:

- The Complete Guide to Prescription and Non-prescription Drugs 2012
- The Pill Book (currently the 15th Edition)
- Nursing 2013 Drug Handbook
- Nurse Pocket Drug Guide 2012
- Drug Identification Bible (available at: www.drugbible.com)

Session 13- Physician's Desk Reference (PDR) and Other Reference Sources

Other Written Sources (Cont.)

Acceptable written examples include:

- **Davis's Drug Guide for Nurses**
- **Tarascon Pocket Pharmacopoeia**
- **The Monthly Prescriber's Reference (MPR)**
- **Disposition of Toxic Drugs and Chemicals in Man**



Drug Recognition Expert Course 13-10

Acceptable written examples include (Cont):

- Davis's Drug Guide for Nurses
- Tarascon Pocket Pharmacopoeia (for those with some pharmacology education)
- The Monthly Prescriber's Reference (MPR)
- Disposition of Toxic Drugs and Chemicals in Man, (*Source: Randall C. Baselt. Biomedical Publications*)

Session 13- Physician's Desk Reference (PDR) and Other Reference Sources

Other Electronic Sources

Acceptable electronic examples include:

- **Drugs.com**
- **RxList.com**
- **WebMD.com/Drugs/Index-drugs.aspx**
- **Eprocrates.com**
- **iMeds – Medical Reference for Android**
- **Monthly Prescriber's Reference (MPR)**
- **PDR.net**



Drug Recognition Expert Course 13-11

Acceptable electronic examples include:

- Drugs.com
- RxList.com
- WebMD.com/Drugs/Index-drugs.aspx
- Eprocrates.com
- iMeds – Medical Reference for Android
- Monthly Prescriber's Reference (MPR)
- PDR.net

Session 13- Physician's Desk Reference (PDR) and Other Reference Sources

Other Information Sources

- **National Highway Traffic Safety Administration, Enforcement and Justice Services Division**
- **State DEC Program Coordinator**
- **The DRE Newsletter**
 Phoenix City Prosecutor's Office
 455 North 5th Street
 Suite 400 Phoenix,
 Arizona, 85004




Drug Recognition Expert Course

13-12

Other Information Sources

- National Highway Safety Administration, Enforcement and Justice Services Division.
- State Drug Evaluation and Classification (DEC) Program Coordinator.
- The DRE Newsletter. Published by the Phoenix City Prosecutor's Office, Phoenix, Arizona.
 - Website: <http://phoenix.gov/AGENCY/PHXPROS/dre.html>
 - This resource also includes past editions that are a very valuable resource for information

Session 13- Physician's Desk Reference (PDR) and Other Reference Sources

Other Information Sources

- **The National Traffic Law Center (NTLC)**
www.ndaa.org/ntlc_home.html
- **Local poison control center**
- **Medical dictionary**



Drug Recognition Expert Course 13-13

- The National Traffic Law Center (NTLC).
NTLC is part of the American Prosecutors Research Institute (APRI).
- Local Poison Control Center.
- Medical Dictionaries.

Session 13- Physician's Desk Reference (PDR) and Other Reference Sources

Other Information Sources (Cont.)

- **Drugs and Human Performance Fact Sheets**
- **Various textbooks, newspaper and magazine articles**



Drug Recognition Expert Course 13-14

- Drugs and Human Performance Fact Sheets
Produced by U.S. DOT-NHTSA, Report No. DOT 809 725, March 2004.
- Newspaper and magazine articles on drugs and drug impaired driving, including counter-culture magazines such as "High Times."
- Software programs such as Pharmacists, Body Works, Mosby's Medical Dictionary and other programs are available on disks and CDs. Various resources are available through online services and the Internet.

Point out that the IACP Drug Evaluation and Classification Program website is www.decp.org

Other texts.

Discuss some other useful and reliable texts known to you.

Session 13- Physician's Desk Reference (PDR) and Other Reference Sources

QUESTIONS?



Drug Recognition Expert Course 13-15

Solicit participants' comments or questions concerning PDR and other reference sources.

Session 14 - Hallucinogens

105 Minutes

Session 14

Hallucinogens



Drug Recognition Expert Course

Session 14 - Hallucinogens

Learning Objectives

- Explain a brief history of the Hallucinogen category of drugs
- Identify common drug names and terms associated with this category
- Identify common methods of administration for this category
- Describe the symptoms, observable signs and other effects associated with this category



Drug Recognition Expert Course 14-2

Briefly review the objectives, content and activities of this session.

Upon successfully completing this session the participant will be able to:

- Explain a brief history of the Hallucinogen category of drugs
- Identify common drug names and terms associated with this category
- Identify common methods of administration for this category
- Describe the symptoms, observable signs and other effects associated with this category

Session 14 - Hallucinogens

Learning Objectives (Cont.)

- Describe the typical time parameters, i.e. onset and duration of effects associated with this category
- List the clues that are likely to emerge when the drug influence evaluation is conducted for a person under the influence of this category of drugs
- Correctly answer the “topics for study” questions at the end of this session




Drug Recognition Expert Course 14-3

- Describe typical time parameters, i.e. onset and duration of effects, associated with this category
- List the clues that are likely to emerge when the drug influence evaluation is conducted for a person under the influence of this category of drugs
- Correctly answer the “topics for study” questions at the end of this session

CONTENT SEGMENTS

- A. Overview of the Category
- B. Possible Effects
- C. Onset and Duration Effects
- D. Overdose Signs and Symptoms
- E. Expected Results of the Evaluation
- F. Classification Exemplars

LEARNING ACTIVITIES

- Instructor-Led Presentations
- Review of Drug Evaluation and Classification Exemplars
- Reading Assignments
- Video Presentations
- Slide Presentations

Session 14 - Hallucinogens

Hallucinogens - Overview

Hallucinogens are drugs that affect a person's perceptions, sensations, thinking, self awareness and emotions





Drug Recognition Expert Course 14-4

A. Overview of the Category

Hallucinogens are drugs that affect a person's perceptions, sensations, thinking, self-awareness and emotions.

The word "Hallucinogen" means something that causes hallucinations.

Definition from The Random House College Dictionary (Revised Edition, 1980)

A hallucination is a sensory experience of something that does not exist outside the mind.

Seeing, hearing, smelling, tasting or feeling something that isn't really there.

Having distorted sensory perceptions, so that things look, sound, smell, etc. differently than they really are.

Hallucinogenic drugs usually produce what are called pseudo-hallucinations: i.e. the user typically is aware that what he or she is seeing, hearing, smelling, etc. isn't real, but is a product of the drug.

But emphasize that the fact that the user knows the hallucinations aren't real doesn't make those hallucinations any less dangerous if they occur while driving.

Session 14 - Hallucinogens

Synesthesia

A transposition of senses

- “Seeing sounds”
- “Hearing colors”






Drug Recognition Expert Course

14-5

Synesthesia

One common type of hallucination produced by these drugs is called Synesthesia, which is a sensory perception disorder, in which an input via one sense is perceived by the brain as an input via another sense. In its simplest terms, it is a transposition of senses.

Note: Synesthesia can occur naturally in a small percentage of the population, and can differ from drug induced synesthesia.

Examples: The user may “see a flash of color, or some other sight, when the telephone rings.”

- Sounds for example, may be transposed into sights.
- Sights may be transposed into odors.
- The user may “smell” a particular fragrance when he or she looks at something painted yellow.
- The illusions and distorted perceptions produced by hallucinogenic drugs may be very alarming, even terrifying.
- They may produce panic and uncontrolled excitement.

Point out that the expression “bad trip” refers principally to these panic filled reactions to Hallucinogens.

The user may be unable to cope with the terror, and may attempt to flee wildly.

A user who is emotionally or mentally unstable may become psychotic in response to this frightening experience.

Session 14 - Hallucinogens

“Flashback”

A vivid recollection of a hallucinogenic experience



Drug Recognition Expert Course

14-6

Flashback

A terrifying “bad trip” sometimes may be re-experienced as a flashback.

In simple terms, a flashback is a vivid recollection of a portion of a hallucinogenic experience.

A flashback does not occur because of a residual quantity of drug in the user’s body.

Instead, a flashback essentially is a very intense daydream.

But point out that subsequent use of the drug may precipitate a flashback, by causing the user to re-experience the frightening illusions of the previous “bad trip.”

Session 14 - Hallucinogens

Types of Flashbacks

Emotional

- **Most dangerous, feelings of panic, fear, etc., sensation of “bad trip”**

Somatic

- **Altered body sensations, tremors, weakness, dizziness, crawly, tingly feeling on the skin**

Perceptual

- **Distortions of vision, hearing, smell, taste and touch (associated with original “trip” least harmful, unless driving a motor vehicle)**



Drug Recognition Expert Course 14-7

Types of Flashback

There are **three types** of flashback:

- Emotional: feelings of panic, fear, etc; the sensations of a “bad trip.”
- Somatic: Altered body sensations, tremors, weakness, dizziness, crawly, tingly feelings on the skin.
- Perceptual: Distortions of vision, hearing, smell and/or other senses. These distortions are “re-runs” of the original “trip.”

Session 14 - Hallucinogens

Types of Flashbacks (Cont.)

Delusion

- A false belief



Illusion

- A false perception



Drug Recognition Expert Course

14-8

Delusion and Illusion

Remember that hallucinogens produce delusions, illusions, or both.

- A delusion is a false belief.

Example of a delusion: "I am an Elephant."

- An illusion is a false perception, i.e. a misrepresentation of what the senses are receiving.

Example of an illusion: "I see an Elephant."

Session 14 - Hallucinogens

Common Hallucinogens




Peyote (Mescaline)




Psilocybin (Both are natural sources)




Drug Recognition Expert Course 14-9

Because they often make the user appear to be insane, Hallucinogens sometimes are called psychotomimetic drugs.

Write “PSYCHOTOMIMETIC” on the dry erase board or flip-chart.

“Psychotomimetic” means “something that mimics psychosis.” A psychosis is a major mental disorder. It implies a loss of touch with reality.

Point out some Hallucinogens may create a psychotomimetic response in the user, meaning that they literally appear to have psychosis.

Some Hallucinogens come from natural sources, while others are synthetically manufactured.

Instructor, for your information: Other naturally occurring Hallucinogens include nutmeg, jimson weed, morning glory seeds, salvia divinorum, and bufotenine, a substance found in the glands of certain toads.

Note: Some regional or local Hallucinogens may be discussed in more detail.

Peyote, Psilocybin and Salvia Divinorum are examples of naturally occurring Hallucinogens.

Session 14 - Hallucinogens

Synthetically Manufactured Hallucinogens

- Lysergic Acid Diethylamide (LSD)
- Trimethoxyamphetamine (TMA)
- Dimethyltryptamine (DMT)
- 3,4-Methylenedioxyamphetamine (MDMA)
- 3,4-Methylenedioxyamphetamine (MDA)
- 2CB




Drug Recognition Expert Course 14-10

LSD, TMA, DMT, MDMA, MDA, and 2CB are examples of synthetically manufactured Hallucinogens.

Instructor, for your information: Drugs such as MDA, MDMA, STP, and TMA all contain amphetamine based compounds. They are for this reason sometimes called “psychedelic amphetamines.” In essence, they are high powered CNS Stimulants that cause hallucinations.

- LSD: Lysergic Acid Diethylamide.

Point out that STP is also known as DOM (2, 5-dimethoxy-4-methylamphetamine). STP is an abbreviation for “Serenity, Tranquility and Peace.”

- TMA: Trimethoxyamphetamine
- DMT: Dimethyltryptamine
- MDMA is an abbreviation for 3,4-Methylenedioxyamphetamine and is commonly referred to as “Ecstasy.” It is a hallucinogen that also acts as a stimulant. It produces an energizing effect, as well as distortions in time and perception and enhances enjoyment from tactile experiences.
- MDA is an abbreviation for 3,4-Methylenedioxyamphetamine. It is normally produced as a clear liquid, or as a white powder in capsule or tablet form.
- 2CB (4-Bromo-2, 5-Dimethoxyphenethylamine) is a white powder usually found in pressed tablets or gel caps. It is considered a synthetic psychedelic amphetamine. (DEA, Feb. 2011)

Session 14 - Hallucinogens

Peyote



Active Ingredient: Mescaline



Drug Recognition Expert Course 14-11

Peyote is a small, spineless cactus.

The active, hallucinogenic ingredient in peyote is Mescaline.

Mescaline is a chemical relative of adrenaline. Effects may be similar to those that would result from a massive rush of adrenalin.

Mescaline was first isolated from Peyote in 1856. It was named after the Mescalero Apaches.

Peyote is used legally in religious ceremonies of the Native American Church.

Session 14 - Hallucinogens

Psilocybin



Found in a number of different species of mushrooms of the genus Psilocybe.



Drug Recognition Expert Course 14-12

Psilocybin is a drug found in a number of different species of mushrooms of the genus Psilocybe.

There are over 185 known species of mushrooms that contain psilocybin and psilocin.

Source: Drug Identification Bible, 2012 Edition.

These mushrooms also have been used in Native American religious ceremonies for thousands of years.

An unstable derivative of Psilocybin, called Psilocin, is also found in these mushrooms and also has hallucinogenic properties.

Psilocybin is chemically very similar to serotonin, a neurotransmitter that is found in the brain.

The effects of psilocybin may be similar to what would happen if the brain were suddenly flooded with Serotonin.

If available, show slides of Psilocybin Mushrooms.

Session 14 - Hallucinogens

Salvia Divinorum



The image displays the Salvia Divinorum plant in two photographs at the top. Below the plants are three images of commercial products: three green packets labeled 'SALVIA DIVINORUM' and a clear plastic bag labeled 'Salvia Divinorum' containing dried plant material. In the bottom left corner is the logo for the International Association of Chiefs of Police (IACP), and in the bottom right corner is the logo for the National Highway Traffic Safety Administration (NHTSA).

Drug Recognition Expert Course

14-13

Salvia Divinorum, also known as *S. divinorum* or Salvia, is a naturally occurring Hallucinogen.

Salvia divinorum is a perennial herb in the mint family native to certain areas of Mexico. The plant, which can grow to over three feet in height, has large green leaves, hollow square stems and white flowers with purple calyces, can also be grown successfully outside of this region.

Salvia divinorum has been used by the Mazatec Indians for its ritual divination and healing. The active constituent of Salvia divinorum has been identified as Salvinorin A. It was not until August 2002 that researchers discovered that Salvia divinorum acts at the kappa opiate receptor (KOR) site, where much of human reception is regulated.

According to a National Survey on Drug Use and Health Report published by SAMHSA in February 2008, it is estimated that 1.8 million persons aged 12 or older used Salvia divinorum in their lifetime.

Session 14 - Hallucinogens

Salvia Divinorum (Cont.)

Effects of Salvia Divinorum include:

- Intense hallucinations
- Feelings of floating through space or flying
- Twisting and spinning

Physical effects include:

• Slurred speech	• Dizziness
• Confused sentence patterns	• Nausea
• Lack of coordination	• Chills




Drug Recognition Expert Course 14-14

There are several methods of ingesting Salvia with varying durations of hallucinogenic effects:

- Dried leaves of Salvia can be smoked like marijuana, in a bong, pipe or as a joint, with the effects lasting up to 15-30 minutes.
- Fresh leaves can be chewed as a quid. The leaves of Salvia produce extractions of Salvinorin A before the leaves are removed from the mouth. Effects from chewing Salvia can last up to one hour.
- Salvinorin A can also be vaporized and inhaled by heating the leaves in a pipe of tin foil and the vapors inhaled through a glass pipe.

Effects of Salvia Divinorum include: intense hallucinations; feelings of floating through space or flying; twisting and spinning. Physical effects include dizziness; nausea; lack of coordination; slurred speech, confused sentence patterns; and chills.


Some common street names for Salvia Divinorum include: Salvia, Sally D, Magic Mint, Maria Pastora, and Diviner's Sage.

Salvia is not listed under the Controlled Substance Act (CSA) or approved for medical use.

Source: DEA Office of National Control Policy Bulletin, November 2008.

Session 14 - Hallucinogens

LSD



LSD derived from Ergot, a Fungus




Drug Recognition Expert Course 14-15

LSD is perhaps the most famous of the synthetically manufactured Hallucinogens.

If available, show slides of various forms of LSD.

- “LSD” is an abbreviation of Lysergic Acid Diethylamide.

It was first produced in 1938, although its hallucinogenic properties were not discovered until 1943.

- LSD was used in psychotherapy during the 1940’s and early 1950’s.

Example: it was occasionally used in the treatment of alcoholism.

Although LSD is a synthetic drug, it was first derived from Ergot, a fungus that grows on rye and other grains.

In the Middle Ages, when people accidentally ate this fungus, their resulting bizarre behavior was thought to stem from possession by the Devil.

- Ergot is still used medically to treat migraine headaches. Sandoz Laboratories markets a combination of caffeine and Ergot called Cafergot.

Session 14 - Hallucinogens

2CB

- **Both psychedelic and an entactogen**
- **White powder usually found in pressed tablets or gel caps**
- **Sometimes referred to as “Venus”; “Nexus”; and “Bromo-Mescaline”**



Drug Recognition Expert Course 14-16

- 2CB (4-Bromo-2, 5-Dimethoxyphenethylamine) is a popular drug first synthesized in 1974.
- 2CB is considered both a psychedelic and an entactogen.
- Note: “Entactogen” is a term used by psychiatrists to classify Ecstasy (MDMA). It literally means “touching within.”
- 2CB is a white powder usually found in pressed tablets or gel caps.
- 2CB is sometimes referred to as “Venus”; “Nexus”; and “Bromo-Mescaline.”

Session 14 - Hallucinogens

Psychedelic Amphetamines

- MDA
- STP
- TMA

Drug Recognition Expert Course

NHTSA
www.nhtsa.gov

14-17

MDA, STP, and TMA are synthetically manufactured hallucinogens that sometimes are called “Psychedelic Amphetamines.”

- MDA is an abbreviation for 3, 4-Methylenedioxyamphetamine.
- STP is an abbreviation for 2,5-Dimethoxy-4-methylamphetamine
- TMA is an abbreviation for 3, 4, 5-Trimethoxyamphetamine.
- Chemically related to Amphetamines and produce many effects similar to those of CNS Stimulants.
- Chemically related to Mescaline.

Among users, MDA sometimes is referred to as the “Mellow Drug of America.”

Point out that there are many more Hallucinogens beyond those listed in this session.


An important fact about Hallucinogens is that they are not addictive, in the sense that cessation of use does not produce withdrawal signs or symptoms; however, regular users do develop tolerance to these drugs.

But point out that many people repeatedly abuse these non-addictive drugs because they enjoy the hallucinogenic effects they produce.

Session 14 - Hallucinogens

Methods of Ingestion of Hallucinogens

- Orally
- Smoked
- Injection
- Insufflation (“snorted”)
- Transdermally (absorbed)



Drug Recognition Expert Course

NHTSA

14-18

Methods of Ingestion of Hallucinogens

The most common method of ingesting Hallucinogens is orally.

Some Hallucinogens can also be smoked. However, LSD cannot be ingested by smoking.

Point out that some Hallucinogens such as LSD can be absorbed through the skin. Officers should make it a practice to wear protective gloves when handling any suspected drugs.

LSD is usually ingested orally, which produces rapid effects. It can also be absorbed by placing drops in the eye.

Some Hallucinogens can be ingested and absorbed through the skin.

MDA can also be insufflated, or “snorted.”

Solicit participants’ comments or questions on this overview of Hallucinogens.

Session 14 - Hallucinogens

Hallucinogen Effects

- **Intensify whatever mood the user is in at the time the drug is taken**
- **Uncover mental or emotional flaws that the user was unaware of possessing**
- **Hallucination: the distorted perception of reality**




Drug Recognition Expert Course 14-19

B. Possible Effects

The effects of Hallucinogens vary widely, and are affected by the user's personality, mood and expectations, and by the surroundings in which the drug is taken.

The most common effect of the Hallucinogen is hallucination: the distorted perception of reality, often with a mixing of senses that makes it virtually impossible for the drug influenced user to function in the real world.

Generally, Hallucinogens intensify whatever mood the user is in at the time the drug is taken.

- If the user is depressed, the drug will deepen the depression.
- If the user is feeling pleasant, the drug will heighten that feeling.

If the user expects that the drug will help him or her achieve new insights or an expanded consciousness, the "trip" will seem to have that effect.

However, Hallucinogens also often uncover mental or emotional flaws that the user was unaware of possessing.

Therefore, many users who expect a positive experience with the drug will encounter instead the panic of a "bad trip."

Solicit participants' comments or questions on this overview of Hallucinogens.

Session 14 - Hallucinogens

Time Factors of Peyote

- **30 minutes: Onset**
 - Nausea, elevated blood pressure, pulse and temperature, heart rate and dilated pupils
- **60 minutes: Development of hallucinogenic effects**
 - Visual distortions, rich colors, changing forms and moving shapes
- **3-4 hours: Peak effects**
 - “Synesthesia”





Drug Recognition Expert Course 14-20

C. Onset and Duration Effects

Time Factors of Peyote

The time parameters associated with Hallucinogens vary from drug to drug.

The effects of Peyote (Mescaline) begin to be felt within approximately one-half hour after eating the cactus “buttons.”

30 minutes: nausea, possibly leading to vomiting; mild rise in blood pressure, pulse, temperature and heart rate; pupils dilate.

One hour: sensory changes begin; visual distortions accompanied by rich colors; objects take on new forms and begin to move; shapes “come alive.”

3 – 4 hours: sensory changes reach their peak; synesthesia (transposition of senses) commonly occurs.

Session 14 - Hallucinogens

Time Factors of Peyote (Cont.)

10 hours: Gradual decline of effects
12 hours: Nearly total recovery
24 hours: Elimination nearly completed



Drug Recognition Expert Course

14-21

10 hours: gradual decline in effects.

12 hours: nearly total recovery from effects.

24 hours: the majority of the Mescaline has been excreted from the body.

Session 14 - Hallucinogens

Time Factors of Psilocybin

- **First 30 minutes – Onset**
- **Dizziness; light headed feeling; giddiness; lightness or heaviness of extremities**
- **30-60 minutes - Beginning of sensory effects**
- **Blurred vision; sharpness of color; increased acuity of hearing**



Drug Recognition Expert Course

14-22

Time Factors of Psilocybin

Psilocybin also begins to exert its effects within one-half hour.

First 30 minutes: dizziness, light headed feeling, giddiness; the extremities (hands, feet, etc.) may feel very light or very heavy.

30 – 60 minutes: vision blurs; colors become brighter, leave longer lasting after images; objects take on sharp visual definition; hearing becomes more acute.

Session 14 - Hallucinogens

Time Factors of Psilocybin (Cont.)

- **60-90 minutes - Sensory effects intensify**
- **Patterns and shapes develop and move; distance perception is impaired; euphoria develops**
- **90-120 minutes - Peak effects**
- **Subject becomes introspective**
- **120-180 minutes - Effects begin to diminish**





Drug Recognition Expert Course 14-23

60 – 90 minutes: color patterns and shapes start to develop; the surfaces of objects appear to develop waves and wave-like patterns; distance perception becomes impaired; feelings of euphoria develop.

90 – 120 minutes: body sensations increase, along with mental perceptions; user commonly becomes introspective, with increased bodily sensations and mental perceptions.

120 – 180 minutes: effects start to diminish.

180 – 300 minutes: Nearly complete resolution of drug-induced effects.

Source: Drug Identification Bible, 2012

Session 14 - Hallucinogens

Time Factors of LSD

- **30 - 45 minutes: Onset**
Blood Pressure, pulse, and temperature rise; pupils dilate, hair starts to stand on end; nausea, dizziness and headache development
- **4 - 6 hours: Peak effects**
- **7 - 9 hours: Effects diminish**
- **10 - 12 hours: Subject feels normal**



Drug Recognition Expert Course

14-24

LSD's effects begin to be felt within 30 – 45 minutes.

30 – 45 minutes: blood pressure, pulse and temperature rise; pupils dilate; hair starts to stand on end (Piloerection); nausea, dizziness and headache development.


4 – 6 hours: effects reach their peak.

7 – 9 hours: effects diminish.

10 – 12 hours: user feels normal.

Session 14 - Hallucinogens

Time Factors of MDMA and 2CB



Drug Recognition Expert Course

NHTSA

14-25

MDMA's effects usually begin within several minutes to a half hour if taken orally.

Psychological effects include confusion, depression, anxiety and paranoia.

The duration effects can last from 1 – 12 hours depending on dosage.

2CB's effects are dose related.

Lower doses (5-15mg) produce enhanced sensual sensations and feelings of being “in one's body.”

At higher doses (15-30mg) it produces intense visual effects that includes moving objects with “trails” behind them and colors appearing from nowhere.

Onset and duration of effects of other Hallucinogens vary widely from about two hours to about 24 hours.

Session 14 - Hallucinogens

Overdose Signs and Symptoms

The most common danger of an overdose of Hallucinogen is an intense “bad trip,” which can result in severe and sometimes permanent damage




Drug Recognition Expert Course

14-26

D. Overdose Signs and Symptoms

The most common danger of an overdose of Hallucinogen is an intense “bad trip,” which can result in severe and sometimes permanent damage.

It is unlikely that other Hallucinogens would directly result in death from overdoses.

However, an overdose can be extremely dangerous and indirectly result in death.

The extreme panic and agitation of a “bad trip” have been known to result in suicide or in accidental death as the user attempts to flee the hallucinations.

Sometimes Hallucinogens induce a perception of invulnerability in the user, leading to bizarre and very dangerous behavior, and death.

Example: at least one LSD user was killed when he attempted to stop a train. Others have died from jumping off buildings believing they can fly.

Some evidence suggests that prolonged use of LSD may produce organic brain damage, leading to impaired memory, reduced attention span, mental confusion and impaired ability to deal with abstract concepts.

Solicit participants’ comments and questions concerning time factors.

Session 14 - Hallucinogens

Evaluation of Subjects Under the Influence of Hallucinogens

- HGN and VGN - None
- Lack of Convergence - No
- Impaired performance will be evident on Modified Romberg, Walk and Turn, One Leg Stand and Finger to Nose




Drug Recognition Expert Course 14-27

E. Expected Results of the Evaluation

Observable Evidence of Impairment

Point out that some subjects under the influence of Hallucinogens may not be able to understand or complete the tests, especially if the subject is hallucinating.

Eye Exams:

- Neither Horizontal Gaze nor Vertical Gaze Nystagmus will be present.
- Lack of Convergence will not be evident.

Psychophysical Tests:

- Performance on the Modified Romberg balance test will be impaired, particularly in the subject's estimation of the passage of 30 seconds.

Emphasize that DRE officers conducting evaluations on subjects under the influence of hallucinogens should be especially careful due to the bizarre and unpredictable behavior of these subjects.

- Performance on the Walk and Turn, One Leg Stand, and Finger to Nose tests will be markedly impaired due to the subject's severe visual distortion, impaired perception of distance and decreased muscle coordination.

Session 14 - Hallucinogens

Evaluation of Subjects Under the Influence of Hallucinogens (Cont.)

Vital Signs:

- **Pulse - Up**
- **Blood Pressure - Up**
- **Body temperature – Up**

Muscle Tone - Rigid



Drug Recognition Expert Course

14-28

Vital Signs

Pulse will generally be elevated

Blood pressure generally will be elevated

Body temperature generally will be elevated

Session 14 - Hallucinogens

Evaluation of Subjects Under the Influence of Hallucinogens (Cont.)

Dark Room Examinations:

- Pupils - Dilated (Mydriasis)
- Reaction to light – Normal ⁽³⁾

⁽³⁾ Certain psychedelic amphetamines may cause slowing



Drug Recognition Expert Course 14-29

Dark Room

Pupils generally will be dilated

Reaction to light will usually be normal. Certain Psychedelic Amphetamines may cause slowing of the pupil's reaction to light.

Session 14 - Hallucinogens

Evaluation of Subjects Under the Influence of Hallucinogens

General Indicators:

- **Body tremors**
- **Dazed appearance**
- **Difficulty with speech**
- **Disoriented**
- **Flashbacks**
- **Hallucinations**
- **Memory loss**



Drug Recognition Expert Course

14-30

General Indicators

- Body tremors
- Dazed appearance
- Difficulty with speech
- Disoriented
- Flashbacks
- Hallucinations
- Memory loss

Session 14 - Hallucinogens

Evaluation of Subjects Under the Influence of Hallucinogens (Cont.)

General Indicators:

- Nausea
- Paranoia
- Perspiring
- Piloerection
- Poor perception of time
- Synesthesia
- Uncoordinated



Drug Recognition Expert Course 14-31

General Indicators (Cont.)

- Nausea
- Paranoia
- Perspiring
- Piloerection (LSD)
- Poor perception of time and distance
- Synesthesia
- Uncoordinated

Session 14 - Hallucinogens

Hallucinogen Symptomatology Chart

HGN	None
VGN	None
Lack of Convergence	None
Pupil Size	Dilated
Reaction to Light	Normal ⁽³⁾
Pulse Rate	Up
Blood Pressure	Up
Temperature	Up
Muscle Tone	Rigid

⁽³⁾ Certain psychedelic amphetamines may cause slowing





Drug Recognition Expert Course 14-32

Symptomatology Chart

Session 14 - Hallucinogens

Hallucinogens



Drug Recognition Expert Course 1-33

Click video to begin

VIDEO DEMONSTRATION

Show video example of subject under the influence of a Hallucinogen. (Approximately 19 minutes).

Session 14 - Hallucinogens

Drug Evaluation and Classification

Exemplar Demonstrations



Drug Recognition Expert Course

14-34

F. Classification Exemplar

Refer students to the exemplars found at the end of Session 14 of their participant manuals.

Point out that the one-page narrative in the example exemplars are not to be construed as the recommended or approved narrative report. The actual narrative report submitted by DREs will be more detailed.

Relate the items on the exemplars to the Hallucinogens Symptomatology Chart.

Relate behavior and observations to the Hallucinogens Symptomatology Chart.

Solicit students' questions or suggestions concerning Expected Results of the Evaluation of subjects under the influence of Hallucinogens.

Session 14 - Hallucinogens

QUESTIONS?



Drug Recognition Expert Course

14-35

Solicit participants' questions or comments concerning expected results of the evaluation of subjects under the influence of Hallucinogens.

Session 14 - Hallucinogens

Topics for Study




Drug Recognition Expert Course 14-36

TOPICS FOR STUDY / ANSWERS

1. What does “synesthesia” mean?

ANSWER: *A sensory perception disorder, in which an input via one sense is perceived by the brain as another sense. “Hearing” a phone ring and “seeing” the sound as a flash of light. Synesthesia sometimes occurs with persons under the influence of hallucinogens.*

2. What is a “flashback”? What are the three types of “flashback”?

ANSWER: *A flashback is a vivid recollection of a portion of a hallucinogenic experience. Essentially, it is a very intense daydream. There are three types: (1) emotional – feelings of panic, fear, etc.; (2) somatic – altered body sensations, tremors, dizziness, etc.; (3) perceptual – distortions of vision, hearing, smell, etc.*

3. Name two naturally occurring Hallucinogens.

ANSWER: *Peyote, Psilocybin, Nutmeg, Jimson Weed, Morning Glory seeds, and/ or Bufotenine*

4. What is a “bad trip”?

ANSWER: *An hallucination where the user becomes panic-stricken by what he/she is seeing or hearing, and may become uncontrollably excited, or even try to flee from the terror.*

5. What does “psychotomimetic” mean?

ANSWER: *Literally “mimicking psychosis,” or “impersonating insanity.” A drug is considered psychotomimetic if persons who are under the influence of the drug look and act insane while they are under the influence of that drug.*

Session 14 - Hallucinogens

Topics for Study (Cont.)



Drug Recognition Expert Course 14-37

6. What is an “illusion”? What is a “delusion”?

ANSWER: An “*illusion*” is a false perception, i.e. a misrepresentation of what the senses are receiving. A “*delusion*” is a false belief.












7. What is the difference between “hallucinations” and “pseudo-hallucinations”?

ANSWER: The difference is that the user typically knows that what he/ she is seeing, hearing, smelling, etc. is not real, but is a product of the drug with a “*pseudohallucinations*.”

8. What is “piloerection”?

ANSWER: Literally, “*hair standing up,*” or goose bumps. This condition of the skin is often observed in persons who are under the influence of LSD.

DRUG INFLUENCE EVALUATION







Evaluator Ofc. Chris Thurman, Louisville Metro PD		DRE # 16444	Rolling Log # 12-07-14	Session XIV #1																																																																																																																					
Recorder/Witness Ofc. Dean Kisling, Louisville Metro PD		Crash: <input checked="" type="checkbox"/> None <input type="checkbox"/> Fatal <input type="checkbox"/> Injury <input type="checkbox"/> Property		Case # 12-07-1145																																																																																																																					
Arrestee's Name (Last, First, Middle) Hoeckle, Rebecca S.		Date of Birth 9/23/62	Sex F	Race I	Arresting Officer (Name, ID#) Ofc. Kevin Belcher, KY Vehicle Enforcement #12849																																																																																																																				
Date Examined / Time /Location 07/29/12 2030 Jefferson Co. Jail		Breath Results: Results: 0.00		Test Refused <input type="checkbox"/> Instrument #: 13340	Chemical Test: Urine <input checked="" type="checkbox"/> Blood <input type="checkbox"/> Test or tests refused <input type="checkbox"/>																																																																																																																				
Miranda Warning Given Given By: Officer Belcher 1935	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? "Nothing, I'm fasting"	What have you been drinking? How much? "I don't drink"	Time of last drink? N/A																																																																																																																					
Time now/ Actual 7 pm / 2040	When did you last sleep? How long Last night 6-7 hours	Are you sick or injured? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No Upset stomach	Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No																																																																																																																						
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No																																																																																																																					
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Attitude: Withdrawn, distracted		Coordination: Very poor, difficulty standing																																																																																																																					
Speech: Rapid, stuttering		Breath Odor: Sour, rancid		Face: Flushed																																																																																																																					
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right	Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal																																																																																																																				
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No																																																																																																																					
Eyelids: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Droopy		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td colspan="2">Pulse and time</td> <td>HGN</td> <td>Left Eye</td> <td>Right Eye</td> <td rowspan="4" style="text-align: center;">  </td> <td rowspan="4" style="text-align: center;">  </td> </tr> <tr> <td colspan="2">1. <u>104</u> / <u>2040</u></td> <td>Lack of Smooth Pursuit</td> <td>No</td> <td>No</td> </tr> <tr> <td colspan="2">2. <u>112</u> / <u>2057</u></td> <td>Maximum Deviation</td> <td>No</td> <td>No</td> </tr> <tr> <td colspan="2">3. <u>104</u> / <u>2112</u></td> <td>Angle of Onset</td> <td>None</td> <td>None</td> </tr> </table>				Pulse and time		HGN	Left Eye	Right Eye			1. <u>104</u> / <u>2040</u>		Lack of Smooth Pursuit	No	No	2. <u>112</u> / <u>2057</u>		Maximum Deviation	No	No	3. <u>104</u> / <u>2112</u>		Angle of Onset	None	None																																																																																														
Pulse and time		HGN	Left Eye	Right Eye																																																																																																																					
1. <u>104</u> / <u>2040</u>		Lack of Smooth Pursuit	No	No																																																																																																																					
2. <u>112</u> / <u>2057</u>		Maximum Deviation	No	No																																																																																																																					
3. <u>104</u> / <u>2112</u>		Angle of Onset	None	None																																																																																																																					
Modified Romberg Balance		Walk and Turn test		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td colspan="2">Cannot keep balance ✓✓✓</td> </tr> <tr> <td>Starts too soon</td> <td>_____</td> </tr> <tr> <td>Stops walking</td> <td>_____</td> </tr> <tr> <td>Misses heel-toe</td> <td>_____</td> </tr> <tr> <td>Steps off line</td> <td>_____</td> </tr> <tr> <td>Raises arms</td> <td>_____</td> </tr> <tr> <td>Actual steps taken</td> <td>_____</td> </tr> </table>		Cannot keep balance ✓✓✓		Starts too soon	_____	Stops walking	_____	Misses heel-toe	_____	Steps off line	_____	Raises arms	_____	Actual steps taken	_____																																																																																																						
Cannot keep balance ✓✓✓																																																																																																																									
Starts too soon	_____																																																																																																																								
Stops walking	_____																																																																																																																								
Misses heel-toe	_____																																																																																																																								
Steps off line	_____																																																																																																																								
Raises arms	_____																																																																																																																								
Actual steps taken	_____																																																																																																																								
 <p>Unable to stand</p>		 <p>Test stopped</p>		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td>1st Nine</td> <td>2nd Nine</td> </tr> <tr> <td>_____</td> <td>_____</td> </tr> </table>		1st Nine	2nd Nine	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____	_____																																																																																																
1st Nine	2nd Nine																																																																																																																								
_____	_____																																																																																																																								
_____	_____																																																																																																																								
_____	_____																																																																																																																								
_____	_____																																																																																																																								
_____	_____																																																																																																																								
_____	_____																																																																																																																								
_____	_____																																																																																																																								
_____	_____																																																																																																																								
_____	_____																																																																																																																								
Internal clock N/A estimated as 30 seconds		Describe Turn N/A		Cannot do test (explain) Test stopped for safety reasons																																																																																																																					
Type of footwear: Sandals		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td colspan="2">Draw lines to spots touched</td> <td colspan="2">PUPIL SIZE</td> <td colspan="2">Room light</td> <td colspan="2">Darkness</td> <td colspan="2">Direct</td> <td colspan="2">Nasal area:</td> </tr> <tr> <td colspan="2" rowspan="3">  </td> <td colspan="2">Left Eye</td> <td colspan="2">2.5 - 5.0</td> <td colspan="2">5.0 - 8.5</td> <td colspan="2">2.0 - 4.5</td> <td colspan="2">Clear</td> </tr> <tr> <td colspan="2">Right Eye</td> <td colspan="2">7.0</td> <td colspan="2">8.5</td> <td colspan="2">6.5</td> <td colspan="2">Oral cavity:</td> </tr> <tr> <td colspan="2"></td> <td colspan="2">7.0</td> <td colspan="2">8.5</td> <td colspan="2">6.5</td> <td colspan="2">Clear</td> </tr> <tr> <td colspan="2">Blood pressure 148/104</td> <td colspan="2">Temperature 100.0</td> <td colspan="4">REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</td> <td colspan="4">REACTION TO LIGHT: Normal</td> </tr> <tr> <td colspan="2">Muscle tone: <input type="checkbox"/> Normal <input type="checkbox"/> Flaccid <input checked="" type="checkbox"/> Rigid</td> <td colspan="2">Comments: Rigidity in arms</td> <td colspan="4">RIGHT ARM</td> <td colspan="4">LEFT ARM</td> </tr> <tr> <td colspan="2">What drugs or medications have you been using? "My company does not permit drugs"</td> <td colspan="2">How much? N/A</td> <td colspan="2">Time of use? N/A</td> <td colspan="2">Where were the drugs used? (Location) N/A</td> <td colspan="4">  </td> </tr> <tr> <td colspan="2">Date / Time of arrest: 07/29/12 1930</td> <td colspan="2">Time DRE was notified: 2010</td> <td colspan="2">Evaluation start time: 2030</td> <td colspan="2">Evaluation completion time: 2135</td> <td colspan="4">Precinct/Station:</td> </tr> <tr> <td colspan="2">Officer's Signature:</td> <td colspan="2">DRE # 16444</td> <td colspan="8">Reviewed/approved by / date:</td> </tr> <tr> <td colspan="2">Opinion of Evaluator:</td> <td colspan="2"><input type="checkbox"/> Rule Out <input type="checkbox"/> Alcohol <input type="checkbox"/> Medical <input type="checkbox"/> CNS Depressant</td> <td colspan="2"><input type="checkbox"/> CNS Stimulant <input checked="" type="checkbox"/> Hallucinogen</td> <td colspan="2"><input type="checkbox"/> Dissociative Anesthetic <input type="checkbox"/> Narcotic Analgesic</td> <td colspan="4"><input type="checkbox"/> Inhalant <input type="checkbox"/> Cannabis</td> </tr> </table>				Draw lines to spots touched		PUPIL SIZE		Room light		Darkness		Direct		Nasal area:				Left Eye		2.5 - 5.0		5.0 - 8.5		2.0 - 4.5		Clear		Right Eye		7.0		8.5		6.5		Oral cavity:				7.0		8.5		6.5		Clear		Blood pressure 148/104		Temperature 100.0		REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No				REACTION TO LIGHT: Normal				Muscle tone: <input type="checkbox"/> Normal <input type="checkbox"/> Flaccid <input checked="" type="checkbox"/> Rigid		Comments: Rigidity in arms		RIGHT ARM				LEFT ARM				What drugs or medications have you been using? "My company does not permit drugs"		How much? N/A		Time of use? N/A		Where were the drugs used? (Location) N/A						Date / Time of arrest: 07/29/12 1930		Time DRE was notified: 2010		Evaluation start time: 2030		Evaluation completion time: 2135		Precinct/Station:				Officer's Signature:		DRE # 16444		Reviewed/approved by / date:								Opinion of Evaluator:		<input type="checkbox"/> Rule Out <input type="checkbox"/> Alcohol <input type="checkbox"/> Medical <input type="checkbox"/> CNS Depressant		<input type="checkbox"/> CNS Stimulant <input checked="" type="checkbox"/> Hallucinogen		<input type="checkbox"/> Dissociative Anesthetic <input type="checkbox"/> Narcotic Analgesic		<input type="checkbox"/> Inhalant <input type="checkbox"/> Cannabis			
Draw lines to spots touched		PUPIL SIZE		Room light		Darkness		Direct		Nasal area:																																																																																																															
		Left Eye		2.5 - 5.0		5.0 - 8.5		2.0 - 4.5		Clear																																																																																																															
		Right Eye		7.0		8.5		6.5		Oral cavity:																																																																																																															
				7.0		8.5		6.5		Clear																																																																																																															
Blood pressure 148/104		Temperature 100.0		REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No				REACTION TO LIGHT: Normal																																																																																																																	
Muscle tone: <input type="checkbox"/> Normal <input type="checkbox"/> Flaccid <input checked="" type="checkbox"/> Rigid		Comments: Rigidity in arms		RIGHT ARM				LEFT ARM																																																																																																																	
What drugs or medications have you been using? "My company does not permit drugs"		How much? N/A		Time of use? N/A		Where were the drugs used? (Location) N/A																																																																																																																			
Date / Time of arrest: 07/29/12 1930		Time DRE was notified: 2010		Evaluation start time: 2030		Evaluation completion time: 2135		Precinct/Station:																																																																																																																	
Officer's Signature:		DRE # 16444		Reviewed/approved by / date:																																																																																																																					
Opinion of Evaluator:		<input type="checkbox"/> Rule Out <input type="checkbox"/> Alcohol <input type="checkbox"/> Medical <input type="checkbox"/> CNS Depressant		<input type="checkbox"/> CNS Stimulant <input checked="" type="checkbox"/> Hallucinogen		<input type="checkbox"/> Dissociative Anesthetic <input type="checkbox"/> Narcotic Analgesic		<input type="checkbox"/> Inhalant <input type="checkbox"/> Cannabis																																																																																																																	

DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: Hoeckle, Rebecca S.

1. **LOCATION:** The evaluation took place at the Jefferson County Jail.
2. **WITNESSES:** The arresting officer, Kevin Belcher observed the evaluation and DRE Instructor Dean Kisling of the Louisville Metro PD recorded the evaluation.
3. **BREATH ALCOHOL TEST:** Hoeckle's breath test was a 0.00%.
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** I was contacted by Officer Belcher and requested to conduct a drug evaluation on Hoeckle. I contacted Officer Belcher at the jail where he advised that he had found the suspect stopped partially in the travel portion of I-65. When contacted, the suspect appeared dazed and disoriented. She pointed to some bright lights near the Interstate and told Officer Belcher that "They told me to stop, so I stopped." She was unable to perform SFST's and was subsequently arrested for DUI.
5. **INITIAL OBSERVATION OF SUSPECT:** The suspect was seated next to the Intoxilyzer and was staring straight ahead. She slowly turned and asked "Are you God?" Writer replied by giving her my name and asking for consent to conduct a drug evaluation. She replied, "They sent you, so you must be good." Her speech was rapid, she stuttered at times and she was perspiring.
6. **MEDICAL PROBLEMS AND TREATMENT:** The suspect indicated that she had an upset stomach and was not feeling good, but she did not require medical assistance.
7. **PSYCHOPHYSICAL TESTS:** The suspect was unable to stand without assistance. It was necessary to terminate the Modified Romberg Balance, Walk and Turn and One Leg Stand tests for her safety. The Finger to Nose test was conducted while she was seated. She missed the tip of her nose on all six attempts.
8. **CLINICAL INDICATORS:** The suspect's pupils were dilated in two of the lighting levels. Her pulse, blood pressure and temperature were elevated and above the DRE average ranges.
9. **SIGNS OF INGESTION:** The suspect's breath was sour smelling and was rancid.
10. **SUSPECT'S STATEMENTS:** The suspect stated she was fasting for religious reasons and that her trucking company forbids the use of alcohol and illegal drugs. The suspect stated she got hungry so she purchased some "organic mushrooms" at a truck stop near Lexington.
11. **DRE'S OPINION:** In my opinion Hoeckle is under the influence of a **Hallucinogen** and unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** The suspect provided a urine sample.
13. **MISCELLANEOUS**

DRUG INFLUENCE EVALUATION







Evaluator Sergeant Allan Kolak, Cape Coral PD		DRE # 8191	Rolling Log # 12-05-209	Session XIV #2	
Recorder/Witness Kyle Clark, IPTM		Crash: <input checked="" type="checkbox"/> None <input type="checkbox"/> Fatal <input type="checkbox"/> Injury <input type="checkbox"/> Property		Case # 12-100978	
Arrestee's Name (Last, First, Middle) Warburton, Cindy T.		Date of Birth 7/18/82	Sex F	Race W	Arresting Officer (Name, ID#) Deputy Darrel Kehne, Collier Co. S.O. #9077
Date Examined / Time / Location 05/07/12, 2310 Collier Co. Jail		Breath Results: Results: 0.00		Test Refused <input type="checkbox"/> Instrument #: 13465	Chemical Test: Urine <input type="checkbox"/> Blood <input checked="" type="checkbox"/> Test or tests refused <input type="checkbox"/>
Miranda Warning Given Given By: Dpty. Kehne	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? Spaghetti lunch	What have you been drinking? Nothing	How much?	Time of last drink? N/A
Time now/ Actual 7:00 PM/2315	When did you last sleep? How long Yesterday 6 hrs.	Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No "I feel hot."		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Attitude: Distracted, paranoid		Coordination: Poor, staggering	
Speech: Rambling, incoherent at times		Breath Odor: Normal		Face: Perspiring	
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right	Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Eyelids <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Droopy
Pulse and time 1. <u>112</u> / <u>2319</u> 2. <u>116</u> / <u>2325</u> 3. <u>116</u> / <u>2340</u>	HGN Lack of Smooth Pursuit Maximum Deviation Angle of Onset	Left Eye No	Right Eye No	Convergence 	18 ONE LEG STAND 31 
Modified Romberg Balance 	Walk and Turn test 	Cannot keep balance <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Starts too soon <input checked="" type="checkbox"/> Stops walking Misses heel-toe Steps off line Raises arms Actual steps taken		1st Nine 2nd Nine Constant Constant	L R <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Sways while balancing <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Uses arms to balance <input type="checkbox"/> <input type="checkbox"/> Hopping <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Puts foot down Leg tremors
Internal clock 10 estimated as 30 seconds	Describe Turn Lost balance, stumbled, nearly fell	Cannot do test (explain) N/A		Type of footwear: Sandals	
Draw lines to spots touched 		PUPIL SIZE	Room light	Darkness	Direct
		Left Eye	6.0	8.5	5.5
Opened her eyes.		Right Eye	6.0	8.5	5.5
		REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		REACTION TO LIGHT: Normal	
Blood pressure 150/102		Temperature 99.8		RIGHT ARM 	
Muscle tone: <input type="checkbox"/> Normal <input type="checkbox"/> Flaccid <input checked="" type="checkbox"/> Rigid		Nothing observed			
Comments: What drugs or medications have you been using? Nothing		How much? N/A		Time of use? N/A	Where were the drugs used? (Location) No answer
Date / Time of arrest: 05/07/12 2215	Time DRE was notified: 2240	Evaluation start time: 2310	Evaluation completion time: 2355	Precinct/Station: Traffic	
Officer's Signature:		DRE # 8191	Reviewed/approved by / date:		
Opinion of Evaluator:		<input type="checkbox"/> Rule Out <input type="checkbox"/> Medical	<input type="checkbox"/> Alcohol <input type="checkbox"/> CNS Depressant	<input type="checkbox"/> CNS Stimulant <input checked="" type="checkbox"/> Hallucinogen	<input type="checkbox"/> Dissociative Anesthetic <input type="checkbox"/> Narcotic Analgesic
		<input type="checkbox"/> Inhalant <input type="checkbox"/> Cannabis			

DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: Warburton, Cindy T.

1. **LOCATION:** The evaluation was conducted at the Collier County Jail.
2. **WITNESSES:** DRE State Coordinator, Kyle Clark witnessed and recorded the evaluation.
3. **BREATH ALCOHOL TEST:** Warburton's breath test was 0.00%.
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** I was on-duty when informed by Dispatch that Deputy Kehne was requesting a drug evaluation. I contacted Deputy Kehne at the Intake Center where he advised the suspect had been arrested after driving along the gravel shoulder of Beach Road trying to pass some stopped vehicles. According to Deputy Kehne, the suspect pointed to his baton and shouted "Look out, there's a big snake hanging from your belt!" She was very paranoid acting and also claimed that the overhead lights on the patrol car were burning her eyes and skin.
5. **INITIAL OBSERVATION OF SUSPECT:** I first observed the suspect sitting in the interview room and she appeared to be disoriented. She was at times talking to herself and at one point she pointed to the clock on the wall and began talking to it.
6. **MEDICAL PROBLEMS AND TREATMENT:** None observed and none stated.
7. **PSYCHOPHYSICAL TESTS:** Modified Romberg Balance: Suspect swayed approximately 3" side to side and estimated 30 seconds in 10 seconds. Walk & Turn: Suspect started walking too soon, lost her balance twice during the instructions, missed heel to toe, stopped walking, stepped off the line, raised her arms, staggered while turning and only took eight steps on the return. One Leg Stand: Suspect swayed, raised her arms, and put her foot down. Finger to Nose: Suspect missed the tip of her nose on each attempt. She also opened her eyes and shouted, "I can't feel my face!" "My face is gone!"
8. **CLINICAL INDICATORS:** The suspect's pulse, blood pressure and temperature were all elevated and above the DRE average ranges. The suspect's pupils were dilated in two of the lighting levels.
9. **SIGNS OF INGESTION:** None observed.
10. **SUSPECT'S STATEMENTS:** The suspect stated that she felt hot and denied drug use.
11. **DRE'S OPINION:** In my opinion Warburton is under the influence of a Hallucinogen and unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** The suspect provided a blood sample.
13. **MISCELLANEOUS:** The suspect was wearing an "XTC" tee-shirt.

DRUG INFLUENCE EVALUATION

Evaluator Officer Daven Byrd, Arizona DPS		DRE # 14598	Rolling Log # 12-01-203	Session XIV #3	
Recorder/Witness Ofc. Tim Merrill, AZ DPS		Crash: <input checked="" type="checkbox"/> None <input type="checkbox"/> Fatal <input type="checkbox"/> Injurv <input type="checkbox"/> Property		Case # 12-004128	
Arrestee's Name (Last, First, Middle) Buchanan, Lew B.		Date of Birth 6/19/76	Sex M	Race B	Arresting Officer (Name, ID#) Deputy Frank Sloup, Maricopa Co. S.O. #14231
Date Examined / Time / Location 01-25-12 0145 Central Testing		Breath Results: Results: 0.00		Test Refused <input type="checkbox"/> Instrument #: 10234	Chemical Test: Urine <input type="checkbox"/> Blood <input checked="" type="checkbox"/> Test or tests refused <input type="checkbox"/>
Miranda Warning Given Given By: Dpty. Sloup 0100	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? Pizza about 6pm	When? 8pm	What have you been drinking? Beer	How much? Two Time of last drink? 8pm
Time now/ Actual "11 pm" / 0125	When did you last sleep? How long Last night 3 hrs.	Are you sick or injured? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No I might throw up		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Attitude: Withdrawn/cooperative		Coordination: Very poor - staggering	
Speech: Difficulty in speaking, rambling		Breath Odor: Normal		Face: Dazed, perspiring heavily	
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input checked="" type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right	
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	
Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal		Eyelids <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Droopy			
Pulse and time 1. 116 / 0153 2. 112 / 0220 3. 104 / 0240	HGN Lack of Smooth Pursuit Maximum Deviation Angle of Onset	Left Eye No No None	Right Eye No No None	Convergence 	ONE LEG STAND 
Modified Romberg Balance 	Walk and Turn test 	Cannot keep balance <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/>		Starts too soon Stops walking Misses heel-toe Steps off line Raises arms Actual steps taken	
Internal clock 35 estimated as 30 seconds	Describe Turn N/A	Cannot do test (explain) Stepped off line 3 times during instruction		Type of footwear: Running shoes	
Draw lines to spots touched 	PUPIL SIZE			REBOUND DILATION	
	Room light	Darkness	Direct	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
	Left Eye	Right Eye		REACTION TO LIGHT: Normal	
Blood pressure 146/102	Temperature 100.5	RIGHT ARM 			
Muscle tone: <input type="checkbox"/> Normal <input type="checkbox"/> Flaccid <input checked="" type="checkbox"/> Rigid		LEFT ARM 			
Comments: Arms, neck, face rigid		Nothing observed			
What drugs or medications have you been using? Nothing		How much? No answer	Time of use? No answer	Where were the drugs used? (Location) Refused	
Date / Time of arrest: 01/25/12 0055	Time DRE was notified: 0120	Evaluation start time: 0145	Evaluation completion time: 0255	Precinct/Station:	
Officer's Signature:		DRE # 14598	Reviewed/approved by / date:		
Opinion of Evaluator:		<input type="checkbox"/> Rule Out	<input type="checkbox"/> Alcohol	<input type="checkbox"/> CNS Stimulant	<input type="checkbox"/> Dissociative Anesthetic
		<input type="checkbox"/> Medical	<input type="checkbox"/> CNS Depressant	<input checked="" type="checkbox"/> Hallucinogen	<input type="checkbox"/> Narcotic Analgesic
				<input type="checkbox"/> Inhalant	<input type="checkbox"/> Cannabis

DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: Buchanan, Lew B.

1. **LOCATION:** The evaluation was conducted at the Maricopa County Jail.
2. **WITNESSES:** The evaluation was recorded by Officer Tim Merrill of the AZ DPS.
3. **BREATH ALCOHOL TEST:** Buchanan's breath test was 0.00%.
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** I was dispatched to the MCSO Jail to conduct a drug evaluation for Deputy Sloup. Deputy Sloup stated that he had observed the suspect driving 20 miles under the posted speed limit on Thomas Road. He also observed the suspect's vehicle drifting from lane to lane. The suspect preformed poorly on the SFST's and was arrested for DUI.
5. **INITIAL OBSERVATION OF SUSPECT:** Writer first observed the suspect in the breath testing room. He was swaying as he stood and appeared dazed and disoriented. He responded slowly to my greeting, but was cooperative and responsive to my questions. He was perspiring heavily and had rambling speech.
6. **MEDICAL PROBLEMS AND TREATMENT:** Suspect stated he felt nauseous.
7. **PSYCHOPHYSICAL TESTS:** Modified Romberg Balance: Suspect swayed approximately 3" in a circular motion and estimated 30 seconds in 35 seconds. Walk & Turn and One Leg Stand: Suspect was unable to perform the tests. Both were terminated for safety reasons. Finger to Nose: Suspect missed the tip of his nose on each attempt.
8. **CLINICAL INDICATORS:** The suspect's pupils were dilated in all three lighting conditions. The suspect's pulse, blood pressure and body temperature were elevated and above the DRE average ranges.
9. **SIGNS OF INGESTION:** None were observed.
10. **SUSPECT'S STATEMENTS:** The suspect admitted to drinking a beer about 2-3 hours prior to driving and denied any drug use.
11. **DRE'S OPINION:** In my opinion Buchanan is under the influence of a **Hallucinogen** and unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** The suspect provided a blood sample.
13. **MISCELLANEOUS:** A small baggy of dried mushrooms were located in the suspect's coat pocket. He denied ownership and said he didn't know what they were.

Session 15

Practice: Test Interpretation



Session 15 - Practice: Test Interpretation

Learning Objectives

- **Analyze the results of a complete drug influence evaluation and identify the category or categories of drugs affecting the individual examined**
- **Articulate the basis for the drug category identification**




Drug Recognition Expert Course 15-2

Briefly review the objectives, content and activities of this session.

Upon successfully completing this session the participant will be able to:

- Analyze the results of a complete drug influence evaluation and identify the category or categories of drugs affecting the individual examined.
- Articulate the basis for the drug category identification.

CONTENT SEGMENTS

- A. Interpretation Demonstration
- B. Interpretation Practice
- C. Session Wrap-Up

LEARNING ACTIVITIES

- Instructor Led Demonstrations
- Small Group Practice
- Participant Led Presentations

Session 15 - Practice: Test Interpretation

Interpretation Demonstrations

Case 1: Subject Adams

- Preliminary examination
- Eye examinations
- Psychophysical tests




Drug Recognition Expert Course 15-3

A. Interpretation Demonstrations

Case One: Subject Adams

Direct participants to review the “Subject Adams” exemplar in Session 15 of their manuals.

Preliminary examination

Review the results of the Preliminary Examination of Subject Adams.

Ask participants: “What category or categories of drugs would produce preliminary examination results consistent with this exemplar?” Probe to draw out the bases for participants’ responses.

Eye examinations

Review the results of the Eye Examinations of Subject Adams.

Ask participants to discuss the category or categories of drugs that would cause these eye examination results.

Psychophysical tests

Review the results of the Psychophysical Tests of Subject Adams.

Ask participants to discuss the category or categories of drugs that would produce these psychophysical test results.

Session 15 - Practice: Test Interpretation

Vital Signs Examinations

- Pulse
- Blood pressure
- Temperature



Drug Recognition Expert Course 15-4

Vital Signs examinations

Review the results of the Vital Signs Examinations of Subject Adams.

Ask participants to discuss the category or categories of drugs that would produce these results.

Session 15 - Practice: Test Interpretation

Dark Room Examinations

- Room light
- Near-total darkness
- Direct light
- Check nasal area and oral cavity



Drug Recognition Expert Course 15-5

Dark Room examinations

Review the results of the Dark Room Examinations of Subject Adams.

Ask participants to discuss the category or categories of drugs that would produce these results. Other evidence and additional observations.

Review the results of the examinations for injection sites and muscle rigidity, and of the final interview of Subject Adams.

Session 15 - Practice: Test Interpretation

Narrative Report

Evaluator:	Subject:	R/L # :
1)Location; 2)Witnesses; 3) Breath Test; 4)Notification/Interview Arresting Off; 5).Initial Observation; 6) Medical problems; 7) Psychophysicals; 8). Clinical Indicators; 9). Signs of Ingestion; 10). Subject Statements; 11). Opinion; 12). Toxicology; 13). Misc.		
The following summarizes the evaluation _____		
1). LOCATION:		
2). WITNESS(ES):		
3). BREATH TEST:		
4). NOTIFICATION/INTERVIEW ARR. OFF:		
5). INITIAL OBSERVATION:		
6). MEDICAL PROBLEMS:		
7). PSYCHOPHYSICALS:		
8). CLINICAL INDICATORS:		
9). SIGNS OF INGESTION:		
10: SUBJECT STATEMENTS:		
11). OPINION:		
12). TOXICOLOGY:		
13). MISC:		




Drug Recognition Expert Course 15-6

Narrative report

Briefly review the narrative report on the reverse side of the “Adams” exemplar.

Point out that the DRE’s opinion is missing from this sample.

Opinion of evaluator: Point out that the evidence indicates that Subject Adams is under the influence of a CNS Depressant.

Solicit participants’ questions concerning this demonstration.

Session 15 - Practice: Test Interpretation

Interpretation Demonstrations

Case 2: Subject Baker

- Preliminary Examination
- Eye Examinations
- Psychophysical Tests




Drug Recognition Expert Course 15-7

Case Two: Subject Baker

Direct participants to review the “Subject Baker” exemplar.

Preliminary examination

Review the results of the Preliminary Examination of Subject Baker.

Ask participants: “What category or categories of drugs would produce preliminary examination results consistent with this exemplar?” Probe to draw out the bases for participants’ responses.

Eye examination

Review the results of the Eye Examinations of Subject Baker.

Ask participants to discuss the category or categories of drugs that would cause these eye examination results.

Psychophysical tests

Review the results of the Psychophysical Test of Subject Baker.

Ask participants to discuss the category or categories of drugs that would produce these psychophysical test results.

Session 15 - Practice: Test Interpretation

Interpretation Demonstrations (Cont.)

Case 2: Subject Baker

- Vital sign examinations
- Dark room examinations
- Other evidence
- Narrative report
- Opinion of the evaluator




Drug Recognition Expert Course 15-8

Vital Signs examinations

Review the results of the Vital Signs Examinations of Subject Baker.

Ask participants to discuss the category or categories of drugs that would produce these results.

Dark Room examinations

Review the results of the Dark Room Examinations of Subject Baker.

Ask participants to discuss the category or categories of drugs that would produce these results.

Other evidence and additional observations

Review the results of the examinations for injection sites and muscle rigidity, and of the final interview of Subject Baker.

Narrative Report

Briefly review the narrative report on the reverse side of the "Baker" exemplar. Point out that the DRE's Opinion is missing from this sample.

Ask participants to comment on the category or categories of drugs that would be consistent with all of the evidence on this exemplar.

Opinion of the evaluator

Point out that the evidence indicates that Subject Baker is under the influence of a CNS Stimulant.

Solicit participants' questions concerning this demonstration.

Session 15 - Practice: Test Interpretation

Interpretation Practice

- **Work in teams**
- **Review exemplars**
- **Present conclusions to class**




Drug Recognition Expert Course 15-9

B. Interpretation Practice

Team Practice

Assign participants to work in teams of three or four members.

Tell teams that they are to review three exemplars (Subjects Charles, Dodge, and Edwards). Team members are to discuss the evidence among themselves and reach a conclusion concerning the category or categories of drugs, if any.

Teams will present their conclusions to the entire class.

Review and discussion of exemplars by teams.

Allow teams approximately 15 minutes to review the three exemplars and reach their conclusions.

Feedback of Results

Poll the teams to determine their conclusions concerning the category or categories of drugs present in each subject.

Subject Charles

Subject Dodge

Subject Edwards

Offer approximate comments concerning the teams performance.

Session 15 - Practice: Test Interpretation

QUESTIONS?










Drug Recognition Expert Course 15-10

C. Session Wrap-Up

Solicit participants' comments and questions concerning this practice session.

DRUG INFLUENCE EVALUATION









Evaluator Officer Mark Ashby, Thornton PD		DRE # 5696	Rolling Log # 12-10-235	Session XV-I- #1													
Recorder/Witness Deputy Mark George, Boulder Co. S.O.		Crash: <input checked="" type="checkbox"/> None <input type="checkbox"/> Fatal <input type="checkbox"/> Injury <input type="checkbox"/> Property		Case # 12-97302													
Arrestee's Name (Last, First, Middle) Adams, Frances A.		Date of Birth 1/1/65	Sex M	Race W	Arresting Officer (Name, ID#) Officer John Blea, Denver PD												
Date Examined / Time / Location 10/06/12 10:30 pm Intake Center		Breath Results: Results: 0.00		Test Refused <input type="checkbox"/> Instrument #: 1235	Chemical Test: Urine <input type="checkbox"/> Blood <input checked="" type="checkbox"/> Test or tests refused <input type="checkbox"/>												
Miranda Warning Given Given By: Officer Blea	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? Hamburger Noon	What have you been drinking? Water	How much?	Time of last drink? N/A												
Time now/ Actual 10:30 pm/ 10:40 pm	When did you last sleep? How long Last night 5 hrs.	Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No													
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No													
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Attitude: Cooperative		Coordination: Poor, stumbling, staggering													
Speech: Slow, slurred, thick		Breath Odor: Normal		Face: Normal													
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right													
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No													
Eyelids <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Droopy		Pulse and time		Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal													
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td>HGN</td> <td>Left Eye</td> <td>Right Eye</td> </tr> <tr> <td>Lack of Smooth Pursuit</td> <td style="text-align: center;">Yes</td> <td style="text-align: center;">Yes</td> </tr> <tr> <td>Maximum Deviation</td> <td style="text-align: center;">Yes</td> <td style="text-align: center;">Yes</td> </tr> <tr> <td>Angle of Onset</td> <td style="text-align: center;">35</td> <td style="text-align: center;">35</td> </tr> </table>		HGN	Left Eye	Right Eye	Lack of Smooth Pursuit	Yes	Yes	Maximum Deviation	Yes	Yes	Angle of Onset	35	35			26 ONE LEG STAND 28 	
HGN	Left Eye	Right Eye															
Lack of Smooth Pursuit	Yes	Yes															
Maximum Deviation	Yes	Yes															
Angle of Onset	35	35															
Modified Romberg Balance 		Walk and Turn test 		Cannot keep balance <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Starts too soon _____ Stops walking _____ Misses heel-toe _____ Steps off line _____ Raises arms _____ Actual steps taken <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td>1st Nine</td> <td>2nd Nine</td> </tr> <tr> <td style="text-align: center;">✓✓✓</td> <td style="text-align: center;">✓</td> </tr> <tr> <td style="text-align: center;">✓✓✓</td> <td style="text-align: center;">✓✓</td> </tr> <tr> <td style="text-align: center;">✓</td> <td style="text-align: center;">✓</td> </tr> <tr> <td style="text-align: center;">✓✓✓</td> <td style="text-align: center;">✓✓</td> </tr> <tr> <td style="text-align: center;">9</td> <td style="text-align: center;">9</td> </tr> </table>		1 st Nine	2 nd Nine	✓✓✓	✓	✓✓✓	✓✓	✓	✓	✓✓✓	✓✓	9	9
1 st Nine	2 nd Nine																
✓✓✓	✓																
✓✓✓	✓✓																
✓	✓																
✓✓✓	✓✓																
9	9																
Internal clock 42 estimated as 30 seconds		Describe Turn Turned backwards		Cannot do test (explain) N/A													
Draw lines to spots touched 		PUPIL SIZE <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td></td> <td>Room light 2.5 - 5.0</td> <td>Darkness 5.0 - 8.5</td> <td>Direct 2.0 - 4.5</td> </tr> <tr> <td>Left Eye</td> <td style="text-align: center;">4.0</td> <td style="text-align: center;">6.0</td> <td style="text-align: center;">3.0</td> </tr> <tr> <td>Right Eye</td> <td style="text-align: center;">4.0</td> <td style="text-align: center;">6.0</td> <td style="text-align: center;">3.0</td> </tr> </table>			Room light 2.5 - 5.0	Darkness 5.0 - 8.5	Direct 2.0 - 4.5	Left Eye	4.0	6.0	3.0	Right Eye	4.0	6.0	3.0	Type of footwear: Work boots Nasal area: Clear Oral cavity: Clear	
			Room light 2.5 - 5.0	Darkness 5.0 - 8.5	Direct 2.0 - 4.5												
Left Eye	4.0	6.0	3.0														
Right Eye	4.0	6.0	3.0														
Blood pressure 104/64		Temperature 97.6		REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No													
Muscle tone: <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Flaccid <input type="checkbox"/> Rigid Comments: Very relaxed		RIGHT ARM 		LEFT ARM 													
What drugs or medications have you been using? "None"		How much? Refused		Time of use? Refused													
Date / Time of arrest: 10/06/12 9:50 pm		Time DRE was notified: 10:15 pm		Evaluation start time: 10:30 pm													
Officer's Signature:		DRE # 5696		Reviewed/approved by / date:													
Opinion of Evaluator:		<input type="checkbox"/> Rule Out <input type="checkbox"/> Alcohol <input type="checkbox"/> CNS Stimulant <input type="checkbox"/> Dissociative Anesthetic <input type="checkbox"/> Inhalant		<input type="checkbox"/> Medical <input checked="" type="checkbox"/> CNS Depressant <input type="checkbox"/> Hallucinogen <input type="checkbox"/> Narcotic Analgesic <input type="checkbox"/> Cannabis													

DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: Adams, Frances A.

1. **LOCATION:** The evaluation was conducted at the Boulder County Jail Intake Center.
2. **WITNESSES:** The evaluation was witnessed and recorded by Deputy Mark George of the Boulder County S.O.
3. **BREATH ALCOHOL TEST:** Adams' breath test was a 0.00%.
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** I was contacted by radio and advised to contact Officer John Blea at the Boulder Co. Jail for a drug evaluation. Officer Blea advised that he arrested Adams for DUI after observing him commit numerous traffic violations and performing poorly on the SFST's.
5. **INITIAL OBSERVATION OF SUSPECT:** I first observed the suspect in the interview room at the jail. His head was tilted forward, his eyes were closed and his breathing was deep and slow. He responded slowly to questions and his speech was slow, slurred and thick.
6. **MEDICAL PROBLEMS AND TREATMENT:** None noted or stated.
7. **PSYCHOPHYSICAL TESTS:** The suspect had difficulty performing the psychophysical tests. Modified Romberg Balance: Suspect had an approximate 3" side to side sway and a 2" front to back sway. He estimated 30 seconds in 42 seconds. Walk & Turn: Suspect lost his balance twice during the instructions, missed heel to toe five times, stopped while walking three times, turned improperly, stepped off the line twice and used his arms for balance. One Leg Stand: Suspect swayed while balancing, used his arms for balance and put his foot down. Finger to Nose: Suspect missed the tip of his nose on five of the six attempts.
8. **CLINICAL INDICATORS:** The suspect had six clues of HGN with a 35 degree angle of onset with a Lack of Convergence. His pulse and blood pressure were below the DRE average ranges.
9. **SIGNS OF INGESTION:** Nothing observed.
10. **SUSPECT'S STATEMENTS:** Suspect stated he was sleepy and denied using drugs.
11. **DRE'S OPINION:** In my opinion Adams is under the influence of a *CNS Depressant and* unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** The suspect provided a blood sample.
13. **MISCELLANEOUS:**

DRUG INFLUENCE EVALUATION







Evaluator Trooper Joseph Germano, NY State Police		DRE # 10712	Rolling Log # 12-07-021	Session XV-I #2													
Recorder/Witness Trooper David Olney, NY SP		Crash: <input checked="" type="checkbox"/> None <input type="checkbox"/> Fatal <input type="checkbox"/> Injury <input type="checkbox"/> Property		Case # 12-128845													
Arrestee's Name (Last, First, Middle) Baker, Sam B.		Date of Birth 10/15/72	Sex M	Race B	Arresting Officer (Name, ID#) Trooper Jim Guerriere, NYSP #5525												
Date Examined / Time / Location 07/04/12 2230 Cooperstown PD		Breath Results: Results: 0.00		Test Refused <input type="checkbox"/>	Chemical Test: Urine <input checked="" type="checkbox"/> Blood <input type="checkbox"/> Test or tests refused <input type="checkbox"/>												
Miranda Warning Given Given By: Tpr. Guerriere	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? Milkshake 3 hrs. ago	What have you been drinking? How much? "No, nothing"	Time of last drink? N/A													
Time now/ Actual 8:30 pm/2242	When did you last sleep? How long? This morning 2 hrs.	Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No													
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No													
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Attitude: Cooperative		Coordination: Poor, stumbling													
Speech: Rapid, slurred at times		Breath Odor: Rancid		Face: Normal, sweaty													
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right													
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No													
Eyelids: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Droopy		Pulse and time		40 ONE LEG STAND 38													
1. 90 / 2235 2. 92 / 2246 3. 88 / 2253		HGN	Left Eye	Right Eye	 												
Modified Romberg Balance		Lack of Smooth Pursuit	No	No													
		Maximum Deviation	No	No													
Walk and Turn test		Angle of Onset	None	None													
		Cannot keep balance _____		<table border="1" style="width: 100%;"> <tr> <td>1st Nine</td> <td>2nd Nine</td> </tr> <tr> <td>✓✓</td> <td>✓</td> </tr> <tr> <td>✓</td> <td>✓</td> </tr> <tr> <td>9</td> <td>9</td> </tr> </table>	1st Nine	2nd Nine	✓✓	✓	✓	✓	9	9					
1st Nine	2nd Nine																
✓✓	✓																
✓	✓																
9	9																
Internal clock 21 estimated as 30 seconds		Describe Turn As instructed		Type of footwear: Athletic shoes													
<p style="text-align: center;">Draw lines to spots touched</p>  <p style="text-align: center;">Quick and jerky movements</p>		<table border="1" style="width: 100%;"> <tr> <th>PUPIL SIZE</th> <th>Room light</th> <th>Darkness</th> <th>Direct</th> </tr> <tr> <td>Left Eye</td> <td>6.5</td> <td>8.0</td> <td>6.0</td> </tr> <tr> <td>Right Eye</td> <td>6.5</td> <td>8.0</td> <td>6.0</td> </tr> </table>		PUPIL SIZE	Room light	Darkness	Direct	Left Eye	6.5	8.0	6.0	Right Eye	6.5	8.0	6.0	REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No REACTION TO LIGHT: Slow	
PUPIL SIZE	Room light	Darkness	Direct														
Left Eye	6.5	8.0	6.0														
Right Eye	6.5	8.0	6.0														
Blood pressure 142/102		Temperature 99.7		 													
Muscle tone: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Flaccid <input type="checkbox"/> Rigid		REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		REACTION TO LIGHT: Slow													
RIGHT ARM 		LEFT ARM 		Old scars left inside forearm													
Comments: None		What drugs or medications have you been using? None		How much? No answer	Time of use? N/A												
Where were the drugs used? (Location) No answer		Date / Time of arrest: 07/04/12 2130		Time DRE was notified: 2200	Evaluation start time: 2230												
Evaluation completion time: 2340		Precinct/Station: Troop C		Officer's Signature:													
DRE # 10712		Reviewed/approved by / date:															
Opinion of Evaluator:		<input type="checkbox"/> Rule Out <input type="checkbox"/> Alcohol <input checked="" type="checkbox"/> CNS Stimulant <input type="checkbox"/> Dissociative Anesthetic <input type="checkbox"/> Inhalant <input type="checkbox"/> Medical <input type="checkbox"/> CNS Depressant <input type="checkbox"/> Hallucinogen <input type="checkbox"/> Narcotic Analgesic <input type="checkbox"/> Cannabis															

DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: Baker, Sam B.

1. **LOCATION:** The evaluation was conducted at the Cooperstown Police Department.
2. **WITNESSES:** The evaluation was witnessed and recorded by Trooper David Olney of the New York State Police.
3. **BREATH ALCOHOL TEST:** Baker's breath test was 0.00%.
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** I was contacted and advised to meet Trooper Guerriere at the Cooperstown Police Department for a drug evaluation. It was determined that Trooper Guerriere arrested Baker for DUI after his vehicle crossed the center line and nearly struck Trooper Guerriere's patrol vehicle.
5. **INITIAL OBSERVATION OF SUSPECT:** I first observed the suspect standing in the breath testing room with Trooper Guerriere. The suspect was repeatedly shifting his weight from foot to foot. He was scratching his head and was perspiring heavily. He appeared nervous, anxious and was very restless. His speech was fast and slurred at times.
6. **MEDICAL PROBLEMS AND TREATMENT:** None noted or stated.
7. **PSYCHOPHYSICAL TESTS:** The suspect had difficulty performing the psychophysical tests. Modified Romberg Balance: Suspect had an approximate 3" front to back and a 2" side to side sway and estimated 30 seconds in 21 seconds. Walk & Turn: Suspect performed the test very quickly, used his arms for balance and missed heel to toe three times. One Leg Stand: Suspect swayed while balancing, used his arms for balance and put his foot down once. He also counted fast during the test. Finger to Nose: Suspect missed the tip of his nose on three of the six attempts and had quick jerky movements.
8. **CLINICAL INDICATORS:** Suspect's pulse, blood pressure and temperature were elevated and above the DRE average ranges. His pupils were dilated in room light and in direct light.
9. **SIGNS OF INGESTION:** The suspect had a reddened nasal area and his nose was runny.
10. **SUSPECT'S STATEMENTS:** Suspect denied using any drugs.
11. **DRE'S OPINION:** In my opinion Baker is under the influence of a CNS Stimulant and unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** The suspect provided a urine sample.
13. **MISCELLANEOUS:**

DRUG INFLUENCE EVALUATION

Evaluator Trooper Kelly Gregerson, WA State Patrol		DRE # 11341	Rolling Log # 12-03-010	Session XV-I #3			
Recorder/Witness Deputy Theodore Boe, King Co. S.O.		Crash: <input checked="" type="checkbox"/> None <input type="checkbox"/> Fatal <input type="checkbox"/> Injury <input type="checkbox"/> Property		Case # 12-10127			
Arrestee's Name (Last, First, Middle) Charles, Mary C.		Date of Birth 6/13/72	Sex F	Race W	Arresting Officer (Name, ID#) Sgt. Courtney Stewart, WA SP #15455		
Date Examined / Time / Location 03/17/12 0045 Olympia WSP Office		Breath Results: Results: 0.07		Test Refused <input type="checkbox"/> Instrument #: 212005	Chemical Test: Urine <input type="checkbox"/> Blood <input checked="" type="checkbox"/> Test or tests refused <input type="checkbox"/>		
Miranda Warning Given Given By: Sgt. Stewart	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? Pizza, Last night	What have you been drinking? "Couple of beers"	How much?	Time of last drink? 9 pm		
Time now/ Actual Midnight/0058	When did you last sleep? How long Last night 7 hrs.	Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			
Are you taking any medication or drugs? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No Birth control pills		Attitude: Cooperative		Coordination: Poor, staggering			
Speech: Slurred		Breath Odor: Odor of alcoholic beverage		Face: Flushed			
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Bloodshot <input type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right			
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No			
Pulse and time 1. 68 / 0050 2. 64 / 0105 3. 72 / 0117		HGN	Left Eye	Right Eye	31 ONE LEG STAND 30		
Modified Romberg Balance 		Walk and Turn test 		Convergence 			
		Cannot keep balance <input checked="" type="checkbox"/>		Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal			
		Starts too soon <input type="checkbox"/>		Eyelids <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Droopy			
		Stops walking <input type="checkbox"/>		ONE LEG STAND results: 8 (L), 9 (R), 27 (L), 27 (R)			
		Misses heel-toe <input type="checkbox"/>		L R <input checked="" type="checkbox"/> Sways while balancing <input checked="" type="checkbox"/> Uses arms to balance			
		Steps off line <input type="checkbox"/>		<input type="checkbox"/> Hopping <input checked="" type="checkbox"/> Puts foot down			
		Raises arms <input type="checkbox"/>					
		Actual steps taken					
		1st Nine		2nd Nine			
		constant		constant			
		0		0			
Internal clock 40 estimated as 30 seconds		Describe Turn Lost balance/staggered		Cannot do test (explain) N/A			
Draw lines to spots touched 		Type of footwear: Tennis shoes		Nasal area: Clear			
		PUPIL SIZE		Oral cavity: Clear			
		Room light 2.5-5.0		Darkness 5.0-8.5		Direct 2.0-4.5	
		Left Eye 4.5		6.5		3.5	
		Right Eye 4.5		6.5		3.5	
Blood pressure 110/76		Temperature 98.0		REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		REACTION TO LIGHT: Slow	
Muscle tone: <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Flaccid <input type="checkbox"/> Rigid		RIGHT ARM 		LEFT ARM 		No visible marks	
Comments: What drugs or medications have you been using? "None, just my pill"		How much? No answer		Time of use? N/A		Where were the drugs used? (Location) No answer	
Date / Time of arrest: 03/17/12 0010		Time DRE was notified: 0025		Evaluation start time: 0045		Evaluation completion time: 0125	
Officer's Signature:		DRE # 11341		Reviewed/approved by / date:			
Opinion of Evaluator:		<input type="checkbox"/> Rule Out <input checked="" type="checkbox"/> Alcohol <input type="checkbox"/> Medical <input type="checkbox"/> CNS Depressant		<input type="checkbox"/> CNS Stimulant <input type="checkbox"/> Hallucinogen		<input type="checkbox"/> Dissociative Anesthetic <input type="checkbox"/> Narcotic Analgesic <input type="checkbox"/> Inhalant <input type="checkbox"/> Cannabis	

DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: Charles, Mary C.

1. **LOCATION:** The evaluation was conducted at the WSP Office in Olympia.
2. **WITNESSES:** The evaluation was recorded and witnessed by Deputy Theodore Boe of the King County S.O.
3. **BREATH ALCOHOL TEST:** Charles' breath test was a 0.07%.
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** Sergeant Stewart contacted the writer at the Olympia Patrol Office requesting a drug evaluation on suspect Charles. Sergeant Stewart advised that the suspect had been reported by several motorists as a possible DUI driver. She located the suspect traveling SB on I-5. The suspect was unable to maintain a single lane of travel and had traffic backed up behind her. When contacted, the suspect had slow, sluggish reactions and slurred speech. She performed poorly on the SFST's and was arrested for DUI.
5. **INITIAL OBSERVATION OF SUSPECT:** Writer first observed the suspect in the interview room with Sergeant Stewart. The suspect was swaying as she stood and was very unstable on her feet. Her speech was slow, thick and slurred.
6. **MEDICAL PROBLEMS AND TREATMENT:** None noted or stated.
7. **PSYCHOPHYSICAL TESTS:** Modified Romberg Balance: Suspect had an approximate 2" circular sway and estimated 30 seconds in 40 seconds. Walk & Turn: Suspect lost her balance during the instructions, missed heel to toe twice, stepped off the line and used her arms for balance. One Leg Stand: Suspect swayed while balancing, used her arms for balance and put her foot down once while standing on her left foot and twice while standing on the right foot. Finger to Nose: Suspect missed the tip of her nose on 3 of the 6 attempts.
8. **CLINICAL INDICATORS:** The suspect exhibited six clues of HGN and a Lack of Convergence.
9. **SIGNS OF INGESTION:** The suspect had an odor of an alcoholic beverage on her breath.
10. **SUSPECT'S STATEMENTS:** Suspect admitted drinking a "couple of beers" earlier in the evening and admitted smoking some marijuana 3 or 4 days ago.
11. **DRE'S OPINION:** In my opinion Charles is under the influence of Alcohol (ETOH) and unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** The suspect provided a blood sample.
13. **MISCELLANEOUS:**

DRUG INFLUENCE EVALUATION

Evaluator Sgt. Joseph Milos, Bellevue PD		DRE # 4477	Rolling Log # 12-02-008	Session XV-I #4	
Recorder/Witness Sgt. Martin Denton, Nebraska SP		Crash: <input checked="" type="checkbox"/> None <input type="checkbox"/> Fatal <input type="checkbox"/> Injury <input type="checkbox"/> Property		Case # 12-12050	
Arrestee's Name (Last, First, Middle) Dodge, Fred D.		Date of Birth 10/13/75	Sex M	Race W	Arresting Officer (Name, ID#) Sgt. Dale Hilderbrand, Grand Island P.D. #6047
Date Examined / Time / Location 02/22/12 2215 Grand Island PD		Breath Results: Results: 0.00		Test Refused <input type="checkbox"/> Instrument #: 43121	Chemical Test: Urine <input type="checkbox"/> Blood <input checked="" type="checkbox"/> Test or tests refused <input type="checkbox"/>
Miranda Warning Given Given By: Sgt. Hilderbrand	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? 2 tacos 2 hrs. ago	What have you been drinking? Nothing	How much?	Time of last drink? N/A
Time now/ Actual 11:00 pm / 2220	When did you last sleep? How long Yesterday 4-5 hrs.	Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Attitude: Excited, Cooperative		Coordination: Poor, jittery, stumbling	
Speech: Rapid		Breath Odor: Normal		Face: Normal	
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right	
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	
Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal		Eyelids: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Droopy			
Pulse and time 1. 100 / 2228 2. 104 / 2235 3. 100 / 2242		HGN Lack of Smooth Pursuit: No Maximum Deviation: No Angle of Onset: None	Left Eye No No None	Right Eye No No None	Convergence Right eye Left eye
Modified Romberg Balance Walk and Turn test Walked rapidly		Cannot keep balance <input checked="" type="checkbox"/> Starts too soon <input checked="" type="checkbox"/> Stops walking <input checked="" type="checkbox"/> Misses heel-toe <input type="checkbox"/> Steps off line <input type="checkbox"/> Raises arms <input type="checkbox"/> Actual steps taken: 9 9		38 ONE LEG STAND 35 L R <input checked="" type="checkbox"/> Sways while balancing <input type="checkbox"/> Uses arms to balance <input type="checkbox"/> Hopping <input checked="" type="checkbox"/> Puts foot down	
Internal clock 22 estimated as 30 seconds		Describe Turn As instructed		Cannot do test (explain) N/A	
Type of footwear: Boots					
Draw lines to spots touched R L		PUPIL SIZE		Nasal area: Redness	
		Room light 2.5-5.0		Darkness 5.0-8.5	
		Direct 2.0-4.5		Oral cavity: Clear	
Left Eye 6.0		Right Eye 6.0		REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
RIGHT ARM 		LEFT ARM 		REACTION TO LIGHT: Slow	
Blood pressure 142/96		Temperature 99.5		Four puncture wounds with red dots	
Muscle tone: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Flaccid <input type="checkbox"/> Rigid		Comments:			
What drugs or medications have you been using? "I'm not answering that man"		How much? No answer		Time of use? No answer	
Where were the drugs used? (Location) No answer		Date / Time of arrest: 02/22/12 2135		Time DRE was notified: 2200	
Evaluation start time: 2215		Evaluation completion time: 2355		Precinct/Station:	
Officer's Signature:		DRE # 4477		Reviewed/approved by / date:	
Opinion of Evaluator:		<input type="checkbox"/> Rule Out <input type="checkbox"/> Alcohol <input type="checkbox"/> Medical <input type="checkbox"/> CNS Depressant		<input checked="" type="checkbox"/> CNS Stimulant <input type="checkbox"/> Hallucinogen <input type="checkbox"/> Dissociative Anesthetic <input type="checkbox"/> Narcotic Analgesic <input type="checkbox"/> Inhalant <input type="checkbox"/> Cannabis	

DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: Dodge, Fred D.

1. **LOCATION:** The evaluation was conducted at the Grand Island Police Department.
2. **WITNESSES:** The evaluation was recorded by the arresting officer, Sergeant Dale Hilderbrand of the Grand Island Police Department and witnessed by Sgt. Martin Denton.
3. **BREATH ALCOHOL TEST:** Dodge's breath test was 0.00%.
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** Sgt. Hilderbrand contacted Dispatch and requested a drug evaluation on suspect Dodge. I contacted Sgt. Hilderbrand at the P.D. where it was determined the suspect had been involved in an attempted elude and was apprehended at E. Bismark Road and S. Oak. The suspect was very restless, animated and unable to stand still. He was also very talkative and his speech was rapid. He performed poorly on SFST's and was arrested for DUI.
5. **INITIAL OBSERVATION OF SUSPECT:** I first observed the suspect in the interview room at the P.D. His speech was rapid and loud. He seemed unconcerned about being under arrest. He had quick movements and was unable to stand still.
6. **MEDICAL PROBLEMS AND TREATMENT:** None noted or stated.
7. **PSYCHOPHYSICAL TESTS:** Modified Romberg Balance: Suspect had an approximate 2" side to side sway and estimated 30 seconds in 22 seconds. Walk & Turn: Suspect twice started the test too soon, lost his balance once during the instructions, stopped walking on his fifth step, raised his arms for balance and performed the test quickly. One Leg Stand: Suspect swayed while balancing and put his foot down once while standing on his right foot. Finger to Nose: Suspect missed the tip of his nose on all six attempts.
8. **CLINICAL INDICATORS:** The suspect's pulse and blood pressure were elevated and above the DRE average ranges. His pupils were dilated and had a slow reaction to light.
9. **SIGNS OF INGESTION:** The suspect had four fresh puncture marks on the inside of his left forearm.
10. **SUSPECT'S STATEMENTS:** Suspect denied any drug use.
11. **DRE'S OPINION:** In my opinion Dodge is under the influence of a CNS Stimulant and unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** The suspect provided a blood sample.
13. **MISCELLANEOUS:**

DRUG INFLUENCE EVALUATION

Evaluator Sgt. Jim Roy, Colchester P.D.		DRE # 12574	Rolling Log # 12-08-018	Session XV-I #5	
Recorder/Witness Lt. John Flannigan, VT State Police		Crash: <input checked="" type="checkbox"/> None <input type="checkbox"/> Fatal <input type="checkbox"/> Injury <input type="checkbox"/> Property		Case # 12-001701	
Arrestee's Name (Last, First, Middle) Edwards, Joan E.		Date of Birth 1/16/84	Sex F	Race W	Arresting Officer (Name, ID#) Officer Ron Hoague, St. Albans PD #13224
Date Examined / Time / Location 08/04/12 2300 Colchester PD		Breath Results: Results: 0.00		Test Refused <input type="checkbox"/> Instrument #: 41478	Chemical Test: Urine <input type="checkbox"/> Blood <input checked="" type="checkbox"/> Test or tests refused <input type="checkbox"/>
Miranda Warning Given Given By: Officer Hoague	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? Nothing N/A	What have you been drinking? How much? Nothing	Time of last drink? N/A	
Time now/ Actual "Don't know"	When did you last sleep? How long "I don't remember"	Are you sick or injured? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No Sick to stomach		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Attitude: Disoriented, cooperative		Coordination: Poor, unsteady	
Speech: Rambling, slurred		Breath Odor: Normal		Face: Sweaty, dazed appearance	
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right	
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	
Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal		Eyelids: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Droopy			
Pulse and time 1. <u>100</u> / <u>2310</u> 2. <u>108</u> / <u>2325</u> 3. <u>104</u> / <u>2337</u>		HGN Lack of Smooth Pursuit Maximum Deviation Angle of Onset	Left Eye No No None	Right Eye No No None	Convergence Right eye Left eye
Modified Romberg Balance 		Walk and Turn test 		ONE LEG STAND 	
		Cannot keep balance _____ Starts too soon _____ Stops walking _____ Misses heel-toe _____ Steps off line _____ Raises arms _____ Actual steps taken		L R <input type="checkbox"/> <input type="checkbox"/> Sways while balancing <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Uses arms to balance <input type="checkbox"/> <input type="checkbox"/> Hopping <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Puts foot down Test stopped	
Internal clock 90 estimated as 30 seconds		Describe Turn: Wrong direction		Cannot do test (explain) Kent stopping	
Type of footwear: Flip-flops		PUPIL SIZE		Nasal area: Clear	
Draw lines to spots touched 		Room light	Darkness	Direct	Oral cavity: Clear
		Left Eye	Right Eye		
		REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		REACTION TO LIGHT: Slow	
		RIGHT ARM 		LEFT ARM 	
		Nothing observed			
Blood pressure 148/110	Temperature 100.0	Muscle tone: <input type="checkbox"/> Normal <input type="checkbox"/> Flaccid <input checked="" type="checkbox"/> Rigid		Comments: Very rigid arms	
What drugs or medications have you been using? "Nothing"		How much? No answer	Time of use? No answer	Where were the drugs used? (Location) No answer	
Date / Time of arrest: 08/04/12 2215	Time DRE was notified: 2245	Evaluation start time: 2300	Evaluation completion time: 2355	Precinct/Station:	
Officer's Signature:		DRE # 12574	Reviewed/approved by / date:		
Opinion of Evaluator:		<input type="checkbox"/> Rule Out	<input type="checkbox"/> Alcohol	<input type="checkbox"/> CNS Stimulant	<input type="checkbox"/> Dissociative Anesthetic
		<input type="checkbox"/> Medical	<input type="checkbox"/> CNS Depressant	<input checked="" type="checkbox"/> Hallucinogen	<input type="checkbox"/> Narcotic Analgesic
				<input type="checkbox"/> Inhalant	<input type="checkbox"/> Cannabis

DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: Edwards, Joan E.

1. **LOCATION:** The evaluation was conducted at the Colchester Police Department.
2. **WITNESSES:** Lt. John Flannigan from the VT State Police recorded the evaluation.
3. **BREATH ALCOHOL TEST:** Edwards' breath test was a 0.00%.
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** I was advised to contact Officer Hoague at the Colchester PD for a drug evaluation. It was determined that Officer Hoague had found the suspect sitting on the hood of her vehicle along I-89-S. She was waving her arms and screaming at cars as they passed by. It was determined that she had driven her vehicle to that location after attending a concert in Canada earlier that day. She was administered SFST's which she had great difficulty completing and was subsequently arrested for DUI.
5. **INITIAL OBSERVATION OF SUSPECT:** I first observed the suspect in the interview room at CPD. She appeared dazed, disoriented and had difficulty standing.
6. **MEDICAL PROBLEMS AND TREATMENT:** Suspect stated she felt sick to her stomach and felt like "throwing-up" but did not require medical assistance.
7. **PSYCHOPHYSICAL TESTS:** The suspect performed very poorly on the psychophysical tests. Modified Romberg Balance: Suspect had an approximate 3" side to side sway and estimated 30 seconds in 90 seconds. Walk & Turn: Suspect missed heel to toe on each step, stopped walking twice, used her arms for balance, took an extra step on the first nine steps and made an improper turn. One Leg Stand: The suspect put her foot down three times on each foot and the test was stopped for safety reasons. Finger to Nose: Suspect missed the tip of her nose on all six attempts.
8. **CLINICAL INDICATORS:** The suspect's pulse, blood pressure and temperature were elevated and above the DRE average ranges. Her pupils were dilated.
9. **SIGNS OF INGESTION:** None were evident.
10. **SUSPECT'S STATEMENTS:** Suspect denied any medicine or drug use.
11. **DRE'S OPINION:** In my opinion Edwards is under the influence of a **Hallucinogen** and unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** The suspect provided a blood sample.
13. **MISCELLANEOUS:** After completing the evaluation the suspect was transported to the local hospital for monitoring and a medical evaluation.

Session 16

Dissociative Anesthetics



Session 16 - Dissociative Anesthetics

Learning Objectives

- Explain a brief history of Dissociative Anesthetics and specifically PCP and its analogs
- Identify common drug names and terms associated with this drug category
- Identify common methods of administration for this drug category
- Describe the symptoms, observable signs and other effects associated with this drug category



Drug Recognition Expert Course 16-2

Briefly review the objectives, content and activities of this session.

Upon successfully completing this session the participant will be able to:

- Explain a brief history of Dissociative Anesthetics and specifically PCP and its analogs.
- Identify common drug names and terms associated with this drug category.
- Identify common methods of administration for this drug category.
- Describe the symptoms, observable signs and other effects associated with this drug category.

Session 16 - Dissociative Anesthetics

Learning Objectives (Cont.)

- Describe the typical time parameters associated with this drug category
- List the clues that are likely to emerge when the drug influence evaluation is conducted for a person under the influence of this drug category
- Correctly answer the “topics for study” questions at the end of this session




Drug Recognition Expert Course 16-3

- Describe the typical time parameters associated with this drug category
- List the clues that are likely to emerge when the drug influence evaluation is conducted for a person under the influence of this drug category
- Correctly answer the “topics for study” questions at the end of this session

CONTENT SEGMENTS

- A. Overview of Dissociative Anesthetics
- B. Possible Effects of Dissociative Anesthetics
- C. Onset and Duration of Effects
- D. Signs and Symptoms of Dissociative Anesthetics Overdose
- E. Expected Results of the Evaluation
- F. Classification Exemplars

LEARNING ACTIVITIES

Instructor-Led Presentations
 Review of DEC Exemplars
 Reading Assignments
 Video Presentations
 Slide Presentations

Session 16 - Dissociative Anesthetics

Overview of Dissociative Anesthetics

- Drugs that inhibit pain by cutting off or dissociating the brain's perception of pain
- Induce a state of sedation, immobility, amnesia and analgesia





Drug Recognition Expert Course 16-4

A. Overview of Dissociative Anesthetics

Point out that this category was changed from PCP to Dissociative Anesthetics by the IACP DRE Technical Advisory Panel in September 2005.

Dissociative Anesthetics include drugs that inhibit pain by cutting off or disassociating the brain's perception of pain. The drugs within this category normally will induce a state of sedation, immobility, amnesia and marked analgesia.

Point out that the term "Dissociative Anesthesia" is derived from the strong feeling of dissociation from the environment that is expected by the user. PCP was the first drug used for this purpose.

Session 16 - Dissociative Anesthetics

Phencyclidine (PCP)

Phenyl Cyclohexyl Piperidine

- Produces some effects that are similar to the effects of CNS Depressants
- Produces some effects that are similar to those of CNS Stimulants
- In some respects it acts like a Hallucinogen




Drug Recognition Expert Course 16-5

Phencyclidine (PCP)

Phencyclidine or PCP, is a drug that, along with its analogs, are examples of this distinct drug category.

The chemical for PCP is Phenyl Cyclohexyl Piperidine.

Write the chemical name on the dry erase board or flip-chart, underlining the first “P”, the first “C” and the last “P”.

PCP shares some characteristics with each of the three categories of drugs.

It produces some effects that are similar to the effects of CNS Depressants.

- Examples of effects PCP shares with Depressants: Nystagmus, slurred speech, slowed responses.

It produces some effects that are similar to those of CNS Stimulants.

- Examples of effects PCP shares with CNS Stimulants: elevated vital signs and restlessness.

In some respects it acts like a Hallucinogen.

Point out that PCP and its analogs have often been referred to as “psychedelic anesthetics” because of the bizarre and varying effects they can cause.

“Phencyclidine” is a contracted or a shortened form of the chemical name. Point out that an “Analog” is a chemical that is very similar to the drug in terms of molecular structure or in psychoactive effects.

Point out that in many medical texts and other reference documents, PCP may be classified as a Hallucinogen. However, for purposes of the Drug Evaluation and Classification program, it is treated as a separate category.

Session 16 - Dissociative Anesthetics

Brief History of PCP

- Developed in the late 1950's
- An effective intravenous anesthetic
- Patented in 1963 under trade name of "Sernyl"
- Used in treating mental and psychological disorders



Drug Recognition Expert Course 16-6

Phencyclidine was first developed in the late 1950's. It was developed by Parke-Davis and Company, a leading pharmaceutical firm.

- The developers were searching for a drug that would serve as an efficient intravenous anesthetic.
- PCP proved to be a very effective anesthetic.
- An anesthetic is an agent that reduces or abolishes pain sensitivity.
- It was patented and marketed in 1963 under the trade name Sernyl.
- It was used in the treatment of mental and psychological disorders, including schizophrenia.

Session 16 - Dissociative Anesthetics

Brief History of PCP (Cont.)

- Produced undesirable side effects
- Use as an anesthetic for humans was discontinued in 1967
- Re-patented in 1968 as an animal tranquilizer under the trade name of “Sernylan”





Drug Recognition Expert Course 16-7

- Many adverse side effects were experienced by persons who had been treated with PCP. ***Point out that some of these side effects will be discussed later.***
- In 1967, use of Phencyclidine as an anesthetic for humans was discontinued.
- In 1968, Parke-Davis re-patented PCP under the trade name Sernylan, which was restricted to use as a veterinary anesthetic.
- Sernyl for animals = Sernylan.
- However, Sernylan was often illicitly diverted to “street” use, so most legitimate manufacturing of PCP was stopped in 1978.

Point out that this is why PCP sometimes goes by the “street” names “Monkey Dust”; “Elephant Tranquilizer”; “Horse Tranquilizer”; etc.

Session 16 - Dissociative Anesthetics

Manufacture of PCP

- **Relatively easy**
- **Chemicals available commercially**
- **Formula for producing PCP has been widely publicized.**
- **Basic hardware**





Drug Recognition Expert Course 16-8

PCP is relatively easy to manufacture.

- The chemicals required to produce it are readily available commercially.
- The formula for producing PCP has been widely publicized.
- The hardware needed to combine the chemicals is very basic.

Emphasize, however, that there is some danger present in the manufacturing process. Illicit PCP laboratories frequently explode and burn.

Emphasize that officers should exercise great caution when they discover an illicit PCP lab.

Note that PCP labs commonly contain potassium cyanide and hydrochloric acid. If combined, those two chemicals produce the same lethal gas used in gas chambers designed for executions.

Review the policy and procedures of the participants' department for dealing with PCP labs and materials.

Session 16 - Dissociative Anesthetics

Common PCP “Street Names”

- Ace
- Amoeba
- Trank
- Jet Fuel
- Juice
- Dust
- Magic Dust
- Monkey Dust
- Crystal Joints
- Krystal
- KJ (Or CJ)
- Devil Dust
- KJ Krystal
- Angel Dust
- Krystal Joints
- Embalming Fluid
- Monkey Tranquilizer
- Lovely



Drug Recognition Expert Course 16-9

Street names for PCP – “angel dust,” “crystal,” “sherm,” “elephant tranquilizer,” and “water.”

Session 16 - Dissociative Anesthetics

More PCP “Street Names”

- Peace
- Peace Pill
- Paz
- Green
- Elephant Tranquilizer
- Horse Tranquilizer
- Animal Tranquilizer
- Green Leaves
- Tic Tac
- Kools
- Super Kools
- Super Grass
- Super Weed
- Zombie Weed
- Peace Weed
- Mint Weed
- Killer Weed
- Sherms



Drug Recognition Expert Course

16-10

Session 16 - Dissociative Anesthetics

PCP and Analogs Methods of Ingestion

- **Smoking**



The slide contains three photographs. The left photo shows a wooden pipe and a small glass bottle with a black cap on a wooden surface. The middle photo is a close-up of a person's mouth with a cigarette, showing smoke rising. The right photo shows a glass bottle with a black cap and a pipe on a wooden surface.




Drug Recognition Expert Course 16-11

Methods of Ingestion: PCP

If available, display slides of the various PCP ingestion paraphernalia.

- Many users ingest PCP by smoking.
- PCP can be applied in either powder or liquid form to a variety of vegetable or leafy substances, which can then be smoked in a pipe or homemade cigarette.
- Popular substances include mint leaves, parsley, oregano, tobacco, or marijuana.

Point out that PCP smoke is very hot and can irritate the mouth and tongue. Mint leaves and similar material help to cool the smoke.

- Commercially prepared cigarettes can also be dipped in liquid PCP, allowed to dry and then smoked.

Note: PCP adulterated cigarettes usually will be wrapped in metal foil to be preserved.

- Some users prefer to dip a string in liquid PCP, and then insert the string into a tobacco cigarette.

Point out that menthol brand cigarettes are popular for this, because they are mentholated. PCP adulterated cigarettes are sometimes called “Super Kools” or “Sherms”, because of the cigarette brand used.

Note: White cigarette paper will be stained brown if adulterated with PCP. Brown cigarette paper will show white crystals, when adulterated.

Session 16 - Dissociative Anesthetics

PCP and Analogs

Methods of Ingestion (Cont.)

- Insufflation (inhaling; snorting)
- Orally
- Injection
- Eyedropper
- Transdermal absorption










Drug Recognition Expert Course 16-12

PCP can also be insufflated or “snorted.”

It can also be taken orally, in capsule or tablet form.

Some users inject liquid PCP, either directly into a vein, under the skin or into a muscle.

Some users have administered PCP to themselves by dripping liquid PCP onto their eyes, using an eyedropper.

Transdermal absorption of PCP has also been reported (i.e. when applied to the skin, especially as a liquid, PCP can penetrate directly into the body and bloodstream).

Note: Liquid PCP is especially dangerous because it can be absorbed through the skin. Hence, it could be used as a weapon.

Re-emphasize the danger to officers handling suspected drugs without proper protective gloves.

Solicit participants' questions and comments about the overview of PCP.

Session 16 - Dissociative Anesthetics

Ketamine

- **Used as a rapid surgical anesthetic in both animals and humans**
- **Brand names of Ketamine: Ketalar, Ketaset, Ketavet, Vetalar and Vetamine**
- **Methoxetamine – Analog of Ketamine**




Drug Recognition Expert Course 16-13

Ketamine

Write Ketamine on the dry erase or flip-chart.

Another drug in this category is called Ketamine. It continues to be manufactured and sold legitimately.

Ketamine is a white, crystalline powder or clear liquid.

Ketamine is used as a rapid surgical anesthetic, both for animals and humans, especially children.

- Some brand names of Ketamine: Ketalar (human use), Ketaset, Ketavet, Vetalar and Vetamine (veterinary use).
- Ketamine is being studied as a possible treatment of depression.
- Methoxetamine – a research chemical not currently approved for human or veterinary use. Methoxetamine has a similar abuse profile to Ketamine, and can cause pain suppression, tachycardia, hypertension, and altered perception and memory. Signs and symptoms include dissociated and catatonic state, nausea, vomiting, and visual hallucinations.

Source: "Society of Forensic Toxicologists Newsletter", Volume 36, Issue 4 (2012)

Session 16 - Dissociative Anesthetics

“Street Names” for Ketamine

- “K”
- “Special K”
- “Vitamin K”
- “Jet”
- “Super acid”
- “Kit Kat”
- “Lady K”
- “Kitty”
- “Cat Valium”
- “Super K”



Drug Recognition Expert Course

16-14

Ketamine street names include “K,” “Special K,” “Vitamin K,” “Jet” and “Super acid.”

Session 16 - Dissociative Anesthetics

Methods of Ingesting Ketamine

- Smoking
- Orally
- Injection
- Eyedropper
- Insufflation (snorting)






Drug Recognition Expert Course 16-15

Methods of Ingestion

Ketamine can be applied in either powder or liquid form to a variety of vegetable or leafy substances, which can then be smoked in a pipe or homemade cigarettes.

Popular substances include mint leaves, parsley, oregano, tobacco, or marijuana.

Commercially prepared cigarettes can also be dipped in liquid Ketamine, allowed to dry and then smoked.

Some users prefer to dip a string in liquid Ketamine, and then insert the string into a tobacco cigarette.

Session 16 - Dissociative Anesthetics

Dextromethorphan (DXM)

- Synthetically produced
- Found in numerous over the counter cough and cold products







Drug Recognition Expert Course 16-16

Dextromethorphan (DXM)

Another drug in this category is Dextromethorphan. It is sometimes referred to as “DXM” and is an ingredient found in numerous over-the-counter cough and cold remedies.

- Point out that DREs frequently encounter persons abusing DXM due to its availability in so many over-the-counter products.
- Point out in some respects, DXM's effects can be similar to a CNS Depressant, CNS Stimulant, and Hallucinogen. It has been classified as a CNS Depressant in some medical texts and scientific/ research reports.
- Point out that DXM is often in other over-the-counter substances containing Acetaminophen, Chlorpheniramine, and Guaifenesin.
- DXM is a synthetically produced substance that is chemically related to Codeine, although it is not an opiate.
- When ingested in recommended dosage levels, DXM generally is a safe and highly effective cough suppressant; however, when ingested in large amounts, it produces negative physiological effects.
- DXM abusers normally ingest the drug orally, although some snort
- Some abusers ingest 250 to 1,500 milligrams in a single dosage.

Session 16 - Dissociative Anesthetics

“Street Names” for DXM

- Triple C
- Robo
- Robo-Tripping
- Skittles
- Robo-dosing
- Robo-fire
- Rojo
- Candy
- Velvet
- DM



Drug Recognition Expert Course 16-17

Street names for Dextromethorphan include:

- Triple C
- Robo
- Robo-Tripping
- Skittles
- Robo-dosing
- Robo-fire
- Rojo
- Candy
- Velvet
- DM

Session 16 - Dissociative Anesthetics

Methods of Ingesting Dextromethorphan

- Orally
- Injection
- Insufflation (snorting)



Drug Recognition Expert Course 16-18

Methods of ingesting Dextromethorphan include:

- Orally
- Injection
- Insufflation (snorting)

Session 16 - Dissociative Anesthetics

Some Adverse Side Effects of PCP

- Delirium
- Agitation, anxiety
- Rigid muscle tone
- Elevated blood pressure
- Convulsions
- Difficulty in speech
- Hallucinations
- Violent reactions




Drug Recognition Expert Course 16-19

B. Possible Effects of Dissociative Anesthetics

Continuing research has demonstrated that PCP and other Dissociative Anesthetics consistently produced the following adverse side effects:

- Delirium: confusion, incoherent speech, excitement, illusions, hallucinations, and disorientation.
- Agitation, anxiety
- Rigid muscle tone
- Elevated blood pressure
- Convulsions: involuntary contortion of the muscles, producing contortion of the body and limbs.
- Difficulty in speech
- Hallucinations
- Violent reactions

Some lingering and long term effects were also noted.

- Some patients complained of dizziness for several hours after their attention and consciousness appeared to be cleared of PCP's effects.
- Some patients report memory disorders and other psychological disorders resembling schizophrenia for several months and even years afterwards.

Session 16 - Dissociative Anesthetics

PCP Psychotomimetic Drug

- **Effects mimic psychosis**
- **PCP cuts off the brain's perceptions of the senses**
- **Bizarre, self-destructive behavior**



Drug Recognition Expert Course 16-20

PCP has sometimes been called a psychotomimetic drug; i.e. it produces effects that mimic psychosis, or “craziness.” When the craziness remains long after the drug has dissipated, we say that its effects were psychogenic, i.e. it didn’t simply mimic craziness, it caused craziness.

PCP is classified as a Dissociative Anesthetic, because it cuts off the brain’s perceptions of the senses.

- PCP users often feel that their heads are physically separated from their bodies.
- They sometimes report feeling they are dead, and that their heads are floating away.

Session 16 - Dissociative Anesthetics

PCP Behavior

- **Man methodically pulled out his own teeth with pliers**
- **Individual has hallucinations of grotesque monsters and gouged out own eyes**
- **Young man drank rat poison, imagining that there were rats inside of his body**




Drug Recognition Expert Course 16-21

Cases of terribly bizarre, self-destructive behavior have been reported with persons under the influence of PCP.

Note: Instructors should feel free to replace or supplement these examples with others known personally to them.

- One young man methodically pulled his own teeth out, using a pair of pliers.
- Point out that PCP can render the user impervious to pain. It anesthetizes the central nervous system to the extent that surgery could be performed on the user while he or she is wide awake.
- Another individual suffered hallucinations of unbelievably grotesque monsters, and gouged out his own eyes to avoid seeing the monsters.
- Another young man drank rat poison, attempting to kill rats that he imagined were inhabiting his body.
- A nude woman plunged a butcher knife into her own eye, chest, groin and abdomen. She then threatened a police officer with the knife and was shot to death.

Source: Washington Post, March 7, 1988.

Session 16 - Dissociative Anesthetics

Onset and Duration of PCP and its Analogs Effects

- **Onset**
 - **Smoked: 1-5 minutes**
 - **Injected: 1-5 minutes**
 - **Snorted: 2-3 minutes**
 - **Orally: 30-60 minutes**
- **Peak effects**
 - **Generally in 15-30 minutes**
- **Duration**
 - **4-6 hours**



Drug Recognition Expert Course 16-22

C. Onset and Duration of Effects

PCP

- When PCP is smoked or injected, onset occurs within 1 – 5 minutes.
- When inhaled (“snorted”) onset occurs in 2 – 3 minutes.
- Onset is considerably slower when PCP is taken orally: 30 – 60 minutes.
- The effects reach their peak in about 15 – 30 minutes, assuming the PCP was smoked, injected or snorted.
- The effects generally last 4 – 6 hours, but they can go somewhat longer.
- The user usually, but not always returns to normal within 24 – 48 hours.

Session 16 - Dissociative Anesthetics

Onset and Duration of Ketamine

Onset

- **Smoked: within seconds**
- **Injected: 1-5 minutes**
- **Snorted: 5-10 minutes**
- **Orally: 15-20 minutes**



Drug Recognition Expert Course 16-23

Onset and Duration of Effects

Ketamine

- Within seconds if smoked; duration varies.

Point out that Ketamine abusers will often “re-administer” the drug due to its relatively short duration of action.

- 1 – 5 minutes if injected; lasting 30 – 45 minutes.
- 5 – 10 minutes if snorted; lasting 45 – 60 minutes.
- 15 – 20 minutes if orally; lasting 1 – 2 hours.

Session 16 - Dissociative Anesthetics

Onset and Duration of Effects for Dextromethorphan (DXM)

- Rapidly absorbed from the gastrointestinal tract
- Peak plasma concentration is reached in approximately 2.5 hours
- Expect antitussive effects in 15 – 30 minutes
- Duration of effects is approximately 3 – 6 hours



Drug Recognition Expert Course 16-24

Dextromethorphan

Point out that Dextromethorphan is demethylated to dextrorphan an active metabolite.

- Rapidly absorbed from the gastrointestinal tract and peak plasma concentrations are reached in approximately 2.5 hours.
- DXM is widely distributed and is rapidly and extensively metabolized by the liver.
- DXM exerts its antitussive effects within 15 – 30 minutes of oral administration. The duration of action is approximately 3 – 6 hours with conventional dosage forms.

Session 16 - Dissociative Anesthetics

DXM Plateau

- **1st Plateau: Mild inebriation**
- **2nd Plateau: An effect similar to alcohol intoxication with mild hallucinations**
- **3rd Plateau: An altered state of consciousness – impaired vision and other senses**
- **4th Plateau: Mind and body dissociation - “out of body” experience**




Drug Recognition Expert Course 16-25

DXM Plateau (or effect)

Abusers will also ingest various amounts of DXM depending on their body weight and the effect or “plateau” that they are attempting to achieve. Plateau’s include:

Point out that the normal recommended therapeutic dosages of DXM are 10 to 20 milligrams for every four hours or 30 milligrams every 6 to 8 hours.

1st Plateau: Mild inebriation.

2nd Plateau: An effect similar to alcohol intoxication with mild hallucinations.

Point out that speech at the 2nd plateau can become slurred, and short term memory may be temporarily impaired.

3rd Plateau: An altered state of consciousness where the abuser’s senses, particularly vision, can become impaired.

4th Plateau: Mind and body dissociation or an “out of body” experience.

Point out that abusers at the 4th plateau can lose some or all contact with his or her senses. The effects at this level are comparable to PCP.

Other effects include: blurred vision, body itching, rash, sweating, fever, hypertension, shallow respiration, diarrhea, toxic psychosis, and an increased heart rate, blood pressure and body temperature.

Acute dose between 250 – 1500 mg.

Solicit participants’ questions and comments concerning onset and duration factors.

Session 16 - Dissociative Anesthetics

Dissociative Anesthetic Overdose

- Deep coma
- Seizures and convulsions
- Respiratory depression
- May trigger a heart attack
- Eyes open with a blank stare



Drug Recognition Expert Course

16-26

D. Signs and Symptoms of Dissociative Anesthetic Overdose

In addition to the bizarre, violent and self-destructive behavior discussed previously, persons severely intoxicated by Dissociative Anesthetics may exhibit definite and extreme symptoms signifying a medically dangerous condition.

- A deep coma, lasting up to 12 hours.
- Seizures and convulsions.
- A danger associated with severe Dissociative Anesthetics intoxication is that the person may die due to respiratory depression.
- There is also some evidence that Dissociative Anesthetics may trigger a heart attack, if the user had some pre-existing condition disposing him or her to possible cardiac problems.
- Eyes generally open with a blank stare.

There is also some evidence that prolonged use of Dissociative Anesthetics can lead to psychosis, which can be permanent.

Solicit students questions and comments concerning signs and symptoms of Dissociative Anesthetic overdose.

Session 16 - Dissociative Anesthetics

Evaluation of Subjects Under the Influence of Dissociative Anesthetics

- HGN - Present with a very early angle of onset (maybe “immediate” or even “resting” nystagmus)
- VGN - Present
- Lack of Convergence – Present
- Impaired performance will be evident on Modified Romberg Balance, Walk and Turn, One Leg Stand and Finger to Nose tests



Drug Recognition Expert Course 16-27

E. Expected Results of the Evaluation

- Horizontal Gaze Nystagmus generally will be present with a very early angle of onset.

Note: So-called “Resting Nystagmus” may be evident, especially with high doses, and is more often associated with a neurological issue.

Remind the participants that Resting Nystagmus is a distinct jerking of the eyeballs even as the subject stares straight ahead.

- Vertical Gaze Nystagmus usually will be present.
- Lack of convergence will generally be present.
- Performance on Modified Romberg Balance will be impaired: internal clock may be slowed.
- Performance on Walk and Turn, One Leg Stand, and Finger to Nose will be impaired: muscle tone will usually be rigid.

With PCP, the subject may exhibit a “high gait ataxia” or “moon walking,” i.e. taking abnormally high and slow steps, as though he or she were trying to step over obstacles in his or her path.

Session 16 - Dissociative Anesthetics

Evaluation of Subjects Under the Influence Dissociative Anesthetics

Vital Signs:

- Blood pressure - Up
- Pulse - Up
- Body temperature - Up

Muscle Tone - Rigid



Drug Recognition Expert Course 16-28

Vital Signs

- Blood pressure will generally be elevated.
- Body temperature will generally be up.

Dark Room

- Pupil size will be within the average ranges.
- Reaction to light will be normal.

Session 16 - Dissociative Anesthetics

Evaluation of Subjects Under the Influence Dissociative Anesthetics

Dark Room:

- Pupil size - within the average ranges
- Pupillary reaction to light - Normal



Drug Recognition Expert Course 16-29

Dark Room

- Pupil size will be within the average ranges.
- Reaction to light will be normal.

Session 16 - Dissociative Anesthetics

General Indicators Subjects Under the Influence of Dissociative Anesthetics

- Blank stare
- Confused
- Chemical odor (PCP)
- Cyclic behavior (PCP)



Drug Recognition Expert Course 16-30

General Indicators

Point out that many, but not all of the general indicators for PCP and DXM are very similar.

- Blank stare
- Confused
- Chemical odor (PCP)
- Cyclic behavior (PCP)

Note: PCP abusers may display “Cyclic behaviors” which mean that the signs and symptoms tend to increase and decrease cyclically.

Session 16 - Dissociative Anesthetics

General Indicators (Cont.)

- Difficulty with speech
- Disoriented
- Early HGN angle of onset
- Hallucinations
- Incomplete verbal responses
- Non- Communicative
- Perspiring (PCP)
- Possibly violent
- Slurred and repetitive speech
- Warm to touch
- Loss of Memory



Drug Recognition Expert Course 16-31

- Difficulty with speech
- Disoriented
- Early HGN angle of onset
- Hallucinations

Note: Especially auditory hallucinations.

- Incomplete verbal responses
- Non-communicative
- Perspiring (PCP)
- Sensory distortions
- Possibly violent
- Slurred and repetitive speech
- Warm to touch (PCP)
- Loss of Memory

Session 16 - Dissociative Anesthetics

Dissociative Anesthetic Symptomatology Chart

HGN	Present
VGN	Present
Lack of Convergence	Present
Pupil Size	Normal
Reaction to Light	Normal
Pulse Rate	Up
Blood Pressure	Up
Temperature	Up
Muscle Tone	Rigid





Drug Recognition Expert Course
16-32

Summary

- Expected Results of the Evaluation. Note: “Normal” for pupil sizes refers to within the DRE average ranges.
- Point out that as with other drug categories, DREs should not specify the exact drug such as PCP, Ketamine or DXM.
- When a DRE concludes that a subject is impaired by a Dissociative Anesthetic, such as PCP or DXM, the report should state that “the subject is under the influence of a Dissociative Anesthetic.”

Session 16 - Dissociative Anesthetics

Dissociative Anesthetic



Drug Recognition Expert Course 1-33

Click video to begin

VIDEO DEMONSTRATION

***Show video example of subject under the influence of a Dissociative Anesthetics.
(Approximately 20 minutes).***

Session 16 - Dissociative Anesthetics

Drug Evaluation and Classification

Exemplar Demonstrations




Drug Recognition Expert Course

16-34

F. Classification Exemplar

Refer students to the exemplars found at the end of Session 16 of their participant manuals.

Point out that the one-page narrative in the example exemplars are not to be construed as the recommended or approved narrative report. The actual narrative report submitted by DREs will be more detailed.

Relate the items on the exemplars to the Dissociative Anesthetics Symptomatology Chart.

Point out that as with other drug categories, DREs should not specify the exact drug such as PCP, Ketamine or DXM.

Point out that tolerance may reduce some Dissociative Anesthetic symptoms. Show video of subject(s) under the influence of Dissociative Anesthetics. Relate behavior and observations to the drug Symptomatology Chart.

Relate behavior and observations to the Dissociative Anesthetics Symptomatology Chart.

Solicit students' questions or suggestions concerning Expected Results of the Evaluation of subjects under the influence of Dissociative Anesthetics.

Session 16 - Dissociative Anesthetics

Topics for study



Drug Recognition Expert Course 16-35

TOPICS FOR STUDY / ANSWERS

1. What was the original purpose for which PCP was first patented and marketed?

ANSWER: It was developed in the 1950's as an intravenous anesthetic.

2. Why do many PCP smokers prefer to adulterate mentholated cigarettes with PCP?

ANSWER: PCP smoke is very hot, so users will cool it through the use of mentholated cigarettes.

3. What is Ketamine?

ANSWER: An analog of PCP used as a surgical anesthetic, both for animals and humans, especially children.

4. What does the term "dissociative anesthetic" mean?

ANSWER: A dissociative anesthetic inhibits pain by cutting off (or dissociating) the brain's perception of the pain. PCP and its analogs are considered dissociative anesthetics.

5. "Phencyclidine" is a contraction of what three words?

ANSWER: Phenyl Cyclohexyl Piperidine

Session 16 - Dissociative Anesthetics







QUESTIONS?



Drug Recognition Expert Course

Solicit questions or comments concerning expected results of the drug evaluation of Dissociative Anesthetic subjects.







DRUG INFLUENCE EVALUATION

Evaluator Officer Steve Dunn, Anchorage P.D.		DRE # 11281	Rolling Log # 12-04-33	Session XVI # 1	
Recorder/Witness Officer Chris Ritala, A.P.D.		Crash: <input checked="" type="checkbox"/> None <input type="checkbox"/> Fatal <input type="checkbox"/> Injury <input type="checkbox"/> Property		Case # 12-788798	
Arrestee's Name (Last, First, Middle) Albright, Jeremy J.		Date of Birth 4/10/86	Sex M	Race W	Arresting Officer (Name, ID#) Officer David Pollock, A.P.D. #1374
Date Examined / Time / Location 04/07/12 1420 4 th Ave. Substation		Breath Results: Results: 0.00	Test Refused <input type="checkbox"/> Instrument #: 75470	Chemical Test: Urine <input type="checkbox"/> Blood <input checked="" type="checkbox"/>	Test or tests refused <input type="checkbox"/>
Miranda Warning Given Given By: Ofc. Pollock	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? Cheeseburger & fries 11AM	What have you been drinking? Water	How much? N/A	Time of last drink? N/A
Time now/ Actual "1:30PM" (1427)	When did you last sleep? How long "Night before last" 1-2 hrs.	Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			
Are you taking any medication or drugs? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No "Just some cold medicine"		Attitude: Cooperative		Coordination: Slow and deliberate	
Speech: Slurred	Breath Odor: Normal	Face: Flushed			
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft	Eyes: [] Reddened Conjunctiva <input type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input type="checkbox"/> Watery	Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right	Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal		
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)	Vertical Nystagmus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Eyelids: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Droopy		
Pulse and time 1. <u>110</u> / <u>1430</u> 2. <u>112</u> / <u>1446</u> 3. <u>110</u> / <u>1501</u>	HGN Lack of Smooth Pursuit: Yes Maximum Deviation: Yes Angle of Onset: Immediate	Left Eye Yes Yes Immediate	Right Eye Yes Yes Immediate	Convergence 	34 ONE LEG STAND 36 
Modified Romberg Balance 	Walk and Turn test 	Cannot keep balance <input checked="" type="checkbox"/> Starts too soon Stops walking Misses heel-toe Steps off line Raises arms Actual steps taken: 9	1 st Nine 2 nd Nine	L R <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Sways while balancing <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Uses arms to balance <input type="checkbox"/> <input type="checkbox"/> Hopping <input type="checkbox"/> <input type="checkbox"/> Puts foot down Leg tremors	
Internal clock 28 estimated as 30 seconds	Describe Turn Shuffled feet	Cannot do test (explain) N/A		Type of footwear: Lace-up boots	
Draw lines to spots touched 		PUPIL SIZE	Room light 2.5 - 5.0	Darkness 5.0 - 8.5	Direct 2.0 - 4.5
		Left Eye	5.0	8.0	4.0
		Right Eye	5.0	8.0	4.0
		REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		REACTION TO LIGHT: Normal	
Used the first pad of each finger		RIGHT ARM 		LEFT ARM 	
Blood pressure 152/102		Temperature 99.7		Nothing observed	
Muscle tone: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Flaccid <input type="checkbox"/> Rigid		Comments:			
What drugs or medications have you been using? Coricidin		How much? 24 pills	Time of use? Last night	Where were the drugs used? (Location) Friend's house	
Date / Time of arrest: 04/07/12 1300	Time DRE was notified: 1350	Evaluation start time: 1420	Evaluation completion time: 1540	Precinct/Station:	
Officer's Signature:		DRE # 11281	Reviewed/approved by / date:		
Opinion of Evaluator:		<input type="checkbox"/> Rate Out	<input type="checkbox"/> Alcohol	<input type="checkbox"/> CNS Stimulant	<input checked="" type="checkbox"/> Dissociative Anesthetic
		<input type="checkbox"/> Medical	<input type="checkbox"/> CNS Depressant	<input type="checkbox"/> Hallucinogen	<input type="checkbox"/> Narcotic Analgesic
				<input type="checkbox"/> Inhalant	<input type="checkbox"/> Cannabis

DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: Albright, Jeremy J.

1. **LOCATION:** The evaluation was conducted at the APD 4th Avenue Substation.
2. **WITNESSES:** Officer Chris Ritala of APD recorded the evaluation.
3. **BREATH ALCOHOL TEST:** Albright's breath test was 0.00%.
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** I was contacted and requested to contact Officer Pollock regarding a drug evaluation. Officer Pollock advised he had stopped the suspect for speeding on Minnesota Ave. The suspect had bloodshot eyes and slurred speech. He appeared impaired, however, there was no odor of alcoholic beverage on his breath. He had six clues of HGN and performed poorly on the SFST's. He admitted taking some cold medicine.
5. **INITIAL OBSERVATION OF SUSPECT:** I first observed the suspect in the interview room at the substation. His face was flushed and his speech slurred. His movements were slow and deliberate. He seemed disoriented and confused.
6. **MEDICAL PROBLEMS AND TREATMENT:** None noted or stated.
7. **PSYCHOPHYSICAL TESTS:** Modified Romberg Balance: Suspect swayed approximately 2" side to side and approximately 2" front to back. Walk & Turn: Suspect lost his balance during the instructions, turned by shuffling his feet and missed heel to toe twice on the second nine steps. One Leg Stand: Suspect had leg tremors, swayed while balancing and used his arms for balance. Finger to Nose: Suspect missed the tip of his nose on four of the six attempts. He used the pad of his finger on each attempt.
8. **CLINICAL INDICATORS:** HGN was present with an immediate onset. Vertical Gaze Nystagmus and Lack of Convergence were also present. His pulse, blood pressure and temperature were all elevated and above the DRE average ranges.
9. **SIGNS OF INGESTION:** None were evident.
10. **SUSPECT'S STATEMENTS:** Suspect admitted taking about 24 Coricidin pills.
11. **DRE'S OPINION:** In my opinion Albright is under the influence of a **Dissociative Anesthetic** and unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** The suspect provided a blood sample.
13. **MISCELLANEOUS:** The suspect stated he had been transported to the hospital several months ago when he overdosed by taking 32 Coricidin pills.






DRUG INFLUENCE EVALUATION					
Evaluator Officer Michael Bovills, LAPD		DRE # 13542	Rolling Log # 12-05-56	Session XVI # 2	
Recorder/Witness Officer Helen Pallares, LAPD		Crash: <input checked="" type="checkbox"/> None <input type="checkbox"/> Fatal <input type="checkbox"/> Injury <input type="checkbox"/> Property		Case # 12-335989	
Arrestee's Name (Last, First, Middle) George, Debra A.		Date of Birth 8/24/84	Sex F	Race W	Arresting Officer (Name, ID#) Officer Helen Pallares, LAPD #10175
Date Examined / Time / Location 05/02/12 2315 Parker Center		Breath Results: Results: 0.00	Test Refused <input type="checkbox"/> Instrument #: 74080	Chemical Test: Urine <input checked="" type="checkbox"/> Blood <input type="checkbox"/> Test or tests refused <input type="checkbox"/>	
Miranda Warning Given Given By: Officer Pallares	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? Pizza 6 PM	What have you been drinking? Nothing	How much? N/A	Time of last drink? N/A
Time now/ Actual 11 PM/11:15 PM	When did you last sleep? How long Last night 6-7 hrs.	Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Attitude: Passive, non-responsive		Coordination: Poor, slow, staggering	
Speech: Slow, confused, thick		Breath Odor: Normal		Face: Sweaty, flushed	
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right	Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Eyelids: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Droopy
Pulse and time 1. 106 / 2325 2. 104 / 2336 3. 104 / 2345		HGN Lack of Smooth Pursuit Maximum Deviation Angle of Onset	Left Eye Yes Yes Immediate	Right Eye Yes Yes Immediate	Convergence  Right eye Left eye
Modified Romberg Balance 		Walk and Turn test 		ONE LEG STAND 	
Internal clock 42 estimated as 30 seconds		Describe Turn Stopped, slow		Cannot do test (explain) N/A	
Draw lines to spots touched 		PUPIL SIZE	Room light 2.5 - 5.0	Darkness 5.0 - 8.5	Direct 2.0 - 4.5
		Left Eye	4.0	6.5	3.5
		Right Eye	4.0	6.5	3.5
REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		REACTION TO LIGHT: Normal			
RIGHT ARM 		LEFT ARM 			
Blood pressure 158/104		Temperature 100.4			
Muscle tone: <input type="checkbox"/> Normal <input type="checkbox"/> Flaccid <input checked="" type="checkbox"/> Rigid		Nothing observed			
Comments:		What drugs or medications have you been using? No response		How much? N/A	Time of use? No response
Where were the drugs used? (Location) No response		Date / Time of arrest: 05/02/12 2210	Time DRE was notified: 2300	Evaluation start time: 2315	Evaluation completion time: 2358
Precinct/Station: Central		Officer's Signature:		DRE # 13542	Reviewed/approved by / date:
Opinion of Evaluator:		<input type="checkbox"/> Rule Out	<input type="checkbox"/> Alcohol	<input type="checkbox"/> CNS Stimulant	<input checked="" type="checkbox"/> Dissociative Anesthetic
		<input type="checkbox"/> Medical	<input type="checkbox"/> CNS Depressant	<input type="checkbox"/> Hallucinogen	<input type="checkbox"/> Inhalant
				<input type="checkbox"/> Narcotic Analgesic	<input type="checkbox"/> Cannabis

DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: George, Debra A.

1. **LOCATION:** The evaluation was conducted at the Parker Center Intake Center.
2. **WITNESSES:** Arresting officer; Helen Pallares, LAPD recorded the evaluation.
3. **BREATH ALCOHOL TEST:** George's breath test was 0.00%.
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** Writer was contacted and requested to contact Officer Pallares at Parker Center for a drug evaluation. Officer Pallares advised she stopped the suspect after observing her nearly hit several parked cars on Broadway near 4th Street. Her speech was slow, thick and slurred. She was very confused and not sure of her surroundings. Her coordination was very poor and she nearly fell attempting the SFST's and was arrested for DUI.
5. **INITIAL OBSERVATION OF SUSPECT:** I first observed the suspect in the Processing Room at Parker Center. She appeared dazed and disoriented. She had a fixed stare and was responding slowly to questions. She was unstable on her feet and several times used the wall to steady herself. Her movements were slow and deliberate.
6. **MEDICAL PROBLEMS AND TREATMENT:** None noted or stated.
7. **PSYCHOPHYSICAL TESTS:** Modified Romberg Balance: Suspect swayed approximately 3" in a circular motion and estimated 30 seconds in 42 seconds. Walk & Turn: Suspect missed heel to toe numerous times and nearly fell twice. She repeatedly used her arms for balance and took a wrong number of steps. One Leg Stand: Suspect lost her balance using the wall to steady herself and the test had to be stopped. Finger to Nose: Suspect missed the tip of her nose on five of the six attempts.
8. **CLINICAL INDICATORS:** Suspect had six clues of HGN with an immediate angle of onset. She had VGN and was unable to convergence her eyes and looked straight ahead. Her pulse, blood pressure and temperature were all elevated and above the DRE average ranges.
9. **SIGNS OF INGESTION:** None were evident.
10. **SUSPECT'S STATEMENTS:** The suspect did not respond when questioned about drug use but did make several "K-Hole" references.
11. **DRE'S OPINION:** In my opinion George is under the influence of a **Dissociative Anesthetic** and unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** The suspect provided a urine sample.
13. **MISCELLANEOUS:**

DRUG INFLUENCE EVALUATION

Evaluators Sgt. Gerry Britt, Yarmouth P.D.		DRE # 5479	Rolling Log # 12-09-112	Session XVI # 3	
Recorder/Witness Don Decker, Nahant PD		Crash: <input checked="" type="checkbox"/> None <input type="checkbox"/> Fatal <input type="checkbox"/> Injury <input type="checkbox"/> Property		Case # 388661	
Arrestee's Name (Last, First, Middle) Ross, Robert H.		Date of Birth 9/6/79	Sex M	Race W	Arresting Officer (Name, ID#) Sgt. Deb Batista, Middleboro P.D. #10423
Date Examined / Time / Location 09/18/12 2145 Middleboro PD		Breath Results: Results: 0.00	Test Refused <input type="checkbox"/> Instrument #: 12838	Chemical Test: Urine <input type="checkbox"/> Blood <input checked="" type="checkbox"/> Test or tests refused <input type="checkbox"/>	
Miranda Warning Given Given By: Sgt. Batista	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? Chicken 6 AM	What have you been drinking? How much? Nothing	Time of last drink? N/A	
Time now/ Actual 8 PM/10 PM	When did you last sleep? How long? Yesterday 6 hrs.	Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Attitude: Passive, cooperative		Coordination: Poor, staggering	
Speech: Slurred, slow and low		Breath Odor: Chemical odor		Face: Flushed and sweaty	
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right	
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	
Pulse and time 1. <u>100</u> / <u>2150</u> 2. <u>102</u> / <u>2204</u> 3. <u>98</u> / <u>2217</u>		HGN Lack of Smooth Pursuit: Yes Maximum Deviation: Yes Angle of Onset: Immediate	Left Eye Yes Yes Immediate	Right Eye Yes Yes Immediate	Convergence 
Modified Romberg Balance  Circular sway		Walk and Turn test  Walked stiff legged		ONE LEG STAND  L R <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Sways while balancing <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Uses arms to balance <input type="checkbox"/> <input type="checkbox"/> Hopping <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Puts foot down Test stopped	
Internal clock 45 estimated as 30 seconds		Describe Turn: Spun around		Cannot do test (explain) N/A	
Draw lines to spots touched 		PUPIL SIZE		Nasal area: Clear	
		Left Eye		Oral cavity: Clear, chemical odor	
		Right Eye		REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Blood pressure 146/100		Temperature 99.8		REACTION TO LIGHT: Normal	
Muscle tone: <input type="checkbox"/> Normal <input type="checkbox"/> Flaccid <input checked="" type="checkbox"/> Rigid		Comments: Very rigid arms		RIGHT ARM 	
What drugs or medications have you been using? Nothing		How much? N/A		LEFT ARM 	
Date / Time of arrest: 09/18/12 2100		Time DRE was notified: 2120		Nothing observed	
Officer's Signature:		DRE # 5479		Reviewed/approved by / date:	
Opinion of Evaluator: <input type="checkbox"/> Rule Out <input type="checkbox"/> Medical		<input type="checkbox"/> Alcohol <input type="checkbox"/> CNS Depressant		<input type="checkbox"/> CNS Stimulant <input type="checkbox"/> Hallucinogen	
				<input checked="" type="checkbox"/> Dissociative Anesthetic <input type="checkbox"/> Narcotic Analgesic	
				<input type="checkbox"/> Inhalant <input type="checkbox"/> Cannabis	

DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: Ross, Robert H.

1. **LOCATION:** The evaluation was conducted at the Middleboro Police Department.
2. **WITNESSES:** Arresting officer Sgt. Deb Batista of the Middleboro PD witnessed the evaluation and Don Decker of Nahant PD recorded the evaluation.
3. **BREATH ALCOHOL TEST:** Ross' breath test was 0.00%.
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** I was contacted and advised to contact Sergeant Batista at the Middleboro Police Department for a drug evaluation. Sergeant Batista advised that she had observed the suspect driving on N. Main Street at approximately 10 mph drifting within his lane and nearly hitting parked vehicles. When stopped, the suspect appeared dazed and did not know where he was or where he was going. He had a blank stare and appeared very confused. He was arrested for DUI after performing poorly on the SFST's.
5. **INITIAL OBSERVATION OF SUSPECT:** I first observed the suspect in the interview room at M.P.D. He appeared dazed and disoriented, had a fixed stare and responded very slowly to questions. He was perspiring heavily and had rambling speech.
6. **MEDICAL PROBLEMS AND TREATMENT:** None noted or stated.
7. **PSYCHOPHYSICAL TESTS:** Modified Romberg Balance: Suspect swayed approximately 3" in a circular motion and estimated 30 seconds in 45 seconds. Walk & Turn: Suspect started walking immediately and lost his balance during the instructions, stepped off the line twice, stopped walking twice, used his arms for balance and missed heel to toe 6 times during the test. One Leg Stand: Suspect was unable to complete the test on either foot and the test was stopped for safety reasons. Finger to Nose: Suspect missed the tip of his nose on four of the six attempts. His arm movements were very rigid.
8. **CLINICAL INDICATORS:** Suspect exhibited an immediate onset of HGN. Vertical Gaze Nystagmus and Lack of Convergence were also present. The suspect's pulse, blood pressure and temperature were all elevated and above the DRE average ranges.
9. **SIGNS OF INGESTION:** There was a strong chemical-type odor on the suspect's breath.
10. **SUSPECT'S STATEMENTS:** The suspect stated that he did not use any drugs.
11. **DRE'S OPINION:** In my opinion Ross is under the influence of a **Dissociative Anesthetic** and unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** The suspect provided a blood sample.
13. **MISCELLANEOUS:**

R5/13

Session 17

Narcotic Analgesics



Session 17 - Narcotic Analgesics

Learning Objectives

- Explain a brief history of the Narcotic Analgesic category of drugs
- Identify common drug names and terms associated with this category
- Identify common methods of administration for this category
- Describe the symptoms, observable signs and other effects associated with this category



Drug Recognition Expert Course 17-2

Briefly review the objectives, content and activities of this session.

Upon successfully completing this session the participant will be able to:

- Explain a brief history of the Narcotic Analgesic category of drugs.
- Identify common drug names and terms associated with this category.
- Identify common methods of administration for this category.
- Describe the symptoms, observable signs and other effects associated with this category.

Session 17 - Narcotic Analgesics

Learning Objectives (Cont.)

- Describe the typical time parameters, i.e. Onset and duration of effects associated with this category
- List the clues that are likely to emerge when the drug influence evaluation is conducted for a person under the influence of this drug category
- Describe the procedures for examining and determining the ages of injection sites
- Correctly answer the “topics for study” questions at the end of this session




Drug Recognition Expert Course 17-3

- Describe typical time parameters, i.e. onset and duration of effects, associated with this category.
- List the clues that are likely to emerge when the drug influence evaluation is conducted for a person under the influence of this category of drugs.
- Describe the procedures for examining and determining the ages of injection sites.
- Correctly answer the “topics for study” questions at the end of this session.

CONTENT SEGMENTS

- Overview of the Category
- Possible Effects
- Onset and Duration
- Overdose Signs and Symptoms
- Expected Results of the Evaluation
- Injection Site Examination
- Expected Location of Injection Marks
- Conclusion
- Classification Exemplar

LEARNING ACTIVITIES

- Instructor-Led Presentations
- Review of Drug Evaluation; Classification Exemplars
- Reading Assignments
- Video Presentations
- Slide Presentations

Session 17 - Narcotic Analgesics

Narcotic Analgesic

- An “Analgesic” is a medication or drug that relieves pain. It differs from an anesthetic, in that it lowers one’s perception or sensations of pain, rather than stopping nerve transmission
- A Narcotic is a drug derived from Opium, or produced synthetically that relieves pain, but also induces euphoria, alters mood, and produces sedation




Drug Recognition Expert Course 17-4

A. Overview of the Category

Narcotic Analgesics

Point out that this category sometimes is called “The Opioids”; the drugs it contains either are found in Opium, derive chemically from Opium, or produce effects similar to those of the Opium Derivatives.

The term “Opioid,” however, most correctly refers to the synthetic subcategory of Narcotic Analgesics.

Narcotic Analgesic Defined

A medical term, not a legal or police term.

An “Analgesic” is a medication or drug that relieves pain. It differs from an anesthetic, in that it lowers one’s perception or sensations of pain, rather than stopping nerve transmission.

Session 17 - Narcotic Analgesics

Narcotic Analgesic (Cont.)

Non-Narcotic Analgesics such as:

- **Aspirin**
- **Tylenol**
- **Motrin**

Do NOT produce narcosis



Drug Recognition Expert Course 17-5

Non-Narcotic Analgesics, such as Aspirin, Tylenol, and Motrin, relieve pain, but do NOT produce narcosis, which means numbness or sedation.

Clarification: non-Narcotic Analgesics relieve pain, but do not alter mood. Therefore, they, in small amounts, are not psychoactive and are not abused for their mind or mood altering actions.

A Narcotic is a drug derived from Opium, or produced synthetically that relieves pain, but also induces euphoria, alters mood, and produces sedation.

Session 17 - Narcotic Analgesics

Types of Narcotic Analgesics

- Opiates
 - Natural alkaloids
 - Opium derivatives
- Synthetics

Drug Recognition Expert Course

17-6

There are two subcategories of Narcotic Analgesics:

- Opiates
- Synthetics

Opiates: drugs that either contain or are derived from Opium.

Natural alkaloids of Opium.

Point out that a “natural alkaloid” is a substance that is found in another substance, and that can be isolated from it. Morphine, for example, is a natural alkaloid of Opium. Codeine is another example of a natural alkaloid.

The term “main ingredient” can be used as a synonym for “alkaloid.”

The Natural Alkaloids

Alkaloids and the Opium derivatives all come from Opium, which is sap from the seed pods of a particular type of poppy.

Note: the Opium poppy is also called “papaver somniferum” (somniferum in Latin means “carrier of sleep”)

An analogy to help participants understand the difference between an alkaloid and a derivative would be to compare opium to wheat. The ‘alkaloid’ of the wheat would be whole wheat flour – a derivative of the wheat would be white flour (wheat flour which has been chemically treated).

Session 17 - Narcotic Analgesics

Types of Narcotic Analgesics (Cont.)

- Opiates
 - Natural alkaloids
 - Opium derivatives
- Synthetics

Drug Recognition Expert Course

17-7

Opium Derivatives

Opium derivatives are obtained by chemically treating the Opium alkaloid. Opium derivatives are therefore derived from Opium.

Synthetics

Synthetics, which do not derive from Opium at all, have similar or identical effects as Opium alkaloids and derivatives.

Point out that the synthetic Narcotic Analgesics are produced from a variety of non-opiate substances. Again, these are sometimes called “Opioids.”

Session 17 - Narcotic Analgesics

Three Characteristics Common to All Narcotic Analgesics

- **Relieve pain**
- **Produce withdrawal signs and symptoms**
- **Suppress the withdrawal signs and symptoms of chronic narcotic analgesic administration**



Drug Recognition Expert Course 17-8

Narcotic Analgesics all share three characteristics:

- They all relieve pain.

Clarification: They produce analgesia.


- They will produce withdrawal signs and symptoms when the user is physically dependent, and drug use is stopped.

Clarification: Physical dependence results from “chronic administration.” This means that the drug has been taken at fairly regular intervals for a period of time.

- They will suppress the withdrawal signs and symptoms of chronic narcotic analgesic administration.

Clarification: This means that the various Narcotic Analgesics can be substituted for each other to relieve withdrawal symptoms.

Morphine is typically used as the standard for comparison with other Narcotic Analgesics.



Point out the chart that is located in the participant manual.
Some Commonly Abused Opiates

Powdered Opium

Powdered Opium (also known as smoking Opium).

A simple refinement of raw Opium.

Used medically to treat diarrhea (administered orally).

The development of more effective opiates and synthetics has virtually eliminated its use medically. In recent years, there has been little street use of Opium. It is important to realize, however, that drug use trends can and do change.

Remains popular as a drug of abuse (smoked) among some Asian-American communities.

Morphine

Instructor, FYI: named after Morpheus, the Greek God of Dreams.


Morphine, the principal natural alkaloid of Opium.

Morphine was first isolated from Opium in 1805.

Used medically to suppress severe pain (e.g., with terminal cancer patients).

Highly addictive.

Morphine was widely used during the Civil War. Morphine addiction was termed "Soldier's disease."



At one time, Morphine was the most commonly abused Narcotic Analgesic.

Codeine

Codeine is another natural alkaloid of Opium.

Its technical name is Methyilmorphine.


First isolated in 1832.

Codeine's pain killing ability is much weaker than Morphine's.

Used medically to suppress coughing or minor pain.

Clarification: Narcotic Analgesic addicts often turn to Codeine when they cannot get more popular drugs.

Codeine is definitely an addictive drug.



Heroin

Heroin is the most commonly abused illicit Narcotic Analgesic.

Point out that the generic, or technical name for heroin is “Diacetyl Morphine.”

Write “Diacetyl Morphine” on the dry erase board or flip-chart.

Derived from Morphine in 1874.


Heroin was first thought to be a non-addictive substitute for Morphine.

It was approved for general use by the American Medical Association in 1906.

By the 1920’s it was evident that Heroin was much more addictive than Morphine.

Importation and manufacture of Heroin have been illegal in this country since 1925.

Heroin is a Schedule I drug, which means it has no legitimate medical uses in the United States.



Dilaudid

Dilaudid is another derivative from Morphine.

Technical Name: Hydromorphone Hydrochloride.

First produced in 1923.


Sometimes called “drug store Heroin,” since it is commercially available from medical and pharmaceutical sources.

Dilaudid has the same addictive liabilities as does Heroin or Morphine.

Used medically for short term relief of moderate to severe pain, and to suppress severe, persistent coughs.

Can be ingested via injection, orally or in suppositories.

Sometimes abused by addicts who are unable to obtain Morphine or Heroin.



Hydrocodone

Hydrocodone is derived from Codeine but is more closely related to Morphine in its pharmacological profile.

Point out that Hydrocodone products are the most frequently prescribed pharmaceutical opiate (Narcotic Analgesic) with over 139 million prescriptions dispensed in 2010. (DEA-June 2011)

Examples include:

- Hycodan
- Vicodin (Note: Vicodin is a commonly prescribed pain reliever containing Hydrocodone and Acetaminophen.)
- Lortab

Thebaine

An opiate alkaloid derived from opium.

Not used therapeutically.

Converted into several drugs including oxycodone and oxymorphone.

Numorphan


Technical Name: Oxymorphone.

Used medically for the relief of chronic pain.

Sold in ampules (injection) and in suppositories.

Previously (pre-1972) it was sold in tablets, and was a favorite substitute for Heroin among addicts; addicts now generally prefer Dilaudid as a Heroin substitute.

A derivative of Thebaine (source: "Disposition of Toxic Drugs and Chemicals in Man" 9th edition, R. Baselt)



Oxycodone

Oxycodone is a semi-synthetic narcotic produced by chemically treating Thebaine. It is somewhat less addictive than Morphine, but more than Codeine.

Two examples are:


Brand Name: OxyContin.

Percodan is one of the most commonly prescribed Narcotic Analgesics.

It is also produced under the brand name of "Percocet", which is Percodan combined with Acetaminophen, such as Tylenol.

OxyContin is a controlled release tablet that contains large amounts of Oxycodone (10-160mg). Abusers learn to circumvent the slow release mechanism.

Street names: "Oxy"; "OC"; "Killer."



Buprenorphine

Buprenorphine is a Thebaine derivative with powerful analgesia approximately twenty five or forty times as potent as morphine and its analgesic effect is due to partial agonist activity at u-opioid receptors.

It is an ingredient of the drug Suboxone.

As an analgesic it is about 25 to 40 times more potent than morphine (Source: "Disposition of Toxic Drugs and Chemicals in Man" 9th Edition, R. Baselt.)

Depending on the application form, buprenorphine is normally prescribed for the treatment of moderate to severe chronic pain (pain that has outlived its use to prevent injury and after three months).

Buprenorphine hydrochloride is normally administered by intramuscular injection, intravenous infusion, via a transdermal patch, or as a sublingual (under the tongue) tablet.

Session 17 - Narcotic Analgesics

Common Synthetic Opiates

- Demerol
- Methadone
- Fentanyl



NDC 0024-0133-01 D-131 Rx only
Demerol[®]
 meperidine hydrochloride, USP
 50 mg
 100 tablets
 Usual Adult Dosage: 1 or 2 tablets.
 Dispense in light, light-resistant container as defined in the USPNF.
 sonofi avents

Multiple Dose Vial
 30 mL (50 mg/mL)
 Similar to Demerol Tablets, USP
Demerol[®]
 meperidine hydrochloride injection, USP
 50 mg/mL
 12 mL

NHTSA
 www.nhtsa.gov

Drug Recognition Expert Course 17-16

Some Common Synthetic Opiates

Demerol

Demerol was first produced in 1939.

Technical Name: Meperidine.

Demerol is one of the most widely used Synthetic Opiates for relief of pain and for sedation.

It is also one of the Narcotic Analgesic that is most frequently abused by medical personnel.

Demerol is widely used as an analgesic in childbirth.

One medical advantage of Demerol is that it produces less respiratory depression than do other Narcotic Analgesics; thus, a fatal overdose is less likely with Demerol.

Medical literature sometimes indicates that Demerol does not cause pupillary constriction. Enforcement experience indicates to the contrary.

Point out that pupillary constriction ordinarily is one of the most reliable indicators of a Narcotic Analgesic.

Session 17 - Narcotic Analgesics

Common Synthetic Opiates (Cont.)

- Demerol
- Methadone
- Fentanyl

Drug Recognition Expert Course

NHTSA
www.nhtsa.gov

17-17

Methadone

Methadone was developed in Germany during World War II and first marketed in America in 1947.

Methadone was developed in Germany because of wartime shortages of Morphine. Methadone's effects are similar to Morphine's, although they develop more slowly and last longer than do Morphine's effects.

Methadone's withdrawal symptoms are slower and milder than are Morphine's.

Ask participants: "What is one of the most common medical uses of Methadone in this country?"

Used extensively in "maintenance programs" as a substitute for Heroin for addicts undergoing therapy and treatment.

Remind participants that one characteristic shared by all Narcotic Analgesics is that they suppress withdrawal symptoms of chronic Morphine administration.

In theory, the daily dose of Methadone given to a Heroin addict allows the addict to function normally with no physical need for up to 24 hours. Methadone's has a much longer duration of effects than Heroin and is not designed to be injected.

Methadone is also used medically to relieve moderate to severe pain, and to suppress coughing.

Session 17 - Narcotic Analgesics

Common Synthetic Opiates (Cont.)

- Demerol
- Methadone
- Fentanyl

Drug Recognition Expert Course

17-18

Fentanyl

A synthetic narcotic analgesic of high potency and short duration of action.

“Sublimaze” is one of numerous brand names for Fentanyl. It is a Schedule II drug. It is frequently found in overdose situations. For example, “Tango and Cash” and “Goodfellas,” which contained Fentanyl, were sold in New York City in 1990 as Heroin.

Many fatal overdoses occurred as a result.

First developed in 1963 as an intravenous anesthetic.

Legally produced as a pain killer and available in an injectable solution or transdermal patches.

Principal abused analog is “Three-Methyl Fentanyl.”

Session 17 - Narcotic Analgesics

Methods of Administration

- Orally
- Smoked
- Snorted
- Suppositories
- Injected
- Transdermal (Patches)

Drug Recognition Expert Course

NHTSA

17-19

Methods of Administration

Methods of administration of Narcotic Analgesics vary from one drug to another. Some are commonly taken orally. Some are smoked. Some are snorted (taken intra-nasally).

Users have stated that the fear of contracting diseases, such as AIDS, from shared needles, has prompted them to either snort or smoke Heroin.

If available, show Heroin injection paraphernalia.

Some are often administered in suppositories. Medically, some Narcotic Analgesics may be administered transdermally or through the skin. Fentanyl patches are often used for chronic pain. Heroin and some others are usually taken by injection.

Solicit participants' comments and questions concerning this overview of Narcotic Analgesics.

Session 17 - Narcotic Analgesics

The Concept of Tolerance for a Drug

- The same dose of the drug will produce diminishing effects
- A steadily larger dose is needed to produce the same effects



Drug Recognition Expert Course 17-20

B. Possible Effects

As with nearly all drugs of abuse, the effects produced by Heroin or other Narcotic Analgesics depend on the tolerance that the user has developed for the drug.

People develop tolerance for Narcotic Analgesics fairly rapidly.

“Tolerance” means that the same dose of the drug will produce diminishing effects or conversely that a steadily larger dose is needed to produce the same effects.

A Narcotic Analgesic user who has developed tolerance and who is using his or her “normal” dose of the drug may exhibit little or no evidence of intellectual or physical impairment.

Emphasize: Habitual users of drugs may develop tolerance to the drug. As a result, they may exhibit relatively little evidence of impairment on the psychophysical tests. Even tolerant drug users, when impaired, usually exhibit clinical evidence (i.e. in the vital signs and eye signs).

Impairment is more evident with new users, and with tolerant users who exceed their “normal” doses.


Clarification: the tolerant addict who has injected his or her “normal dose” of Heroin may appear to be much less impaired than an inexperienced user who had taken the same dose.

Session 17 - Narcotic Analgesics

Observable Effects of Narcotic Analgesics

“On the Nod”

- Semiconscious
- Droopy eyelids (Ptosis)
- Head slumped forward, chin on chest
- Easily awakened
- Normally alert to questions





Drug Recognition Expert Course 17-21

Observable Effects

Observable effects of Heroin and other Narcotic Analgesics.

Sedation – “On the Nod.”

The condition known as “on the nod” is a semiconscious state of deep relaxation.

Point out that “on the nod” occurs most often with new users or with users exceeding normal doses.

The user’s eyelids become very droopy.

Remind participants that the technical term for “droopy eyelids” is Ptosis.

Their head will slump forward until the chin rests on the chest.

In this condition, the user usually can be aroused easily and will be sufficiently alert to respond to questions.

Point out that this condition is different from someone under the influence of a CNS Depressant at the point of passing out or someone “crashing” after high doses of CNS Stimulants.

Session 17 - Narcotic Analgesics

Other Effects

- **Slowed reflexes**
- **Slow and raspy speech**
- **Slow, deliberate movements**
- **Inability to concentrate**
- **Slowed breathing**
- **Skin cool to the touch**
- **Possible vomiting**
- **Itching of the face, arms or body**



Drug Recognition Expert Course 17-22

Other Effects

Note: these effects may be dose-related, and most often occur with non-tolerant users.

- slowed reflexes
- slow and raspy speech
- slow, deliberate movements
- inability to concentrate
- slowed breathing

Instructor, FYI: Technical terms are Hypopnea or Bradypnea.

- skin cool to the touch
- possible vomiting
- itching of the face, arms or body

Solicit participants' comments and questions concerning possible effects of Narcotic Analgesics.

Session 17 - Narcotic Analgesics

Onset and Duration of Effects

Immediate:

- Pleasure or euphoria
- Relief from withdrawal
- Relief from pain





Drug Recognition Expert Course 17-23

C. Onset and Duration of Effects

Psychological Effects

The psychological effects of Heroin begin immediately after the injection.

- A feeling of pleasure or euphoria.

Point out that the intensity of the euphoria will depend on a number of factors, one of which is the addict's tolerance. A heavily addicted user who is beginning withdrawal symptoms may experience only mild euphoria.

- Relief from the symptoms of withdrawal.
- Relief from pain.

Session 17 - Narcotic Analgesics

Onset and Duration of Effects (Cont.)

5-30 minutes: Onset of physical effects

- “On the nod”
- Poor motor coordinatic
- Depressed reflexes
- Slowed breathing



Drug Recognition Expert Course 17-24

Observable Signs

The observable signs will usually become evident within 5 – 30 minutes after the user has injected.

- User may nod head and move in and out of consciences
- User may display poor motor coordination, depressed reflexes, and slowed breathing

Remind participants that the physical effects may not be observed at all, if the addict is tolerant and has injected a “normal” or “maintenance” dose.

Session 17 - Narcotic Analgesics

Onset and Duration of Effects (Cont.)

Physical effects usually are observable for up to 4-6 hours



Drug Recognition Expert Course

17-25

The effects will usually be observable for up to 4 – 6 hours.

As the drug wears off, withdrawal signs and symptoms start to develop until the addict user injects again.

Point out that the development of withdrawal symptoms implies that the narcotic analgesic has worn off.

Session 17 - Narcotic Analgesics

Signs and Symptoms of Withdrawal From Heroin

Symptoms normally begin 4-6 hours following injection:

- Aches
- Chills
- Insomnia
- Nausea



Drug Recognition Expert Course 17-26

As the effects of Heroin diminish, withdrawal symptoms begin.

- Aches
- Chills
- Insomnia
- Nausea

As with nearly all drugs, the withdrawal signs and symptoms are essentially the opposite of the “high” or intoxicated state.

Session 17 - Narcotic Analgesics

Signs and Symptoms of Withdrawal From Heroin (Cont.)

Signs appear 8-12 hours following injection:

- Goose bumps
- Sweating
- Runny nose
- Tearing
- Vomiting
- Yawning

Withdrawal signs and symptoms closely resemble those of Influenza or the common cold



Drug Recognition Expert Course 17-27

Withdrawal signs start to become observable 8 – 12 hours following injection.

- Goose bumps (piloerection) on the skin
- Sweating
- Runny nose
- Tearing
- Vomiting
- Yawning

Point out that yawning, tearing, runny nose and vomiting usually appear only after marked withdrawal of many hours.

Withdrawal signs and symptoms closely resemble those of Influenza or the common cold.

Session 17 - Narcotic Analgesics

Signs and Symptoms of Withdrawal From Heroin (Cont.)

Signs and symptoms intensify 14 - 24 hours after injection:

- Dilation of pupils
- Slight tremors
- Goosebumps
- Loss of appetite



Drug Recognition Expert Course 17-28

These symptoms begin to intensify from 14 – 24 hours after injection, and may be accompanied by goose bumps (piloerection), slight tremors, loss of appetite and dilation of the pupils.

Point out that “withdrawal” signs of Narcotic Analgesics are essentially the opposite of their “under the influence” signs.

Session 17 - Narcotic Analgesics

Signs and Symptoms of Withdrawal From Heroin (Cont.)

Situation worsens 24 - 36 hours after injection:

- Depression
- Diarrhea
- Hot and cold flashes
- Insomnia
- Vomiting
- Weakness



Drug Recognition Expert Course 17-29

Approximately 24 - 36 hours after injection, the addicted user experiences insomnia, vomiting, diarrhea, weakness, depression and hot and cold flashes.

Session 17 - Narcotic Analgesics

Signs and Symptoms of Withdrawal From Heroin (Cont.)

Reaching the peak 2 - 3 days after injection:

- Muscular and abdominal cramps
- Severe tremors and twitching
- Elevated temperature
- Sharp loss of weight




Drug Recognition Expert Course 17-30

Withdrawal symptoms and signs generally reach their peak 2 – 3 days after injection:

- Muscular and abdominal cramps
- Severe tremors and twitching
- Elevated temperature
- Sharp loss of weight

Point out that the involuntary tremors and twitching of the legs give rise to the expression “kicking the habit.”

The addicted user at this point is nauseated, gags, vomits and may lose 10 – 15 pounds within 24 hours.

The withdrawal syndrome continues to decrease in intensity over time, and is usually greatly reduced by the fifth day, disappearing in one week to 10 days.

A common misconception regarding withdrawal from Narcotic Analgesics is that they may be fatal. In reality, however, although Narcotic withdrawal is extremely uncomfortable, it rarely, if ever proves fatal.

Solicit participants’ comments or questions concerning onset and duration of the effects of Narcotic Analgesics.

Session 17 - Narcotic Analgesics

Overdose Signs and Symptoms

- **Breathing will become slow and shallow**
- **Death can occur from severe respiratory depression**



Drug Recognition Expert Course

17-31

D. Overdose Signs and Symptoms

Narcotic Analgesics depress respiration.

In overdoses, the user's breathing will become slow and shallow.

Death can occur from severe respiratory depression.

The danger of death is heightened by the fact that the addicted user may not know the strength of the drug he or she is taking.

Clarification: the percentage of pure Heroin in the sample the addict uses may be much higher than what the addict expects and is used to.

Session 17 - Narcotic Analgesics

Overdose Signs and Symptoms (Cont.)

Other signs:

- clammy skin
- convulsions and coma
- blue lips and pale or blue body
- extremely constricted pupils
- recent needle marks



Drug Recognition Expert Course 17-32

Other signs and symptoms of an overdose of a Narcotic Analgesic include clammy skin, convulsions and coma, blue lips and pale or blue body, extremely constricted pupils (unless there is brain damage, in which pupils may be dilated), recent needle marks, or perhaps a needle still in the user's arm.

Point out that a person suffering from Narcotic Analgesic overdose may appear to be in shock.

Narcotic Analgesic overdoses are sometimes treated by the administration of a Narcotic antagonist such as Narcan. A Narcotic antagonist works at neuron receptor sites, blocking or counteracting the effects of Narcotic Analgesics. In effect, these substances precipitate withdrawal. The short duration of effects produced by Narcotic antagonists, however, require continued medical monitoring of the user.

Solicit participants' comments and questions concerning signs and symptoms of an overdose of Narcotic Analgesics.

Session 17 - Narcotic Analgesics

Evaluation of Subjects Under the Influence of Narcotic Analgesics

- HGN - None
- VGN - None
- Lack of convergence - None



Drug Recognition Expert Course 17-33

E. Expected Results of the Evaluation

Observable Evidence of Impairment

Neither Horizontal Gaze Nystagmus nor Vertical Gaze Nystagmus will be present.

Eyes will not exhibit Lack of Convergence.

Session 17 - Narcotic Analgesics

Evaluation of Subjects Under the Influence of Narcotic Analgesics (Cont.)

Psychophysical Tests: Performance on Modified Romberg Balance, Walk and Turn, One Leg Stand and Finger to Nose will be impaired and will reflect slow and deliberate movements



Drug Recognition Expert Course 17-34

Psychophysical Tests

Performance on the Modified Romberg Balance Test will be impaired. Generally, the subject will appear drowsy, and will have a slow internal clock.

Point out that, if the user has ingested enough Narcotic Analgesic to exceed his or her level of tolerance, his or her performance on the Standardized Field Sobriety Tests will be uncoordinated and “rubber-legged,” similar to that caused by CNS Depressants.

Performance on the Walk and Turn and One Leg Stand will be impaired, and will reflect the slow and deliberate movements caused by this category of drugs.

Performance on Finger to Nose will also be impaired. Generally, the subject will appear drowsy, possibly “on the nod,” and exhibit slow and deliberate movements.

Session 17 - Narcotic Analgesics

Evaluation of Subjects Under the Influence of Narcotic Analgesics (Cont.)

Vital Signs:

- Pulse - Down
- Blood pressure - Down
- Body temperature - Down

Muscle tone - Flaccid



Drug Recognition Expert Course 17-35

Vital Signs

Pulse will be down.

Blood pressure will be down.

Body temperature will be down.

Remind participants that these cardiovascular indicators may not be present if the subject is a tolerant user who has taken a “normal” dose of the drug.

Muscle tone will be flaccid.

Session 17 - Narcotic Analgesics

Evaluation of Subjects Under the Influence of Narcotic Analgesics (Cont.)

Dark Room:

- Pupils - Constricted (Miosis)
- Reaction to light - Little or none visible



Drug Recognition Expert Course 17-36

Dark Room

Pupil size generally will be constricted (below 3.0 mm in diameter).

Point out that constricted pupils are one of the most reliable indicators of a Narcotic Analgesic. The technical term for “constricted pupils” is “Miosis.”

Pupil reaction to light will be little or none visible.

Session 17 - Narcotic Analgesics

Evaluation of Subjects Under the Influence of Narcotic Analgesics (Cont.)

General Indicators

- Constricted pupils
- Depressed reflexes
- Droopy eyelids
- Drowsiness
- Dry mouth
- Euphoria
- Facial itching



Drug Recognition Expert Course 17-37

General Indicators

- Constricted pupils (Miosis)
- Depressed reflexes
- Droopy eyelids (Ptosis)
- Drowsiness
- Dry mouth
- Euphoria
- Facial itching

Itching – caused by the release of Histamines

Session 17 - Narcotic Analgesics

Evaluation of Subjects Under the Influence of Narcotic Analgesics (Cont.)

General Indicators

- Nausea
- “On the nod”
- Puncture marks
- Slowed reflexes
- Slow, low, raspy speech
- Slowed breathing



Drug Recognition Expert Course 17-38

- Nausea
- “On the nod”
- Puncture marks

If available, show slide of typical addicts “track” marks.

- Slowed reflexes
- Slow, low, raspy speech
- Slowed breathing

Session 17 - Narcotic Analgesics

Narcotic Analgesic Symptomatology Chart

HGN	None
VGN	None
Lack of Convergence	None
Pupil Size	Constricted
Reaction to Light	Little or None Visible
Pulse Rate	Down
Blood Pressure	Down
Temperature	Down
Muscle Tone	Flaccid



Drug Recognition Expert Course 17-39

Symptomatology Chart



F. Injection Site Examination


Examination of subject's injection sites can give many clues to their drug habits.

- The slang term for an injection site is a "mark."
- Many drugs can be injected.
- The presence of injection sites doesn't ensure the subject is under the influence of drugs. Examination of injection sites is just one of the twelve steps in the evaluation.
- Injection sites are a sign of drug abuse which may or may not be present.
- May be evidence of habitual use.
- The trauma to the skin, muscles and the blood is the basic concept of injection sites.

Session 17 - Narcotic Analgesics

Types of Injections

- Intramuscular
- Intravenous
- Subcutaneous



Drug Recognition Expert Course

NHTSA

17-41

Drugs and medication are injected into the body in three ways:

Intramuscular

Legal injections are usually Intramuscular.

- Abbreviated as I/M
- “Intramuscular” is defined as administering by entering a muscle.

Intravenous

• For medically drawing of blood or emergency medical procedures, the injection is made into a blood vessel (Intravenous). Veins are usually used. Arteries are deep, thus not lending themselves to injection.

- Abbreviated as I/V
- “Intravenous” defined as entering a vein.

Subcutaneous

- Subcutaneous means just under the skin.
- Commonly referred to as “skin popping.”

Note: Insulin injections are “Subcutaneous” (S/C) and are not normally I/M or I/V injections.

Note: Insulin is never injected into a blood vessel, because the person could go into a coma.

Session 17 - Narcotic Analgesics

Primary Injection Instrument

Hypodermic syringe

- Greater the number of gauge, the smaller diameter of the needle
- Most illegal drug users prefer a larger gauge needle



Top to bottom
 Brown - 26G
 Orange - 25G
 Black - 22G
 Green - 21G
 Yellow - 20G
 White - 19G




Drug Recognition Expert Course

NHTSA
www.nhtsa.gov

17-42

The primary instrument for injection is the hypodermic syringe.

- It consists of a hollow needle, a Barrel (tube) and a plunger.
- Needles vary in size, with the primary variance being the inside diameter of the needle or the gauge.
- A 26 gauge needle is used by a diabetic.
- The greater the number the larger the gauge, the smaller the inside diameter of the needle.
- Most illegal drug users prefer a larger gauge needle.
- The hypodermic marks are smaller and are therefore, less noticeable making it more difficult for the DRE to see them.

Session 17 - Narcotic Analgesics

User's Equipment – Hype Kit

- **Cooker**
- **Handle**
- **Lighter**
- **Tourniquet**
- **Cottons**



Drug Recognition Expert Course

NHTSA
www.nhtsa.gov

17-43

The user's equipment is commonly referred to as a "hype kit" or "works."

- The kit contains a "cooker" which is any device such as a bottle cap, a metal spoon, etc., that is used to heat the drug with water to form an injectable solution. Other parts of the "kit" include:
- A handle to hold the "cooker" over the flames.
- Matches, lighters (primarily disposable, adjustable flame types) used to heat the substance in the "cooker."
- A tourniquet, which can be a rubber tubing, a tie, belt, etc. It is tied around the arm, above the injection site, to cause the vein to bulge or rise, thus making it easier to inject.
- "Cottons" are the cotton balls or cigarette filters used to "purify" the drug. The user places the "cottons" into their cooker and draws the drug up through the cottons.
- The cottons are saved for later use since they contain some of the drug.

Session 17 - Narcotic Analgesics

Medical Injection Site

- **Medical mark is usually intramuscular**
- **There may be multiple injections, if the technician is unable to find a vein during the first try**
- **Usually there will be only one mark and it will be larger than the typical illegal injection.**
- **Legal injections are made with new, sterile needles**




Drug Recognition Expert Course 17-44

As a DRE, you may be asked in court to describe the difference between a medical and non-medical injection site.

A medical injection is usually intramuscular

Some exceptions would be in a blood donation, an emergency or a lab test.

There may be multiple injections, if the technician is unable to find a vein during the first try. There may also be bruising near the site.

The injection mark for medical purposes can be described as:

- Clean
- No scarring or scabbing

Most intramuscular medical injections will not be evident during a DRE evaluation.

- Usually there will be only one mark and it will be larger than the typical non-medical injection.
- Medical injections are made with new, sterile needles.

Session 17 - Narcotic Analgesics

Non-Medical Injection Site

- **Non-Medical (illicit) mark is usually over a vein**
- **Usually multiple marks in various stages of healing**
- **Use of same needle over and over again causes them to be dull or barbed**
- **Injection sites may be jagged**




Drug Recognition Expert Course 17-45

The non-medical (illicit) mark is usually over a vein.

- There will usually be multiple marks in various stages of healing. It takes approximately two weeks for a “mark” to totally heal.
- For example, the Heroin addict will inject approximately four to six times each day (every four to six hours). Therefore, they will inject approximately 2,000 times in one year.
- Users frequently use the same needle over and over again. Thus making it become dull or barbed.
- Frequently the needles are carried in pockets or socks and the rubbing against clothing causes them to be dull or barbed.
- Since the used needles make it more difficult to pierce the skin and vein, the injection sites may be jagged.
- A barbed needle may tear the skin on the way in and on the way out.
- Use of old, dirty and shared needles cause the spread of infections and diseases such as AIDS.

ALWAYS WEAR PROTECTIVE GLOVES PRIOR TO CONDUCTING THE EXAMINATION.

Session 17 - Narcotic Analgesics

Injection Site Terms



“Thrombosed”

***“Tunnel”
or
“Corn”***





Drug Recognition Expert Course 17-46

Users may frequently use the same spot to inject, as an attempt to reduce their likelihood of detection.

The veins may become hard and thick from continuous injections and makes them difficult to find. This is an obstruction by a clot of coagulated blood shutting off the passage of blood.

- The technical term is “Thrombosed.”

After about 10 to 20 injections, a large sore forms causing the site to enlarge and bruise. Upon close examination, the site reveals there are numerous puncture wounds in the same area, overlapping each other.

- This is referred to as “tunnel” or “corn.”

Session 17 - Narcotic Analgesics

Puncture Healing

**“Scabbing”
and
“Trap Dooring”**



Drug Recognition Expert Course 17-47

Basic Principles of Puncture Healing

The healing is greatly retarded.

Any needle that punctures the skin leaves a scab. A scab is simply a crust formed by the drying of the discharge from the puncture.

Scab is the dried remains of blood, plasma (a cellular, colorless fluid part of the blood), lymph fluid (a thin fluid that bathes all the tissues of the body) and puss (a thick yellowish/greenish fluid that forms at an injection(s) site).

These dried remains fill the gap caused by the puncture of the skin. As the fluids dry they harden (clot and gel).

Users will sometimes peel a corner of a healing scab up and inject into that area then cover the injection site with the scab.

This injecting under a scab to hide multiple puncture wounds is referred to as “Trap Dooring.”

Session 17 - Narcotic Analgesics

Puncture Healing Timetable

- Scabs develop in about 18-24 hours
- Scab peels, flakes, falls off in about 14 days






Drug Recognition Expert Course 17-48

Puncture Healing Timetable

There are no exact timetables for wounds to heal, but there are some general guidelines.

- Chronic disease, poor nutrition and etc. retard the puncture healing process.
- Scabs develop within about 18 – 24 hours after a puncture.
- A general rule: when the scab first forms, it is bright red. With age, the color gets darker and darker.

After about 14 days a scab usually starts to peel or flake and then falls off. The skin under the scab is shriveled and is lighter in color than the surrounding tissue.

Session 17 - Narcotic Analgesics

Classifying the Age of Puncture Wounds

- **Fresh - Under 12 hours after injection;**
 - will be a red dot and have an oozing appearance or blood crater with no scab formation
- **Early - 12-96 hours after injection;**
 - will have a light scab, light bruise, reddened border and a crater appearance






Drug Recognition Expert Course 17-49

There is no exact science to classifying the age of puncture wounds. Some general guidelines are:

- Fresh puncture wounds are defined as under 12 hours after injection and will be a red dot and have an oozing appearance or blood crater with no scab formation.
- Early puncture wound is 12 – 96 hours (half day to 4 days) after injection. It will have a light scab, light bruise, reddened border and a crater appearance.

Session 17 - Narcotic Analgesics

Classifying the Age of Puncture Wounds (Cont.)

- **Late - 5-14 days after injection;**
 - will have a dark scab, dark bruise and the crater will flatten
- **Healing - Over 14 days after injection;**
 - scab will be flaking and falling off with shriveled light-colored skin underneath




Drug Recognition Expert Course 17-50

- Late puncture wound is 5 – 14 days old and will have a dark scab, dark bruise and the crater will flatten.
- Healing puncture wound is over 14 days. The scab will be flaking and falling off with shriveled light colored skin underneath.

Session 17 - Narcotic Analgesics

Other Indicators of Injection Sites

- **Tattooing**
- **Track Marks**



The images show: 1) A close-up of a person's arm with a tattoo. 2) A close-up of a track mark on a person's arm. 3) A close-up of a person's arm with a tattoo and a needle being inserted. 4) A close-up of a person's arm with a tattoo of a rose and the name 'MARIA'.

Drug Recognition Expert Course

NHTSA
www.nhtsa.gov

17-51

Other Indicators of Injection Sites

In an attempt to hide puncture wounds, users may inject into tattoos.

Tattoos that are designed to hide puncture wounds are frequently colored and found on the inner arms.

- Tattooing also refers to dark carbon deposits that result from using a flame to “sterilize” a needle. Carbon deposits on the needle are then injected into the skin, causing a tattoo effect.
- A “track” is a hardened part of a vein where numerous injections have been administered. The entire vein becomes scarred and hardened and with time may no longer be able to inject into. The area becomes silvery-blue in color and raised. This is referred to as “silver streaks.”
- **AS A GENERAL RULE:** one inch of tracks indicates that approximately 50 – 100 separate injections have been administered in this area.

Session 17 - Narcotic Analgesics

Location of Injection Marks

- Anywhere
- Arm
- Hand



Drug Recognition Expert Course

NHTSA

17-52

G. Expected Location of Injection Marks

Prior to conducting the injection site examination, always remember to wear gloves. Injection sites may be located anywhere on the subject's body.

Conduct a thorough, slow, methodical examination of the subject's arms beginning with the left.

- Using a magnifying light or "ski light" examine the inner arm as it is extended with the palm facing you.

Point out that "ski light" is short for schematic light. An ideal light is a 10 power magnification light.

- Beginning at the bicep, slowly examine the arm. Document the findings of your examination.
- Ask the subject to contract the arm, grasping their shoulder. Starting at the wrist, slowly examine the arm to the elbow documenting the results.
- This forces the individual's veins to protrude.
- Next examine the outer arm as it is extended palm facing downward. Start the examination at the shoulder moving to the wrist.
- Subject should extend and spread his/her fingers when examining the hands. Examine both sides of the hands, with particular attention to the areas between the fingers, under watch bands and rings.
- Conduct the entire procedure for the right side.

Session 17 - Narcotic Analgesics

Location of Injection Marks (Cont.)

- Ankles
- Feet
- Legs



The slide contains three photographs. The top-left photo shows a hand injecting a foot. The top-right photo shows a hand injecting an ankle. The bottom photo is a close-up of a leg with a small, dark, circular mark on the skin.

Drug Recognition Expert Course 17-53

Ankles are a common injection area.

- Subject should be instructed to remove their shoes and socks to allow the DRE to examine them for puncture wounds.
- The most common area is on the foot or the ankle.

Subject's sometimes hide hypodermic needles in their socks, shoes and the heel compartments of their shoes.

On a case by case basis, the DRE may need to examine other parts of the body for marks. Another such area may be the legs.

- **ALWAYS follow your Agency's rules, policies and procedures and laws regarding invasive type searches.**

Session 17 - Narcotic Analgesics

Conclusion






Drug Recognition Expert Course 17-54

H. Conclusion

The injection site examination may reveal evidence of recent use.

Point out that DREs may want to photograph new or recent injection marks for evidential purposes.


The presence of marks, however, doesn't mean drug influence or impairment at the time of the evaluation.

Conducting an injection site examination is a skill.

As with all skills, such as taking blood pressure, competency improves with practice.

Session 17 - Narcotic Analgesics

Narcotic Analgesics



Drug Recognition Expert Course 1-55

Click video to begin

VIDEO DEMONSTRATION

***Show video example of subject under the influence of a Narcotic Analgesic.
(Approximately 23 minutes).***

Session 17 - Narcotic Analgesics

Drug Evaluation and Classification

Exemplar Demonstrations



Drug Recognition Expert Course

17-56

I. Classification Exemplar

Refer students to the exemplars found at the end of Session 17 of their participant manuals.

Point out that the one-page narrative in the example exemplars are not to be construed as the recommended or approved narrative report. The actual narrative report submitted by DREs will be more detailed.

Relate the items on the exemplars to the Narcotic Analgesics Symptomatology Chart.

Relate behavior and observations to the Narcotic Analgesic Symptomatology Chart.

Solicit students' questions or suggestions concerning Expected Results of the Evaluation of subjects under the influence of Narcotic Analgesics.

Session 17 - Narcotic Analgesics

QUESTIONS?



Drug Recognition Expert Course 17-57

Solicit participants' comments and questions concerning the Narcotic Analgesic and Injection Site Examination.

Session 17 - Narcotic Analgesics

Topics for Study



Drug Recognition Expert Course

17-58

TOPICS FOR STUDY / ANSWERS

1. What are the two subcategories of Narcotic Analgesics?

ANSWER: Natural Opiates and Synthetic Opiates

2. What three distinguishing characteristics do all Narcotic Analgesics share?

ANSWER: They relieve pain, they will produce withdrawal signs and symptoms, and their use will suppress the withdrawal signs and symptoms of chronic morphine administration.

3. Consider this situation: A heroin addict injects what is, for him, a “normal” dose of the drug. One hour later a DRE examines the addict and finds that he is not impaired. What is the most likely explanation for this?

ANSWER: The addict has developed a tolerance and is using his/her “normal” dose of the drug.

4. What is another, more common, name for the drug called Diacetyl Morphine?

ANSWER: Heroin

Session 17 - Narcotic Analgesics

Topics for Study (Cont.)



Drug Recognition Expert Course 17-59

5. What is Methadone?

ANSWER: A drug used extensively in maintenance programs as a substitute for heroin.








6. An analgesic is a drug that _____?

ANSWER: Relieves pain

7. What is Oxycodone?

ANSWER: A semi-synthetic narcotic prescribed for chronic or long-lasting pain.

DRUG INFLUENCE EVALUATION








Evaluator Officer Karl Nieberlein, Sparks PD		DRE # 7266	Rolling Log # 12-08-014	Session XVII #1	
Recorder/Witness Officer Charles Sheffield, Reno PD		Crash: <input checked="" type="checkbox"/> None <input type="checkbox"/> Fatal <input type="checkbox"/> Injury <input type="checkbox"/> Property		Case # 12-44745	
Arrestee's Name (Last, First, Middle) Vaughn, Gerald T.		Date of Birth 5/14/80	Sex M	Race B	Arresting Officer (Name, ID#) Deputy William Ames, Washoe Co SO #8428
Date Examined / Time / Location 08/24/12 1805 Washoe Co. Jail		Breath Results: 0.00		Test Refused <input type="checkbox"/>	Chemical Test: Urine <input type="checkbox"/> Blood <input checked="" type="checkbox"/>
Miranda Warning Given Given By: Deputy Ames	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? Nothing N/A	What have you been drinking? Dr. Pepper	How much? N/A	Time of last drink? N/A
Time now/ Actual 7:00 PM/1810	When did you last sleep? How long Last night 4 hrs.	Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Are you taking any medication or drugs? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No "Methadone"		Attitude: Cooperative, passive		Coordination: Relaxed, slow, unstable	
Speech: Low, raspy		Breath Odor: Normal		Face: Normal	
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right	
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	
Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal		Eyelids <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Droopy			
Pulse and time 1. <u>56</u> / <u>1817</u> 2. <u>58</u> / <u>1825</u> 3. <u>58</u> / <u>1832</u>	HGN Lack of Smooth Pursuit Maximum Deviation Angle of Onset	Left Eye No	Right Eye No	Convergence 	36 ONE LEG STAND 35 
Modified Romberg Balance 	Walk and Turn test 	Cannot keep balance <input checked="" type="checkbox"/>		L R <input checked="" type="checkbox"/> Sways while balancing <input checked="" type="checkbox"/> Uses arms to balance <input type="checkbox"/> Hopping <input checked="" type="checkbox"/> Puts foot down	
Internal clock 44 estimated as 30 seconds	Describe Turn Slow, deliberate	Cannot do test (explain) N/A		Type of footwear: Lace-up boots	
Draw lines to spots touched 		PUPIL SIZE	Room light 2.5 - 5.0	Darkness 5.0 - 8.5	Direct 2.0 - 4.5
Slow movements		Left Eye	2.0	2.0	2.0
Blood pressure 110/64		Right Eye	2.0	2.0	2.0
Temperature 98.0		REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		REACTION TO LIGHT: None	
Muscle tone: <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Flaccid <input type="checkbox"/> Rigid		RIGHT ARM 		LEFT ARM 	
Comments:		Scar tissue		Red, oozing puncture mark	
What drugs or medications have you been using? "Just methadone, man"		How much? "The normal"	Time of use? 3PM	Where were the drugs used? (Location) "The clinic"	
Date / Time of arrest: 08/24/12 1720	Time DRE was notified: 1745	Evaluation start time: 1805	Evaluation completion time: 1920	Precinct/Station:	
Officer's Signature:		DRE # 7266	Reviewed/approved by / date:		
Opinion of Evaluator:		<input type="checkbox"/> Rule Out	<input type="checkbox"/> Alcohol	<input type="checkbox"/> CNS Stimulant	<input type="checkbox"/> Dissociative Anesthetic
		<input type="checkbox"/> Medical	<input type="checkbox"/> CNS Depressant	<input type="checkbox"/> Hallucinogen	<input type="checkbox"/> Narcotic Analgesic
				<input type="checkbox"/> Inhalant	<input type="checkbox"/> Cannabis

DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: Vaughn, Gerald T.

1. **LOCATION:** The evaluation was conducted at the Washoe County Jail.
2. **WITNESSES:** Officer Charles Sheffield of the Reno P.D recorded the evaluation.
3. **BREATH ALCOHOL TEST:** Vaughn's breath test was 0.00%.
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** Writer was contacted and requested to contact Deputy Ames at the Washoe County Jail for a drug evaluation. Deputy Ames advised the suspect was operating a vehicle reported stolen earlier in the day by Reno PD. After stopping the suspect, Deputy Ames noted that suspect's speech was slow, slurred and raspy. His coordination was poor and he was licking his lips repeatedly. His pupils were constricted and he performed poorly on the SFST's.
5. **INITIAL OBSERVATION OF SUSPECT:** Writer first observed the suspect in the interview room at the Washoe County Jail. He appeared to be "on the nod." His eyes were closed, his head kept nodding forward and his breathing was slow. The suspect responded to questions and became more alert as time passed. His voice was raspy and his pupils appeared constricted. He was licking his lips and his movements were slow and deliberate.
6. **MEDICAL PROBLEMS AND TREATMENT:** None noted or stated.
7. **PSYCHOPHYSICAL TESTS:** Modified Romberg Balance: Suspect swayed approximately 2" front to back and 3" side to side. He estimated 30 seconds in 44 seconds. Walk & Turn: Suspect lost his balance during the instructions, missed heel to toe three times on the first nine steps and twice on the return. He stepped off the line three times and used his arms for balance. One Leg Stand: He counted slowly, swayed and used his arms for balance. He put his foot down once while standing on the left foot and twice when standing on the right. Finger to Nose: Suspect missed the tip of his nose with 5 of the 6 attempts.
8. **CLINICAL INDICATORS:** Suspect's pulse and blood pressure were below the DRE average ranges. His pupils were constricted in all lighting levels with no visible reaction to light. His eyelids were droopy.
9. **SIGNS OF INGESTION:** Subject had scar tissue on both his left and right forearms and a fresh oozing puncture wound on the back his left hand. (Photographed).
10. **SUSPECT'S STATEMENTS:** Suspect admitted using Methadone earlier in the day.
11. **DRE'S OPINION:** In my opinion Vaughn is under the influence of a **Narcotic Analgesic** and unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** The suspect provided a blood sample.
13. **MISCELLANEOUS:**

DRUG INFLUENCE EVALUATION








Evaluator Trooper Evan Sether, Oregon State Police		DRE # 15569	Rolling Log # 12-06-17	Session XVII #2		
Recorder/Witness Sgt. Mike Iwai, Oregon State Police		Crash: <input type="checkbox"/> None <input type="checkbox"/> Fatal <input checked="" type="checkbox"/> Injury <input type="checkbox"/> Property		Case # 12-25250		
Arrestee's Name (Last, First, Middle) Bursten, David L		Date of Birth 4/20/80	Sex M	Race W	Arresting Officer (Name, ID#) Officer Darke Hull, Portland Police Bureau #12581	
Date Examined / Time / Location 06/01/12 8:40 pm Central Precinct		Breath Results: Results: 0.00		Test Refused <input type="checkbox"/> Instrument #: 21250	Chemical Test: Urine <input checked="" type="checkbox"/> Blood <input type="checkbox"/> Test or tests refused <input type="checkbox"/>	
Miranda Warning Given Given By: Ofc. Hull	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? Nothing	When? N/A	What have you been drinking? Nothing	How much? N/A	Time of last drink? N/A
Time now/ Actual Don't know	When did you last sleep? How long Last night "a few hours"	Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Attitude: Cooperative		Coordination: Poor, sluggish, stumbling		
Speech: Slow and deliberate		Breath Odor: Normal		Face: Normal		
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right		Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		Eyelids: <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Droopy
Pulse and time 1. 58 / 8:50 2. 56 / 9:05 3. 54 / 9:20	HGN Lack of Smooth Pursuit Maximum Deviation Angle of Onset	Left Eye No No None	Right Eye No No None	Convergence 		20 ONE LEG STAND 
Modified Romberg Balance 	Walk and Turn test 	Cannot keep balance <input checked="" type="checkbox"/> Starts too soon _____ Stops walking _____ Misses heel-toe _____ Steps off line _____ Raises arms <input checked="" type="checkbox"/> <input checked="" type="checkbox"/>		1st Nine: <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> 2nd Nine: <input checked="" type="checkbox"/>		L R <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Sways while balancing <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Uses arms to balance <input type="checkbox"/> <input type="checkbox"/> Hopping <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Puts foot down Counted slowly
Internal clock 58 estimated as 30 seconds	Describe Turn Lost balance, staggered to the left	Cannot do test (explain) N/A		Type of footwear: Loafers		
Draw lines to spots touched 		PUPIL SIZE	Room light 2.5 - 5.0	Darkness 5.0 - 8.5	Direct 2.0 - 4.5	Nasal area: Clear
		Left Eye	2.5	3.0	2.0	Oral cavity: Clear
		Right Eye	2.5	3.0	2.0	
		REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		REACTION TO LIGHT: None visible		
		RIGHT ARM 		LEFT ARM 		
		Scar tissue 				
Blood pressure 108/60	Temperature 97.0	Muscle tone: <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Flaccid <input type="checkbox"/> Rigid		Comments: Arms and neck very relaxed		
What drugs or medications have you been using? None		How much? Refused	Time of use? Refused	Where were the drugs used? (Location) Refused		
Date / Time of arrest: 06/01/12 8:05 pm	Time DRE was notified: 8:20 pm	Evaluation start time: 8:40 pm	Evaluation completion time: 9:50 pm	Precinct/Station: Central		
Officer's Signature: /		DRE # 15569	Reviewed/approved by / date:			
Opinion of Evaluator:		<input type="checkbox"/> Rule Out	<input type="checkbox"/> Alcohol	<input type="checkbox"/> CNS Stimulant	<input type="checkbox"/> Dissociative Anesthetic	<input type="checkbox"/> Inhalant
		<input type="checkbox"/> Medical	<input type="checkbox"/> CNS Depressant	<input type="checkbox"/> Hallucinogen	<input checked="" type="checkbox"/> Narcotic Analgesic	<input type="checkbox"/> Cannabis

DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: Bursten, David L.

1. **LOCATION:** The evaluation was conducted at the PPB Central Traffic Precinct.
2. **WITNESSES:** Sgt Mike Iwai of the Oregon State Police recorded the evaluation.
3. **BREATH ALCOHOL TEST:** Bursten's breath test was 0.00%.
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** Writer was contacted and advised to contact Sgt. Iwai and Officer Darke Hull for a drug evaluation. Officer Hull advised the suspect had failed to stop at a red light on N.E. Burnside and struck a pedestrian in a crosswalk. Officer Hull noted that the suspect had slow and deliberate movements and his speech was slow, slurred and raspy. He was unable to perform the SFST's as directed and was arrested for DUI.
5. **INITIAL OBSERVATION OF SUSPECT:** Writer first observed the suspect in the interview room at the Central Precinct. He was repeatedly scratching his face and neck. His head kept nodding forward and he appeared to be "on the nod." His voice was raspy, his pupils appeared to be constricted and his eyelids were droopy.
6. **MEDICAL PROBLEMS AND TREATMENT:** None noted or stated.
7. **PSYCHOPHYSICAL TESTS:** Modified Romberg Balance: Suspect swayed approximately 3" in a circular motion and he estimated 30 seconds in 58 seconds. Walk & Turn: Suspect lost his balance during the instructions, stopped while walking once on the first nine steps and twice on the return. He walked very slowly and used his arms for balance. One Leg Stand: Suspect counted slowly, swayed, used his arms for balance and put his foot down twice while standing on his left foot and once while standing on his right foot. Finger to Nose: Suspect missed the tip of his nose on four of the six attempts.
8. **CLINICAL INDICATORS:** Suspect's pulse, blood pressure and body temperature were below the DRE average ranges. His pupils were constricted in all three lighting conditions.
9. **SIGNS OF INGESTION:** Suspect had scars on his right forearm and fresh puncture wounds on the inside of his left arm. The puncture wounds were photographed.
10. **SUSPECT'S STATEMENTS:** The suspect refused to answer questions about drug use.
11. **DRE'S OPINION:** In my opinion Bursten is under the influence of a **Narcotic Analgesic** and unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** The suspect provided a urine sample.
13. **MISCELLANEOUS:**

DRUG INFLUENCE EVALUATION

Evaluator Officer Peter Manukas, Raleigh PD		DRE # 14031	Rolling Log # 12-03-031	Session XVII #3													
Recorder/Witness Lt. Tim Tomczak, Raleigh PD		Crash: <input checked="" type="checkbox"/> None <input type="checkbox"/> Fatal <input type="checkbox"/> Injury <input type="checkbox"/> Property		Case # 12-35125													
Arrestee's Name (Last, First, Middle) Sheehan, Thomas		Date of Birth 5/16/76	Sex M	Race W	Arresting Officer (Name, ID#) Sgt. Brandon Craft, North Carolina H.P. #10334												
Date Examined / Time / Location 03/17/12 2000 Raleigh PD Intake		Breath Results: Results: 0.00		Test Refused <input type="checkbox"/> Instrument #: 4200	Chemical Test: Urine <input checked="" type="checkbox"/> Blood <input type="checkbox"/> Test or tests refused <input type="checkbox"/>												
Miranda Warning Given Given By: Sgt. Craft	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? "Nothing" "Don't know"	What have you been drinking? "I don't drink"	How much?	Time of last drink? N/A												
Time now/ Actual 8 PM/2215 hours	When did you last sleep? How long This morning 4 hrs.	Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No													
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No													
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No "I don't take drugs"		Attitude: Sarcastic		Coordination: Slow, stumbling, staggering													
Speech: Slow, raspy		Breath Odor: Normal		Face: Pale													
Corrective Lenses: <input type="checkbox"/> None (removed glasses) <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right													
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal													
Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		Eyelids <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Droopy															
Pulse and time 1. <u>60</u> / <u>2020</u> 2. <u>58</u> / <u>2035</u> 3. <u>58</u> / <u>2055</u>		HGN Lack of Smooth Pursuit: No Maximum Deviation: No Angle of Onset: None	Left Eye No	Right Eye No	Convergence 												
Modified Romberg Balance 		Walk and Turn test 		24 ONE LEG STAND 26 													
Internal clock 55 estimated as 30 seconds		Describe Turn As instructed, slow		Cannot do test (explain) N/A													
Type of footwear: Dress shoes		Nasal area: Clear		Oral cavity: Clear													
Draw lines to spots touched 		<table border="1" style="width: 100%; text-align: center;"> <tr> <th>PUPIL SIZE</th> <th>Room light 2.5 - 5.0</th> <th>Darkness 5.0 - 8.5</th> <th>Direct 2.0 - 4.5</th> </tr> <tr> <td>Left Eye</td> <td>2.5</td> <td>3.0</td> <td>1.5</td> </tr> <tr> <td>Right Eye</td> <td>2.5</td> <td>3.0</td> <td>1.5</td> </tr> </table>		PUPIL SIZE	Room light 2.5 - 5.0	Darkness 5.0 - 8.5	Direct 2.0 - 4.5	Left Eye	2.5	3.0	1.5	Right Eye	2.5	3.0	1.5	REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
		PUPIL SIZE	Room light 2.5 - 5.0	Darkness 5.0 - 8.5	Direct 2.0 - 4.5												
Left Eye	2.5	3.0	1.5														
Right Eye	2.5	3.0	1.5														
REACTION TO LIGHT: Little to none visible		RIGHT ARM 		LEFT ARM 													
Blood pressure 112/64		Temperature 97.7		None observed													
Muscle tone: <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Flaccid <input type="checkbox"/> Rigid		Comments:															
What drugs or medications have you been using? "Nothing"		How much? "I don't do drugs"		Time of use? "I didn't"													
Where were the drugs used? (Location) No answer																	
Date / Time of arrest: 03/17/12 1905	Time DRE was notified: 1920	Evaluation start time: 2000	Evaluation completion time: 2115	Precinct/Station:													
Officer's Signature:		DRE # 14031	Reviewed/approved by / date:														
Opinion of Evaluator:		<input type="checkbox"/> Rule Out <input type="checkbox"/> Alcohol <input type="checkbox"/> CNS Stimulant <input type="checkbox"/> Dissociative Anesthetic <input type="checkbox"/> Inhalant <input type="checkbox"/> Medical <input type="checkbox"/> CNS Depressant <input type="checkbox"/> Hallucinogen <input checked="" type="checkbox"/> Narcotic Analgesic <input type="checkbox"/> Cannabis															

DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: Sheehan, Thomas

1. **LOCATION:** The evaluation was conducted at the Raleigh Police Department.
2. **WITNESSES:** Lt. Tim Tomczak of Raleigh PD recorded the evaluation.
3. **BREATH ALCOHOL TEST:** Sheehan had a 0.00% breath test result.
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** I was requested to contact Sergeant Craft for a drug evaluation. Sergeant Craft advised the suspect was observed drifting in and out of his traffic lane and driving 20 mph under the posted speed on Highway 64. Sergeant Craft noted the suspect had poor coordination and had slow and deliberate movements. His speech was slow and slurred. His pupils were constricted. He performed poorly on the SFST's and was arrested for DUI.
5. **INITIAL OBSERVATION OF SUSPECT:** I first observed the suspect in the interview room at the Raleigh Police Department. He was sitting at the interview table scratching his face and appeared to be "on the nod." His voice was low, slow and raspy. His pupils were constricted and his eyelids were droopy. He stated he was cold.
6. **MEDICAL PROBLEMS AND TREATMENT:** None noted or stated.
7. **PSYCHOPHYSICAL TESTS:** Modified Romberg Balance: Suspect swayed approximately 2" front to back and side to side and estimated 30 seconds in 55 seconds. Walk & Turn: Suspect lost his balance twice during the instructions, missed heel to toe three times, stopped walking and used his arms for balance. One Leg Stand: Suspect counted slowly, swayed, used his arms for balance and put his foot down. Finger to Nose: Suspect missed the tip of his nose on five of the six attempts and did not touch as his nose as directed.
8. **CLINICAL INDICATORS:** Two of the suspect's three pulse rates and his blood pressure were below the DRE average ranges. His pupils were constricted and they had little to no visible reaction to light.
9. **SIGNS OF INGESTION:** None evident.
10. **SUSPECT'S STATEMENTS:** The suspect denied drug use.
11. **DRE'S OPINION:** In my opinion Sheehan is under the influence of a **Narcotic Analgesic** and unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** The suspect provided a urine sample.
13. **MISCELLANEOUS:** An empty bottle of Vicodin was located in the suspect's vehicle.

Session 18 - Practice: Test Interpretation

45 Minutes

Session 18

Practice: Test Interpretation



Drug Recognition Expert Course

Reference “Test Interpretation” wall chart.

Session 18 - Practice: Test Interpretation

Learning Objectives

- **Analyze the results of a complete drug influence evaluation and identify the category or categories of drugs affecting the individual examined**
- **Articulate the bases for the drug category identification**




Drug Recognition Expert Course 18-2

Briefly review the objectives, content and activities of this session.

Upon successfully completing this session the participant will be able to:

- Analyze the results of a complete drug influence evaluation and identify the category or categories of drugs affecting the individual examined.
- Articulate the bases for the drug category identification.

CONTENT SEGMENTS

- A. Interpretation Demonstrations
- B. Interpretation Practice

LEARNING ACTIVITIES

- Instructor Led Demonstrations
- Small Group Practice
- Participant Led Presentations

Session 18 - Practice: Test Interpretation

Practice: Test Interpretation

Case No. 1: “Subject Martinez”

- Preliminary Examination
- Eye Examinations




Drug Recognition Expert Course 18-3

A. Interpretation Demonstrations

Case No.1: “Subject Martinez”

Direct participants to turn to the “Subject Martinez” exemplar in Session 18 of their manual.

Preliminary Examination

- Review the results of the preliminary examination of Subject Martinez.

Ask participants: “What category or categories of drugs would produce preliminary examination results consistent with this exemplar?” Probe to draw out the basis for participants’ responses.

Eye Examinations

- Review the results of the eye examination of Subject Martinez.

Ask participants to discuss the category or categories of drugs that would cause these examination results.

Session 18 - Practice: Test Interpretation

Practice: Test Interpretation (Cont.)

Case No. 1: “Subject Martinez”

- Psychophysical Tests
- Vital Signs Examinations
- Dark Room Examinations




Drug Recognition Expert Course 18-4

Psychophysical Tests

- Review the results of the psychophysical tests of Subject Martinez.

Ask participants to discuss the category or categories of drugs that would produce these psychophysical test results.

Vital Signs Examinations

- Review the results of the vital signs examinations of Subject Martinez.

Ask participants to discuss the category or categories of drugs that would cause these results.

Dark Room Examinations

- Review the results of the dark room examinations of Subject Martinez.

Ask participants to discuss the category or categories of drugs that would produce these results.

Session 18 - Practice: Test Interpretation

Practice: Test Interpretation (Cont.)

Case No. 1: "Subject Martinez"

- Other Evidence
- Opinion of the Evaluator



Drug Recognition Expert Course 18-5

Other Evidence

- Review the results of the examinations for injection sites and muscle rigidity, and of the final interview of Subject Martinez.

Ask participants to comment on the category or categories of drugs that would be consistent with all of the evidence on this exemplar.

Opinion of the Evaluator

Point out that the evidence indicates that Subject Martinez is under the influence of a Dissociative Anesthetic. Solicit participants' questions concerning this demonstration.

Session 18 - Practice: Test Interpretation

Practice: Test Interpretation (Cont.)

Case No. 2: “Subject Groves”

- Preliminary Examination
- Eye Examinations




Drug Recognition Expert Course 18-6

Case No.2: “Subject Groves”

Direct participants to review the “Subject Groves” exemplar.

Preliminary Examination

- Review the results of the preliminary examination of Subject Groves.

Ask participants: “What category or categories of drugs would produce preliminary examination results consistent with this exemplar?” Probe to draw out the basis for participants’ response.

Eye Examination

- Review the results of the eye examinations of Subject Groves.

Ask participants to discuss the category or categories of drugs that would cause these eye examination results.

Session 18 - Practice: Test Interpretation

Practice: Test Interpretation (Cont.)

Case No. 2: “Subject Groves”

- Psychophysical Tests
- Vital Signs Examinations
- Dark Room Examinations



Drug Recognition Expert Course 18-7

Psychophysical Tests

- Review the results of the psychophysical tests of Subject Groves.

Ask participants to discuss the category or categories of drugs that would produce these psychophysical test results.

Vital Signs Examinations

- Review the results of the vital signs examinations of Subject Groves.

Ask participants to discuss the category or categories of drugs that would produce these results.

Dark Room Examinations

- Review the results of the dark room examinations of Subject Groves.

Ask participants to discuss the category or categories of drugs that would produce these results.

Session 18 - Practice: Test Interpretation

Practice: Test Interpretation (Cont.)

Case No. 2: "Subject Groves"

- Other Evidence
- Opinion of the Evaluator



Drug Recognition Expert Course 18-8

Other Evidence

- Review the results of the examinations for injection sites and muscle rigidity, and of the final interview of Subject Groves.

Ask participants to comment on the category or categories of drugs that would be consistent with all of the evidence on this exemplar.

Opinion of the Evaluator

Point out that the evidence indicates that Subject Groves is under the influence of a Narcotic Analgesic.

Solicit participants' questions concerning this demonstration.

Session 18 - Practice: Test Interpretation

Interpretation Practice

Team Practice

- **Review and Discussion of Exemplars by Teams**




Drug Recognition Expert Course 18-9

B. Interpretation Practice

Team Practice

- **Assign participants to work in teams of three or four members.**
- **Tell teams that they are to review four exemplars (Subjects Hatos, Jackson, Stevens, and Sholly). Team members are to discuss the evidence among themselves and reach a conclusion concerning the category or categories of drugs, if any.**
- **Teams will present their conclusions to the entire class.**

Review and Discussion of Exemplars by Teams

Allow teams approximately 15 minutes to review the three exemplars and reach their conclusions.

Feedback of Results

Poll the teams to determine their conclusions concerning the category or categories of drugs present in each subject.

Subject Martinez

Subject Groves

Subject Hatos

Subject Jackson

Subject Stevens

Subject Sholly

Offer appropriate comments concerning the teams' performance.

Session 18 - Practice: Test Interpretation

QUESTIONS?









Drug Recognition Expert Course

18-10

Solicit participants' comments and questions concerning this practice session.

DRUG INFLUENCE EVALUATION






Evaluator Officer Troy Bartell, Laramie PD		DRE # 16843	Rolling Log # 12-02-012	Session XVIII - I #1	
Recorder/Witness Lt. Jonlee Anderle, Laramie PD		Crash: <input checked="" type="checkbox"/> None <input type="checkbox"/> Fatal <input type="checkbox"/> Injury <input type="checkbox"/> Property		Case # 12-20014	
Arrestee's Name (Last, First, Middle) Martinez, Juan M.		Date of Birth 5/20/80	Sex M	Race H	Arresting Officer (Name, ID#) Trooper Scott Keane, Wyoming HP #14677
Date Examined / Time / Location 02/22/12 2330 County Jail Intake		Breath Results: Results: 0.00		Test Refused <input type="checkbox"/> Instrument #: 3669	Chemical Test: Urine <input type="checkbox"/> Blood <input checked="" type="checkbox"/> Test or tests refused <input type="checkbox"/>
Miranda Warning Given Given By: Tpr. Keane	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? "Nothing" N/A	What have you been drinking? How much? "Nothing" N/A	Time of last drink? N/A	
Time now/ Actual No answer	When did you last sleep? How long No answer N/A	Are you sick or injured? <input type="checkbox"/> Yes <input type="checkbox"/> No "Not sick"		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input type="checkbox"/> No "Not sick"	
Do you take insulin? <input type="checkbox"/> Yes <input type="checkbox"/> No "Not sick"		Do you have any physical defects? <input type="checkbox"/> Yes <input type="checkbox"/> No "Not sick"		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input type="checkbox"/> No No answer	
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input type="checkbox"/> No "Not sick"		Attitude: Non-responsive, passive		Coordination: Unsteady, staggering	
Speech: Slow, slurred		Breath Odor: Chemical-like odor		Face: Blank stare	
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Bloodshot <input type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right	Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Eyelids: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Droopy
Pulse and time 1. <u>104</u> / <u>2340</u> 2. <u>108</u> / <u>2356</u> 3. <u>104</u> / <u>0010</u>	HGN Lack of Smooth Pursuit Maximum Deviation Angle of Onset	Left Eye Yes Yes 30	Right Eye Yes Yes 30	Convergence  Right eye Left eye	33 ONE LEG STAND 
Modified Romberg Balance 	Walk and Turn test  "Moonwalking", Rigid legs and arms	Cannot keep balance <input checked="" type="checkbox"/> Starts too soon _____ Stops walking _____ Misses heel-toe _____ Steps off line _____ Raises arms _____ Actual steps taken		1 st Nine <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> 2 nd Nine <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/>	L R <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Sways while balancing <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Uses arms to balance <input type="checkbox"/> <input type="checkbox"/> Hopping <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Puts foot down Test stopped for safety reasons
Internal clock 33 estimated as 30 seconds	Describe Turn Turned backwards	Cannot do test (explain) N/A		Type of footwear: Boots	
Draw lines to spots touched  Rigid movements		PUPIL SIZE	Room light 2.5 - 5.0	Darkness 5.0 - 8.5	Direct 2.0 - 4.5
		Left Eye	5.0	6.0	4.0
		Right Eye	5.0	6.0	4.0
		REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		REACTION TO LIGHT: Normal	
		RIGHT ARM 		LEFT ARM 	
		Nothing observed			
Blood pressure 156/98	Temperature 99.4	Muscle tone: <input type="checkbox"/> Normal <input type="checkbox"/> Flaccid <input checked="" type="checkbox"/> Rigid		Comments: Arms and legs	
What drugs or medications have you been using? No answer		How much? N/A	Time of use? No answer	Where were the drugs used? (Location) No answer	
Date / Time of arrest: 2/22/12 2245	Time DRE was notified: 2315	Evaluation start time: 2330	Evaluation completion time: 0020 2/23/12	Precinct/Station:	
Officer's Signature:		DRE # 16843	Reviewed/approved by / date:		
Opinion of Evaluator:		<input type="checkbox"/> Rule Out	<input type="checkbox"/> Alcohol	<input type="checkbox"/> CNS Stimulant	<input checked="" type="checkbox"/> Dissociative Anesthetic
		<input type="checkbox"/> Medical	<input type="checkbox"/> CNS Depressant	<input type="checkbox"/> Hallucinogen	<input type="checkbox"/> Narcotic Analgesic
				<input type="checkbox"/> Inhalant	<input type="checkbox"/> Cannabis

DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: Martinez, Juan M.

1. **LOCATION:** The evaluation was conducted at Albany County Jail.
2. **WITNESSES:** Lt. Jonlee Anderle of L.P.D recorded the evaluation.
3. **BREATH ALCOHOL TEST:** Martinez had a breath test of 0.00%.
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** Writer was contacted and requested to contact Trooper Keane at the County Jail Intake Center for a drug evaluation. Trooper Keane advised he had observed the suspect on Hwy 287 drifting over the lane divider line nearly hitting other vehicles. When stopped, the suspect appeared dazed and confused. He had a blank stare and was non-responsive at times. He did poorly on the SFST's and was arrested for DUI.
5. **INITIAL OBSERVATION OF SUSPECT:** Writer first observed the suspect in the Intake Center. He appeared dazed and disoriented. He had a fixed, blank stare and responded very slowly to questions. His speech was slow, slurred and confused.
6. **MEDICAL PROBLEMS AND TREATMENT:** None noted or stated.
7. **PSYCHOPHYSICAL TESTS:** Modified Romberg Balance: Suspect swayed approximately 3" side to side and estimated 30 seconds in 33 seconds. Walk & Turn: Suspect lost his balance twice during the instructions, stopped walking twice and used his arms for balance. One Leg Stand: Suspect put his foot down twice while standing on his left foot and nearly fell while attempting to stand on his right and the test was stopped. Finger to Nose: Suspect missed the tip of his nose on three of the six attempts and his arm movements were very rigid.
8. **CLINICAL INDICATORS:** Suspect had six clues of HGN and exhibited an early onset of Nystagmus. Vertical Gaze Nystagmus and Lack of Convergence were also present. The suspect's pulse and blood pressure were elevated and above the DRE average ranges.
9. **SIGNS OF INGESTION:** There was a chemical-like odor on the suspect's breath.
10. **SUSPECT'S STATEMENTS:** The suspect did not respond to questions about drug use.
11. **DRE'S OPINION:** In my opinion Martinez is under the influence of a **Dissociative Anesthetic** and unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** The suspect provided a blood sample.
13. **MISCELLANEOUS:** A glass vial with an unknown liquid was found on the suspect.

DRUG INFLUENCE EVALUATION

Evaluator Trooper Sam Ketchum, Idaho State Police		DRE # 9323	Rolling Log # 12-04-56	Session XVIII - I #2	
Recorder/Witness Sgt. Dean Matlock, Idaho State Police		Crash: <input checked="" type="checkbox"/> None <input type="checkbox"/> Fatal <input type="checkbox"/> Injury <input type="checkbox"/> Property		Case # 12-55575	
Arrestee's Name (Last, First, Middle) Groves, Robert G.		Date of Birth 8/10/77	Sex M	Race W	Arresting Officer (Name, ID#) Officer Casey Hancuff, Boise PD #9335
Date Examined / Time / Location 4/15/12 1430 Ada County Jail		Breath Results: Results: 0.00		Test Refused <input type="checkbox"/> Instrument #: 4410	Chemical Test: Urine <input checked="" type="checkbox"/> Blood <input type="checkbox"/> Test or tests refused <input type="checkbox"/>
Miranda Warning Given Given By: Officer Hancuff	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? Burger & Fries About noon	What have you been drinking? Nothing	How much? N/A	Time of last drink? N/A
Time now/ Actual 1:00 PM/1434	When did you last sleep? How long Last night 4 hours	Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	
Are you taking any medication or drugs? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No "Pain pills for my back"		Attitude: Cooperative		Coordination: Poor, wobbly, stumbling	
Speech: Slow, mumbling		Breath Odor: Normal, slow, shallow		Face: Normal	
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right	
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	
Eyelids <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Droopy		Pulse and time		HGN	
1. <u>60</u> / <u>1445</u>		Left Eye		Right Eye	
2. <u>60</u> / <u>1500</u>		Lack of Smooth Pursuit		No	
3. <u>60</u> / <u>1520</u>		Maximum Deviation		No	
		Angle of Onset		None	
Modified Romberg Balance		Walk and Turn test		Convergence	
					
		Cannot keep balance <input checked="" type="checkbox"/> <input checked="" type="checkbox"/>		22 ONE LEG STAND 24	
		Starts too soon			
		Stops walking		L R	
		Misses heel-toe		<input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Sways while balancing	
		Steps off line		<input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Uses arms to balance	
		Raises arms		<input type="checkbox"/> <input type="checkbox"/> Hopping	
		Actual steps taken		<input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Puts foot down	
		1 st Nine		Counted slowly	
		2 nd Nine			
		9			
Internal clock 53 estimated as 30 seconds		Describe Turn Lost balance, staggered to right		Cannot do test (explain) N/A	
Type of footwear: Lace-up boots		PUPIL SIZE		Nasal area: Clear	
Draw lines to spots touched		Room light 2.5 - 5.0		Darkness 5.0 - 8.5	
		Direct 2.0 - 4.5		Oral cavity: Clear	
Slow movements		Left Eye 2.0		Right Eye 2.0	
Blood pressure 106/64		Temperature 97.8		REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Muscle tone: <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Flaccid <input type="checkbox"/> Rigid		COMMENTS		REACTION TO LIGHT: None	
What drugs or medications have you been using? "A couple of pills for my back"		How much? "Just a couple is all"		Time of use? "About noon"	
Where were the drugs used? (Location) McDonald's		Date / Time of arrest: 4/15/12 1335		Time DRE was notified: 1400	
Evaluation start time: 1430		Evaluation completion time: 1545		Precinct/Station: Boise ISP	
Officer's Signature:		DRE # 9323		Reviewed/approved by / date:	
Opinion of Evaluator:		<input type="checkbox"/> Rule Out <input type="checkbox"/> Alcohol <input type="checkbox"/> Medical <input type="checkbox"/> CNS Depressant		<input type="checkbox"/> CNS Stimulant <input type="checkbox"/> Hallucinogen <input checked="" type="checkbox"/> Narcotic Analgesic <input type="checkbox"/> Inhalant <input type="checkbox"/> Cannabis	








DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: Groves, Robert G.

1. **LOCATION:** The evaluation was conducted at the Ada County Jail Intake Center.
2. **WITNESSES:** Sergeant Dean Matlock of the Idaho State Police recorded the evaluation.
3. **BREATH ALCOHOL TEST:** Groves' breath test was 0.00%.
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** I was contacted by ISP Dispatch and requested to contact Officer Hancuff at the Intake Center for a drug evaluation. Officer Hancuff advised that he had observed the suspect's vehicle drifting over the center line and traveling 15 mph under the posted speed zone on W. Overland Road. When stopped, the suspect had slow and slurred speech. His balance and coordination was poor and he did poorly on the SFST's and was arrested for DUI. He admitted to taking a "couple pain pills" for his back.
5. **INITIAL OBSERVATION OF SUSPECT:** I first observed the suspect in the Intake Center. He appeared sleepy and his head was nodding forward. His speech was slow and slurred. When he stood, his balance was poor and he staggered when he walked.
6. **MEDICAL PROBLEMS AND TREATMENT:** The suspect stated he was taking pain medicine for a back injury he suffered about five years ago.
7. **PSYCHOPHYSICAL TESTS:** Modified Romberg Balance: Suspect swayed approximately 3" in a circular sway and estimated 30 seconds in 53 seconds. Walk & Turn: Suspect lost his balance twice during the instructions, missed heel to toe three times, stepped off the line three times and used his arms for balance. One Leg Stand: Suspect put his foot down twice while standing on each foot and counted slowly. Finger to Nose: Suspect missed the tip of his nose on all six attempts and had slow arm movements.
8. **CLINICAL INDICATORS:** The suspect's pulse rates were all at the low end of the DRE average ranges. His blood pressure was below the DRE average ranges. His pupils were constricted and had little to no reaction to light.
9. **SIGNS OF INGESTION:** None were evident.
10. **SUSPECT'S STATEMENTS:** Suspect admitted taking a "couple pain pills" with lunch.
11. **DRE'S OPINION:** In my opinion Groves is under the influence of a Narcotic Analgesic and unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** The suspect provided a urine sample.
13. **MISCELLANEOUS:**

R5/13

DRUG INFLUENCE EVALUATION

Evaluator Deputy Susan Cotter, Harris County SO		DRE # 8063	Rolling Log # 12-01-104	Session XVIII - I #3									
Recorder/Witness Officer Joshua Bruegger, Pasadena PD		Crash: <input checked="" type="checkbox"/> None <input type="checkbox"/> Fatal <input type="checkbox"/> Injury <input type="checkbox"/> Property		Case # 12041105									
Arrestee's Name (Last, First, Middle) Hatos, Carlos		Date of Birth 7/13/79	Sex M	Race H	Arresting Officer (Name, ID#) Deputy P. Lillibridge, Harris Co SO #10331								
Date Examined / Time / Location 01/22/12 2210 Harris Co. Jail		Breath Results: Results: 0.00		Test Refused <input type="checkbox"/> Instrument #: 12835	Chemical Test: Urine <input checked="" type="checkbox"/> Blood <input type="checkbox"/> Test or tests refused <input type="checkbox"/>								
Miranda Warning Given Given By: Dpty. Lillibridge	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? Steak dinner 7 PM	What have you been drinking? How much? "Nothing"	Time of last drink? 8 PM									
Time now/ Actual 11 PM/2215	When did you last sleep? How long Last night 8 hrs.	Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No									
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No									
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Attitude: Cooperative, nervous		Coordination: Poor, jerky, stumbling									
Speech: Talkative and Rapid		Breath Odor: Normal		Face: Normal									
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right									
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No									
Eyelids: <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Droopy													
Pulse and time 1. $\frac{100}{2222}$ 2. $\frac{100}{2235}$ 3. $\frac{98}{2255}$		HGN Lack of Smooth Pursuit Maximum Deviation Angle of Onset	Left Eye No No None	Right Eye No No None	35 ONE LEG STAND 37 								
Modified Romberg Balance  Eyelid tremors		Walk and Turn test  Cannot keep balance <input checked="" type="checkbox"/> Starts too soon _____ Stops walking _____ Misses heel-toe _____ Steps off line _____ Raises arms _____ Actual steps taken		Convergence  Right eye Left eye 1st Nine 2nd Nine <table border="1" style="display: inline-table;"><tr><td><input checked="" type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td><input checked="" type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td><input checked="" type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td><input checked="" type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></table> 9 9		<input checked="" type="checkbox"/>							
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>												
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>												
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>												
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>												
Internal clock 26 estimated as 30 seconds		Describe Turn As instructed		Cannot do test (explain) N/A									
Type of footwear: Lace-up boots													
Draw lines to spots touched  Eyelid tremors		PUPIL SIZE	Room light 2.5 - 5.0	Darkness 5.0 - 8.5	Direct 2.0 - 4.5								
		Left Eye	6.5	8.0	5.5								
		Right Eye	6.5	8.0	5.5								
		REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		REACTION TO LIGHT: Slow									
		RIGHT ARM 		LEFT ARM 									
		Nothing observed											
Blood pressure 146/92	Temperature 99.2	Muscle tone: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Flaccid <input type="checkbox"/> Rigid											
Comments:													
What drugs or medications have you been using? "I don't do drugs anymore"		How much? N/A	Time of use? N/A	Where were the drugs used? (Location) N/A									
Date / Time of arrest: 01/22/12 2105	Time DRE was notified: 2145	Evaluation start time: 2210	Evaluation completion time: 2315	Precinct/Station: Central									
Officer's Signature:		DRE # 8063	Reviewed/approved by / date:										
Opinion of Evaluator:		<input type="checkbox"/> Rule Out <input type="checkbox"/> Alcohol <input checked="" type="checkbox"/> CNS Stimulant <input type="checkbox"/> Dissociative Anesthetic <input type="checkbox"/> Inhalant	<input type="checkbox"/> Medical <input type="checkbox"/> CNS Depressant <input type="checkbox"/> Hallucinogen <input type="checkbox"/> Narcotic Analgesic <input type="checkbox"/> Cannabis										







DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: Hatos, Carlos

1. **LOCATION:** The evaluation was conducted in the booking area of the Harris County Jail.
2. **WITNESSES:** DRE Joshua Bruegger of the Pasadena PD recorded the evaluation.
3. **BREATH ALCOHOL TEST:** Hatos had a breath test of 0.00%.
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** At approximately 2145 hours I was requested to meet Deputy Lillibridge at Harris Co. Jail for a drug evaluation. Deputy Lillibridge advised he had observed the suspect's vehicle traveling at a high rate of speed on Red Bluff Road. When stopped, the suspect appeared nervous and was very talkative. The suspect did poorly on the SFST's and was arrested for DUI.
5. **INITIAL OBSERVATION OF SUSPECT:** Writer first observed the suspect in the booking area at the County Jail. The suspect was very talkative, repeatedly shifted his weight from foot to foot and was making abrupt, quick hand movements. When not speaking, he appeared to be grinding his teeth.
6. **MEDICAL PROBLEMS AND TREATMENT:** None noted and none stated.
7. **PSYCHOPHYSICAL TESTS:** Modified Romberg Balance: Suspect swayed approximately 3" side to side and approximately 2" front to back. He estimated 30 seconds in 26 seconds. Walk & Turn: Suspect lost his balance during the instructions, stopped twice while walking, missed heel-to-toe four times and raised his arms for balance four times. One Leg Stand: Suspect put his foot down once while standing on each foot, swayed while balancing and used his arms for balance. Finger to Nose: Suspect missed the tip of his nose on three of the six attempts and performed attempt #5 and #6 with the wrong hand.
8. **CLINICAL INDICATORS:** The suspect's pulse and blood pressure were elevated and above the DRE average ranges. His pupils were dilated in two lighting levels and he had a slow reaction to light.
9. **SIGNS OF INGESTION:** None were evident.
10. **SUSPECT'S STATEMENTS:** Suspect admitted drinking "two beers" earlier in the day and denied using any other drugs.
11. **DRE'S OPINION:** In my opinion Hatos is under the influence of a CNS Stimulant and unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** The suspect provided a urine sample.
13. **MISCELLANEOUS:**

R5/13

DRUG INFLUENCE EVALUATION

Evaluator Officer Virgil Miller, Wichita PD		DRE # 10828	Rolling Log # 12-03-035	Session XVIII - I #4	
Recorder/Witness Det. Karrina Brasser, Sedgwick Co. S.O.		Crash: <input checked="" type="checkbox"/> None <input type="checkbox"/> Fatal <input type="checkbox"/> Injury <input type="checkbox"/> Property		Case # 12-99115	
Arrestee's Name (Last, First, Middle) Jackson, Scott M.		Date of Birth 7/15/75	Sex M	Race W	Arresting Officer (Name, ID#) Trooper Mark Crump, Kansas H.P. #7949
Date Examined / Time / Location 03/18/12 2030 Sedgwick Co. Jail		Breath Results: Results: 0.00		Test Refused <input type="checkbox"/> Instrument #: 88075	Chemical Test: Urine <input type="checkbox"/> Blood <input checked="" type="checkbox"/> Test or tests refused <input type="checkbox"/>
Miranda Warning Given Given By: Tpr. Crump	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? Eggs and toast 9AM	What have you been drinking? How much? Coffee 2 cups	Time of last drink? N/A	
Time now/ Actual Midnight/2042	When did you last sleep? How long Last night 7 hrs.	Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Attitude: Passive, cooperative		Coordination: Poor, unsteady	
Speech: Slow, thick, slurred		Breath Odor: Halitosis		Face: Flushed, blank stare	
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right	
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	
Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal		Eyelids: <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Droopy			
Pulse and time 1. <u>54</u> / <u>2040</u> 2. <u>56</u> / <u>2055</u> 3. <u>58</u> / <u>2118</u>		HGN Lack of Smooth Pursuit: No Maximum Deviation: No Angle of Onset: None	Left Eye No	Right Eye No	Convergence 
Modified Romberg Balance 		Walk and Turn test 		ONE LEG STAND 	
		Cannot keep balance <input checked="" type="checkbox"/>		L R <input checked="" type="checkbox"/> Sways while balancing <input checked="" type="checkbox"/> Uses arms to balance <input type="checkbox"/> Hopping <input checked="" type="checkbox"/> Puts foot down	
		Starts too soon		1st Nine 2nd Nine	
		Stops walking		<input checked="" type="checkbox"/> <input checked="" type="checkbox"/>	
		Misses heel-toe		<input checked="" type="checkbox"/> <input checked="" type="checkbox"/>	
		Steps off line		<input checked="" type="checkbox"/> <input checked="" type="checkbox"/>	
		Raises arms		<input checked="" type="checkbox"/> <input checked="" type="checkbox"/>	
		Actual steps taken		9 9	
Internal clock 42 estimated as 30 seconds		Describe Turn: Abrupt spin		Cannot do test (explain) N/A	
				Type of footwear: Lace-up shoes	
Draw lines to spots touched 		PUPIL SIZE	Room light 2.5 - 5.0	Darkness 5.0 - 8.5	Direct 2.0 - 4.5
		Left Eye	2.0	3.0	2.0
		Right Eye	2.0	3.0	2.0
		REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		REACTION TO LIGHT: None visible	
		RIGHT ARM 		LEFT ARM 	
				Fresh puncture wounds, red, oozing	
Blood pressure 122/68		Temperature 98.0			
Muscle tone: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Flaccid <input type="checkbox"/> Rigid		Comments:			
What drugs or medications have you been using? "I didn't use anything today"		How much? N/A		Time of use? N/A	Where were the drugs used? (Location) N/A
Date / Time of arrest: 03/18/12 1910	Time DRE was notified: 1950	Evaluation start time: 2030	Evaluation completion time: 2145	Precinct/Station:	
Officer's Signature:		DRE # 10828	Reviewed/approved by / date:		
Opinion of Evaluator:		<input type="checkbox"/> Rule Out <input type="checkbox"/> Alcohol <input type="checkbox"/> CNS Stimulant <input type="checkbox"/> Dissociative Anesthetic <input type="checkbox"/> Inhalant	<input type="checkbox"/> Medical <input type="checkbox"/> CNS Depressant <input type="checkbox"/> Hallucinogen <input checked="" type="checkbox"/> Narcotic Analgesic <input type="checkbox"/> Cannabis		

DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: Jackson, Scott M.

1. **LOCATION:** The evaluation was conducted at the Sedgwick County Jail.
2. **WITNESSES:** Detective Karrina Brassler witnessed and recorded the evaluation.
3. **BREATH ALCOHOL TEST:** Jackson's breath test was 0.00%.
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** Writer was contacted and requested to contact Trooper Crump at the Sedgwick County Jail for a drug evaluation. Trooper Crump advised he located the suspect's vehicle traveling E/B on Highway 54 near the Garden Plain exit. The suspect was traveling at approximately 45 mph and drifting in and out of his lane. When Trooper Crump tried to stop the suspect, he continued without stopping for over a mile. The suspect had a blank stare and his speech was thick and slow. The suspect did poorly on the SFST's and was arrested for DUI.
5. **INITIAL OBSERVATION OF SUSPECT:** Writer first observed the suspect in the interview room at the jail. He was cooperative and had slow, thick, slurred speech. He was slow to respond to questions and was unstable on his feet.
6. **MEDICAL PROBLEMS AND TREATMENT:** None noted or stated.
7. **PSYCHOPHYSICAL TESTS:** Modified Romberg Balance: Suspect swayed approximately 3" side to side and front to back. He estimated 30 seconds in 42 seconds. Walk & Turn: Suspect lost his balance during the instructions, stepped off the line twice on the first nine steps and once on the second nine steps. He also missed heel-to-toe five times, stopped while walking twice and raised his arms for balance. He also made an improper turn. One Leg Stand: Both tests were stopped for safety reasons after he put his down numerous times and nearly fell. Finger to Nose: Suspect missed the tip of his nose on five of the six attempts.
8. **CLINICAL INDICATORS:** The suspect's pulse and blood pressure were below the DRE average ranges. His pupils were constricted in two of the three lighting levels.
9. **SIGNS OF INGESTION:** The suspect had two fresh puncture marks on his left forearm.
10. **SUSPECT'S STATEMENTS:** Suspect denied using drugs.
11. **DRE'S OPINION:** In my opinion Jackson is under the influence of a Narcotic Analgesic and unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** The suspect provided a blood sample.
13. **MISCELLANEOUS:**

R5/13

DRUG INFLUENCE EVALUATION

Evaluator Trooper Scott Singleton, Utah HP		DRE # 4740	Rolling Log # 12-01-121	Session XVIII - I #5											
Recorder/Witness Tpr. Jason Marshall, Utah Highway Patrol		Crash: <input type="checkbox"/> None <input type="checkbox"/> Fatal <input type="checkbox"/> Injury <input type="checkbox"/> Property		Case # 12-004345											
Arrestee's Name (Last, First, Middle) Stevens, William A.		Date of Birth 4/14/84	Sex M	Race W	Arresting Officer (Name, ID#) Officer Jody Whitaker, Salt Lake City P.D. #7614										
Date Examined / Time / Location 01/17/12 2200 Salt Lake City PD		Breath Results: Results: 0.00		Test Refused <input type="checkbox"/> Instrument #: 47745	Chemical Test: Urine <input type="checkbox"/> Blood <input checked="" type="checkbox"/> Test or tests refused <input type="checkbox"/>										
Miranda Warning Given Given By: Ofc. Whitaker	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? "Burger" Noon	What have you been drinking? "Just water"	How much? N/A	Time of last drink? N/A										
Time now/ Actual 9 PM/10:05 PM	When did you last sleep? How long Last night 2 hrs.	Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No											
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No Dr. Frank at the Clinic											
Are you taking any medication or drugs? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No Valium - 2 each day		Attitude: Cooperative		Coordination: Poor, staggering											
Speech: Thick, slow, slurred		Breath Odor: Normal		Face: Normal, dazed look											
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input checked="" type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right	Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal										
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Eyelids <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Droopy										
Pulse and time 1. <u>60</u> / <u>2214</u> 2. <u>58</u> / <u>2225</u> 3. <u>56</u> / <u>2243</u>		HGN Lack of Smooth Pursuit Maximum Deviation Angle of Onset	Right Eye Yes Yes 30	Left Eye Yes Yes 30	Convergence Right eye Left eye	34 ONE LEG STAND 35 L R <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Sways while balancing <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Uses arms to balance <input type="checkbox"/> <input type="checkbox"/> Hopping <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Puts foot down									
Modified Romberg Balance 2" 2" 2" 2"		Walk and turn test Cannot keep balance <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Starts too soon _____ Stops walking _____ Misses heel-toe _____ Steps off line _____ Raises arms _____ Actual steps taken		1 st Nine 2 nd Nine <table border="1" style="display: inline-table;"><tr><td><input checked="" type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td><input checked="" type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td><input checked="" type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td><input checked="" type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td><input checked="" type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></table> 9 10		<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>														
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>														
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>														
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>														
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>														
Internal clock 38 estimated as 30 seconds	Describe Turn: Lost balance	Cannot do test (explain) N/A		Type of footwear: Boots											
Draw lines to spots touched Slow movements		PUPIL SIZE	Room light 2.5 - 5.0	Darkness 5.0 - 8.5	Direct 2.0 - 4.5										
		Left Eye	5.5	6.5	4.0										
		Right Eye	5.5	6.5	4.0										
		REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		REACTION TO LIGHT: Slow											
		RIGHT ARM LEFT ARM Nothing observed													
Blood pressure 112/68	Temperature 98.0	Muscle tone: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Flaccid <input type="checkbox"/> Rigid													
Comments: What drugs or medications have you been using? "Just my pills"		How much? 2 a day	Time of use? 10AM	Where were the drugs used? (Location) At home											
Date / Time of arrest: 01/17/12 2100	Time DRE was notified: 2140	Evaluation start time: 2200	Evaluation completion time: 2315	Precinct/Station:											
Officer's Signature:		DRE # 4740	Reviewed/approved by / date:												
Opinion of Evaluator:		<input type="checkbox"/> Rule Out <input type="checkbox"/> Medical	<input type="checkbox"/> Alcohol <input checked="" type="checkbox"/> CNS Depressant	<input type="checkbox"/> CNS Stimulant <input type="checkbox"/> Hallucinogen	<input type="checkbox"/> Dissociative Anesthetic <input type="checkbox"/> Narcotic Analgesic	<input type="checkbox"/> Inhalant <input type="checkbox"/> Cannabis									






DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: Stevens, William A.

1. **LOCATION:** The evaluation was conducted at the Salt Lake City Police Department.
2. **WITNESSES:** Trooper Jason Marshall of the Utah H.P. witnessed the evaluation.
3. **BREATH ALCOHOL TEST:** Stevens had a breath test of 0.00%.
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** I was requested to contact Officer Whitaker at the Salt Lake City Police Department for a drug evaluation. Officer Whitaker advised she had located the suspect's vehicle stopped in the intersection at California and S. 900th. She contacted the suspect who was sitting in the driver's seat. He had a dazed appearance and his speech was thick, slurred and slow. He had six clues of HGN, did poorly on the SFST's and was arrested for DUI.
5. **INITIAL OBSERVATION OF SUSPECT:** I first observed the suspect in the interview room at the P.D. The suspect was cooperative and had slow, thick, slurred speech. He was slow to respond to questions. His balance was poor and he staggered when walking.
6. **MEDICAL PROBLEMS AND TREATMENT:** The suspect stated he was seeing Dr. Frank at the Clinic who had prescribed him Valium for anxiety problems.
7. **PSYCHOPHYSICAL TESTS:** Modified Romberg Balance: Suspect swayed approximately 2" in a circular motion and he estimated 30 seconds in 38 seconds. Walk & Turn: Suspect lost his balance twice during the instructions, stepped off the line twice, missed heel to toe three times, stopped twice, used his arms for balance and also took one extra step on the second nine steps. He also lost his balance when he turned. One Leg Stand: Suspect put his foot down twice on each attempt, swayed while balancing and used his arms for balance. Finger to Nose: Suspect missed the tip of his nose on three of the six attempts and used the pads of his fingers on attempts #1, #3 and #6.
8. **CLINICAL INDICATORS:** Suspect had 6 clues of HGN with a 30 degree angle of onset. He also had VGN and a Lack of Convergence. His pulse was below the DRE average range on two of the three checks and his blood pressure was also below the DRE average range.
9. **SIGNS OF INGESTION:** Nothing observed or detected.
10. **SUSPECT'S STATEMENTS:** Suspect admitted taking two Valium earlier in the day.
11. **DRE'S OPINION:** In my opinion Stevens is under the influence of a CNS Depressant and unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** The suspect provided a urine sample.
13. **MISCELLANEOUS:**

R5/13

DRUG INFLUENCE EVALUATION

Evaluator Officer Aaron Rohner, California H.P.		DRE # 10803	Rolling Log # 12-06-25	Session XVIII - I #6		
Recorder/Witness Officer Kevin Craig, CHP		Crash: <input type="checkbox"/> None <input type="checkbox"/> Fatal <input type="checkbox"/> Injury <input checked="" type="checkbox"/> Property		Case # 127418		
Arrestee's Name (Last, First, Middle) Sholly, Cameron H.		Date of Birth 10/3/78	Sex M	Race W	Arresting Officer (Name, ID#) Officer Tom Flahaven, CHP #88744	
Date Examined / Time / Location 06/10/12 1445 Sacramento Co. Jail		Breath Results: Results: 0.00		Test Refused <input type="checkbox"/> Instrument #: 015233A	Chemical Test: Urine <input type="checkbox"/> Blood <input checked="" type="checkbox"/> Test or tests refused <input type="checkbox"/>	
Miranda Warning Given Given By: Ofc. Flahaven	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? Nothing N/A	What have you been drinking? How much? "I didn't drink anything"	Time of last drink? N/A		
Time now/ Actual "Don't know"	When did you last sleep? How long "About 2 days ago"	Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No "I don't go to the doctor"		
Are you taking any medication or drugs? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No "Took Tylenol this morning"		Attitude: Cooperative		Coordination: Slow, sluggish		
Speech: Slow		Breath Odor: Normal		Face: Normal		
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input checked="" type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right		
Pupil Size: <input type="checkbox"/> Equal <input checked="" type="checkbox"/> Unequal (explain) Left pupil larger than right		Vertical Nystagmus <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		
Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal		Eyelids: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Droopy				
Pulse and time	HGN	Left Eye	Right Eye	Convergence		
1. 92 / 1505	Lack of Smooth Pursuit	No	No			
2. 92 / 1518	Maximum Deviation	No	No			
3. 90 / 1530	Angle of Onset	None	None			
Modified Romberg Balance	Walk and Turn test	Cannot keep balance _____		30 ONE LEG STAND 29		
		Starts too soon <input checked="" type="checkbox"/> <input checked="" type="checkbox"/>				
	Stated, "This is impossible." Stepped off line and would not continue.	Stops walking _____		L R		
		Misses heel-toe _____		<input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Sways while balancing		
		Steps off line <input checked="" type="checkbox"/>		<input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Uses arms to balance		
		Raises arms <input checked="" type="checkbox"/>		<input type="checkbox"/> <input type="checkbox"/> Hopping		
		Actual steps taken		<input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Puts foot down		
Internal clock 28 estimated as 30 seconds	Describe Turn N/A	Cannot do test (explain) Refused to complete		Type of footwear: Work boots		
Draw lines to spots touched		PUPIL SIZE	Room light	Darkness	Direct	Nasal area: Clear
		Left Eye	6.0	8.5	5.0	Oral cavity: Clear
		Right Eye	4.5	7.0	3.5	
		REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			REACTION TO LIGHT: Normal	
Blood pressure 146/88		Temperature 98.8		RIGHT ARM		LEFT ARM
Muscle tone: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Flaccid <input type="checkbox"/> Rigid						
Comments:						
What drugs or medications have you been using? "Just two Tylenol"		How much? "Two"		Time of use? This morning		Where were the drugs used? (Location) Home
Date / Time of arrest: 06/10/12 1400	Time DRE was notified: 1420	Evaluation start time: 1445	Evaluation completion time: 1555	Precinct/Station:		
Officer's Signature:		DRE # 10803	Reviewed/approved by / date:			
Opinion of Evaluator:		<input checked="" type="checkbox"/> Rule Out	<input type="checkbox"/> Alcohol	<input type="checkbox"/> CNS Stimulant	<input type="checkbox"/> Dissociative Anesthetic	<input type="checkbox"/> Inhalant
		<input checked="" type="checkbox"/> Medical	<input type="checkbox"/> CNS Depressant	<input type="checkbox"/> Hallucinogen	<input type="checkbox"/> Narcotic Analgesic	<input type="checkbox"/> Cannabis

DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: Sholly, Cameron H.


1. **LOCATION:** The evaluation was conducted at the Sacramento County Jail.
2. **WITNESSES:** Officer Kevin Craig of the CHP witnessed and recorded the evaluation.
3. **BREATH ALCOHOL TEST:** Sholly had a breath test of 0.00%.
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** I was requested to meet Officers Flahaven and Craig at the Sacramento County Jail for a drug evaluation. According to Officer Flahaven, Sholly was a driver involved in a crash on I-5 north of Sacramento. His vehicle rear-ended a stopped vehicle at a construction site. Sholly was not injured but was sluggish acting at the scene and was slow to respond to questions. His speech was slow and slurred at times and at times was unstable on his feet.
5. **INITIAL OBSERVATION OF SUSPECT:** Writer first observed Sholly in the interview room at the jail. He was cooperative but was slow to respond to questions and he slurred his speech at times. He seemed confused and anxious.
6. **MEDICAL PROBLEMS AND TREATMENT:** Sholly was slow to respond when asked about medical problems and/or medical treatment. He eventually stated, "I don't go to the doctor. They don't know what they're doing."
7. **PSYCHOPHYSICAL TESTS:** Modified Romberg Balance: Sholly exhibited no sway and he estimated 30 seconds in 28 seconds. Walk & Turn: Sholly started too soon twice, took two steps, stepped off the line and said, "This is impossible!" and refused to continue. One Leg Stand: Sholly put his foot down one time while standing on the left foot and three times while standing on his right foot and swayed while balancing on both attempts. Finger to Nose: Sholly missed the tip of his nose on two of the six attempts.
8. **CLINICAL INDICATORS:** Sholly's pulse and systolic blood pressure were elevated and above the DRE average ranges. His pupils were unequal in all three lighting levels.
9. **SIGNS OF INGESTION:** None were evident or stated.
10. **SUSPECT'S STATEMENTS:** Sholly admitted taking Tylenol only.
11. **DRE'S OPINION:** In my opinion Sholly is under the influence of a medical condition and unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** Sholly provided a blood sample.
13. **MISCELLANEOUS:**

Mid-Course Review

2 Hours 30 Minutes

Mid-Course Review

Review of Drugs, Drug Categories, and the Drug Influence Evaluation





Drug Recognition Expert Course

MID-COURSE REVIEW

This is an after-normal-class-hours session that participants are free to attend or not, but are encouraged to attend. Its principal purpose is to help solidify the knowledge and skills they have begun to acquire, from the Pre-School and from the first four days of the DRE School.

This session must be conducted in a highly interactive fashion. Don't simply present information or conduct demonstrations. Make the participants do it. Ask questions, and call upon participants to conduct the demonstrations that are required. Try to involve everybody, and convey your gratitude for the fact that they have attended this session.

CONTENT SEGMENTS

- A. Drugs, Drug Categories and the Drug Influence Evaluation
- B. Eyes and Vital Signs
- C. Physiology
- D. Questions and Answers

LEARNING ACTIVITIES

- Instructor / Participant Dialogues
- Participant-Led Demonstrations

Mid-Course Review

Drugs, Drug Categories, and the Drug Influence Evaluation

- Define the word “drug”
- Name the seven drug categories
- Name the six subcategories of Depressants
- Name three subcategories of CNS Stimulants
- Name two sub-categories of Narcotic Analgesics




Drug Recognition Expert Course Mid - 2

A. Drugs, Drug Categories, and the Drug Influence Evaluation

Define the word “drug.”

- Any substance that, when taken into the human body, can impair the ability of the person to operate a vehicle safely.

Name the seven drug categories.

- CNS Depressants, CNS Stimulants, Hallucinogens, Dissociative Anesthetics, Narcotic Analgesics, Inhalants, and Cannabis

Name the six subcategories of Depressants.

- Barbiturates, Non-Barbiturates, Anti-Anxiety Tranquilizers, Anti-Depressants, Anti-Psychotic Tranquilizers, and Combinations of the first five

Name three subcategories of CNS Stimulants.

- Cocaine, the Amphetamines, and “Others.”

Name two sub-categories of Narcotic Analgesics.

- Opiates and Synthetics

Mid-Course Review

Name the Drug Category for:

- **Desoxyn**
- **Secobarbital**
- **Dilaudid**
- **Alprazolam**
- **Phenyl Cyclohexyl Piperidine**
- **“Ecstasy”**
- **ETOH**
- **Numorphan**
- **Psilocybin**




Drug Recognition Expert Course Mid - 3

Identify the category for each of the listed drugs:

Desoxyn

- CNS Stimulant

Secobarbital (Seconal)

- CNS Depressant (Barbiturate)

Dilaudid

- Narcotic Analgesic

Alprazolam (Xanax)

- CNS Depressant (Anti-Anxiety)

Phenyl Cyclohexyl Peperidine

- Dissociative Anesthetics

“Ecstasy” (MDMA)

- Hallucinogen

ETOH

- CNS Depressant

Numorphan

- Narcotic Analgesic

Psilocybin

- Hallucinogen

Mid-Course Review

12 Components of the Drug Influence Evaluation



Drug Recognition Expert Course

Mid - 4

List the twelve components of the Drug Influence Evaluation in the proper sequence.

1. Breath Alcohol Test
2. Interview of Arresting Officer
3. Preliminary Examination
4. Eye Examinations
5. Divided Attention Tests
6. Vital Signs Examinations
7. Darkroom Examinations
8. Check for Muscle Tone
9. Injection Sites Inspection
10. Statement of Suspect
11. Evaluator's Opinion
12. Toxicological Examination

Mid-Course Review

Demonstrations

- Preliminary Examination
- Eye Examinations
- Administration of the Divided Attention Tests
- Vital Signs Examinations
- Darkroom Examinations
- Check for Muscle Tone and the Inspection for Injection Sites



Drug Recognition Expert Course

Mid - 5

For demonstrations, allow participants to refer to the standard Drug Influence Evaluation Form.

Be sure to provide appropriate positive feedback and constructive criticism of the demonstrators' performances.

- Demonstrate the Preliminary Examination.
- Demonstrate the Eye Examinations.
- Demonstrate the Administration of the Divided Attention Tests.
- Demonstrate the Vital Signs Examinations.
- Demonstrate the Darkroom Examinations.
- Demonstrate the Check for Muscle Tone and the inspection for Injection Sites.

Mid-Course Review

Name the Drug Category for:

- Demerol
- Adderall
- Chlordiazepoxide
- Ketamine
- Percodan
- Ritalin
- Isopropanol
- Bufotenine
- Methaqualone




Drug Recognition Expert Course Mid - 6

Identify the category for each of the listed drugs:

Demerol

- Narcotic Analgesic

Adderall

- CNS Stimulant

Chlordiazepoxide

- CNS Depressant

Ketamine

- Dissociative Anesthetics

Percodan

- Narcotic Analgesic

Ritalin

- CNS Stimulant

Isopropanol

- CNS Depressant

Bufotenine

- Hallucinogen

Methaqualone

- CNS Depressant

Mid-Course Review

Eyes and Vital Signs Review

Horizontal Gaze Nystagmus




Drug Recognition Expert Course

Mid - 7

B. Eyes and Vital Signs

Name the three clues of Horizontal Gaze Nystagmus

Lack of smooth pursuit, distinct and sustained nystagmus at maximum deviation, angle of onset

Demonstrate the check for "Lack of smooth pursuit."

Demonstrate the check for "Distinct and sustained nystagmus at maximum deviation."

Ask the participant demonstrator: How long should the eye be held at maximum deviation? (A minimum of four seconds)

Demonstrate the check for "Angle of Onset."

Ask the participant demonstrator: What is the formula that expresses the approximate relationships between BAC and Angle of Onset? (BAC = 50 – Angle of Onset)

Name the categories of drugs that will cause Horizontal Gaze Nystagmus.

CNS Depressants, Dissociative Anesthetics, Inhalants

Mid-Course Review

Eyes and Vital Signs Review

Vertical Gaze Nystagmus



Drug Recognition Expert Course

Mid - 8

Name the categories that will cause Vertical Gaze Nystagmus.

- CNS Depressants, Dissociative Anesthetics, Inhalants

Demonstrate the check for Vertical Gaze Nystagmus.

Name the test that is always administered immediately after Vertical Gaze Nystagmus.

- Lack of Convergence

Demonstrate the test for Lack of Convergence.

Name the categories of drugs that usually will cause Lack of Convergence.

- CNS Depressants, Dissociative Anesthetics, Inhalants, Cannabis

Mid-Course Review

Eyes and Vital Signs Review

Pupil Size and Rebound Dilation

- Name the lighting conditions under which we make estimations of pupil size
- Name the other things a DRE looks for while shining the light directly into the subject's eye



Drug Recognition Expert Course

Mid - 9

Name the lighting conditions under which we make estimations of pupil size.

- Room light, near-total darkness, direct light

Name the other things a DRE looks for while shining the light directly into the subject's eye.

- Pupil reaction to light and rebound dilation

Mid-Course Review

Eyes and Vital Signs Review

Pupil Size and Rebound Dilation

- **How quickly must the pupil start to constrict if it is considered to exhibit normal reaction to light?**
- **Define Rebound Dilation**
- **State the normal ranges of pupil size for the three lighting conditions**



Drug Recognition Expert Course Mid - 10

How quickly must the pupil start to constrict if it is considered to exhibit normal reaction to light?

- Within one second

Define Rebound Dilation.

- A period of papillary constriction followed by a period of papillary dilation where the pupil steadily increases in size and does not return to its original constricted size.

State the normal ranges of pupil size for the three lighting conditions.

- Room light: 2.5 – 5.0 mm.
- Near Total Darkness: 5.0 – 8.5 mm.
- Direct Light: 2.0 – 4.5 mm.

Mid-Course Review

What Do These Words Mean?

- **Miosis**
- **Mydriasis**
- **Ptosis**



Drug Recognition Expert Course

Mid - 11

Define each of the listed terms:

- Miosis
Abnormally constricted pupils
- Mydriasis
Abnormally dilated pupils
- Ptosis
Droopy eyelids

Mid-Course Review

Pupil Dilation and Constriction

- **What categories of drugs will cause dilation of the pupils?**
- **What categories of drugs will cause constriction?**



Drug Recognition Expert Course

Mid - 12

What categories of drugs will cause dilation of the pupils?

- CNS Stimulants, Hallucinogens, Cannabis (although sometimes only slight dilation, if any)

What categories of drugs will cause constriction?

- Narcotic Analgesics

Mid-Course Review

More Drugs to Categorize

- Oxycodone
- Halcion
- Librium
- Peyote
- Preludin
- Diazepam
- Dexedrine
- Hycodan




Drug Recognition Expert Course Mid - 13

Identify the category for each of the listed drugs:

Oxycodone

- Narcotic Analgesic

Halcion

- CNS Depressant

Librium

- CNS Depressant

Peyote

- Hallucinogen

Preludin

- CNS Stimulant

Diazepam

- CNS Depressant

Dexedrine

- CNS Stimulant

Hycodan

- Narcotic Analgesic

Klonopin

- CNS Depressant

Mid-Course Review

Circulatory System Review

- Define “Pulse”
- Define “Pulse Rate”
- Define “Artery”
- Define “Vein”



Drug Recognition Expert Course Mid - 14

Define “Pulse.”

- The expansion and relaxation of an artery, generated by the pumping action of the heart.

(Also acceptable: the expansion and relaxation of an artery, caused by the surging flow of blood)

Define “Pulse Rate.”

- The number of pulsations in an artery per minute

Define “Artery.”

- A strong, elastic blood vessel that carries blood from the heart to the body tissues.

Define “Vein.”

- A blood vessel that carries blood back to the heart from the body tissues.

Mid-Course Review

Where Are These Pulse Points Located?

- Radial
- Brachial
- Carotid



Drug Recognition Expert Course

Mid - 15

Mid-Course Review

Pulse Point Location

- Radial
- Brachial




- Carotid






Drug Recognition Expert Course
Mid - 16

Identify the location of each listed pulse point:

Radial

- In the wrist, at the base of the thumb

Brachial

- In the crook of the arm

Carotid

- In the neck, on either side of the Adam's Apple

Demonstrate a pulse measurement, using the left Radial pulse point.

State the normal range of adult human pulse rate.

- 60 – 90 beats per minute

Name the drug categories that usually cause elevated pulse rate.

- CNS Stimulants, Hallucinogens, Dissociative Anesthetics, Inhalants, Cannabis

Name the drug categories that usually cause lowered pulse rate.

- CNS Depressants, Narcotic Analgesics

Mid-Course Review

Blood Pressure Review



Drug Recognition Expert Course

Mid - 17

Define "Blood Pressure."

- The force exerted by blood on the walls of the arteries

How often does a person's blood pressure change?

- It is always changing, from instant to instant.

When does the blood pressure reach its highest value?

- When the heart is fully contracted, and blood is sent rushing into the arteries.

When does the blood pressure reach its lowest value?

- When the heart is fully expanded, just before it starts to contract for the next "pumping" action.

Mid-Course Review

Blood Pressure Review (Cont.)



Drug Recognition Expert Course

Mid - 18

Name the two medical instruments that are used to measure blood pressure.

- SPHYGMOMANOMETER and STETHOSCOPE

Select a participant to come to the dry erase board or flip-chart and print “SPHYGMOMANOMETER” and “STETHOSCOPE.”

Name the sounds that we hear through the stethoscope when we make a blood pressure measurement.

- KOROTKOFF SOUNDS

Select a participant to come to the dry erase board or flip-chart and print “KOROTKOFF SOUNDS.”

Mid-Course Review

Blood Pressure Review (Cont.)




Drug Recognition Expert Course

Mid - 19

What does this “Hg” mean?

- Chemical symbol for the element Mercury; abbreviation for the Latin word Hydrargyrum, meaning “Mercury.”

Print “Hg” on the dry erase board or flip-chart

In what units is blood pressure measured?

- Millimeters of Mercury

Print “mm” on the dry erase board or flip-chart, right in front of the “Hg.”

Suppose that, at some particular instant, a person has a blood pressure of 120 mmHg. What does that “120 mmHg” mean?

- It means the pressure would be strong enough to push a column of liquid Mercury up a glass tube to a height of 120 millimeters.

If one is available, display a Sphygmomanometer that has a liquid mercury pressure gauge.

Mid-Course Review

Drugs and Blood Pressure

- Name the drug categories that usually cause a lowered blood pressure
- Name the drug categories that elevate blood pressure



Drug Recognition Expert Course

Mid - 20

Name the drug categories that usually cause a lowered blood pressure.

- CNS Depressants, Narcotic Analgesics, and the Anesthetic Gases subcategory of Inhalants

Name the drug categories that elevate blood pressure.

- CNS Stimulants, Hallucinogens, Dissociative Anesthetics, Cannabis, and the other two subcategories (Volatile Solvents and Aerosols) of Inhalants

Mid-Course Review

Some Technical Terms to Define

- **Systolic**
- **Diastolic**
- **Bradycardia**
- **Tachycardia**
- **Hypertension**
- **Hypotension**



Drug Recognition Expert Course Mid - 21

State the meaning of each of the listed terms:

Systolic

- The highest value of blood pressure

Diastolic

- The lowest value of blood pressure

Bradycardia

- Abnormally slow heart rate, pulse rate below the normal range

Tachycardia

- Abnormally rapid heart rate, pulse rate above the normal range

Hypertension

- Abnormally high blood pressure

Hypotension

- Abnormally low blood pressure

Mid-Course Review

Blood Pressure Measurement



Drug Recognition Expert Course

Mid - 22

State the normal range of systolic blood pressure.


- 120 – 140 mmHg

State the normal range of diastolic blood pressure.

- 70 – 90 mmHg

Demonstrate the measurement of blood pressure.

Tell the participant demonstrator to explain out loud everything he or she does to take blood pressure measurement.



C. Physiology

Define "Physiology."

- Physiology is the branch of biology dealing with the functions and activities of life or living matter and the physical and chemical phenomena involved.

What is the expression we use to remember the names of the ten major body systems?

- MURDERS INC

Mid-Course Review

MURDERS INC.




Drug Recognition Expert Course

Mid - 24

Select a participant to come to the dry erase board of flip-chart, and print “MURDERS INC” vertically.

Have participant write while class states what each letter stands for.

- Muscular (have a student print out each name)
- Urinary
- Respiratory (or, reproductive)
- Digestive
- Endocrine
- Reproductive (or, respiratory)
- Skeletal
- Integumentary
- Nervous
- Circulatory



State the word that means “dynamic balance involving levels of salts, water, sugars and other materials in the body’s fluids.”

- Homeostasis

Which artery carries blood from the heart to the lungs?

- Pulmonary

What is unique about the Pulmonary artery, compared to all other arteries?


- It is the only artery that takes blood from the right side of the heart
- It is the only artery that carries deoxygenated blood (i.e., blood that is depleted of oxygen)

What are the Pulmonary veins?

- The veins that carry blood back to the heart from the lungs

What is unique about the Pulmonary veins?


- They are the only veins that bring blood to the left side of the heart
- They are the only veins that carry oxygenated blood



Name the various types of nerves.

Ask participants to "fill in" the missing names

- Sensory nerves, carry messages to the brain. Also known as Afferent Nerves
- Motor nerves, carry messages from the brain. Also known as Efferent Nerves
- Voluntary nerves are motor nerves that carry messages to the muscles that we consciously control.
- Autonomic nerves are motor nerves that carry messages to the muscles and organs we do not consciously control.
- Sympathetic nerves are autonomic nerves that carry messages commanding the body to react to fear, stress, excitement, etc. Clarification: Sympathetic nerves carry the brain's "fire alarms" and "wake up calls".
- Parasympathetic nerves are autonomic nerves that carry messages to produce relaxed and tranquil activities. Clarification: Parasympathetic nerves carry the brain's "all clear" and "at ease" messages.



Mid-Course Review

Some More Technical Terms to Define

- **Neuron**
- **Synapse**
- **Neurotransmitter**
- **Axon**
- **Dendrite**



Drug Recognition Expert Course Mid - 28

Define each of the listed terms:

Neuron

- A nerve cell, the basic “building block” of a nerve

Synapse

- The gap or space between two nerve cells

Neurotransmitter


- A chemical that flows across the synapse, to carry a message from one neuron to the next

Axon

- The end of a neuron that sends out the neurotransmitter

Dendrite

- The end of a neuron that receives the neurotransmitter



D. Questions and Answers

Segment D can last as long as necessary.

Solicit and answer participants' questions about anything covered thus far in their training.

1 Hour and 35 Minutes

Session 19

Inhalants



Session 19 - Inhalants

Learning Objectives

- Explain a brief history of the Inhalant category of drugs
- Identify common drug names and terms associated with this category
- Identify common methods of administration for this category
- Describe the symptoms, observable signs, and other effects associated with this category




Drug Recognition Expert Course 19-2

Briefly review the objectives, content and activities of this session.

Upon successfully completing this session the participant will be able to:

- Explain a brief history of the Inhalant category of drugs.
- Identify common drug names and terms associated with this category.
- Identify common methods of administration for this category.
- Describe the symptoms, observable signs and other effects associated with this category.

CONTENT SEGMENTS

- A. Overview of the Category
- B. Possible Effects
- C. Onset and Duration of Effects
- D. Overdose Signs and Symptoms
- E. Expected Results of the Evaluation
- F. Classification Exemplar

LEARNING ACTIVITIES

- Instructor Led Presentations
- Review of the Drug Evaluation and Classification Exemplars
- Reading Assignments
- Video Presentations
- Slide Presentations

Session 19 - Inhalants

Learning Objectives (Cont.)

- Describe the typical time parameters, i.e. onset and duration of effects associated with this category
- List the clues that are likely to emerge when the drug influence evaluation is conducted for a person under the influence of this category of drugs
- Correctly answer the “topics for study” questions at the end of this session



Drug Recognition Expert Course 19-3

- Describe the typical time parameters, i.e. onset and duration of effects associated with this category.
- List the clues that are likely to emerge when the drug influence evaluation is conducted for a person under the influence of this drug category.
- Correctly answer the “topics for study” questions at the end of this session.

Session 19 - Inhalants

Inhalants - Overview

- Inhalants are breathable chemicals that produce mind altering results
- Sometimes called “Deliriant’s”
- Effects similar to CNS Stimulants, Depressants, or Hallucinogens







Drug Recognition Expert Course 19-4

A. Overview of the Category

Inhalants are breathable chemicals that produce mind altering results.

Inhalants are sometimes called “Deliriant’s,” in that they may produce delirium. Delirium is usually a brief state characterized by incoherent excitement, confused speech, restlessness and possible hallucinations.

Inhalants vary widely in terms of the chemical involved and the specific effects produced.

Depending on the nature of the particular Inhalant, the effects produced may be similar to those of CNS Stimulants, Depressants or Hallucinogens.

Session 19 - Inhalants

Subcategories of Inhalants

- Volatile solvents
- Aerosols
- Anesthetic gases








Drug Recognition Expert Course

19-5

There are three major subcategories of Inhalants:

- Volatile Solvents
- Aerosols
- Anesthetic Gases

Volatile Solvents

The Volatile Solvents include a large number of readily available substances, none of which are intended by their manufacturers to be used as drugs.

“Volatile” means that they evaporate easily to produce fumes.

Ask participants to name a Volatile Solvent that often is abused as a drug.

One widely abused Volatile Solvent is plastic cement, or “model airplane glue.”

Plastic cement includes the following volatile chemicals:

- Toluene
- Acetone
- Naphtha
- Aliphatic Acetates (straight-chained hydrocarbons)
- Hexane
- Cyclohexane
- Benzene

Session 19 - Inhalants

Volatile Solvents

- **Fingernail polish remover**
- **Household cements and glue**
- **Lighter fluid**
- **Petroleum products**
 - **Plastic cement**
 - **Gasoline**
 - **Kerosene**



The image displays several common household products that are volatile solvents. On the left, there is a red plastic jug labeled 'GASOLINE'. Next to it is a white plastic jug labeled 'Kerosene 1-K'. In the center, there is a yellow can of 'LIGHTER FLUID' with a red flame icon and '133 ml e' printed on it. To the right of the lighter fluid are two bottles of 'ACETONE' in different packaging. At the top right, there is a collection of various household products, including bottles of glue and cement. In the bottom left corner, there is a logo for the 'FEDERAL BUREAU OF INVESTIGATION' and 'DEPARTMENT OF JUSTICE'. In the bottom right corner, there is a logo for 'NHTSA' with four stars and the website 'www.nhtsa.gov'.

Drug Recognition Expert Course

19-6

Other frequently abused Volatile Solvents include:

- Fingernail polish remover (contains Acetone)
- Household cements and glues (rubber cements contain Benzene)
- Lighter fluid (contains Naphtha)

Petroleum products:

- Plastic Cement (Model airplane Glue)
- Gasoline
- Kerosene

Session 19 - Inhalants

Volatile Solvents (Cont.)

- Dry cleaning fluids
- Paints (particularly oil or solvent based)
- Paint thinners
- Spray paints
- Liquid correction fluid
- Engine degreasers



The image displays several types of volatile solvents: two cans of 'GOLD' brand dry cleaning fluid, a small spray bottle of correction fluid, a can of 'Paint Thinner', a can of 'PROFESSIONAL STRENGTH DRY CLEANING FLUID', and a can of 'Engine Degreaser'. There are also logos for the International Association of Chiefs of Police (IACP) and the National Highway Traffic Safety Administration (NHTSA).

Drug Recognition Expert Course

19-7

- Dry cleaning fluids
- Paints (particularly oil or solvent based)
- Paint thinners
- Spray paints
- Liquid correction fluid
- Engine degreasers

Session 19 - Inhalants

Abused Aerosols

- Hair sprays
- Deodorants
- Insecticides
- Glass chillers (freeze spray)
- Vegetable frying pan lubricants



The image displays several types of aerosol products: a row of five deodorant cans (Axe, Old Spice, etc.), a red hair spray can, three Raid insecticide cans, a green glass chiller can with a mosquito icon, a yellow PAM vegetable frying pan lubricant can, and a white 'CAN of FROST' glass chiller can.




Drug Recognition Expert Course 19-8

Aerosols

Aerosols are chemicals discharged from a pressurized container by the propellant force of a compressed gas.

If available, display slides of typically abused Aerosols.

Commonly abused Aerosols include hair sprays, deodorants, insecticides, glass chillers (freeze spray), and vegetable frying pan lubricants.

If available, display slides of typically abused Aerosols.

e.g., Freon, which is now available primarily in many medical Aerosols.

All of these abused Aerosols contain various hydrocarbon gases that produce drug effects.

Session 19 - Inhalants

Typical Abusers of Inhalants

- Pre-teens and teenagers



Drug Recognition Expert Course

19-9

The overwhelming majority of abusers of Volatile Solvents and Aerosols are pre-teens and teenagers.

Some reasons:

- These substances appear in nearly every household.
- They are inexpensive and readily accessible.

Session 19 - Inhalants

Anesthetic Gases Abolish Pain

- Ether
- Nitrous Oxide

Drug Recognition Expert Course

19-10

Anesthetic Gases

The third subcategory is Anesthetic Gases. Anesthetic gases are drugs that abolish pain. They are used medically during surgical procedures such as childbirth, dental surgery, etc.

Adults may be more frequent users of the anesthetic gases subcategory than of the Aerosols or Volatile Solvents.

Anesthetic gases that sometimes are abused as Inhalants:

- Ether
- Nitrous Oxide

Many of these substances have a long history of medical and illicit use, e.g., Ether abuse dates to the 1790's in England.

Nitrous Oxide has been used since 1845. It is still used in certain dental procedures.

Nitrous Oxide is a propellant for whipped cream. Drug paraphernalia stores often sell Nitrous Oxide in cartridges that are identical to carbon dioxide containers. They are termed by users "whippets," and are allegedly sold to purchasers as devices to propel whipped cream.

Session 19 - Inhalants

Anesthetic Gases Do Not Abolish Pain

- Amyl Nitrite
- Butyl Nitrite (Isobutyl Nitrite)



Drug Recognition Expert Course

NHTSA

19-11

Other common Inhalants in this subcategory that do not relieve pain are:

- Amyl Nitrite
- Butyl Nitrite (Isobutyl Nitrite)

Nitrates are vasodilating substances used medically to relieve angina pectoris (heart-related chest pain) and for treatment of cyanide poisoning. In angina, the nitrates work by dilating blood vessels near the heart so that more blood can reach the heart.

Nitroglycerin, ordinarily not abused as an intoxicant, is also used for this purpose.

Isobutyl Nitrite and Butyl Nitrite have essentially identical effects of Amyl Nitrite.

Session 19 - Inhalants

Anesthetic Gases (Cont.)

- Lower blood pressure

Slang names:

- “Rush”
- “Locker room”



Drug Recognition Expert Course

NHTSA

19-12

Anesthetic gases can dilate the blood vessels around the heart thus causing a lowered blood pressure.

Common slang and brand names for the nitrites are: “Rush” and “Locker Room.”

Examples: Amyl Nitrite and Butyl Nitrite are sold in small glass bottles or bulbs. The user simply opens the bottle and breathes in the fumes. They have been marketed in drug paraphernalia stores as room deodorizers.

Session 19 - Inhalants

Ingesting Inhalants

- Breathing in from the source
- Inhaling fumes
- Soaked materials
- Common street names:
 - Huffing
 - Hacking
 - Ballooning
 - Glading






Drug Recognition Expert Course

19-13

Inhalants obviously are ingested by breathing, or inhaling the fumes.

- Some are ingested directly from the source.
- Some are soaked into rags, handkerchiefs, or tissue paper for repeated inhalation.
- Some are placed in paper or plastic bags which the user places over the face or head. These may be placed in twist lock beverage containers.
- Some are used by breathing the fumes or vapors from balloons.

Some common street names that Inhalant users use are: huffing, hacking, ballooning and glading.

Solicit participants' comments or questions concerning this overview of Inhalants.

Session 19 - Inhalants

Possible Effects of Inhalants

- Altered shapes and colors
- Antagonistic behavior
- Bizarre thoughts
- Distorted perceptions of space and time
- Dizziness and numbness
- Drowsiness and weakness



Drug Recognition Expert Course 19-14

B. Possible Effects

The effects of Inhalants vary somewhat from one substance to another. In fact, many of the Inhalants are classified as Depressants in medical texts. Their effects, consequently, often mirror alcohol intoxication.

Common effects of Inhalants include:

- Altered shapes and colors
- Antagonistic behavior
- Bizarre thoughts
- Distorted perceptions of time and distance
- Dizziness and numbness
- Drowsiness and weakness

Session 19 - Inhalants

Possible Effects of Inhalants (Cont.)

- **Floating sensations**
- **Inebriation similar to alcohol intoxication**
- **Intense headaches**
- **Light headedness**
- **Nausea and excessive salivation**
- **Possible hallucinations**



Drug Recognition Expert Course

19-15

- Floating sensations
- Inebriation similar to alcohol intoxication
- Intense headaches
- Light headedness
- Nausea and excessive salivation
- Possible hallucinations

Persons under the influence of Inhalants generally will appear confused and disoriented, and their speech will be slurred.

Session 19 - Inhalants

Inhalants

Onset and Duration of Effects

- Effects felt immediately
- Nitrous Oxide \leq 5 minutes
- Amyl Nitrite and Isobutyl Nitrite – few seconds to 20 minutes
- Glue, paint, gasoline – several or more hours
- Generally 6-8 hours for most volatile solvents




Drug Recognition Expert Course 19-16

C. Onset and Duration of Effects

Inhalants' effects are felt virtually immediately.

Point out that the route of passage of the drugs from lungs to brain can be traveled very quickly.

Duration depends on the particular substance.

- The effects of nitrous oxide last 5 minutes or less.
- Amyl Nitrite and Isobutyl Nitrite produce effects that last a few seconds up to 20 minutes.

Users claim these substances enhance sexual excitement. This may occur from dilation of genital arteries (vasodilation) and relaxation of other smooth muscles.

Inhalation of these produces a distinct "rush" similar to that of the related substance, Nitrous Oxide.

Glue, paint, gasoline and other commonly abused Inhalants produce effects that last several or more hours. (Generally 6-8 hours for most volatile solvents depending on exposure).

Point out that residue of these substances may be deposited inside the nostrils, causing the user to breathe the fumes constantly.

Solicit participants' comments and questions concerning the time parameters of Inhalants.

Session 19 - Inhalants

Inhalants

Overdose Signs and Symptoms

- Risk of death
- Cardiac arrhythmia - “sudden sniffing death” (SSD)
- Respiration ceases
- Severe nausea and vomiting
- Long term abuse:
 - Permanent damage to Central Nervous System
 - Reduced mental and physical abilities



Drug Recognition Expert Course 19-17

D. Overdose Signs and Symptoms

There is a risk of death due to overdose of Inhalants.

All volatile solvents make the heart more sensitive to adrenaline. This sometimes causes a dangerous cardiac arrhythmia. The term “sudden sniffing death” (SSD) has been used to describe death resulting from physical exertion and the breathing of Inhalants in an enclosed, poorly ventilated space.

Some Inhalants will depress the Central Nervous System to the point where respiration ceases. Others can produce instant death from heart failure.

Overdoses of Inhalants frequently induce severe nausea and vomiting. If the user vomits while he or she is unconscious, death can result from aspiration of the vomitus.

Death can also result indirectly, if a person places a plastic bag over the head, loses consciousness and suffocates.

Long term abuse of Inhalants can cause permanent damage to the Central Nervous System, and greatly reduce mental and physical abilities.

Evidence also exists of liver, kidney, bone and bone marrow damage resulting from long term Inhalant abuse.

There are no well-defined withdrawal symptoms for these substances. Physical dependence has not been documented, although habituation is common.

Solicit questions and comments concerning overdose signs and symptoms.

Session 19 - Inhalants

Expected Results of the Evaluation

Significant variation in effects from one substance to another



The collage features several images: a person using a blue inhaler, a hand spraying a substance, a collection of aerosol cans (one labeled 'PAINT'), a yellow can labeled 'RUSH' with the slogan 'NEVER FAKE IT', a brown bottle labeled 'ETHER', and a small metal can with a yellow nozzle.

Drug Recognition Expert Course 19-18

E. Expected Results of the Evaluation

Emphasize that, with Inhalants, there is significant variation in effects from one substance to another.

Session 19 - Inhalants

Evaluation of Subjects Under the Influence of Inhalants

- HGN - Present
- VGN - Present (high dose for that individual person)
- Lack of Convergence - Present
- Impaired performance will be evident on Modified Romberg Balance, Walk and Turn, One Leg Stand and Finger to Nose tests




Drug Recognition Expert Course 19-19

Observable Evidence of Impairment

Eye Exam

- HGN: Horizontal Gaze Nystagmus will generally be present.

Point out that immediate onset of Nystagmus may be observed.

- VGN: Vertical Gaze Nystagmus may be present.

Point out that high doses (for that individual) of Inhalants may cause Vertical Gaze Nystagmus.

- LOC: Lack of Convergence will be present.

Psychophysical Exercise

Drug Evaluation Tests

Performance on the Modified Romberg Balance, Walk and Turn, One Leg Stand, and Finger to Nose tests will be impaired.

Point out that subjects' may sway when performing the Romberg, One Leg Stand, and Finger to Nose tests.

Point out that subjects may take slow, deliberative steps on the Walk and Turn, and will tend to stagger.

Session 19 - Inhalants

Evaluation of Subjects Under the Influence of Inhalants (Cont.)

Vital Signs:

- Pulse - Up
- Blood Pressure - Up or Down⁽⁵⁾
- Body temperature - Up, Down or Normal

Muscle tone - Flaccid or Normal

⁽⁵⁾ Down with anesthetic gases, Up with volatile solvents and aerosols




Drug Recognition Expert Course 19-20

Vital Signs

Pulse will be up.

Pulse increase is due to many factors, including oxygen displacement. The heart may beat faster in order to supply body tissues with a sufficient supply of oxygen.

Blood pressure will be up or down.

Note: The Anesthetic Gases generally lower blood pressure while elevating pulse rate. The Volatile Solvents and the Aerosols usually elevate both blood pressure and pulse rate.

The lowering of blood pressure by Anesthetic Gases is due to their vasodilation effect. The heart compensates for this vasodilation by increasing its heart rate.

Effect on body temperature may be up, down or normal range.

Point out that muscle tone can be either normal or flaccid. Anesthetic gases normally cause the muscles to be flaccid.

Session 19 - Inhalants

Evaluation of Subjects Under the Influence of Inhalants (Cont.)

Dark Room:

- Pupil size - Normal⁽⁴⁾ (DRE average ranges)
- Pupil reaction to light - Slow

⁽⁴⁾ May be dilated



Drug Recognition Expert Course 19-21

Dark Room

Pupil size will be normal (DRE Average Ranges) but may be dilated.

Anesthetic gases may produce some dilation, although usually not to the extent seen with CNS Stimulants or Hallucinogens. No Inhalants produce pupillary constriction.

Session 19 - Inhalants

Evaluation of Subjects Under the Influence of Inhalants (Cont.)

General Indicators:

- Bloodshot, watery eyes
- Confused
- Disoriented
- Flushed face, possibly sweating
- Intense headaches



Drug Recognition Expert Course

19-22

General Indicators

- Bloodshot, watery eyes
- Confusion
- Disoriented
- Flushed face
- Intense headaches

Session 19 - Inhalants

Evaluation of Subjects Under the Influence of Inhalants (Cont.)

General Indicators (Cont.)

- Lack of muscle control
- Non-communicative
- Odor of the inhaled substance
- Possible nausea
- Possible traces of the substance around the face and nose
- Slow, thick, slurred speech



Drug Recognition Expert Course 19-23

- Lack of muscle control
- Non-communicative
- Normal or Flaccid muscle tone
- Odor of the inhaled substance
- Possible nausea
- Residue of the substance around the face and nose and on the hands or clothing
- Slow, thick, slurred speech

Speech usually clears up quickly when substance is no longer being inhaled.

Session 19 - Inhalants

Inhalants Symptomatology Chart

HGN	Present
VGN	Present (High dose for that individual)
Lack of Convergence	Present
Pupil Size	Normal ⁽⁴⁾
Reaction to Light	Slow
Pulse Rate	Up
Blood Pressure	Up or Down ⁽⁵⁾
Temperature	Up, Down or Normal
Muscle Tone	Normal or Flaccid

(4) Normal but may be dilated

(5) Down with anesthetic gases – Up with volatile solvents & aerosols





Drug Recognition Expert Course
19-24

Point out that “Normal” referenced in the pupil size indicates the DRE averages for the pupil sizes.

Session 19 - Inhalants

Inhalants



Drug Recognition Expert Course

19-25

Click video to begin

VIDEO DEMONSTRATION

Show video example of subject under the influence of an Inhalant. (Approximately 20 minutes).

Session 19 - Inhalants

Drug Evaluation and Classification

Exemplar Demonstrations



Drug Recognition Expert Course

19-26

F. Classification Exemplar

Refer students to the exemplars found at the end of Session 19 of their participant manuals.

Point out that the one-page narrative in the example exemplars are not to be construed as the recommended or approved narrative report. The actual narrative report submitted by DREs will be more detailed.

Relate the items on the exemplars to the Inhalant Symptomatology Chart.

Relate behavior and observations to the CNS Depressant Symptomatology Chart.

Solicit students' questions or suggestions concerning Expected Results of the Evaluation of subjects under the influence of Inhalants.

Session 19 - Inhalants

QUESTIONS?



Drug Recognition Expert Course 19-27

Solicit participants' comments and questions concerning expected results of the evaluation of subjects under the influence of Inhalants.

Session 19 - Inhalants

Topics for Study



Drug Recognition Expert Course 19-28

Topics for Study / ANSWERS

1. What are the three major subcategories of Inhalants?

ANSWER: Volatile Solvents, Aerosols, Anesthetic Gases

2. What are some of the principal active ingredients in many volatile substances?

ANSWER: Toluene, Acetone, Naphtha, Aliphatic Acetates, Hexane, Cyclohexane, Benzene

3. In what important respect do the effects of Anesthetic Gases differ from the effects of Volatile Solvents and Aerosols?

ANSWER: Anesthetic gases lower blood pressure while keeping the pulse rate elevated, Volatile Solvents and Aerosols elevate blood pressure and pulse.

4. Do any of the subcategories of Inhalants cause pulse rate to decrease?

ANSWER: No

5. The effects of Amyl Nitrite and Butyl Nitrite last from a few seconds to up to _____ minutes.

ANSWER: 20

DRUG INFLUENCE EVALUATION







Evaluator Sgt. Joe Armstrong, Missouri HP		DRE # 11850	Rolling Log # 12-07-015	Session XIX - #1	
Recorder/Witness Sgt. Art Amato, Union PD		Crash: <input checked="" type="checkbox"/> None <input type="checkbox"/> Fatal <input type="checkbox"/> Injury <input type="checkbox"/> Property		Case # 12-77997	
Arrestee's Name (Last, First, Middle) Graves, James L.		Date of Birth 6/8/88	Sex M	Race W	Arresting Officer (Name, ID#) Trooper Blaine Adams, MO HP #7134
Date Examined / Time / Location 07/04/12 2200 Union PD		Breath Results: Results: 0.00		Test Refused <input type="checkbox"/> Instrument #: 77880	Chemical Test: Urine <input type="checkbox"/> Blood <input checked="" type="checkbox"/> Test or tests refused <input type="checkbox"/>
Miranda Warning Given Given By: Tpr. Adams	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? Hamburger 6PM	What have you been drinking? Coke	How much? N/A	Time of last drink? N/A
Time now/ Actual 10 PM/10:10 PM	When did you last sleep? How long Last night 6 hrs.	Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Attitude: Cooperative		Coordination: Poor, unsteady, barely standing	
Speech: Slurred, mumbling		Breath Odor: Paint/chemical odor		Face: Paint residue on cheeks and chin	
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right	
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	
Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal		Eyelids: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Droopy			
Pulse and time 1. <u>104</u> / <u>2215</u> 2. <u>102</u> / <u>2234</u> 3. <u>104</u> / <u>2250</u>	HGN Lack of Smooth Pursuit Maximum Deviation Angle of Onset	Left Eye Yes Yes 30	Right Eye Yes Yes 30	Convergence Right eye Left eye	
Modified Romberg Balance 	Walk and Turn test 	Cannot keep balance <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Starts too soon _____ Stops walking _____ Misses heel-toe _____ Steps off line _____ Raises arms _____ Actual steps taken _____		ONE LEG STAND L R <input checked="" type="checkbox"/> <input type="checkbox"/> Sways while balancing <input checked="" type="checkbox"/> <input type="checkbox"/> Uses arms to balance <input type="checkbox"/> <input type="checkbox"/> Hopping <input checked="" type="checkbox"/> <input type="checkbox"/> Puts foot down Stopped - fell into wall	
Internal clock N/A estimated as 30 seconds	Describe Turn N/A	Cannot do test (explain) Unable to stand heel to toe		Type of footwear: Athletic shoes	
Draw lines to spots touched Test administered in seated position		PUPIL SIZE			Nasal area: Red
		REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			REACTION TO LIGHT: Slow
Blood pressure 140/100		Temperature 98.6		RIGHT ARM LEFT ARM Gold paint on hands	
Muscle tone: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Flaccid <input type="checkbox"/> Rigid		Comments:			
What drugs or medications have you been using? "I huffed some Gold."		How much? "The usual"		Time of use? 9:30 pm	Where were the drugs used? (Location) In the park
Date / Time of arrest: 07/04/12 2130	Time DRE was notified: 2145	Evaluation start time: 2200	Evaluation completion time: 2310	Precinct/Station:	
Officer's Signature:		DRE # 11850	Reviewed/approved by / date:		
Opinion of Evaluator:		<input type="checkbox"/> Rule Out <input type="checkbox"/> Alcohol <input type="checkbox"/> CNS Stimulant <input type="checkbox"/> Dissociative Anesthetic <input checked="" type="checkbox"/> Inhalant	<input type="checkbox"/> Medical <input type="checkbox"/> CNS Depressant <input type="checkbox"/> Hallucinogen <input type="checkbox"/> Narcotic Analgesic <input type="checkbox"/> Cannabis		

DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: Graves, James L.

1. **LOCATION:** The evaluation was conducted at the Union Police Department.
2. **WITNESSES:** Sgt. Art Amato of the Union PD witnessed the evaluation.
3. **BREATH ALCOHOL TEST:** Graves had a breath test of 0.00%.
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** Writer was requested to contact Trooper Adams at the Union Police Department for a drug evaluation. Trooper Adams advised he arrested Graves for DUI after observing him fail to stop at a red traffic light at Main and 3rd Street. The suspect was cooperative but appeared dazed. He performed poorly on the SFST's and was arrested for DUI. A can of gold spray paint was located on the front seat of the suspect's vehicle along with some paint soaked rags.
5. **INITIAL OBSERVATION OF SUSPECT:** Writer first observed the suspect in the interview room at the P.D. He appeared passive and dazed. He had very poor coordination and balance. Gold paint smears were visible on his hands and face.
6. **MEDICAL PROBLEMS AND TREATMENT:** None noted or stated.
7. **PSYCHOPHYSICAL TESTS:** Modified Romberg Balance: The suspect was unable to perform the test and it was stopped for safety reasons. Walk & Turn: The suspect lost his balance three times and the test was stopped for safety reasons. One Leg Stand: The suspect put his foot down three times while standing on the left foot and the test was stopped. He was unable to perform the test when attempting to stand on the right foot and the test was stopped for safety reasons. Finger to Nose: The suspect was allowed to sit down for this test. He used the palm of his hands and touched in the general area of his nose.
8. **CLINICAL INDICATORS:** The suspect had six clues of HGN with a 30 degree angle of onset and a Lack of Convergence. His pulse and blood pressure were elevated and above the DRE average ranges.
9. **SIGNS OF INGESTION:** Paint-like odor on his breath. Paint smears on hands and face.
10. **SUSPECT'S STATEMENTS:** Suspect admitted "huffing" some gold spray paint in his car while in the park to celebrate the 4th of July.
11. **DRE'S OPINION:** In my opinion Graves is under the influence of an **Inhalant** and unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** The suspect provided a blood sample.
13. **MISCELLANEOUS:**

DRUG INFLUENCE EVALUATION

Evaluator Trooper Marc Griggs, Iowa State Patrol		DRE # 8332	Rolling Log # 12-08-124	Session XIX - #2	
Recorder/Witness Sgt. Russ Belz, Story Co. S.O.		Crash: <input checked="" type="checkbox"/> None <input type="checkbox"/> Fatal <input type="checkbox"/> Injury <input type="checkbox"/> Property		Case # 12-12859	
Arrestee's Name (Last, First, Middle) Mashburn, Cathy L.		Date of Birth 9/1/88	Sex F	Race W	Arresting Officer (Name, ID#) Trooper Bryan Beckman, IA SP #9990
Date Examined / Time / Location 08/07/12 2015 Story Co. Jail		Breath Results: Results: 0.00		Test Refused <input type="checkbox"/> Instrument #: 16670	Chemical Test: Urine <input checked="" type="checkbox"/> Blood <input type="checkbox"/> Test or tests refused <input type="checkbox"/>
Miranda Warning Given Given By: Trooper Beckman	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? Pizza After work	What have you been drinking? Wine coolers	How much? "A couple"	Time of last drink? 7 PM
Time now/ Actual 9pm/8:10 pm	When did you last sleep? How long Last night 7 hrs.	Are you sick or injured? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No "I feel dizzy"		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Attitude: Cooperative, slow to respond		Coordination: Poor, staggering at times	
Speech: Slow, slurred		Breath Odor: Paint-like odor		Face: Flushed	
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Bloodshot <input checked="" type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right	
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	
Eyelids: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Droopy		Pulse and time 1. <u>100</u> / <u>2028</u> 2. <u>100</u> / <u>2100</u> 3. <u>96</u> / <u>2120</u>		ONE LEG STAND 	
Modified Romberg Balance  Circular sway - nearly fell		Walk and Turn test  Test stopped after six steps		Convergence  Right eye Left eye	
Internal clock 19 estimated as 30 seconds		Describe Turn N/A		Cannot do test (explain) Stopped - nearly fell	
Type of footwear: Sandals		Nasal area: Runny nose, red		Oral cavity: Paint like odor	
REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		REACTION TO LIGHT: Normal		N/A	
RIGHT ARM 		LEFT ARM 		Nothing observed	
Blood pressure 146/104		Temperature 98.8		Muscle tone: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Flaccid <input type="checkbox"/> Rigid	
Comments: What drugs or medications have you been using? "I don't do drugs."		How much? N/A		Time of use? Refused	
Where were the drugs used? (Location) Refused		Date / Time of arrest: 08/07/12 1940		Time DRE was notified: 1955	
Evaluation start time: 2015		Evaluation completion time: 2140		Precinct/Station: N/A	
Officer's Signature:		DRE # 8332	Reviewed/approved by / date:		
Opinion of Evaluator: <input type="checkbox"/> Rule Out <input type="checkbox"/> Medical		<input type="checkbox"/> Alcohol <input type="checkbox"/> CNS Depressant		<input type="checkbox"/> CNS Stimulant <input type="checkbox"/> Hallucinogen	
<input type="checkbox"/> Dissociative Anesthetic <input type="checkbox"/> Narcotic Analgesic		<input checked="" type="checkbox"/> Inhalant <input type="checkbox"/> Cannabis			

DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: Mashburn, Cathy

1. **LOCATION:** The evaluation was conducted at the Story County Jail.
2. **WITNESSES:** The evaluation was recorded by Sergeant Russ Belz of the Story CO SO.
3. **BREATH ALCOHOL TEST:** Mashburn's breath test was 0.00%.
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** Writer was notified by radio to contact Trooper Beckman at the Story County Jail for a drug evaluation. Trooper Beckman advised he arrested Mashburn after observing her pull out in front of oncoming traffic nearly causing a crash. The suspect was cooperative but slow to respond to questions. She performed poorly on the SFST's and was arrested for DUI. After arresting her, Trooper Beckman located a can of paint remover and several rags in her vehicle.
5. **INITIAL OBSERVATION OF SUSPECT:** Writer first observed the suspect in the interview room at the jail. Her speech was slow and slurred. Her coordination was poor and she staggered several times. Her eyes were watery and bloodshot.
6. **MEDICAL PROBLEMS AND TREATMENT:** The suspect stated she felt dizzy.
7. **PSYCHOPHYSICAL TESTS:** Modified Romberg Balance: The suspect had an approximate 3" circular sway and she estimated 30 seconds in 19 seconds. Walk & Turn: The suspect lost her balance twice during the instructions, staggered and nearly fell. The test was stopped after six steps when she again nearly fell. One Leg Stand: After putting her right foot down three times and nearly falling, the test was stopped. Finger to Nose: The suspect had difficulty with this test. She touched the tip of her nose on one of the six attempts. She also used the wrong hand on attempts #5 and #6.
8. **CLINICAL INDICATORS:** The suspect had six clues of HGN and a Lack of Convergence. Her pulse rates and blood pressure were elevated and above the DRE average ranges.
9. **SIGNS OF INGESTION:** The suspect had a red, runny nose. Her eyes were bloodshot and watery. She also had a paint-like odor on her breath and clothing.
10. **SUSPECT'S STATEMENTS:** Suspect admitted drinking a "couple of wine coolers" but denied using any other substances.
11. **DRE'S OPINION:** In my opinion Mashburn is under the influence of an **Inhalant** and unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** The suspect provided a urine sample.
13. **MISCELLANEOUS:**

R5/13

Session 20

Practice: Vital Signs Examinations



Session 20 - Practice: Vital Signs Examinations

Learning Objectives

- **Conduct examinations of pulse, blood pressure and temperature**
- **Describe the vital signs examination procedures**
- **Document the results of the vital signs examinations**




Drug Recognition Expert Course
20-2

Briefly review the objectives, content and activities of this session.

Upon successfully completing this session the participant will be able to:

- Conduct examinations of pulse, and blood pressure.
- Describe the vital signs examination procedures.
- Document the results of the vital signs examinations.

CONTENT SEGMENTS

- A. Procedures for this Session
- B. Pulse Measurements
- C. Blood Pressure Measurements
- D. Session Wrap-Up

LEARNING ACTIVITIES

- Instructor Led Presentations
- Participant Hands-On Practice
- Instructor Led Coaching
- Participant Led Coaching

Session 20 - Practice: Vital Signs Examinations

Session Procedures

- Team Assignments
- Examinations Conducted



Drug Recognition Expert Course 20-3

A. Procedures for this Session

Refer to Session 7 if there are any questions on vital signs.

Team Assignments

Participants will work in three or four member teams.

Make team assignments.

At any given time, one member of the team will be engaged in conducting and recording vital signs examinations of another member.

The remaining member(s) will help coach and critique the participant who is conducting the examinations.

Emphasize that Participants can help each other learn by pointing out errors of omission or commission.

Participants will take turns serving as test administrator, test subject, and coach.

Participants will record their measurements using the *Vital Signs Examination Data Sheet*.

Session 20 - Practice: Vital Signs Examinations

Vital Signs Pulse Measurement Practice






Drug Recognition Expert Course 20-4

B. Pulse Measurements

Vital Signs Practice

Teams initially will practice taking one another's pulse.

Point out that the participant who is "coaching" should simultaneously take the subject's pulse along with the test administrator.

Example: Administrator can take pulse at subject's left wrist, coach can take it at subject's right wrist.

Then, the administrator and coach can compare the measurements they obtain.

Demonstrate this, using a participant subject and two instructors.

Hand out copies of the Vital Signs Examination Data Sheet to each participant. Solicit participants' questions concerning procedures for this practice session.

Pulse Measurements

Monitor teams and coach participants as necessary and appropriate.

Terminate this segment after 20 minutes, or after each participant has administered a pulse measurement to each of their team members (whichever comes first)

Session 20 - Practice: Vital Signs Examinations

Vital Signs Blood Pressure Measurement



Drug Recognition Expert Course 20-5

C. Blood Pressure Measurements

Teams subsequently will practice taking one another's blood pressure.

If specially designed training stethoscopes are available, the participant coach can "listen in" on the blood pressure measurements being taken by the participant administrator.

Monitor teams and coach participants as necessary and appropriate

Terminate this segment after 25 minutes, or after each participant has measured the blood pressure of each member of their team (whichever comes first).

Session 20 - Practice: Vital Signs Examinations

QUESTIONS?



Drug Recognition Expert Course 20-6

D. Session Wrap-Up

Offer appropriate comments and observations about the participants' performance.

Solicit participants' comments concerning the practice session.

VITAL SIGNS EXAMINATIONS DATA SHEET

EXAMINER'S NAME:

DATE ____ / ____ / ____

PULSE MEASUREMENTS

BLOOD PRESSURE MEASUREMENTS

SUBJECT'S NAME _____ SUBJECT'S NAME _____

TIME _____ TIME _____

PULSE POINT USED _____ SYSTOLIC _____

BEATS PER MINUTES _____ DIASTOLIC _____

SUBJECT'S NAME _____ SUBJECT'S NAME _____

TIME _____ TIME _____

PULSE POINT USED _____ SYSTOLIC _____

BEATS PER MINUTES _____ DIASTOLIC _____

SUBJECT'S NAME _____ SUBJECT'S NAME _____

TIME _____ TIME _____

PULSE POINT USED _____ SYSTOLIC _____

BEATS PER MINUTES _____ DIASTOLIC _____

Session 21 - Cannabis

85 Minutes

Session 21

Cannabis



Drug Recognition Expert Course

Session 21 - Cannabis

Learning Objectives

- **Explain a brief history of Cannabis**
- **Identify common names and terms associated with Cannabis**
- **Identify common methods of administration for Cannabis**
- **Describe the symptoms, observable signs and other effects associated with Cannabis**




Drug Recognition Expert Course 21-2

Briefly review the objectives, content and activities of this session.

- Upon successfully completing this session the participant will be able to:
- Explain a brief history of Cannabis.
- Identify common names and terms associated with Cannabis.
- Identify common methods of administration for Cannabis.
- Describe the symptoms, observable signs and other effects associated with Cannabis.

CONTENT SEGMENTS

- A. Overview of the Category
- B. Possible Effects of Cannabis
- C. Onset and Duration of Effects
- D. Overdose Signs and Symptoms
- E. Expected Results of the Evaluation
- F. Classification Exemplars

LEARNING ACTIVITIES

- Instructor-Led Presentations
- Review of the Drug Evaluation and Classification Exemplars
- Reading Assignments
- Video Presentation
- Slide Presentations

Session 21 - Cannabis

Learning Objectives (Cont.)

- Describe the typical time parameters, i.e. Onset and duration of effects associated with Cannabis
- List the clues that are likely to emerge when the drug influence evaluation is conducted for a person under the influence of Cannabis
- Correctly answer the “topics for study” questions at the end of this session



Drug Recognition Expert Course 21-3


- Describe the typical time parameters, i.e. onset and duration of effects associated with Cannabis.
- List the clues that are likely to emerge when the drug influence evaluation is conducted for a person under the influence of this drug category.
- Correctly answer the “topics for study” questions at the end of this session.

Session 21 - Cannabis

Cannabis Overview

- **Derived primarily from various species of Cannabis plants**
- **Primary psychoactive ingredient is Delta-9 Tetrahydrocannabinol (THC)**





Δ-9-TETRAHYDROCANNABINOL




Drug Recognition Expert Course 21-4

A. Overview of the Category

If available, display slides of Cannabis plants, leaves, flowers, etc.

“Cannabis” is a category of drugs derived primarily from various species of Cannabis plants, such as Cannabis Sativa and Cannabis Indica. Note that some jurisdictions as well as botanists don’t recognize Cannabis Indica as a separate plant species.

Cannabis grows readily throughout the temperate zones of the world.

It has been cultivated for centuries.

Example: At the first permanent English settlement in America, Jamestown, VA, where it was grown to produce hemp.

Print “Δ - 9 THC” on dry erase board or flip-chart

The primary psychoactive ingredient in Cannabis is Delta-9 Tetrahydrocannabinol.

THC is found principally in the leaves and flowers of the plant rather than in the stem or branches.

Session 21 - Cannabis

Cannabis Overview (Cont.)

Different varieties of the Cannabis have different concentrations of THC



Drug Recognition Expert Course 21-5

Point out that the highest known THC content is 37.2%, from a sample of marijuana analyzed in a DEA lab in California in 2007.

Source: Drug Identification Bible, 2012

Different varieties of the Cannabis have different concentrations of THC.

Source: Drug ID Bible, 2008.

One variety that has a relatively high concentration of THC is Sinsemilla, which is the unfertilized female Cannabis Sativa plant.

Explanatory note: "Sinsemilla" in Spanish means "without seeds."

Session 21 - Cannabis

Forms of Cannabis



Marijuana



Hashish



Hash Oil



Marinol




Drug Recognition Expert Course 21-6

Forms of Cannabis

There are four principal forms of Cannabis.

- Marijuana – the dried leaves of the plant.
- Hashish – a form of Cannabis made from the dried and pressed resin of a marijuana plant.
- Hash Oil – sometimes referred to as “marijuana oil,” it is a highly concentrated syrup-like oil extracted from Marijuana. It is normally produced by soaking Marijuana in a container of solvent, such as acetone or alcohol for several hours after the solvent has evaporated. A thick syrup-like oil is produced with a higher THC content. The average THC content of hash oil seized in the U.S. in 2010 was 29.89%.

Source: Drug Identification Bible, 2012.

- Marinol (or Dronabinol) – a synthetic form of THC. This is a prescription drug used to treat nausea and vomiting. It is prescribed for certain cancer patients undergoing chemotherapy.
- “Dronabinol” is the generic or chemical name for the synthetic THC.
- “Marinol” is a trade name for Dronabinol.
- “Nabilone – an analog of Dronabinol used as an anti-vomiting agent. Trade name: Cesamet

Session 21 - Cannabis

Synthetic Cannabinoid Products

Synthetic cannabinoid products typically include:

- Olive colored herbs;
- Combination of herbs;
- Plant materials;



All enhanced with a delta-9-tetrahydrocannabinol (THC) synthetic analog
When smoked, synthetic cannabinoid products mimic the hallucinogenic effects of marijuana



Drug Recognition Expert Course 21-7

Synthetic Cannabinoid Products

Synthetic cannabinoid products typically include olive colored herbs, combination of herbs, or plant materials enhanced with a delta-9-tetrahydrocannabinol (THC) synthetic analog. When smoked, synthetic cannabinoid products mimic the hallucinogenic effects of marijuana.

Point out that there are literally hundreds of different chemical synthetic cannabinoids, and hundreds of names for the synthetic cannabinoids.

Session 21 - Cannabis

Synthetic Cannabinoid Products Effects

- **Panic attacks**
- **Agitation**
- **Tachycardia (range of 110 to 150 BPM)**
- **Elevated blood pressure**
- **Anxiety**
- **Pallor**
- **Numbness and tingling**




Drug Recognition Expert Course

NHTSA

21-8

Synthetic Cannabinoid Products Effects

They have many adverse effects that include:

- Panic attacks
- Agitation
- Tachycardia (range of 110 to 150 BPM)
- Elevated blood pressure
- Anxiety
- Pallor
- Numbness and tingling

User report effects lasting between 30 minutes and 2 hours.

Common brand names for synthetic cannabinoids include K2, Spice, Spice Gold, Spice Diamond, Yucatan fire, Solar Flare, K2 Summit, Genie, PEP Spice, and Fire n Ice, to name a few.

Session 21 - Cannabis

Cannabis Applications

- **Lowers intraocular pressure**
- **Suppresses nausea**
- **Helps inhibit seizures**
- **Appetite enhancer**
- **A muscle relaxant**
- **A tumor growth retardant**




Drug Recognition Expert Course 21-9

Cannabis Applications

Cannabis has some limited medical applications.

- It lowers intraocular pressure, which can be helpful for glaucoma patients.
 “Intraocular” – within the eyeball.
 Cannabis lowers the intraocular pressure by dilating in size the blood vessels of the eyes (more size – less pressure). This causes reddening of the conjunctiva. Conjunctiva is the clear membrane of the sclera (white portion of the eye) and lines the inside of the eyelids and is made of lymphoid tissue. Conjunctivae refers to both eyes. Conjunctiva is singular.
- It suppresses nausea, and sometimes is recommended for cancer patients to relieve the nausea accompanying chemotherapy.
- Cannabidiol, a non-psychoactive ingredient found in Cannabis, is used in treating Epilepsy; it helps to inhibit seizures.

Cannabis has also had some limited medical application as:

- An appetite enhancer for victims of Anorexia Nervosa.
- A muscle relaxant.
- A tumor growth retardant.

Session 21 - Cannabis

Potency, Purity and Dose

- **Domestic marijuana - 4.89%**
- **Non domestic marijuana - 11.86%**
- **Hash - 30.3%**
- **Hash Oil - 30.3%**



Drug Recognition Expert Course 21-10

Potency, Purity and Dose

Average THC Concentration in marijuana:

- Domestic marijuana – 4.89%
- Non domestic marijuana - 11.86%
- Hash - 30.3%
- Hash Oil - 30.3%

Source: Drug Identification Bible, 2012

Note: THC levels can vary greatly depending upon areas of the country.

Recreational doses are highly variable.

The lower the THC, the more hits required to achieve desired effects.

Session 21 - Cannabis

Ingestion

- Smoked
- Orally



The slide features three images illustrating different methods of cannabis ingestion. The top-left image shows two brownies on a white plate, representing oral ingestion. The bottom-left image shows a lit pipe with smoke rising, representing smoking. The right-side image shows a person using a bong, representing smoking through a water pipe. The slide also includes logos for the National Highway Traffic Safety Administration (NHTSA) and the Drug Recognition Expert Course.

Drug Recognition Expert Course

NHTSA
www.nhtsa.gov

21-11

Marijuana usually is smoked.

Marijuana, Hash and Hash Oil also can be ingested orally, for example, baked in cookies or brownies and eaten.

Research related to passive inhalation of marijuana smoke causing behavioral effects as well as measurably amounts in toxicology samples is mixed, and is generally dependent on the amount of smoke inhaled.

Source: Cannabis (Marijuana) Effects on Human Behavior and Performance, M.A. Huestis, NIDA, 2002

Solicit participants' comments and questions concerning this overview of Cannabis.

Session 21 - Cannabis

Possible Effects of Cannabis

- Interferes with divided attention
- Brief attention span




Drug Recognition Expert Course

21-12

B. Possible Effects of Cannabis

One major effect of Cannabis is that it appears to interfere with a person's ability to divide attention.

People under the influence of Cannabis have difficulty paying attention, with brief attention spans.

In particular, they do not divide their attention very successfully.

Clarification: They have a difficult time dealing with more than one or two tasks at once.

This can make them very unsafe drivers, since driving requires the ability to divide attention among many simultaneous tasks.

Ask participants: "What are some of the things that drivers have to do simultaneously?"

Steering, Operating the accelerator, Signaling, Observing other traffic, Recognizing traffic control devices, Shifting

Session 21 - Cannabis

Possible Effects of Cannabis (Cont.)

- Loss of depth perception
- Short Attention Span
- Erratic speeds
- Failing to maintain a single lane
- Stopping for a red light then continuing on



Drug Recognition Expert Course 21-13

Loss of depth perception would be demonstrated by stopping improperly.

Short attention span would be indicated by erratic speeds, failing to maintain a single lane and stopping for a red light then continuing on.

People under the influence of Cannabis may attend to one or a few of these driving tasks, but simply ignore the other tasks.

Because Cannabis impairs attention, Standardized Field Sobriety Tests like Walk and Turn and One Leg Stand are excellent tools for recognizing people under the influence of Cannabis.

Remind participants that WAT and OLS are divided attention Standardized Field Sobriety Tests.

Session 21 - Cannabis

Pharmacological Effects

- **Relaxation**
- **Euphoria**
- **Relaxed inhibitions**
- **Disorientation**
- **Altered time and distance perception**
- **Sedation**



Drug Recognition Expert Course 21-14

Pharmacological Effects of Cannabis:

Effects will vary with dose, route of administration, experience of user, and other factors.

- Relaxation
- Euphoria
- Relaxed inhibitions
- Disorientation
- Altered time and distance perception
- Sedation

Session 21 - Cannabis

Other Characteristic Indicators

- Odor of Marijuana
- Marijuana debris in the mouth
- Possible green coating on the tongue
- Reddening of the conjunctivae
- Body tremors
- Eyelid tremors




Drug Recognition Expert Course 21-15

Other characteristic indicators:

- Odor of Marijuana
- Marijuana debris in the mouth
- Possible green coating on the tongue

Point out that there are no known studies that confirm Marijuana causing a green coating on the tongue.

- Reddening of the conjunctivae
- Body tremors

Point out that this may become evident when the subject attempts to estimate the passage of 30 seconds when performing the Modified Romberg Balance test.

- Eyelid tremors

Solicit participants' comments or questions concerning possible effects of Cannabis.

Session 21 - Cannabis

Onset and Duration of Marijuana's Effects

- **8-9 seconds - User begins to feel and exhibit effects**
- **10-30 minutes - Peak effects are reached**
- **2-3 hours - User continues to feel and exhibit effects**
- **3-6 hours - User feels “normal”**

Note: Evidence of marijuana use may be present in blood/urine tests for extended periods after use




Drug Recognition Expert Course 21-16

C. Onset and Duration of Effects

Persons begin to feel and exhibit the effects within 8 – 9 seconds after smoking Marijuana.

The effects reach their peak within 10 – 30 minutes.

- A 1985 Stanford University study showed that pilots had difficulty in holding patterns and in lining up with runways for up to 24 hours after using Marijuana.

Depending on the amount smoked and on the concentration of THC in the Marijuana, the person will continue to feel and exhibit the effects for 2 – 3 hours.

- In 1990, a second Stanford University study showed: Marijuana impaired performance at .25, 4, 8, and 24 hours after smoking. While 7 of the 9 pilots showed some degree of impairment at 24 hours after smoking Cannabis, only one reported any awareness of the drug's effects.

Generally, the person will feel “normal” within 3 – 6 hours after smoking Marijuana.

- The user may be impaired long after the euphoric feelings have ceased.

Solicit participants' comments and questions concerning onset and duration factors.

Session 21 - Cannabis

Onset and Duration of Marijuana's Effects (Cont.)

- 8-9 seconds - User begins to feel and exhibit effects
- 10-30 minutes - Peak effects are reached
- 2-3 hours - User continues to feel and exhibit effects
- 3-6 hours - User feels “normal”

Note: Evidence of marijuana use may be present in blood/urine tests for extended periods after use.



Drug Recognition Expert Course 21-17

Note that blood and urine tests will continue to disclose evidence of the use of Marijuana long after the effects of Marijuana have disappeared.

- Blood tests may disclose Marijuana use for at least 3 days after smoking.

Source: NIDA Study, “Blood Brain Barrier.”

- Urine tests may indicate the presence of metabolites of THC for a month or more.

Note that it can take as long as 4 hours for THC to appear in the urine at sufficient to trigger a positive drug screen (50 ng/ml) following smoking.

Session 21 - Cannabis

Metabolites of THC

- **Hydroxy THC**
 - **Causes Impairment and Euphoria**
- **Carboxy THC**
 - **Not psychoactive**



Drug Recognition Expert Course 21-18

There are two important metabolites, or chemical byproducts of THC.

Write “Hydroxy THC: Causes Impairment and Euphoria” on the dry erase board or flip-chart.

- Hydroxy THC, which causes the user to feel euphoric.
- Carboxy THC, there is no evidence at this time that it is psychoactive.
- Hydroxy THC usually is eliminated from the blood plasma within six hours.
- Carboxy THC may be found in the blood plasma for several days following Marijuana use.

Cannabis is a fat soluble (i.e. it dissolves easily into fatty tissue); therefore, it can remain for long periods in the brain tissue, which is about one-third fat.

Cannabis principally is eliminated from the body in feces and urine.

Session 21 - Cannabis

Overdose Signs and Symptoms

Is there danger of death from Cannabis overdose?



Drug Recognition Expert Course 21-19

D. Overdose Signs and Symptoms

Excessive or long term use of Marijuana can have very undesirable consequences.

Ask participants: "Is there danger of death from Cannabis overdose?"

Answer: It is not likely that there is a direct risk of death from overdose; however, persons impaired by Cannabis may behave in foolishly dangerous ways and become injured or killed as a result.

Session 21 - Cannabis

Long Term Effects

- Lung damage
- Chronic Bronchitis
- Lowering of Testosterone
- Possible birth defects
- Acute anxiety attacks
- Chronic reduction of attention span



Drug Recognition Expert Course 21-20

Marijuana has been observed to produce sharp personality changes, especially in adolescent users.

It can create paranoia and possible psychosis.

Long term effects include:

- Lung damage
- Chronic Bronchitis
- Lowering of Testosterone (male sex hormone)
- Possible birth defects, still births and infant deaths
- Acute anxiety attacks
- Chronic reduction of attention span

Research indicates that life threatening overdoses rarely if ever occur.

Withdrawal – is similar to alcohol dependence withdrawal

Physical dependence can occur with chronic use

Solicit participants' questions concerning signs and symptoms of Cannabis overdose.

Session 21 - Cannabis

Evaluation of Subjects Under the Influence of Cannabis

- HGN - None
- VGN - None
- Lack of Convergence - Present
- Impaired performance will be evident on Modified Romberg Balance, Walk and Turn, One Leg Stand and Finger to Nose




Drug Recognition Expert Course 21-21

E. Expected Results of the Evaluation

Observable Evidence of Impairment

Clinical Indicators

- Neither Horizontal Gaze nor Vertical Gaze Nystagmus will be present.
- Lack of Convergence generally will be present.

Remind participants that Marijuana users often drink alcohol in conjunction with their smoking, and that others often lace their Marijuana with PCP. Either combination would cause Nystagmus.

- Performance on the Modified Romberg Balance, Walk and Turn, One Leg Stand, and Finger to Nose tests will be impaired.

Remind participants to be especially alert for evidence of the subject's distorted perception of time when performing the Modified Romberg Balance test.

Point out that, with subjects under the influence of Cannabis, poor performance on these tests usually will result principally from their inability to divide attention, and less so from impaired coordination or balance.

Session 21 - Cannabis

Evaluation of Subjects Under the Influence of Cannabis (Cont.)

Vital Signs:

- Pulse - Up
- Blood pressure - Up
- Body temperature - Normal

Muscle tone - Normal



Drug Recognition Expert Course 21-22

Vital Signs:

- Pulse generally will be elevated.
- Blood pressure generally will be elevated.
- Body temperature will be normal.
- Muscle tone will be normal.

Session 21 - Cannabis

Evaluation of Subjects Under the Influence of Cannabis (Cont.)

Dark Room:

- Pupil size - Dilated (6)
- Pupil reaction to light - Normal

(6) Possibly normal



Drug Recognition Expert Course 21-23

Pupil size generally will be dilated or possibly normal (within DRE average ranges).

- The content and potency could effect pupil size. The higher THC content will increase the likelihood of pupil dilation. However, Cannabis does not cause pupil constriction.
- Government grown Cannabis has low THC levels. Studies using it tend to show a normal range for pupil size.

Pupil reaction to light will be normal.

Session 21 - Cannabis

Rebound Dilation

A period of pupillary constriction followed by a period of pupillary dilation where the pupil steadily increases in size and does not return to its original constricted size



Drug Recognition Expert Course 21-24

DREs report a phenomenon termed “Rebound Dilation” in subjects under the influence of Cannabis.

Clarification: “Rebound Dilation” is a period of pupillary constriction followed by a period of pupillary dilation where the pupil steadily increases in size and does not return to its original constricted size.

This revised definition was approved by the IACP Technical Advisory Panel (TAP), November 2008. Note, however, that this phenomenon has not been scientifically investigated in a controlled research study.

Draw an eye on the balloon and squeeze it to demonstrate Rebound Dilation.

Remind the participants that the final size determination being estimated is at the end of the 15 second time period when the light from the pen-light is directed into the eye.

Caution should be used by the DRE so as not to move the light beam or allow the bulb to change in light intensity.

Session 21 - Cannabis

Evaluation of Subjects Under the Influence of Cannabis

General Indicators

- Body tremors
- Disoriented
- Debris in mouth (possible)
- Eyelid tremors
- Impaired perception of time and distance
- Increased appetite
- Marked reddening of conjunctiva



Drug Recognition Expert Course 21-25

General Indicators

- Body tremors
- Disoriented
- Debris in the mouth

Note: Occasionally some users of Marijuana have displayed a green coating on their tongue after recent use. However, this does not occur with all users.

- Eyelid tremors
- Impaired perception of time and distance
- Increased appetite
- Marked reddening of the conjunctivae

Point out that this is properly called Conjunctival Injection. Conjunctiva is the mucous membrane that lines the inner surface of the eyelids and is continued over the forepart of the eyeball.

Point out that this should not be confused with conjunctivitis which is a disease of the eye. The vasodilation is the primary cause of the reddening of the eyes not the Cannabis smoke.

Visine causes vasoconstriction in the eyes and is often used to reduce reddening.

Session 21 - Cannabis

Evaluation of Subjects Under the Influence of Cannabis (Cont.)

General Indicators (Cont.)

- Odor of marijuana
- Possible paranoia
- Relaxed inhibitions



Drug Recognition Expert Course 21-26

General Indicators (Cont.)

- Odor of Marijuana
- Possible paranoia
- Relaxed inhibitions

Session 21 - Cannabis

Cannabis Symptomatology Chart

HGN	None
VGN	None
Lack of Convergence	Present
Pupil Size	Dilated ⁽⁶⁾
Reaction to Light	Normal
Pulse Rate	Up
Blood Pressure	Up
Temperature	Normal
Muscle Tone	Normal

⁽⁶⁾ possibly normal




Drug Recognition Expert Course 21-27

Symptomology Matrix

Session 21 - Cannabis

Cannabis



Drug Recognition Expert Course 21-28

Click video to begin

VIDEO DEMONSTRATION

Show video example of subject under the influence of a Cannabis . (Approximately 20 minutes).

Session 21 - Cannabis

Drug Evaluation and Classification

Exemplar Demonstrations



Drug Recognition Expert Course

21-29

F. Classification Exemplar

Refer students to the exemplars found at the end of Session 21 of their participant manuals.

Point out that the one-page narrative in the example exemplars are not to be construed as the recommended or approved narrative report. The actual narrative report submitted by DREs will be more detailed.

Relate the items on the exemplars to the Cannabis Symptomatology Chart.

Relate behavior and observations to the Cannabis Symptomatology Chart.

Solicit students' questions or suggestions concerning Expected Results of the Evaluation of subjects under the influence of Cannabis .

Session 21 - Cannabis

QUESTIONS?



Drug Recognition Expert Course

21-30

Solicit participants' comments and questions concerning expected results of the evaluation.

Session 21 - Cannabis

Topics for Study




Drug Recognition Expert Course 21-31

TOPICS FOR STUDY / ANSWERS

1. What is the active ingredient in Cannabis?

ANSWER: Delta 9 THC

2. Why are the Walk and Turn and the One Leg Stand tests excellent tools for recognizing persons under the influence of Marijuana?

ANSWER: Cannabis appears to interfere with a person's ability or willingness to pay attention. People under the influence of Marijuana do not divide their attention very well. Walk and Turn and the One Leg Stand tests are divided attention tests.

3. What is Marinol?

ANSWER: A synthetic form of THC that is not derived from Cannabis plants. It is a prescriptive drug that is sometimes administered to cancer patients to suppress nausea that may accompany chemotherapy. Also known as Dronabinol.

4. What is Sinsemilla?

ANSWER: The unpollinated female Cannabis plant, having a relatively high concentration of THC.

Session 21 - Cannabis

Topics for Study (Cont.)



Drug Recognition Expert Course 21-32








TOPICS FOR STUDY / ANSWERS

5. Name two important metabolites of THC, and describe how they affect the duration and perception of the effects of Cannabis.

ANSWER: Hydroxy THC – causes the user to feel euphoric so they are aware of the effects.

Carboxy THC – there is no evidence at this time that this metabolite is psychoactive.

DRUG INFLUENCE EVALUATION

Evaluator Sgt. Christopher Dudzik, Toms River PD		DRE # 15133	Rolling Log # 12-04-015	Session XXI- #1	
Recorder/Witness Trooper Thomas Synder, NJ SP		Crash: <input checked="" type="checkbox"/> None <input type="checkbox"/> Fatal <input type="checkbox"/> Injury <input type="checkbox"/> Property		Case # 347817	
Arrestee's Name (Last, First, Middle) Clark, Kenneth A.		Date of Birth 5/24/84	Sex M	Race W	Arresting Officer (Name, ID#) Trooper Michael Gibson, NJ SP #14810
Date Examined / Time / Location 04/05/12 2200 Toms River PD		Breath Results: Results: 0.00		Test Refused <input type="checkbox"/> Instrument #: 47451	Chemical Test: Urine <input type="checkbox"/> Blood <input checked="" type="checkbox"/> Test or tests refused <input type="checkbox"/>
Miranda Warning Given Given By: Tpr. Gibson	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? Couple of hot dogs 5 PM	What have you been drinking? Nothing	How much?	Time of last drink? N/A
Time now/ Actual 11:00 pm / 2205	When did you last sleep? How long Last night 6 hrs.	Are you sick or injured? "Hell no <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No I feel great."	Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No "No, are you?"		
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No "I don't do drugs man."		Attitude: Boisterous, cooperative		Coordination: Unsteady, relaxed	
Speech: Loud, talkative		Breath Odor: Odor of marijuana		Face: Flushed, sweaty	
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input checked="" type="checkbox"/> Reddened Conjunctiva <input type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right	
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	
Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal		Eyelids: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Droopy			
Pulse and time 1. 94 / 2212 2. 92 / 2227 3. 92 / 2250		HGN Lack of Smooth Pursuit: No Maximum Deviation: No Angle of Onset: None	Left Eye No No None	Right Eye No No None	32 ONE LEG STAND 28 
Modified Romberg Balance  Circular Sway		Walk and Turn test  Laughing during test		Convergence  Right eye Left eye	
		Cannot keep balance <input checked="" type="checkbox"/> <input checked="" type="checkbox"/>		L R <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Sways while balancing <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Uses arms to balance <input type="checkbox"/> <input type="checkbox"/> Hopping <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Puts foot down	
		Starts too soon		1st Nine 2nd Nine	
		Stops walking		<input checked="" type="checkbox"/>	
		Misses heel-toe		<input checked="" type="checkbox"/>	
		Steps off line		<input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/>	
		Raises arms		<input checked="" type="checkbox"/> <input checked="" type="checkbox"/>	
		Actual steps taken		9 9	
Internal clock 43 estimated as 30 seconds		Describe Turn: Stopped		Cannot do test (explain): N/A	
Type of footwear: Boots					
Draw lines to spots touched 		PUPIL SIZE		Nasal area: Clear	
		Room light 2.5-5.0		Darkness 5.0-8.5	
		Direct 2.0-4.5		Oral cavity: Clear	
		Left Eye 5.5		9.0	
		5.5 - 7.0			
		Right Eye 5.5		9.0	
		5.5 - 7.0			
		REBOUND DILATION <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		REACTION TO LIGHT: Normal	
Laughing and eyelid tremors		RIGHT ARM 		LEFT ARM 	
Blood pressure 154/106		Temperature 98.6		Nothing observed	
Muscle tone: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Flaccid <input type="checkbox"/> Rigid					
Comments: What drugs or medications have you been using? "I told you, I don't do drugs."		How much? No answer		Time of use? No answer	
		Where were the drugs used? (Location) "I ain't saying anything."			
Date / Time of arrest: 04/05/12 2115		Time DRE was notified: 2140		Evaluation start time: 2200	
		Evaluation completion time: 2315		Precinct/Station:	
Officer's Signature:		DRE # 15133		Reviewed/approved by / date:	
Opinion of Evaluator: <input type="checkbox"/> Rule Out <input type="checkbox"/> Medical <input type="checkbox"/> Alcohol <input type="checkbox"/> CNS Depressant		<input type="checkbox"/> CNS Stimulant <input type="checkbox"/> Hallucinogen		<input type="checkbox"/> Dissociative Anesthetic <input type="checkbox"/> Narcotic Analgesic <input type="checkbox"/> Inhalant <input checked="" type="checkbox"/> Cannabis	

DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: Clark, Kenneth A.

1. **LOCATION:** The evaluation was conducted at the Toms River Police Department.
2. **WITNESSES:** Trooper Thomas Snyder of the NJ SP recorded the evaluation.
3. **BREATH ALCOHOL TEST:** Clark's breath test was a 0.00%.
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** I was contacted by radio and advised to meet Trooper Gibson at the Toms River Police Department for a drug evaluation. Trooper Gibson advised he stopped Clark after observing his vehicle westbound on Hwy 37 drifting out of his traffic lane. When stopped, Clark seemed unconcerned about his driving and told Trooper Gibson that he was "just a little tired." After performing poorly on the SFST's Clark was arrested for DUI.
5. **INITIAL OBSERVATION OF SUSPECT:** I first observed the suspect in the interview room at the PD. He was laughing a lot and several times said, "I'm not drunk man!" He was having problems with his coordination and several times he bumped into the interview table. He had a noticeable reddening of the conjunctiva.
6. **MEDICAL PROBLEMS AND TREATMENT:** None noted or stated.
7. **PSYCHOPHYSICAL TESTS:** Modified Romberg Balance: Suspect had a circular sway of approximately 3" and estimated 30 seconds in 43 seconds. Walk & Turn: Suspect lost his balance twice during the instructions stage, missed heel to toe three times on the first nine steps. On the return nine steps he missed heel-to-toe four times and began laughing. He also used his arms for balance. One Leg Stand: Suspect put his foot down three times while standing on the left foot and twice while standing on the right foot. He also used his arms for balance on both and laughed while completing the test. Finger to Nose: The suspect missed the tip of his nose on four of the attempts and laughed while completing the test.
8. **CLINICAL INDICATORS:** Suspect had a Lack of Convergence and Rebound Dilation. His pupils were dilated and his pulse and blood pressure were elevated.
9. **SIGNS OF INGESTION:** The suspect had an odor of marijuana on his breath and clothes.
10. **SUSPECT'S STATEMENTS:** Suspect stated, "I smoke a little pot. What's the big deal?"
11. **DRE'S OPINION:** In my opinion Clark is under the influence of a **Cannabis** and unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** The suspect provided a blood sample.
13. **MISCELLANEOUS:**

R5/13





DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: Peltier, Charles E.

1. **LOCATION:** The evaluation was conducted in the interview room at the Linn County Jail.
2. **WITNESSES:** The evaluation was witnessed and recorded by Sgt. Greg Plummer of the Oregon State Police.
3. **BREATH ALCOHOL TEST:** Peltier's breath test was a 0.00%.
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** I was dispatched to contact Sr. Trooper Webster at the Linn County Jail for a drug evaluation. Senior Trooper Webster advised he had arrested Peltier for DUI after he attempted to elude officers on I-5 south of Salem. The suspect was detained with the use of spike strips. The suspect had poor balance and coordination and after performing poorly on the SFST's he was arrested for DUI.
5. **INITIAL OBSERVATION OF SUSPECT:** I first observed the suspect in the interview room at the jail. He seemed impatient and anxious. He had poor coordination and balance and his speech was slow and slurred.
6. **MEDICAL PROBLEMS AND TREATMENT:** None noted or stated.
7. **PSYCHOPHYSICAL TESTS:** Modified Romberg Balance: Suspect had an approximate 3" circular sway and estimated 30 seconds in 35 seconds. Walk & Turn: Suspect lost his balance during the instructions stage, missed heel to toe three times on the first nine steps and twice on the second nine steps. He stopped twice while walking and raised his arms for balance. One Leg Stand: Suspect swayed while balancing, used his arms for balance, put his foot down once, hopped once and had leg tremors. Finger to Nose: Suspect missed the tip of his nose on four of the six attempts and exhibited eyelid tremors.
8. **CLINICAL INDICATORS:** Suspect had a Lack of Convergence and Rebound Dilation. His pupils were dilated in room light and in direct light. His pulse and blood pressure were elevated and above the DRE average ranges.
9. **SIGNS OF INGESTION:** The suspect had a green coating on his tongue.
10. **SUSPECT'S STATEMENTS:** Suspect admitted drinking a beer earlier and laughed when asked about other drug use.
11. **DRE'S OPINION:** In my opinion Peltier is under the influence of **Cannabis** and unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** The suspect provided a urine sample.
13. **MISCELLANEOUS:** Suspect was also charged with Attempting to Elude.

R5/13

DRUG INFLUENCE EVALUATION

Evaluator Officer Ed Harris, Seattle Police Department		DRE # 9532	Rolling Log # 12-06-134	Session XXI-#3	
Recorder/Witness Sgt. Mark Crandall, Washington State Patrol		Crash: <input type="checkbox"/> None <input type="checkbox"/> Fatal <input type="checkbox"/> Injury <input checked="" type="checkbox"/> Property		Case # 12-887452	
Arrestee's Name (Last, First, Middle) Wright, James B.		Date of Birth 10/20/83	Sex W	Race M	Arresting Officer (Name, ID#) Officer Jon Huber, Seattle Police Department #12367
Date Examined / Time / Location 06/18/12 2130 SPD West Precinct		Breath Results: Results: 0.00		Test Refused <input type="checkbox"/> Instrument #: 4773	Chemical Test: Urine <input type="checkbox"/> Blood <input checked="" type="checkbox"/> Test or tests refused <input type="checkbox"/>
Miranda Warning Given Given By: Ofc. Huber	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? "Couple of burgers" 7 PM	What have you been drinking? How much? "Nothing, I don't drink."	Time of last drink? N/A	
Time now/ Actual 9-10 pm/9:40 pm	When did you last sleep? How long Last night 9 hours	Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No "I feel fine."		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Attitude: Relaxed, carefree		Coordination: Unsteady	
Speech: Slow and deliberate		Breath Odor: Odor of marijuana		Face: Normal	
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input checked="" type="checkbox"/> Reddened Conjunctiva <input type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right	
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	
Eyelids: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Droopy		Pulse and time 1. 94 / 2140 2. 92 / 2152 3. 92 / 2215		HGN Lack of Smooth Pursuit: No Maximum Deviation: No Angle of Onset: None	
Modified Romberg Balance  Circular sway		Walk and Turn test 		Convergence 	
Internal clock 38 estimated as 30 seconds		Describe Turn: Spun around		Cannot do test (explain): N/A	
Type of footwear: Flip flops		REBOUND DILATION <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		REACTION TO LIGHT: Normal	
Draw lines to spots touched 		PUPIL SIZE		Nasal area: Clear	
Eyelid tremors		Room light 2.5 - 5.0		Oral cavity: Green coating on tongue	
Blood pressure 140/96		Darkness 5.0 - 8.5		RIGHT ARM	
Temperature 98.8		Direct 2.0 - 4.5		LEFT ARM	
Muscle tone: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Flaccid <input type="checkbox"/> Rigid		Left Eye 6.0		Nothing observed	
Comments: What drugs or medications have you been using? "Pot's legal man. What's the big deal?"		Right Eye 6.0		None observed	
Date / Time of arrest: 06/18/12 2045		How much? "Not enough"		Time of use? 2 hours ago	
Time DRE was notified: 2045		Where were the drugs used? (Location) "I ain't saying."		Evaluation start time: 2130	
Officer's Signature:		Evaluation completion time: 2240		Precinct/Station:	
DRE # 9532		Reviewed/approved by / date:			
Opinion of Evaluator: <input type="checkbox"/> Rule Out <input type="checkbox"/> Medical		<input type="checkbox"/> Alcohol <input type="checkbox"/> CNS Depressant		<input type="checkbox"/> CNS Stimulant <input type="checkbox"/> Hallucinogen	
		<input type="checkbox"/> Dissociative Anesthetic <input type="checkbox"/> Narcotic Analgesic		<input type="checkbox"/> Inhalant <input checked="" type="checkbox"/> Cannabis	

DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: Wright, James B.

1. **LOCATION:** The evaluation was conducted at the West Precinct of the Seattle P.D.
2. **WITNESSES:** Sergeant Mark Crandall, Washington State Patrol.
3. **BREATH ALCOHOL TEST:** Wright's breath test was a 0.00%.
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** Writer was on duty at the West Precinct when contacted by Officer Huber requesting a drug evaluation. Officer Huber advised he arrested Wright after his vehicle struck another vehicle on Highway 99 north of Seattle. There was an odor of marijuana coming from the suspect's vehicle. He had poor balance and coordination and was unable to perform the SFST's as directed. A small pipe containing marijuana residue was located in the suspect's vehicle.
5. **INITIAL OBSERVATION OF SUSPECT:** Writer first observed the suspect in the interview room at the West Precinct. He was very relaxed and carefree acting. He had poor coordination and balance and his speech was slow and deliberate.
6. **MEDICAL PROBLEMS AND TREATMENT:** None noted or stated.
7. **PSYCHOPHYSICAL TESTS:** Modified Romberg Balance: Suspect had an approximate 2" circular sway and estimated 30 seconds in 38 seconds. Walk & Turn: Suspect lost his balance during the instructions stage, started walking too soon, raised his arms for balance and failed to touch heel to toe five times on the first nine steps and on all his steps during the second nine steps. One Leg Stand: Suspect swayed while balancing, used his arms for balance and put his foot down twice while standing on the left foot and once while standing on the right foot. Finger to Nose: Suspect missed the tip of his nose on three of the six attempts and exhibited eyelid tremors.
8. **CLINICAL INDICATORS:** Suspect had a lack of convergence. His pupils were dilated in all three lighting levels and he had rebound dilation. His pulse and blood pressure were elevated and were above the DRE average ranges.
9. **SIGNS OF INGESTION:** The suspect had a green coating on his tongue.
10. **SUSPECT'S STATEMENTS:** Suspect stated, "Pot's legal man. What's the big deal?"
11. **DRE'S OPINION:** In my opinion Wright is under the influence of **Cannabis** and unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** The suspect provided a blood sample.
13. **MISCELLANEOUS:** The suspect was also charged with possession of marijuana.

Session 22 - Overview of Signs and Symptoms

60 Minutes

Session 22

Overview of Signs and Symptoms





Drug Recognition Expert Course

PRIOR TO THE START OF THIS SESSION, DRAW THE FOLLOWING MATRIX ON THE DRY ERASE BOARD OR FLIP-CHART:

MAJOR INDICATOR	POSSIBLE EFFECTS	CNS DEPRESS	CNS STIM	HALLUC	DISS ANESTETIC	NARC ANALGESIC	INHALANT	CANNABIS
HGN								
VGN								
LACK OF CONVERGENCE								
PUPIL SIZE								
REACT LIGHT								
PUSE RATE								
BLOOD PRESSURE								
BODY TEMPERATURE								
MUSCLE TONE								

Session 22 - Overview of Signs and Symptoms

Learning Objectives

- Describe the possible effects that may be observed in each major indicator of drug impairment
- Identify the effects that will most likely be observed with subjects under the influence of each drug category




Drug Recognition Expert Course
22-2

Briefly review the objectives, content and activities of this session.

Upon successfully completing this session the participant will be able to:

- Describe the possible effects that may be observed in each major indicator of drug impairment.
- Identify the effects that will most likely be observed with subjects under the influence of each drug category.

CONTENT SEGMENTS

- A. The Major Indicators and their Possible Effects
- B. Effects Associated with the Drug Categories

LEARNING ACTIVITIES

- Instructor-Led Presentations
- Interactive Discussions

Session 22 - Overview of Signs and Symptoms

DRE Major and General Indicators

- **Major Indicators: Physiological Indicators**
- **General Indicators: Observational and Behavioral Indicators**



Drug Recognition Expert Course 22-3

DRE Major and General Indicators

- For DRE purposes, Major Indicators are physiological signs that are specifically addressed and are, for the most part, involuntary; reflecting the status of the Central Nervous System homeostasis.
- For DRE purposes, General Indicators are behaviors or observations of the subject that are observed and not specifically tested for.

Both are of equal value in making a decision in the totality of the evaluation.

Session 22 - Overview of Signs and Symptoms

Major Physiological Indicators of Drug Impairment

- Horizontal Gaze Nystagmus
- Vertical Gaze Nystagmus
- Lack of Convergence
- Pupil Size
- Reaction to Light
- Pulse Rate
- Blood Pressure
- Body Temperature
- Muscle Tone




Drug Recognition Expert Course 22-4

A. The Major Physiological Indicators and Their Possible Effects

Major Physiological Indicators of Drug Impairment

The major physiological indicators of drug impairment are (point to the major indicators on the matrix):

- Horizontal Gaze Nystagmus
- Vertical Gaze Nystagmus
- Lack of Convergence
- Pupil Size
- Reaction to Light
- Pulse Rate
- Blood Pressure
- Body Temperature
- Muscle Tone

Point out that the first five major physiological indicators concern the eyes and that three of the last four major indicators concern the vital signs.

Announce to the participants: “we will now review all of the possible effects that we might observe with each major physiological indicator.”

Session 22 - Overview of Signs and Symptoms

Possible Effects: HGN

- Possible effects that might be observed with Nystagmus
- With Horizontal Gaze Nystagmus, there are only two possible effects that might be observed




Drug Recognition Expert Course 22-5

Possible Effects: HGN

Possible effects that might be observed with **Nystagmus**. With Horizontal Gaze Nystagmus, there are only two possible effects that might be observed.

- Either HGN will be **present**;
- Or it will be **none (meaning that it is not present)**.

Under the “Possible Effects” column of the matrix, opposite “HGN,” write:

**PRESENT
OR
NONE**

There is no drug that stops Horizontal Gaze Nystagmus. Some drugs cause HGN to be present, others do not; but there is no drug that “cures” HGN.

Session 22 - Overview of Signs and Symptoms

Possible Effects: VGN

What are the possible effects we might observe with Vertical Gaze Nystagmus?

- With Vertical Gaze Nystagmus, there are also only two possible effects



Drug Recognition Expert Course 22-6

Possible Effects: VGN

Ask participants: “What are the possible effects we might observe with Vertical Gaze Nystagmus?”

With Vertical Gaze Nystagmus, there are also only two possible effects.

- Either it will be **present**;
- Or it will be **none (meaning that it is not present)**.

Opposite “VGN,” write:

**PRESENT
OR
NONE**

Session 22 - Overview of Signs and Symptoms

Possible Effects: LOC

What effects might we observe with Lack of Convergence?

- For Lack of Convergence, there are also only two possible effects




Drug Recognition Expert Course 22-7

Possible Effects: LOC

Ask participants: “What effects might we observe with Lack of Convergence?”

For **Lack of Convergence**, there are also only two possible effects.

- Either Lack of Convergence will be **present**;
- Or it will be **none (meaning that it is not present)**.

Opposite “Lack Conv.” write:

**PRESENT
OR
NONE**

Point out that, when we say that “Lack of Convergence is present,” we mean that the eyes are unable to converge or cross properly.

Just as with Nystagmus, there is no drug that “cures” Lack of Convergence.

Session 22 - Overview of Signs and Symptoms

Possible Effects: Pupil Size

What effects might we observe with Pupil Size?

- For Pupil Size, there are three possible effects



Drug Recognition Expert Course 22-8

Possible Effects: Pupil Size

Ask participants: “What effects might we observe with Pupil Size?”

For **Pupil Size**, there are three possible effects that might be seen.

- The pupils might be **normal** (within the DRE average ranges);
- Or, the pupils might be **dilated**;
- Or, they might be **constricted**.

Opposite “Pupil Size,” write:

**NORMAL
OR
DILATED
OR
CONSTRICTED**

Session 22 - Overview of Signs and Symptoms

Possible Effects: Pupil Size (Cont.)

What effects might we observe with Pupils' Reaction to light?

- There are a number of effects that might be observed in the pupils' Reaction to Light




Drug Recognition Expert Course 22-9

Possible Effects: Reaction to Light

Ask participants: “What effects might we observe with the pupils’ reaction to light?”

There are a number of effects that might be observed in the pupils’ **Reaction to Light**.

- The pupils might react in a **normal** manner, i.e. by constricting somewhat in one second or less.
- Or, the pupils might react **slow**, i.e. by constricting somewhat, but requiring more than one second to do so.

Opposite “React Light,” write:

NORMAL
OR
SLOW
OR
LITTLE TO NONE VISIBLE

Note that we should not report that the “pupils did not react at all,” but rather we should report “no visible reaction.”

In some instances, you may observe very little, or no visible reaction to light. If there is a visible reaction of the pupils, it is possible that Rebound Dilation was seen.

Session 22 - Overview of Signs and Symptoms

Possible Effects: Vital Signs

For each of the **Vital Signs**, there are three possible effects:

- The pulse rate, or blood pressure, or body temperature could be **Normal** (within the DRE average ranges)




Drug Recognition Expert Course 22-10

Possible Effects: Vital Signs

For each of the **Vital Signs**, there are three possible effects.

The pulse rate, or blood pressure, or body temperature could be **NORMAL (within the DRE average ranges)**.

- Or, it could be **UP**;
- Or, it could be **DOWN**.

Opposite “Pulse Rate,” write:

**NORMAL
OR
UP
OR
DOWN**

Write exactly the same things opposite “Blood Press” and “Body Temp.”

Session 22 - Overview of Signs and Symptoms

Possible Effects: Muscle Tone

What effects might we observe with muscle tone?

- There are three possible effects that might be seen




Drug Recognition Expert Course 22-11

Possible Effects: Muscle Tone

Ask participants: What effects might we observe with muscle tone?

For **Muscle Tone**, there are three possible effects that might be seen.

- Normal (meaning nothing unusual)
- Flaccid
- Rigid

Opposite “Muscle Tone,” write:

NORMAL
OR
FLACCID
OR
RIGID

Solicit participants’ comments and questions about the possible effects of the eight major indicators.

Session 22 - Overview of Signs and Symptoms

CNS Depressant Effects




Drug Recognition Expert Course 22-12

B. Effects Associated with the Drug Categories

CNS Depressants

Ask for a participant to volunteer to state the major effects that usually will be seen in a subject under the influence of a CNS Depressant.

Correct the participants' responses, as necessary, and write the correct effects on the matrix, under the CNS Depressant column.

- HGN: **present**
- VGN: **present** (i.e. at high doses for that individual)
- Lack of Convergence: **present**
- Pupil Size: **normal** (within the average DRE ranges) except Soma, Quaaludes (Methaqualone) and some anti-depressants usually **dilate** pupils.
- Reaction to Light: **slow**
- Pulse Rate: **down** except Quaaludes (Methaqualone), ETOH and possibly some anti-depressants may **elevate**.
- Blood Pressure: **down**
- Body Temperature: **normal** (within the average DRE ranges)
- Muscle Tone: **flaccid**

Emphasize that these are the usual major effects that will be observed with CNS Depressants, but we cannot always be certain that all of these effects will be seen. Thank the "volunteer" participant for their help.

Session 22 - Overview of Signs and Symptoms

CNS Stimulant Effects



Drug Recognition Expert Course 22-13

CNS Stimulants

Select another volunteer to help with the CNS Stimulant category effects.

Correct the participant's responses as necessary, and write the correct effects under the "Stimulant" column.

- HGN: **none** (Not present)
- VGN: **none** (Not present)
- Lack of Convergence: **none** (Not present)
- Pupil Size: **dilated**
- Reaction to Light: **slow**
- Pulse Rate: **up**
- Blood Pressure: **up**
- Body Temperature: **up**
- Muscle Tone: **rigid**

Emphasize that these are the effects usually seen with CNS Stimulants, but we can't guarantee that all of these effects will be observed in each and every case.

Thank the "volunteer" participant for his or her help.

Session 22 - Overview of Signs and Symptoms

Hallucinogen Effects




Drug Recognition Expert Course 22-14

Hallucinogens

Select another volunteer to help with identifying the usual major effects of the Hallucinogen category.

Correct the participant's responses as necessary, and write the correct effects under the "Hallucinogens" column.

- HGN: **none** (Not present)
- VGN: **none** (Not present)
- Lack of Convergence: **none** (Not present)
- Pupil Size: **dilated**
- Reaction to Light: **normal**, certain psychedelic amphetamines may cause slowing.
- Pulse Rate: **up**
- Blood Pressure: **up**
- Body Temperature: **up**
- Muscle Tone: **rigid**

Point out that "Reaction to Light" is the only major indicator that distinguishes Hallucinogens from CNS Stimulants, and "Reaction to Light" is a relatively subtle clue. For this reason, it can be very difficult to differentiate between these two categories.

Thank the "volunteer" for their help with the Hallucinogen effects.

Session 22 - Overview of Signs and Symptoms

Dissociative Anesthetic Effects




Drug Recognition Expert Course 22-15

Dissociative Anesthetics

Select another volunteer to help with the Dissociative Anesthetic category effects.

Correct the participant's responses as necessary, and write the correct effects under the "D/A" column.

- HGN: **present**
- VGN: **present** (i.e. at high doses; however, it is more common to see Vertical Gaze Nystagmus in someone under the influence of a **Dissociative Anesthetic**)
- Lack of Convergence: **present**
- Pupil Size: **normal** (within the DRE average ranges)
- Reaction to Light: **normal**
- Pulse Rate: **up**
- Blood Pressure: **up**
- Body Temperature: **up**
- Muscle Tone: **rigid**

Thank the "volunteer" for their help with the Dissociative Anesthetic effects.

Session 22 - Overview of Signs and Symptoms

Narcotic Analgesic Effects



Drug Recognition Expert Course 22-16

Narcotic Analgesics

Select another volunteer to help with the Narcotic Analgesic category.

Correct the participant's responses as necessary, and write the correct effects under the "Narcotic Analgesics" column.

- HGN: **none** (Not present)
- VGN: **none** (Not present)
- Lack of Convergence: **none** (Not present)
- Pupil Size: **constricted**
- Reaction to Light: **little or none visible**
- Pulse Rate: **down**
- Blood Pressure: **down**
- Body Temperature: **down**
- Muscle Tone: **flaccid**

Thank the "volunteer" for their help with the Narcotic Analgesic effects.

Session 22 - Overview of Signs and Symptoms

Inhalant Effects




Drug Recognition Expert Course 22-17

Inhalants

Select another volunteer to help with the Inhalant category. Remind the volunteer that, with Inhalants, many of the effects noted on the major indicators will depend upon the specific substance inhaled.

Correct the participant's responses as necessary, and write the correct effects under the "Inhalants" column.

- HGN: **present**
- VGN: **present** (high dose for that individual)
- Lack of Convergence: **present**
- Pupil Size: **normal (within the DRE average ranges) but may be dilated**
- Reaction to Light: **slow**
- Pulse Rate: **up**
- Blood Pressure: **up/down** (the Volatile Solvents and the Aerosols usually cause blood pressure to be **above the average ranges**; but the Anesthetic Gases can cause blood pressure to be **below the average ranges**, even though they **elevate** the pulse rate)
- Body Temperature: **up/down/normal**
- Muscle Tone: **normal or flaccid**

Thank the "volunteer" for their help with the Inhalant effects.

Session 22 - Overview of Signs and Symptoms

Cannabis Effects



Drug Recognition Expert Course 22-18


Cannabis

Select another volunteer to help with the Cannabis category effects.

Correct the participant's responses as necessary, and write the correct effects under the "Cannabis" column.

- HGN: **none** (not present)
- VGN: **none** (not present)
- Lack of Convergence: **present**
- Pupil Size: **dilated or possibly normal (within the DRE average ranges)**
- Reaction to Light: **normal**
- Pulse Rate: **up**
- Blood Pressure: **up**
- Body Temperature: **normal (within the DRE average ranges)**

Thank the "volunteer" for their help with the Cannabis effects.



Solicit participants' comments or questions about the drug categories.

Drug Symptomatology Sources

Refer participants to the addendum at the end of this session; describing some available scientific literature dealing with drug influence symptomatology. The sources are considered to be reliable sources of drug symptomatology.

Note: Literature on LOC was approved for addition into the addendum by the IACP Technical Advisory Panel (TAP), November 2008.

Stress that not all symptoms associated with a drug category will be observed in all subjects in all cases. The excerpts from the references are consistent with DRE instruction and experience.

**COMPARISON OF DRE SYMPTOMATOLOGY
WITH CROSS SECTION OF DRUG SYMPTOMATOLOGY SOURCES**

CNS DEPRESSANTS:

DRE Symptomatology:

Nystagmus	decreased pulse
decreased blood pressure	uncoordinated
disoriented	sluggish
thick slurred speech	drunk-like appearance

The Pharmacological Basis of Therapeutics, Seventh Edition, Gilman, A.; Goodman, I.; MacMillan Publishing Co. 1985, Barbiturates, pages 546-547:

Nystagmus	Strabismus
difficulty in visual accommodation	
vertigo	ataxia gait
positive Romberg sign	Hypotonia
Dysmetria	Diplopia
sluggishness	difficulty in thinking
slowness, slurring of speech	poor comprehension
poor memory	faulty judgement
emotional lability	

A Primer of Drug Action, Julien, Robert M. W.H. Freeman and Company, New York, 8 Ed. 1997.

Drug and Alcohol Abuse, A Clinical Guide to Diagnosis and Treatment, (3rd Ed. , Schuckit, M.D., Mark A. Plenum Medical Book Co, New York 1989. p.19.

Encyclopedia of Drug Abuse, O'Brien, Robert; Cohen, Sydney. M.D. Facts on File, INC New York (1984), page 36: barbiturates effects like alcohol (staggering, poor motor control).

Drug Abuse and Dependence, Grinspoon, Lester,MD; Bakalar,James B., Harvard Medical School Mental Health Review No. 1 (1990), page 11: sedative hypnotics same as alcohol and other depressants

Drugs of Abuse, Giannini, A. James, M.D.; Slaby, Andrew E. M.D., Ph.D. Medical Economics Books, Oradell, New Jersey (1989), page 72: Benzodiazepines same as barbiturate effects; pages 247; 292): Barbiturates:

Nystagmus	depressed pulse
depressed blood pressure	diminished concentration
incoordination	decreased reaction time

Manual of Drug and Alcohol Abuse. Guidelines for Teaching in Medical and Health Institutions, ed Arif, Awni. M.D., Westermeyer, Joseph, M.D.. Ph.D..D Plenum Medical Book Company, New York (1988), p. 135.

Diagnostic and Statistical Manual of Mental Disorders (Third Ed, Revised), American Psychiatric Association (1987), p. 159

Maladaptive behavioral changes, e.g., disinhibition of sexual or aggressive impulses, mood lability, impaired judgment, impaired social or occupational functioning.

slurred speech
unsteady gait

incoordination
impairment in attention or memory

CNS STIMULANTS:

DRE Symptomatology:

dilated pupils
increased temperature
body tremors
excited
talkative
anxiety
redness to nasal area
loss of appetite
increased alertness

increased pulse rate
increased blood pressure
restlessness
euphoric
exaggerated reflexes
grinding teeth
runny nose
insomnia

The Pharmacological Basis of Therapeutics, Seventh Edition,

Gilman, A.; Goodman, I.; MacMillan Publishing Co. 1985, Cocaine 551-554

Medical Toxicology-Diagnosis and Treatment of Human Poisoning, Ellenhorn, Matthew J., Barceloux, Donald G. Elsevier Science Pub. Co. 1988, Amphetamines, Page 634:

Mild influence:

Mydriasis
restlessness
irritability
tremor
Diaphoresis
nausea
pallor

hyperreflexia
talkativeness
insomnia
flushing
combativeness
vomiting
dry mucous membranes

Moderate:

hyperactivity
hypertension
Tachycardia
chest discomfort
abdominal pain
mild temperature
elevation
repetitive behavior
panic reactions

confusion
Tachypnea
premature ventricular contraction
vomiting
Profuser Diaphoresis

impulsivity
hallucinations

Serious:	
delirium	marked Hypertension/Tachycardia
Hyperreflexia	convulsions
Hypotension	coma

Cocaine, page 650-659

Early Stimulation:	
euphoria	Garrulity
excitement	apprehension
irritable behavior	Mydriasis
sudden headache	nausea
vomiting	dizziness
twitching of small muscles	tics
tremor	jerks
Cocaine Psychosis	hallucinations
elevation of pulse	increased respiration

Advanced:	
convulsions	Hyperreflexia
decreased consciousness	increased pulse and blood pressure

Later Stages:	
Hypotension	Hypothermia
Dyspnea et al	

A Primer of Drug Action, Julien, Robert M. W.H. Freeman and Company, New York, 1992, pages 120-123: Amphetamines and cocaine (CNSS):

dilation of pupils	increased blood pressure
slight tremor	restlessness
agitation	possibly hallucinations

Drug and Alcohol Abuse, A Clinical Guide to Diagnosis and Treatment, (3rd Ed. , Schuckit, M.D., Mark A. Plenum Medical Book Co, New York 1989, page 99: CNSS cause:

dilation of pupils	rapid heart rate
elevation of blood pressure	tremor in hands
increased body temperature	restlessness

Encyclopedia of Drug Abuse, O'Brien, Robert; Cohen, Sydney. M.D. Facts on File, INC New York (1984), pages 25, 121: Amphetamine:

dilation of pupils	increase heart rate
blood pressure	flushing
teeth grinding	dry mouth
tremors	lack of coordination

pages 64, 100, 121:

dilation of pupils	increased heartbeat
increased temperature	similar to Amphetamine

Drug Abuse and Dependence, Grinspoon, Lester, MD; Bakalar, James B., Harvard Medical School Mental Health Review No. 1 (1990), pages 8 and 10 Cocaine and Amphetamine:

dilated pupils	increased pulse
increased blood pressure	vasoconstriction
agitation tremors	increased temperature

Drugs of Abuse, Giannini, A. James, M.D.; Slaby, Andrew E. M.D., Ph.D. Medical Economics Books, Oradell, New Jersey (1989), page 29 Amphetamines:

pupil dilation (Mydriasis)	increased pulse rate
elevated blood pressure	hyperactive
talkative	irritable
restless	Anorexia
tremors	urinary retention
teeth grinding (Bruxism)	fidgety, jerky, random motions
illogical, loose thoughts	

Page 295: Cocaine:

dilated pupils	Tachycardia
increased blood pressure	vasoconstriction
Hyperpyrexia	

Manual of Drug and Alcohol Abuse, Guidelines for Teaching in Medical and Health Institutions, ed Arif, Awni. M.D., Westermeyer, Joseph, M.D.. Ph.D..D Plenum Medical Book Company, New York (1988) page 142: Amphetamine:

increased pulse	increased blood pressure
possibly increased temperature	increased wakefulness
general increase in psychomotor activity	

page 145: Cocaine

Mydriasis (dilated pupils);	may cause psychosis
euphoria	agitation

Diagnostic and Statistical Manual of Mental Disorders (Third Ed, Revised), American Psychiatric Association (1987), p. 142.

COCAINE:

Maladaptive behavioral changes, e.g., euphoria, fighting, grandiosity, hyper-vigilance, psychomotor agitation, impaired judgment, impaired social or occupational functioning.

pupillary dilation	Tachycardia
elevated blood pressure	perspiration or chills
nausea or vomiting	visual or tactile hallucinations

AMPHETAMINE:

Maladaptive behavioral changes, e.g., fighting, grandiosity, hyper-vigilance, psychomotor agitation, impaired judgment, impaired social or occupational functioning.

pupillary dilation	Tachycardia
elevated blood pressure	perspiration or chills
nausea or vomiting	

HALLUCINOGENS:

DRE Symptomatology:

dilated pupils	increased pulse rate
increased blood pressure	increased temperature
dazed appearance	body tremors
Synesthesia	hallucinations
paranoia	uncoordinated
nausea	disoriented
difficulty in speech	perspiring
poor perception of time/distance	

The Pharmacological Basis of Therapeutics, Seventh Edition, Gilman, A.; Goodman, I.; MacMillan Publishing Co. 1985, LSD and Related Drugs, page 564

pupillary dilation	increased blood pressure
Tachycardia	Hyperreflexia
tremor	nausea
Piloerection	muscular weakness
increased body temperature	hallucinations
Hyper vigilance	Synesthesia
loss of boundaries	

Medical Toxicology-Diagnosis and Treatment of Human Poisoning, Ellenhorn, Matthew J., Barceloux, Donald G. Elsevier Science Pub. Co. 1988, LSD, pages 667-669:

pupillary dilation	increased heart rate
increased body temperature	Piloerection
weakness	tremor
Hyperreflexia	Ataxia
hallucinations	depersonalization
poor judgment	mood swings

A Primer of Drug Action, Julien, Robert M.; W. H. Freeman and Company, New York, 1992

Drug and Alcohol Abuse, A Clinical Guide to Diagnosis and Treatment, (3rd Ed.), Schuckit, M.D., Mark A. Plenum Medical Book Co, New York 1989 page 160:

dilated pupils	increased blood pressure
increased awareness	faltered body images
sensory input	fine tremor
flushed face	increased body temperature

Encyclopedia of Drug Abuse, O'Brien, Robert; Cohen, Sydney. M.D. Facts on File, Inc New York (1984), pages 100; 115 120, 153): Hallucinogens:

dilated pupils	increased heart rate
increased blood pressure	increased temperature
profuse perspiration	loss of appetite
hallucinations	

Drug Abuse and Dependence, Grinspoon, Lester, MD; Bakalar, James B., Harvard Medical School Mental Health Review No. 1 (1990)

Drugs of Abuse, Giannini, A. James, M.D.; Slaby, Andrew E. M.D., Ph.D. Medical Economics Books, Oradell, New Jersey (1989), page 218: LSD:

Ataxia	high blood pressure
Hyperreflexia	incoordination
Tachycardia	

Manual of Drug and Alcohol Abuse. Guidelines for Teaching in Medical and Health Institutions, ed Arif, Awni. M.D., Westermeyer, Plenum Medical Book Company, New York (1988)

Diagnostic and Statistical Manual of Mental Disorders (Third Ed, Revised), American Psychiatric Association (1987), p. 145.

Maladaptive behavioral changes, e.g., marked anxiety or depression, ideas of reference, fear of losing one's mind, paranoid ideation, impaired judgment, impaired social or occupational functioning.

Perceptual changes occurring in a state of full wakefulness and alertness, e.g., subjective intensification of perceptions, depersonalization, derealization, illusions, hallucinations, Synesthesia

pupillary dilation	Tachycardia
sweating	palpitations
blurring of vision	tremors
incoordination	

DISSOCIATIVE ANESTHETICS (PHENCYCLIDINE)

DRE Symptomatology:

Nystagmus	increased pulse
increased blood pressure	increased temperature
perspiring	warm to the touch

blank stare	early onset of nystagmus
"moon walking"	difficulty in speech
incomplete responses	repetitive response
repetitive speech	increased pain threshold
cyclic behavior	confused, agitated
hallucinations	possibly violent and combative

The Pharmacological Basis of Therapeutics, Seventh Edition, Gilman, A.; Goodman, I.; MacMillan Publishing Co. 1985, PCP, page 565-567

Nystagmus	elevated heart rate
elevated blood pressure	feeling of intoxication
staggering gait	slurred speech
numbness of extremities	sweaty
muscular rigidity	blank stare
drowsiness	hostile behavior
repetitive movements	

Medical Toxicology-Diagnosis and Treatment of Human Poisoning, Ellenhorn, Matthew J., Barceloux, Donald G. Elsevier Science Pub. Co. 1988, PCP 768-777:

Nystagmus	Miosis
depressed light reflexes	blurred vision
diminished pain	Ataxia
tremors	muscle weakness
slurred speech	drowsiness
increased pulse rate	increased blood pressure
Amnesia	anxiety/agitation
body image distortion	euphoria
depersonalization	disordered thought processes
hallucinations	

A Primer of Drug Action, Julien, Robert M. W.H. Freeman and Company, New York, 1997, page 262: PCP:

increased blood pressure	blank stare
disinhibition	mood swings
muscle rigidity	agitation
delirium excitement	disorientation
hallucinations	analgesia
speech difficulty	pain tolerance
elevated blood pressure	

Drug and Alcohol Abuse, A Clinical Guide to Diagnosis and Treatment, (3rd Ed.), Schuckit, M.D., Mark A. Plenum Medical Book Co, New York 1989 p. 178

sweating	muscle rigidity
fever convulsions	increased blood pressure

Encyclopedia of Drug Abuse, O'Brien, Robert; Cohen, Sydney. M.D. Facts on File, INC New York (1984), page 100, 208: PCP:

Nystagmus	increased blood pressure
increased pulse rate	flushing
mood swings	hallucinations
changes in body awareness	speech difficulties
violent behavior	decreased responsiveness

Drug Abuse and Dependence, Grinspoon, Lester, M.D.; Bakalar, James B., Harvard Medical School Mental Health Review No. 1 (1990), page 25: PCP:

body image distortions	increased blood pressure
Nystagmus	muscle rigidity
loss of muscle control	incoherent speech
memory loss drooling	blank stare

Drugs of Abuse, Giannini, A. James, M.D.; Slaby, Andrew E. M.D., Ph.D. Medical Economics Books, Oradell, New Jersey(1989) page 296: PCP:

Nystagmus	disorientation
hallucination	extreme agitation
loss of motor control	disassociation from
automated speech	environment
Nystagmus at rest	

Manual of Drug and Alcohol Abuse. Guidelines for Teaching in Medical and Health Institutions, ed Arif, Awni. M.D., Westermeyer, Joseph, M.D. Ph.D.D Plenum Medical Book Company, New York (1988), page 156: PCP:

Ataxia	tremors,
muscular hypertonicity	Hyperreflexia
Ptosis	Tachycardia
Horizontal Gaze, Vertical Gaze and Rotary Nystagmus	
elevated blood pressure	
mood swings	

Diagnostic and Statistical Manual of Mental Disorders (Third Ed, Revised), American Psychiatric Association (1987), p. 155.

Maladaptive behavioral changes, e.g., belligerence, assaultiveness, impulsiveness, unpredictability, psychomotor agitation, impaired judgment, impaired social or occupational functioning.

Vertical or Horizontal Gaze Nystagmus
increased blood pressure or heart rate
numbness or diminished responsiveness to pain.

Ataxia
Dysarthria (slurred speech)
muscle rigidity
seizures
Hyperacusis

NARCOTICS:

DRE Symptomatology:	
constricted pupils	decreased pulse rate
decreased blood pressure	decreased temperature
Ptosis (droopy eyelids)	"on the nod"
drowsiness	depressed reflexes
low, raspy speech	dry mouth
facial itching	euphoria
fresh puncture marks	

The Pharmacological Basis of Therapeutics, Seventh Edition, Gilman, A.,; Goodman, I.; MacMillan Publishing Co. 1985, Opioids page 541-545

Medical Toxicology-Diagnosis and Treatment of Human Poisoning, Ellenhorn, Matthew J., Barceloux, Donald G. Elsevier Science Pub. Co. 1988; Heroin, pages 702-703. See also Methadone, Demerol, etc.:

A Primer of Drug Action, Julien, Robert M. W.H. Freeman and Company, New York, 1997: Morphine:

constricted pupils	decreased blood pressure
drowsiness	Dysphoria
mental clouding	sedation
depressed respiration	Analgesia
euphoria	

Drug and Alcohol Abuse, A Clinical Guide to Diagnosis and Treatment, (3rd Ed., Schuckit, M.D., Mark A. Plenum Medical Book Co, New York 1989

Decrease pain (p.6)

Encyclopedia of Drug Abuse, O'Brien, Robert, Cohen, Sydney. M.D. Facts on File, INC New York (1984) page 100, 120, 123, 124: Narcotics:

constricted pupils	reduced heart rate
Analgesia	depressed appetite
euphoria	going "on the nod"

Drug Abuse and Dependence, Grinspoon, Lester,MD; Bakalar,James B., Harvard Medical School Mental Health Review No. 1 (1990), page 14: Narcotics:

constricted pupils	"nodding off"
--------------------	---------------

dreamy state
euphoria

pain suppression

Drugs of Abuse, Giannini, A. James, M.D.; Slaby, Andrew E. M.D., Ph.D. Medical Economics Books, Oradell, New Jersey (1989) page 293 - 294:

Miosis (constricted pupils)	Bradycardia
Hypothermia (decreased temperature)	(decreased heart beat)
drowsiness lethargy	euphoria/dysphoria
flaccid muscle tone	confusion
Analgesia	depressed respiration

Manual of Drug and Alcohol Abuse, Guidelines for Teaching in Medical and Health Institutions, ed Arif, Awni. M.D., Westermeyer, Joseph, M.D.. Ph.D..D Plenum Medical Book Company, New York (1988), page 132

Miosis (constricted pupils)	low blood pressure
itching	flushing sweating

Diagnostic and Statistical Manual of Mental Disorders (Third Ed, Revised), American Psychiatric Association (1987), p. 152.

Maladaptive behavioral changes, e.g., initial euphoria followed by apathy, dysphoria, psychomotor retardation, impaired judgment, impaired social or occupational functioning.

pupillary constriction	drowsiness
slurred speech	impairment in attention or memory

INHALANTS: (Toluene)

DRE Symptomatology:	
Nystagmus	increased pulse rate
increased blood pressure	residue around nose
odor on mouth	nausea disorientation
slurred speech	confusion

The Pharmacological Basis of Therapeutics, Seventh Edition, Gilman, A.; Goodman, I.; MacMillan Publishing Co. 1985, Inhalants, page 567

Drug and Alcohol Abuse, A Clinical Guide to Diagnosis and Treatment, (3rd Ed. , Schuckit, M.D., Mark A. Plenum Medical Book Co, New York 1989. p. 185

decreased inhibitions	floating sensation
drowsiness	light sensitivity
sneezing runny nose	

Encyclopedia of Drug Abuse, O'Brien, Robert; Cohen, Sydney. M.D. Facts on File, INC New York (1984)

lowered inhibitions
incoordination confusion
nausea

restlessness
disorientation
impaired judgment

Drug Abuse and Dependence, Grinspoon, Lester, MD; Bakalar, James B., Harvard Medical School Mental Health Review No. 1 (1990)

Drugs of Abuse, Giannini, A. James, M.D.; Slaby, Andrew E. M.D., Ph.D. Medical Economics Books, Oradell, New Jersey (1989), pages 265, 272, 297: Toluene:

nystagmus
tremors cerebellar
rambling speech
light headedness
CNS depression that mimics Ataxia
Narcotic Analgesics
blank stare
euphoric mood

mental dulling
Ataxia
irritability
tremors

Manual of Drug and Alcohol Abuse, Guidelines for Teaching in Medical and Health Institutions, ed Arif, Awni. M.D., Westermeyer, Joseph, M.D.. Ph.D..D Plenum Medical Book Company, New York (1988)

brief euphoria
giddy intoxication, similar to alcohol
CNS depression (volatile solvents/toluene)
dizziness
Vertigo

Diagnostic and Statistical Manual of Mental Disorders (Third Ed, Revised), American Psychiatric Association (1987), p. 149.

Maladaptive behavioral changes, e.g., belligerence, assaultiveness, apathy, impaired judgment, impaired social or occupational functioning.

Nystagmus
incoordination
unsteady gait
depressed reflexes
tremor generalized muscle
stupor or coma
euphoria

dizziness
slurred speech
lethargy
psychomotor retardation
blurred vision or diplopia
weakness

CANNABIS

DRE Symptomatology:
dilated pupils
odor of Marijuana
body tremors

marked reddening of conjunctivae
debris in mouth
eyelid tremors

relaxed inhibitions
paranoia
impaired perception of time and distance

increased appetite
disorientation

The Pharmacological Basis of Therapeutics, Seventh Edition, Gilman, A.; Goodman, I.; MacMillan Publishing Co. 1985, Cannabis, pages 559-561

euphoria
temporal disintegration
information processing impairment
dry mouth

short term memory impairment
balance and stance impairment
increased hunger
additive to alcohol

Lower doses

affects perception, impairing well beyond when subject subjectively feels effects; alters all information processing; relatively simple motor skills unaffected

High doses:

anxiety
increased heart rate
marked reddening of Conjunctiva

hallucinations
increased systolic blood pressure
simple motor skills affected

Medical Toxicology-Diagnosis and Treatment of Human Poisoning, Ellenhorn, Matthew J., Barceloux, Donald G. Elsevier Science Pub. Co. 1988; Cannabis, page 678-681

reddening of Conjunctiva
motor coordination impairment
relaxation
temporal distortion
(time slows)
impairment of motor tasks and
reaction times requires higher
dosages
loss of short term memory
systematic thinking impaired
dry mouth

alteration in mood
euphoria
sleepiness
decrease in balance, steadiness and
muscle strength

elective attention
stimulated appetite

A Primer of Drug Action, Julien, Robert M. W.H. Freeman and Company, New York, 1997, Marijuana

reddening of Conjunctiva
increased blood pressure
dry mouth
altered sensory perception

Drug and Alcohol Abuse, A Clinical Guide to Diagnosis and Treatment, (3rd Ed. , Schuckit, M.D., Mark A. Plenum Medical Book Co, New York 1989, page 145: Cannabis:

red Conjunctiva
relaxation

euphoria
dry mouth

increased heart rate	possibly Nystagmus
time distortion	short term memory
impairment in ability to do	tremors
multi-step tasks	
decrease level of motor coordination	

Encyclopedia of Drug Abuse, O'Brien, Robert; Cohen, Sydney. M.D. Facts on File, INC New York (1984), pages 100, 120: Marijuana:

red eye	increased appetite
increased heart beat	time and space distortions
dryness of mouth and throat	increased heart rate
increased pulse rate	lack of coordination

Drug Abuse and Dependence, Grinspoon, Lester, MD; Bakalar, James B., Harvard Medical School Mental Health Review No. 1 (1990).page 19: Marijuana:

increased appetite	faster heartbeat
bloodshot eyes	confusion
agitation	incoordination
hallucinations	

Drugs of Abuse, Giannini, A. James, M.D.; Slaby, Andrew E. M.D., Ph.D. Medical Economics Books, Oradell, New Jersey(1989), page 296: Cannabis:

red Conjunctiva	increased appetite
pleasant relaxation	intensification of sensations
slowed time	passivity
apathy	Tachycardia (increased heart rate)
problems with motor coordination	

Manual of Drug and Alcohol Abuse, Guidelines for Teaching in Medical and Health Institutions, ed Arif, Awni. M.D., Westermeyer, Joseph, M.D.. Ph.D..D Plenum Medical Book Company, New York (1988), page 147: Cannabis:

red Conjunctiva	increased hunger
changes in time sense	short-term memory loss
memory	dry mouth
coordination	Tachycardia (rapid heart beat)
balance and stance	elevated systolic pressure affected

Diagnostic and Statistical Manual of Mental Disorders (Third Ed, Revised), American Psychiatric Association (1987), p. 140.

Maladaptive behavioral changes, e.g., euphoria anxiety, suspiciousness, or paranoid ideation, sensation of slowed time, impaired judgment, social withdrawal.

red Conjunctiva	increased appetite
Tachycardia (rapid heart)	dry mouth

LACK OF CONVERGENCE:

Clinical Procedures for Ocular Examination, Kurtz and Carlson; McGraw-Hill Medical, 3rd Edition, September 26, 2003.

A Recognized Clinical Trial of Treatment for Convergence Insufficiency in Children, Scheiman, Cotter, Cooper, et al, Arch Ophthalmology, Jan 2005.

Session 23

Curriculum Vitae Preparation and Maintenance



Session 23 - Curriculum Vitae Preparation and Maintenance

Learning Objectives

- Describe and discuss the purpose of the DRE Curriculum Vitae
- Identify the elements of a DRE Curriculum Vitae
- Prepare a basic Curriculum Vitae summarizing relevant training, education, experience and accomplishments to date
- Update and extend the Curriculum Vitae as relevant achievements continue to expand




Drug Recognition Expert Course 23-2

Briefly review the objectives, content segments and learning activities of this session.

Upon successfully completing this session the participant will be able to:

- Describe and discuss the purpose of the DRE Curriculum Vitae.
- Identify the elements of a DRE Curriculum Vitae.
- Prepare a basic Curriculum Vitae summarizing their relevant training, education, experience, and accomplishments to date.
- Update and extend the Curriculum Vitae, as relevant achievements continue to expand.

CONTENT SEGMENTS

- A. Purpose of the Curriculum Vitae
- B. Preparation for Court Qualification
- C. Curriculum Vitae Content
- D. Guidelines for Curriculum Vitae Preparation and Maintenance

LEARNING ACTIVITIES

- Instructor Led Presentations
- Group Work Session
- Reading Assignments

Session 23 - Curriculum Vitae Preparation and Maintenance

Witness

- **Generally can testify only to personal knowledge - facts which they observed or witnessed**
- **Cannot give an opinion**





Drug Recognition Expert Course
23-3

A. Purpose of the Curriculum Vitae

The basic purpose of the Curriculum Vitae is to record education, training, and experience in a single document for use in establishing qualifications when testifying in court.

Generally a witness can testify only to personal knowledge.

Point out that this generally consists of facts which they observed or witnessed.

Witness cannot give an opinion on a matter.

Point out that opinions are allowed only if the witness is qualified as an expert.

Session 23 - Curriculum Vitae Preparation and Maintenance

Expert Witness

- **Basic rule - person skilled in some art, trade, science, or profession, having knowledge of matters not within knowledge of persons of average education, learning and experience**
- **May assist jury in arriving at a verdict by expressing an opinion on a state of facts shown by the evidence and based upon their special knowledge**



Drug Recognition Expert Course 23-4

Basic rule is that a person skilled in some art, trade, science, or profession, having a knowledge of matters not within the knowledge of persons of average education, learning and experience, may assist the jury in arriving at a verdict by expressing an opinion on a state of facts shown by the evidence and based upon his or her special knowledge.

Source: People vs. Willis, 70 Cal APP. 465

A witness is not qualified as an expert witness unless it is shown he or she is familiar with the subject upon which he or she is asked to give an opinion.

Source: People vs. McLean, 56 Cal 2d 660

Session 23 - Curriculum Vitae Preparation and Maintenance

Expert Witness (Cont.)

ONLY the court can determine whether a witness is qualified to testify as an expert



Drug Recognition Expert Course 23-5

Only the court can determine whether a witness is qualified to testify as an expert.

Where a witness is qualified to give expert testimony, any question as to degree of knowledge goes to weight rather than admissibility.

Source: *People vs. Perry*, 44 Cal 2d 861

Session 23 - Curriculum Vitae Preparation and Maintenance

Voir Dire:

To seek the truth
(Literally, "To see, to say")



Drug Recognition Expert Course

23-6

Witnesses' qualification is achieved through Voir Dire Examination.

Voir Dire – literally, French for “to see, to say;” loosely translated as “to seek the truth.”

Session 23 - Curriculum Vitae Preparation and Maintenance

Preparation for Court Qualification

- Can be simple or complex
- Good “credentials” help your testimony weight
- Accurate, up to date information is essential



Drug Recognition Expert Course 23-7

B. Preparation for Court Qualification

Being qualified as an expert may be as simple as stating your occupation, or take several hours of exhausting questioning by both the prosecutor and the defense attorney.

Although knowledge only greater than what the public has is required to qualify you as an expert, your testimony will carry much more “weight” if you have good credentials.

Accurate, up-to-date information is essential for an officer who is called upon to give his or her qualification as an expert in any field.

Point out that it is imperative that each officer maintain an ongoing Curriculum Vitae to establish their credentials as an expert.

Session 23 - Curriculum Vitae Preparation and Maintenance

Expertise/Qualifications

Based on:

- **Formal education and training**
- **Experience**
- **Outside readings and studies**



Drug Recognition Expert Course

23-8

Drug Recognition Experts will base their expertise on the following areas:

- Formal education and training
- Relevant experience
- Outside readings and studies

Session 23 - Curriculum Vitae Preparation and Maintenance

Curriculum Vitae Content

Formal Education

- **High Schools attended**
- **Colleges and Universities attended**
- **University level courses**
- **Specialized College**





Drug Recognition Expert Course 23-9

C. Curriculum Vitae Content

Formal Education

- High School(s) attended
List dates – highlight classes which provided knowledge in the area of drugs.
- Colleges and Universities attended
List dates, instructor, subject(s) covered, credits, etc.
- University level courses
List dates, instructor, subject(s) covered, credits, etc.
- Specialized College
List dates, length, major topics covered, etc. Highlight classes which provided knowledge or skills in the area of drugs.

Session 23 - Curriculum Vitae Preparation and Maintenance

Curriculum Vitae Content

Formal Training

- **Police Academy (recruit training)**
- **Specialized police or in-service training**
- **Other specialized training**
- **Military training**
- **Lectures and seminars**








Drug Recognition Expert Course

23-10

Formal Training

- Police Academy (recruit training).
- Specialized police training or in-service training.
List dates, length, instructor(s), subject(s) covered, etc. Highlight training which provided knowledge or skills in the area of drugs.
- Other specialized training.
- Military training.
- Lectures and seminars.
List dates, length, instructor(s), subject(s) covered, etc. Highlight training which provided knowledge or skills in the area of drugs.

Session 23 - Curriculum Vitae Preparation and Maintenance

Curriculum Vitae Content (Cont.)

Experience





Drug Recognition Expert Course

23-11

Experience

- Job experience – years.
List dates, division, duties, etc., include loans to specialized units.
- Assignments.
- List agencies, dates, assignments, etc.
- Prior law enforcement experience.
List employer, dates, duties, assignments, etc. which provided experience in the area of drugs.
- Other job related experience.

Drug enforcement/ evaluation experiences:

- Total vehicle stops
- Total DWI investigations
- Total DWI arrests
- Total drug evaluations
- Total filings
- Total convictions

Point out that it is important to maintain accurate records of all enforcement activities; documentation of the ratio of stops to investigations and investigations to arrests is essential. Not all stops result in arrests; demonstrate that the officer is fair and impartial and that each case is decided on individual merits.

Session 23 - Curriculum Vitae Preparation and Maintenance

Curriculum Vitae Content (Cont.)

Prior testimony

- **Municipal court**
- **Superior court**
- **Number of times qualified as an expert in drug cases**
- **Number of times qualified as an expert in other cases**





Drug Recognition Expert Course 23-12

Prior Testimony


- Municipal court
- Superior court
- Number of times qualified as an expert in drug cases
- Number of times qualified as an expert in other cases

For bulleted items above: list dates, courts, judges, charges, areas qualified, etc.

Session 23 - Curriculum Vitae Preparation and Maintenance

Curriculum Vitae Content (Cont.)

Outside Readings and Studies



Drug Recognition Expert Course

23-13

Outside Reading and Studies

- Drug related texts read.
- List title(s), author(s), subject(s), etc.
- Departmental training bulletins.
- Journals.
- Research papers.
- Drug related videos viewed.

Session 23 - Curriculum Vitae Preparation and Maintenance

Curriculum Vitae Content (Cont.)

Training/Research Conducted





Drug Recognition Expert Course

23-14


Training or Research Conducted (if applicable)

List classes, briefings, training officer assignments, etc. where you served as an instructor or coach, etc. or conducted or participated in research, e.g. Alcohol Workshop.

Session 23 - Curriculum Vitae Preparation and Maintenance

Curriculum Vitae Content (Cont.)

Published Works



Drug Recognition Expert Course

23-15

Published Works (if applicable)

List all relevant writings that you authored or co-authored, including departmental briefing papers, training manuals/bulletins, magazine articles, books, etc.

Session 23 - Curriculum Vitae Preparation and Maintenance

Curriculum Vitae Preparation and Maintenance

- List information in chronological order
- Review and update Curriculum Vitae frequently and record date of review



Drug Recognition Expert Course

23-16

D. Guidelines for Curriculum Vitae Preparation and Maintenance

Refer participants to sample Curriculum Vitae's in their manuals and review steps for preparing the Curriculum Vitae and keeping it up-to-date.

- List information in chronological order.
- Review and update Curriculum Vitae frequently and record date of review.

Review the sample Curriculum Vitae's briefly with the participants.

Session 23 - Curriculum Vitae Preparation and Maintenance

QUESTIONS?



Drug Recognition Expert Course

Solicit participants' comments or questions about Curriculum Vitae Preparation and Maintenance.

Sgt. David C. Regan

Introduction

Sergeant David Carroll Regan is a supervisor in the Traffic Division, Shelton Police Department. He currently commands the special Impaired Driving Enforcement Activities Squad (IDEAS), a unit he was instrumental in forming. Sgt. Regan is a 15 year veteran of law enforcement. Prior to joining the Shelton Police Department ten years ago, he served for five years as a deputy with the Fairfield County Sheriff's Department.

Sergeant Regan has been assigned to the Traffic Division since his promotion to sergeant on 11/18/YY. His duties have included coordination of speed and DWI enforcement activities, the Joint Shelton-Derby Task Force for Sobriety Checkpoints, the Officer Friendly Program, the Motorcycle Safety Education Project, and general supervision of Traffic Division officers. He also serves as the Department's principal instructor for radar speed measurement, Standardized Field Sobriety Testing and Drug Recognition Expert training.

Sergeant Regan holds a Bachelor's Degree in the Administration of Justice from Fairfield University, and currently is a candidate for a Master's Degree in Police Science and Administration at the University of Stratford. He also holds an Instructor Certificate from the State Law Enforcement Training Board.

Sergeant Regan has served on two committees of the Governor's Task Force to Prevent Drunk Driving: The Standardized Field Sobriety Tests Committee and The Paperwork Reduction Committee. The one page Standard Notetaking Guide for Field Sobriety Testing that is employed by all departments statewide was designed by him.

Law Enforcement Experience

11/18/YY to Present	Sergeant, Traffic Division Shelton Police Department Supervisor, IDEAS Unit Drug Recognition Expert Program Coordinator
7/8/ZZ to 11/17/YY	Patrol Officer First Class Training and Operations Shelton Police Department Unit Supervisor, Traffic Law Enforcement Training Branch
9/11/XX to 7/7/ZZ	Patrol Officer Third Precinct, Motorcycle Shelton Police Department

Sgt. David C. ReganLaw Enforcement Experience (continued)

11/5/MM to 9/10/XX	Patrol Officer First Precinct Shelton Police Department
10/10/NN to 11/4/MM	Deputy Traffic Patrol Fairfield County Sheriff's Department

Special Police Training

10/XX	NHTSA/IACP DRE Instructor Training (Certified as a DRE Instructor on 11/12/XX)
8/XX	Drug Enforcement Administration Drug Interdiction Seminar
11/YY	NHTSA/IACP Drug Evaluation and Classification Training: DRE School (Certified as a DRE on 1/28/XX)
10/YY	NHTSA/IACP Drug Evaluation and Classification Training: PRE School
3/YY	Southeastern University Institute of Police Technology Special Conference: Managing DWI Squads
4/ZZ	International Association of Chiefs of Police Instructor Training in Horizontal Gaze Nystagmus and Divided Attention Field Sobriety Tests
10/MM	University of Stanford, Northern Police Institute Standardized Field Sobriety Testing
6/NN	Acme Scientific Instruments, Inc. (Certified to perform inspection and repair of the Intoxotector J2Z breath testing instrument on 6/22/NN)

Sgt. David C. Regan

Court Qualification Record

8/VV	Qualified as Drug Recognition Expert in a case involving Phencyclidine impairment. (Judge Sally Grey, 8th District)
11/WW	Qualified as Drug Recognition Expert in a case involving a combination of CNS Stimulant and Narcotic Analgesic. (Judge Lewis Buchanan, Superior Court)
3/WW	Qualified as Drug Recognition Expert in a case involving Cannabis impairment. (Judge Sally Grey, 8th District)
9/UU	Qualified as Drug Recognition Expert in a case involving Narcotic Analgesic impairment. (Judge Jerome Byrnes, 8th District)

Specialized Readings

<u>Title</u>	<u>Author</u>
Drug and Alcohol Abuse	Marc A. Schuckit, M.D.
A Primer of Drug Action	Jerome Jaffee, Robert Petersen and Ray Hodgson
The Practitioner's Guide to Psychoactive Drugs	Ellen L. Bassuk, M.D. and Stephen C. Schoonover, M.D.
Drug Abuse: A Manual for Law Enforcement Officers	Smith, Kline & French (pub.)
Licit and Illicit Drugs	Edward M. Brecher
Chocolate to Morphine	Andrew Weil, M.D. and Winifred Rosen
Cocaine Addiction	U.S. Department of Health and Human Services
Marijuana Alert	Peggy Mann

SAMPLE Curriculum Vitae NUMBER TWO

TRUMBULL POLICE DEPARTMENT

The Curriculum Vitae of:

OFFICER ANN MARIE REED
Drug Recognition Expert

Latest Update: 4/25/YY

Officer Ann M. Reed

Introduction

Officer Ann Marie Reed is an eight year veteran with the Trumbull Police Department. She is currently assigned to the Special Operations Branch of the Administrative Division, where she serves as a Narcotics Enforcement Officer. Previously, she has served in the same Branch as a Vice Enforcement Officer, and as a patrol officer in the Department's first and second precincts.

Officer Reed is a graduate of Monroe College, with the Bachelor's Degree in Police Science and Administration. She is currently a candidate for the JD Degree at the Law School of the University of Bridgeport.

Law Enforcement Experience

5/12/VV to Present	Narcotics Enforcement Officer and Drug Recognition Expert Special Operations Branch Trumbull Police Department
3/26/WW to 5/11/VV	Vice Enforcement Officer Special Operations Branch Trumbull Police Department
9/23/XX to 3/25/WW	Patrol Officer First Precinct Trumbull Police Department
8/28/NN to 9/22/XX	Patrol Officer Second Precinct Trumbull Police Department
5/15/NN to 8/25/NN	Trainee Fairfield County Regional Police Academy (Graduated 8/25/NN)

Special Police Training

2/YY	University of Norwalk, Police Science Institute Seminar: Packaging and Transport of Illicit Drugs
10/VV	University of Norwalk, Police Science Institute Seminar: Suppression of Drug-related Crime
3/VV	NHTSA/IACP Drug Evaluation and Classification Training: DRE School (Certified as a DRE on 5/22/VV)

Officer Ann M. Reed

Special Police Training (Continued)

- 2/VV Fairfield County Regional Police Academy
Drug Evaluation and Classification Training: PRE-School
- 10/WW Fairfield County Regional Police Academy
Standardized Field Sobriety Testing

Publications Authored

Reed, Ann M. and Cockroft, Robert S., "Narcotics Enforcement Tactics for the Medium-sized Department"; The Police Chief. January 17, 19XX.

Reed, Ann M., Procedures for Requesting Drug Recognition Expert Services; Training Bulletin for the Trumbull Police Department. 6/VV.

Reed, Ann M., Recognizing the Heroin Addict; Training Bulletin for the Trumbull Police Department. 1/VV.

Court Qualification Record

- 11/WW Qualified as an expert witness for identification of Heroin impairment.
(Judge Michael Adkins, 7th District)
- 3/WW Qualified as a Drug Recognition Expert in a case involving a
combination of CNS Stimulant and Narcotic Analgesic. (Judge
Roberta Mayer, 7th District)
- 9/ZZ Qualified as an expert witness for identification of "track" marks.
(Judge Charles Peltier, 7th District)

Specialized Readings

<u>Title</u>	<u>Author</u>
Signs and Symptoms Handbook	Barbara McVan, M.D.
Drugs From A to Z	Richard R. Lingeman
Guide to Psychoactive Drugs	Richard Seymour and David E. Smith, M.D.
Addictions: Issues and Answers	Robert M. Julien, M.D.
Report on Synthetic China White: Fentanyl	Det. James Miller, LAPD

Session 24

Drug Combinations



Session 24- Drug Combinations

Learning Objectives

- **Explain the prevalence of polydrug use among drug impaired subjects and identify common combinations of drugs abused by those subjects**
- **Describe the possible effects that combinations of drugs can produce on the major indicators of drug impairment**




Drug Recognition Expert Course 24-2

Briefly review the objectives, content and activities of this session.

Upon successfully completing this session the participant will be able to:

- Explain the prevalence of polydrug use among drug impaired subjects and identify common combinations of drugs abused by those subjects.
- Describe the possible effects that combinations of drugs can produce on the major indicators of drug impairment.

CONTENT SEGMENTS

- A. The Prevalence of Polydrug Use
- B. Possible Effects of Drug Combinations
- C. Identifying Expected Indicators of Specific Combinations

LEARNING ACTIVITIES

Instructor-Led Presentations
 Interactive Discussions
 Workbook Exercise
 Video Presentations

Session 24- Drug Combinations

Learning Objectives (Cont.)

- Define the terms “Null”, “Overlapping”, “Additive” and “Antagonistic” as they relate to polydrug effects
- Identify specific effects that are most likely to be observed in persons under the influence of particular drug combinations



Drug Recognition Expert Course 24-3

- Define the terms “Null,” “Overlapping,” “Additive” and “Antagonistic” as they relate to polydrug effects.
- Identify the specific effects that are most likely to be observed in persons under the influence of particular drug combinations.

Session 24- Drug Combinations

What is Polydrug Use?

Ingesting drugs from two or more drug categories



Drug Recognition Expert Course

24-4

A. The Prevalence of Polydrug Use

Polydrug

Polydrug use means ingesting drugs from two or more drug categories.

Session 24- Drug Combinations

Prevalence of Polydrug Use

Los Angeles Field Validation Study (1985)

- **72% of suspects had two or more drug categories in them (including alcohol)**
- **45% had two or more drugs other than alcohol**



Drug Recognition Expert Course 24-5

Prevalence of Polydrug Use

It is actually more common for a DRE to encounter polydrug users than single drug users.

- In the Los Angeles Field Study (1985), 72% of the suspects had two or more drugs in them.

Point out that 81 of the 173 suspects (47%) in the Los Angeles Field Study had alcohol in combination with one or more other drugs.

- If we discount alcohol, nearly half (45%) of the Field Study suspects had two or more other drugs in them.

Session 24- Drug Combinations

Prevalence of Polydrug Use

The National DRE database indicates that approximately 35% of all DRE reported cases revealed two or more drug categories detected

 Source: NHTSA/IACP DRE Database (2012) 

Drug Recognition Expert Course 24-6

National DRE


2011-2012 data collected from the national DRE tracking database from DREs throughout the U.S. indicates that approximately 35% of all cases with toxicology resulted in two or more drug categories detected.

Emphasize: Not all states are represented in the database therefore, the 35% may be low. DRE's nationwide are required to enter their evaluations in the national DRE database. Contact your state coordinator.

Solicit participants' comments and questions about the prevalence of polydrug use.

Session 24- Drug Combinations

Common Combinations of Drugs



Cocaine and Cannabis



Cocaine and Heroin



PCP and Cannabis



Alcohol and practically anything else




Drug Recognition Expert Course 24-7

Common Combinations

- Cocaine and Cannabis.
- Cocaine and Heroin.
- PCP and Cannabis.

Many of the subjects you examine will be exhibiting the effects of two or more drugs acting together.

Session 24- Drug Combinations

Drug Combinations

- Cocaine and Heroin - “Speedball”
- PCP and Heroin - “Fireball”
- Crack and PCP - “Space base”
- Crack and Marijuana - “Primo”
- Crack and Methamphetamine - “Croak”




Drug Recognition Expert Course 24-8

B. Possible Effects of Drug Combinations

Combos

Let us examine the possible ways in which two or more drug categories might interact.

Some common combinations of drug categories and their street names include:

- Cocaine and Heroin - “Speedball”
- PCP and Heroin - “Fireball”
- Crack and PCP - “Space base”
- Crack and Marijuana - “Primo”
- Crack and Methamphetamine - “Croak”

Point out that there are hundreds of street names for drug combinations and the combinations vary and are always evolving.

Solicit drug combination street names from participants.

Session 24- Drug Combinations

The Effects of Drug Combinations on Major Indicators of Impairment

- Null Effect
- Overlapping Effect
- Additive Effect
- Antagonistic Effect



Drug Recognition Expert Course 24-9

There are four effects of drug combinations on major indicators of impairment:

- Null Effect
- Overlapping Effect
- Additive Effect
- Antagonistic Effect

Session 24- Drug Combinations

Null Effect

- **If neither drug affects a particular indicator of impairment, their combination also will not affect that indicator**
- **No action plus no action equals no action**



Drug Recognition Expert Course 24-10

Four Effects

- Null Effect

The first effect is called the “Null Effect.”

Clarify: “Null Effect” is the combination of no action plus no action equals no action.

Session 24- Drug Combinations

Null Effect (Cont.)

Example #1: HGN

- If neither drug affects HGN...

Example: Narcotic Analgesic and Cannabis

- (Neither category affects HGN)
- ...the combination should also not affect HGN, so HGN will not be present in this combination




Drug Recognition Expert Course 24-11

Example #1: HGN

- Neither drug affects HGN.

The combination would not result in HGN being present.

Point out a general principle: if neither drug affects a major indicator, the combination of those two drugs also will not affect that indicator.

Example #1 is called the Null Effect.

Clarification of “Null Effect” – the combination of no action plus no action equals no action.

Session 24- Drug Combinations

Null Effect (Cont.)

Example #2: Reaction to Light

- If neither drug affects reaction to light...

Example: Dissociative Anesthetics and Cannabis

- (Neither category affects the reaction to light)
- ...the combination will also not affect reaction to light, so reaction to light will be a normal response




Drug Recognition Expert Course 24-12

Example #2: Reactions to Light

Another example of the Null Effect:

Reaction to Light: neither drug affects reaction to light. Example: a Dissociative Anesthetic and Cannabis.

Ask participants to suggest a specific combination of drugs that will exhibit the Null Effect on Pupil Size.

Session 24- Drug Combinations

Null Effect (Cont.)

Example #3: Body Temperature

- If neither drug affects body temperature...

Example: CNS Depressants and Cannabis

- (Neither category affects the body temperature)
- ...the combination should also not affect body temperature, so body temperature will be in the DRE average range



Drug Recognition Expert Course 24-13

Example #3: Body Temperature

Another example of the Null Effect:

Body Temperature: neither a CNS Depressant nor Cannabis usually affects body temperature; the combination of the two leaves body temperature in the DRE average range.

Solicit participants' questions about the Null Effect.

Session 24- Drug Combinations

Overlapping Effect

- If one drug affects a particular indicator of impairment, and another drug has no effect on that indicator, the combination of those two drugs will affect the indicator, in the same way as the first drug alone
- Action plus no action equals action



Drug Recognition Expert Course 24-14

Overlapping Effect

The second effect is called the “Overlapping Effect.”

Clarify: “Overlapping Effect” - action plus no action equals action.

Session 24- Drug Combinations

Overlapping Effect (Cont.)

Example #1: Pupil Size

- One drug affects the pupil size, but the other does not

Example: CNS Stimulants and Dissociative Anesthetics

- (CNS Stimulants dilate pupils, Dissociative Anesthetics don't affect pupil size)
- Pupils should be dilated



Drug Recognition Expert Course 24-15

Example #1: Pupil Size

Example #1: one drug affects pupil size, but the other does not.

Example: CNS Stimulants and Dissociative Anesthetics. CNS Stimulants dilate pupils, Dissociative Anesthetics do not affect pupil size.

Therefore, pupils should be dilated.

Session 24- Drug Combinations

Overlapping Effect (Cont.)

Example #2: HGN

- One drug causes HGN, but the other does not

Example: CNS Depressants and Narcotic Analgesics

- (CNS Depressants cause HGN but Narcotic Analgesics don't)
- HGN should be present



Drug Recognition Expert Course 24-16

Example #2: HGN

(Prior to showing slide)

Ask a participant to give an example of a specific combination of drugs that will produce an “Overlapping Effect” on Horizontal Gaze Nystagmus.

HGN: a CNS Depressant will cause HGN, but Cannabis will not cause HGN; a person under the combined influence of a CNS Depressant and Cannabis will usually have HGN.

Session 24- Drug Combinations

Overlapping Effect (Cont.)

Example #3: Lack of Convergence

- One drug causes lack of convergence, but the other does not

Example: Dissociative Anesthetics and Hallucinogens

- (Dissociative Anesthetics cause lack of convergence, Hallucinogens don't)
- Lack of Convergence should be present




Drug Recognition Expert Course 24-17

Example #3: Lack of Convergence

Another example of the “Overlapping Effect”:

Lack of Convergence. Dissociative Anesthetics cause Lack of Convergence, Hallucinogens do not. Under the influence, lack of convergence should be present.

Ask a participant to give an example of a specific combination of drugs that will produce an “Overlapping Effect” on body temperature.

Session 24- Drug Combinations

Additive Effect

- If two drugs independently affect some indicator in the same way, their use in combination will also affect the indicator and the effect may be reinforced
- Action plus the same action produces reinforced action



Drug Recognition Expert Course 24-18

Additive Effect

The third effect is called the Additive Effect.

- If two drugs independently affect some indicator in the same way, their use in combination will also affect the indicator and the effect may be reinforced
- Action plus the same action produces reinforced action

Clarification of the “Additive Effect” – action plus the same action produces reinforced action.

Session 24- Drug Combinations

Additive Effect (Cont.)

Example #1: Pulse Rate

- Both drugs affect pulse rate in the same way

Example: Cannabis and Inhalants

- (Cannabis and Inhalants both elevate pulse rate)
- Pulse rate should be elevated



Drug Recognition Expert Course 24-19

Example #1: Pulse Rate

Pulse Rate. Cannabis and Inhalants both elevate pulse rate. Therefore, pulse rate should be elevated, or up.

Session 24- Drug Combinations

Additive Effect (Cont.)

Example #2: Pupil Size

- Both drugs affect pupil size in the same way

Example: CNS Stimulants and Hallucinogens

- (CNS Stimulants and Hallucinogens both dilate pupils)
- Pupils should be dilated



Drug Recognition Expert Course 24-20

Example #2: Pupil Size

Pupil Size. CNS Stimulants and Hallucinogens both dilate the pupils; therefore, pupils should be dilated.

Session 24- Drug Combinations

Additive Effect (Cont.)

Example #3: Blood Pressure

- Both drugs affect Blood Pressure in the same way

Example: CNS Depressants and Narcotic Analgesics

- (CNS Depressants and Narcotic Analgesics both depress blood pressure)
- Blood Pressure should be depressed



Drug Recognition Expert Course 24-21

Example #3: Blood Pressure

Ask a participant to give an example of a drug combination that will produce an additive effect on blood pressure.

Blood Pressure. CNS Depressants and Narcotic Analgesics both depress blood pressure. Therefore, the blood pressure should be depressed or down.

Session 24- Drug Combinations

Antagonistic Effect

- If two drugs affect some indicator in exactly opposite ways, their use in combination could affect that indicator in any possible way
- Action versus opposite action yields you can't predict the outcome




Drug Recognition Expert Course
24-22

Antagonistic Effect

The fourth effect is called the Antagonistic Effect.

Clarification of “Antagonistic Effect” – action versus opposite action: can’t predict the outcome.

When two drugs produce an “Antagonistic Effect,” they tend to try to override or compete with the effect of the other drug(s) until the drug with the longest duration of effects prevails. Normally, whichever drug is more psychoactive at the time determines what we’ll see.

Point out that a common example is when a person takes a “speedball” (Heroin plus Cocaine), the two drugs try to compete with their effects on the pupil size.

Session 24- Drug Combinations

Antagonistic Effect (Cont.)

Whichever drug is more psychoactive at the time determines what we'll see

There is not an Antagonistic Effect for:

- HGN
- VGN
- Lack of Convergence
- Reaction to Light



Drug Recognition Expert Course 24-23

There is not an Antagonistic Effect for :

- HGN,
- VGN,
- Lack of Convergence and
- Reaction to Light.

Question participants as to why this would be the case.

Session 24- Drug Combinations

Antagonistic Effect (Cont.)

Example #1: Pulse Rate

- One drug affects pulse rate one way, the other drug affects pulse rate in the opposite way

Example: CNS Stimulants and CNS Depressants

- (CNS Stimulants elevate pulse rate, CNS Depressants depress pulse rate)
- Pulse Rate will be up, down or within the DRE average ranges



Drug Recognition Expert Course 24-24

Example #1: Pulse Rate

Pulse Rate. CNS Stimulants elevate pulse rate, CNS Depressants depress pulse rate; therefore, pulse rate will be up, down or within the DRE average ranges.

Session 24- Drug Combinations

Antagonistic Effect (Cont.)

Example #2: Pupil Size

- One drug affects pupil size one way, the other drug affects pupil size in the opposite way

Example: CNS Stimulants and Narcotic Analgesics

- (CNS Stimulants dilates pupils, and Narcotic Analgesics constricts pupils)
- Pupils will be dilated, constricted or within the DRE average ranges



Drug Recognition Expert Course 24-25

Example #2: Pupil Size

Pupil Size. CNS Stimulants dilate pupils, Narcotic Analgesics constrict pupils. Pupil size will be dilated, constricted or within the DRE average ranges.

Session 24- Drug Combinations

Antagonistic Effect (Cont.)

Example #3: Body Temperature

- One drug affects body temperature one way, the other drug affects body temperature in the opposite way

Example: Hallucinogens and Narcotic Analgesics

- (Hallucinogens elevate body temperature, Narcotic Analgesics depress body temperature)
- Body Temperature will be up, down or within the DRE average ranges




Drug Recognition Expert Course
24-26

Example #3: Body Temperature

Body Temperature. Hallucinations elevate body temperature, Narcotic Analgesics depress body temperature. Body temperature will be up, down or within the DRE average ranges.

With an “Antagonistic Effect,” we just can’t predict what we will see.

Summary

When drugs from two or more drug categories are taken together, they tend to produce a combination of Null Effects, Overlapping Effects, Additive Effects and Antagonistic Effects.

Solicit participants’ questions about the Null, Overlapping, Additive and Antagonistic Effects.

Proceed to the following slides of drug combinations involving the input from the participants.

Session 24- Drug Combinations

Cannabis and CNS Stimulant

Impairment Indicator	Cannabis	CNS Stimulant	Type of Effect	What We Will See?
HGN				




Drug Recognition Expert Course
24-27

HGN

A specific example: consider a person who is under the influence of a combination of Cannabis and a CNS Stimulant.

Ask participants: “will you see HGN with this particular combination?”

Session 24- Drug Combinations

Cannabis and CNS Stimulant

Impairment Indicator	Cannabis	CNS Stimulant	Type of Effect	What We Will See?
HGN				




Drug Recognition Expert Course 24-28

Neither Cannabis nor a CNS Stimulant causes HGN.

Point out that the combination of Cannabis and CNS Stimulant produces a Null Effect on HGN.

This is a case of no action plus no action equals no action.

We will not see HGN with this combination.

Session 24- Drug Combinations

Cannabis and CNS Stimulant

Impairment Indicator	Cannabis	CNS Stimulant	Type of Effect	What We Will See?
HGN	None	None	Null	No HGN
VGN				




Drug Recognition Expert Course
24-29

Vertical Gaze Nystagmus

Ask participants: “Will we see Vertical Gaze Nystagmus?”

Session 24- Drug Combinations

Cannabis and CNS Stimulant

Impairment Indicator	Cannabis	CNS Stimulant	Type of Effect	What We Will See?
HGN	None	None	Null	No HGN
VGN	None	None	Null	No VGN




Drug Recognition Expert Course
24-30

Neither Cannabis nor a CNS Stimulant causes VGN.

This is another Null Effect.

We won't see VGN.

Session 24- Drug Combinations

Cannabis and CNS Stimulant

Impairment Indicator	Cannabis	CNS Stimulant	Type of Effect	What We Will See?
HGN	None	None	Null	No HGN
VGN	None	None	Null	No VGN
LOC				




Drug Recognition Expert Course
24-31

Lack of Convergence

Ask participants “What will we see when we examine LOC?”

Session 24- Drug Combinations

Cannabis and CNS Stimulant

Impairment Indicator	Cannabis	CNS Stimulant	Type of Effect	What We Will See?
HGN	None	None	Null	No HGN
VGN	None	None	Null	No VGN
LOC	Present	None	Overlapping	LOC




Drug Recognition Expert Course
24-32

Cannabis causes Lack of Convergence; a CNS Stimulant does not.

Point out that the combination of Cannabis and CNS Stimulant produces an Overlapping Effect on Lack of Convergence.

This is a case of action plus no action equals action.

We will see Lack of Convergence with this combination.

Session 24- Drug Combinations

Cannabis and CNS Stimulant

Impairment Indicator	Cannabis	CNS Stimulant	Type of Effect	What We Will See?
HGN	None	None	Null	No HGN
VGN	None	None	Null	No VGN
LOC	Present	None	Overlapping	LOC
Pupil Size				




Drug Recognition Expert Course 24-33

Pupil Size

Ask participants: “What will we see when we examine pupil size?”

Session 24- Drug Combinations

Cannabis and CNS Stimulant

Impairment Indicator	Cannabis	CNS Stimulant	Type of Effect	What We Will See?
HGN	None	None	Null	No HGN
VGN	None	None	Null	No VGN
LOC	Present	None	Overlapping	LOC
Pupil Size	Dilated ⁽⁶⁾	Dilated	Overlapping or Additive	Dilated

⁽⁶⁾ Pupil Size Possibly Normal.




Drug Recognition Expert Course 24-34

CNS Stimulants dilate pupils; Cannabis either dilates pupils or has no effect on them.

Point out that the combination of Cannabis and CNS Stimulant produces either an Additive Effect or an Overlapping Effect on pupil size.

This may be a case of action plus no action equals action.

Or it may be a case of action plus same action reinforces action.

In either case, we should see dilated pupils with this combination.

Point out that the term “normal” in Exception 6 refers to a pupil size within the DRE average ranges.

Session 24- Drug Combinations

Cannabis and CNS Stimulant

Impairment Indicator	Cannabis	CNS Stimulant	Type of Effect	What We Will See?
HGN	None	None	Null	No HGN
VGN	None	None	Null	No VGN
LOC	Present	None	Overlapping	LOC
Pupil Size	Dilated ⁽⁶⁾	Dilated	Overlapping or Additive	Dilated
Reaction to Light				

⁽⁶⁾ Pupil Size Possibly Normal.




Drug Recognition Expert Course 24-35

Reaction to Light

Ask participants: “What should we see when we examine the pupils’ reaction to light?”

Session 24- Drug Combinations

Cannabis and CNS Stimulant

Impairment Indicator	Cannabis	CNS Stimulant	Type of Effect	What We Will See?
HGN	None	None	Null	No HGN
VGN	None	None	Null	No VGN
LOC	Present	None	Overlapping	LOC
Pupil Size	Dilated ⁽⁶⁾	Dilated	Overlapping or Additive	Dilated
Reaction to Light	Normal	Slow	Overlapping	Slow

⁽⁶⁾ Pupil Size Possibly Normal.




Drug Recognition Expert Course 24-36

CNS Stimulants slow the pupils' Reaction to Light; Cannabis usually doesn't affect the pupils' reaction.

Here we have another Overlapping Effect.

We should observe a slowed reaction of the pupils.

Session 24- Drug Combinations

Cannabis and CNS Stimulant

Impairment Indicator	Cannabis	CNS Stimulant	Type of Effect	What We Will See?
Pulse Rate				




Drug Recognition Expert Course
24-37

Pulse Rate

Ask participants: “What should we see when we measure this person’s pulse rate?”

Session 24- Drug Combinations

Cannabis and CNS Stimulant

Impairment Indicator	Cannabis	CNS Stimulant	Type of Effect	What We Will See?
Pulse Rate	Up	Up	Additive	Up



Drug Recognition Expert Course 24-38

Both Cannabis and CNS Stimulants usually elevate pulse rate.

This is an Additive Effect.

We should see a pulse rate that is up or elevated.

Session 24- Drug Combinations

Cannabis and CNS Stimulant

Impairment Indicator	Cannabis	CNS Stimulant	Type of Effect	What We Will See?
Pulse Rate	Up	Up	Additive	Up
Blood Pressure				




Drug Recognition Expert Course
24-39

Blood Pressure

Ask participants: “What should we see when we measure this person’s blood pressure?”

Session 24- Drug Combinations

Cannabis and CNS Stimulant

Impairment Indicator	Cannabis	CNS Stimulant	Type of Effect	What We Will See?
Pulse Rate	Up	Up	Additive	Up
Blood Pressure	Up	Up	Additive	Up




Drug Recognition Expert Course
24-40

Cannabis usually causes blood pressure to be up or elevated; so does a CNS Stimulant.

This is another Additive Effect.

We should see a blood pressure that is up or elevated.

Session 24- Drug Combinations

Cannabis and CNS Stimulant

Impairment Indicator	Cannabis	CNS Stimulant	Type of Effect	What We Will See?
Pulse Rate	Up	Up	Additive	Up
Blood Pressure	Up	Up	Additive	Up
Body Temperature				




Drug Recognition Expert Course
24-41

Body Temperature

Ask participants: “What can we expect to find when we check this person’s temperature?”

Session 24- Drug Combinations

Cannabis and CNS Stimulant

Impairment Indicator	Cannabis	CNS Stimulant	Type of Effect	What We Will See?
Pulse Rate	Up	Up	Additive	Up
Blood Pressure	Up	Up	Additive	Up
Body Temperature	Normal	Up	Overlapping	Up




Drug Recognition Expert Course
24-42

Cannabis usually does not affect body temperature. But CNS Stimulants usually elevate temperature.

Point out that Cannabis in combination with CNS Stimulant produces an Overlapping Effect on body temperature.

This is another case of action plus no action equals action.

We can expect to see an elevated temperature with this combination.

Session 24- Drug Combinations

Cannabis and CNS Stimulant

Impairment Indicator	Cannabis	CNS Stimulant	Type of Effect	What We Will See?
Pulse Rate	Up	Up	Additive	Up
Blood Pressure	Up	Up	Additive	Up
Body Temperature	Normal	Up	Overlapping	Up
Muscle Tone	Normal	Rigid	Overlapping	Rigid




Drug Recognition Expert Course
24-43

Muscle Tone

Cannabis usually does not affect muscle tone. CNS Stimulants cause muscle tone to be rigid.

Point out that this particular combination produces no Antagonistic Effects.

This is another case of action plus no action equals action.

We can expect to see rigid muscle tone with this combination.

Session 24- Drug Combinations

Dissociative Anesthetic and Narcotic Analgesic



Drug Recognition Expert Course

24-44

Dissociative Anesthetics and Narcotic Analgesics

Another specific example: consider a person under the influence of a combination of a Dissociative Anesthetic and a Narcotic Analgesic.

Session 24- Drug Combinations

Dissociative Anesthetic and Narcotic Analgesic

Impairment Indicator	Dissociative Anesthetic	Narcotic Analgesic	Type of Effect	What Will We See?
HGN	Present	None	Overlapping	HGN




Drug Recognition Expert Course
24-45

HGN

Ask participants: “What will we see when we examine this person for HGN?”

A Dissociative Anesthetic causes HGN, Narcotic Analgesics do not.

This is an Overlapping Effect.

We can expect to see HGN with this subject.

Session 24- Drug Combinations

Dissociative Anesthetic and Narcotic Analgesic

Impairment Indicator	Dissociative Anesthetic	Narcotic Analgesic	Type of Effect	What Will We See?
HGN	Present	None	Overlapping	HGN
VGN				




Drug Recognition Expert Course 24-46

Vertical Gaze Nystagmus

Ask participants: “What will we see when we examine this person for VGN?”

Session 24- Drug Combinations

Dissociative Anesthetic and Narcotic Analgesic

Impairment Indicator	Dissociative Anesthetic	Narcotic Analgesic	Type of Effect	What Will We See?
HGN	Present	None	Overlapping	HGN
VGN	Present	None	Overlapping	VGN




Drug Recognition Expert Course 24-47

A Dissociative Anesthetic should cause Vertical Gaze Nystagmus, especially at high doses. A Narcotic Analgesic will not cause Vertical Gaze Nystagmus.

This is another Overlapping Effect.

We should see Vertical Gaze Nystagmus in this subject.

Session 24- Drug Combinations

Dissociative Anesthetic and Narcotic Analgesic

Impairment Indicator	Dissociative Anesthetic	Narcotic Analgesic	Type of Effect	What Will We See?
HGN	Present	None	Overlapping	HGN
VGN	Present	None	Overlapping	VGN
LOC				




Drug Recognition Expert Course 24-48

Lack of Convergence

Ask participants: “Can we expect to see a Lack of Convergence?”

Session 24- Drug Combinations

Dissociative Anesthetic and Narcotic Analgesic

Impairment Indicator	Dissociative Anesthetic	Narcotic Analgesic	Type of Effect	What Will We See?
HGN	Present	None	Overlapping	HGN
VGN	Present	None	Overlapping	VGN
LOC	Present	None	Overlapping	LOC




Drug Recognition Expert Course 24-49

A Dissociative Anesthetic causes Lack of Convergence; Narcotic Analgesics do not.

Another Overlapping Effect.

We can expect to see Lack of Convergence.

Session 24- Drug Combinations

Dissociative Anesthetic and Narcotic Analgesic

Impairment Indicator	Dissociative Anesthetic	Narcotic Analgesic	Type of Effect	What Will We See?
HGN	Present	None	Overlapping	HGN
VGN	Present	None	Overlapping	VGN
LOC	Present	None	Overlapping	LOC
Pupil Size				




Drug Recognition Expert Course 24-50

Pupil Size

Ask participants: “What are we likely to see when we check the size of this subject’s pupils?”

Session 24- Drug Combinations

Dissociative Anesthetic and Narcotic Analgesic

Impairment Indicator	Dissociative Anesthetic	Narcotic Analgesic	Type of Effect	What Will We See?
HGN	Present	None	Overlapping	HGN
VGN	Present	None	Overlapping	VGN
LOC	Present	None	Overlapping	LOC
Pupil Size	Normal	Constricted	Overlapping	Constricted




Drug Recognition Expert Course 24-51

A Dissociative Anesthetic doesn't affect pupil size, but a Narcotic Analgesic constricts pupils.

This is another Overlapping Effect.

We can expect to see constricted pupils with this subject.

Remind the participants that the term "Normal" refers to the DRE average ranges for the pupil sizes.

Session 24- Drug Combinations

Dissociative Anesthetic and Narcotic Analgesic

Impairment Indicator	Dissociative Anesthetic	Narcotic Analgesic	Type of Effect	What Will We See?
Reaction to Light				




Drug Recognition Expert Course 24-52

Reaction to Light

Ask participants: “What are we likely to observe when we check the reaction of this subject’s pupils to light?”

Session 24- Drug Combinations

Dissociative Anesthetic and Narcotic Analgesic

Impairment Indicator	Dissociative Anesthetic	Narcotic Analgesic	Type of Effect	What Will We See?
Reaction to Light	Normal	Little or None Visible	Overlapping	Little or None Visible




Drug Recognition Expert Course 24-53

A Dissociative Anesthetic doesn't affect pupil's Reaction to Light; but a Narcotic Analgesic usually produces a "little or none visible" reaction.

Point out that the combination of Dissociative Anesthetics and a Narcotic Analgesic produces Overlapping Effects on all major eye indicators of drug impairment.

This, too, is an Overlapping Effect.

We can expect a "little or none visible" reaction in this subject's pupils.

Session 24- Drug Combinations

Dissociative Anesthetic and Narcotic Analgesic

Impairment Indicator	Dissociative Anesthetic	Narcotic Analgesic	Type of Effect	What Will We See?
Reaction to Light	Normal	Little or None Visible	Overlapping	Little or None Visible
Pulse Rate				




Drug Recognition Expert Course
24-54

Pulse Rate

Ask participants: “What can we expect to find when we check this subject’s pulse rate?”

Session 24- Drug Combinations

Dissociative Anesthetic and Narcotic Analgesic

Impairment Indicator	Dissociative Anesthetic	Narcotic Analgesic	Type of Effect	What Will We See?
Reaction to Light	Normal	Little or None Visible	Overlapping	Little or None Visible
Pulse Rate	Up	Down	Antagonistic	Up, Down or Normal




Drug Recognition Expert Course 24-55

A Dissociative Anesthetic usually causes pulse rate to be elevated; a Narcotic Analgesic usually produces a depressed or lower pulse rate.

This is our first Antagonistic Effect.

We cannot predict what this subject's pulse rate will be.

The pulse rate could be elevated, or depressed, or within the DRE average ranges.

This subject's pulse rate will depend on many factors, including:

- How much of each drug was taken.
- How and when each drug was taken.
- How tolerant the subject is of each drug.

Session 24- Drug Combinations

Dissociative Anesthetic and Narcotic Analgesic

Impairment Indicator	Dissociative Anesthetic	Narcotic Analgesic	Type of Effect	What Will We See?
Reaction to Light	Normal	Little or None Visible	Overlapping	Little or None Visible
Pulse Rate	Up	Down	Antagonistic	Up, Down or Normal
Blood Pressure				




Drug Recognition Expert Course
24-56

Blood Pressure

Ask participants: “What are we likely to find when we check this subject’s blood pressure?”

Session 24- Drug Combinations

Dissociative Anesthetic and Narcotic Analgesic

Impairment Indicator	Dissociative Anesthetic	Narcotic Analgesic	Type of Effect	What Will We See?
Reaction to Light	Normal	Little or None Visible	Overlapping	Little or None Visible
Pulse Rate	Up	Down	Antagonistic	Up, Down or Normal
Blood Pressure	Up	Down	Antagonistic	Up, Down or Normal




Drug Recognition Expert Course
24-57

A Dissociative Anesthetic usually elevates blood pressure; a Narcotic Analgesic usually lowers blood pressure.

This is another Antagonistic Effect.

We can't predict what the blood pressure will be.

It could be above DRE average ranges, below DRE average ranges, or within the DRE average ranges.

Session 24- Drug Combinations

Dissociative Anesthetic and Narcotic Analgesic

Impairment Indicator	Dissociative Anesthetic	Narcotic Analgesic	Type of Effect	What Will We See?
Body Temperature				




Drug Recognition Expert Course
24-58

Temperature

Ask participants: “What are we likely to find when we check this subject’s temperature?”

Session 24- Drug Combinations

Dissociative Anesthetic and Narcotic Analgesic

Impairment Indicator	Dissociative Anesthetic	Narcotic Analgesic	Type of Effect	What Will We See?
Body Temperature	Up	Down	Antagonistic	Up, Down or Normal




Drug Recognition Expert Course
24-59

A Dissociative Anesthetic usually elevates temperature; a Narcotic Analgesic usually lowers it.

This, too, is an Antagonistic Effect.

The temperature could be elevated (up), or depressed (down) or within the DRE average range.

Point out that the combination of a Dissociative Anesthetic and Narcotic Analgesics produce Antagonistic Effects on all three vital signs.

Point out that the term “Normal” refers to the DRE average range for body temperature which is 98 degrees plus or minus 1 degree.

Session 24- Drug Combinations

Dissociative Anesthetic and Narcotic Analgesic

Impairment Indicator	Dissociative Anesthetic	Narcotic Analgesic	Type of Effect	What Will We See?
Body Temperature	Up	Down	Antagonistic	Up, Down or Normal
Muscle Tone				




Drug Recognition Expert Course 24-60

Muscle Tone

Ask the participants: What are we likely to find when we check this subject's muscle tone?

Session 24- Drug Combinations

Dissociative Anesthetic and Narcotic Analgesic

Impairment Indicator	Dissociative Anesthetic	Narcotic Analgesic	Type of Effect	What Will We See?
Body Temperature	Up	Down	Antagonistic	Up, Down or Normal
Muscle Tone	Rigid	Flaccid	Antagonistic	Normal, rigid, or flaccid




Drug Recognition Expert Course 24-61

A Dissociative Anesthetic usually causes rigid muscle tone. A Narcotic Analgesic usually causes flaccid muscle tone.

This could be an Overlapping or Antagonistic Effect.

Muscle tone could be normal, rigid, or flaccid.

Solicit participants' comments and questions about the combination of a Dissociative Anesthetic and a Narcotic Analgesic.

Session 24- Drug Combinations

Dissociative Anesthetic and Narcotic Analgesic

Impairment Indicator	Dissociative Anesthetic	Narcotic Analgesic	Type of Effect	What Will We See?
Body Temperature	Up	Down	Antagonistic	Up, Down or Normal
Muscle Tone	Rigid	Flaccid	Antagonistic	Normal, Rigid, or Flaccid




Drug Recognition Expert Course 24-62

A Dissociative Anesthetic usually causes rigid muscle tone. A Narcotic Analgesic usually causes flaccid muscle tone.

This could be an Overlapping or Antagonistic Effect.

Muscle tone could be normal, rigid, or flaccid.

Solicit participants' comments and questions about the combination of a Dissociative Anesthetic and a Narcotic Analgesic.

Session 24- Drug Combinations

Cannabis, CNS Stimulants and Hallucinogens

Impairment Indicator	Cannabis	CNS Stimulant	Hallucinogen	Type of Effect	What Will We See?
HGN					




Drug Recognition Expert Course 24-63

Cannabis, CNS Stimulant and Hallucinogens

Another specific example: consider a person under the influence of Cannabis, a CNS Stimulant and a Hallucinogen.

Session 24- Drug Combinations

Cannabis, CNS Stimulants and Hallucinogens

Impairment Indicator	Cannabis	CNS Stimulant	Hallucinogen	Type of Effect	What Will We See?
HGN	None	None	None	Null	No HGN




Drug Recognition Expert Course 24-64

HGN

None of the three categories causes HGN. This is an example of the Null Effect.

Session 24- Drug Combinations

Cannabis, CNS Stimulants and Hallucinogens

Impairment Indicator	Cannabis	CNS Stimulant	Hallucinogen	Type of Effect	What Will We See?
HGN	None	None	None	Null	No HGN
VGN	None	None	None	Null	No VGN




Drug Recognition Expert Course
24-65

VGN

None of the three drug categories cause Vertical Gaze Nystagmus, another example of the Null Effect.

Session 24- Drug Combinations

Cannabis, CNS Stimulants and Hallucinogens

Impairment Indicator	Cannabis	CNS Stimulant	Hallucinogen	Type of Effect	What Will We See?
HGN	None	None	None	Null	No HGN
VGN	None	None	None	Null	No VGN
LOC	Present	None	None	Overlapping	LOC




Drug Recognition Expert Course 24-66

LOC

Cannabis causes a Lack of Convergence while CNS Stimulants and Hallucinogens do not. This is an example of an Overlapping Effect and Lack of Convergence should be present.

Session 24- Drug Combinations

Cannabis, CNS Stimulants and Hallucinogens

Impairment Indicator	Cannabis	CNS Stimulant	Hallucinogen	Type of Effect	What Will We See?
HGN	None	None	None	Null	No HGN
VGN	None	None	None	Null	No VGN
LOC	Present	None	None	Overlapping	LOC
Pupil Size	Dilated ⁽⁶⁾	Dilated	Dilated	Additive/ Overlapping ⁽⁶⁾	Dilated

⁽⁶⁾ Pupil size possibly normal




Drug Recognition Expert Course 24-67

Pupil Size

Cannabis usually dilates pupils. CNS Stimulants and Hallucinogens also dilate the pupils.

This is an example of an Additive or Overlapping Effect.

Ask participants: What effect will take place and the result.

The pupils should be dilated.

Remind the participants that the term “Normal” refers to pupil sizes within the DRE average ranges.

Session 24- Drug Combinations

Cannabis, CNS Stimulants and Hallucinogens

Impairment Indicator	Cannabis	CNS Stimulant	Hallucinogen	Type of Effect	What Will We See?
Reaction to Light	Normal	Slow	Normal ⁽³⁾	Overlapping/ Additive ⁽³⁾	Slow


⁽³⁾ Certain psychedelic amphetamines may cause slowing


Drug Recognition Expert Course 24-68

Reaction to Light

Cannabis does not effect the Reaction to Light. CNS Stimulants will slow down the reaction. Most Hallucinogens, with some exceptions, will cause a normal Reaction to Light.

This is an example of either an Overlapping or Additive Effect.

Ask participants: What effect would take place and the result.

We could probably see a slow Reaction to Light.

Remind participants that certain psychedelic amphetamines may cause a slowed reaction to light. (Exception #3)

Session 24- Drug Combinations

Cannabis, CNS Stimulants and Hallucinogens

Impairment Indicator	Cannabis	CNS Stimulant	Hallucinogen	Type of Effect	What Will We See?
Reaction to Light	Normal	Slow	Normal ⁽³⁾	Overlapping/Additive ⁽³⁾	Slow
Pulse Rate	Up	Up	Up	Additive	Up

 ⁽³⁾ *Certain psychedelic amphetamines may cause slowing*



Drug Recognition Expert Course 24-69

Pulse Rate

Cannabis will normally elevate the pulse rate as will CNS Stimulants and Hallucinogens.

This is an example of an Additive Effect.

Ask participants: What effect would take place and the result.

The result would be an elevated pulse rate.

Session 24- Drug Combinations

Cannabis, CNS Stimulants and Hallucinogens

Impairment Indicator	Cannabis	CNS Stimulant	Hallucinogen	Type of Effect	What Will We See?
Reaction to Light	Normal	Slow	Normal ⁽³⁾	Overlapping/ Additive ⁽³⁾	Slow
Pulse Rate	Up	Up	Up	Additive	Up
Blood Pressure	Up	Up	Up	Additive	Up


⁽³⁾ Certain psychedelic amphetamines may cause slowing


Drug Recognition Expert Course 24-70

Blood Pressure

All three drug categories will elevate blood pressure.

This is an example of an Additive Effect.

Ask participants: What effect would take place and the result.

Blood pressure should be elevated with this combination.

Session 24- Drug Combinations

Cannabis, CNS Stimulants and Hallucinogens

Impairment Indicator	Cannabis	CNS Stimulant	Hallucinogen	Type of Effect	What Will We See?
Body Temperature	Normal	Up	Up	Additive/ Overlapping	Up




Drug Recognition Expert Course
24-71

Body Temperature

Cannabis usually causes a body temperature in the average range. CNS Stimulants and Hallucinogens elevate body temperature.

This would be an example of an Additive or Overlapping Effect.

Ask participants: What effect would take place and the result.

The body temperature should be elevated with this combination.

Session 24- Drug Combinations

Cannabis, CNS Stimulants and Hallucinogens

Impairment Indicator	Cannabis	CNS Stimulant	Hallucinogen	Type of Effect	What Will We See?
Body Temperature	Normal	Up	Up	Additive/ Overlapping	Up
Muscle Tone	Normal	Rigid	Rigid	Additive/ Overlapping	Rigid




Drug Recognition Expert Course
24-72

Muscle Tone

Cannabis causes a normal muscle tone, while CNS Stimulants and Hallucinogens will cause rigid muscle tone.

This would be an example of an Additive or an Overlapping Effect.

Ask participants: What effect would take place and the effect.

The muscle tone should be rigid with this combination.

Session 24- Drug Combinations

Identifying Expected Indicators of Specific Combinations

The *Drug Symptomatology Matrix* outlines the expected results of the drug influence evaluation for each drug category




Drug Recognition Expert Course 24-73

C. Identifying Expected Indicators of Specific Combinations

Direct the participants' attention to the Cumulative Drug Symptomatology Matrix, found in Session 24 of their Participant's Manual. A copy also appears for your reference in Appendix A located in your Instructor Guide, Session 24 folder.


Drug Symptomatology Matrix

The Matrix outlines the expected results of the drug influence evaluation for each drug category.

We will refer to the Matrix to help us interpret what we are likely to see when we examine drug combinations.

Remind participants that we "never say never" and we "always avoid saying always" when it comes to signs and symptoms of drugs. The Matrix summarizes what we usually see but doesn't guarantee we will always see exactly that, or every indicator.

Show the video of subjects under the influence of specific drug combinations. Point out the Null, Overlapping, Additive and Antagonistic Effects exhibited by the subjects.



Worksheet Exercises

Assign the participants to work in three member teams. Direct the participants' attention to the three worksheets located at the end of Session 24 in their Participant's Manual.

Instruct the teams that they have only 15 minutes to fill out all three worksheets (5 minutes per worksheet).

Worksheet #1: Dissociative Anesthetic and a Hallucinogen.

Worksheet #2: Cannabis and CNS Depressant.

Worksheet #3: CNS Depressant and CNS Stimulant.

Solicit participants' questions about this assignment.

Tell the teams to start working. Terminate their work after 15 minutes.

Discussion of Worksheets

For each worksheet, select a team member to lead the discussion. Critique and correct the participants' analyses of the drug combinations, as appropriate.

Session 24- Drug Combinations

Questions?



Drug Recognition Expert Course

24-75

Solicit participants' comments and questions about drug combinations.

INDICATORS CONSISTENT WITH DRUG CATEGORIES

MAJOR INDICATORS	CNS DEPRESSANTS	CNS STIMULANTS	HALLUCINOGENS	DISSOCIATIVE ANESTHETICS	NARCOTIC ANALGESICS	INHALANTS	CANNABIS
HGN	PRESENT	NONE	NONE	PRESENT	NONE	PRESENT	NONE
VGN	PRESENT (HIGH DOSE)	NONE	NONE	PRESENT	NONE	PRESENT (HIGH DOSE)	NONE
LACK OF CONVERGENCE	PRESENT	NONE	NONE	PRESENT	NONE	PRESENT	PRESENT
PUPIL SIZE	NORMAL (1)	DILATED	DILATED	NORMAL	CONSTRICTED	NORMAL (4)	DILATED (6)
REACTION TO LIGHT	SLOW	SLOW	NORMAL (3)	NORMAL	LITTLE OR NONE VISIBLE	SLOW	NORMAL
PULSE RATE	DOWN (2)	UP	UP	UP	DOWN	UP	UP
BLOOD PRESSURE	DOWN	UP	UP	UP	DOWN	UP / DOWN (5)	UP
BODY TEMPERATURE	NORMAL	UP	UP	UP	DOWN	UP / DOWN / NORMAL	NORMAL
MUSCLE TONE	FLACCID	RIGID	RIGID	RIGID	FLACCID	NORMAL OR FLACCID	NORMAL

FOOTNOTE: These indicators are those most consistent with the category, keep in mind that there may be variations due to individual reaction, dose taken and drug interactions.

- (1) Soma, Quaaludes and possibly some anti-depressants usually dilate pupils.
- (2) Quaaludes, ETOH and possibly some anti-depressants may elevate.
- (3) Certain psychedelic amphetamines may cause slowing.
- (4) Normal, but may be dilated.
- (5) Down with anesthetic gases, up with volatile solvents and aerosols.
- (6) Pupil size possibly normal.

	CNS DEPRESSANTS	CNS STIMULANTS	HALLUCINOGENS	DISSOCIATIVE ANESTHETICS	NARCOTIC ANALGESICS	INHALANTS	CANNABIS
GENERAL INDICATORS	Disoriented Droopy eyes (Ptosis) Drowsiness Drunk-like behavior Gait ataxia Slow, sluggish reactions Thick, slurred speech Uncoordinated <u>NOTE:</u> With Methaqualone, pulse will be elevated and body tremors will be evident. Alcohol and Quaaludes elevate pulse. Soma and Quaaludes dilate pupils.	Anxiety Body tremors Dry mouth Euphoria Exaggerated reflexes Excited Eyelid tremors Grinding teeth (Bruxism) Increased alertness Insomnia Irritability Redness to nasal area Restlessness Runny nose Talkative	Body tremors Dazed appearance Difficulty w/speech Disoriented Flashbacks Hallucinations Memory loss Nausea Paranoia Perspiring Poor perception of time and distance Synesthesia Uncoordinated <u>NOTE:</u> With LSD, piloerection may be observed (goose bumps, hair standing on end).	Blank stare Confused Chemical odor Cyclic behavior Difficulty w/speech Disoriented Early HGN Onset Hallucinations Incomplete verbal responses Increased pain threshold "Moon Walking" Muscle rigidity Warm to touch Non communicative Perspiring Possibly violent Sensory distortions Slow, slurred speech	Constricted pupils Depressed reflexes Drowsiness Droopy eyelids (Ptosis) Dry mouth Euphoria Facial itching Nausea "On the Nod" Puncture marks Slow, low, raspy speech Slowed breathing <u>NOTE:</u> Tolerant users exhibit relatively little psychomotor impairment.	Bloodshot, watery eyes Confusion Disoriented Flushed face Intense headaches Lack of muscle control Non-communicative Odor of substance Possible nausea Residue of substance Slow, thick, slurred speech <u>NOTE:</u> Anesthetic gases cause below normal blood pressure; volatile solvents and aerosols cause above normal blood pressure.	Body tremors Disoriented Debris in mouth Eyelid tremors Impaired perception of time & distance Increased appetite Marked reddening of conjunctiva Odor of Marijuana Possible paranoia Relaxed inhibitions
DURATION OF EFFECTS	Barbiturates: 1-16 hours Tranquilizers: 4-8 hours Methaqualone: 4-8 hours	Cocaine: 5-90 minutes Amphetamines: 4-8 hours Meth: 12 hours	Duration varies widely from one hallucinogen to another. LSD: 4-6 hours Psilocybin: 2-3 hours	PCP Onset: 1-5 minutes Peak Effects: 15-30 minutes Exhibits effects up to 4-6 hours DXM: Onset 15-30 min. Effects 3-6 hours	Heroin: 4-6 hours Methadone: Up to 24 hours Others: Vary	6-8 hours for most volatile solvents Anesthetic gases and aerosols – very short duration	2-3 hours – exhibit effects (Impairment may last up to 24 hours, without awareness effects.)
USUAL METHODS OF ADMINISTRATION	Oral Injected (occasionally)	Insufflation (snorting) Smoked Injected Oral	Oral Insufflation Smoked Injected Transdermal	Smoked (PCP) Oral Insufflation (PCP) Injected (PCP) Eye drops	Injected Oral Smoked Insufflation	Insufflation (Historically, have been taken orally.)	Smoked Oral
OVERDOSE SIGNS	Shallow breathing Cold, clammy skin Pupils dilated Rapid, weak pulse Coma	Agitation Increased body temperature Hallucinations Convulsions/Seizures	Long intense "trip"	Long intense "trip"	Slow, shallow breathing Clammy skin Coma Convulsions	Coma	Fatigue Paranoia

D. Specific Examples of Drug Combinations: An Exercise for the Student

On the final five pages of this session, you will find examples of specific drug combinations. The expected results for the first two of these combinations (Cannabis and Stimulants, and Dissociative Anesthetic and Narcotic Analgesic) have been worked out for you. Study those examples, then complete the work sheets for the three remaining combinations.

CANNABIS AND CNS STIMULANT
IN COMBINATION

IMPAIRMENT INDICATOR	EFFECT DUE TO CANNABIS	EFFECT DUE TO CNS STIMULANT	TYPE OF COMBINED EFFECT	WHAT WILL WE SEE
VERTICAL GAZE NYSTAGMUS	NONE	NONE	NULL	NONE
LACK OF CONV.	PRESENT	NONE	OVERLAPPING	PRESENT
PUPIL SIZE	DILATED OR NORMAL	DILATED	OVERLAPPING OR ADDITIVE	DILATED
REACTION TO LIGHT	NORMAL	SLOW	OVERLAPPING	SLOW
PULSE RATE	UP	UP	ADDITIVE	UP
BLOOD PRESSURE	UP	UP	ADDITIVE	UP
BODY TEMP	NORMAL	UP	OVERLAPPING	UP
MUSCLE TONE	NORMAL	RIGID	OVERLAPPING	RIGID

DISSOCIATIVE ANESTHETIC AND NARCOTIC ANALGESIC
IN COMBINATION

IMPAIRMENT INDICATOR	EFFECT DUE TO PHENCYCLIDINE	EFFECT DUE TO HEROIN	TYPE OF COMBINED EFFECT	WHAT WILL WE SEE
HORIZONTAL GAZE NYSTAGMUS	PRESENT	NONE	OVERLAPPING	PRESENT
VERTICAL GAZE NYSTAGMUS	PRESENT	NONE	OVERLAPPING	PRESENT
LACK OF CONV.	PRESENT	NONE	OVERLAPPING	PRESENT
PUPIL SIZE	NORMAL	CONSTRICTED	OVERLAPPING	CONSTRICTED
REACTION TO LIGHT	NORMAL	LITTLE OR NONE VISIBLE	OVERLAPPING	LITTLE OR NONE VISIBLE
PULSE RATE	UP	DOWN	ANTAGONISTIC	DOWN/ NORMAL/UP
BLOOD PRESSURE	UP	DOWN	ANTAGONISTIC	DOWN/ NORMAL/UP
BODY TEMP	UP	DOWN	ANTAGONISTIC	DOWN/ NORMAL/UP
MUSCLE TONE	RIGID	FLACCID	ANTAGONISTIC	RIGID/ FLACCID/ NORMAL

WORKSHEET #1
KETAMINE AND LSD

IMPAIRMENT INDICATOR	EFFECT DUE TO DISSOCIATIVE ANESTHETICS	EFFECT DUE TO HALLUCINOGEN (Hall)	TYPE OF COMBINED EFFECT*	WHAT WILL WE SEE
HORIZONTAL GAZE NYSTAGMUS				
VERTICAL GAZE NYSTAGMUS				
LACK OF CONV.				
PUPIL SIZE				
REACTION TO LIGHT				
PULSE RATE				
BLOOD PRESSURE				
BODY TEMP				
MUSCLE TONE				

*Null; Overlapping; Additive; or, Antagonistic

WORKSHEET #2
CANNABIS AND CNS DEPRESSANT

IMPAIRMENT INDICATOR	EFFECT DUE TO CANNABIS	EFFECT DUE TO DEPRESSANT	TYPE OF COMBINED EFFECT*	WHAT WILL WE SEE
HORIZONTAL GAZE NYSTAGMUS				
VERTICAL GAZE NYSTAGMUS				
LACK OF CONV.				
PUPIL SIZE				
REACTION TO LIGHT				
PULSE RATE				
BLOOD PRESSURE				
BODY TEMP				
MUSCLE TONE				

*Null; Overlapping; Additive; or, Antagonistic

WORKSHEET #3
CNS STIMULANT AND CNS DEPRESSANT

IMPAIRMENT INDICATOR	EFFECT DUE TO CNS STIMULANT	EFFECT DUE TO DEPRESSANT	TYPE OF COMBINED EFFECT*	WHAT WILL WE SEE
HORIZONTAL GAZE NYSTAGMUS				
VERTICAL GAZE NYSTAGMUS				
LACK OF CONV.				
PUPIL SIZE				
REACTION TO LIGHT				
PULSE RATE				
BLOOD PRESSURE				
BODY TEMP				
MUSCLE TONE				

*Null; Overlapping; Additive; or, Antagonistic

**WORKSHEET #1
KETAMINE AND LSD**

IMPAIRMENT INDICATOR	EFFECT DUE TO DISSOCIATIVE ANESTHETICS	EFFECT DUE TO HALLUCINOGEN (Hall)	TYPE OF COMBINED EFFECT*	WHAT WILL WE SEE
HORIZONTAL GAZE NYSTAGMUS				
VERTICAL GAZE NYSTAGMUS				
LACK OF CONV.				
PUPIL SIZE				
REACTION TO LIGHT				
PULSE RATE				
BLOOD PRESSURE				
BODY TEMP				
MUSCLE TONE				

*Null; Overlapping; Additive; or, Antagonistic

WORKSHEET #2
CANNABIS AND CNS DEPRESSANT

IMPAIRMENT INDICATOR	EFFECT DUE TO CANNABIS	EFFECT DUE TO DEPRESSANT	TYPE OF COMBINED EFFECT*	WHAT WILL WE SEE
HORIZONTAL GAZE NYSTAGMUS				
VERTICAL GAZE NYSTAGMUS				
LACK OF CONV.				
PUPIL SIZE				
REACTION TO LIGHT				
PULSE RATE				
BLOOD PRESSURE				
BODY TEMP				
MUSCLE TONE				

*Null; Overlapping; Additive; or, Antagonistic

WORKSHEET #3
CNS STIMULANT AND CNS DEPRESSANT

IMPAIRMENT INDICATOR	EFFECT DUE TO CNS STIMULANT	EFFECT DUE TO DEPRESSANT	TYPE OF COMBINED EFFECT*	WHAT WILL WE SEE
HORIZONTAL GAZE NYSTAGMUS				
VERTICAL GAZE NYSTAGMUS				
LACK OF CONV.				
PUPIL SIZE				
REACTION TO LIGHT				
PULSE RATE				
BLOOD PRESSURE				
BODY TEMP				
MUSCLE TONE				

*Null; Overlapping; Additive; or, Antagonistic

Session 25

Practice: Test Interpretation



Session 25 - Practice: Test Interpretation

Learning Objectives

- **Analyze the results of completed drug influence evaluations and identify the category or categories of drugs affecting the individual examined**
- **Describe the basis for the drug category identification**




Drug Recognition Expert Course 25-2

Briefly review the objectives, content and activities of this session.

Upon successfully completing this session the student will be able to:

- Analyze the results of completed drug influence evaluations and identify the category or categories of drugs affecting the individual examined.
- Describe the basis for the drug category identification.

CONTENT SEGMENTS

- A. Interpretation Demonstrations
- B. Interpretation Practice

LEARNING ACTIVITIES

- Instructor Led Demonstrations
- Small Group Practice
- Participant Led Presentations

Session 25 - Practice: Test Interpretation

Case One: Subject Allen

- Preliminary Examination
- Eye Examinations
- Psychophysical Tests
- Vital Signs Examinations




Drug Recognition Expert Course 25-3

A. Interpretation Demonstrations

Case One: Subject Allen

Preliminary Examination

Review the results of the Preliminary Examination of Subject Allen.

Ask participants: “What category or categories of drugs would produce preliminary examination results consistent with this exemplar?” Probe to draw out the basis for participants’ responses.

Eye Examinations

Review the results of the Eye Examinations of Subject Allen.

Ask participants to discuss the category or categories of drugs that would cause these eye examination results.

Psychophysical Tests

Review the results of the Psychophysical Tests of Subject Allen.

Ask participants to discuss the category or categories of drugs that would produce these psychophysical results.

Vital Signs Examinations

Review the results of the Vital Signs Examinations of Subject Allen.

Ask participants to discuss the category or categories of drugs that would produce these results.

Session 25 - Practice: Test Interpretation

Case One: Subject Allen (Cont.)

- Dark Room Examinations
- Other Evidence
- Opinions of the Evaluator



Drug Recognition Expert Course 25-4

Dark Room Examinations

Review the results of the Dark Room Examinations of Subject Allen.

Ask participants to discuss the category or categories of drugs that would produce these results.

Other Evidence

Review the results of the examinations for injection sites and muscle tone, and of the final interview of Subject Allen.

Ask participants to comment on the category or categories of drugs that would be consistent with all of the evidence on this exemplar.

Opinions of Evaluator

Point out that the evidence indicates that Subject Allen is under the influence of Cannabis.

Solicit participants' questions concerning this demonstration.

Session 25 - Practice: Test Interpretation

Case Two: Subject Brown

- Preliminary Examination
- Eye Examinations
- Psychophysical Tests
- Vital Signs Examinations




Drug Recognition Expert Course 25-5

Case Two: Subject Brown

Preliminary Examination

Review the results of the Preliminary Examination of Subject Brown.
Ask participants: “What category or categories of drugs would produce preliminary examination results consistent with this exemplar?” Probe to draw out the basis for participants’ responses.

Eye Examinations

Review the results of the Eye Examinations of Subject Brown.
Ask participants to discuss the category or categories of drugs that would cause these eye examination results.

Psychophysical Tests

Review the results of the Psychophysical Tests of Subject Brown.
Ask participants to discuss the category or categories of drugs that would produce these psychophysical results.

Vital Signs Examinations

Review the results of the Vital Signs Examinations of Subject Brown.
Ask participants to discuss the category or categories of drugs that would produce these results.

Session 25 - Practice: Test Interpretation

Case Two: Subject Brown (Cont.)

- Dark Room Examinations
- Other Evidence
- Opinions of the Evaluator



Drug Recognition Expert Course 25-6

Dark Room Examinations

Review the results of the Dark Room Examinations of Subject Brown.

Ask participants to discuss the category or categories of drugs that would produce these results.

Other Evidence

Review the results of the examinations for injection sites and muscle tone, and of the final interview of Subject Brown.

Ask participants to comment on the category or categories of drugs that would be consistent with all of the evidence on this exemplar.

Opinions of Evaluator

Point out that the evidence indicates that Subject Brown is under the influence of Cannabis.

Solicit participants' questions concerning this demonstration.

Session 25 - Practice: Test Interpretation

Interpretation Practice

- **Team Practice**
- **Feedback of Results**




Drug Recognition Expert Course 25-7

B. Interpretation Practice

Team Practice

- ***Assign participants to work in teams of 3 or 4 members.***
- ***Review and discussion of exemplars by teams.***
- ***Tell teams that they are to review three exemplars (Subjects Cole, Davis, and Elliott). Team members are to discuss the evidence among themselves and reach a conclusion concerning the category or categories of drugs, if any.***
- ***Teams will present their conclusions to the entire class.***
- ***Allow teams approximately 15 minutes to review the three exemplars and reach their conclusions.***

Feedback of Results

Poll the teams to determine their conclusions concerning the category or categories of drugs present in each subject.

- ***Subject Cole***
- ***Subject Davis***
- ***Subject Elliott***

Session Wrap-Up

Offer appropriate comments concerning the teams' performance.

Session 25 - Practice: Test Interpretation

QUESTIONS?



Drug Recognition Expert Course

Solicit participants' comments and questions concerning this practice session.

DRUG CATEGORIES FOR INTERPRETATION PRACTICE

<u>SUBJECT</u>	<u>CATEGORY(IES)</u>
Allen	Cannabis
Brown	Dissociative Anesthetics (PCP) and Cannabis
Cole	Inhalants
Davis	Narcotic Analgesic
Elliott	Hallucinogen

DRUG INFLUENCE EVALUATION








Evaluator Officer Ed Finnegan, Rockland PD		DRE # 8070	Rolling Log # 12-03-79	Session XXV - I #1																									
Recorder/Witness Lt. Tom Reagan, Bangor PD		Crash: <input checked="" type="checkbox"/> None <input type="checkbox"/> Fatal <input type="checkbox"/> Injury <input type="checkbox"/> Property		Case # 12-55790																									
Arrestee's Name (Last, First, Middle) Allen, Thomas E.		Date of Birth 9/3/78	Sex M	Race W	Arresting Officer (Name, ID#) Tpr. Aaron Turcotte, Maine SP, #11644																								
Date Examined / Time / Location 03/21/12 2030 Bangor PD		Breath Results: Results: 0.00		Test Refused <input type="checkbox"/> Instrument #: 44773	Chemical Test: Urine <input checked="" type="checkbox"/> Blood <input type="checkbox"/> Test or tests refused <input type="checkbox"/>																								
Miranda Warning Given Given By: Tpr. Turcotte	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? Cookies "Few hours ago"	What have you been drinking? Coffee	How much? 2 cups	Time of last drink? N/A																								
Time now/ Actual "No idea"	When did you last sleep? How long "Don't remember"	Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No																									
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No																									
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Attitude: Cooperative, slow, disinterested		Coordination: Disoriented, unsteady																									
Speech: Slow, thick		Breath Odor: Stale odor		Face: Normal																									
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input checked="" type="checkbox"/> Reddened Conjunctiva <input type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right	Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal																								
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Eyelids: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Droopy																								
Pulse and time		HGN	Left Eye	Right Eye	<div style="display: flex; justify-content: space-between;"> 34 32 </div>																								
1. <u>90</u> / <u>2040</u>		Lack of Smooth Pursuit	No	No																									
2. <u>90</u> / <u>2056</u>		Maximum Deviation	No	No																									
3. <u>88</u> / <u>2110</u>		Angle of Onset	None	None																									
Modified Romberg Balance		Walk and Turn test		<div style="display: flex; justify-content: space-around;"> <div style="text-align: center;"> <p>Eyelid tremors Circular sway</p> </div> <div style="text-align: center;"> <p>Lower body tremors</p> </div> </div>																									
		Cannot keep balance <input checked="" type="checkbox"/>		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td colspan="2" style="text-align: center;">1st Nine</td> <td colspan="2" style="text-align: center;">2nd Nine</td> </tr> <tr> <td style="text-align: center;">Stops walking</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td style="text-align: center;">Misses heel-toe</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td style="text-align: center;">Steps off line</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> <tr> <td style="text-align: center;">Raises arms</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> <tr> <td style="text-align: center;">Actual steps taken</td> <td style="text-align: center;"><u>9</u></td> <td style="text-align: center;"><u>9</u></td> <td style="text-align: center;"><u>9</u></td> </tr> </table>		1 st Nine		2 nd Nine		Stops walking	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Misses heel-toe	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Steps off line	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Raises arms	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Actual steps taken	<u>9</u>	<u>9</u>	<u>9</u>
1 st Nine		2 nd Nine																											
Stops walking	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																										
Misses heel-toe	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																										
Steps off line	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>																										
Raises arms	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>																										
Actual steps taken	<u>9</u>	<u>9</u>	<u>9</u>																										
		Starts too soon <input type="checkbox"/>																											
		Stops walking <input type="checkbox"/>																											
		Misses heel-toe <input type="checkbox"/>																											
		Steps off line <input checked="" type="checkbox"/>																											
		Raises arms <input checked="" type="checkbox"/>																											
		Actual steps taken <u>9</u>																											
Internal clock 43 estimated as 30 seconds		Describe Turn: As instructed, but slow		Cannot do test (explain): N/A																									
<p style="text-align: center;">Draw lines to spots touched</p>		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th>PUPIL SIZE</th> <th>Room light 2.5 - 5.0</th> <th>Darkness 5.0 - 8.5</th> <th>Direct 2.0 - 4.5</th> </tr> <tr> <td>Left Eye</td> <td style="text-align: center;">7.0</td> <td style="text-align: center;">9.0</td> <td style="text-align: center;">6.0</td> </tr> <tr> <td>Right Eye</td> <td style="text-align: center;">7.0</td> <td style="text-align: center;">9.0</td> <td style="text-align: center;">6.0</td> </tr> </table>			PUPIL SIZE	Room light 2.5 - 5.0	Darkness 5.0 - 8.5	Direct 2.0 - 4.5	Left Eye	7.0	9.0	6.0	Right Eye	7.0	9.0	6.0	Nasal area: Clear												
		PUPIL SIZE	Room light 2.5 - 5.0	Darkness 5.0 - 8.5	Direct 2.0 - 4.5																								
		Left Eye	7.0	9.0	6.0																								
		Right Eye	7.0	9.0	6.0																								
			Oral cavity: Brownish-green coating on tongue																										
			REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No																										
			REACTION TO LIGHT: Normal																										
Eyelid tremors		RIGHT ARM		LEFT ARM																									
		Nothing observed																											
Blood pressure 152/92		Temperature 98.6																											
Muscle tone: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Flaccid <input type="checkbox"/> Rigid																													
Comments:																													
What drugs or medications have you been using? "Nothing"		How much? N/A		Time of use? No answer	Where were the drugs used? (Location) No answer																								
Date / Time of arrest: 03/21/12 1940	Time DRE was notified: 2000	Evaluation start time: 2030	Evaluation completion time: 2130	Precinct/Station:																									
Officer's Signature:		DRE # 8070	Reviewed/approved by / date:																										
Opinion of Evaluator:																													
<input type="checkbox"/> Rule Out		<input type="checkbox"/> Alcohol		<input type="checkbox"/> CNS Stimulant																									
<input type="checkbox"/> Medical		<input type="checkbox"/> CNS Depressant		<input type="checkbox"/> Dissociative Anesthetic																									
				<input type="checkbox"/> Inhalant																									
				<input type="checkbox"/> Narcotic Analgesic																									
				<input checked="" type="checkbox"/> Cannabis																									

DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: Allen, Thomas E.

1. **LOCATION:** The evaluation was conducted in the interview room at the Bangor PD.
2. **WITNESSES:** Lt. Tom Reagan of Bangor PD witnessed and recorded the evaluation.
3. **BREATH ALCOHOL TEST:** Allen's breath test was 0.00%.
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** Writer was on duty when contacted by Tpr. Turcotte requesting a drug evaluation. Writer met Tpr. Turcotte at B.P.D. where he advised that he had arrested Allen for DUI after observing his vehicle without headlights and driving 15 mph under the posted speed limit. The suspect seemed disoriented and had slow, unsteady movements. He had poor balance and coordination and was unable to perform the SFST's as directed.
5. **INITIAL OBSERVATION OF SUSPECT:** Writer first observed the suspect in the interview room. He seemed disinterested in what was going on around him. He had poor coordination and balance and his speech was slow and thick.
6. **MEDICAL PROBLEMS AND TREATMENT:** None noted or stated.
7. **PSYCHOPHYSICAL TESTS:** Modified Romberg Balance: Suspect had an approximate 2" circular sway and estimated 30 seconds in 43 seconds. Walk & Turn: Suspect lost his balance during the instructions stage and raised his arms for balance. He stepped off the line twice, once during the first nine steps and once during the second nine steps. He also had lower body tremors when performing the test. One Leg Stand: Suspect swayed while balancing, used his arms for balance and put his foot down once while standing on his left foot and twice when standing on his right foot. Finger to Nose: Suspect missed the tip of his nose on four of the six attempts and exhibited eyelid tremors.
8. **CLINICAL INDICATORS:** Suspect had a lack of convergence and his pupils were dilated. His pulse and blood pressure were elevated.
9. **SIGNS OF INGESTION:** The suspect had a brownish-green coating on his tongue.
10. **SUSPECT'S STATEMENTS:** Suspect denied using drugs.
11. **DRE'S OPINION:** In my opinion Allen is under the influence of Cannabis and unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** The suspect provided a blood sample.
13. **MISCELLANEOUS:** Suspect had eyelid and body tremors throughout the evaluation.

DRUG INFLUENCE EVALUATION

Evaluator Sgt. Matt Shapiro, New Hampshire SP		DRE # 5754	Rolling Log # 12-08-012	Session XXV - I #2	
Recorder/Witness Trooper Marc Beaudoin, NH SP		Crash: <input checked="" type="checkbox"/> None <input type="checkbox"/> Fatal <input type="checkbox"/> Injury <input type="checkbox"/> Property		Case # 12-23334	
Arrestee's Name (Last, First, Middle) Brown, Jerome A.		Date of Birth 4/6/77	Sex M	Race B	Arresting Officer (Name, ID#) Officer Jessica Humphrey, Bedford PD #16387
Date Examined / Time / Location 08/08/12 2210 Bedford PD		Breath Results: Results: 0.00		Test Refused <input type="checkbox"/> Instrument #: 451130	Chemical Test: Urine <input checked="" type="checkbox"/> Blood <input type="checkbox"/> Test or tests refused <input type="checkbox"/>
Miranda Warning Given Given By: Officer Humphrey	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? No response	What have you been drinking? How much? No response	Time of last drink? N/A	
Time now/ Actual No response	When did you last sleep? How long "Eat? I had a hot dog"	Are you sick or injured? <input type="checkbox"/> Yes <input type="checkbox"/> No No response	Are you diabetic or epileptic? <input type="checkbox"/> Yes <input type="checkbox"/> No No response		
Do you take insulin? <input type="checkbox"/> Yes <input type="checkbox"/> No No response	Do you have any physical defects? <input type="checkbox"/> Yes <input type="checkbox"/> No "I didn't drink anything"	Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input type="checkbox"/> No No response			
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No Answered "no" very slow	Attitude: Passive, non-responsive	Coordination: Very poor, staggering			
Speech: Slow, repetitive at times	Breath Odor: Chemical like odor	Face: Sweaty, blank stare			
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft	Eyes: <input type="checkbox"/> Reddened Conjunctiva <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Bloodshot <input type="checkbox"/> Watery	Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right	Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal		
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)	Vertical Nystagmus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Eyelids: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Droopy		
Pulse and time 1. 108 / 2224 2. 110 / 2240 3. 108 / 2255	HGN Lack of Smooth Pursuit: Yes Maximum Deviation: Yes Angle of Onset: 30	Left Eye Yes Yes 30	Right Eye Yes Yes 30	Convergence 	ONE LEG STAND 
Modified Romberg Balance  Very rigid	Walk and Turn test  Arms and legs rigid	Cannot keep balance <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Starts too soon Stops walking Misses heel-toe Steps off line Raises arms Actual steps taken	L R <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Sways while balancing <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Uses arms to balance <input type="checkbox"/> <input type="checkbox"/> Hopping <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Puts foot down Test stopped		
Internal clock 55 estimated as 30 seconds	Describe Turn: Stopped, walked in circle	Cannot do test (explain): N/A		Type of footwear: Running shoes	
Draw lines to spots touched  Rigid arms	PUPIL SIZE	Room light 2.5 - 5.0	Darkness 5.0 - 8.5	Direct 2.0 - 4.5	Nasal area: Clear
	Left Eye	6.0	7.5	6.0 - 7.5	Oral cavity: Green material in teeth
	Right Eye	6.0	7.5	6.0 - 7.5	
	REBOUND DILATION <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		REACTION TO LIGHT: Normal		
	RIGHT ARM 		LEFT ARM 		
	Nothing observed				
Blood pressure 148/102	Temperature 99.8	Muscle tone: <input type="checkbox"/> Normal <input type="checkbox"/> Flaccid <input checked="" type="checkbox"/> Rigid		Comments:	
What drugs or medications have you been using? No response (blank stare)	How much? No response	Time of use? No response	Where were the drugs used? (Location) "I'm not saying"		
Date / Time of arrest: 08/08/12 2130	Time DRE was notified: 2145	Evaluation start time: 2210	Evaluation completion time: 2315	Precinct/Station:	
Officer's Signature:	DRE # 5754	Reviewed/approved by / date:			
Opinion of Evaluator:		<input type="checkbox"/> Rule Out	<input type="checkbox"/> Alcohol	<input type="checkbox"/> CNS Stimulant	<input checked="" type="checkbox"/> Dissociative Anesthetic
		<input type="checkbox"/> Medical	<input type="checkbox"/> CNS Depressant	<input type="checkbox"/> Hallucinogen	<input type="checkbox"/> Narcotic Analgesic
					<input type="checkbox"/> Inhalant <input checked="" type="checkbox"/> Cannabis







DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: Brown, Jerome A.

1. **LOCATION:** The evaluation was conducted in the interview room at Bedford PD.
2. **WITNESSES:** Trooper Beaudoin witnessed and recorded the evaluation.
3. **BREATH ALCOHOL TEST:** Brown's breath test was 0.00%.
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** Writer was contacted by telephone by Officer Humphrey requesting a drug evaluation. Writer and Trooper Beaudoin contacted Officer Humphrey at the Bedford Police Department where it was determined that the suspect had nearly hit a B.P.D. officer while on a traffic stop. The suspect was non-responsive when contacted. He had a blank stare and was sweating profusely. He performed very poorly on the SFST's and was arrested for DUI.
5. **INITIAL OBSERVATION OF SUSPECT:** Writer first observed the suspect in the breath testing room. He was looking straight ahead with a blank stare. When asked questions he responded slowly and at times did not respond at all. He was perspiring heavily and his speech was slow and thick. When he stood, he would stagger and nearly fell several times.
6. **MEDICAL PROBLEMS AND TREATMENT:** None noted or stated.
7. **PSYCHOPHYSICAL TESTS:** Modified Romberg Balance: Suspect had an approximate 3" side to side sway and estimated 30 seconds in 55 seconds. Walk & Turn: Suspect lost his balance during the instructions, stopped once while walking, missed heel to toe on every step and used his arms for balance. One Leg Stand: The suspect lost his balance while attempting this test and nearly fell and the test was stopped. He also swayed and used his arms for balance. Finger to Nose: Suspect missed the tip of his nose on each attempt and kept his finger in contact with his face on each attempt.
8. **CLINICAL INDICATORS:** Suspect had HGN, VGN, a Lack of Convergence and Rebound Dilation. His pulse, blood pressure and temperature were all elevated.
9. **SIGNS OF INGESTION:** Suspect had a marijuana odor on his breath.
10. **SUSPECT'S STATEMENTS:** Suspect denied using any medication or drugs.
11. **DRE'S OPINION:** In my opinion Brown is under the influence of a *Dissociative Anesthetic and Cannabis* and unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** The suspect provided a urine sample.
13. **MISCELLANEOUS:**

R5/13

DRUG INFLUENCE EVALUATION

Evaluator Officer Cullen Kau, Honolulu PD		DRE # 5992	Rolling Log # 12-05-61	Session XXV-I #3	
Recorder/Witness Sgt. Ben Moszkowicz, Honolulu PD		Crash: <input checked="" type="checkbox"/> None <input type="checkbox"/> Fatal <input type="checkbox"/> Injury <input type="checkbox"/> Property		Case # 12-55778	
Arrestee's Name (Last, First, Middle) Cole, Ricky Lee		Date of Birth 6/4/88	Sex M	Race W	Arresting Officer (Name, ID#) Officer Michelle Yoshiki, HPD #13052
Date Examined / Time / Location 05/07/12 0200 HPD		Breath Results: Test Refused <input type="checkbox"/> Results: 0.00 Instrument #: 45704		Chemical Test: Urine <input type="checkbox"/> Blood <input checked="" type="checkbox"/> Test or tests refused <input type="checkbox"/>	
Miranda Warning Given Given By: Ofc. Yoshiki	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? Sandwich "don't remember"	What have you been drinking? Mountain Dew	How much? One	Time of last drink? N/A
Time now/ Actual 1 AM/0208	When did you last sleep? How long Last night 8-9 hours	Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Attitude: Withdrawn, passive		Coordination: Poor, stumbling	
Speech: Slow, slurred		Breath Odor: Rancid odor		Face: Flushed	
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Bloodshot <input checked="" type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right	
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	
Eyelids: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Droopy		ONE LEG STAND			
Pulse and time 1. 102 / 0214 2. 104 / 0222 3. 104 / 0240		HGN Lack of Smooth Pursuit: Yes Maximum Deviation: Yes Angle of Onset: 35		Convergence 	
Modified Romberg Balance  Circular sway		Walk and Turn test 		Cannot keep balance: <input checked="" type="checkbox"/> Starts too soon: <input type="checkbox"/> Stops walking: <input type="checkbox"/> Misses heel-toe: <input checked="" type="checkbox"/> Steps off line: <input checked="" type="checkbox"/> Raises arms: <input type="checkbox"/> Actual steps taken: 9	
Internal clock 45 estimated as 30 seconds		Describe Turn: Slow		Cannot do test (explain) N/A	
Type of footwear: Flip-flops		PUPIL SIZE		Nasal area: Runny nose, redness to nasal area	
Draw lines to spots touched  Swaying Opened eyes		Room light: 2.5-5.0 Left Eye: 5.0 Right Eye: 5.0		Darkness: 5.0-8.5 5.0 6.5	
Blood pressure: 142/98		Direct: 2.0-4.5 4.0		Direct: 4.0	
Temperature: 98.8		REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		REACTION TO LIGHT: Normal	
Muscle tone: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Flaccid <input type="checkbox"/> Rigid		RIGHT ARM 		LEFT ARM 	
Comments: What drugs or medications have you been using? "Nothing"		How much? No answer		Time of use? No answer	
Where were the drugs used? (Location) No answer		Date / Time of arrest: 05/07/12 0135		Time DRE was notified: 0145	
Evaluation start time: 0200		Evaluation completion time: 0310		Precinct/Station:	
Officer's Signature:		DRE # 5992		Reviewed/approved by / date:	
Opinion of Evaluator: <input type="checkbox"/> Rule Out <input type="checkbox"/> Medical		<input type="checkbox"/> Alcohol <input type="checkbox"/> CNS Depressant		<input type="checkbox"/> CNS Stimulant <input type="checkbox"/> Hallucinogen	
		<input type="checkbox"/> Dissociative Anesthetic <input type="checkbox"/> Narcotic Analgesic		<input checked="" type="checkbox"/> Inhalant <input type="checkbox"/> Cannabis	








DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: Cole, Ricky L.

1. **LOCATION:** The evaluation was conducted at the Honolulu Police Department.
2. **WITNESSES:** Sgt. Ben Moszkowicz of the Honolulu Police Department witnessed and recorded the evaluation.
3. **BREATH ALCOHOL TEST:** Cole's breath test was 0.00%.
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** Writer was on-duty and was contacted by Officer Yoshiki requesting a drug evaluation. Officer Yoshiki advised that she detained the suspect after observing him fail to stop at a red traffic light at King Street at University Ave. The suspect's speech was slow and slurred. He had a strong chemical type odor on his hands and clothing. He performed poorly on the SFST's and was arrested for DUI.
5. **INITIAL OBSERVATION OF SUSPECT:** Writer first observed the suspect in the interview room at HPD. He appeared passive and withdrawn. He had poor balance and coordination. He swayed as he stood and stumbled several times when walking.
6. **MEDICAL PROBLEMS AND TREATMENT:** None noted or stated.
7. **PSYCHOPHYSICAL TESTS:** Modified Romberg Balance: The suspect swayed approximately 2" in a circular motion and estimated 30 seconds in 45 seconds. When asked how he estimated the 30 seconds the suspect stated, "Just guessed." Walk & Turn: The suspect lost his balance twice during the instructions, stopped walking twice on the first nine steps and once on the second nine steps. He missed heel to toe seven times and stepped off the line twice. One Leg Stand: The suspect was unable to maintain his balance and the test was stopped for safety reasons. Finger to Nose: The suspect was unable to touch the tip of his nose on any of the six attempts, repeatedly opened his eyes and swayed noticeably.
8. **CLINICAL INDICATORS:** Suspect had six clues of HGN. VGN and LOC were also present. His pulse and blood pressure were elevated and above the DRE average ranges.
9. **SIGNS OF INGESTION:** The suspect had a severe redness to his nasal area.
10. **SUSPECT'S STATEMENTS:** Suspect denied using any medication or drugs.
11. **DRE'S OPINION:** In my opinion Cole is under the influence of an Inhalant and unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** The suspect provided a blood sample.
13. **MISCELLANEOUS:**

R5/13

DRUG INFLUENCE EVALUATION









Evaluator Trooper Mathew Sorenson, Minnesota SP		DRE # 5665	Rolling Log # 12-10-045	Session XXV – I #4	
Recorder/Witness Sgt. Bryan Schafer, Minneapolis PD		Crash: <input checked="" type="checkbox"/> None <input type="checkbox"/> Fatal <input type="checkbox"/> Injury <input type="checkbox"/> Property		Case # 110334	
Arrestee's Name (Last, First, Middle) Davis, Paul Allen		Date of Birth 1/21/75	Sex M	Race W	Arresting Officer (Name, ID#) Officer John Engle, Minneapolis PD #7388
Date Examined / Time / Location 10/02/12 1925 Hennepin Co Jail		Breath Results: Results: 0.00		Test Refused <input type="checkbox"/> Instrument #: 43210	Chemical Test: Urine <input type="checkbox"/> Blood <input checked="" type="checkbox"/> Test or tests refused <input type="checkbox"/>
Miranda Warning Given Given By: Ofc. Engle	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? Pancakes 7AM	What have you been drinking? How much? Nothing N/A	Time of last drink? N/A	
Time now/ Actual 11 PM/1930	When did you last sleep? How long "I don't remember"	Are you sick or injured? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No "I feel sick"		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input type="checkbox"/> No "I'm clean"		Attitude: Cooperative, slow		Coordination: Poor, unstable	
Speech: Slow, low, raspy		Breath Odor: Normal		Face: Drowsy looking, pale	
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right	
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	
Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal		Eyelids: <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Droopy			
Pulse and time 1. <u>56</u> / <u>1935</u> 2. <u>58</u> / <u>1950</u> 3. <u>56</u> / <u>2005</u>	HGN Lack of Smooth Pursuit: No Maximum Deviation: No Angle of Onset: None	Left Eye No	Right Eye No	Convergence 	
Modified Romberg Balance 	Walk and Turn test 	Cannot keep balance: <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Starts too soon: _____ Stops walking: _____ Misses heel-toe: _____ Steps off line: _____ Raises arms: _____ Actual steps taken: _____		ONE LEG STAND 	
Internal clock 68 estimated as 30 seconds	Describe Turn: Lost balance	Cannot do test (explain) N/A		Type of footwear: Lace-up boots	
Draw lines to spots touched 		PUPIL SIZE	Room light 2.5 - 5.0	Darkness 5.0 - 8.5	Direct 2.0 - 4.5
Kept leaning forward		Left Eye	2.0	3.0	1.5
Blood pressure 110/60		Right Eye	2.0	3.0	1.5
Temperature 97.5		REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		REACTION TO LIGHT: Slow	
Muscle tone: <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Flaccid <input type="checkbox"/> Rigid		RIGHT ARM 		LEFT ARM 	
Comments: What drugs or medications have you been using? "I'm not using"		How much?	Time of use? No answer	Where were the drugs used? (Location) No answer	
Date / Time of arrest: 10/02/12 1840	Time DRE was notified: 1900	Evaluation start time: 1925	Evaluation completion time: 2030	Precinct/Station:	
Officer's Signature:		DRE # 5665	Reviewed/approved by / date:		
Opinion of Evaluator:		<input type="checkbox"/> Rule Out	<input type="checkbox"/> Alcohol	<input type="checkbox"/> CNS Stimulant	<input type="checkbox"/> Dissociative Anesthetic
		<input type="checkbox"/> Medical	<input type="checkbox"/> CNS Depressant	<input type="checkbox"/> Hallucinogen	<input checked="" type="checkbox"/> Narcotic Analgesic
				<input type="checkbox"/> Inhalant	<input type="checkbox"/> Cannabis

DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: Davis, Paul A.

1. **LOCATION:** The evaluation was conducted in interview room at the Hennepin Co Jail.
2. **WITNESSES:** Sgt. Bryan Schafer of the Minneapolis PD recorded the evaluation.
3. **BREATH ALCOHOL TEST:** Davis' breath test was 0.00%.
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** I was on-duty and requested to contact Officer Engle for a drug evaluation. Officer Engle advised that he had located the suspect slumped over behind the steering wheel of his vehicle parked along the shoulder of W. 13th Street with the vehicle in drive and his foot on the brake. The suspect's speech was slow, low and raspy. His coordination was poor and he was very unstable on his feet. He performed poorly on the SFST's and was arrested for DUI.
5. **INITIAL OBSERVATION OF SUSPECT:** Writer first observed the suspect in the interview room at the Jail. He appeared drowsy and was having difficulty keeping his eyes open. His head was nodding forward and he had droopy eyelids. His voice was slow, low and raspy and his pupils appeared to be constricted.
6. **MEDICAL PROBLEMS AND TREATMENT:** The suspect said he felt sick but did not request or need medical assistance.
7. **PSYCHOPHYSICAL TESTS:** Modified Romberg Balance: Suspect swayed approximately two inches side to side and two inches front to back. He estimated 30 seconds in 68 seconds. Walk & Turn: Suspect lost his balance twice during the instructions, stopped walking four times, missed heel to toe three times, stepped off the line three times and used his arms for balance. One Leg Stand: Suspect put his foot down three times on both the left and right foot and the tests were stopped for safety reasons. Finger to Nose: Suspect missed the tip of his nose on five of the six attempts. His movements were slow and his head was leaning forward towards his chest.
8. **CLINICAL INDICATORS:** Suspect's pupils were constricted and had a slow reaction to light. His pulse, blood pressure and temperature were below the DRE average ranges.
9. **SIGNS OF INGESTION:** A fresh puncture mark was located on the back of his left hand.
10. **SUSPECT'S STATEMENTS:** The suspect made several references to being "clean."
11. **DRE'S OPINION:** In my opinion Davis is under the influence of a Narcotic Analgesic and unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** The suspect provided a blood sample.
13. **MISCELLANEOUS:**

DRUG INFLUENCE EVALUATION

Evaluator Officer Susan Reidenbach, Indianapolis PD		DRE # 3983	Rolling Log # 12-01-087	Session XXV - I #5	
Recorder/Witness Deputy Zach Dodd, Hamilton Co. SO		Crash: <input checked="" type="checkbox"/> None <input type="checkbox"/> Fatal <input type="checkbox"/> Injury <input type="checkbox"/> Property		Case # 12-003453	
Arrestee's Name (Last, First, Middle) Elliott, John B.		Date of Birth 6/1/88	Sex M	Race W	Arresting Officer (Name, ID#) Officer Lance Rector, Indianapolis PD #10058
Date Examined / Time / Location 01/05/12 2210 Marion Co. Jail		Breath Results: Results: 0.00		Test Refused <input type="checkbox"/> Instrument #: 51547	Chemical Test: Urine <input checked="" type="checkbox"/> Blood <input type="checkbox"/> Test or tests refused <input type="checkbox"/>
Miranda Warning Given Given By: Ofc. Rector	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? Tacos lunch	What have you been drinking? How much? "I don't drink"	Time of last drink? N/A	
Time now/ Actual "Don't know"	When did you last sleep? How long Today 2 hrs.	Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No "I'm okay"		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Attitude: Emotional changes (laughing/crying)		Coordination: Poor, stumbling	
Speech: Mumbled, incoherent		Breath Odor: Normal		Face: Flushed, sweaty	
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right	Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Eyelids: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Droopy
Pulse and time 1. <u>116</u> / <u>2218</u> 2. <u>110</u> / <u>2224</u> 3. <u>112</u> / <u>2235</u>	HGN Lack of Smooth Pursuit Maximum Deviation Angle of Onset	Left Eye No No None	Right Eye No No None	Convergence 	ONE LEG STAND 
Modified Romberg Balance 	Walk and Turn test 	Cannot keep balance <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Starts too soon Stops walking Misses heel-toe Steps off line Raises arms Actual steps taken		1 st Nine 2 nd Nine 	L R <input checked="" type="checkbox"/> <input type="checkbox"/> Sways while balancing <input checked="" type="checkbox"/> <input type="checkbox"/> Uses arms to balance <input type="checkbox"/> <input type="checkbox"/> Hopping <input checked="" type="checkbox"/> <input type="checkbox"/> Puts foot down Test stopped
Internal clock 42 estimated as 30 seconds	Describe Turn: N/A	Cannot do test (explain) Lost balance three (3) times		Type of footwear: Boots	
Draw lines to spots touched 		PUPIL SIZE Room light 2.5 - 5.0 Darkness 5.0 - 8.5 Direct 2.0 - 4.5			Nasal area: Clear
		Left Eye 6.5 9.0 6.0			Oral cavity: Clear
		Right Eye 6.5 9.0 6.0			
		REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		REACTION TO LIGHT: Normal	
		RIGHT ARM 		LEFT ARM 	
		Nothing observed			
Blood pressure 156/102	Temperature 99.8	Muscle tone: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Flaccid <input type="checkbox"/> Rigid			
Comments: What drugs or medications have you been using? No answer, started laughing		How much? No answer	Time of use? N/A	Where were the drugs used? (Location) No answer - started laughing	
Date / Time of arrest: 01/05/12 2115	Time DRE was notified: 2135	Evaluation start time: 2210	Evaluation completion time: 2315	Precinct/Station:	
Officer's Signature:		DRE # 3983	Reviewed/approved by / date:		
Opinion of Evaluator:		<input type="checkbox"/> Rule Out	<input type="checkbox"/> Alcohol	<input type="checkbox"/> CNS Stimulant	<input type="checkbox"/> Dissociative Anesthetic
		<input type="checkbox"/> Medical	<input type="checkbox"/> CNS Depressant	<input checked="" type="checkbox"/> Hallucinogen	<input type="checkbox"/> Inhalant
				<input type="checkbox"/> Narcotic Analgesic	<input type="checkbox"/> Cannabis

DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: Elliott, John B.

1. **LOCATION:** The evaluation was conducted at the Marion Co Jail Intake Center.
2. **WITNESSES:** Deputy Zach Dodd of the Hamilton Co SO and recorded the evaluation.
3. **BREATH ALCOHOL TEST:** Elliott's breath test was a 0.00%.
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** I was on-duty and dispatched to the Marion Co. Jail to conduct a drug evaluation. I contacted Officer Reidenbach of the Indianapolis PD who advised me that the suspect had just left a concert when she stopped him for driving without headlights and for failure to yield the right of way. The suspect was acting very strange and was highly emotional and his speech was incoherent at times. He preformed poorly on the SFST's and was arrested for DUI.
5. **INITIAL OBSERVATION OF SUSPECT:** I first observed the suspect in the interview room at the Jail. He had very poor balance and was unsteady on his feet. He was very emotional. At times he was laughing uncontrollably and then would start crying for no reason. His speech was mumbled and mostly incoherent. His pupils appeared dilated.
6. **MEDICAL PROBLEMS AND TREATMENT:** None noted or stated.
7. **PSYCHOPHYSICAL TESTS:** Modified Romberg Balance: Suspect swayed approximately 4" front to back and 4" side to side until losing his balance and the test was stopped for safety reasons. Walk & Turn: The suspect could not maintain his balance in the instructions stage and the test had to be stopped for safety reasons. One Leg Stand: Suspect could not stand on one foot and nearly fell each time. The test was stopped for safety reasons. Finger to Nose: The suspect was unable to complete the test and it was also stopped for safety reasons.
8. **CLINICAL INDICATORS:** The suspect's pupils were dilated in all three lighting conditions. His pulse, blood pressure and body temperature were elevated and above the DRE average ranges.
9. **SIGNS OF INGESTION:** None noted or stated.
10. **SUSPECT'S STATEMENTS:** When asked about drug use, the suspect started laughing.
11. **DRE'S OPINION:** In my opinion Elliott is under the influence of a Hallucinogen and unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** The suspect provided a urine sample.
13. **MISCELLANEOUS:**

R5/13

Session 26

Preparing the Narrative Report



Session 26- Preparing the Narrative Report

Learning Objectives

- **Discuss the essential elements of the drug influence evaluation report**
- **Prepare a clear and concise narrative description of the results of the drug influence evaluation**




Drug Recognition Expert Course 26-2

Briefly review the objectives, content and activities of this session.

Upon successfully completing this session the participant will be able to:

- Discuss the essential elements of the drug influence evaluation report.
- Prepare a clear and concise narrative description of the results of the drug influence evaluation.

CONTENT SEGMENTS

- A. Components of the Process
- B. Components of the Drug Evaluation Report
- C. Drug Evaluation Narrative Report Format
- D. Sample Report

LEARNING ACTIVITIES

Instructor Led Presentations
Interactive Discussion

Session 26- Preparing the Narrative Report

The DRE Report

- **Complete, clear, convincing**
- **Well written**
- **Descriptive, detailed and complete**
- **Organized, clearly documented, and compelling**




Drug Recognition Expert Course
26-3

A. Components of the Process

The DRE Report

Successful prosecution depends on how clearly, completely and convincingly the DRE presents their observations, measurements, and conclusions.

A well written, clear, and convincing drug evaluation report increases the likelihood that the suspect will be convicted.

- A prosecutor is more likely to file the charge if the evidence is organized, clearly documented and compelling.

Point out that prosecutor's decision is generally based on the offense/arrest report and, consequently, if they cannot find the information they need, they are more likely to plea bargain or dismiss the charge.

- The defense is less likely to contest the charge when the report is descriptive, detailed, and complete.

Point out that evidence gathered during the drug influence evaluation is rarely challenged when it is well documented on the evaluation form and backed up by a detailed narrative report.

Session 26- Preparing the Narrative Report

Sample Drug Influence Evaluation Face Sheet

Drug Recognition Expert Course

26-4

B. Components of the Drug Influence Evaluation Report

The Face Sheet

The Drug Influence Evaluation Face Sheet is part of your drug influence evaluation report; but it is not the entire report.

The Face Sheet contains some very important information.

Examples:

- Suspect's pulse rate was elevated on all three measurements.
- Suspect's eyes failed to converge.
- Suspect's pupils were constricted.

Point out some of the key information on the sample Face Sheet.

But the Face Sheet does not contain all of the important information that is available concerning this suspect.

Session 26- Preparing the Narrative Report

Drug Influence Evaluation Face Sheet

- The Drug Influence Evaluation Face Sheet is a technical document
- Trained DREs know how to complete and interpret the Face Sheet
- To assist with the interpretation of the information on the face sheet, boxes on the face sheet should not be left blank
- It is recommended that “N/A” or “None Observed” be used




Drug Recognition Expert Course 26-5

Most importantly, the Drug Influence Evaluation Face Sheet is a technical document.

- Trained DREs know how to complete and interpret the Face Sheet.

Remind participants that to assist with the interpretation of the information on the face sheet, boxes on the face sheet should not be left blank. It is recommended that “N/A” or “None Observed” be used.

Ask participants to suggest some important information that might be available that wouldn't appear on the Face Sheet.

Examples:

- Information obtained during the interview of the arresting officer.
- Elaborate or lengthy statements made by the suspect.
- Paraphernalia found in the suspect's possession.

Many prosecutors, judges, and jurors won't know how to interpret the face sheet.

- It is up to you to take all of the information you work so hard to obtain, and put it into a clear, plain English, written report so that the prosecutor, the judge, and the jury will understand what you observed and what it means.

Session 26- Preparing the Narrative Report

Drug Influence Evaluation Face Sheet (Cont.)

- K.I.S.S. Principle

“Keep It Simple Stupid”



Drug Recognition Expert Course 26-6

Remind participants of the K.I.S.S. principle – (Keep It Simple Stupid). While using very technical terminology is OK, the DRE must remember that it does no good to have a report that no one but them can understand.

As a DRE, you have a special ability to secure powerful, scientific evidence that can make the difference between success and failure in court.

It would be a shame to waste that special ability by submitting an inadequate written report.

Session 26- Preparing the Narrative Report

Drug Influence Evaluation Face Sheet (Cont.)

The information contained on the Face Sheet is systematic, standardized, and the results are recorded in detail




Drug Recognition Expert Course 26-7

To ensure that the information contained on the Face Sheet is systematic and standardized, the results of the tests should be recorded as follows:

Lack of Convergence

- A dot should be made where the pupil is and draw an arrow to indicate the movement and where the pupil stops.

Modified Romberg Balance

- The first figure indicates the sway from front to back and should be estimated in inches from center.

Show the participants an example.

Remind them that in their participant manuals are a complete description of the correct way to mark their evaluations.

- The second figure indicates the sway from side to side and is estimated in inches from center.

Show the participants an example.

- Put the approximate number of inches from center the suspect sways on either end of the arrows.
- Record actual elapsed time.

Demonstrate how each clue is to be documented using flip-charts or dry erase board.

Session 26- Preparing the Narrative Report

Drug Influence Evaluation Face Sheet (Cont.)

How to record the Walk and Turn test results




Drug Recognition Expert Course 26-8

Walk and Turn

- The first two – cannot keep balance and stops too soon – are observed during the instruction stage.
- Indicate by a check mark the number of times the suspect stops, misses heel-to-toe, steps off line, or raises arms.
- Record the actual number of steps taken.
- If the suspect stops walking, indicate where with a vertical slash mark and an “S” under that mark.
- If the suspect steps off the line, indicate with half of a slash mark at an angle in the direction the step was off the line.
- If the suspect misses heel-to-toe, indicate with a vertical slash mark and an “M” under that mark.
- Describe turn.

Demonstrate how each clue is to be documented using flip-charts or dry erase board.

Session 26- Preparing the Narrative Report

Drug Influence Evaluation Face Sheet (Cont.)

How to record the One Leg Stand and the Finger to Nose tests




Drug Recognition Expert Course 26-9

One Leg Stand

Demonstrate how each clue is to be documented using flip-charts or dry erase board.

- Indicate in the one leg stand box the number they were counting when they put their foot down.
- Check marks should be made to indicate the number of times the suspect swayed, used arms, hopped, or put foot down.
- Indicate how far the suspect counted in 30 seconds in the top area of the box above the foot raised.

Demonstrate how each clue is to be documented using flip-charts or dry erase board.

Finger to Nose

- A line should be drawn to the appropriate triangle or circle to indicate where the suspect touched their nose.
- Suggestion – If the DRE draws the line from the place where the suspect touches to the triangle it enables them to draw a straighter line.

Solicit participants' comments and questions about the Narrative Report.

Session 26- Preparing the Narrative Report

Components of the Drug Evaluation Narrative Report

- **Location**
- **Witnesses**
- **Breath Alcohol Test**
- **Notification and Interview of Arresting Officer**




Drug Recognition Expert Course 26-10

C. Drug Evaluation Narrative Report Format

The Narrative Report

The typical Drug Evaluation Narrative Report format contains 13 components.

First item: Location (i.e. where the evaluation was conducted).

Second item: Witnesses

- List the person who served as the evaluator and the recorder with the complete agency name spelled out.
- Other officers who helped to conduct the evaluation.
- Others who observed the evaluation.
- Include any instructors who witnessed the evaluation.

Third item: the Breath Alcohol Test

- Indicate BAC.
- Who administered the breath alcohol test.
- Time the test was administered.

Fourth item: Notification and Interview of the Arresting Officer

- When were you first notified of the request for a drug evaluation?
- Summarize the information you were given at that time.
- Document any information provided by the arresting officer.
- Summary of your interview with the arresting officer and other witnesses.

Session 26- Preparing the Narrative Report

Components of the Drug Evaluation Narrative Report (Cont.)

- Initial observations of the suspect
- Medical problems and treatment
- Psychophysical indicators of impairment




Drug Recognition Expert Course
26-11

Fifth item: Initial Observation of the Suspect

- Where you first saw the suspect.
- Noteworthy aspects of your initial observations.
- Findings of the Preliminary Examination of the suspect.

Sixth item: Medical Problems and Treatment

- Your observations of any apparent injury or illness affecting the suspect.
- suspect's statements of injury or illness.
- Summary of any medical treatment provided to the suspect.

Point out that DREs should document as much information as possible about any reported medical issues claimed by the suspect, and if medical treatment is warranted, it should be arranged.

Seventh item: Psychophysical Indicators of Impairment

- Briefly summarize performance of the Modified Romberg Balance, Walk and Turn, One Leg Stand, and Finger to Nose tests.
- Include any relevant behaviors on the tests that are not included on the face sheet.

Session 26- Preparing the Narrative Report

Components of the Drug Evaluation Narrative Report (Cont.)

- Clinical indicators of impairment
- Signs of ingestion




Drug Recognition Expert Course 26-12

Eighth item: Clinical Indicators of Impairment

Point out that in this section of the DRE's report the word "normal" or words "normal ranges" refers to the results of the specific test within the DRE average range(s).

Eye signs

- Briefly summarize your observations of HGN, VGN, Lack of Convergence, pupil size, reaction to light, and appearance of the suspect's eyes.
- Document any observations of eyelid tremors.

Vital signs

- Briefly summarize the suspect's pulse rate, blood pressure, and temperature.
- Document if body, leg, or eyelid tremors are present.

Ninth item: Signs of Ingestion

- Results of examinations of oral and nasal cavities.
- Results of examinations for injection marks.
- Odors detected on suspect's breath, hands, clothing, etc.
- Physical debris of drugs or drug paraphernalia found on suspect's person.

Session 26- Preparing the Narrative Report

Components of the Drug Evaluation Narrative Report (Cont.)

- Suspect's statements
- DRE's opinion




Drug Recognition Expert Course 26-13

Tenth item: Suspect's Statements.

- "Miranda" waiver and responses.

Remind participants to contact their local prosecutor's office for information on when to give Miranda during the evaluation.

- Volunteered or spontaneous statements.
- Statements made as a result of your interview.
- Include admission or denial of drug use, time, location drugs were used, and statements relating to the suspect's perception of their impairment, if applicable.

Eleventh item: DRE's Opinion.

Remind the participants that anytime they have a positive BAC reading, they must list alcohol (ETOH) as part of the opinion.

- State the category or categories of drugs that you believe is/are affecting the suspect.
- State your opinion concerning the suspect's ability to operate a vehicle safely, if applicable to this case.

Write on a flipchart or dry erase board the proper wording of the DRE's opinion: "It is my opinion that the suspect (name) is under the influence of (drug category) and unable to operate a vehicle safely."

Session 26- Preparing the Narrative Report

Components of the Drug Evaluation Narrative Report (Cont.)

- Toxicological sample
- Miscellaneous



Drug Recognition Expert Course 26-14

Twelfth item: Toxicological Sample

If available, show participants a copy of a toxicology request form that they will be using.

Remind the participants that if they have a tracking number on the toxicology request form, that they should also include that number in the report.

State the type of sample (urine, blood, etc.) obtained from the suspect.

- State who drew the sample or observed the collection of the sample.
- State where the sample was taken and to whom it was given.
- If the suspect refused to provide a sample, state that fact.

Thirteenth item: Miscellaneous

Any other pertinent information such as drugs or drug paraphernalia found in the suspect's possession.

Session 26- Preparing the Narrative Report

Sample Report



Drug Recognition Expert Course 26-15

D. Sample Report

Direct the participants' attention to the Sample Drug Evaluation Report (Richardson) in Session 26 of their Participant Manual.

A copy of this report is found at the end of this lesson plan, for your reference.

Briefly review all thirteen items of the report with the participants , including the proper terminology for the DRE's opinion.

Session 26- Preparing the Narrative Report

QUESTIONS?



Drug Recognition Expert Course

Solicit their comments and questions about the report.

DRUG INFLUENCE EVALUATION

Evaluator Officer Alan Haywood, AZ DPS		DRE # 10149	Rolling Log # 12-10-124	Session XXVI									
Recorder/Witness Sgt. Paul White, Maricopa Co. S.O.		Crash: <input checked="" type="checkbox"/> None <input type="checkbox"/> Fatal <input type="checkbox"/> Injury <input type="checkbox"/> Property		Case # 12-398776									
Arrestee's Name (Last, First, Middle) Richardson, John M.		Date of Birth 9/6/84	Sex M	Race W	Arresting Officer (Name, ID#) Officer Kemp Layden, Phoenix PD #7022								
Date Examined / Time / Location 10/21/12 2130 Maricopa Co. Jail		Breath Results: Results: 0.00		Test Refused <input type="checkbox"/> Instrument #: 474501	Chemical Test: Urine <input checked="" type="checkbox"/> Blood <input type="checkbox"/> Test or tests refused <input type="checkbox"/>								
Miranda Warning Given Given By: Officer Layden	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? Hamburger 5 PM	What have you been drinking? Nothing	How much? N/A	Time of last drink? N/A								
Time now/ Actual 7 pm/9:40 pm	When did you last sleep? How long Last night 4 hrs.	Are you sick or injured? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No "Bad back"		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No									
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No									
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No Long pause before answering		Attitude: Cooperative, withdrawn		Coordination: Poor, trouble standing									
Speech: Low, slow, raspy		Breath Odor: Normal		Face: Pale									
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Reddened Conjunctiva <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Bloodshot <input type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right									
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No									
Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal		Eyelids: <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Droopy											
Pulse and time 1. <u>58</u> / <u>2142</u> 2. <u>56</u> / <u>2154</u> 3. <u>58</u> / <u>2212</u>	HGN Lack of Smooth Pursuit Maximum Deviation Angle of Onset	Left Eye No No None	Right Eye No No None	Convergence Right eye Left eye									
Modified Romberg Balance Head dropped forward	Walk and Turn test Cannot keep balance <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Starts too soon Stops walking Misses heel-toe Steps off line Raises arms Actual steps taken		1st Nine 2nd Nine <table border="1" style="display: inline-table;"><tr><td>✓✓✓</td><td>✓✓✓</td></tr><tr><td>✓✓✓</td><td>✓✓✓</td></tr><tr><td>✓✓✓</td><td>✓✓✓</td></tr><tr><td>9</td><td>9</td></tr></table>		✓✓✓	✓✓✓	✓✓✓	✓✓✓	✓✓✓	✓✓✓	9	9	21 ONE LEG STAND 23 L R <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Sways while balancing <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Uses arms to balance <input type="checkbox"/> <input type="checkbox"/> Hopping <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> Puts foot down Counted slowly
✓✓✓	✓✓✓												
✓✓✓	✓✓✓												
✓✓✓	✓✓✓												
9	9												
Internal clock 52 estimated as 30 seconds	Describe Turn: Pivoted		Cannot do test (explain): N/A		Type of footwear: Athletic shoes								
Draw lines to spots touched Switched hands on #5 and #6		PUPIL SIZE	Room light	Darkness	Direct								
		Left Eye	2.0	4.5	1.5								
		Right Eye	2.0	4.5	1.5								
		REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		REACTION TO LIGHT: Little to None Visible									
		RIGHT ARM 		LEFT ARM Scars 									
Blood pressure 114/68	Temperature 97.2	Muscle tone: <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Flaccid <input type="checkbox"/> Rigid		Comments: Arms cool to the touch									
What drugs or medications have you been using? "I don't do drugs"		How much? No answer	Time of use? No answer	Where were the drugs used? (Location) No answer									
Date / Time of arrest: 10/21/12 2025	Time DRE was notified: 2115	Evaluation start time: 2130	Evaluation completion time: 2230	Precinct/Station:									
Officer's Signature:		DRE # 10149	Reviewed/approved by / date:										
Opinion of Evaluator:		<input type="checkbox"/> Rule Out	<input type="checkbox"/> Alcohol	<input type="checkbox"/> CNS Stimulant	<input type="checkbox"/> Dissociative Anesthetic								
		<input type="checkbox"/> Medical	<input type="checkbox"/> CNS Depressant	<input type="checkbox"/> Hallucinogen	<input type="checkbox"/> Inhalant								
				<input checked="" type="checkbox"/> Narcotic Analgesic	<input type="checkbox"/> Cannabis								

DRUG INFLUENCE EVALUATION NARRATIVE

Suspect: **Richardson, John**

1. **LOCATION:** The evaluation was conducted in the DRE interview room at the Maricopa County Jail. The room has adequate lighting and has a concrete floor with sufficient space for conducting an evaluation.
2. **WITNESSES:** Sergeant Paul White of the Maricopa County SO witnessed and recorded the entire evaluation. Arresting officer Kemp Layden observed the preliminary exam and the psychophysical tests.
3. **BREATH ALCOHOL TEST:** Officer Layden obtained a breath test from the suspect prior to my arrival. Officer Layden used the Intoxilyzer 8000 at the Jail and obtained a 0.00 BrAC at 2100 hours.
4. **NOTIFICATION AND INTERVIEW OF THE ARRESTING OFFICER:** I was on-duty and at approximately 2115 hours was dispatched to the Maricopa Co. Jail to conduct a drug evaluation for Officer Layden. I contacted Officer Layden at the Jail where he informed me that the suspect had been arrested during a DUI crackdown event. The suspect was observed driving slowly and failed to stop at a red light at McDowell Road and 40th Street. When Officer Layden activated his emergency lights to stop the suspect, he continued on for approximately a half mile before stopping and when he did, his right front tire struck the curb. When contacted, the suspect's voice was low and raspy sounding. When asked for his operator's license and other documents, he appeared confused and had slow and deliberate movements. When he exited his vehicle he had to use the car door to balance himself and he was unsteady with poor balance and coordination. The suspect was administered SFST's which he had difficulty with. Several times during the Walk and Turn and the One Leg Stand he lost his balance and nearly fell and the tests had to be stopped for his safety. According to Officer Layden, the suspect did not show any clues of HGN and he did not detect an odor of alcoholic beverage on the suspect's breath. The suspect was arrested for DUI and transported to the Maricopa County Jail.
5. **INITIAL OBSERVATION OF SUSPECT:** I first observed the suspect in the interview room at the Jail. He moved very slowly, was unsteady of his feet and when he walked across the room he lost his balance and had to use the wall to steady himself. Several times his head nodded forward and he appeared to be "on the nod." When he answered questions from Officer Layden, his speech was slow and at times he slurred his words. His eyelids were droopy appearing and he was frequently licking his lips.
6. **MEDICAL PROBLEMS AND TREATMENT:** During the preliminary examination the suspect indicated that he had a "bad back." When asked about his back, he indicated that it was sore and that he was not under a doctor's care for it. He was asked if his back would create any problems for him in performing the drug evaluation he said "it shouldn't." He was asked if he needed any medical assistance and he said he did not.

7. **PSYCHOPHYSICAL TESTS:** Each of the tests were explained and demonstrated to the suspect prior to him attempting them. After each demonstration, the suspect indicated that he understood the instructions. The suspect exhibited impairment throughout all portions of the psychophysical tests. At no time did he indicate that his difficulties were related to his back or any other condition.

Modified Romberg Balance: The suspect exhibited a front to back sway of approximately 2 inches and a side to side sway of approximately 3 inches. He had a slowed internal clock estimating 30 seconds in 52 seconds. While doing the test his head repeatedly dropped forward towards his chest.

Walk and Turn: Twice during the instruction stage the suspect lost his balance. Once he began walking, his steps were slow and deliberate. He missed heel to toe three times during the first nine steps and three times on the second nine steps. He turned incorrectly making a pivot. He also raised his arms for balance for the majority of the test.

One Leg Stand: The suspect counted slowly throughout the test making it to 1021 in 30 seconds while attempting to stand on his left foot and to 1023 while attempting to stand on his right foot. He also put his foot down three times while standing on his left foot and twice while standing on his right. Additionally, he swayed and used his arms for balance throughout both attempts.

Finger to Nose: The suspect responded to the commands very slowly and used the wrong hands on attempts #5 and #6. He did not touch the tip of his nose on any of the six attempts.

8. **CLINICAL INDICATORS:** Eyes: No clues of HGN were observed. His pupils were constricted in all three lighting conditions and his pupils showed little to no visible reaction to light.

Vital Signs: The suspect's pulse rates (58, 56, 58 bpm) were below the DRE average ranges for pulse rate and his blood pressure (114/68) was also below the DRE average range for blood pressure. His body temperature (97.2) was also below the DRE average range.

9. **SIGNS OF INGESTION:** Some old scars were located on the inside of his left forearm. When asked about the scars, the suspect stated, "That was a long time ago man." The suspect's muscle tone was flaccid and his arms felt cool to the touch.
10. **SUSPECT'S STATEMENTS:** The suspect repeatedly denied using drugs stating, "I told you, I don't do drugs."
11. **DRE'S OPINION:** In my opinion Richardson is under the influence of a Narcotic Analgesic and unable to operate a vehicle safely.
12. **TOXICOLOGICAL SAMPLE:** At 2220 hours a blood sample was collected from the suspect and was delivered to the Evidence Property Room pending an analysis by Arizona Crime Laboratory.
13. **MISCELLANEOUS:** The suspect was also cited for Driving While Suspended.

Session 27

Practice: Test Administration



Session 27 - Practice: Test Administration

Learning Objectives

- **Administer selected portions of the battery of examinations that constitute the drug influence evaluation**
- **Describe the evaluation procedures**
- **Document the results of the examinations**




Drug Recognition Expert Course
27-2

Briefly review the objectives, content and activities of this session.

Upon successfully completing this session the student will be able to:

- Administer selected portions of the battery of examinations that constitute the drug influence evaluation.
- Describe the evaluation procedures.
- Document the results of the examinations.

CONTENT SEGMENTS

- A. Procedures for this Session
- B. Hands-On Practice
- C. Session Wrap-Up

LEARNING ACTIVITIES

- Instructor Led Presentations
- Instructor Led Coaching
- Participant Led Coaching

Session 27 - Practice: Test Administration

Procedures for this Session

- Participants will work in teams
- At any given time, one member will be conducting and recording exams of the other member
- The third member of the team will coach and critique the conducting member
- Participants take turns performing each role




Drug Recognition Expert Course 27-3

A. Procedures for this Session

Team Assignments

- Participants will work in two or three member teams.

Three member teams are preferable. However, no four member teams should be constructed. Thus, for example, if the class has 25 participants, assign 7 three member teams and 2 two member teams.

Make team assignments.

- At any given time, one member of the team will be engaged in conducting and recording examinations of another member.
- The third member of the team will help coach and critique the participant who is conducting the examinations.
- Participants will take turns serving as test administrator, test subject, and coach.

Emphasize that participants can help each other learn by pointing out errors of omission or commission.

Session 27 - Practice: Test Administration

Hands-On Practice



Drug Recognition Expert Course 27-4

B. Hands-On Practice

Instruct participants to begin their practice.

Monitor the teams, and offer encouragement and constructive criticism, as appropriate.

Make sure each participant serves as the test administrator for at least one complete drug influence evaluation

Session 27 - Practice: Test Administration

Drug Influence Evaluation

- **Begin with the Preliminary Examination**
- **Ask all of the prescribed questions**
- **Conduct the initial check of the eyes**
- **Check the pulse for the first time**



Drug Recognition Expert Course 27-5

Drug Influence Evaluation

For this practice session, each participant will conduct a complete drug influence evaluation.

Instruct participants to review the standardized drug influence evaluation form in their manual.

Begin with the Preliminary Examination.

For practical purposes, not all 12-steps will be completed in this Session. Instructors should provide information to participants regarding steps one and two.

Ask all of the prescribed questions.

Conduct the initial check of the eyes.

Check the pulse for the first time.

Point out that the participant who is “coaching” should simultaneously take the subject’s pulse along with the test administrator.

Session 27 - Practice: Test Administration

Drug Influence Evaluation (Cont.)

- Conduct the test of Horizontal Gaze Nystagmus, Vertical Gaze Nystagmus and Lack of Convergence
- Administer the four divided attention psychophysical tests
- Check the vital signs




Drug Recognition Expert Course 27-6

Conduct the test of Horizontal Gaze Nystagmus, Vertical Gaze Nystagmus, and Lack of Convergence.

Point out that, when conducting the HGN test, the “coach” should check the participant administrator’s ability to estimate angles of 30, 40, and 45 degrees. If available, a template should be used for this check.

Administer the four divided attention psychophysical tests.

- Modified Romberg Balance test
- Walk and Turn test
- One Leg Stand test
- Finger to Nose test

Point out that it will not be necessary for the participant (subject) actually to perform these tests (except for Finger to Nose). It will suffice for the participant (administrator) simply to give the test instructions accurately and completely.

Check the vital signs.

- Blood pressure
- Temperature
- Check the pulse for the second time

Session 27 - Practice: Test Administration

Dark Room Examinations

- Conduct the dark room examinations
- Check for muscle tone
- Examine the participant (subject's) neck, arms, and ankles for signs of injection
- Check the pulse for the third time



Drug Recognition Expert Course 27-7

Dark Room Examinations

- Conduct the dark room examinations.

Point out that, for this practice session, these examinations will not actually be given in the dark

- Check for muscle tone.
- Examine the participant (subject's) neck, arms, and ankles for signs of injection.
- Check the pulse for the third time.

Solicit participants' questions concerning procedures for this practice session.

Session 27 - Practice: Test Administration

QUESTIONS?



Drug Recognition Expert Course

C. Session Wrap-Up

Solicit participants' comments and questions concerning Test Administration.

Session 28

Case Preparation and Testimony



Session 28 - Case Preparation and Testimony

Learning Objectives

- **Conduct a thorough pre-trial review of all evidence and prepare for testimony**
- **Provide clear, accurate and descriptive direct testimony concerning drug influence evaluations**
- **Respond effectively and appropriately to cross examination in DRE cases**




Drug Recognition Expert Course 28-2

Briefly review the objectives, content, and activities of this section.

Upon successfully completing this session, participants will be able to:

- Conduct a thorough pre-trial review of all evidence and prepare for testimony.
- Provide clear, accurate, and descriptive direct testimony concerning drug influence evaluations.
- Respond effectively and appropriately to cross examine in DRE cases.

CONTENT SEGMENTS

- A. Guidelines for Case Preparation
- B. Guidelines for Direct Testimony
- C. Typical Defense Tactics

LEARNING ACTIVITIES

- Instructor Led Presentations
- Instructor Led Demonstrations
- Reading Assignments

Session 28 - Case Preparation and Testimony

Preparation

- **Begins during your initial investigation**
- **Review all records and reports**
- **Review all evidence and your conclusion**
- **Review notes with arresting officer**
- **Clarify or resolve any discrepancies**





Drug Recognition Expert Course 28-3

A. Guidelines for Case Preparation

Preparation

Preparation to present your case in court begins during your initial investigation.

The quality of your investigation and documentation will ultimately determine your ability to accurately present information during trial.

Point out that it is especially important to take complete and accurate notes of your investigation and observations. Complete documentation of this information is essential.

When you receive the trial notice you should schedule a pre-trial conference with the prosecutor.

- Review all records and reports associated with the case.
- Review all evidence and your conclusion.
- Review notes with arresting officer.
- Review any weak areas.
- Clarify or resolve any discrepancies.

Session 28 - Case Preparation and Testimony

Preparation (Cont.)

- Review and prepare for defense tactics
- Review C.V. and other credentials



Drug Recognition Expert Course 28-4

- Review questions the prosecutors will be asking.
- Review typical tactics the prosecutors expect the defense to use.
- Review your curriculum vitae and credentials.

If a pre-trial conference is not possible, identify the main points of the case and discuss them with the prosecutor during the few minutes before the trial.

- It is very important to meet with prosecutors that have never been exposed to the DEC Program before trial to explain that it can not be treated like a typical DUI trial. You must explain that there are different protocols for DUI vs. DRE cases.
- Excellent resources for prosecutors can be obtained through the National Traffic Law Center. Another excellent resource is your state's Traffic Safety Resource Prosecutor (TSRP).

Session 28 - Case Preparation and Testimony

Direct Testimony

- **Relate training and experience**
- **If possible, don't allow defense to stipulate that you are an expert**




Drug Recognition Expert Course 28-5

B. Guidelines for Direct Testimony

Direct Testimony

Although knowledge only greater than what the public has is required to qualify as an “expert,” your testimony will carry much more weight if you have good credentials.

Qualifications will be established during Voir Dire:

Voir Dire is a French expression literally meaning “to see, to say.” Loosely, this would be rendered in English as “to seek the truth,” or “to call it as you see it.” In a law or court context, one application of voir dire is to question a witness to assess his or her qualifications to be considered an expert in some matter pending before the court.

When testifying, relate training and experience to the type of arrest being tried (e.g., DWI, Methamphetamine, Cocaine, etc.)

Being qualified as an expert in the past does not automatically qualify you as an expert in a particular court case.

- Highlight fact that you were selected to attend specialized DRE training, not just assigned randomly.

Point out that officers should document all previous cases where they were qualified as an expert.

- If possible, do not allow the defense to stipulate that you are an expert.

Session 28 - Case Preparation and Testimony

Direct Testimony (Cont.)

- **Document and record evaluations conducted**
- **Establish your credibility**
- **Make sure to include minor details**
- **Be fair and impartial**



Drug Recognition Expert Course 28-6

- Document and record all evaluations conducted. Establish ratio of evaluations that resulted in a finding that the subject was not under the influence.
- Highlight the number of times you have seen a person under the influence of the drug(s) in question and have observed the symptomatology, etc.
- Ability to answer specific questions with confidence, skill and exactness will bolster a professional image in the eyes of the judge and/or jury.

Session 28 - Case Preparation and Testimony

New Scientific Principle

- Remember that jurors are unfamiliar with most scientific principles
- American courts employ either the Frye or the Daubert standards for determining the admissibility of scientific evidence

“Frye vs. U.S.” (D.C. Cir. 1923)





Drug Recognition Expert Course 28-7

New Scientific Principle

Point out that they aren't really new just not within the common realm of knowledge of the average person.

- The scientific principles are unfamiliar to the jury or judge.

Your task is to establish that your hard work through training will be acceptable in the court.

- American courts employ either the Frye or the Daubert standards for determining the admissibility of scientific evidence.

Discuss the appropriate rule of evidence for your jurisdiction.

The landmark case “Frye vs. U.S.” “Frye vs. U.S.” 293F 1013 (D.C. Cir. 1923).

Frye requires that the scientific principle or theory used to support “evidence” be in conformity with a generally accepted explanatory theory, if the “evidence” is to be admissible.

Point out it is not enough that qualified experts testify that a particular scientific technique is valid. The technique must be generally accepted by the relevant scientific community.

Session 28 - Case Preparation and Testimony

New Scientific Principle (Cont.)

Courts assess scientific testimony by considering four factors:

- **Opinions that are testable**
- **Peer reviewed methods/principles**
- **Known error rates**
- **Methodology accepted within the scientific/technical community**



Drug Recognition Expert Course 28-8

In Daubert, courts serve as a gatekeeper for all scientific evidence.

Source: *Daubert vs. Merrell Dow Pharmaceuticals, Inc.*, 509 U.S. 579 (1993).

Courts assess evidence by considering four factors:

- Opinions are testable.
- Methods/principles have been subject to peer review.
- Known error rate can be identified.
- Opinions rest on methodology that is generally accepted within the relevant scientific/technical community.

Session 28 - Case Preparation and Testimony

General Guidelines

- **Basic job – To present the findings of your investigation that the suspect was under the influence of a drug or some combination of drugs**
- **Don't be afraid to say "I don't know"**
- **Remember that some jurors focus on officer demeanor more than content of testimony**





Drug Recognition Expert Course
28-9

General Guidelines

- Basic job is to present the findings of your investigation that the suspect was under the influence of a drug or some combination of drugs. Keep this in mind at all times.
- Don't be afraid to say "I don't know."

Point out that the officer is not expected to be an expert on all aspects of all drugs.

- Testify to only what you know.
- Remember, an expert witness can rely on hearsay to develop his or her expertise.

Avoid contact with the defense attorney if possible.

Don't be upset if prosecutor and defense attorney appear friendly to each other.

Remind participants that both sides have a specific role to play in the case at hand, but that does not preclude a personal or professional relationship.

- Remember, some jurors focus on an officer's demeanor more than content of testimony.

Point out that an officer should be polite and courteous during testimony. Do not become agitated as a result of defense questions. Do not take personal issue with defense statements, stick to the facts.

Session 28 - Case Preparation and Testimony

General Guidelines (Cont.)

- Review materials before court
- Use layman's language
- Don't testify on subject matter that was excluded
- Do not use "pass" or "fail"
- Be prepared to describe DRE terms if used





Drug Recognition Expert Course 28-10

Do not bring manuals or articles into court for reference.

- Review materials before court to become familiar with contents.
- Explain technical terms in layman's language. For example, HGN means an involuntary jerking of the eyes occurring as the eyes gaze to the side.
- Pay attention to what evidence or testimony can be and is excluded.

Point out that if the officer testifies on subject matter that was excluded, it could result in a mistrial.

When describing subject's performance on SFST's, explicitly describe exactly what the subject did or neglected to do.

Point out that the terms "pass" or "fail" should not be used. Describe actual performance. The defense will try to trip you up on this point...there are no passing and failing marks.

Point out that if terms "normal" or "within normal" are used in the DRE report, be prepared to describe what those terms mean and how they relate to the DRE average ranges (i.e., pupil size, pulse, blood pressure, etc.)

Session 28 - Case Preparation and Testimony

General Guidelines (Cont.)

- **Subject's performance is describable evidence**
- **All evidence taken into account before forming an opinion**
- **Explain "why" in great detail**



Drug Recognition Expert Course 28-11

- Results of subject's performance are describable evidence.
- Be sure to emphasize that all evidence is taken into account before forming an opinion.
- If defense attorney asks a "why" question, take the opportunity to explain in great detail if appropriate.

Point out that this suggestion does not mean that the officer should embellish his or her testimony...be careful not to open any doors for the defense.

Session 28 - Case Preparation and Testimony

Typical Defense Tactics

- **Challenging your observations and interpretations**
- **Challenging your credentials**



Drug Recognition Expert Course

NHTSA
www.nhtsa.gov

28-12

C. Typical Defense Tactics

Point out that the defense attorney's job is to try and create a "reasonable doubt." Don't take it personally.

The defense relies on several factors to "impeach" or discredit your testimony.

The defense will challenge your observations and interpretations. They will attempt to show that the signs, symptoms and behaviors observed have other explanations.

Defense will challenge your credentials...a bona fide expert has both formal training resulting in a high degree of knowledge and experience in applying knowledge, resulting in a skill.

Point out that if the defense can discredit your training and /or experience, your testimony will have little "weight" with the jury.

By demonstrating the officer lacks depth of knowledge in the drug field by contrasting his or her knowledge with the defense expert's knowledge.

- The trial tactic is to show that the officer does not have the expertise to accurately determine the cause of intoxication / impairment because of inadequate formal training which lessens the value of his/her field experience and increases likelihood that he/she is mistaken in his/her conclusion.

Session 28 - Case Preparation and Testimony

Typical Defense Tactics (Cont.)

Challenging your credibility through:

- Inconsistencies
- Comparison with past testimony
- Testimony at odds with other experts
- Lack of recall
- Demonstrating that parts of the drug evaluation were conducted incorrectly




Drug Recognition Expert Course 28-13

Some examples of challenging your credibility are:

Inconsistencies:

- Arresting officer's and examining officer's testimony must be complimentary. Any differences must be explained.
- Get your facts straight and stick to them.

Comparison with past testimony:

- Try to get copies of transcripts of previous trials to review your strong/weak points. If possible, review your testimony with the prosecutor.

Testimony that is at odds with other established experts:

- Do your homework...review the literature. Explain any differences if possible.

Lack of recall:

- Try to be prepared, but don't be afraid to say "I don't know." Be honest.

By demonstrating that the officer incorrectly performed part of the evaluation, resulting in an erroneous conclusion.

Point out that the evaluation should be performed "by the book" each and every time it is conducted.

Session 28 - Case Preparation and Testimony

Role of Defense Expert

Pupillary Examinations

- **Where the examinations took place**
- **How dark was the examining room**
- **The size and power of the penlight**
- **Where the defendant was placed in relationship to the examiner**
- **Where the penlight was directed during the examination**




Drug Recognition Expert Course 28-14

Role of Defense Expert

To impeach credibility of the arresting officer and/or the prosecution expert

- My expert vs. your expert. Usually they are 180 degrees apart in their opinions.

To present alternative conditions and states that could have produced the same or similar symptoms

Typical Defense Questions

Pupillary examinations:

- Where the examination took place.
- How dark was the examining room.
- The size or power of the penlight.
- Where the defendant was placed in relationship to the examiner.
- Where the penlight was directed during the examination?

Session 28 - Case Preparation and Testimony

Role of Defense Expert (Cont.)

- Where the defendant was looking during the examination
- How many times each pupil was checked
- Are there any physical illnesses or conditions that manifest the same signs as the drug(s) in question



Drug Recognition Expert Course 28-15

Typical Defense Questions (Cont.)

- Where the defendant was looking during the examination?
- How many times each pupil was checked?
- Are there any physical illnesses or conditions that manifest the same signs as the drug(s) in question?

Point out that the list of possible answers is almost interminable.

Session 28 - Case Preparation and Testimony

Role Play

- **What is a DRE**
- **What is involved in DEC Training Program**
- **How do you properly identify the drug category or categories**
- **How do explain the DRE opinion**
- **What are the components of a drug influence evaluation**



Drug Recognition Expert Course

28-16

Suggested role play to discuss the following questions:

- What is a DRE?
- What is involved in the DEC training program?
- How do you properly identify the drug category or categories?
- How do you explain the DRE opinion?
- What are the components of a drug influence evaluation?

Session 28 - Case Preparation and Testimony

QUESTIONS?



Drug Recognition Expert Course

28-17

Solicit participants' comments and questions concerning case preparation and testimony.

DRE DEFENSE CROSS EXAMINATION QUESTIONS

The following are representative of questions the defense may use to challenge the DRE's in court. (The defendant is identified as Miss Alicia Ann Ace.)

Missing Symptoms/Normals

This line of questions attempts to elicit the fact that the defendant did not have all of the expected signs or symptoms of the drug (s) in question.

Officer, you were taught that bruxism or grinding of the teeth is a sign of CNS Stimulant influence, isn't it? Miss Ace didn't have that sign, did she?

The defense may also focus on those signs or symptoms that were normal, and were therefore, not consistent with the drug in question.

Officer, you learned the normal range of temperature in DRE training, didn't you? And that range is 98.6 plus or minus one degree, isn't it? What was Miss Ace's temperature? (98) 98 is within normal ranges, isn't it? Miss Ace's temperature was normal, wasn't it? CNS Stimulants cause elevated temperature, don't they? Miss Ace's was not elevated, was it?

Alternative Explanations

The defense elicits alternative explanations for the signs and symptoms of the drug (s) in question. These alternative explanations usually deal with medical conditions, stress, a traffic crash, etc.

Officer, an elevated pulse rate can be caused by things other than drugs, can't it? Excitement may cause it? Stress may cause it? Being involved in a traffic crash is stressful, isn't it? And being involved in a traffic crash may cause elevated pulse, right? Being interviewed in the early morning by three police officers is stressful? And that may also cause the pulse to be elevated, can't it?

Defendant's Normals

The defense attempts to emphasize the fact that not everyone is so-called normal, that normal is subjective.

Officer, you were taught the normal range for pulse in DRE training, weren't you? And you agree that not all people fall in that normal range, don't you? That there are people with pulse rates above normal that aren't on drugs, right? A person's pulse changes over time, doesn't it? You don't know what Miss Ace's normal pulse is, do you? It could be in the normal range, right? But it could be above or below the normal range - normally for her, isn't that so?

Doctor Cop

The line of questioning challenges the credibility of the officer's teachers - that they are police officers, rather than medical professionals.

Officer, the teachers in this DRE school weren't doctors, were they? They weren't nurses either? Toxicologists? Pharmacologists? Paramedics? They were police officer, right?

Just a Cop

This line of questioning challenges the DRE's credentials - that they are "just a cop." This infers that the DRE evaluation is actually a medical evaluation that should be undertaken only by a medical professional.

Officer, you're not a doctor, are you? A toxicologist? A pharmacologist? A nurse? A physiologist? You don't have a degree in chemistry, do you? You're a police officer, right?

The Unknown

By causing the officer to state that they don't know how a sign or symptom is caused, the defense attacks the officer's credibility. This line of questioning challenges the officer's expertise, by implying that a real expert would know these things.

Officer, you don't know how CNS Stimulants dilate the pupil, do you? You don't know how alcohol supposedly causes Nystagmus, do you? You don't know how CNS Stimulants supposedly elevate the heart rate, do you?

Guessing Game

This tactic attacks the DRE's opinion as a subjective guess, a belief, rather than objective. Guesses can be wrong.

Officer, your opinion in a DRE case is subjective, isn't it? It's a belief on your part? You've made these beliefs in DRE cases in the past, haven't you? A sometimes toxicology didn't find the drug you predicted, isn't that so? And, in fact, sometimes, toxicology didn't find any drug, isn't that so? And so, sometimes your opinion is not correct, right? Sometimes, you guess wrong?

Review of the DRE School

Review of the DRE School



Drug Recognition Expert Course

Review of the DRE School

How do we define the term “drug” for DRE purposes?

“Any substance that, when taken into the human body, can impair the ability of the person to operate a vehicle safely”



Drug Recognition Expert Course Review-2

How do we define the term “drug” for DRE purposes?

“Any substance that, when taken into the human body, can impair the ability of the person to operate a vehicle safely.”

Review of the DRE School

Basic Drug Statistics

- What drug other than alcohol was found most frequently in the Los Angeles Field Validation Study?
- What does “polydrug use” mean?



Drug Recognition Expert Course Review-3

Basic Drug Statistics

- What drug other than alcohol was found most frequently in the Los Angeles Field Validation Study?

PCP

- What does “polydrug use” mean?

Ingesting drugs from two or more drug categories

Review of the DRE School

Basic Drug Statistics

- How common was polydrug use in the LA Field Validation Study?
- How good were the DREs in the Field Validation Study?



Drug Recognition Expert Course Review-4

Basic Drug Statistics

- How common was polydrug use in the LA Field Validation Study?

More than 70% of the suspects had two or more drug categories in them

- How good were the DREs in the Field Validation Study?

Nearly 80% of the time when the DREs said a particular category of drugs was present, that category was found in the suspect's blood.

In more than 90% of the suspects, the DREs correctly identified at least one of the categories that were present

Review of the DRE School

Basic Drug Statistics

- In the University of Tennessee Study, what percentage of injured drivers had drugs other than alcohol in them?



Drug Recognition Expert Course

Review-5

Basic Drug Statistics

- In the University of Tennessee Study, what percentage of injured drivers had drugs other than alcohol in them?

40% of those drivers had evidence of other drugs in their urine

Review of the DRE School

Review of Symptomatology

- **Name six different CNS Depressants**
- **Name four different CNS Stimulants**
- **Name two naturally-occurring Hallucinogens**
- **Name four different synthetic Hallucinogens**



Drug Recognition Expert Course Review-6

Review of Symptomatology

- Name six different CNS Depressants
- Name four different CNS Stimulants
- Name two naturally-occurring Hallucinogens
- Name four different synthetic Hallucinogens

Review of the DRE School

Review of Symptomatology

- **Name a major analog of PCP**
- **Name the three sub-categories of Inhalants**
- **What is the active ingredient in Cannabis?**



Drug Recognition Expert Course Review-7

Review of Symptomatology

- Name a major analog of PCP
- Name the three sub-categories of Inhalants
- What is the active ingredient in Cannabis?

Review of the DRE School

Review of Vital Signs: Pulse Rate

- Define “Pulse”
- True or false: Pulse rate is measured in units of “millimeters of mercury”.



Drug Recognition Expert Course Review-8

Review of Vital Signs

- Define “Pulse”

Contraction and expansion of an artery, generated by the pumping action of the heart

- True or false: Pulse rate is measured in units of “millimeters of mercury”.

FALSE: pulse rate is measured in “beats per minute”

Review of the DRE School

Review of Vital Signs: Pulse Rate (Cont.)

- Name three different pulse points, and indicate where they are located.
- What is the “normal” range of adult human pulse rate, for DRE purposes?



Drug Recognition Expert Course Review-9

Review of Vital Signs: Pulse Rate (Cont.)

- Name three different pulse points, and indicate where they are located.

Radial, Brachial and Carotid pulse points

- What is the “normal” range of adult human pulse rate, for DRE purposes?

60-90 beats per minute

Review of the DRE School

Review of Vital Signs: Blood Pressure

- Define “Blood Pressure”.
- Name the instrument used to measure blood pressure.
- When does blood pressure reach its highest value? What is the highest value called?




Drug Recognition Expert Course Review-10

Review of Vital Signs: Blood Pressure

- Define “Blood Pressure”.

The force that the circulating blood exerts on the walls of the arteries

- Name the instrument used to measure blood pressure.

Sphygmomanometer

- When does blood pressure reach its highest value? What is the highest value called?

The systolic pressure is reached when the heart contracts and pushes blood into the arteries

Review of the DRE School

Review of Vital Signs: Blood Pressure (Cont.)

- When does blood pressure reach its lowest value? What is the lowest value called?
- What is the “normal” range of adult human blood pressure, for DRE purposes?



Drug Recognition Expert Course

Review-11

Review of Vital Signs: Blood Pressure (Cont.)

- When does blood pressure reach its lowest value? What is the lowest value called?

The diastolic pressure is reached when the heart is fully expanded

- What is the “normal” range of adult human blood pressure, for DRE purposes?

Systolic: 120-140mmHg

Diastolic: 70-90mmHg

Review of the DRE School

Review of Vital Signs: Blood Pressure (Cont.)

- What does “Hg” stand for?



Drug Recognition Expert Course

Review-12

Review of Vital Signs: Blood Pressure (Cont.)

- What does “Hg” stand for?

***Chemical symbol for mercury (“Hydrargyrum”, Latin word for “Mercury”).
Blood pressure is measured in millimeters of mercury***

Review of the DRE School

Review of the Eye Examinations: Horizontal Gaze Nystagmus

- **What are the three validated clues of impairment that have been established for HGN?**



Drug Recognition Expert Course

Review-13

Review of the Eye Examinations: Horizontal Gaze Nystagmus

- What are the three validated clues of impairment that have been established for HGN?

Lack of Smooth Pursuit

Distinct and Sustained Nystagmus at Maximum Deviation

Angle of Onset of Nystagmus Prior to 45 Degrees

Review of the DRE School

Review of the Eye Examinations: Horizontal Gaze Nystagmus (Cont.)

- What formula expresses the approximate statistical relationship between BAC and the angle of onset of nystagmus?
- What categories of drugs usually will cause HGN?




Drug Recognition Expert Course Review-14

Review of the Eye Examinations: Horizontal Gaze Nystagmus (Cont.)

- What formula expresses the approximate statistical relationship between BAC and the angle of onset of nystagmus?

BAC = 50 – Angle of Onset

- What categories of drugs usually will cause HGN?

CNS Depressants

Dissociative Anesthetics

Inhalants

Review of the DRE School

Review of the Eye Examinations: Vertical Gaze Nystagmus

- **True or False: Any drug that causes HGN may also produce Vertical Gaze Nystagmus.**
- **What category of drugs causes Vertical Gaze Nystagmus but not Horizontal Gaze Nystagmus?**




Drug Recognition Expert Course Review-15

Review of the Eye Examinations: Vertical Gaze Nystagmus

- True or False: Any drug that causes HGN may also produce Vertical Gaze Nystagmus.

TRUE: All drugs that cause Horizontal Gaze Nystagmus will cause Vertical Gaze Nystagmus, if the dose is large enough

- What category of drugs causes Vertical Gaze Nystagmus but not Horizontal Gaze Nystagmus?

NO drug causes Vertical Gaze Nystagmus but not HGN

Review of the DRE School

Review of the Eye Examinations: Lack of Convergence

- **True or False: Any drug that causes nystagmus will also usually cause the eyes to be unable to converge.**
- **What category of drugs usually causes lack of convergence but does not cause nystagmus?**




Drug Recognition Expert Course Review-16

Review of the Eye Examinations: Lack of Convergence

- True or False: Any drug that causes nystagmus will also usually cause the eyes to be unable to converge.

TRUE: CNS Depressants, Dissociative Anesthetics and Inhalants usually cause the eyes to be unable to converge

- What category of drugs usually causes lack of convergence but does not cause nystagmus?

CANNABIS usually causes Lack of Convergence, but doesn't cause nystagmus

Review of the DRE School

Review of the Darkroom Examinations

- What are the three lighting conditions under which we must estimate the size of the suspect's pupils?
- How long should we wait in the Darkroom before beginning to check the suspect's pupils?



Drug Recognition Expert Course

Review-17

Review of the Darkroom Examinations

- What are the three lighting conditions under which we must estimate the size of the suspect's pupils?

Room Light

Near Total Darkness

Direct Light

- How long should we wait in the Darkroom before beginning to check the suspect's pupils?

At least 90 seconds

Review of the DRE School

Review of the Darkroom Examinations

- Name the device that we use to estimate the size of the suspect's pupils.
- What do the numbers on the Pupillometer refer to?
- In what units of measurement are those numbers given?




Drug Recognition Expert Course Review-18

Review of the Darkroom Examinations

- Name the device that we use to estimate the size of the suspect's pupils.

Pupillometer

- What do the numbers on the Pupillometer refer to?

The diameters of the dark circles/semi-circles

- In what units of measurement are those numbers given?

In millimeters

Review of the DRE School

Review of the Darkroom Examinations

- For DRE purposes, what is the “normal” range of an adult pupil in room light?
- What does the term “MIOSIS” mean?



Drug Recognition Expert Course

Review-19

Review of the Darkroom Examinations

- For DRE purposes, what is the “normal” range of an adult pupil in room light?

The diameter of the pupil normally ranges from about 2.5 to 5.0 mm

- What does the term “MIOSIS” mean?

“Miosis” means an abnormally small or constricted pupil

Review of the DRE School

Review of the Darkroom Examinations

- What does the term “MYDRIASIS” mean?
- What category of drugs usually causes Miosis, or constricted pupils?



Drug Recognition Expert Course

Review-20

Review of the Darkroom Examinations

- What does the term “MYDRIASIS” mean?

“Mydriasis” means an abnormally large or dilated pupil

- What category of drugs usually causes Miosis, or constricted pupils?

Narcotic Analgesics usually cause pupils to constrict below the normal range

Review of the DRE School

Review of the Darkroom Examinations

- What categories usually cause Mydriasis, or dilated pupils?
- What is unique about the drug Methaqualone (Quaaludes) and SOMA?



Drug Recognition Expert Course

Review-21

Review of the Darkroom Examinations

- What categories usually cause Mydriasis, or dilated pupils?

CNS Stimulants and Hallucinogens usually cause pupils to dilate above the normal range. Cannabis also may cause dilation. Some inhalants will also cause dilation.

- What is unique about the drug Methaqualone (Quaaludes) and SOMA?

Both are CNS Depressants that cause pupil dilation.

Review of the DRE School

Review of the Divided Attention Tests

- Name the four Divided Attention Tests administered during the DRE drug influence evaluation.



Drug Recognition Expert Course

Review-22

Review of the Divided Attention Tests

- Name the four Divided Attention Tests administered during the DRE drug influence evaluation.

Romberg Balance

Walk and Turn

One Leg Stand

Finger to Nose

Review of the DRE School

Review of the Divided Attention Tests

- **Why is the Modified Romberg Balance always the first test administered?**



Drug Recognition Expert Course

Review-23

Review of the Divided Attention Tests

- Why is the Modified Romberg Balance always the first test administered?

For standardization

The test requires the subject to estimate the passage of 30 seconds; thus it should be administered before the One Leg Stand test, in which the suspect estimates the passage of 30 seconds.

Review of the DRE School

Review of the Divided Attention Tests

- **What four validated clues of impairment have been established for the One Leg Stand Test?**



Drug Recognition Expert Course Review-24

Review of the Divided Attention Tests

- What four validated clues of impairment have been established for the One Leg Stand Test?

Swaying

Raising the arms

Hopping

Putting the foot down

Review of the DRE School

Review of the Divided Attention Tests

- How many times is the One Leg Stand administered during the DRE drug influence evaluation?
- Which foot must the suspect stand on first when performing the One Leg Stand?



Drug Recognition Expert Course

Review-25

Review of the Divided Attention Tests

- How many times is the One Leg Stand administered during the DRE drug influence evaluation?

Twice

- Which foot must the suspect stand on first when performing the One Leg Stand?

Left

Review of the DRE School

Review of the Divided Attention Tests

- How many validated clues of impairment have been established for the Walk and Turn test? Name them.



Drug Recognition Expert Course

Review-26

Review of the Divided Attention Tests

- How many validated clues of impairment have been established for the Walk and Turn test? Name them.

Eight validated clues

Cannot keep balance during the instructions

Starts too soon

Stops while walking

Does not touch heel to toe

Steps off the line

Uses arms to balance

Improper turn

Incorrect number of steps

Review of the DRE School

Review of the Divided Attention Tests

- In what sequence is the suspect instructed to touch the index fingers to the nose on the Finger to Nose test?



Drug Recognition Expert Course

Review-27

Review of the Divided Attention Tests

- In what sequence is the suspect instructed to touch the index fingers to the nose on the Finger to Nose test?

Left, Right, Left, Right, Right, Left

Review of the DRE School

General Review Questions

- **What is the medical or technical term for “droopy eyelids”?**
- **What does “Piloerection” mean? What drug often causes piloerection?**
- **What is the medical or technical term for Heroin?**




Drug Recognition Expert Course Review-28

General Review Questions

- What is the medical or technical term for “droopy eyelids”?

Ptosis

- What does “Piloerection” mean? What drug often causes piloerection?

“Piloerection” means “Hair Standing Up”, or “Goose Bumps”. It is often caused by LSD

- What is the medical or technical term for Heroin?

Diacetyl Morphine

Review of the DRE School

General Review Questions

- Explain the terms “Null”, “Additive”, “Antagonistic” and “Overlapping” Effect as they apply to polydrug use. Give examples




Drug Recognition Expert Course Review-29

General Review Questions

- Explain the terms “Null”, “Additive”, “Antagonistic” and “Overlapping” Effect as they apply to polydrug use. Give examples

***“Null”:* neither drug affects some specific indicator**

***“Additive”:* the two drugs produce some identical effects**

***“Antagonistic”:* the two drugs produce some directly opposite effects**

***“Overlapping”:* one drug affects some symptom that the other doesn’t affect, and vice versa**

Review of the DRE School

General Review Questions

- What is “Rebound Dilation”?



Drug Recognition Expert Course

Review-30

General Review Questions

- What is “Rebound Dilation”?

“Rebound Dilation” is a period of pupillary constriction followed by a period of pupillary dilation where the pupil steadily increases in size and does not return to its original size.

Review of the DRE School

General Review Questions

- What is pupillary unrest?
- What does “Bruxism” mean?



Drug Recognition Expert Course

Review-31

General Review Questions

- What is pupillary unrest?

The continuous change in the size of the pupils that may be observed under room or steady light conditions.

- What does “Bruxism” mean?

Grinding the teeth

Review of the DRE School

General Review Questions

- What does the number denoting the size of a hypodermic needle refer to?
- What does “Synesthesia” mean?
- What is “Sinsemilla”?



Drug Recognition Expert Course

Review-32

General Review Questions

- What does the number denoting the size of a hypodermic needle refer to?

The inside diameter of the needle

- What does “Synesthesia” mean?

A mixing of senses, i.e. hearing colors or seeing sounds

- What is “Sinsemilla”?

A variety of marijuana with a high concentration of THC

Review of the DRE School

General Review Questions

- What are the twelve major components of the DRE drug influence evaluation?



Drug Recognition Expert Course

Review-33

General Review Questions

- What are the twelve major components of the DRE drug influence evaluation?

Breath Alcohol Test

Interview of Arresting Officer

Preliminary Examination

Examinations of the Eyes

Divided Attention Tests

Vital Signs Examinations

Dark Room Examinations

Examination for Muscle Tone

Examination for Injection Sites

Suspect's Statements

Opinion of the Evaluator

Toxicological Exam

Review of the DRE School

Review of Physiology

- Name the ten major body systems.



Drug Recognition Expert Course

Review-34

Review of Physiology

M is for Muscular System

U is for Urinary System

R is for Respiratory System

D is for Digestive System

E is for Endocrine System

R is for Reproductive System

S is for Skeletal System

I is for Integumentary System

N is for Nervous System

C is for Circulatory System

Review of the DRE School

Review of Physiology

- **What is the distinction between the “Smooth” muscles and the ”Striated” muscles?**
- **What do we call the chemicals that are produced by the Endocrine System?**
- **What is a neuron?**




Drug Recognition Expert Course
Review-35

Review of Physiology

- What is the distinction between the “Smooth” muscles and the ”Striated” muscles?

We consciously control the Striated; we don't consciously control the Smooth

- What do we call the chemicals that are produced by the Endocrine System?

Hormones

- What is a neuron?

A nerve cell

Review of the DRE School

Review of Physiology

- What do we call the space between two nerve cells?
- What do we call the chemicals that pass from one nerve cell to the next?
- What do we call the part of the nerve cell



Drug Recognition Expert Course

Review-36

Review of Physiology

- What do we call the space between two nerve cells?

Synapse, or synaptic gap

- What do we call the chemicals that pass from one nerve cell to the next?

Neurotransmitters

- What do we call the part of the nerve cell that sends out the neurotransmitter?

Axon

Review of the DRE School

Review of Physiology

- What do we call the part of a nerve cell that receives the neurotransmitter?
- What do the Sensory Nerves do?
- What do the Motor Nerves do?



Drug Recognition Expert Course

Review-37

Review of Physiology

- What do we call the part of a nerve cell that receives the neurotransmitter?

Dendrite

- What do the Sensory Nerves do?

Carry messages to the brain, from the sense organs, pain sensors, etc.

- What do the Motor Nerves do?

Carry messages from the brain, to the muscles, etc.

Review of the DRE School

Review of Physiology

- **Name the two sub-divisions of Motor Nerves.**
- **Name the two sub-divisions of Autonomic Nerves and describe their functions.**



Drug Recognition Expert Course

Review-38

Review of Physiology

- Name the two sub-divisions of Motor Nerves.

Voluntary (control striated muscles) and Autonomic (control smooth muscles)

- Name the two sub-divisions of Autonomic Nerves and describe their functions.

Sympathetic (command the body's response to fear, excitement, etc.), and Parasympathetic (promote the body's tranquil activities)

Review of the DRE School

Review of Physiology

- What does it mean to say that a drug is “sympathomimetic”?
- What does it mean to say that a drug is “parasympathomimetic”?



Drug Recognition Expert Course

Review-39

Review of Physiology

- What does it mean to say that a drug is “sympathomimetic”?

It means that the drug’s effects mimic those caused by messages transmitted along sympathetic nerves (excitement, agitation, arousal, etc.)

- What does it mean to say that a drug is “parasympathomimetic”?

The drug’s effects mimic those caused by messages transmitted along parasympathetic nerves (relaxation, calm, sleep, etc.)

Review of the DRE School

Review of Physiology

- Which two categories of drugs can most appropriately be called sympathomimetic?
- Which category can most appropriately be called parasympathomimetic?



Drug Recognition Expert Course

Review-40

Review of Physiology

- Which two categories of drugs can most appropriately be called sympathomimetic?

CNS Stimulants and Hallucinogens

- Which category can most appropriately be called parasympathomimetic?

Narcotic Analgesics

Clarification: Cannabis, Dissociative Anesthetics, and Inhalants have some sympathomimetic characteristics, but not as many as do the Stimulants and Hallucinogens. Depressants have some parasympathomimetic characteristics, but not as many as do the Narcotic Analgesics.

Review of the DRE School

Review of Physiology

- What is an artery?
- What is a vein?



Drug Recognition Expert Course

Review-41

Review of Physiology

- What is an artery?

Strong, elastic blood vessel that carries blood from the heart to the body's tissues and organs

- What is a vein?

Blood vessel that carries blood back to the heart from tissues and organs

Review of the DRE School

Review of Physiology

- **What is the Pulmonary Artery, and what is unique about it?**
- **What are the Pulmonary Veins and what is so special about them?**



Drug Recognition Expert Course Review-42


Review of Physiology

- What is the Pulmonary Artery, and what is unique about it?

It is the artery that carries blood from the heart to the lungs. It is the only artery that carries blood depleted of oxygen

- What are the Pulmonary Veins and what is so special about them?

They are the veins that carry blood back to the heart from the lungs. They are the only veins that carry blood rich in oxygen.



Solicit participants' comments and questions concerning the Review of the DRE School

A SELF-TEST FOR REVIEW AND STUDY

Circle the letters corresponding to the correct answers. Note that some questions have **more than one** correct answer.

1. Suppose you examine a suspect that you know is under the combined influence of Demerol and Thorazine. Which of the following would you **not** expect to find in that suspect? (Circle all that you wouldn't expect to see.)
 - A. Tachycardia is present
 - B. Horizontal Gaze Nystagmus is present
 - C. Hypotension is present
 - D. Mydriasis is present
 - E. Lack of Convergence is present

2. The Autonomic Nervous System has **sympathetic** nerves and _____ nerves.
 - A. parasympathetic
 - B. metasympathetic
 - C. postsympathetic
 - D. mesosympathetic
 - E. pilosympathetic

3. Suppose you examine a suspect that you know is under the combined influence of Ketamine and Methamphetamine, and you observe that he or she exhibits Horizontal Gaze Nystagmus. This is an example of
 - A. A Synergistic Effect
 - B. An Antagonistic Effect
 - C. The Null Effect
 - D. An Overlapping Effect
 - E. An Additive Effect

4. The technical term meaning "constricted pupils" is
 - A. Mydriasis
 - B. Occulosis
 - C. Miosis
 - D. Bruxism
 - E. Ptosis

5. **Chloral Hydrate** is an example of
- A. a Non-Barbiturate
 - B. an Anti-Psychotic Tranquilizer
 - C. an Anti-Depressant
 - D. a Barbiturate
 - E. an Anti-Anxiety Tranquilizer
6. **Numorphan** is an example of
- A. a Synthetic Opiate
 - B. an Analog of Phencyclidine
 - C. a Natural Alkaloid of Opium
 - D. an Opium Derivative
 - E. a non-Amphetamine-based Stimulant
7. Which of the following ordinarily will cause Horizontal Gaze Nystagmus? (Circle all that usually cause nystagmus.)
- A. Methamphetamine
 - B. Valium
 - C. The combination of Cocaine and Xanax
 - D. The combination of Cannabis and LSD
 - E. The combination of Heroin and Dilaudid
8. **Ritalin** is an example of
- A. a CNS Stimulant
 - B. a Narcotic Analgesic
 - C. an Hallucinogen
 - D. a CNS Depressant
 - E. an Analog of Phencyclidine
9. Suppose you examine a suspect that you know is under the combined influence of Heroin and PCP, and you observe that he or she exhibits **miosis**. This is most likely due to
- A. The "Downside" of Heroin
 - B. An Overlapping Effect between the two drugs
 - C. An Antagonistic Effect between the two drugs
 - D. An Additive Effect between the two drugs
 - E. The "Downside" of PCP

10. Which of the following usually will be true in a subject who is under the influence of an Hallucinogen? (Circle all that usually will be true.)
- A. Pupils will be constricted
 - B. Body temperature will be elevated
 - C. Eyes will be unable to converge
 - D. Blood pressure will be elevated
 - E. Horizontal Gaze Nystagmus will be present
11. Which of the following is not classified as an Hallucinogen? (Circle all that **are not** Hallucinogens.)
- A. ETOH
 - B. DOM
 - C. MDMA
 - D. 2CB
 - E. THC
12. Which of the following ordinarily will leave body temperature within the DRE average range? (Circle all that usually don't affect body temperature.)
- A. CNS Stimulants
 - B. Dissociative Anesthetics
 - C. Cannabis
 - D. CNS Depressants
 - E. All of the above **usually do** affect body temperature
13. Suppose you examine a suspect that you know is under the combined influence of Percodan and Cannabis, and you find that the suspect's pulse rate is 74 bpm. This is most likely due to
- A. An Additive Effect between the two drugs
 - B. The "Downside" of Cannabis
 - C. An Overlapping Effect between the two drugs
 - D. An Antagonistic Effect between the two drugs
 - E. The "Downside" of Percodan
14. How many distinct, validated clues have been established for the Modified Romberg Balance test?
- A. Eight
 - B. Six
 - C. Four
 - D. Three
 - E. There are **no validated** clues for that test.

15. A person under the combined influence of Ritalin and LSD usually will have above normal blood pressure. This is an example of
- A. An Overlapping Effect
 - B. A Synergistic Effect
 - C. The Null Effect
 - D. An Additive Effect
 - E. An Antagonistic Effect
16. The gap between two nerve cells is called the
- A. Vesicle
 - B. Neuron
 - C. Synapse
 - D. Dendrite
 - E. Axon
17. "**Ptosis**" most nearly means
- A. Dilated pupils
 - B. Grinding the teeth
 - C. Constricted pupils
 - D. Droopy eyelids
 - E. Goose bumps
18. How many distinct, validated clues have been established for the Walk-and-Turn test?
- A. Eight
 - B. Six
 - C. Four
 - D. Three
 - E. There are **no validated** clues for that test.
19. Which of the following are not subcategories of Inhalants? (Circle all that are not proper names for Inhalant Subcategories.)
- A. Fluorocarbons
 - B. Anesthetic Gases
 - C. Aerosols
 - D. Volatile Solvents
 - E. Propellants

20. **Phencyclidine** is best described as
- A. parasympathomimetic
 - B. an anti-depressant
 - C. a cellular stimulant
 - D. psychotophobic
 - E. a dissociative anesthetic
21. Which of the following usually **will not cause** the pupils to dilate? (Circle all that usually do not cause dilation.)
- A. MDMA
 - B. Methaqualone
 - C. Desoxyn
 - D. Peyote
 - E. Ketamine
22. Which subcategory or subcategories of Inhalants usually cause blood pressure to **be depressed**? (Circle all that usually cause a depressed pressure.)
- A. Anesthetic Gases
 - B. Propellants
 - C. Volatile Solvents
 - D. Aerosols
 - E. Fluorocarbons
23. Which of the following are **Natural Alkaloids** of opium? (Circle all that are Natural Alkaloids.)
- A. Lortab
 - B. Dilaudid
 - C. Codeine
 - D. Thebaine
 - E. Hycodan
24. "**Crank**" is a street name for
- A. Heroin
 - B. Cocaine
 - C. PCP
 - D. Methamphetamine
 - E. LSD

25. Which of the following are **not validated clues** for the One Leg Stand test? (Circle all that aren't validated clues.)
- A. Hopping
 - B. Raising the arms
 - C. Putting the foot down
 - D. Failing to count out loud
 - E. Swaying
26. Which of the following would be considered **sympathomimetic** drugs? (Circle all that are sympathomimetic.)
- A. MDMA
 - B. Dexedrine
 - C. Xanax
 - D. Oxycontin
 - E. Desoxyn
27. Suppose you examine a suspect, and you observe **all** of the following: Horizontal Gaze Nystagmus is present, with an onset of approximately 30 degrees; BAC is 0.00; eyes are unable to converge; pupil size is 5.5 mm in near-total darkness and 3.5 mm in direct light; pupil reaction to light is within normal; pulse rate is 100 bpm; blood pressure is 148/96; body temperature is 99.8 degrees. In your opinion, this suspect is under the influence of
- A. a combination of a CNS Depressant and a CNS Stimulant
 - B. a CNS Depressant alone
 - C. a Dissociative Anesthetic alone
 - D. a combination of a Dissociative Anesthetic and a CNS Stimulant
 - E. a combination of a CNS Depressant and Cannabis
28. The only artery that carries **de-oxygenated** blood is the ____ artery.
- A. Carotid
 - B. Brachial
 - C. Pulmonary
 - D. Radial
 - E. Coronal
29. Suppose a subject is under the influence of **Hycodan** and nothing else. Indicate whether each of the following will be true or false:
- A. T F Horizontal Gaze Nystagmus will not be present
 - B. T F Pupils will be constricted
 - C. T F Bradycardia will be present
 - D. T F Eyes will be able to converge
 - E. T F Hypotension will be present

30. "**Bruxism**" most nearly means
- A. Dilated pupils
 - B. Grinding the teeth
 - C. Constricted pupils
 - D. Droopy eyelids
 - E. Goose bumps
31. Suppose a suspect is under the influence of a combination of Marijuana and Cocaine, but nothing else. Indicate whether each of the following will be true or false:
- A. T F Pulse rate will be elevated
 - B. T F Pupils will be dilated
 - C. T F Horizontal Gaze Nystagmus will be present
 - D. T F Eyes will be able to converge
 - E. T F Blood pressure will be elevated
32. How many distinct, validated clues have been established for the Finger-to-Nose test?
- A. Eight
 - B. Six
 - C. Four
 - D. Three
 - E. There are **no validated** clues for this test.
33. The drug ____ is an example of an Anti-Anxiety Tranquilizer. (Circle all that are Anti-Anxiety Tranquilizers.)
- A. Librium
 - B. Valium
 - C. Amobarbital
 - D. Chloral Hydrate
 - E. Xanax

ANSWER KEY FOR THE SELF-TEST

1. Correct answers are A and D.
Demerol is a Narcotic Analgesic, Thorazine is a CNS Depressant. The combination should **not produce** elevated heart rate (Tachycardia) nor dilated pupils (Mydriasis). But Horizontal Gaze Nystagmus and Lack of Convergence should be present, due to the Depressant, Thorazine. And, lowered blood pressure (Hypotension) should be present as an Additive Effect of both drugs.
2. Correct answer is A, **parasympathetic**.
3. Correct answer is D, **Overlapping**.
Ketamine is an Analog of PCP, a drug that usually does cause Horizontal Gaze Nystagmus. Methamphetamine is a CNS Stimulant, a type of drug that doesn't affect nystagmus (Dissociative Anesthetic). This is a case of **action plus no action equals action**, i.e., an Overlapping Effect.
4. Correct answer is C, **Miosis**.
5. Correct answer is A, **Non-Barbiturate**.
6. Correct answer is D, **Opiate Derivative**.
7. Correct answers are B and C.
Valium is a CNS Depressant, which of course causes nystagmus. The combination of Cocaine and Xanax gives us a Stimulant and a Depressant (Xanax), which causes Nystagmus via an Overlapping Effect. None of the other drugs mentioned cause Nystagmus: Methamphetamine is a Stimulant; LSD is an Hallucinogen; Heroin and Dilaudid are Narcotics; Cannabis, of course, is its own category.
8. Correct answer is A, **CNS Stimulant**.
9. Correct answer is B, **Overlapping**.
Heroin, a Narcotic, causes constriction of the pupils (Miosis); PCP does not affect pupil size. This is another case of **action plus no action equals action**.
10. Correct answers are B and D.
Hallucinogens are **sympathomimetic** drugs, and therefore usually elevate the vital signs. But they have no effect on either Nystagmus or Lack of Convergence. And, instead of constricting the pupils, Hallucinogens usually cause pupils to dilate.
11. Correct answers are A, D and E.
ETOH is the chemical name for Ethyl Alcohol, the common beverage form of alcohol that remains the most commonly-abused drug. **THC** is the primary active ingredient in Cannabis. But "MDMA" (also known as "Ecstasy") and "DOM" (also known as "STP") and 2CB **are** Hallucinogens.

12. Correct answers are C and D, **Cannabis and Depressants**.
13. Correct answer is D, **Antagonistic**.
A pulse rate of 74 bpm is within the normal range. Percodan, a Narcotic Analgesic, usually lowers the pulse, while Cannabis usually elevates the pulse. The Antagonistic Effect of the two drugs has put this suspect's pulse into a precarious, and probably temporary, state of balance.
14. Correct answer is E, **no validated clues**.
It is important to understand that, when we say there are no validated clues for Modified Romberg Balance Test, that does **not mean** that the test is invalid. It simply means that we do not have the research data to attest that specific clues on that test are statistically reliable indicators of impairment. Those kinds of research data, at the present time, are available only for Horizontal Gaze Nystagmus, Walk and Turn and One Leg Stand.
15. Correct answer is D, **Additive**.
Ritalin (a Stimulant) and LSD (an Hallucinogen) both usually elevate blood pressure.
16. Correct answer is C, **Synapse**.
17. Correct answer is D, **Droopy Eyelids**.
18. Correct answer is A, **Eight**.
Of the eight **validated** clues for Walk and Turn, two may be observed during the Instructions Stage of the test. They are can't keep balance (which means the suspect breaks away from the heel-to-toe stance) and starts too soon. The other six clues pertain to the Walking Stage of the test. They include:
- o misses heel-to-toe
 - o uses arms to balance
 - o steps off line
 - o stops walking
 - o turns improperly
 - o takes the wrong number of steps
- Although these eight are the only validated clues for Walk and Turn, they aren't the only things that might be observed that could serve as evidence of impairment. All of your observations of the suspect are important.
19. Correct answers are A and E, **Fluorocarbons and Propellants**.
The only proper names for subcategories of Inhalants are Volatile Solvents, Aerosols and Anesthetic Gases.
20. Correct answer is E, dissociative anesthetic.

21. Correct answer is E, **Ketamine**.
Ketamine is an analog of PCP, a drug that doesn't affect pupil size. MDMA and Peyote are Hallucinogens, and Desoxyn is a CNS Stimulant; all of those dilate pupils. Methaqualone is a very special CNS Depressant; unlike almost all other Depressants, Methaqualone does affect pupil size (by dilating the pupils).
22. Correct answer is A, **Anesthetic Gases**.
Volatile Solvents and Aerosols usually produce an elevated blood pressure. "Fluorocarbons" and "Propellants" are, of course, not proper names for subcategories of Inhalants.
23. Correct answers are C and D, **Codeine and Thebaine**.
Lortab, Dilaudid and Hycodan are all **opium derivatives**. Dilaudid derives from Morphine, and Hycodan and Lortab from Codeine.
24. Correct answer is D, **Methamphetamine**.
25. Correct answer is D, **Failing to Count Out Loud**.
Hopping, Raising the Arms, Putting the Foot Down and Swaying are the four (and only four) **validated** clues of impairment for One Leg Stand.
26. Correct answers are A, B and E: **MDMA, Dexedrine and Desoxyn**.
Dexedrine and Desoxyn are members of the Amphetamine family of CNS Stimulants. MDMA is a "Psychedelic Amphetamine" belonging to the Hallucinogens. CNS Stimulants and Hallucinogens are the two categories that make up the **sympathomimetic** drugs. That means they simulate the responses that the body makes to messages conveyed along the **sympathetic** nerves, i.e., elevated vital signs, dilated pupils, etc. Three other categories, namely the Inhalants, Phencyclidine and Cannabis have **some** sympathomimetic characteristics, but they are not considered to be fully sympathomimetic, and not to the degree of the CNS Stimulants and Hallucinogens. Xanax and Oxycontin aren't even close to being sympathomimetic. Xanax (a Depressant) and Oxycontin (a Narcotic) are better described as wholly or partially **parasympathomimetic**.
27. Correct answer is C, **a Dissociative Anesthetic**.
Dissociative Anesthetics, by themselves, can account for all of the observations listed. Dissociative Anesthetics cause Nystagmus, and Lack of Convergence; they do not affect pupil size, so the pupils remain within the normal range; they do not affect the reaction of the pupils to light; they usually elevate all three vital signs.

A Depressant, by itself, could not account for the elevated vitals, and usually would slow the pupils' reaction to light.

If we had a combination of a Depressant and a Stimulant, we'd expect to see the pupils dilated beyond the normal range (due to an Overlapping Effect), and we'd expect to see the reaction of the pupils slowed (due to an Additive Effect). Also,

although it is possible that the vital signs could all be elevated with a combination of Depressant and Stimulant, we'd probably expect to see some "moderation" of the vitals due to an Antagonistic Effect.


If we had a combination of a Dissociative Anesthetic and a Stimulant, we could expect to see pupil dilation and some slowing of the reaction to light, due to Overlapping Effects.

If we had a combination of a Dissociative Anesthetic and a Stimulant, we could expect to see an elevated body temperature, since both of those drugs elevate temperature.

28. Correct answer is C, **Pulmonary**.
29. Correct answers are:
 (A) True: **no nystagmus** will be present
 (B) True: we will see miosis, or **constricted pupils**
 (C) True: we will find a slow pulse, or **Bradycardia**
 (D) True: we won't see a Lack of Convergence, so the eyes **will be able to converge**
 (E) True: we will find a lowered blood pressure, or **Hypotension**
 Hycodan is a Narcotic Analgesic, and these observations will be consistent with impairment by Narcotics.
30. Correct answer is B, **Grinding the Teeth**
31. Correct answers are:
 (A) True: An Additive Effect will **elevate the pulse** for this combo
 (B) True: **pupils will dilate** due to an Overlapping or Additive Effect
 (C) False: neither drug causes Nystagmus, so the Null Effect will also **cause no nystagmus**
 (D) False: Marijuana causes Lack of Convergence, so the Overlapping Effect means the **eyes won't converge**
 (E) True: An Additive Effect will **elevate the blood pressure**
32. Correct answer is E, **no validated clues**
33. Correct answers are A, B and E: **Librium, Valium and Xanax**

Session 29

Classifying a Suspect (Role Play)



Session 29 - Classifying a Suspect (Role Play)

Learning Objectives

- **Conduct a complete drug influence evaluation using the systematic and standardized 12-step process**
- **Compile a complete, clear and accurate report documenting the results of a drug influence evaluation using the 13-step component narrative report format**




Drug Recognition Expert Course 29-2

Briefly review the objectives, content and activities of this session.

Upon successfully completing this session the student will be able to:

- Conduct a complete drug influence evaluation using the systematic and standardized 12-step process.
- Compile a complete, clear and accurate report documenting the results of a drug influence evaluation using the 13-step component narrative report format.

Content Segments

- A. Scenarios: Simulated Examinations
- B. Report Preparation Practice
- C. Report Review and Critique

Learning Activities

- Interviewing Practice
- Note-taking Practice
- Small Group Work Session
- Instructor-Led Presentations
- Participant-Led Presentations
- Participant-Led Critiques

A. Scenarios: Simulated Examinations

Team Assignments

Assign the students to teams of 3-4 members.

The total number of student teams should not be more than the number of “role players” participating in this session. Otherwise, one or more teams would be unoccupied during major portions of this segment.

Session 29 - Classifying a Suspect (Role Play)

Procedures

- **Each team will examine as many as possible of the “role players”**
- **Each examination will be carried out fully**
- **At certain points in the examination, the “role player” will inform the team what to record**



Drug Recognition Expert Course 29-3

Procedures

Explain procedures to the students.

Each team will examine as many as possible of the “role players”, until the time scheduled for this segment elapses.

Each examination will be carried out fully: nothing will be omitted except for the breath alcohol test.

At certain points in the examination, the “role player” will inform the team what to record. Example: the “role players” will instruct the teams concerning the evidence to be recorded from the Horizontal Gaze Nystagmus test.

Session 29 - Classifying a Suspect (Role Play)

Role Playing

- **Some “role players” will be simulating the signs and symptoms of exactly one category of drugs**
- **Some “role players” may be simulating the signs and symptoms of two or more categories in combination**
- **All students will participate in critiquing the reports**




Drug Recognition Expert Course 29-4

All data will be recorded on the standard Drug Influence Evaluation Form.

- Some “role players” will be simulating the signs and symptoms of exactly one category of drugs. Clarification: “Role player Alpha” might be simulating a person who is under the influence of a CNS Stimulant only.

“Role player Delta” might be simulating a person under the influence of an Inhalant only.

Some “role players” may be simulating the signs and symptoms of two or more categories in combination. “Role player Bravo” might be simulating someone who is under the influence of both PCP and Marijuana.

It is possible that one or more “role players” may be simulating persons who are not under the influence of any drugs.

At the completion of each examination, the team will discuss the evidence obtained and reach a consensus concerning the category or categories of drugs present.

Subsequently, each team will be assigned the responsibility of preparing and presenting a complete narrative report on one “role player.”

All students will participate in critiquing the reports.

Verify that all teams understand the procedures.

Solicit students’ questions concerning the procedures.

Session 29 - Classifying a Suspect (Role Play)

Drug Evaluation and Classification Practice

Practice will continue for approximately 2 hours, or until each team has completed the evaluation of at least three “role players”



Drug Recognition Expert Course 29-5

Drug Evaluation and Classification Practice

Assign a “role player” to each team. Example: “Alpha” to team #1, “Bravo” to team #2, “Charlie” to team #3, etc.

As each team completes the entire evaluation, the team will hand over its “role player” to the next team. That is, team #1 hand off to team #2, team #2 to team #3, etc.

Make sure that each team member fully participates, and conducts some portion of the evaluation of each “role player.”

Allow the practice to continue for approximately 2 hours, or until each team has completed the evaluation of at least three “role players” (whichever occurs later).

Session 29 - Classifying a Suspect (Role Play)

Report Preparation Practice

- Team Assignments
- Group Writing Exercise



Drug Recognition Expert Course 29-6

B. Report Preparation Practice

Team Assignments

Instruct each team to prepare a report based on the third “role player” evaluated by the team.

Verify that each team understands who is to be the subject of the report.

Group Writing Exercise

Team members may divide the report writing work among themselves in any way they see fit.

Session 29 - Classifying a Suspect (Role Play)

Report Review and Critique

- Read Report
- Explain Conclusions
- Critique



Drug Recognition Expert Course 29-7

C. Report Review and Critique

Report Presentation

- Each team should appoint a speaker to read its report. The speaker should explain exactly what led the team to its conclusion concerning the category or categories of drugs.

Report Critique

Inquire whether other teams that evaluated this same “role player” reached a different conclusion about the drug category or categories.

In turn, present and critique the other teams’ reports.

If necessary, this segment can be conducted simultaneously in two separate classrooms, with half of the teams present in each classroom, to allow all reports to be presented and critiqued within the allotted time.






Session 29 - Classifying a Suspect (Role Play)







QUESTIONS?















Drug Recognition Expert Course







Solicit participants' comments and questions concerning Classifying a Suspect.









	DRUG INFLUENCE EVALUATION				EVALUATOR:						
	REPORT NUMBER:				IACP#: XXIX #1						
	TYPE OF EVALUATION:				SCRIBE:						
ARRESTEE'S NAME (Last, First, Middle) ALPHA		Date of Birth	Age	Sex	Race	Arresting Officer (Name, ID#)					
Date Examined / Time / Location		Breath Results: Results: 0.00		Test Refused <input type="checkbox"/> Instrument #: 1234		Chemical Test: Urine <input type="checkbox"/> Blood <input type="checkbox"/> Test or tests refused <input type="checkbox"/>					
Miranda Warning Given Given By:	<input type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? "Nothing today"		What have you been drinking? How much "Just coffee"		Time of last drink? N/A					
Time now/ Actual /	When did you last sleep? How long "Two days ago"		Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No						
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No							
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Attitude: Passive, Cooperative			Coordination: Slow, Unsteady at times						
Speech: Normal		Breath Odor: Normal		Face: Flushed							
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Bloodshot <input type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> X None <input type="checkbox"/> Left <input type="checkbox"/> Right		Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal					
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		Eyelids <input type="checkbox"/> Normal <input checked="" type="checkbox"/> X Droopy					
Pulse and time		HGN	Right Eye	Left Eye	ONE LEG STAND						
1. 80 / _____		Lack of Smooth Pursuit	No	No	  L R <input type="checkbox"/> <input type="checkbox"/> Sways while balancing <input type="checkbox"/> <input type="checkbox"/> Uses arms to balance <input type="checkbox"/> <input type="checkbox"/> Hopping <input type="checkbox"/> <input type="checkbox"/> Puts foot down						
2. 76 / _____		Maximum Deviation	No	No							
3. 76 / _____		Angle of Onset	None	None							
Modified Romberg Balance		Walk and turn test		Cannot keep balance _____							
				Starts too soon _____							
				Stops walking _____							
				Misses heel-toe _____							
				Steps off line _____							
				Raises arms _____							
				Actual steps taken							
				<table border="1" style="margin-left: auto; margin-right: auto;"> <tr> <td style="width: 50px;">1st Nine</td> <td style="width: 50px;">2nd Nine</td> </tr> <tr> <td style="height: 20px;"></td> <td style="height: 20px;"></td> </tr> <tr> <td style="text-align: center;">9</td> <td style="text-align: center;">9</td> </tr> </table>		1 st Nine	2 nd Nine			9	9
1 st Nine	2 nd Nine										
9	9										
Internal clock 27 estimated as 30 seconds		Describe Turn: Correct, Slow		Cannot do test (explain) N/A		Type of footwear: Lace-up shoes					
Draw lines to spots touched 		PUPIL SIZE		Room light	Darkness	Direct					
		Left Eye		4.5	6.5	3.5	Nasal area: Clear				
		Right Eye		4.5	6.5	3.5	Oral cavity: Clear				
		REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No				REACTION TO LIGHT: Normal					
		RIGHT ARM		LEFT ARM							
											
		No Visible Marks									
Blood pressure 128/84		Temperature 98.7°									
Muscle tone: <input checked="" type="checkbox"/> Near Normal <input type="checkbox"/> Flaccid <input type="checkbox"/> Rigid											
Comments:											
What drugs or medications have you been using? "Nothing, I just need some sleep."		How much? N/A		Time of use? N/A		Where were the drugs used? (Location) N/A					
Date / Time of arrest:		Time DRE was notified:		Evaluation start time:		Evaluation completion time:					
						Precinct/Station:					
Opinion of Evaluator:		<input type="checkbox"/> Depressant <input type="checkbox"/> Stimulant		<input type="checkbox"/> Hallucinogen <input type="checkbox"/> Dissoc. Anesthetic		<input type="checkbox"/> Narcotic Analgesic <input type="checkbox"/> Inhalant					
						<input type="checkbox"/> Cannabis <input type="checkbox"/> Alcohol					
						<input type="checkbox"/> Medical Rule Out <input type="checkbox"/> No Opinion					
Officer's Signature:		Felony Offense:		Misdemeanor Offense:		Reviewed/approved by / date:					






	DRUG INFLUENCE EVALUATION				EVALUATOR:	
	REPORT NUMBER:				IACP#: XXIX-2	
	TYPE OF EVALUATION:				SCRIBE:	
ARRESTEE'S NAME (Last, First, Middle) BRAVO		Date of Birth	Age	Sex	Race	Arresting Officer (Name, ID#)
Date Examined / Time / Location		Breath Results: Results: 0.00		Test Refused <input type="checkbox"/> Instrument #: 1234		Chemical Test: Urine <input type="checkbox"/> Blood <input type="checkbox"/> Test or tests refused <input type="checkbox"/>
Miranda Warning Given Given By:	<input type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? "Sandwich" "Noon"		What have you been drinking? How much "Nothing"		Time of last drink? N/A
Time now/ Actual	When did you last sleep? How long "Last night" "About 8 hrs"		Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Attitude: Carefree, Cooperative			Coordination: Fair, Unsteady at times	
Speech: Normal		Breath Odor: Normal		Face: Normal		
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Bloodshot <input type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> X None <input type="checkbox"/> Left <input type="checkbox"/> Right		Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		Eyelids <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Droopy
Pulse and time		HGN	Right Eye	Left Eye	ONE LEG STAND	
1. 120 / _____		Lack of Smooth Pursuit	No	No		
2. 116 / _____		Maximum Deviation	No	No		
3. 118 / _____		Angle of Onset	None	None		
Modified Romberg Balance		Walk and turn test		Convergence 		
				Cannot keep balance _____		
				Starts too soon _____		
Eyelid Tremors		Stops walking _____ Misses heel-toe _____ Steps off line _____ Raises arms _____ Actual steps taken		1 st Nine		2 nd Nine
				9		11
Internal clock 17 estimated as 30 seconds		Describe Turn: Proper		Cannot do test (explain) N/A		Type of footwear: Tennis Shoes
Draw lines to spots touched 		PUPIL SIZE	Room light	Darkness	Direct	Nasal area: Clear
		Left Eye	6.5	8.5	5.5	Oral cavity: Green Coating on Tongue
		Right Eye	6.5	8.5	5.5	
		REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		REACTION TO LIGHT: Normal		
		RIGHT ARM		LEFT ARM		
						
		No Visible Marks				
Blood pressure 168/100		Temperature 98.6°				
Muscle tone: <input checked="" type="checkbox"/> Near Normal <input type="checkbox"/> Flaccid <input type="checkbox"/> Rigid						
Comments:						
What drugs or medications have you been using? "Nothing man, it's all good."		How much? N/A		Time of use? N/A	Where were the drugs used? (Location) N/A	
Date / Time of arrest:	Time DRE was notified:	Evaluation start time:	Evaluation completion time:	Precinct/Station:		
Opinion of Evaluator:		<input type="checkbox"/> Depressant <input type="checkbox"/> Hallucinogen <input type="checkbox"/> Narcotic Analgesic <input type="checkbox"/> Cannabis <input type="checkbox"/> Medical Rule Out		<input type="checkbox"/> Stimulant <input type="checkbox"/> Dissoc. Anesthetic <input type="checkbox"/> Inhalant <input type="checkbox"/> Alcohol <input type="checkbox"/> No Opinion		
Officer's Signature:		Felony Offense:	Misdemeanor Offense:	Reviewed/approved by / date:		






	DRUG INFLUENCE EVALUATION				EVALUATOR:			
	REPORT NUMBER:				IACP#: XXIX-3			
	TYPE OF EVALUATION:				SCRIBE:			
ARRESTEE'S NAME (Last, First, Middle) CHARLIE				Date of Birth	Age	Sex	Race	Arresting Officer (Name, ID#)
Date Examined / Time /Location		Breath Results: Results: 0.00			Test Refused <input type="checkbox"/> Instrument #: 1234		Chemical Test: Urine <input type="checkbox"/> Blood <input type="checkbox"/> Test or tests refused <input type="checkbox"/>	
Miranda Warning Given	<input type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? Today? (Long Pause) "No"		What have you been drinking? How much "Drink?" "No"		Time of last drink? N/A		
Time now/ Actual	When did you last sleep? How long "This morning" "4 hours"		Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No "I'm hot"		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No				
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			Attitude: Dazed, Confused			Coordination: Slow, Rigid movements		
Speech: Slow to respond, Confused		Breath Odor: Normal			Face: Sweaty			
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Bloodshot <input type="checkbox"/> Watery		Blindness: None <input type="checkbox"/> Left <input type="checkbox"/> Right		Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal		
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		Eyelids: <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Droopy		
Pulse and time		HGN	Right Eye	Left Eye	Convergence		ONE LEG STAND	
1. 104 / _____		Lack of Smooth Pursuit	Yes	Yes				
2. 106 / _____		Maximum Deviation	Yes	Yes				
3. 108 / _____		Angle of Onset	Immed	Immed				
Modified Romberg Balance		Walk and turn test		Cannot keep balance _____		L R <input type="checkbox"/> <input type="checkbox"/> Sways while balancing <input type="checkbox"/> <input type="checkbox"/> Uses arms to balance <input type="checkbox"/> <input type="checkbox"/> Hopping <input type="checkbox"/> <input type="checkbox"/> Puts foot down Reminded twice to count out loud		
 <p>Circular Sway. Test stopped after 90 seconds</p>				Starts too soon _____				
		Stopped after first 9 steps. Had to be reminded to continue walking.		Stops walking _____				
				Misses heel-toe _____				
				Steps off line _____				
				Raises arms _____				
		Actual steps taken		1 st Nine	2 nd Nine			
				9	9			
Internal clock 90 estimated as 30 seconds		Describe Turn: Did not leave foot on line when making turn.		Cannot do test (explain) N/A		Type of footwear: Lace-up boots		
Draw lines to spots touched 		PUPIL SIZE		Room light	Darkness	Direct	Nasal area: Clear	
		Left Eye		4.0	6.5	3.5	Oral cavity: Clear	
		Right Eye		4.0	6.5	3.5	REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
				REACTION TO LIGHT: Normal				
				RIGHT ARM 		LEFT ARM 		
				No Visible Marks				
Blood pressure 170/98		Temperature 100.6⁰		Muscle tone: Near Normal <input type="checkbox"/> Flaccid <input type="checkbox"/> Rigid <input checked="" type="checkbox"/>				
Comments: Arms very rigid								
What drugs or medications have you been using? "Drugs? ... Nothing man"		How much? N/A		Time of use? N/A		Where were the drugs used? (Location) N/A		
Date / Time of arrest:		Time DRE was notified:		Evaluation start time:		Evaluation completion time:		
						Precinct/Station:		
Opinion of Evaluator:		<input type="checkbox"/> Depressant <input type="checkbox"/> Stimulant		<input type="checkbox"/> Hallucinogen <input type="checkbox"/> Dissoc. Anesthetic		<input type="checkbox"/> Narcotic Analgesic <input type="checkbox"/> Inhalant		
						<input type="checkbox"/> Cannabis <input type="checkbox"/> Alcohol		
						<input type="checkbox"/> Medical Rule Out <input type="checkbox"/> No Opinion		
Officer's Signature:		Felony Offense:		Misdemeanor Offense:		Reviewed/approved by / date:		







	DRUG INFLUENCE EVALUATION				EVALUATOR:			
	REPORT NUMBER:				IACP#: XXIX-4			
	TYPE OF EVALUATION:				SCRIBE:			
ARRESTEE'S NAME (Last, First, Middle) DELTA				Date of Birth	Age	Sex	Race	Arresting Officer (Name, ID#)
Date Examined / Time / Location		Breath Results: Results: 0.00		Test Refused <input type="checkbox"/> Instrument #: 1234		Chemical Test: Urine <input type="checkbox"/> Blood <input type="checkbox"/> Test or tests refused <input type="checkbox"/>		
Miranda Warning Given Given By:	<input type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? "I didn't eat today"	What have you been drinking? How much "Nothing, No alcohol today"	Time of last drink? N/A				
Time now/ Actual	When did you last sleep? How long "I don't remember"	Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No				
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No				
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No "I'm clean"		Attitude: Passive, Uncaring		Coordination: Slow, Sluggish, Unstable				
Speech: Slow to respond, Low		Breath Odor: Normal		Face: Red marks; Continually rubbed his face				
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right		Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal		
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus Yes <input checked="" type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		Eyelids <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Droopy		
Pulse and time		HGN	Right Eye	Left Eye	Convergence		ONE LEG STAND	
1. <u>52</u> / _____		Lack of Smooth Pursuit	No	No				
2. <u>56</u> / _____		Maximum Deviation	No	No				
3. <u>54</u> / _____		Angle of Onset	None	None				
Modified Romberg Balance		Walk and turn test		Cannot keep balance _____		L R		
				Starts too soon _____		<input type="checkbox"/> <input type="checkbox"/> Sways while balancing		
Circular Sway. Test stopped after 90 seconds		Slow, lethargic movements		Stops walking _____		<input type="checkbox"/> <input type="checkbox"/> Uses arms to balance		
				Misses heel-toe _____		<input type="checkbox"/> <input type="checkbox"/> Hopping		
				Steps off line _____		<input type="checkbox"/> <input type="checkbox"/> Puts foot down		
				Raises arms _____		Counted slowly, very unsteady		
				Actual steps taken 9 9				
Internal clock 90 estimated as 30 seconds		Describe Turn: Slow, unstable		Cannot do test (explain) N/A		Type of footwear: Tennis Shoes		
Draw lines to spots touched 		PUPIL SIZE	Room light	Darkness	Direct	Nasal area: Clear		
		Left Eye	2.0	2.5	2.0	Oral cavity: Clear		
		Right Eye	2.0	2.5	2.0			
		REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		REACTION TO LIGHT: Slow				
		RIGHT ARM		LEFT ARM				
								
				Four fresh puncture wounds on left forearm.				
Blood pressure 108/60		Temperature 97.0⁰		Muscle tone: Near Normal <input type="checkbox"/> <input checked="" type="checkbox"/> Flaccid <input type="checkbox"/> Rigid				
Comments:		What drugs or medications have you been using? "Honest man, I'm clean"		How much? N/A		Time of use? N/A		
Date / Time of arrest:		Time DRE was notified:		Evaluation start time:		Where were the drugs used? (Location) N/A		
Opinion of Evaluator:		<input type="checkbox"/> Depressant <input type="checkbox"/> Hallucinogen <input type="checkbox"/> Narcotic Analgesic <input type="checkbox"/> Cannabis <input type="checkbox"/> Medical Rule Out		<input type="checkbox"/> Stimulant <input type="checkbox"/> Dissoc. Anesthetic <input type="checkbox"/> Inhalant <input type="checkbox"/> Alcohol <input type="checkbox"/> No Opinion				
Officer's Signature:		Felony Offense:		Misdemeanor Offense:		Reviewed/approved by / date:		







	DRUG INFLUENCE EVALUATION				EVALUATOR:	
	REPORT NUMBER:				IACP#: XXIX-5	
	TYPE OF EVALUATION:				SCRIBE:	
ARRESTEE'S NAME (Last, First, Middle)		Date of Birth	Age	Sex	Race	Arresting Officer (Name, ID#)
ECHO		Date Examined / Time / Location		Breath Results: Test Refused <input type="checkbox"/> Results: 0.00 Instrument #: 1234		Chemical Test: Urine <input type="checkbox"/> Blood <input type="checkbox"/> Test or tests refused <input type="checkbox"/>
Miranda Warning Given	<input type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? "Nothing today"	What have you been drinking? How much "Water"	Time of last drink? N/A		
Time now/ Actual	When did you last sleep? How long "Last night" "About 2 hrs"	Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No "I used to"	Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No				
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No "Not now"	Attitude: Cooperative, Passive	Coordination: Staggering, Poor balance				
Speech: Slurred, mumbled	Breath Odor: Normal	Face: Normal looking				
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft	Eyes: <input type="checkbox"/> Reddened Conjunctiva <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input type="checkbox"/> Watery	Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right	Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal			
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)	Vertical Nystagmus Yes <input checked="" type="checkbox"/> No	Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Eyelids: <input type="checkbox"/> Normal <input checked="" type="checkbox"/> Droopy			
Pulse and time	HGN	Right Eye	Left Eye	Convergence		
1. 48 / _____	Lack of Smooth Pursuit	Yes	Yes			
2. 46 / _____	Maximum Deviation	Yes	Yes			
3. 46 / _____	Angle of Onset	40	40			
Modified Romberg Balance	Walk and turn test	Cannot keep balance _____		ONE LEG STAND		
		Starts too soon _____				
Head slumped forward	Stopped test, nearly fell	Stops walking _____		<input type="checkbox"/> <input type="checkbox"/> Sways while balancing		
		Misses heel-toe _____		<input type="checkbox"/> <input type="checkbox"/> Uses arms to balance		
		Steps off line _____		<input type="checkbox"/> <input type="checkbox"/> Hopping		
		Raises arms _____		<input type="checkbox"/> <input type="checkbox"/> Puts foot down		
		Actual steps taken		Test stopped for safety reasons		
		N/A				
Internal clock 70 estimated as 30 seconds	Describe Turn: N/A	Cannot do test (explain) N/A		Type of footwear: Boots		
Draw lines to spots touched 	PUPIL SIZE	Room light	Darkness	Direct	Nasal area: Clear	
	Left Eye	2.0	2.5	2.0	Oral cavity: Clear	
	Right Eye	2.0	2.5	2.0		
	REBOUND DILATION <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			REACTION TO LIGHT: None		
	RIGHT ARM		LEFT ARM			
						
	Two fresh puncture wounds on inside left forearm.					
Blood pressure 104/58	Temperature 97.2^o	Muscle tone: Near Normal <input type="checkbox"/> <input checked="" type="checkbox"/> Flaccid <input type="checkbox"/> Rigid				
Comments: Arms very flaccid						
What drugs or medications have you been using? "I stopped using about two years ago"	How much? N/A	Time of use? N/A	Where were the drugs used? (Location) N/A			
Date / Time of arrest:	Time DRE was notified:	Evaluation start time:	Evaluation completion time:	Precinct/Station:		
Opinion of Evaluator:	<input type="checkbox"/> Depressant <input type="checkbox"/> Stimulant	<input type="checkbox"/> Hallucinogen <input type="checkbox"/> Dissoc. Anesthetic	<input type="checkbox"/> Narcotic Analgesic <input type="checkbox"/> Inhalant	<input type="checkbox"/> Cannabis <input type="checkbox"/> Alcohol	<input type="checkbox"/> Medical Rule Out <input type="checkbox"/> No Opinion	
Officer's Signature:	Felony Offense:	Misdemeanor Offense:	Reviewed/approved by / date:			






	DRUG INFLUENCE EVALUATION				EVALUATOR:			
	REPORT NUMBER:				IACP#: XXIX-6			
	TYPE OF EVALUATION:				SCRIBE:			
ARRESTEE'S NAME (Last, First, Middle) FOXTROT				Date of Birth	Age	Sex	Race	Arresting Officer (Name, ID#)
Date Examined / Time / Location		Breath Results: 0.00		Test Refused <input type="checkbox"/>		Chemical Test: Urine <input type="checkbox"/> Blood <input type="checkbox"/>		Instrument #: 1234
Miranda Warning Given	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	What have you eaten today? When? "Chips & Cookies" "10 am"		What have you been drinking? How much "Nothing"		Time of last drink? N/A		
Time now/ Actual	When did you last sleep? How long "Last night" "Three hrs"		Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No				
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No "Not now"			Attitude: Cooperative, Mellow			Coordination: Relaxed, Unsteady		
Speech: Talkative		Breath Odor: Normal		Face: Normal				
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right		Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal		
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus Yes <input checked="" type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		Eyelids: <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Droopy		
Pulse and time		HGN	Right Eye	Left Eye	Convergence		ONE LEG STAND	
1. 112 / _____		Lack of Smooth Pursuit	No	No				
2. 110 / _____		Maximum Deviation	No	No				
3. 110 / _____		Angle of Onset	None	None				
Modified Romberg Balance		Walk and turn test		Cannot keep balance _____				
				Starts too soon _____				
				Stops walking _____				
Eyelid Tremors		Laughed during test. Had to be reminded to count out loud.		Misses heel-toe _____				
				Steps off line _____				
				Raises arms _____				
				Actual steps taken 9 8				
Internal clock 25 estimated as 30 seconds		Describe Turn: Abrupt swivel		Cannot do test (explain) N/A		Type of footwear: Sandals		
Draw lines to spots touched 		PUPIL SIZE		Room light	Darkness	Direct	Nasal area: Clear	
		Left Eye		5.0	8.5	3.0 - 5.5	Oral cavity: Clear	
		Right Eye		5.0	8.5	3.0 - 5.5	REBOUND DILATION <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	
						REACTION TO LIGHT: Slow		
Eyelid tremors. Used first pad of fingers		No visible marks		RIGHT ARM		LEFT ARM		
								
Blood pressure 160/98		Temperature 98.6⁰						
Muscle tone: <input checked="" type="checkbox"/> Near Normal <input type="checkbox"/> Flaccid <input type="checkbox"/> Rigid								
Comments:								
What drugs or medications have you been using? "None"		How much? N/A		Time of use? N/A		Where were the drugs used? (Location) N/A		
Date / Time of arrest:		Time DRE was notified:		Evaluation start time:		Evaluation completion time:		
Precinct/Station:								
Opinion of Evaluator:		<input type="checkbox"/> Depressant <input type="checkbox"/> Hallucinogen <input type="checkbox"/> Narcotic Analgesic <input type="checkbox"/> Cannabis <input type="checkbox"/> Medical Rule Out		<input type="checkbox"/> Stimulant <input type="checkbox"/> Dissoc. Anesthetic <input type="checkbox"/> Inhalant <input type="checkbox"/> Alcohol <input type="checkbox"/> No Opinion				
Officer's Signature:		Felony Offense:		Misdemeanor Offense:		Reviewed/approved by / date:		

	DRUG INFLUENCE EVALUATION				EVALUATOR:						
	REPORT NUMBER:				IACP#: XXIX-8						
	TYPE OF EVALUATION:				SCRIBE:						
ARRESTEE'S NAME (Last, First, Middle)		Date of Birth	Age	Sex	Race	Arresting Officer (Name, ID#)					
HOTEL		Date Examined / Time / Location		Breath Results: Results: 0.00		Test Refused <input type="checkbox"/> Instrument #: 1234					
Miranda Warning Given		<input type="checkbox"/> Yes <input type="checkbox"/> No		What have you eaten today? When?		Time of last drink?					
Given By:		"I don't remember"		What have you been drinking? How much		"Uh,Water"					
Time now/ Actual		When did you last sleep? How long		Are you sick or injured?		Are you diabetic or epileptic?					
/		(No response)		<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No					
Do you take insulin?		Do you have any physical defects?		Are you under the care of a doctor or dentist?							
<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No (No response)							
Are you taking any medication or drugs?		Attitude:		Coordination:							
<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No (No response)		Dazed, Indifferent		Poor, Staggering							
Speech: Slow, Deliberate		Breath Odor: Normal		Face: Flushed							
Corrective Lenses: <input checked="" type="checkbox"/> None		Eyes: <input type="checkbox"/> Reddened Conjunctiva		Blindness:		Tracking:					
<input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Normal <input checked="" type="checkbox"/> Bloodshot Watery		<input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right		<input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal					
Pupil Size: <input checked="" type="checkbox"/> Equal		Vertical Nystagmus		Able to follow stimulus		Eyelids: <input checked="" type="checkbox"/> Normal					
<input type="checkbox"/> Unequal (explain)		<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		<input checked="" type="checkbox"/> Droopy					
Pulse and time		HGN		Convergence		ONE LEG STAND					
1. 112 / _____		Lack of Smooth Pursuit		Right eye Yes Left eye Yes							
2. 110 / _____		Maximum Deviation		Yes Yes							
3. 114 / _____		Angle of Onset		Immed Immed							
Modified Romberg Balance		Walk and turn test		Cannot keep balance _____		L R <input type="checkbox"/> <input type="checkbox"/> Sways while balancing <input type="checkbox"/> <input type="checkbox"/> Uses arms to balance <input type="checkbox"/> <input type="checkbox"/> Hopping <input type="checkbox"/> <input type="checkbox"/> Puts foot down Leg tremors					
 <p>Eyelid tremors Circular sway</p>		 <p>Did not touch heel to toe after the turn.</p>		Starts too soon _____							
		Stops walking _____		Misses heel-toe _____							
		Steps off line _____		Raises arms _____							
		Actual steps taken		<table border="1" style="width:100%; text-align: center;"> <tr> <td>1st Nine</td> <td>2nd Nine</td> </tr> <tr> <td>9</td> <td>8</td> </tr> </table>			1 st Nine	2 nd Nine	9	8	
		1 st Nine	2 nd Nine								
9	8										
Internal clock		Describe Turn: Staggered		Cannot do test (explain) N/A		Type of footwear: Boots					
60 estimated as 30 seconds											
Draw lines to spots touched  <p>Had to be reminded to actually touch nose</p>		PUPIL SIZE		Room light		Darkness		Direct		Nasal area: Clear	
		Left Eye		7.0		9.0		6.5		Oral cavity: Bits of greenish/brown material in teeth	
		Right Eye		7.0		9.0		6.5		REBOUND DILATION	
										Yes <input checked="" type="checkbox"/> No	
Blood pressure		Temperature		RIGHT ARM 				LEFT ARM 			
172/104		100.4°									
Muscle tone:		Near Normal <input type="checkbox"/> Flaccid <input type="checkbox"/> Rigid <input checked="" type="checkbox"/>									
What drugs or medications have you been using?		How much?		Time of use?		Where were the drugs used? (Location)					
(No response)		N/A		N/A		N/A					
Date / Time of arrest:		Time DRE was notified:		Evaluation start time:		Evaluation completion time:		Precinct/Station:			
Opinion of Evaluator:		<input type="checkbox"/> Depressant <input type="checkbox"/> Hallucinogen <input type="checkbox"/> Narcotic Analgesic <input type="checkbox"/> Cannabis <input type="checkbox"/> Medical Rule Out		<input type="checkbox"/> Stimulant <input type="checkbox"/> Dissoc. Anesthetic <input type="checkbox"/> Inhalant <input type="checkbox"/> Alcohol <input type="checkbox"/> No Opinion							
Officer's Signature:		Felony Offense:		Misdemeanor Offense:		Reviewed/approved by / date:					

	DRUG INFLUENCE EVALUATION				EVALUATOR:		
	REPORT NUMBER:				IACP#: XXIX-9		
	TYPE OF EVALUATION:				SCRIBE:		
ARRESTEE'S NAME (Last, First, Middle) INDIA		Date of Birth	Age	Sex	Race	Arresting Officer (Name, ID#)	
Date Examined / Time / Location		Breath Results: Results: 0.00			Test Refused <input type="checkbox"/>	Chemical Test: Urine <input type="checkbox"/> Blood <input type="checkbox"/>	
Miranda Warning Given Given By: <input type="checkbox"/> Yes <input type="checkbox"/> No		What have you eaten today? When? "Eggs" "At lunch"		What have you been drinking? How much "Nothing"		Time of last drink? N/A	
Time now/ Actual /		When did you last sleep? How long "This morning" "2 hours"		Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No "I feel okay"		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No (No response)			
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No (No response)		Attitude: Cooperative, Confused			Coordination: Stumbling, Staggering		
Speech: Low, Slow, Mumbling		Breath Odor: Gas-like odor		Face: Flushed			
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva Normal <input checked="" type="checkbox"/> Bloodshot Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right		Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal	
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus Yes <input checked="" type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		Eyelids <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Droopy	
Pulse and time 1. 96 / _____ 2. 92 / _____ 3. 94 / _____		HGN Lack of Smooth Pursuit Maximum Deviation Angle of Onset	Right Eye Yes Yes 30	Left Eye Yes Yes 30	Convergence  Right eye Left eye		
Modified Romberg Balance  Lost balance and nearly fell.		Walk and turn test  Reminded to count out loud		ONE LEG STAND  L R <input type="checkbox"/> <input type="checkbox"/> Sways while balancing <input type="checkbox"/> <input type="checkbox"/> Uses arms to balance <input type="checkbox"/> <input type="checkbox"/> Hopping <input type="checkbox"/> <input type="checkbox"/> Puts foot down Leg tremors, nearly fell			
Internal clock 42 estimated as 30 seconds		Describe Turn: Staggered		Cannot do test (explain) N/A		Type of footwear: Boots	
Draw lines to spots touched  Had to be reminded to actually touch nose		PUPIL SIZE		Room light	Darkness	Direct	
		Left Eye		5.0	6.5	3.5	Nasal area: Redness, runny
		Right Eye		5.0	6.5	3.5	Oral cavity: Clear
Blood pressure 148/88		Temperature 98.8°		REBOUND DILATION Yes <input checked="" type="checkbox"/> No		REACTION TO LIGHT: Normal	
Muscle tone: Near Normal Flaccid <input checked="" type="checkbox"/> Rigid		Comments:		RIGHT ARM  LEFT ARM  No visible marks			
What drugs or medications have you been using? "Nothing"		How much? N/A		Time of use? N/A		Where were the drugs used? (Location) N/A	
Date / Time of arrest:		Time DRE was notified:		Evaluation start time:		Evaluation completion time:	
Opinion of Evaluator:		<input type="checkbox"/> Depressant <input type="checkbox"/> Hallucinogen <input type="checkbox"/> Narcotic Analgesic <input type="checkbox"/> Cannabis <input type="checkbox"/> Medical Rule Out		<input type="checkbox"/> Stimulant <input type="checkbox"/> Dissoc. Anesthetic <input type="checkbox"/> Inhalant <input type="checkbox"/> Alcohol <input type="checkbox"/> No Opinion			
Officer's Signature:		Felony Offense:		Misdemeanor Offense:		Reviewed/approved by / date:	

	DRUG INFLUENCE EVALUATION				EVALUATOR:		
	REPORT NUMBER:				IACP#: XXIX-10		
	TYPE OF EVALUATION:				SCRIBE:		
ARRESTEE'S NAME (Last, First, Middle) JULIET		Date of Birth	Age	Sex	Race	Arresting Officer (Name, ID#)	
Date Examined / Time / Location		Breath Results: 0.06		Test Refused <input type="checkbox"/>	Chemical Test: Urine <input type="checkbox"/> Blood <input type="checkbox"/>		
Miranda Warning Given Given By:	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	What have you eaten today? When? "Cereal" "About 7 am"		What have you been drinking? How much "Two beers"		Time of last drink? "Hour ago"	
Time now/ Actual	When did you last sleep? How long "Last night" "8 hours"	Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Attitude: Cooperative, Withdrawn			Coordination: Unsteady		
Speech: Low, Mumbling		Breath Odor: Alcoholic Beverage		Face: Flushed			
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva Normal <input checked="" type="checkbox"/> Bloodshot Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right		Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal	
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus Yes <input checked="" type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		Eyelids Normal <input checked="" type="checkbox"/> Droopy	
Pulse and time		HGN	Right Eye	Left Eye	Convergence		
1. 82 / _____		Lack of Smooth Pursuit	Yes	Yes			
2. 80 / _____		Maximum Deviation	Yes	Yes	Right eye Left eye		
3. 80 / _____		Angle of Onset	45	45			
Modified Romberg Balance		Walk and turn test				ONE LEG STAND	
							
Circular Sway		Cannot keep balance _____				L R	
		Starts too soon _____				<input type="checkbox"/> <input type="checkbox"/> Sways while balancing	
		Stops walking _____				<input type="checkbox"/> <input type="checkbox"/> Uses arms to balance	
		Misses heel-toe _____				<input type="checkbox"/> <input type="checkbox"/> Hopping	
		Steps off line _____				<input type="checkbox"/> <input type="checkbox"/> Puts foot down	
		Raises arms _____				Reminded to count out loud	
		Actual steps taken					
		9 9					
Internal clock 38 estimated as 30 seconds		Describe Turn: Proper, Slow		Cannot do test (explain) N/A		Type of footwear: Boots	
Draw lines to spots touched 		PUPIL SIZE	Room light	Darkness	Direct	Nasal area: Clear	
		Left Eye	4.5	6.0	3.5	Oral cavity: Clear	
		Right Eye	4.5	6.0	3.5		
		REBOUND DILATION Yes <input checked="" type="checkbox"/> No			REACTION TO LIGHT: Normal		
		RIGHT ARM			LEFT ARM		
							
							
							
		No visible marks					
Blood pressure 128/84		Temperature 98.7°					
Muscle tone: Near Normal Flaccid <input checked="" type="checkbox"/> Rigid							
What drugs or medications have you been using? "Nothing"		How much? N/A		Time of use? N/A	Where were the drugs used? (Location) N/A		
Date / Time of arrest:	Time DRE was notified:	Evaluation start time:	Evaluation completion time:	Precinct/Station:			
Opinion of Evaluator:		<input type="checkbox"/> Depressant	<input type="checkbox"/> Hallucinogen	<input type="checkbox"/> Narcotic Analgesic	<input type="checkbox"/> Cannabis	<input type="checkbox"/> Medical Rule Out	
		<input type="checkbox"/> Stimulant	<input type="checkbox"/> Dissoc. Anesthetic	<input type="checkbox"/> Inhalant	<input type="checkbox"/> Alcohol	<input type="checkbox"/> No Opinion	
Officer's Signature:		Felony Offense:	Misdemeanor Offense:	Reviewed/approved by / date:			

	DRUG INFLUENCE EVALUATION				EVALUATOR:	
	REPORT NUMBER:				IACP#: XXIX-11	
	TYPE OF EVALUATION:				SCRIBE:	
ARRESTEE'S NAME (Last, First, Middle) KILO		Date of Birth	Age	Sex	Race	Arresting Officer (Name, ID#)
Date Examined / Time / Location		Breath Results: Results: 0.05		Test Refused <input type="checkbox"/> Instrument #: 1234		Chemical Test: Urine <input type="checkbox"/> Blood <input type="checkbox"/> Test or tests refused <input type="checkbox"/>
Miranda Warning Given Given By:	<input type="checkbox"/> Yes <input type="checkbox"/> No	What have you eaten today? When? "Nothing"		What have you been drinking? How much? "Couple of beers"		Time of last drink? "Couple hours ago"
Time now/ Actual	When did you last sleep? How long? "Last night" "5 hours"	Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Attitude: Cooperative, Drowsy acting			Coordination: Unsteady, Slow	
Speech: Slurred, Slow, Raspy		Breath Odor: Alcoholic Beverage		Face: Flushed, Licking Lips, Dry Mouth		
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input checked="" type="checkbox"/> Normal <input type="checkbox"/> Bloodshot <input type="checkbox"/> Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right		Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus Yes <input checked="" type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		Eyelids: Normal <input checked="" type="checkbox"/> Droopy
Pulse and time		HGN	Right Eye	Left Eye	Convergence	
1. 60 / _____		Lack of Smooth Pursuit	Yes	Yes		
2. 58 / _____		Maximum Deviation	No	No	Right eye Left eye	
3. 58 / _____		Angle of Onset	None	None		
Modified Romberg Balance		Walk and turn test		ONE LEG STAND		
 Head nodded forward				Cannot keep balance _____ Starts too soon _____ Stops walking _____ Misses heel-toe _____ Steps off line _____ Raises arms _____ Actual steps taken: 9 9		
Internal clock 48 estimated as 30 seconds		Describe Turn: Staggered		Cannot do test (explain) N/A		Type of footwear: Boots
Draw lines to spots touched  Had to be reminded to actually touch nose		PUPIL SIZE	Room light	Darkness	Direct	Nasal area: Clear
		Left Eye	1.5	1.5	1.5	Oral cavity: Clear
		Right Eye	1.5	1.5	1.5	
		REBOUND DILATION Yes <input checked="" type="checkbox"/> No		REACTION TO LIGHT: None		
		RIGHT ARM		LEFT ARM		
						
		No visible marks				
Blood pressure 108/64		Temperature 97.2°		Muscle tone: Near Normal <input type="checkbox"/> Flaccid <input checked="" type="checkbox"/> Rigid <input type="checkbox"/>		
What drugs or medications have you been using? "Nothing, I'm clean now"		How much? N/A		Time of use? N/A	Where were the drugs used? (Location) N/A	
Date / Time of arrest:	Time DRE was notified:	Evaluation start time:	Evaluation completion time:	Precinct/Station:		
Opinion of Evaluator:		<input type="checkbox"/> Depressant <input type="checkbox"/> Stimulant		<input type="checkbox"/> Hallucinogen <input type="checkbox"/> Dissoc. Anesthetic		<input type="checkbox"/> Narcotic Analgesic <input type="checkbox"/> Inhalant
Officer's Signature:		Felony Offense:		Misdemeanor Offense:		Reviewed/approved by / date:

	DRUG INFLUENCE EVALUATION				EVALUATOR:			
	REPORT NUMBER:				IACP#: XXIX-12			
	TYPE OF EVALUATION:				SCRIBE:			
ARRESTEE'S NAME (Last, First, Middle) LIMA		Date of Birth	Age	Sex	Race	Arresting Officer (Name, ID#)		
Date Examined / Time / Location		Breath Results: 0.03			Test Refused <input type="checkbox"/>	Chemical Test: Urine <input type="checkbox"/> Blood <input type="checkbox"/>		
Miranda Warning Given Given By: <input type="checkbox"/> Yes <input type="checkbox"/> No		What have you eaten today? When? "Eggs and Toast" "Noon"		What have you been drinking? How much "Wine" "One glass"		Time of last drink? "Hour ago"		
Time now/ Actual /		When did you last sleep? How long "Yesterday" "5 hours"		Are you sick or injured? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you diabetic or epileptic? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		
Do you take insulin? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Do you have any physical defects? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Are you under the care of a doctor or dentist? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No				
Are you taking any medication or drugs? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Attitude: Nervous, Anxious			Coordination: Unsteady, Jittery			
Speech: Rapid, slurred		Breath Odor: Alcoholic Beverage		Face: Normal				
Corrective Lenses: <input checked="" type="checkbox"/> None <input type="checkbox"/> Glasses <input type="checkbox"/> Contacts, if so <input type="checkbox"/> Hard <input type="checkbox"/> Soft		Eyes: <input type="checkbox"/> Reddened Conjunctiva <input checked="" type="checkbox"/> Normal Bloodshot Watery		Blindness: <input checked="" type="checkbox"/> None <input type="checkbox"/> Left <input type="checkbox"/> Right		Tracking: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal		
Pupil Size: <input checked="" type="checkbox"/> Equal <input type="checkbox"/> Unequal (explain)		Vertical Nystagmus Yes <input checked="" type="checkbox"/> No		Able to follow stimulus <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No		Eyelids <input checked="" type="checkbox"/> Normal Droopy		
Pulse and time 1. 100 / _____ 2. 102 / _____ 3. 102 / _____		HGN Lack of Smooth Pursuit Maximum Deviation Angle of Onset	Right Eye Yes No None	Left Eye Yes No None	Convergence  Right eye Left eye			
Modified Romberg Balance  Circular Sway		Walk and turn test  Had to be reminded to count out loud. Quick steps.		ONE LEG STAND  L R <input type="checkbox"/> <input type="checkbox"/> Sways while balancing <input type="checkbox"/> <input type="checkbox"/> Uses arms to balance <input type="checkbox"/> <input type="checkbox"/> Hopping <input type="checkbox"/> <input type="checkbox"/> Puts foot down Counted quickly				
Internal clock 18 estimated as 30 seconds		Describe Turn: Spun around		Cannot do test (explain) N/A		Type of footwear: Boots		
Draw lines to spots touched  Kept opening eyes. Quick movements.		PUPIL SIZE			Nasal area: Redness in nostrils, no nasal hair			
		Room light			Darkness		Direct	
		Left Eye			7.5		9.0	
Right Eye			7.5		9.0			
			REBOUND DILATION Yes <input checked="" type="checkbox"/> No			REACTION TO LIGHT: Slow		
Blood pressure 170/96		Temperature 99.6⁰		RIGHT ARM 			LEFT ARM 	
Muscle tone: Near Normal <input checked="" type="checkbox"/> Flaccid <input type="checkbox"/> Rigid <input type="checkbox"/>		No visible marks						
What drugs or medications have you been using? "Nothing, just a little wine"		How much? N/A		Time of use? N/A		Where were the drugs used? (Location) N/A		
Date / Time of arrest:		Time DRE was notified:		Evaluation start time:		Evaluation completion time:		
Opinion of Evaluator:		<input type="checkbox"/> Depressant <input type="checkbox"/> Hallucinogen <input type="checkbox"/> Narcotic Analgesic <input type="checkbox"/> Cannabiz <input type="checkbox"/> Medical Rule Out		<input type="checkbox"/> Stimulant <input type="checkbox"/> Dissoc. Anesthetic <input type="checkbox"/> Inhalant <input type="checkbox"/> Alcohol <input type="checkbox"/> No Opinion				
Officer's Signature:		Felony Offense:		Misdemeanor Offense:		Reviewed/approved by / date:		

Session 30

Transition to the Certification Phase of Training



Session 30 - Transition to the Certification Phase of Training

Learning Objectives

- **Demonstrate mastery of the knowledge and skills the course was intended to help develop**
- **Summarize the key topics covered**
- **Offer comments and suggestions for improving the course**
- **Receive their assignments for Field Certification Training**




Drug Recognition Expert Course 30-2

Briefly review the objectives, content and activities of this session.

Upon successfully completing this session the participant will be able to:

Demonstrate their mastery of the knowledge and skills the course was intended to help develop.

- Summarize the key topics covered.
- Offer comments and suggestions for improving the course.
- Receive assignments for Field Certification Training.
- Understand the steps involved in the DRE certification process.

CONTENT SEGMENTS

- A. Summary
- B. Post Test
- C. Session Wrap-Up
- D. Certification Process, Training Assignments and Schedule
- E. Closing Remarks

LEARNING ACTIVITIES

- Participant-Led Presentations
- Participants' Anonymous Critique of Course
- Knowledge Examination
- Instructor-Led Presentation

Session 30 - Transition to the Certification Phase of Training

The Seven Categories of Drugs

- CNS Depressants
- CNS Stimulants
- Hallucinogens
- Dissociative Anesthetics
- Narcotic Analgesics
- Inhalants
- Cannabis



Drug Recognition Expert Course 30-3

A. Summary

The Seven Categories of Drugs

Ask participants to name the seven categories.

Make sure all categories are named, then reveal the bottom of the slide with the list.

- CNS Depressants
- CNS Stimulants
- Hallucinogens
- Dissociative Anesthetics
- Narcotic Analgesics
- Inhalants
- Cannabis

Session 30 - Transition to the Certification Phase of Training

Drug Evaluation and Classification Procedure

What are the components of the procedure?

- **Breath Alcohol Test**
- **Interview of Arresting Officer**
- **Preliminary Examination**
- **Examinations of Eyes**
- **Divided Attention Tests**



Drug Recognition Expert Course 30-4

The Drug Evaluation and Classification Procedure

Ask participants to name the components of the procedure. Make sure all components are named, then reveal the bottom portion of the slide with the components listed.

- Breath Alcohol Test
- Interview of Arresting Officer
- Preliminary Examination
- Examinations of Eyes
- Divided Attention Tests

Ask participants to discuss the kinds of evidence/ information gleaned from each component.

Session 30 - Transition to the Certification Phase of Training

Drug Evaluation and Classification Procedure (Cont.)

What are the components of the procedure?

- Vital Signs Examinations
- Check for Muscle Tone
- Inspection for Injection Sites
- Statements and Observations
- Opinion of the Evaluator
- Toxicological Examination



Drug Recognition Expert Course 30-5

The Drug Evaluation and Classification Procedure

Ask participants to name the components of the procedure. Make sure all components are named, then reveal the bottom portion of the slide with the components listed.

- Vital Signs Examinations
- Check for Muscle Tone
- Inspection for Injection Sites
- Statements and Observations
- Opinion of the Evaluator
- Toxicological Examination

Ask participants to discuss the kinds of evidence/ information gleaned from each component.

Session 30 - Transition to the Certification Phase of Training

Major Signs and Symptoms

- CNS Depressants
- CNS Stimulants
- Hallucinogens
- Dissociative Anesthetics
- Narcotic Analgesics
- Inhalants
- Cannabis



Drug Recognition Expert Course 30-6

Major Signs and Symptoms

Instruct participants to turn to the symptomatology chart in their manuals.

Briefly summarize and review the major signs and symptoms associated with each drug category. Reveal each category one at a time and conduct the review.

Solicit participants' questions concerning the major content topics of the course.

Inform the participants that the final exam in a "closed book" test. Instruct them to put all books and notes away.

Session 30 - Transition to the Certification Phase of Training

Knowledge Examination



Post-Test



Drug Recognition Expert Course 30-7

B. Post-Test

Knowledge Examination

- ***Distribute post-test knowledge examinations.***
- ***Allow students approximately 80 minutes to complete the knowledge examination.***
- ***Collect the completed knowledge examination.***
- ***Grade the knowledge exams***

Session 30 - Transition to the Certification Phase of Training

Critique



Critique Form



Drug Recognition Expert Course 30-8

C. Session Wrap-Up

Critique

Hand-out critique forms to the participants for completion.

Session 30 - Transition to the Certification Phase of Training

The Three-Phases of Training for the DEC Program

Certification involves three-phase training process:

1. Phase I- Two-day (16-hour) Pre-school
2. Phase II- Seven-day (56-hour) DRE School
3. Phase III- Field Certifications (usually within 60 to 90 days, but not longer than six months following the completion of the classroom training)



Drug Recognition Expert Course 30-9

D. Certification Training Assignments and Schedule

Remind the participants of the three phases of training needed to complete their certification process:

1. Phase I - Pre-School
2. Phase II - DRE School
3. Phase III - Field Certifications

Session 30 - Transition to the Certification Phase of Training

Field Evaluations Requirements

- 12 evaluations (minimum)
- 9 toxicology samples collected
- 7 positive (confirmed) toxicology samples from the lab
- 6 of the 12 evaluations conducted - YOU must be the evaluator
- 3 of the 7 drug categories must be encountered
- Evaluations must be witnessed and supervised by a DRE Instructor




Drug Recognition Expert Course 30-10

Review with the participants the IACP International Standards for DRE certification.

- IACP Standard 1.10 requires that the candidate DRE satisfactorily complete a minimum of twelve (12) evaluations, identifying subjects under the influence of at least three of the drug categories. All three must be supported by toxicology.
- The candidate DRE must also act as the evaluator for at least six evaluations.
- All evaluations, either administered or observed must be documented on the candidate's rolling log.
- Candidate DREs need to have toxicology samples from at least nine (9) subjects evaluated during the certification process.
- The candidate DRE cannot be certified unless the opinion concerning the drug category(s) is supported by toxicology 75 percent of the time or in at least seven (7) of the nine samples submitted for certification.

Remind participants that during certification all evaluations must be supervised by instructors to count towards minimum certification requirements.

Session 30 - Transition to the Certification Phase of Training

Field Certifications

What's needed for the Field Certification nights?

- DRE kits
- Certification Progress Log
- Your Participant Manual
- Your Rolling Log
- A prepared mind





Drug Recognition Expert Course 30-11

Field Certifications

Remind the participants of what will be needed for the field certifications.

Should include the following:

- DRE kits
- Certification Progress Log
- DRE Participant Manual
- Rolling Log
- A “prepared mind”

Remind participants that DRE field certifications must be completed as soon as possible following completion of the classroom training.

Remind the participants that by the time they have completed field certification(s), they shall have prepared a Curriculum Vitae (C.V.).

Session 30 - Transition to the Certification Phase of Training

The Final Certification Knowledge Examination

- **Standard 1.12...*Prior to concluding field certification training, the candidate shall satisfactorily complete an approved "Certification Knowledge Examination"***
- **...*The examination shall only be administered after the candidate has completed not less than three drug evaluations***



Drug Recognition Expert Course 30-12

- Standard 1.12...Prior to concluding field certification training, the candidate shall satisfactorily complete an approved "Certification Knowledge Examination"
- ...The examination shall only be administered after the candidate has completed not less than three drug evaluations

Session 30 - Transition to the Certification Phase of Training

Final Certification Knowledge Examination (Cont.)

- **A multi-part, comprehensive examination**
- **No significant errors or omissions allowed**
- **Examines candidate's overall knowledge**



Drug Recognition Expert Course 30-13

Final Certification Knowledge Examination

- Prior to concluding the certification process, the candidate DRE must satisfactorily complete an IACP approved Final Certification Knowledge Examination.
- The Final Certification Knowledge Examination is a multi-part comprehensive examination where the participant can not make significant errors or omissions.
- Examination consists of five parts which tests the candidate DRE's knowledge of the drug symptomatology matrix, drug effects, drug combinations, and report writing skills.

Session 30 - Transition to the Certification Phase of Training

IACP Certification Progress Log

- After each component required for certification is completed, a DRE Instructor must sign off on your log
- You must be recommended for certification by two DRE Instructors
 - ✓ Instructors will sign off in the *Authorized Signature* portion at the bottom of the Progress Log



Drug Recognition Expert Course 30-14

- After each component required for certification is completed, a DRE Instructor must sign off on the DRE candidate's log.
- The candidate DRE must be recommended for certification by two DRE instructors.

Session 30 - Transition to the Certification Phase of Training

How Long Am I Certified For?

- **DRE Certification is good for two years**
- **DRE's shall be required to renew their certificate of continuing proficiency every two years**



Drug Recognition Expert Course 30-15

DRE Certification

DRE certification is for a period of two years.

DRE's shall be required to renew their certificate of continuing proficiency every two years

Session 30 - Transition to the Certification Phase of Training

How Do I Maintain Proficiency?

IACP International Standard 3.4...A DRE shall demonstrate continuing proficiency by:

- **Performing a minimum of four (4) acceptable evaluations since the date of last certification...**
- **Completing a minimum of eight (8) hours of recertification training...**
- **Presenting an updated Curriculum Vitae and Rolling Log to the appropriate coordinator for review and approval**



Drug Recognition Expert Course 30-16

Once certified, DREs shall be required to renew their certificates of continuing proficiency every two years.

Continuing proficiency requires:

- Performing a minimum of four (4) acceptable drug evaluations since the last date of certification;
- Completing a minimum of eight (8) hours of approved re-certification training; and
- Presenting an updated C.V. and Rolling Log to the appropriate coordinator for review.

Session 30 - Transition to the Certification Phase of Training


QUESTIONS?



Drug Recognition Expert Course

30-17

Solicit questions from participants regarding the field certifications and certification process.



E. Closing Remarks

Closing remarks will be offered by appropriate representatives of the department of faculty.

INSTRUCTOR'S GUIDELINES FOR THE FINAL EXAMINATION

ADMINISTERING THE FINAL EXAMINATION

The IACP/NHTSA approved Final Examination (Form A) is administered at the completion of this training. Each student must receive one copy of the examination and an answer sheet. To guard against loss of a copy of the examination, do not simply hand over a large supply of examinations to the first row of students and ask them to "pass them back". Instead, instructors must physically hand a single copy to each individual student. **EMPHASIZE THAT STUDENTS MUST WRITE NOTHING ON THE EXAMINATION ITSELF.** When a student completes the test, make sure you collect their copy of the examination along with the answer sheet. Carefully inspect the copy of the examination to make sure nothing has been written on it. Destroy completely any copies that have been marked in any way.

GRADING THE EXAMINATION

The Final Examination contains 100 multiple choice questions. A student must correctly answer at least 80 questions to pass the examination and progress to Certification Training. A student who is totally correct on at least 80 questions passes. A student who answers 21 or more questions incorrectly fails.

WHAT DO WE DO WHEN A STUDENT FAILS?

The International Standards established for this program by IACP, and endorsed by NHTSA, grant every student who fails the Final Examination one additional attempt to pass. **BUT PLEASE NOTE THAT SOME OF THE STATES AND LAW ENFORCEMENT AGENCIES PARTICIPATING IN THE DRUG EVALUATION AND CLASSIFICATION PROGRAM HAVE ADOPTED A MORE EXACTING STANDARD.** For example, some agencies will not allow a "failed" student a second attempt unless he or she scored at least 70 on the first attempt.

All participating agencies have the right to set standards that are more stringent than those promulgated by IACP. Therefore, when a student fails the Final Examination, your first duty is to determine whether the student qualifies for a second attempt.

Assuming a "failed" student qualifies, the second attempt cannot occur sooner than two weeks following the completion of the school, and must occur not later than four weeks after the School end. In other words, there is an enforced waiting period of two weeks, to provide time for remedial study; then, there is a two week "window of opportunity". **NO EXCEPTION CAN BE MADE TO THIS.**

During the two week waiting period, the student is expected to study the manual and their class notes. Tutoring by certified DRE instructors is permissible and encouraged. However, if you tutor a "failed" student, be sure that you do not simply "teach the test". **DO NOT GO OVER THE FINAL EXAMINATION WITH THE STUDENT. DO NOT LET HIM OR HER KNOW WHICH QUESTIONS WERE ANSWERED INCORRECTLY.** Do use the available quizzes and other study guides to help tutor the student. These include the "Challenge Quiz" found at the end of the PRE-School Student's Manual; the Pre-test for this

School; the five quizzes that are used in this School; and, the "Self-Test for Review and Study" that is found at the end of Session XXVIII of the DRE School Student's Manual.

One thing that the "failed" student cannot do during the two-week waiting period is formally enroll in Certification Training. It is permissible for him or her to attend Certification Training events as an observer. But the "failed" student cannot administer any subject evaluations, nor can they serve as the recorder for any evaluations. And, of course, the "failed" student will receive absolutely no credit for any evaluations they observe.

The second attempt at the Final Examination must employ Form B Final Written Examination. If the student correctly answers at least 80 questions on the second attempt, they pass. If the score is 79 or lower, or if the two to four week "window" elapses and the student has not been re-tested, they irrevocably fail, and are no longer a participant in the Drug Evaluation and Classification Program. The only way that the student can be re-admitted to the Program would be to enroll in another DRE School, complete it in its entirety, and pass the Final Examination.

DRUG EVALUATION AND CLASSIFICATION PROGRAM

LOG OF DRUG INFLUENCE EVALUATIONS

Drug Recognition Expert _____ Page: _____

IACP Certification Number _____

CONTROL NUMBER	SUSPECT'S NAME	WITNESS	DATE	OPINION OF DRE	TOXICOLOGICAL RESULTS

**PROFICIENCY EXAMINATION CHECKLIST
(For Use During Certification Training)**

Student's Name: _____ Date: _____

Examiner: _____

I. Preliminary Examination

1. Did the student ask all preliminary examination questions?

_____ yes _____ no

(If No: What questions were deleted? _____

2. Did the student properly estimate pupil size?

_____ yes _____ no

3. Did the student properly assess the eyes' tracking ability?

_____ yes _____ no

4. Did the student properly measure pulse rate?

_____ yes _____ no

II. Eye Examinations

1. Did the student properly administer the Horizontal Gaze Nystagmus test?

_____ yes _____ no

(If No, explain deficiencies? _____

2. Did the student properly administer the Vertical Gaze Nystagmus test?

_____ yes _____ no

(If No, explain deficiencies? _____

3. Did the student properly administer the test for Lack of Convergence?

_____ yes _____ no

(If No, explain deficiencies? _____

III. Psychophysical Tests

1. Did the student properly administer the Romberg Balance test?

_____ yes _____ no

(If No, explain deficiencies? _____

2. Did the student properly administer the Walk and Turn test?

_____ yes _____ no

(If No, explain deficiencies? _____

3. Did the student properly administer the One Leg Stand test?

_____ yes _____ no

(If No, explain deficiencies? _____

4. Did the student properly administer the Finger to Nose test?

_____ yes _____ no

(If No, explain deficiencies? _____

IV. Vital Signs Examinations

1. Did the student properly measure blood pressure?

_____ yes _____ no

(If No, explain deficiencies? _____

2. Did the student properly measure temperature?

_____ yes _____ no

(If No, explain deficiencies? _____

3. Did the student properly measure pulse?

_____ yes _____ no

(If No, explain deficiencies? _____

V. Dark Room Examinations

1. Did the student properly control the pen light for the two checks of pupil size?

_____ yes _____ no

(If No, explain deficiencies? _____

2. Did the student accurately estimate pupil size?

_____ yes _____ no

3. Did the student properly check the nasal area?

_____ yes _____ no

4. Did the student properly the oral cavity?

_____ yes _____ no

VI. Examinations of Muscle Tone

1. Did the student adequately inspect for muscle tone?

_____ yes _____ no

(If No, explain deficiencies? _____

VII. Examinations of Injection Sites and Third Pulse

1. Did the student adequately inspect for injection sites?

_____ yes _____ no

(If No, explain deficiencies? _____

2. Did the student properly measure pulse?

_____ yes _____ no

(If No, explain deficiencies? _____

VIII. Evaluator's Opinion of Student's Proficiency

(Offer appropriate, specific comments concerning the student's progress)
